



07-10-2016

| | | |
|---------------|---|--------|
| 10:15 - 11:45 | Type: Educational session Title: Cancer Immunotherapy (CIT): What every oncologist should know Chair(s): I. Melero, ES; S. van der Burg, NL | Vienna |
|---------------|---|--------|

10:15 - 10:30 Back to the basics
S. van der Burg, Leiden, NL

10:30 - 10:55 Cancer vaccines: Can we make them work?
C.(. Melief, Leiden, NL

10:55 - 11:20 T cell therapy: For whom and when?
I.-M. Svane, Herlev, DK

11:20 - 11:45 Immune checkpoints: Do we really know how they work?
I. Melero, Pamplona, ES



| | | |
|---------------|---|------------|
| 12:00 - 13:20 | Type: Opening session Title: Opening Session and Award lectures - Followed by welcome refreshments Chair(s): F. Ciardiello, IT | Copenhagen |
| 12:00 - 12:10 | ESMO Presidential Address <u>F. Ciardiello</u> , Napoli, IT | |
| 12:10 - 12:15 | Welcome to Copenhagen <u>U. Lassen</u> , Copenhagen, DK | |
| 12:15 - 12:20 | ESMO 2016 Scientific address <u>A. Cervantes</u> , Valencia, ES | |
| 12:20 - 12:25 | Presentation of the ESMO Award by <u>C. Zielinski</u> , Vienna, AT | |
| 12:25 - 12:40 | ESMO Award lecture <u>A. Sobrero</u> , Genoa, IT | |
| 12:40 - 12:45 | Presentation of the ESMO Hamilton Fairley Award by <u>C. Zielinski</u> , Vienna, AT | |
| 12:45 - 13:00 | ESMO Hamilton Fairley Award lecture - The new genome driver-based stratification of breast cancer <u>C. Caldas</u> , Cambridge, GB | |
| 13:00 - 13:05 | Presentation of the ESMO Lifetime Achievement Award by <u>C. Zielinski</u> , Vienna, AT | |
| 13:05 - 13:20 | ESMO Lifetime Achievement Award lecture <u>R. Peto</u> , Oxford, GB | |
| 13:20 - 13:20 | Welcome refreshments in the exhibition | |



| | | |
|---------------|--|------------|
| 14:00 - 15:30 | Type: Proffered Paper session Title: Genitourinary tumours, prostate Chair(s): F. Feng, US; G. Attard, GB | Copenhagen |
| 14:00 - 14:15 | 7170 - Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP) <u>W. Xie</u> ¹ , C. Sweeney ¹ , M. Regan ¹ , M. Nakabayashi ¹ , M. Buyse ² , N. Clarke ³ , L. Collette ⁴ , J. Dignam ⁵ , K. Fizazi ⁶ , M. Habibian ⁷ , S. Halabi ⁸ , P. Kantoff ⁹ , W. Parulekar ¹⁰ , H. Sandler ¹¹ , O. Sartor ¹² , H. Soule ¹³ , M. Sydes ¹⁴ , B. Tombal ⁴ , S. Williams ¹⁵ ; ¹ Boston, MA/US, ² Louvain-La-neuve, BE, ³ Manchester, GB, ⁴ Brussels, BE, ⁵ Chicago, US, ⁶ Villejuif, FR, ⁷ Paris, FR, ⁸ Durham, US, ⁹ New York, US, ¹⁰ Kinston, CA, ¹¹ Los Angeles, CA/US, ¹² New Orleans, US, ¹³ Santa Monica, US, ¹⁴ London, GB, ¹⁵ East Melbourne, AU | |
| 14:15 - 14:30 | 7180 - PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) <u>J. de Bono</u> ¹ , U. De Giorgi ² , C. Massard ³ , S. Bracarda ⁴ , D. Nava Rodrigues ¹ , I. Kocak ⁵ , A. Font ⁶ , J. Arranz Arijia ⁷ , K. Shih ⁸ , G. Radavoi ⁹ , W. Yu ¹⁰ , W. Chan ¹¹ , S. Gendreau ¹¹ , L. Zhang ¹¹ , R. Riisnaes ¹ , M. Wongchenko ¹⁰ , D. Maslyar ¹¹ , V. Jinga ⁹ ; ¹ London, GB, ² Meldola, IT, ³ Villejuif, FR, ⁴ Arezzo, IT, ⁵ Brno, CW, ⁶ Badalona, ES, ⁷ Madrid, ES, ⁸ Nashville, TN/US, ⁹ Bucharest, RO, ¹⁰ South San Francisco, CA/US, ¹¹ South San Francisco, US | |
| 14:30 - 14:45 | Invited discussant abstracts 7170 and 7180 <u>F. Feng</u> , Ann Arbor, US | |
| 14:45 - 15:00 | LBA29 - A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC) <u>H. Beltran</u> ¹ , D. Danila ² , B. Montgomery ³ , R. Szmulewitz ⁴ , U. Vaishampayan ⁵ , A. Armstrong ⁶ , M. Stein ⁷ , C. Hoimes ⁸ , J. Pinski ⁹ , H. Scher ¹ , L. Puca ¹ , R. Bareja ¹ , W. Wong ¹ , M. Rubin ¹ , J.M. Mosquera ¹ , A. Sboner ¹ , C. Oromendia ¹ , D. Nanus ¹ , K. Ballman ¹ , S. Tagawa ² ; ¹ New York, NY, US, ² New York, US, ³ Seattle, US, ⁴ Chicago, US, ⁵ Detroit, US, ⁶ Durham, NC/US, ⁷ New Brunswick, US, ⁸ Cleveland, US, ⁹ Los Angeles, US | |
| 15:00 - 15:15 | 7190 - First Evidence of Significant Clinical Activity of PD-1 Inhibitors in Metastatic, Castration Resistant Prostate Cancer (mCRPC) <u>J. Graff</u> ¹ , J. Alumkal ¹ , C. Drake ² , G. Thomas ¹ , W. Redmond ³ , M. Farhad ¹ , R. Slotke ¹ , T. Beer ¹ ; ¹ Portland, OR/US, ² Baltimore, US, ³ Portland, US | |
| 15:15 - 15:30 | Invited discussant abstracts LBA29 and 7190 <u>W. Gerritsen</u> , Nijmegen, NL | |



| | | |
|---------------|---|-----------|
| 14:00 - 15:30 | Type: Educational session Title: Metastatic colorectal cancer: Providing the continuum of care Chair(s): C. Tournigand, FR; C. Qvortrup, DK | Vienna |
| 14:00 - 14:30 | What can be done beyond first line targeted agents: Switch or continue? <u>D. Arnold</u> , Freiburg, DE | |
| 14:30 - 15:00 | Re-introduction: Is it a valid concept? <u>C. Tournigand</u> , Créteil, FR | |
| 15:00 - 15:30 | On-treatment biomarkers: Do they help to define the best sequence? <u>C. Montagut</u> , Barcelona, ES | |
| 14:00 - 15:30 | Type: Educational session Title: New developments in the management of ER-positive metastatic breast cancer Chair(s): R. Coleman, GB; G. Curigliano, IT | Stockholm |
| 14:00 - 14:30 | Unlocking the pathways of endocrine resistance <u>G. Curigliano</u> , Milan, IT | |
| 14:30 - 15:00 | Current and emerging treatment approaches: An embarrassment of riches? <u>N. Harbeck</u> , München, DE | |
| 15:00 - 15:30 | Minimising the toxicities of targeted therapies <u>T. Bachelot</u> , Lyon, FR | |



| | | |
|---------------|--|--------|
| 14:00 - 15:30 | Type: Proffered Paper session Title: Non-metastatic NSCLC and other thoracic malignancies Chair(s): D. De Ruyscher, NL; P. Garrido, ES | Madrid |
| 14:00 - 14:15 | LBA41_PR - Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer <u>P. Forde</u> ¹ , K. Smith ¹ , J. Chaff ² , M. Hellmann ³ , T. Merghoub ² , J. Wolchok ² , S. Yang ¹ , R. Battafarano ¹ , E. Gabrielson ¹ , C. Georgiades ¹ , F. Verde ¹ , G. Rosner ¹ , J. Naidoo ¹ , T. Cottrell ¹ , J. Taube ¹ , V. Anagnostou ¹ , V. Velculescu ¹ , S. Topalian ¹ , D. Pardoll ¹ , J. Brahmer ¹ ; ¹ Baltimore, MD/US, ² New York, NY/US, ³ New York, US | |
| 14:15 - 14:30 | 1178O - Multi-centre randomized controlled study comparing adjuvant vs neo-adjuvant chemotherapy with docetaxel plus carboplatin in resectable stage IB to IIIA NSCLCfinal results of CSLC0501 <u>Y.-L. Wu</u> ¹ , X.-N. Yang ¹ , W. Zhong ¹ , X. Ben ¹ , G.-B. Qiao ¹ , Q. Wang ² , C. Wang ³ , H.-H. Luo ¹ , Z. Wang ⁴ , H.-H. Yan ¹ ; ¹ Guangzhou, CN, ² Shanghai, CN, ³ Tianjin, CN, ⁴ Shenzhen, CN | |
| 14:30 - 14:45 | Invited discussant LBA41 and abstract 1178O <u>P. Baas</u> , Amsterdam, NL | |
| 14:45 - 15:00 | 1423O - Randomized phase 2 study of investigational aurora A kinase (AAK) inhibitor alisertib (MLN8237) + paclitaxel (P) vs placebo + P as second line therapy for small-cell lung cancer (SCLC) <u>T. Owonikoko</u> ¹ , K. Nackaerts ² , T. Csoszi ³ , G. Ostoros ⁴ , C. Baik ⁵ , Z. Mark ⁶ , E. Sheldon-Waniga ⁷ , D. Huebner ⁷ , E.J. Leonard ⁷ , D. Spiegel ⁸ ; ¹ Atlanta, GA/US, ² Leuven, BE, ³ Szolnok, HU, ⁴ Budapest, HU, ⁵ Seattle, WA/US, ⁶ Törökbálint, HU, ⁷ Cambridge, MA/US, ⁸ Nashville, TN/US | |
| 15:00 - 15:15 | 1424O - Small cell lung carcinoma harbors targetable alterations including MYCL1 fusions responding to aurora kinase inhibitor <u>S. Ali</u> ¹ , B. Kolla ² , M. Bailey ¹ , A. Schrock ³ , S. Klemptner ⁴ , G. Frampton ³ , D. Fabrizio ¹ , S.-H. Ou ⁵ , J. He ¹ , J. Suh ¹ , J. Ross ⁶ , P. Stephens ¹ , V. Miller ¹ , M. Patel ² ; ¹ Cambridge, MA/US, ² Minneapolis, US, ³ Cambridge, US, ⁴ Los Angeles, US, ⁵ Irvine, CA/US, ⁶ Albany, NY/US | |
| 15:15 - 15:30 | Invited discussant abstracts 1423O and 1424O <u>P. Garrido Lopez</u> , Madrid, ES | |



| | | |
|---------------|---|------|
| 14:00 - 15:30 | Type: Proffered Paper session Title: Gynaecological cancers Chair(s): A. Poveda, ES; C. Sessa, CH | Oslo |
| 14:00 - 14:15 | 854O - Results of a phase 2 trial of selinexor, an oral selective inhibitor of nuclear export (SINE) in 114 patients with gynaecological cancers <u>I. Vergote</u> ¹ , B. Lund ² , H. Havsteen ³ , Z. Ujmajuridze ⁴ , E. Van Nieuwenhuysen ¹ , C. Haslund ² , T. Juhler-Nøttrup ⁴ , P. Neven ¹ , M. Mau-Sørensen ⁴ , P. Berteloot ¹ , A. Kranich ⁵ , T. Rasha ⁶ , J. Meade ⁶ , Y. Landesman ⁶ , J.-R. Saint-Martin ⁷ , G. Wright ⁶ , M. Crochiere ⁶ , S. Shacham ⁶ , M. Kauffman ⁶ , M. Raza Mirza ⁶ ; ¹ Leuven, BE, ² Aalborg, DK, ³ Herlev, DK, ⁴ Copenhagen, DK, ⁵ Hamburg, DE, ⁶ Newton, MA/US, ⁷ Natick, US | |
| 14:15 - 14:30 | 855O - A phase II study of the cell cycle checkpoint kinases 1 and 2 inhibitor (LY2606368; Prexasertib monomesylate monohydrate) in sporadic high-grade serous ovarian cancer (HGSOC) and germline BRCA mutation-associated ovarian cancer (gBRCAm+ OvCa) <u>J.-M. Lee</u> , F. Karzai, A. Zimmer, C. Annunziata, S. Lipkowitz, B. Parker, N. Houston, I. Ekwede, E. Kohn; Rockville, US | |
| 14:30 - 14:45 | Invited discussant abstract 854O and 855O <u>C. Gourley</u> , Edinburgh, GB | |
| 14:45 - 15:00 | 856O - Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2) <u>R. Kristeleit</u> ¹ , R. Shapira-Frommer ² , A. Oaknin ³ , J. Balmaña ³ , I. Ray-Coquard ⁴ , S. Domchek ⁵ , A. Tinker ⁶ , C. Castro ⁷ , S. Welch ⁸ , A. Poveda ⁹ , K. Bell-McGuinn ¹⁰ , G. Konecny ¹¹ , H. Giordano ¹² , L. Maloney ¹³ , S. Goble ¹³ , L. Rolfe ¹⁴ , A. Oza ¹⁵ ; ¹ London, GB, ² Ramat Gan, IL, ³ Barcelona, ES, ⁴ Lyon, FR, ⁵ Philadelphia, PA/US, ⁶ Vancouver, CA, ⁷ Boston, MA/US, ⁸ London, ON/CA, ⁹ Valencia, ES, ¹⁰ New York, NY/US, ¹¹ Los Angeles, US, ¹² San Francisco, US, ¹³ Boulder, CO/US, ¹⁴ Cambridge, GB, ¹⁵ Toronto, CA | |
| 15:00 - 15:20 | LBA33_PR - Principal results of the cancer of the ovary abiraterone trial (CORAL): A phase II study of abiraterone in patients with recurrent epithelial ovarian cancer (CRUKE/12/052) <u>S. Banerjee</u> ¹ , L. Kilburn ¹ , R. Bowen ² , H. Tovey ¹ , M. Hall ³ , S. Kaye ¹ , G. Rustin ³ , M. Gore ¹ , J. McLachlan ⁴ , A. Attygalle ¹ , N. Tunariu ¹ , J.P. Lima ⁴ , P. Chatfield ¹ , L. Jeffs ¹ , E. Folkerd ¹ , M. Hills ¹ , S. Perry ¹ , G. Attard ⁴ , M. Dowsett ⁴ , J. Bliss ¹ ; ¹ London, GB, ² Bath, GB, ³ Northwood, GB, ⁴ Sutton, GB | |
| 15:20 - 15:35 | Invited discussant abstract 856O and LBA33 <u>D. Lorusso</u> , Milan, IT | |



| | | |
|---------------|--|--------|
| 14:00 - 15:30 | Type: Educational session Title: Imaging in metastatic prostate cancer Chair(s): U. Haberkorn, DE; F. Lecouvet, BE | Rome |
| 14:00 - 14:30 | The role of whole body MRI <u>F. Lecouvet</u> , Brussels, BE | |
| 14:30 - 15:00 | The role of PET/CT <u>U. Haberkorn</u> , Heidelberg, DE | |
| 15:00 - 15:30 | Radiographic progression free survival: A new biomarker of response to treatment? <u>M. Morris</u> , New York, US | |
| 14:00 - 15:30 | Type: Joint Symposium Title: Joint Symposium ESMO-ESP: How to select patients for immunotherapy: The role of pathology Chair(s): R.A. Stahel, CH; P. Schirmacher, DE | Athens |
| 14:00 - 14:05 | Introduction <u>P. Schirmacher</u> , Heidelberg, DE | |
| 14:05 - 14:25 | PDL 1 immunohistochemistry laboratory validation <u>M. Vyberg</u> , Aalborg, DK | |
| 14:25 - 14:45 | PDL 1 Immunohistochemistry clinical validation with the example of thoracic tumours <u>S. Peters</u> , Lausanne, CH | |
| 14:45 - 15:05 | Beyond immunohistochemistry <u>I. Cree</u> , Coventry, GB | |
| 15:05 - 15:25 | How to determine neoantigens <u>M. Bassani-Sternberg</u> , Epalinges, CH | |
| 15:25 - 15:30 | Conclusions and clinical perspectives <u>R.A. Stahel</u> , Zürich, CH | |



| | | |
|---------------|---|----------|
| 14:00 - 15:30 | Type: Joint Symposium Title: Joint Symposium ESMO-EACR: How mouse models can help develop better targeted therapies Chair(s): F. Ciardiello, IT; A. Berns, NL | Helsinki |
| 14:00 - 14:05 | Introduction <u>F. Ciardiello</u> , Napoli, IT | |
| 14:05 - 14:25 | Modelling thoracic cancers in the mouse <u>A. Berns</u> , Amsterdam, NL | |
| 14:25 - 14:45 | Deciphering mechanisms of resistance to macrophage-targeted therapies <u>J. Joyce</u> , Lausanne, CH | |
| 14:45 - 15:05 | Integrating immune and molecular targeted therapies <u>A. Bardelli</u> , Candiolo, IT | |
| 15:05 - 15:25 | Clinical evolution mouse models <u>S. Siena</u> , Milan, IT | |
| 15:25 - 15:30 | Conclusions and clinical perspectives <u>A. Berns</u> , Amsterdam, NL | |
| 14:00 - 15:30 | Type: Educational session Title: Wind of change: Challenges in neuro-oncology in 2016 Chair(s): A. Brandes, IT; M. Brada, GB | Brussels |
| 14:00 - 14:30 | The new WHO classification: Is molecular diagnosis ready for prime time? <u>P. Wesseling</u> , Nijmegen, NL | |
| 14:30 - 15:00 | Newly diagnosed and recurrent glioblastoma: Where are we going? <u>A. Brandes</u> , Bologna, IT | |
| 15:00 - 15:30 | Standard and future approaches in the treatment of rare CNS tumours <u>M. Brada</u> , London, GB | |



| | | |
|---------------|--|--------|
| 14:00 - 15:30 | Type: Joint Symposium Title: Joint Symposium ESMO-WHO Europe: To screen or not to screen for breast cancer? Chair(s): M. Corbex, CH; F. Cardoso, PT | Berlin |
| 14:00 - 14:05 | Introduction <u>F. Cardoso</u> , Lisboa, PT | |
| 14:05 - 14:25 | Pro and cons of cancer screening <u>M. Kalager</u> , Oslo, NO | |
| 14:25 - 14:45 | Breast cancer screening in low and middle resources settings: More harms than benefits? <u>O. Ginsburg</u> , Geneva, CH | |
| 14:45 - 15:05 | Breast cancer screening: The unhealthy controversy <u>D. Cameron</u> , Edinburgh, GB | |
| 15:05 - 15:25 | The cost of breast cancer screening <u>H. De Koning</u> , Rotterdam, NL | |
| 15:25 - 15:30 | Conclusions / Questions and Answers <u>M. Corbex</u> , Geneva, CH | |
| 14:00 - 15:30 | Type: Special Session Title: Communication findings of clinical trials: The first 12 months from analysis Chair(s): E. de Azambuja, BE; M. Sydes, GB | Bern |
| 14:00 - 14:05 | Introduction <u>E. de Azambuja</u> , Brussels, BE | |
| 14:05 - 14:25 | Disseminating results: What are we trying to achieve and who needs to hear? <u>A. South</u> , London, GB | |
| 14:25 - 14:45 | What, when and how patients and the public want to know: New results and implications for practice <u>R. Stephens</u> , Stevenage, GB | |
| 14:45 - 15:05 | The role of the press office and the role of the media <u>E. de Azambuja</u> , Brussels, BE | |
| 15:05 - 15:25 | How clinical trial data leads to changes in practice: The perspective of the cost-effectiveness body <u>S. Garner</u> , London, GB | |
| 15:25 - 15:30 | Conclusions <u>M. Sydes</u> , London, GB | |



| | | |
|---------------|--|--------|
| 14:00 - 14:30 | Type: Patient Advocacy Track Title: Welcome Chair(s): P. Casali, IT; B. Ryll, SE | Warsaw |
| 14:00 - 14:15 | Welcome by ESMO <u>P. Casali</u> , Milano, IT | |
| 14:15 - 14:30 | Welcome by the ESMO PAWG Chair <u>B. Ryll</u> , Uppsala, SE | |
| 14:45 - 15:45 | Type: Patient Advocacy Track Title: Knowledge is power Chair(s): K. Apostolidis, BE | Warsaw |
| 14:45 - 15:00 | Facilitating patient advocates scientific learning at SABCS <u>S. Stanford</u> , St Antonio, Tx, US | |
| 15:00 - 15:15 | From research on patients to patient researchers <u>M. Seres</u> , Watford, GB | |
| 15:15 - 15:30 | How to educate yourself in research and development: EUPATI the European Patient Academy for Therapeutical Innovation <u>J. Geissler</u> , Munich, DE | |
| 15:30 - 15:45 | Discussion | |



| | | |
|---------------|---|------------|
| 16:00 - 17:30 | Type: Proffered Paper session Title: Immunotherapy of cancer Chair(s): J. Haanen, NL; I.-M. Svane, DK | Copenhagen |
| 16:00 - 16:15 | 1055O - Changes in serum IL8 levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients <u>M. Sanmamed</u> ¹ , J.L. Perez-Gracia ² , J.P. Fusco ² , C. Oñate ² , G. Perez ² , C. Alfaro ² , S. Martín-Algarra ² , A. González ² , M.E. Rodríguez-Ruiz ² , M.P. Andueza ² , J. Wang ¹ , A. Bacchiocchi ¹ , R. Halaban ¹ , H. Kluger ¹ , M. Szno ¹ , I. Melero ² ; ¹ New Haven, CT/US, ² Pamplona, ES | |
| 16:15 - 16:30 | LBA37 - Active8: A randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with motolimod immunotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck <u>E. Cohen</u> ¹ , N. Saba ² , B. Gitlitz ³ , R. Haddad ⁴ , A. Sukari ⁵ , P. Neupane ⁶ , J. Morris ⁷ , K. Misiukiewicz ⁸ , K. Manjarrez ⁹ , G. Dietsch ⁹ , J. Bryan ⁹ , R. Hershberg ⁹ , R. Ferris ¹⁰ ; ¹ La Jolla, CA/US, ² Atlanta, GA/US, ³ Los Angeles, CA/US, ⁴ Boston, US, ⁵ Detroit, MI/US, ⁶ Kansas City, KS/US, ⁷ Cincinnati, US, ⁸ New York, NY/US, ⁹ Seattle, WA/US, ¹⁰ Pittsburgh, Pa, US | |
| 16:30 - 16:45 | Invited discussant abstract 1055O and LBA37 <u>C.(. Melief</u> , Leiden, NL | |
| 16:45 - 17:00 | 1047O - Baseline tumor T cell receptor (TcR) sequencing analysis and neo antigen load is associated with benefit in melanoma patients receiving sequential nivolumab and ipilimumab <u>J. Weber</u> ¹ , C. Horak ² , F.S. Hodi ³ , H. Chang ² , D. Woods ⁴ , C. Sanders ⁵ , H. Robins ⁵ , E. Yusko ⁵ ; ¹ New York, Ny, US, ² Princeton, NJ/US, ³ Boston, US, ⁴ New York, Ny, NY/US, ⁵ Seattle, WA/US | |
| 17:00 - 17:15 | 1048O - Ongoing complete remissions in phase 1 of ZUMA-1: A phase 1-2 multi-center study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in patients with refractory aggressive B cell non-Hodgkin lymphoma (NHL) <u>F. Locke</u> ¹ , S. Neelapu ² , N. Bartlett ³ , T. Siddiqi ⁴ , J. Chavez ¹ , C. Hosing ² , A. Cashen ³ , L. Budde ⁴ , M. Sherman ⁵ , J. Rossi ⁵ , L. Navale ⁵ , Y. Jiang ⁵ , J. Aycocock ⁵ , M. Elias ⁵ , J. Wieszorek ⁵ , W. Go ⁵ ; ¹ Tampa, FL/US, ² Houston, TX/US, ³ St. Louis, MO/US, ⁴ Duarte, CA/US, ⁵ Santa Monica, CA/US | |
| 17:15 - 17:30 | Invited discussant abstracts 1047O and 1048O <u>I.-M. Svane</u> , Herlev, DK | |



| | | |
|---------------|--|--------|
| 16:00 - 17:30 | Type: Educational session Title: What is new in liver cancer Chair(s): J. Llovet, US; M. Ducreux, FR | Vienna |
| 16:00 - 16:30 | The biology of liver cancer <u>J. Zucman-Rossi</u> , Paris, FR | |
| 16:30 - 17:00 | Stage-dependent management of HCC and news in systemic treatment <u>J. Llovet</u> , New York, Ny, US | |
| 17:00 - 17:30 | New developments in locoregional treatment <u>J. Ricke</u> , Magdeburg, DE | |



| | | |
|---------------|---|-----------|
| 16:00 - 17:30 | Type: Proffered Paper session Title: Breast cancer, early Chair(s): M. Colleoni, IT; K. Gelmon, CA | Stockholm |
| 16:00 - 16:15 | 145O - Prognostic role for derived neutrophil-to-lymphocyte ratio in early breast cancer <u>A. Ocana Fernandez</u> ¹ , A. Templeton ² , M. Casas ³ , M. Sánchez-Aragó ³ , R. Caballero ³ , A. Rodríguez Lescure ⁴ , A. Ruiz ⁵ , E. Alba ⁶ , L. Calvo ⁷ , M. Ruiz ⁸ , A. Santaballa ⁵ , C. Rodríguez ⁹ , C. Crespo ³ , M. Ramos ⁷ , J.M. Gracia Marco ¹⁰ , A. Lluch-Hernandez ⁵ , I. Alvarez ¹¹ , E. Carrasco ³ , E. Amir ¹² , M. Martin ³ ; ¹ Albacete, ES, ² Basel, CH, ³ Madrid, ES, ⁴ Alicante, ES, ⁵ Valencia, ES, ⁶ Malaga, ES, ⁷ A Coruna, ES, ⁸ Sevilla, ES, ⁹ Salamanca, ES, ¹⁰ Gijon, ES, ¹¹ San Sebastian, ES, ¹² Toronto, ON/CA | |
| 16:15 - 16:30 | 146O - Outcome disparities by age and 21-gene recurrence score® (RS) result in hormone receptor positive (HR+) breast cancer (BC) <u>S. Shak</u> ¹ , D. Miller ¹ , N. Howlander ² , N. Gliner ¹ , W. Howe ³ , N. Schussler ³ , K. Cronin ² , F. Baehner ¹ , L. Penberthy ² , V. Petkov ² ; ¹ Redwood City, CA/US, ² Rockville, MD/US, ³ Calverton, MD/US | |
| 16:30 - 16:45 | Invited discussant abstracts 145O and 146O <u>N. Harbeck</u> , München, DE | |
| 16:45 - 17:00 | LBA13 - Interim results from neoMONARCH: a neoadjuvant phase II study of abemaciclib in postmenopausal women with HR+/HER2- breast cancer (BC) <u>S. Hurvitz</u> ¹ , M.F. Abad ² , R. Rostorfer ³ , D. Chan ⁴ , D. Egle ⁵ , C.-S. Huang ⁶ , S. Barriga ² , T. Costigan ⁷ , C. Caldwell ⁸ , J.M. Schilder ⁸ , M. Press ⁹ , D. Slamon ¹ , M. Martin ² ; ¹ Santa Monica, US, ² Madrid, ES, ³ Orlando, US, ⁴ Redondo Beach, US, ⁵ Innsbruck, AT, ⁶ Taipei, TW, ⁷ Indianapolis, IN/US, ⁸ Indianapolis, US, ⁹ Los Angeles, US | |
| 17:00 - 17:15 | 144O - Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort <u>X. Pivot</u> ¹ , J.-Y. Pierga ² , S. Delaloge ³ , P. Fumoleau ⁴ , H. Bonnefoi ⁵ , T. Bachelot ⁶ , C. Jouannaud ⁷ , H. Bourgeois ⁸ , M. Rios ⁹ , P. Soulie ¹⁰ , J.P. Jacquin ¹¹ , S. Lavau-Denes ¹² , P. Kerbrat ¹³ , C. Faure Mercier ¹⁴ , I. Pauporte ¹⁴ , J. Gligorov ² , E. Curtit ¹⁵ , J. Henriques ¹⁵ , S. Paget-Bailly ¹⁵ , G. Romieu ¹⁶ ; ¹ Besançon, CEDEX/FR, ² Paris, FR, ³ Villejuif, FR, ⁴ Dijon, FR, ⁵ Bordeaux, FR, ⁶ Lyon, FR, ⁷ Reims, FR, ⁸ Le Mans, FR, ⁹ Vandoeuvre Les Nancy, FR, ¹⁰ Angers, FR, ¹¹ Saint Priest En Jarred, FR, ¹² Limoges, FR, ¹³ Rennes, FR, ¹⁴ Boulogne-Billancourt, FR, ¹⁵ Besançon, FR, ¹⁶ Montpellier, FR | |
| 17:15 - 17:30 | Invited discussant LBA13 and abstract 144O <u>M. Colleoni</u> , Milano, IT | |



| | | |
|---------------|--|--------|
| 16:00 - 17:30 | Type: Special Symposium Title: Adapting clinical trials to tumour biology: Shooting at a moving target Chair(s): A. Bardelli, IT; P. Jänne, US | Madrid |
| 16:00 - 16:05 | Introduction <u>P. Jänne</u> , Boston, US | |
| 16:05 - 16:25 | What have we learned from failures? <u>E. Dean</u> , Manchester, GB | |
| 16:25 - 16:45 | Master protocols and basket trials: Have we found the answer? <u>K. Flaherty</u> , Boston, Ma, US | |
| 16:45 - 17:05 | Modulating responses using CtDNA <u>A. Bardelli</u> , Candiolo, IT | |
| 17:05 - 17:25 | New clinical trial design <u>S. Galbraith</u> , Stockport, GB | |
| 17:25 - 17:30 | Conclusions and clinical perspectives <u>A. Bardelli</u> , Candiolo, IT | |
| 16:00 - 17:30 | Type: Educational session Title: Emerging concepts in daily management of urothelial tumours Chair(s): A. Bamias, GR; V. Khoo, GB | Oslo |
| 16:00 - 16:30 | How to select systemic therapy in bladder cancer <u>A. Bamias</u> , Athens, GR | |
| 16:30 - 17:00 | How to interpret genomic reports in the management of urothelial malignancies | |
| 17:00 - 17:30 | Targeted therapies in urothelial malignancies <u>J. Rosenberg</u> , New York, US | |



| | | |
|---------------|---|--------|
| 16:00 - 17:30 | Type: Educational session Title: Optimal treatment of stage III NSCLC Chair(s): J. Vansteenkiste, BE; D. De Ruyscher, NL | Rome |
| 16:00 - 16:30 | Which induction therapy for potentially resectable cases? <u>W. Eberhardt</u> , Essen, DE | |
| 16:30 - 17:00 | Which systemic therapy in concurrent chemoradiotherapy? <u>J. Vansteenkiste</u> , Leuven, BE | |
| 17:00 - 17:30 | Which radiotherapy in concurrent chemoradiotherapy? <u>S. Senan</u> , Amsterdam, NL | |
| 16:00 - 17:30 | Type: Joint Symposium Title: Joint Symposium ESMO-ASCO: Rare Cancers Chair(s): F. Ciardiello, IT; D. Hayes, US | Athens |
| 16:00 - 16:05 | Introduction <u>F. Ciardiello</u> , Napoli, IT | |
| 16:05 - 16:25 | Rare Cancers Europe <u>P. Casali</u> , Milano, IT | |
| 16:25 - 16:45 | The "pediatric" model for rare cancer research organisation <u>G. Vassal</u> , Villejuif, FR | |
| 16:45 - 17:05 | Clinical trials of rare cancers in the North American Cooperative Groups: The SWOG experience <u>A. Schott</u> , Ann Arbor, Mi, US | |
| 17:05 - 17:25 | The Rare Cancer Genetics Registry in North America <u>D. Finkelstein</u> , Boston, Ma, US | |
| 17:25 - 17:30 | Conclusions and clinical perspectives <u>D. Hayes</u> , Ann Arbor, Mi, US | |



16:00 - 17:30 Type: Special Session Helsinki
 Title: Early detection of cachexia, multimodal intervention and results
 Chair(s): K. Jordan, DE; M. Aapro, CH

16:00 - 16:20 The role of nutritional support during radio-/chemotherapy
J. Arends, Freiburg, DE

16:20 - 16:40 New drugs to treat patients with cancer anorexia cachexia syndrome
C. Ripamonti, Milano, IT

16:40 - 17:00 The evidence of physical activity interventions during radio-/chemotherapy
M. Maddocks, London, GB

17:00 - 17:20 Elderly patients: Often malnourished
M. Aapro, Genolier, CH

17:20 - 17:30 General discussion: How to integrate cachexia management in routine cancer care

16:00 - 17:30 Type: Special Session Brussels
 Title: Active Surveillance for low risk prostate cancer. Session proposed by ESO
 Chair(s): A. Horwich, GB; R. Valdagni, IT

16:00 - 16:20 Why do we need Active Surveillance? The problem of overdiagnosis, indolent cancer and overtreatment
M. Roobol, Rotterdam, NL

16:20 - 16:40 What do we mean by Active Surveillance? Definition, criteria for inclusion and management, overview of protocols open for recruitment
C. Bangma, Rotterdam, NL

16:40 - 16:50 What do we need to improve the selection and management? Genetic profiling and serum markers
A. Bjartell, Lund, SE

16:50 - 17:00 What do we need to improve the selection and management? MRI and targeted biopsy
C. Moore, London, GB

17:00 - 17:10 Living with an untreated cancer. The quality of life of men on Active Surveillance
L. Bellardita, Milan, IT

17:10 - 17:30 Discussion



| | | |
|---------------|--|--------|
| 16:00 - 17:30 | Type: Joint Symposium Title: Joint Symposium ESMO Global Policy Committee / AORTIC-SLACOM-UICC-WHO: Innovative strategies for affordability of value-based cancer care Chair(s): A. Eniu, RO; A. Elzawawy, EG | Berlin |
| 16:00 - 16:05 | Introduction <u>A. Elzawawy</u> , Port Said, EG | |
| 16:05 - 16:20 | Core healthcare infrastructure and skills <u>R. Sullivan</u> , London, GB | |
| 16:20 - 16:35 | WHO Essential Medicines List <u>N. Magrini</u> , Geneva, CH | |
| 16:35 - 16:50 | WHO Essential Technologies List <u>A. Velazquez Berumen</u> , Geneva, CH | |
| 16:50 - 17:05 | The realpolitik of reimbursement and pricing: What can be done | |
| 17:05 - 17:20 | Workforce Requirements <u>E. Cazap</u> , Buenos Aires, AR | |
| 17:20 - 17:30 | Conclusions / Questions and Answers <u>A. Eniu</u> , Cluj-Napoca, RO | |



| | | |
|---------------|--|------|
| 16:00 - 17:30 | Type: Proffered Paper session Title: CNS tumours Chair(s): A. Brandes, IT; G. Reifenberger, DE | Bern |
| 16:00 - 16:15 | LBA19_PR - The first study of dabrafenib in pediatric patients with BRAF V600-mutant relapsed or refractory low-grade gliomas <u>M. Kieran</u> ¹ , E. Bouffet ² , U. Tabori ² , A. Broniscer ³ , K. Cohen ⁴ , J. Hansford ⁵ , B. Geoerger ⁶ , P. Hingorani ⁷ , I. Dunkel ⁸ , M. Russo ⁹ , L. Tseng ⁹ , Q. Liu ⁹ , N. Nebot ⁹ , J. Whitlock ² , D. Hargrave ¹⁰ ; ¹ Boston, MA/US, ² Toronto, ON/CA, ³ Memphis, TN/US, ⁴ Baltimore, MD/US, ⁵ Melbourne, VIC/AU, ⁶ Villejuif Cedex, FR, ⁷ Phoenix, AZ/US, ⁸ New York, NY/US, ⁹ East Hanover, NJ/US, ¹⁰ London, GB | |
| 16:15 - 16:30 | 323O - Clinical risk or molecular risk: What matters in low grade gliomas? A study from the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) <u>E. Franceschi</u> ¹ , D. De Biase ¹ , A. Paccapelo ¹ , M. Reni ² , A. Mura ¹ , G. Tallini ¹ , C. Bortolotti ¹ , L. Volpin ³ , G. Marucci ¹ , L. Cirillo ¹ , A. Pession ¹ , C. Ghimenton ⁴ , R. Poggi ¹ , S. Bartolini ¹ , L. Albini Riccioli ¹ , A. Tosoni ¹ , C. Degli Esposti ¹ , D. Danieli ³ , G. Genestreti ¹ , A. Brandes ¹ ; ¹ Bologna, IT, ² Milano, IT, ³ Vicenza, IT, ⁴ Verona, IT | |
| 16:30 - 16:45 | Invited discussant LBA19 and abstract 323O <u>G. Reifenberger</u> , Düsseldorf, DE | |
| 16:45 - 17:00 | 324O - ANG1005, a novel peptide-paclitaxel conjugate crosses the BBB and shows activity in patients with recurrent CNS metastasis from breast cancer, results from a phase II clinical study <u>S.-C. Tang</u> ¹ , P. Kumthekar ² , A. Brenner ³ , S. Kesari ⁴ , D. Piccioni ⁵ , C. Anders ⁶ , J. Carillo ⁷ , P. Chalasani ⁸ , P. Kabos ⁹ , S. Puhalla ¹⁰ , A. Garcia ¹¹ , K. Tkaczuk ¹² , M. Ahluwalia ¹³ , N. Lakhani ¹⁴ , N. Ibrahim ¹⁵ ; ¹ Augusta, GA/US, ² Chicago, IL/US, ³ San Antonio, TX/US, ⁴ Santa Monica, CA/US, ⁵ San Diego, CA/US, ⁶ Chapel Hill, NC/US, ⁷ Orange, CA/US, ⁸ Tucson, AZ/US, ⁹ Aurora, CO/US, ¹⁰ Pittsburgh, PA/US, ¹¹ Los Angeles, US, ¹² Baltimore, US, ¹³ Cleveland, OH/US, ¹⁴ Grand Rapids, US, ¹⁵ Houston, US | |
| 17:00 - 17:15 | 325O - Routine molecular subgrouping of medulloblastoma: Bridging the divide between research and the clinic using low-cost, mass spectrometry-based DNA methylomics <u>E. Schwalbe</u> ¹ , D. Hicks ¹ , G. Rafiee ¹ , M. Bashton ¹ , H. Gohlke ² , A. Enshaei ¹ , S. Potluri ¹ , J. Matthiesen ¹ , M. Mather ¹ , P. Taleongpong ¹ , R. Chaston ¹ , S. Crosier ¹ , A. Smith ¹ , D. Williamson ¹ , S. Bailey ¹ , S. Clifford ¹ ; ¹ Newcastle Upon Tyne, GB, ² Hamburg, DE | |
| 17:15 - 17:30 | Invited discussant abstracts 324O and 325O <u>M. Preusser</u> , Vienna, AT | |



| | | |
|---------------|--|-----------|
| 16:15 - 17:15 | Type: Patient Advocacy Track Title: No time to waste. Patient networks driving research Chair(s): J. Geissler, DE; E. Low, GB | Warsaw |
| 16:15 - 16:30 | Partnerships, Priorities, Pirates and Limes: the story of a patient-focused approach to identifying unanswered research questions <u>K. Oliver</u> , Surrey, GB | |
| 16:30 - 16:45 | Running your own clinical trials: The myeloma clinical trials network <u>E. Low</u> , Edinburgh, GB | |
| 16:45 - 17:00 | Research and drug development for patient groups <u>O. Timmis</u> , London, GB | |
| 17:00 - 17:15 | Re-purposing of drugs <u>P. Pantziarka</u> , Kingston Upon Thames, GB | |
| 17:30 - 18:45 | Type: Patient Advocacy Track Title: Myths and reality: Cancer and pregnancy Chair(s): J. Apperley, GB; G. Sharf, IL | Warsaw |
| 17:30 - 17:40 | Patient's perspective <u>S. Distante</u> , Bishop's Cleeve, GB | |
| 17:40 - 17:55 | Despite cancer: Challenges and public awareness <u>P. Wallroth</u> , Hadfield, GB | |
| 17:55 - 18:10 | Consideration for maintaining fertility during cancer treatment <u>J. Apperley</u> , London, GB | |
| 18:10 - 18:20 | Building the evidence based for saving mother and child: The Pan-Eu pregnancy registry <u>F. Amant</u> , Leuven, BE | |
| 18:20 - 18:30 | A Life saved , a future lost <u>G. Spurrier-Bernard</u> , Clermont-Ferrand, FR | |
| 18:30 - 18:45 | Discussion | |
| 18:00 - 20:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Stockholm |
| 18:00 - 20:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium | Madrid |



| | | |
|---------------|--|----------|
| 18:00 - 20:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Oslo |
| 18:00 - 20:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Rome |
| 18:00 - 20:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Athens |
| 18:00 - 19:30 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Helsinki |
| 18:00 - 20:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium | Brussels |
| 18:00 - 20:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Berlin |
| 18:00 - 20:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Bern |
| 18:00 - 20:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium | Lisbon |
| 18:00 - 20:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium | Zagreb |
| 18:30 - 20:30 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Vienna |

08-10-2016

| | | |
|---------------|--|------------|
| 08:00 - 09:00 | Type: Poster Discussion session Title: Gastrointestinal tumours, non-colorectal | Copenhagen |
| 08:00 - 08:00 | LBA26 - A randomised phase II study of perioperative epirubicin, cisplatin and capecitabine (ECX) ± lapatinib for operable, HER-2 positive gastric, oesophagogastric junctional (OGJ) or lower oesophageal adenocarcinoma: Results from the UK MRC ST03 lapatinib feasibility study (ISRCTN 46020948) <u>E. Smyth</u> ¹ , S. Rowley ² , W. Allum ² , S. Stenning ² , A. Wotherspoon ¹ , C. Robb ² , H. Grabsch ³ , D. Alderson ⁴ , T. Crosby ⁵ , R. Mason ² , M. Griffin ⁶ , W. Mansoor ⁷ , S. Darby ⁸ , M. Seymour ³ , J. Thompson ⁴ , S. Sothi ⁹ , K. Sumpter ⁶ , J. Blazeby ¹⁰ , R. Langley ² , D. Cunningham ¹ ; ¹ Sutton, GB, ² London, GB, ³ Leeds, GB, ⁴ Birmingham, GB, ⁵ Cardiff, GB, ⁶ Newcastle Upon Tyne, GB, ⁷ Manchester, GB, ⁸ Sheffield, GB, ⁹ Coventry, GB, ¹⁰ Bristol, GB | |
| 08:00 - 08:00 | LBA27 - Randomized, open-label, phase III study comparing irinotecan plus S-1 with S-1 alone in patients with advanced esophageal squamous cell carcinoma after failure of prior platinum- or taxane-based chemotherapy: Results of an interim analysis | |



J. Huang¹, Y. Liu², S. Dai³, P. Lu⁴, Y. Ba⁵, L. Wu⁶, Y. Bai⁷, S. Zhang⁸, J. Feng⁹, Y. Cheng¹⁰, J. Li¹¹, L. Wen¹¹, X. Yuan¹², C. Ma¹³, Q. Fan¹⁴, X. Wang¹, B. Xu¹; ¹Beijing, CN, ²Zhangzhou, CN, ³Taizhou, CN, ⁴Xinxiang, CN, ⁵Tianjin, CN, ⁶Changsha, CN, ⁷Herbin, CN, ⁸Jinan, CN, ⁹Nanjing, CN, ¹⁰Changchun, CN, ¹¹Taiyuan, CN, ¹²Wuhan, CN, ¹³Chifeng, CN, ¹⁴Zhengzhou, CN

- 08:00 - 08:00 616PD - Phase III study comparing intraperitoneal paclitaxel plus S-1/paclitaxel with S-1/cisplatin in gastric cancer patients with peritoneal metastasis: PHOENIX-GC trial
Y. Fujiwara¹, H. Ishigami², R. Fukushima², A. Nashimoto³, H. Yabusaki⁴, H. Imamoto⁵, M. Imano⁵, Y. Kodera⁶, Y. Uenosono⁷, K. Amagai⁸, S. Kadowaki⁶, H. Miwa⁹, H. Yamaguchi¹⁰, T. Yamaguchi¹¹, J. Kitayama¹⁰; ¹Osaka, JP, ²Tokyo, JP, ³Gosen, JP, ⁴Niigata, JP, ⁵Osakasayama, JP, ⁶Nagoya, JP, ⁷Kagoshima, JP, ⁸Kasama, JP, ⁹Nishinomiya, JP, ¹⁰Shimotsuke, JP, ¹¹Sendai, JP
- 08:00 - 08:10 Invited discussant abstracts 616PD and two LBAs
E. Van Cutsem, Leuven, BE
- 08:10 - 08:20 Questions to discussant
- 08:20 - 08:20 617PD - Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Prognosis, efficacy, and safety by liver disease etiology
T. Okusaka¹, J.-F. Blanc², I. Chau³, L. Yang⁴, P. Abada⁵, A. Zhu⁶; ¹Tokyo, JP, ²Bordeaux, FR, ³London And Surrey, GB, ⁴Bridgewater, NJ/US, ⁵Indianapolis, IN/US, ⁶Boston, MA/US
- 08:20 - 08:20 LBA28 - Efficacy, safety, and health-related quality of life (HRQoL) of regorafenib in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of the international, double-blind phase 3 RESORCE trial
J. Bruix¹, P. Merle², A. Granito³, Y.-H. Huang⁴, G. Bodoky⁵, O. Yokosuka⁶, O. Rosmorduc⁷, V. Breder⁸, R. Gerolami⁹, G. Masi¹⁰, P. Ross¹¹, S. Qin¹², T. Song¹³, J.-P. Bronowicki¹⁴, I. Ollivier-Hourmand¹⁵, M. Kudo¹⁶, M.-A. Leberre¹⁷, A. Baumhauer¹⁸, G. Meinhardt¹⁹, G. Han²⁰; ¹Barcelona, ES, ²Lyon, FR, ³Bologna, IT, ⁴Taipei, TW, ⁵Budapest, HU, ⁶Chiba, JP, ⁷Paris, FR, ⁸Moscow, RU, ⁹Marseille, FR, ¹⁰Pisa, IT, ¹¹London, GB, ¹²Nanjing, CN, ¹³Tianjin, CN, ¹⁴Nancy, FR, ¹⁵Caen, FR, ¹⁶Osaka, JP, ¹⁷Loos, FR, ¹⁸Leverkusen, DE, ¹⁹Whippany, US, ²⁰Xi'an, CN
- 08:20 - 08:20 618PD - Molecular characteristics of hepatocellular carcinomas (HCC) from different age groups
C. Ang¹, A. Shields², J. Xiu³, Z. Gatalica⁴, S. Reddy⁴, M. Salem⁵, C. Farhangfar⁶, J. Hwang⁷, I. Astsaturov⁸, J. Marshall⁵; ¹New York, NY/US, ²Detroit, US, ³Phoenix, AZ/US, ⁴Phoenix, US, ⁵Washington, DC/US, ⁶Charlotte, NC/US, ⁷Charlotte, US, ⁸Philadelphia, PA/US
- 08:20 - 08:20 619PD - Prognostic factors in curative treatment of gallbladder cancer - Data of 950 cases of "The German- Registry"
S.-E. Al-Batran, T. Goetze; Frankfurt Am Main, DE
- 08:20 - 08:30 Invited discussant abstracts 617PD, 618PD, 619PD and one LBA



- 08:30 - 08:40 Questions to discussant
- 08:40 - 08:40 620PD - Comparative molecular analyses of pancreatic cancer (PC): Younger vs. older patients (pts)
M. Salem¹, P. Philip², R. Feldman³, J. Hwang⁴, M. Pishvaian¹, J. Xiu³, W. Eldeiry⁵, S. Reddy⁶, Z. Gatalica⁶, N. Trivedi¹, A. Zareb⁷, B.S. Colton¹, H. Wang¹, A. Shields², J. Marshall¹; ¹Washington, DC/US, ²Detroit, US, ³Phoenix, AZ/US, ⁴Charlotte, US, ⁵Philadelphia, US, ⁶Phoenix, US, ⁷Dammam, SA
- 08:40 - 08:40 621PD - Randomized phase II study of S-1 and concurrent radiotherapy with versus without induction chemotherapy of gemcitabine for locally advanced pancreatic cancer (LAPC): Final analysis of JCOG1106
T. Ioka¹, A. Fukutomi², J. Mizusawa³, H. Katayama³, S. Nakamura¹, Y. Ito³, N. Hiraoka³, M. Ueno⁴, M. Ikeda⁵, K. Sugimori⁴, K. Shimizu³, T. Okusaka³, M. Ozaka³, H. Yanagimoto⁶, S. Nakamori¹, T. Azuma⁷, A. Hosokawa⁸, N. Sata⁹, T. Mine¹⁰, J. Furuse³; ¹Osaka, JP, ²Shizuoka, JP, ³Tokyo, JP, ⁴Yokohama, JP, ⁵Kashiwa, JP, ⁶Hirakata, JP, ⁷Kobe, JP, ⁸Toyama, JP, ⁹Shimotsuke, JP, ¹⁰Isehara, JP
- 08:40 - 08:40 622PD - Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
L.-T. Chen¹, A. Wang-Gillam², C.-P. Li³, G. Bodoky⁴, A. Dean⁵, Y.-S. Shan¹, G. Jameson⁶, T. Macarulla⁷, K.-H. Lee⁸, D. Cunningham⁹, J.-F. Blanc¹⁰, R. Hubner¹¹, C.-F. Chiu¹², G. Schwartzmann¹³, F. Braiteh¹⁴, B. Belanger¹⁵, E. Bayever¹⁵, F. de Jong¹⁶, D. von Hoff⁶, J. Siveke¹⁷; ¹Tainan, TW, ²St. Louis, US, ³Taipei, TW, ⁴Budapest, HU, ⁵Subiaco, AU, ⁶Phoenix, US, ⁷Barcelona, ES, ⁸Seoul, KR, ⁹London, GB, ¹⁰Bordeaux, FR, ¹¹Manchester, GB, ¹²Taichung, TW, ¹³Porto Alegre, BR, ¹⁴Las Vegas, NV/US, ¹⁵Cambridge, US, ¹⁶Zürich, CH, ¹⁷Essen, DE
- 08:40 - 08:50 Invited discussant abstracts 620PD, 621PD and 622PD
E. Diaz Rubio, Madrid, ES
- 08:50 - 09:00 Questions to discussant

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Brussels
Title: Minimising the complications of ADT and bone disease in prostate cancer

08:00 - 08:30 Minimising the complications of ADT and bone disease in prostate cancer
M. Smith, Boston, Ma, US

08:30 - 09:00 Discussion



08:00 - 09:00 Type: Challenge Your Expert (CYE) session Berlin
Title: Fragile patients with non-metastatic lung cancer: Facts and myths

08:00 - 08:30 Fragile patients with non-metastatic lung cancer: Facts and myths
J. van Loon, Maastricht, NL

08:30 - 09:00 Discussion

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Bern
Title: Neurotoxicities assessment, prophylaxis and treatment
Chair(s): M. Fallon, GB

08:00 - 08:30 Neurotoxicities assessment, prophylaxis and treatment
L. Eckhoff, Odense C, DK

08:30 - 09:00 Discussion

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Lisbon
Title: Primary and secondary resistance to targeted therapy and immunotherapy

08:00 - 08:30 Primary and secondary resistance to targeted therapy and immunotherapy
J. Engelman, Boston, Ma, US

08:30 - 09:00 Discussion

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Zagreb
Title: The revolution of molecular diagnosis in anaplastic gliomas

08:00 - 08:30 The revolution of molecular diagnosis in anaplastic gliomas
W. Wick, Heidelberg, DE

08:30 - 09:00 Discussion



| | | |
|---------------|--|------|
| 08:15 - 09:15 | Type: Controversy session Title: The current way to measure PDL-1 biomarkers will not stand the test of time Chair(s): T. Powles, GB | Rome |
| 08:15 - 08:25 | Introduction and first vote <u>T. Powles</u> , Albany, LA/US | |
| 08:25 - 08:45 | Yes | |
| 08:45 - 09:05 | No <u>K. Kerr</u> , Aberdeen, GB | |
| 09:05 - 09:15 | Second vote and conclusions <u>T. Powles</u> , Albany, LA/US | |



| | | |
|---------------|--|------------|
| 09:15 - 10:45 | Type: Proffered Paper session Title: Gastrointestinal tumours, non-colorectal 1 Chair(s): F. Lordick, DE; P. Pfeiffer, DK | Copenhagen |
| 09:15 - 09:27 | 6090 - Is centralization needed for esophago-gastric cancer patients with low operative risk? A nationwide study <u>C. Gronnier</u> ¹ , A. Pasquer ¹ , F. Renaud ¹ , F. Hec ¹ , A. Gandon ¹ , M. Vanderbeken ¹ , V. Drubay ¹ , G. Caranhac ² , G. Piessen ¹ , C. Mariette ¹ ; ¹ Lille, FR, ² Paris, FR | |
| 09:27 - 09:39 | 6100 - An AGITG trial –A randomised phase II study of pre-operative cisplatin, fluorouracil and DOCetaxel +/-radioTherapy based on poOR early response to cisplatin and fluorouracil for resectable esophageal adenocarcinoma <u>A. Barbour</u> ¹ , E. Walpole ¹ , G.T. Mai ¹ , H. Chan ² , E. Barnes ² , D. Watson ³ , S. Ackland ⁴ , V. Wills ⁴ , J. Martin ⁴ , M. Burge ⁵ , C. Karapetis ³ , J. Shannon ⁶ , L. Nott ⁷ , V. GebSKI ² , K. Wilson ⁸ , J. Thomas ¹ , G. Lampe ¹ , J. Zalberg ⁹ , J. Simes ¹⁰ , M. Smithers ¹ ; ¹ Brisbane, AU, ² Sydney, AU, ³ Bedford Park, AU, ⁴ Newcastle, AU, ⁵ Herston, AU, ⁶ Kingswood, AU, ⁷ Hobart, Tasmania 7008, AU, ⁸ Camperdown, NSW/AU, ⁹ Melbourne, AU, ¹⁰ Sydney, NSW/AU | |
| 09:39 - 09:51 | 6110 - A phase III clinical trial of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus <u>H. Yang</u> ¹ , J. Fu ¹ , M. Liu ¹ , Y. Chen ² , Z. Chen ² , C. Zhu ³ , H. Yang ³ , W. Fang ⁴ , J. Wang ⁴ , Z. Yu ⁵ , Q. Pang ⁵ , W. Mao ⁶ , X. Zheng ⁶ , J. Xiang ⁴ , H. Yang ⁴ , Y. Han ⁷ ; ¹ Guangzhou, CN, ² Shantou, CN, ³ Taizhou, CN, ⁴ Shanghai, CN, ⁵ Tianjin, CN, ⁶ Hangzhou, CN, ⁷ Chengdu, CN | |
| 09:51 - 10:06 | Invited discussant abstracts 6090, 6100 and 6110 <u>F. Lordick</u> , Leipzig, DE | |
| 10:06 - 10:18 | One LBA TBC | |
| 10:18 - 10:30 | LBA25 - Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy: Phase III GOLD study <u>Y.-J. Bang</u> ¹ , N. Boku ² , K. Chin ² , K.-W. Lee ³ , S.H. Park ¹ , S. Qin ⁴ , S.Y. Rha ¹ , L. Shen ⁵ , N. Xu ⁶ , S.-A. Im ¹ , G. Locker ⁷ , P. Rowe ⁸ , X. Shi ⁹ , D. Hodgson ⁸ , Y.-Z. Liu ⁸ , R. Xu ¹⁰ ; ¹ Seoul, KR, ² Tokyo, JP, ³ Seongnam, KR, ⁴ Nanjing, CN, ⁵ Beijing, CN, ⁶ Hangzhou, CN, ⁷ Gaithersburg, MD/US, ⁸ Macclesfield, GB, ⁹ Shanghai, CN, ¹⁰ Guangzhou, CN | |
| 10:30 - 10:45 | Invited discussant LBA25 and one LBA <u>Y. Janjigian</u> , New York, US | |



| | | |
|---------------|--|-----------|
| 09:15 - 10:45 | Type: Special Symposium Title: Lung cancer early detection and prevention Chair(s): J.H. Pedersen, DK; S. Janes, GB | Vienna |
| 09:15 - 09:20 | Introduction <u>S. Janes</u> , London , GB | |
| 09:20 - 09:40 | The NELSON trial <u>H. De Koning</u> , Rotterdam, NL | |
| 09:40 - 10:00 | How to implement the NELSON trial <u>S. Janes</u> , London , GB | |
| 10:00 - 10:20 | Defining risk populations for CT screening <u>J.H. Pedersen</u> , Copenhagen, DK | |
| 10:20 - 10:40 | Smoking cessation <u>H. Ashraf</u> , Lørenskog , NO | |
| 10:40 - 10:45 | Conclusions and clinical perspectives <u>J.H. Pedersen</u> , Copenhagen, DK | |
| 09:15 - 10:45 | Type: Educational session Title: The neoadjuvant approach in the multidisciplinary setting Chair(s): M. Colleoni, IT; S. Loibl, DE | Stockholm |
| 09:15 - 09:45 | Systemic neoadjuvant treatment <u>S. Loibl</u> , Neu-Isenburg, DE | |
| 09:45 - 10:15 | Surgical challenges after neoadjuvant therapy <u>I. Rubio</u> , Barcelona, ES | |
| 10:15 - 10:45 | The impact of tumour stage and response on radiotherapy indications <u>J. Bernier</u> , Genolier, CH | |



| | | |
|---------------|---|--------|
| 09:15 - 10:30 | Type: Proffered Paper session Title: Genitourinary tumours, non-prostate | Madrid |
| 09:15 - 09:30 | LBA30_PR - CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial <u>T. Choueiri</u> ¹ , S. Halabi ² , B. Sanford ² , O. Hahn ³ , M.D. Michaelson ⁴ , M. Walsh ¹ , T. Olencki ⁵ , J. Picus ⁶ , E. Small ⁷ , S. Dakhil ⁸ , D. George ² , M. Morris ⁹ ; ¹ Boston, US, ² Durham, US, ³ Chicago, US, ⁴ Boston, MA/US, ⁵ Columbus, OH/US, ⁶ St Louis, US, ⁷ San Francisco, CA/US, ⁸ Wichita, KS/US, ⁹ New York, US | |
| 09:30 - 09:45 | Invited discussant LBA30 | |
| 09:45 - 10:00 | LBA31_PR - Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study <u>M. Galsky</u> ¹ , M. Retz ² , A. Siefker-Radtke ³ , A. Baron ⁴ , A. Necchi ⁵ , J. Bedke ⁶ , E. Plimack ⁷ , D. Vaena ⁸ , M.-O. Grimm ⁹ , S. Bracarda ¹⁰ , J. Arranz Arijia ¹¹ , S. Pal ¹² , C. Ohyama ¹³ , A. Saci ¹⁴ , A. Lambert ¹⁵ , S. Krishnan ¹⁵ , A. Azrilevich ¹⁵ , P. Sharma ³ ; ¹ New York, US, ² München, DE, ³ Houston, TX/US, ⁴ San Francisco, CA/US, ⁵ Milan, IT, ⁶ Tübingen, DE, ⁷ Philadelphia, US, ⁸ Iowa City, IA/US, ⁹ Jena, DE, ¹⁰ Arezzo, IT, ¹¹ Madrid, ES, ¹² Duarte, US, ¹³ Hirosaki, JP, ¹⁴ Lawrenceville, NJ/US, ¹⁵ Princeton, NJ/US | |
| 10:00 - 10:15 | LBA32_PR - Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study <u>A. Balar</u> ¹ , J. Bellmunt ² , P. O'Donnell ³ , D. Castellano ⁴ , P. Grivas ⁵ , J. Vuky ⁶ , T. Powles ⁷ , E. Plimack ⁸ , N. Hahn ⁹ , R. de Wit ¹⁰ , L. Pang ¹¹ , M. Savage ¹¹ , R. Perini ¹² , S. Keefe ¹¹ , D. Bajorin ¹ ; ¹ New York, NY/US, ² Boston, US, ³ Chicago, US, ⁴ Madrid, ES, ⁵ Cleveland, OH/US, ⁶ Portland, OR/US, ⁷ London, GB, ⁸ Philadelphia, US, ⁹ Indianapolis, IN/US, ¹⁰ Rotterdam, NL, ¹¹ Kenilworth, NJ/US, ¹² North Wales, PA/US | |
| 10:15 - 10:30 | Invited discussant LBA31 and LBA32 | |



| | | |
|---------------|--|----------|
| 09:15 - 10:45 | Type: Special Symposium Title: Whither immunotherapy? Chair(s): I. Melero, ES | Oslo |
| 09:15 - 09:20 | Introduction <u>I. Melero</u> , Pamplona, ES | |
| 09:20 - 09:40 | Tumour landscape: Clues for new targets <u>J. Galon</u> , Paris, FR | |
| 09:40 - 10:00 | Converting a non-immunogenic into an immunogenic tumour <u>J. Luke</u> , Chicago, IL/US | |
| 10:00 - 10:20 | Inflamed phenotype and immunotherapy: The H&N case <u>T. Seiwert</u> , Chicago, IL, US | |
| 10:20 - 10:40 | Combining immunotherapy: (ir)rational choices <u>J. Larkin</u> , London, GB | |
| 10:40 - 10:45 | Conclusions and clinical perspectives | |
| 09:15 - 10:45 | Type: Special Session Title: Will we ever conquer resistance? Chair(s): J. Seoane, ES; D. Peeper, NL | Helsinki |
| 09:15 - 09:20 | Introduction <u>D. Peeper</u> , Amsterdam, NL | |
| 09:20 - 09:40 | Tumour evolution under the selective pressure of treatment <u>C. Swanton</u> , London, GB | |
| 09:40 - 10:00 | Mechanisms of resistance mediated by the tumour stroma <u>E. Sahai</u> , London, GB | |
| 10:00 - 10:20 | New approaches to BRAF resistant disease <u>R. Marais</u> , Manchester, GB | |
| 10:20 - 10:40 | What can we learn from single patients? <u>D. Peeper</u> , Amsterdam, NL | |
| 10:40 - 10:45 | Conclusions and clinical perspectives | |



| | | |
|---------------|---|--------|
| 09:15 - 10:45 | Type: Special Session Title: Accessing innovative treatments in Europe: Managed entry/ risk sharing schemes for pharmaceuticals Chair(s): B. Ryll, SE; P. Kanavos, GB | Zagreb |
| 09:15 - 09:30 | Introduction to Managed Entry Schemes <u>P. Kanavos</u> , London, GB | |
| 09:30 - 09:45 | The Early Access to Medicines Scheme (EAMS) in the UK <u>D. O'Connor</u> , London, GB | |
| 09:45 - 10:00 | The Italian Pay-for-Performance Scheme <u>P. Foggi</u> , Roma, IT | |
| 10:00 - 10:15 | The Dutch experience: DMTR <u>M. Wouters</u> , Leiden, NL | |
| 10:15 - 10:30 | Patient advocacy involvement <u>V. Astratinei</u> , Almere , NL | |
| 10:30 - 10:45 | Discussion: How to get involved <u>B. Ryll</u> , Uppsala, SE | |
| 09:30 - 10:30 | Type: Controversy session Title: Early termination of drugs in oncology: Are we throwing the baby out with the bathwater? Chair(s): J.-P. Armand, FR | Rome |
| 09:30 - 09:40 | Introduction and first vote <u>J.-P. Armand</u> , Villejuif, FR | |
| 09:40 - 10:00 | Yes <u>U. Banerji</u> , Sutton, GB | |
| 10:00 - 10:20 | No <u>C.-C. Lin</u> , Taipei, TW | |
| 10:20 - 10:30 | Second vote and conclusions <u>J.-P. Armand</u> , Villejuif, FR | |



| | | |
|---------------|--|----------|
| 09:30 - 10:30 | Type: Multidisciplinary patient cases Title: Pulmonary NETs Chair(s): J. Yao, US | Athens |
| 09:30 - 09:40 | The grey zone in between intermediate and high grade NENs: A particular case <u>G. Rindi</u> , Roma, IT | |
| 09:40 - 09:50 | The minimal surgical approach for lung carcinoids: Pros and cons <u>M. Garcia-Yuste</u> , Valladolid, ES | |
| 09:50 - 10:00 | The evolving landscape of systemic therapy for well differentiated neuroendocrine tumours of the lung <u>J. Yao</u> , Houston, US | |
| 10:00 - 10:30 | Discussion | |
| 09:30 - 10:30 | Type: Poster Discussion session Title: Supportive and palliative care Chair(s): B. Rapoport, ZA | Brussels |
| 09:30 - 09:30 | 1301PD - Characteristics and level of integration of ESMO Designated Centres of integrated oncology and palliative care <u>D. Hui</u> ¹ , N. Cherny ² , N. Latino ³ , F. Strasser ⁴ ; ¹ Houston, US, ² Jerusalem, IL, ³ Lugano, CH, ⁴ St. Gallen, CH | |
| 09:30 - 09:30 | 1349PD - Unsung heroes of lung cancer: Perspectives from caregivers in the lung cancer Canada survey <u>M. Doherty</u> ¹ , C. Sit ² , N. Leigh ³ , P. Wheatley-Price ⁴ ; ¹ Dublin, IE, ² Toronto, ON/CA, ³ Toronto, CA, ⁴ Ottawa, ON/CA | |
| 09:30 - 09:30 | 1350PD - Psychological discomfort among operatives in oncology: Can burn-out be considered the main issue? <u>M. Romeo</u> , R. Giampieri, T. Meletani, S. Formentini, M. De Lisa, M.G. Baleani, R. Berardi; Ancona, IT | |
| 09:30 - 09:30 | LBA49 - Evaluation of effects of early palliative care on quality of life of advanced cancer patients. A multicenter controlled randomised clinical trial <u>V. Franciosi</u> ¹ , G. Caruso ¹ , G. Maglietta ¹ , C. Degli Esposti ² , L. Cavanna ³ , R. Bertè ³ , G. Bacchini ¹ , L. Bocchi ¹ , E. Piva ⁴ , M. Monfredo ³ , V. Scafuri ⁴ , P. Di Cesare ³ , B. Melotti ² , M. Sequino ¹ , A. Rimanti ¹ , C. Binovi ¹ , F. Ghisoni ⁵ , C. Caminiti ¹ ; ¹ Parma, IT, ² Bologna, IT, ³ Piacenza, IT, ⁴ Ferrara, IT, ⁵ Fidenza, IT | |
| 09:30 - 09:50 | Invited discussant abstracts 1301PD, 1349PD, 1350PD and LBA49 | |
| 09:50 - 10:00 | Questions to discussant | |



- 10:00 - 10:00 1436PD - Risk of serious adverse events (SAEs) and fatal adverse events (FAEs) with sorafenib use in patients with solid cancers: A meta-analysis of phase 3 RCTs
B. Gyawali, T. Shimokata, K. Honda, Y. Ando; Nagoya, JP
- 10:00 - 10:00 1437PD - Pooled analysis of treatment-related hypothyroidism with anti-PD-1/PD-L1 therapies in cancer patients
S. Hong, W. Fang, L. Zhang; Guangzhou, CN
- 10:00 - 10:00 1438PD - Identifying cancer patients at high risk for chemotherapy-induced nausea and vomiting (CINV): The development of a prediction tool
G. Dranitsaris¹, A. Molasiotis², M. Clemons³, E. Roeland⁴, L. Schwartzberg⁵, D. Warr⁶, K. Jordan⁷, P. Dielenseger⁸, M. Aapro⁹; ¹Toronto, ON/CA, ²Hong Kong, HK, ³Ottawa, CA, ⁴La Jolla, CA/US, ⁵Memphis, TN/US, ⁶Toronto, CA, ⁷Halle, DE, ⁸Villejuif, FR, ⁹Genolier, CH
- 10:00 - 10:00 1439PD - Impact of art therapy (AT) on fatigue and quality of life (QoL) during adjuvant external beam irradiation (EBI) in breast cancer patients (pts): A randomized trial
F. Joly¹, D. Pasquier², C. Hanzen³, N. Heutte¹, C. Levy¹, F. Le Tinier², M. Mousseau⁴, C. Ciais⁵, C. Murariu⁶, M.-C. D'almeida¹, V. Szymczak², C. Leon³, S. Darbas⁴, M.-P. Rousselot⁵, S. Mineur⁶, C. Rieux¹, A. Leconte¹, O. Rigal³, B. Clarisse¹, D. Allouache¹; ¹Caen, FR, ²Lille, FR, ³Rouen, FR, ⁴Grenoble, FR, ⁵Nice, FR, ⁶Reims, FR
- 10:00 - 10:00 LBA50 - Influence of concomitant clopidogrel consumption on development of paclitaxel-associated toxicity: A pharmacoepidemiological study
K. Agergaard¹, M. Mau-Sørensen², T. Stage¹, T. Jørgensen¹, R. Hassel³, K. Steffensen⁴, J. Pedersen⁵, M.L. Milo⁶, S. Poulsen², A. Pottgård¹, J. Hallas¹, K. Brøsen¹, T. Bergmann¹; ¹Odense C, DK, ²Copenhagen, DK, ³Aarhus C, DK, ⁴Vejle, DK, ⁵Herlev, DK, ⁶Aalborg, DK
- 10:00 - 10:20 Invited discussant abstracts 1436PD, 1437PD, 1438PD, 1439PD and LBA50
B. Rapoport, Sandton, ZA
- 10:20 - 10:30 Questions to discussant

09:30 - 10:30 Type: Challenge Your Expert (CYE) session Berlin
 Title: Challenges in bone sarcoma

09:30 - 10:00 Challenges in bone sarcoma
S. Bielack, Stuttgart, DE

10:00 - 10:30 Discussion

09:30 - 10:30 Type: Poster Discussion session Bern
 Title: Gynaecological cancers



Chair(s): I. Vergote, BE; F. Joly, FR

- 09:30 - 09:30 LBA34 - A novel oncologist-led BRCA1/2 germline mutation (gBRCAm) testing and counselling model for patients with ovarian cancer: Interim results from the ENGAGE (NCT02406235) study
G. Scambia¹, E. Chalas², G. Huang³, B. Graña Suárez⁴, S. González-Santiago⁵, N. Colombo⁶, S. Pignata⁷, P. Huot-Marchand⁸, S. Karve⁹, C. Blakeley¹⁰; ¹Roma, IT, ²Mineola, NY/US, ³Bronx, NY/US, ⁴A Coruna, ES, ⁵Cáceres, ES, ⁶Milano, IT, ⁷Napoli, IT, ⁸Lyon, FR, ⁹Gaithersburg, MD/US, ¹⁰Cambridge, GB
- 09:30 - 09:30 857PD - The predictive value of the CA-125 modeled kinetic parameter KELIM is validated in 3 independent datasets (AGO-OVAR 7 & 9; ICON 7 AGO/GINECO/GCIG trials)
B.M. You¹, O. Colombar², M. Tod¹, I. Ray-Coquard¹, A. Lortholary³, A.C. Hardy-Bessard⁴, A. Du Bois⁵, J. Huober⁶, W. Meier⁷, C. Kurzeder⁵, J. Pfisterer⁸; ¹Lyon, FR, ²Pierre Bénite, FR, ³Nantes, FR, ⁴PIÉrin, FR, ⁵Essen, DE, ⁶Ulm, DE, ⁷Düsseldorf, DE, ⁸Kiel, DE
- 09:30 - 09:30 858PD - A DGOG open-label multicenter phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer
L.E. Boom¹, P.B. Ottevanger², A. Reyners³, J.R. Kroep⁴, P. Witteveen⁵, R. Lalisang⁶, A. Westermann¹; ¹Amsterdam, NL, ²Nijmegen, NL, ³Groningen, NL, ⁴Leiden, NL, ⁵Utrecht, NL, ⁶Maastricht, NL
- 09:30 - 09:50 Invited discussant 857PD. 858PD and LBA34
F. Joly, Caen, FR
- 09:50 - 10:00 Questions to discussant
- 10:00 - 10:00 LBA35 - A phase 1 study of PF-06647020, an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients with advanced solid tumors including platinum resistant ovarian cancer (OVCA)
J. Sachdev¹, M. Maitland², M. Sharma², V. Moreno³, V. Boni³, S. Kummar⁴, B. Gibson⁵, D. Xuan⁵, T. Joh⁵, E. Powell⁵, A. Jackson-Fisher⁵, M. Damelin⁵, X. Xin⁵, A. Tolcher⁶, E. Calvo³; ¹Scottsdale, AZ/US, ²Chicago, IL/US, ³Madrid, ES, ⁴Palo Alto, CA/US, ⁵San Diego, CA/US, ⁶San Antonio, US
- 10:00 - 10:00 859PD - The CHIVA study: A GINECO randomized double blind phase II trial of nintedanib versus placebo with the neo-adjuvant chemotherapy (NACT) strategy for patients (pts) with advanced unresectable ovarian cancer (OC). Report of the interval debulking surgery (IDS) safety outcome
G. Ferron¹, G. De Rauglaudre², I. Ray-Coquard³, A. Lesoin⁴, F. Joly⁵, A. Lortholary⁶, N. Raban⁷, J. Peron⁸, E. Malariaie-Agostini⁹, S. Gouy¹⁰, M.-C. Kaminsky¹¹, J. Meunier¹², J. Alexandre¹³, D. Berton-Rigaud¹⁴, F. Coussy¹⁵, L. Favier¹⁶, L. Venat-Bouvet¹⁷, F. Marmion¹³, P. Combe¹³, E. Pujade-Lauraine¹³; ¹Toulouse, FR, ²Avignon, FR, ³Lyon, FR, ⁴Lille, FR, ⁵Caen, FR, ⁶Nantes, FR, ⁷Poitiers, FR, ⁸Pierre Bénite, FR, ⁹Créteil, FR, ¹⁰Villejuif, FR, ¹¹Vandoeuvre Les Nancy, FR, ¹²Orleans, FR, ¹³Paris, FR, ¹⁴St. Herblain, FR, ¹⁵Saint-Cloud, FR, ¹⁶Dijon, FR, ¹⁷Limoges, FR
- 10:00 - 10:00 860PD - Complete resection rate at interval debulking surgery after bevacizumab containing neoadjuvant therapy: Primary objective of the ANTHALYA trial



R. Rouzier¹, S. Gouy², F. Selle¹, E. Lambaudie³, F. Guyon⁴, V. Fourchette⁴, C. Pomel⁵, P.-E. Colombo⁶, E. Kalbacher⁷, S. Martin-Francoise⁸, R. Fauvet⁹, P. Follana¹⁰, A. Lesoin¹¹, F. Lecuru¹, Y. Ghazi¹², J. Dupin¹², E. Chereau³, S. Zohar¹, P. Cottu¹, F. Joly⁸; ¹Paris, FR, ²Villejuif, FR, ³Marseille, FR, ⁴Bordeaux, FR, ⁵Clermont-Ferrand, FR, ⁶Montpellier, FR, ⁷Besançon, FR, ⁸Caen, FR, ⁹Amiens, FR, ¹⁰Nice, FR, ¹¹Lille, FR, ¹²Boulogne-Billancourt, FR

10:00 - 10:20 Invited discussant abstracts 859PD, 860PD and LBA35
I. Vergote, Leuven, BE

10:20 - 10:30 Questions to discussant

09:30 - 10:30 Type: Special Session Amsterdam
Title: Practising Oncologists "How I treat" session: Managing side effects and treatment related to advanced colorectal cancer
Chair(s): D. Arnold, DE

09:30 - 09:35 Introduction
S. Rauh, Esch-Sur-alzette, LU

09:35 - 09:55 Managing treatment side effects in advanced colorectal cancer
D. Arnold, Freiburg, DE

09:55 - 10:30 Discussion
D. Arnold¹, S. Rauh²; ¹Freiburg, DE, ²Esch-Sur-alzette, LU



| | | |
|---------------|--|------------|
| 11:00 - 12:30 | Type: Special Symposium Title: A molecular profile in NSCLC patients: How? When? Why? Chair(s): F. Blackhall, GB; F. Barlesi, FR | Copenhagen |
| 11:00 - 11:05 | Introduction <u>F. Blackhall</u> , Manchester, GB | |
| 11:05 - 11:25 | Molecular profiling for precision lung cancer <u>R. Thomas</u> , Cologne, DE | |
| 11:25 - 11:45 | Organisation: Local, regional and national <u>F. Barlesi</u> , Marseille, FR | |
| 11:45 - 12:05 | Clinical application of serial molecular biomarker monitoring <u>S. Finn</u> , Dublin, IE | |
| 12:05 - 12:25 | Getting the right drug to the right patient based upon molecular profiling <u>J.-C. Soria</u> , Villejuif, FR | |
| 12:25 - 12:30 | Conclusions and clinical perspectives <u>F. Barlesi</u> , Marseille, FR | |



| | | |
|---------------|---|--------|
| 11:00 - 12:30 | Type: Proffered Paper session Title: Breast cancer, metastatic Chair(s): R. Coleman, GB; J. Cortes, ES | Vienna |
| 11:00 - 11:15 | LBA14_PR - FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer M. Ellis ¹ , I. Bondarenko ² , E. Trishkina ³ , M. Dvorkin ⁴ , L. Panasci ⁵ , A. Manikhas ⁶ , Y. Shparyk ⁷ , S. Cardona-Huerta ⁸ , K.-L. Cheung ⁹ , M. Philco-Salas ¹⁰ , M. Ruiz-Borrego ¹¹ , Z. Shao ¹² , S. Noguchi ¹³ , L. Grinsted ¹⁴ , M. Fazal ¹⁵ , M. Stuart ¹⁶ , J. Robertson ⁹ ; ¹ Houston, US, ² Dnepropetrovsk, UA, ³ St-Petersburg, RU, ⁴ Omsk, RU, ⁵ Montreal, CA, ⁶ St. Petersburg, RU, ⁷ Lviv, UA, ⁸ Monterrey, MX, ⁹ Nottingham, GB, ¹⁰ Lima, PE, ¹¹ Sevilla, ES, ¹² Shanghai, CN, ¹³ Osaka, JP, ¹⁴ Cambridge, GB, ¹⁵ Gaithersburg, MD/US, ¹⁶ Macclesfield, GB | |
| 11:15 - 11:30 | LBA15 - Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER+/HER2- advanced breast cancer (ABC) R. Finn ¹ , Y. Jiang ² , H. Rugo ³ , S. Moulder ⁴ , S.-A. Im ⁵ , K. Gelmon ⁶ , V. Dieras ⁷ , M. Martin ⁸ , A.A. Joy ⁹ , M. Toi ¹⁰ , E. Gauthier ² , D.R. Lu ² , C. Bartlett ¹¹ , D. Slamon ¹² ; ¹ Los Angeles, CA/US, ² La Jolla, CA/US, ³ San Francisco, CA/US, ⁴ Houston, TX/US, ⁵ Seoul, KR, ⁶ Vancouver, CA, ⁷ Paris, FR, ⁸ Madrid, ES, ⁹ Edmonton, CA, ¹⁰ Kyoto, JP, ¹¹ New York, NY/US, ¹² Santa Monica, US | |
| 11:30 - 11:45 | Invited discussant LBA14 and LBA15 P. Schmid, London, GB | |
| 11:45 - 12:00 | 2220 - BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) M. Royce ¹ , C. Villanueva ² , M. Ozguroglu ³ , T. Bachelot ⁴ , S. Azevedo ⁵ , F. Melo Cruz ⁶ , R. Hegg ⁶ , M. Debled ⁷ , W. Gradishar ⁸ , C. Manlius ⁹ , A. Ridolfi ¹⁰ , J. Lin ¹¹ , F. Ringeisen ⁹ , F. Cardoso ¹² ; ¹ Albuquerque, NM/US, ² Besançon, FR, ³ Istanbul, TR, ⁴ Lyon, FR, ⁵ Porto Alegre, BR, ⁶ Sao Paulo, BR, ⁷ Bordeaux, FR, ⁸ Chicago, IL/US, ⁹ Basel, CH, ¹⁰ Rueil-Malmaison, FR, ¹¹ East Hanover, NJ/US, ¹² Lisboa, PT | |
| 12:00 - 12:15 | 2230 - Anti-tumor activity of PM01183 (lurbinectedin) in BRCA1/2-associated metastatic breast cancer patients: Results of a single-agent phase II trial J. Balmaña ¹ , C. Cruz ¹ , B. Arun ² , M. Telli ³ , J. Garber ⁴ , S. Domchek ⁵ , C. Fernandez ⁶ , C. Kahatt ⁷ , S. Szyldergemajn ⁷ , A. Soto-Matos ⁷ , A. Perez de la Haza ⁷ , J. Perez Fidalgo ⁸ , A. Lluch-Hernandez ⁸ , S. Antolin ⁹ , N. Tung ⁴ , L. Vahdat ¹⁰ , R. Lopez ¹¹ , S.J. Isakoff ⁴ ; ¹ Barcelona, ES, ² Houston, TX/US, ³ Stanford, CA/US, ⁴ Boston, MA/US, ⁵ Philadelphia, PA/US, ⁶ Colmenar Viejo, España/ES, ⁷ Colmenar Viejo, ES, ⁸ Valencia, ES, ⁹ A Coruna, ES, ¹⁰ New York, NY/US, ¹¹ Santiago De Compostela, ES | |
| 12:15 - 12:30 | Invited discussant abstracts 2220 and 2230 J. Cortes, Madrid, ES | |



| | | |
|---------------|--|-----------|
| 11:00 - 12:30 | Type: Special Symposium Title: Genetics and epigenetics of gastric cancer: What clinicians should know Chair(s): F. Carneiro, PT; A. Hillmer, SG | Stockholm |
| 11:00 - 11:05 | Introduction <u>A. Hillmer</u> , SG | |
| 11:05 - 11:25 | How to detect and manage familial and hereditary gastric cancer <u>F. Carneiro</u> , Porto, PT | |
| 11:25 - 11:45 | Genetics of gastric cancer: Clinical implications <u>I. Chau</u> , Sutton, GB | |
| 11:45 - 12:05 | DNA methylation and epigenetic changes in gastric cancer: From bench to bedside <u>T. Ushijima</u> , Tokyo, JP | |
| 12:05 - 12:25 | As a clinician, what do I make of this information? <u>P. Pfeiffer</u> , Odense C, DK | |
| 12:25 - 12:30 | Conclusion <u>F. Carneiro</u> , Porto, PT | |



| | | |
|---------------|---|--------|
| 11:00 - 12:30 | Type: Proffered Paper session Title: Basic science and translational research Chair(s): R. Marais, GB; J. Seoane, ES | Madrid |
| 11:00 - 11:15 | 1519O - Availability of tumour gene expression data facilitates clinical decision-making for patients with advanced cancers <u>J. Laskin</u> ¹ , C. Ho ¹ , Y. Shen ¹ , M. Jones ² , K. Gelmon ¹ , H. Lim ¹ , D. Renouf ¹ , S. Yip ¹ , A. Tinker ¹ , K. Khoo ³ , C. Lohrisch ¹ , S. Chia ¹ , B. Deol ¹ , K. Schrader ¹ , Y. Ma ² , R. Moore ² , A. Mungall ² , S. Jones ² , M. Marra ² ; ¹ Vancouver, CA, ² Vancouver, BC/CA, ³ Kelowna, CA | |
| 11:15 - 11:30 | 52O - Assessment and comparison of tumor mutational burden and microsatellite instability status in >40,000 cancer genomes <u>G. Frampton</u> ¹ , D. Fabrizio ² , Z. Chalmers ² , J. Sun ² , V. Miller ² , P. Stephens ² ; ¹ Cambridge, US, ² Cambridge, MA/US | |
| 11:30 - 11:45 | Invited discussant abstracts 1519O and 52O <u>C. Isacke</u> , London, GB | |
| 11:45 - 12:00 | 1O - EPHA2 blockade overcomes primary and acquired resistance to anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (mCRC) <u>G. Martini</u> , V. Belli, P.P. Vitiello, T. Troiani, C. Cardone, S. Napolitano, V. Desiderio, V. Sforza, M. Ferrara, G. Papaccio, L. Mele, G. Liguori, G. Botti, R. Franco, F. Morgillo, F. Ciardiello, E. Martinelli; Napoli, IT | |
| 12:00 - 12:15 | 1520O - Lurbinectedin (PM01183) exhibits antitumor activity in PARP-inhibitor resistant germline BRCA PDX and lacks cross-resistance with cisplatin <u>C. Cruz</u> ¹ , G. Caratu ¹ , A. Llop-Guevara ¹ , M. Castroviejo ¹ , S. Gutierrez-Enriquez ¹ , B. Morancho ¹ , E. Álvarez de la Campa ¹ , L. Prudkin ¹ , P. Nuciforo ¹ , J. Arribas ¹ , A. Vivancos ¹ , X. de la Cruz ¹ , C. Galmarini ² , P.M. Avilés ² , C. Saura ¹ , O. Díez ¹ , V. Serra ¹ , J. Balmaña ¹ ; ¹ Barcelona, ES, ² Madrid, ES | |
| 12:15 - 12:30 | Invited discussant abstracts 1O and 1520O <u>J. Seoane</u> , Barcelona, ES | |



| | | |
|---------------|---|------|
| 11:00 - 12:30 | Type: Special Symposium Title: Optimal combination and sequencing strategies in melanoma Chair(s): R. Dummer, CH; P. Ascierto, IT | Oslo |
| 11:00 - 11:05 | Introduction <u>R. Dummer</u> , Zürich, CH | |
| 11:05 - 11:25 | Rationale for combining <u>P. Ascierto</u> , Napoli, IT | |
| 11:25 - 11:45 | Rationale for sequencing <u>C. Robert</u> , Villejuif, FR | |
| 11:45 - 12:05 | Can biomarkers help make the decision? <u>A. Ribas</u> , Los Angeles, Ca, US | |
| 12:05 - 12:25 | A closer look at the current guidelines on sequencing and combination <u>P. Lorigan</u> , Manchester, GB | |
| 12:25 - 12:30 | Conclusions and clinical perspectives <u>P. Ascierto</u> , Napoli, IT | |



| | | |
|---------------|---|------|
| 11:00 - 12:30 | Type: Proffered Paper session Title: Developmental therapeutics Chair(s): C. Rolfo, BE; C. Twelves, GB | Rome |
| 11:00 - 11:15 | 357O - A phase I study evaluating DLYE5953A, an antibody-drug conjugate targeting the tumor-associated antigen lymphocyte antigen 6 complex locus E (Ly6E), in patients (Pts) with solid tumors <u>S. Modi</u> ¹ , J. Eder ² , P. Lorusso ² , C. Weekes ³ , S. Chandarlapaty ⁴ , S. Tolaney ⁵ , J. McLaughlin ² , D. Camidge ⁶ , C.-W. Chang ⁷ , D. Nazzari ⁷ , S.-C. Chen ⁷ , E. Schuth ⁷ , F. Brunstein ⁷ , W. Darbonne ⁷ , W. Flanagan ⁷ , A. Ungewickell ⁷ , G. Shapiro ⁸ ; ¹ New York, US, ² New Haven, CT/US, ³ Aurora, CO/US, ⁴ New York, NY/US, ⁵ Boston, MA/US, ⁶ Aurora, US, ⁷ South San Francisco, CA/US, ⁸ Boston, US | |
| 11:15 - 11:30 | 358O - 89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation in a dose-dependent manner and role of IL-2 receptor-binding <u>C. Menke-van der Houven van Oordt</u> ¹ , E. van Brummelen ¹ , T. Nayak ² , M. Huisman ¹ , L. de Wit-van der Veen ¹ , E. Mulder ¹ , O. Hoekstra ¹ , M. Stokkel ¹ , G. van Dongen ¹ , H. Verheul ¹ , M. Feilke ³ , C. Guizani ² , E. Guarin ² , S. Evers ⁴ , J. Saro ⁵ , J. Schellens ¹ ; ¹ Amsterdam, NL, ² Basel, CH, ³ Prensbach, DE, ⁴ Zürich, CH, ⁵ Schlieren, CH | |
| 11:30 - 11:45 | Invited discussant abstracts 357O and 358O <u>C. Massard</u> , Villejuif, FR | |
| 11:45 - 12:00 | 359O - First-in-human study of AC0010, a novel irreversible, mutant-selective EGFR inhibitor in patients with 1st generation EGFR TKI-resistant non-small cell lung cancer (NSCLC) <u>L. Zhang</u> ¹ , H. Zhao ¹ , B. Hu ² , J. Jiang ² , X. Zheng ² , Y. Zhang ¹ , Y. Ma ³ , J. Ge ¹ , B. Zou ¹ , X. Fang ⁴ , W. Xu ⁴ , X. Xu ⁴ ; ¹ Guangzhou, CN, ² Beijing, CN, ³ Guangzhou, Guangdong/CN, ⁴ Hangzhou, CN | |
| 12:00 - 12:15 | 360O_PR - Phase I study of the pan-fibroblast growth factor receptor (FGFR) inhibitor BAY 1163877 with expansion cohorts for subjects based on tumor FGFR mRNA expression levels <u>M. Joerger</u> ¹ , R. Soo ² , B.C. Cho ³ , A. Navarro Mendivil ⁴ , C. Sayehli ⁵ , H. Richly ⁶ , D. Tai ² , D.-W. Kim ⁷ , J. Wolf ⁸ , P. Cassier ⁹ , P. Ellinghaus ¹⁰ , S. Hildebrandt ¹⁰ , S. Behre ¹¹ , C. Helmbrecht ¹¹ , S. Kerpen ¹¹ , D. Zielinski ¹² , S. Ince ¹³ , P. Rajagopalan ¹³ , M. Ocker ¹⁰ , M. Schuler ⁶ ; ¹ St. Gallen, CH, ² Singapore, SG, ³ Seoul, KR, ⁴ Barcelona, ES, ⁵ Würzburg, DE, ⁶ Essen, DE, ⁷ Seoul, ⁸ Cologne, DE, ⁹ Lyon, FR, ¹⁰ Berlin, DE, ¹¹ Frankfurt Am Main, DE, ¹² Kassel, DE, ¹³ Whippany, NJ/US | |
| 12:15 - 12:30 | Invited discussant abstracts 359O and 360O_PR <u>C. Rolfo</u> , Edegem, BE | |



| | | |
|---------------|--|----------|
| 11:00 - 12:30 | Type: Joint Symposium Title: Joint Symposium ESMO-KACO: Rectal cancer Chair(s): D. Arnold, DE; T.W. Kim, KR | Athens |
| 11:00 - 11:05 | Introduction <u>T.W. Kim</u> , Seoul, KR | |
| 11:05 - 11:25 | Focus molecular diagnostics: Will "liquid biopsies"/cell-free DNA replace or add to the conventional diagnostic work-up? <u>K.-L. Spindler</u> , Aarhus C, DK | |
| 11:25 - 11:45 | Do all patients need "tri-modality"? | |
| 11:45 - 12:05 | Focus radiochemotherapy: How intensive, if at all? <u>D. Arnold</u> , Freiburg, DE | |
| 12:05 - 12:25 | Focus systemic control: The role of adjuvant chemotherapy <u>T.W. Kim</u> , Seoul, KR | |
| 12:25 - 12:30 | Conclusions and clinical perspectives <u>D. Arnold</u> , Freiburg, DE | |
| 11:00 - 12:00 | Type: Multidisciplinary patient cases Title: Complex symptomatic RCC with bone metastasis Chair(s): V. Grünwald, DE | Helsinki |
| 11:00 - 11:05 | Case presentation <u>V. Grünwald</u> , Hannover, DE | |
| 11:05 - 11:15 | Every patient with bone metastases should be evaluated for surgical intervention <u>A. Bex</u> , Amsterdam, NL | |
| 11:15 - 11:25 | Local therapy should implement radiotherapy in bone disease <u>V. Khoo</u> , London, GB | |
| 11:25 - 11:35 | When medical treatment is just enough in bone disease <u>V. Grünwald</u> , Hannover, DE | |
| 11:35 - 12:00 | Discussion | |



| | | |
|---------------|---|----------|
| 11:00 - 12:15 | Type: Proffered Paper session Title: Sarcoma | Brussels |
| 11:00 - 11:15 | 1395O - Randomized phase 3, multicenter, open-label study comparing evofosfamide (Evo) in combination with doxorubicin (D) vs. D alone in patients (pts) with advanced soft tissue sarcoma (STS): Study TH-CR-406/SARC021 <u>W. Tap</u> ¹ , Z. Papai ² , B. van Tine ³ , S. Attia ⁴ , K. Ganjoo ⁵ , R. Jones ⁶ , S. Schuetze ⁷ , D. Reed ⁸ , S. Chawla ⁹ , R. Riedel ¹⁰ , A. Krarup-Hansen ¹¹ , A. Italiano ¹² , P. Hohenberger ¹³ , G. Grignani ¹⁴ , L. Cranmer ¹⁵ , T. Alcindor ¹⁶ , A. Lopez-Pousa ¹⁷ , T. Pearce ¹⁸ , S. Kroll ¹⁸ , P. Schoffski ¹⁹ ; ¹ New York, NY/US, ² Budapest, HU, ³ St Louis, MO/US, ⁴ Jacksonville, FL/US, ⁵ Stanford, CA/US, ⁶ London, GB, ⁷ Ann Arbor, MI/US, ⁸ Tampa, FL/US, ⁹ Santa Monica, US, ¹⁰ Durham, NC/US, ¹¹ Gentofte, DK, ¹² Bordeaux, FR, ¹³ Mannheim, DE, ¹⁴ Candiolo, IT, ¹⁵ Seattle, WA/US, ¹⁶ Montreal, CA, ¹⁷ Barcelona, ES, ¹⁸ South San Francisco, US, ¹⁹ Leuven, BE | |
| 11:15 - 11:30 | Invited discussant abstract 1395O <u>W. van der Graaf</u> , London, GB | |
| 11:30 - 11:45 | 1396O - Results of a prospective randomized phase III T-SAR trial comparing trabectedin vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS) <u>A. Le Cesne</u> ¹ , J.-Y. Blay ² , D. Cupissol ³ , A. Italiano ⁴ , C. Delcambre ⁵ , N. Penel ⁶ , N. Isambert ⁷ , C. Chevreau ⁸ , E. Bompas ⁹ , F. Bertucci ¹⁰ , L. Chaigneau ¹¹ , S. Piperno-Neumann ¹² , S. Salas ¹⁰ , M. Rios ¹³ , C. Guillemet ¹⁴ , J.-O. Bay ¹⁵ , I. Ray-Coquard ² , O. Mir ¹ , L. Haddag ¹ , S. Foulon ¹ ; ¹ Villejuif, FR, ² Lyon, FR, ³ Montpellier, FR, ⁴ Bordeaux, FR, ⁵ Caen, FR, ⁶ Lille, FR, ⁷ Dijon, FR, ⁸ Toulouse, FR, ⁹ Saint-Herblain, FR, ¹⁰ Marseille, FR, ¹¹ Besançon, FR, ¹² Paris, FR, ¹³ Nancy, FR, ¹⁴ Rouen, FR, ¹⁵ Clermont-Ferrand, FR | |
| 11:45 - 12:00 | 1397O - The nationwide cohort of 26,883 patients with sarcomas treated in NETSARC reference network between 2010 and 2015 in France: Major impact of multidisciplinary board presentation prior to 1st treatment <u>J.-Y. Blay</u> ¹ , A. Le Cesne ² , N. Penel ³ , E. Bompas ⁴ , C. Chevreau ⁵ , F. Duffaud ⁶ , M. Rios ⁷ , P. Kerbrat ⁸ , D. Cupissol ⁹ , P. Anract ¹⁰ , J.-E. Kurtz ¹¹ , C. Lebbe ¹⁰ , F. Bertucci ⁶ , S. Piperno-Neumann ¹⁰ , P. Rosset ¹² , N. Isambert ¹³ , P. Dubray-Longeras ¹⁴ , F. Ducimetière ¹ , J.-M. Coindre ¹⁵ , A. Italiano ¹⁵ ; ¹ Lyon, FR, ² Villejuif, FR, ³ Lille, FR, ⁴ Saint-Herblain, FR, ⁵ Toulouse, FR, ⁶ Marseille, FR, ⁷ Vandoeuvre Les Nancy, FR, ⁸ Rennes, FR, ⁹ Montpellier, FR, ¹⁰ Paris, FR, ¹¹ Strasbourg, FR, ¹² Tours, FR, ¹³ Dijon, FR, ¹⁴ Clermont-Ferrand, FR, ¹⁵ Bordeaux, FR | |
| 12:00 - 12:15 | Invitd discussant abstracts 1396O and 1397O <u>R. Jones</u> , London, GB | |



| | | |
|---------------|---|--------|
| 11:00 - 12:30 | Type: Special Symposium Title: Emerging therapeutic strategies in lymphoma Chair(s): P. Johnson, GB; A. Ferreri, IT | Berlin |
| 11:00 - 11:05 | Introduction <u>A. Ferreri</u> , Milano, IT | |
| 11:05 - 11:25 | Hodgkin's Lymphoma: How to incorporate novel agents into standard care of treatment <u>P. Johnson</u> , London, GB | |
| 11:25 - 11:45 | CLL: Moving towards chemotherapy and free approaches <u>P. Ghia</u> , Milano, IT | |
| 11:45 - 12:05 | Mantle cell lymphoma: Impact of novel agents on treatment algorithms <u>S. Rule</u> , Devon, GB | |
| 12:05 - 12:25 | Follicular lymphoma: Novel developments beyond chemotherapy <u>C. Buske</u> , Ulm, DE | |
| 12:25 - 12:30 | Conclusions and clinical perspectives <u>P. Johnson</u> , London, GB | |
| 11:00 - 12:00 | Type: Multidisciplinary patient cases Title: Low grade glioma: Back to the future Chair(s): M. van den Bent, NL | Bern |
| 11:00 - 11:05 | Case presentation <u>M. van den Bent</u> , Rotterdam, NL | |
| 11:05 - 11:15 | The role of surgery in low grade gliomas: Do timing and extent of resection matter? <u>H. Duffau</u> , Montpellier, FR | |
| 11:15 - 11:25 | When and how treat low grade gliomas? <u>M. van den Bent</u> , Rotterdam, NL | |
| 11:25 - 12:00 | Discussion | |



| | | |
|---------------|--|-----------|
| 11:00 - 12:00 | Type: Young Oncologist Brunch Title: EMA approval process for anticancer agents: What should the oncologist know? Chair(s): R. Califano, GB; M. Strijbos, BE | Lisbon |
| 11:00 - 11:25 | EMA approval process for anticancer agents: What should the oncologist know? <u>F. Pignatti</u> , London, GB | |
| 11:25 - 12:00 | Interactive discussion with audience | |
| 13:00 - 13:45 | Type: Keynote lecture Title: The development of checkpoint inhibitors Chair(s): R.A. Stahel, CH | Vienna |
| 13:00 - 13:45 | The development of checkpoint inhibitors <u>J. Allison</u> , Houston, Tx, US | |
| 13:00 - 14:30 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Stockholm |
| 13:00 - 14:30 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium | Madrid |
| 13:00 - 14:30 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium | Oslo |
| 13:00 - 14:30 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Rome |
| 13:00 - 14:30 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium | Athens |
| 13:00 - 14:30 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Helsinki |
| 13:00 - 14:30 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium | Brussels |
| 13:00 - 14:30 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium | Berlin |



| | | |
|---------------|---|--------|
| 13:00 - 14:30 | Type: Patient Advocacy Track Title: Cancer inequalities: Bring me solutions not just the problems! Chair(s): A. Eniu, RO; I. Banks, BE | Zagreb |
| 13:00 - 13:10 | Mapping cancer disparities: What we know so far <u>A.-M. Forsea</u> , Bucharest , RO | |
| 13:10 - 13:20 | The 70:35 vision: What we can achieve <u>P. Selby</u> , Leeds, GB | |
| 13:20 - 14:30 | Panel discussion: Practical actions to be taken <u>F. De Lorenzo</u> ¹ , <u>P. Selby</u> ² ; ¹ Brussels, BE, ² Leeds, GB | |
| 13:00 - 14:00 | Type: Poster Display Title: Poster Display | Hall E |
| 13:00 - 13:00 | Endocrine and neuroendocrine tumours | |
| 13:00 - 13:00 | 429P - The clinicopathologic features and treatment of 607 hindgut neuroendocrine tumor (NET) patients at a single institution <u>S.T. Kim</u> , Y.S. Park, W. Kang, J. Park, M. Heo, H. Lee; Seoul, KR | |
| 13:00 - 13:00 | 430P - Neuroendocrine carcinomas of the colorectal origin - Polish experience <u>A. Kolasinska-Cwikla</u> ¹ , <u>A. Lewczuk</u> ² , <u>A. Cichocki</u> ¹ , <u>K. Maciejkiwicz</u> ¹ , <u>E. Nowicka</u> ¹ , <u>K. Roszkowska-Purska</u> ¹ , <u>Z. Jodkiewicz</u> ¹ , <u>M. Tenderenda</u> ¹ , <u>J. Cwikla</u> ³ ; ¹ Warsaw, PL, ² Gdansk, PL, ³ Olsztyn, PL | |
| 13:00 - 13:00 | 431P - Neuroendocrine neoplasms of the appendix including goblet cell carcinoids <u>A. Kolasinska-Cwikla</u> ¹ , <u>L. Jaskiewicz</u> ² , <u>A. Lewczuk</u> ³ , <u>A. Cichocki</u> ¹ , <u>K. Roszkowska</u> ¹ , <u>M. Tenderenda</u> ¹ , <u>J. Cwikla</u> ² ; ¹ Warsaw, PL, ² Olsztyn, PL, ³ Gdansk, PL | |
| 13:00 - 13:00 | 432P - Prognostic validity of AJCC staging system in neuroendocrine tumors of the appendix <u>A. Mehrvarz Sarshekeh</u> ¹ , <u>S. Advani</u> ² , <u>M. Patel</u> ² , <u>A. Dasari</u> ² ; ¹ Houston, US, ² Houston, TX/US | |
| 13:00 - 13:00 | 433P - Enhancer of zest homolog 2 (EZH2) expression in well and moderately differentiated pancreatic neuroendocrine tumor (pNET) <u>R. Marconcini</u> , <u>P. Faviana</u> , <u>D. Campani</u> , <u>L. Galli</u> , <u>A. Antonuzzo</u> , <u>C. Orlandini</u> , <u>A. Falcone</u> , <u>S. Ricci</u> ; Pisa, IT | |
| 13:00 - 13:00 | 434P - Differential clinical and pathological characteristics of hereditary neuroendocrine pancreatic tumours (NEPT) <u>G. Marín Zafra</u> ¹ , <u>J. Tebar Masso</u> ¹ , <u>J.M. Rodriguez Gonzalez</u> ¹ , <u>P. Segura Luque</u> ¹ , <u>J.L. Alonso Romero</u> ¹ , <u>T. García</u> ¹ , <u>P. Sanchez Henarejos</u> ¹ , <u>A. Soto</u> ¹ , <u>M.J. Martinez</u> ² ; ¹ Murcia, ES, ² Cartagena, ES | |
| 13:00 - 13:00 | 435P - Natural course of thyroid cancer nodules compared with benign thyroid nodules | |



K.-J. Yun, Seoul, KR

- 13:00 - 13:00 436P - Reassessment of proliferative activity at disease progression in neuroendocrine neoplasms
N. Cicchese¹, F. Panzuto¹, M. Rinzivillo¹, E. Merola¹, G. Capurso¹, S. Partelli², M. Manzoni², E. Pucci¹, E. Iannicelli¹, E. Pilozzi¹, M. Falconi², G. Delle Fave¹; ¹Rome, IT, ²Milano, IT
- 13:00 - 13:00 437P - UK phase IV, observational study to assess quality of life in patients (pts) with pancreatic neuroendocrine tumours (pNETS) receiving treatment with everolimus: The "real-world" OBLIQUE study
J. Ramage¹, P. Punia², O. Faluyi³, A. Frilling¹, T. Meyer¹, G. Kapur⁴, J. Cave⁵, J. Wadsley⁶, S. Cummins⁷, D. Farrugia⁸, N. Starling⁹, L. Wall¹⁰, R. Saharan¹¹, J. Valle¹²; ¹London, GB, ²Birmingham, GB, ³Liverpool, GB, ⁴Norwich, GB, ⁵Southampton, GB, ⁶Sheffield, GB, ⁷Guildford, GB, ⁸Cheltenham, GB, ⁹Sutton, GB, ¹⁰Edinburgh, GB, ¹¹Frimley, GB, ¹²Manchester, GB
- 13:00 - 13:00 438P - Efficacy of lanreotide autogel/depot (LAN) vs placebo (PBO) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT study
E. Wolin¹, G. Fisher, Jr², P. Kunz³, N. Liyanage⁴, S. Lowenthal⁵, B. Mirakhur⁵, R. Pommier⁶, M. Shaheen⁷, A. Vinik⁸; ¹New York, NY/US, ²Stanford, CA/US, ³Palo Alto, CA/US, ⁴Boulogne-Billancourt, FR, ⁵Basking Ridge, NJ/US, ⁶Portland, OR/US, ⁷Albuquerque, NM/US, ⁸Norfolk, VA/US
- 13:00 - 13:00 439P - Long-term safety/tolerability of lanreotide autogel/depot (LAN) treatment for metastatic intestinal and pancreatic neuroendocrine tumours (NETs): Final results of the CLARINET open-label extension (OLE)
M. Caplin¹, M. Pavel², J.C. Cwikla³, A. Phan³, M. Raderer⁴, E. Sedláčková⁵, G. Cadiot⁶, E. Wolin⁷, J. Capdevila⁸, L. Wall⁹, G. Rindi¹⁰, N. Liyanage¹¹, S. Braun¹², P. Ruzsniwski¹³; ¹London, GB, ²Berlin, DE, ³Olsztyn, PL, ⁴Vienna, AT, ⁵Prague, CZ, ⁶Reims, FR, ⁷Lexington, KY/US, ⁸Barcelona, ES, ⁹Edinburgh, GB, ¹⁰Rome, IT, ¹¹Boulogne-Billancourt, FR, ¹²Lisieux, FR, ¹³Paris, FR
- 13:00 - 13:00 440P - Longer term efficacy of lanreotide autogel/depot (LAN) for symptomatic treatment of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT open label study
G. Fisher Jr¹, E. Wolin², P. Kunz³, N. Liyanage⁴, B. Mirakhur⁵, S. Pitman Lowenthal⁵, R. Pommier⁶, M. Shaheen⁷, A. Vinik⁸; ¹Stanford, CA/US, ²Bronx, NY/US, ³Palo Alto, CA/US, ⁴Boulogne-Billancourt, FR, ⁵Basking Ridge, NJ/US, ⁶Portland, OR/US, ⁷Albuquerque, NM/US, ⁸Norfolk, VA/US
- 13:00 - 13:00 441P - Retrospective analysis of the efficacy of somatostatin analogs (SSA) in metastatic pulmonary neuroendocrine tumors and prognostic significance of FDG-PET
A. Bongiovanni¹, F. Recine¹, G. Marcantognini¹, N. Riva¹, V. Fausti¹, C. Liverani¹, A. de vita¹, L. Mercatali¹, F. Foca¹, M. Sansovini¹, F. Pieri², D. Oboldi¹, R. Galassi¹, D. Cavaliere², A. Zaccaroni², A. Tartaglia², V. Lunedei², A. Gardini², D. Amadori¹, T. Ibrahim¹; ¹Meldola, IT, ²Forlì, IT
- 13:00 - 13:00 442P - Role of somatostatin analogs(SSA)in combination with targeted agents(TTA)for neuroendocrine tumors(NETs)A systematic review
R. Guardefo, M. Beltran; Girona, ES
- 13:00 - 13:00 443P - Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors (PNETs)



R. Berardi¹, M. Torniai¹, S. Pusceddu², F. Spada², T. Ibrahim³, C. Zichi⁴, L. Antonuzzo⁵, P. Ferolla⁶, M. Rinzivillo⁷, N. Silvestris⁸, S. Partelli², B. Ferretti⁹, A. Bongiovanni³, L. Giustini¹⁰, F. Di Costanzo⁵, G. Delle Fave⁷, N. Fazio², F. De Braud², M. Falconi², S. Cascinu¹; ¹Ancona, IT, ²Milano, IT, ³Meldola, IT, ⁴Orbassano, IT, ⁵Firenze, IT, ⁶Perugia, IT, ⁷Rome, IT, ⁸Bari, IT, ⁹San Severino Marche, IT, ¹⁰Fermo, IT

- 13:00 - 13:00 444P - Phase II study of everolimus (EVL) and octreotide (OCT) LAR in patients with non-functioning gastrointestinal neuroendocrine tumours (GI-NETs): EVERLAR study
J. Capdevila¹, A. Teulé¹, J. Barriuso², D. Castellano², C. Lopez³, J.L. Manzano⁴, V. Alonso⁵, R. Garcia-Carbonero², E. Dotor⁶, I. Matos¹, A. Custodio², O. Casanovas⁴, R. Salazar¹; ¹Barcelona, ES, ²Madrid, ES, ³Santander, ES, ⁴Badalona, ES, ⁵Zaragoza, ES, ⁶Sabadell, ES
- 13:00 - 13:00 445P - Efficacy and safety of targeted agents for treatment of gastroenteropancreatic (GEP) neuroendocrine tumor (NET)
H. Chae, C. Yoo, K.-P. Kim, H.-M. Chang, T.W. Kim, Y.S. Hong, S.-M. Hong, S.C. Kim, B.-Y. Ryoo; Seoul, KR
- 13:00 - 13:00 446P - Capecitabine and streptozocin ± cisplatin for gastroenteropancreatic neuroendocrine tumours: predictors of long-term survival in the NET01 trial
T. Meyer¹, W. Qian², J. Valle³, D. Talbot⁴, D. Cunningham⁵, N. Reed⁶, L. Wall⁷, J. Waters⁸, P. Ross¹, A. Anthoney⁹, K. Sumpter¹⁰, N. Sarwar¹¹, T. Crosby¹², N. Begum², G. Young², R. Hardy², P. Corrie²; ¹London, GB, ²Cambridge, GB, ³Manchester, GB, ⁴Oxford, GB, ⁵Sutton, GB, ⁶Glasgow, GB, ⁷Edinburgh, GB, ⁸Kent, GB, ⁹Leeds, GB, ¹⁰Newcastle Upon Tyne, GB, ¹¹Southend, GB, ¹²Cardiff, GB
- 13:00 - 13:00 447P - Progressing G1-G2 neuroendocrine tumors (WD NET) in treatment with capecitabine (Cp) plus somatostatin analog (SSA): A single center experience
R. Marconcini, S. Ricci, L. Galli, A. Antonuzzo, C. Orlandini, E. Vasile, A. Falcone; Pisa, IT
- 13:00 - 13:00 448P - Efficacy of amrubicin monotherapy after platinum chemotherapy for non-gastrointestinal extrapulmonary neuroendocrine carcinoma
T. Ebata¹, T. Shimoi², S. Bun², M. Yunokawa², K. Yonemori², T. Ishiwata³, S. Iwasawa³, K. Tamura², Y. Takiguchi³; ¹Chiba, Chiba/JP, ²Tokyo, JP, ³Chiba, JP
- 13:00 - 13:00 449TiP - Safety and efficacy of lanreotide autogel/depot (LAN) every 14 days for patients with pancreatic or midgut neuroendocrine tumours (NETs) progressing on LAN every 28 days: The prospective, international CLARINET FORTE study
M. Pavel¹, C. Dromain², C. Massien³, A. Houchard³; ¹Berlin, DE, ²Villejuif, FR, ³Boulogne-Billancourt, FR
- 13:00 - 13:00 450TiP - Safety of lanreotide 120 mg ATG in combination with metformin in patients with advanced well-differentiated gastro-intestinal (GI) or lung carcinoids. A pilot, one-arm, open-label, prospective study: The MetNET-2 trial
F. De Braud, R. Buzzoni, L. Concas, D. Femia, N. Prinzi, M. Milione, E. Tamborini, F. Perrone, G. Lo Russo, C. Vernieri, I. Pulice, F. Piras, G. Dinoi, S. Pusceddu; Milano, IT
- 13:00 - 13:00 451TiP - Combined lanreotide autogel and temozolomide therapy in progressive neuroendocrine tumours: The SONNET study



D. Hörsch¹, M. Raderer², H. Lahner³, A. Rinke⁴, T. Denecke⁵, A. Koch⁵, A. Raspel⁶, P. Hoffmanns⁶, M. Pavel⁵; ¹Bad Berka, DE, ²Vienna, AT, ³Essen, DE, ⁴Marburg, DE, ⁵Berlin, DE, ⁶Ettlingen, DE

13:00 - 13:00 Gastrointestinal tumours, colorectal

13:00 - 13:00 470P - Efficacy and safety of cobimetinib (cobi) and atezolizumab (atezo) in an expanded phase 1b study of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC)

J. Desai¹, Y.S. Hong², J.E. Kim², T.W. Kim², S.W. Han², Y.-J. Bang², C.E. Chee³, V. Heong³, A. McRee⁴, L. Chow⁵, E. Kwak⁶, J. Infante⁷, J. Wallin⁸, M. Das Thakur⁸, G. Mwawasi⁸, P. Foster⁸, E. Cha⁸, J. Bendell⁷; ¹Melbourne, AU, ²Seoul, KR, ³Singapore, SG, ⁴Chapel Hill, NC/US, ⁵Seattle, WA/US, ⁶Boston, MA/US, ⁷Nashville, TN/US, ⁸South San Francisco, US

13:00 - 13:00 471P - A phase IB/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT)

A. Townsend¹, N. Tebbutt², C. Karapetis³, P. Cooper⁴, N. Singhal⁴, S. Yeend⁴, L. Pirc⁴, R. Joshi⁴, T. Price⁴; ¹Woodville, AU, ²Heidelberg, AU, ³Bedford Park, AU, ⁴Adelaide, AU

13:00 - 13:00 472P - A multicentre phase I/II study of TAS-102 with nintedanib in patients with metastatic colorectal cancer refractory to standard therapies (N-TASK FORCE: EPOC1410); Phase I results

T. Nishina¹, Y. Kuboki², E. Shinozaki³, S. Fukuoka², T. Kajiwara¹, K. Shitara², K. Yamaguchi³, Y. Komatsu⁴, S. Yuki⁵, K. Yamazaki⁶, H. Hara⁷, N. Mochizuki², M. Fukutani², H. Hasegawa², S. Matsuda², M. Wakabayashi², S. Nomura², A. Sato², A. Ohtsu², T. Yoshino²; ¹Matsuyama, JP, ²Kashiwa, JP, ³Tokyo, JP, ⁴Sapporo, JP, ⁵Sapporo, Hokkaido/Jp, ⁶Shizuoka, JP, ⁷Saitama, JP

13:00 - 13:00 473P - Targeting FGF2 expression against chemoresistance in colorectal cancer (CRC) cell lines - a potential prognostic biomarker in patients with metastatic colorectal cancer (mCRC) treated with FUFIRI or mlrOx (FIRE1)

A. Stahler¹, S. Stintzing², M. Urbiscek², D.P. Modest³, L. Fischer von Weikersthal⁴, J. Kumbrink², V. Heinemann², T. Kirchner², A. Jung²; ¹Munich, DE, ²München, DE, ³DE, ⁴Amberg, DE

13:00 - 13:00 474P - A phase I study to determine the effect of regorafenib (REG) on the pharmacokinetics (PK) of substrates of P-glycoprotein (P-gp; digoxin) and breast cancer resistant protein (BCRP; rosuvastatin) in patients with advanced solid tumors

D. Strumberg¹, S.-E. Al-Batran², I. Takacs³, L. Gécz³, A. Cleton⁴, F. Huang⁵, U. Mueller⁴, K. Graudenz⁴, Z. Trnkova⁴, I. Sturm⁴; ¹Bochum, DE, ²Frankfurt Am Main, DE, ³Budapest, HU, ⁴Berlin, DE, ⁵Whippany, NJ/US

13:00 - 13:00 476P - Phase II clinical trial with axitinib as maintenance therapy in patients (p) with metastatic colorectal carcinoma (CRC)

C. Gravalos¹, A. Carrato¹, M. Tobeña², E. Grande Pulido¹, G. Soler³, J. Vieitez⁴, L. Robles¹, M. Valladares-Ayerbes⁵, E. Polo⁶, M.L. Limon⁷, M.J. Safont⁸, C. Lopez⁹, P. García Alfonso¹, E. Aranda¹⁰; ¹Madrid, ES, ²Barcelona, ES, ³Hospitalet, ES, ⁴Oviedo, ES, ⁵A Coruna, ES, ⁶Zaragoza, ES, ⁷Sevilla, ES, ⁸Valencia, ES, ⁹Santander, ES, ¹⁰Cordoba, ES



- 13:00 - 13:00 477P - A multicenter phase II study of preoperative concurrent chemoradiotherapy with S-1 plus irinotecan for locally advanced rectal cancer: SAMRAI-2
M. Noda¹, T. Sato², K. Hayakawa², N. Tomita¹, N. Kamikonya¹, S. Matoba³, A. Uki³, H. Baba⁴, N. Oya⁴, H. Hasegawa⁵, N. Shigematu⁵, K. Hida⁶, T. Furuhashi⁷, T. Naitou⁸, M. Shimada⁹, K. Otuka¹⁰, Y. Higuchi¹¹, Y. Sakai⁶, M. Takeuchi³, M. Watanabe²; ¹Nishinomiya, JP, ²Sagamihara, JP, ³Minato-Ku, JP, ⁴Kumamoto, JP, ⁵Shinjyuku, JP, ⁶Kyoto, JP, ⁷Sapporo, JP, ⁸Sendai, JP, ⁹Tokushima, JP, ¹⁰Morioka, JP, ¹¹Itabashi, JP
- 13:00 - 13:00 478P - Temozolimide and capecitabine in patients with refractory KRAS wildtype metastatic colorectal cancer. A phase II trial
C. Qvortrup¹, N. Keldsen², F. Andersen³, H. Jensen¹, M. Krogh¹, L. Vestermark¹, J. Bjerregaard¹, P. Pfeiffer¹; ¹Odense C, DK, ²Herning, DK, ³Hillerod, DK
- 13:00 - 13:00 479P - Nivolumab ± ipilimumab treatment (Tx) efficacy, safety, and biomarkers in patients (Pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): Results from the CheckMate-142 study
M. Overman¹, S. Kopetz¹, S. Lonardi², R. McDermott³, F. Leone⁴, J. Leach⁵, H.-J. Lenz⁶, A. Hendlisz⁷, M. Morse⁸, P. Garcia-Alfonso⁹, J. Desai¹⁰, A. Hill¹¹, R. Moss¹², M. Goldberg¹², C.-S. Lin¹², H. Tang¹², T. André¹³; ¹Houston, TX/US, ²Padova, IT, ³Dublin, IE, ⁴Candiolo, IT, ⁵Minneapolis, US, ⁶Los Angeles, US, ⁷Brussels, BE, ⁸Durham, NC/US, ⁹Madrid, ES, ¹⁰Melbourne, AU, ¹¹Southport, QLD/AU, ¹²Princeton, US, ¹³Paris, FR
- 13:00 - 13:00 480P - MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours
R. Wilson¹, M. Middleton², J. Houlden², S. Van Schaeybroeck¹, C. Rolfo³, E. Elez⁴, J. Taieb⁵, T. André⁵, A. Bardelli⁶, P. Laurent-Puig⁵, J. Tabernero⁴, M. Peeters³, T. Maughan², C. Roberts², S. Love², M. Lawler¹, M. Salto-Tellez¹, M. Grayson¹, V. Popovici⁷, F. Di Nicolantonio⁶; ¹Belfast, GB, ²Oxford, GB, ³Edegem, BE, ⁴Barcelona, ES, ⁵Paris, FR, ⁶Candiolo, IT, ⁷Brno, CZ
- 13:00 - 13:00 481P - The correlation between tumor regression grade and retrieved lymph nodes status in locally advanced rectal cancer after neoadjuvant treatment: results from a prospective study
J. Zhang, Y. Deng, Y. Cai, H. Hu, J. Ling, J. Xiao, P. Lan, L. Wang, M. Huang, L. Kang, X. Wu, J. Wang; Guangzhou, CN
- 13:00 - 13:00 482P - Importance of tumour symptoms and extent of disease on efficacy of first-line FOLFOX4 ± panitumumab (pmab) in patients (pts) with RAS wild-type (WT)/BRAF WT metastatic colorectal cancer (mCRC) in the PRIME study
J. Taieb¹, M. Peeters², S. Siena³, F. Rivera Herrero⁴, R. Koukakis⁵, G. Demonty⁶, J.-Y. Douillard⁷; ¹Paris, FR, ²Edegem, BE, ³Milano, IT, ⁴Santander, ES, ⁵Uxbridge, GB, ⁶Zug, CH, ⁷St. Herblain, FR
- 13:00 - 13:00 483P - Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: Baseline characteristics



C. Lepage¹, J.-M. Phelip², L. Cany³, E. Maillard¹, A. Lievre⁴, T. Chatellier⁵, R. Faroux⁶, J.-C. Duchmann⁷, M. Ben Abdelghani⁸, G. Breysacher⁹, P. Geoffroy¹⁰, D. Pere-Verge¹¹, A. Pelaquier¹², D. Pillon¹³, J. Ezenfis¹⁴, Y. Rinaldi¹⁵, A. Darut-Jouve¹, M. Duluc¹⁵, A. Adenis¹⁶, O. Bouché¹⁷; ¹Dijon, FR, ²St. Etienne, FR, ³Périgueux, FR, ⁴Rennes, FR, ⁵St. Nazaire, FR, ⁶La Roche Sur Yon, FR, ⁷Compiègne, FR, ⁸Strasbourg, FR, ⁹Colmar, FR, ¹⁰Epernay, FR, ¹¹Lyon, FR, ¹²Montelimar, FR, ¹³Bourg En Bresse, FR, ¹⁴Longjumeau, FR, ¹⁵Marseille, FR, ¹⁶Lille, FR, ¹⁷Reims, FR

13:00 - 13:00 484P - A multicenter phase II trial to evaluate the efficacy of mFOLFOX6+cetuximab as induction chemotherapy to achieve R0 surgical resection for advanced colorectal liver metastases (NEXTO trial)

K. Hasegawa¹, A. Saiura¹, M. Oba¹, S. Aosasa², N. Tanaka³, T. Takayama¹, Y. Hashiguchi¹, Y. Bandai¹, H. Sakamoto², S. Yamagata¹, N. Aoyanagi³, H. Kaneko¹, H. Koyama¹, S. Miyagawa⁴, J. Yamamoto², Y. Mise¹, E. Shinozaki¹, S. Yoshida¹, T. Watanabe¹, N. Kokudo¹; ¹Tokyo, JP, ²Saitama, JP, ³Chiba, JP, ⁴Matsumoto, JP

13:00 - 13:00 485P - Impact of depth of response (DpR) on survival in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line panitumumab+FOLFOX4 vs FOLFOX4

S. Siena¹, J.-Y. Douillard², F. Rivera Herrero³, J. Taieb⁴, R. Koukakis⁵, G. Demonty⁶, M. Peeters⁷; ¹Milano, IT, ²St. Herblain, FR, ³Santander, ES, ⁴Paris, FR, ⁵Uxbridge, GB, ⁶Zug, CH, ⁷Edegem, BE

13:00 - 13:00 486P - Brain metastasis in advanced colorectal cancer: Results from the South Australian metastatic colorectal cancer (SAmCRC) registry

T. Price¹, C. Karapetis², C. Piantadosi³, G. Tapia Rico³, R. Padbury³, G. Maddern³, J. Moore³, S. Carruthers³, D. Roder³, A. Townsend¹; ¹Adelaide, AU, ²Bedford Park, AU, ³Adelaide, SA/AU

13:00 - 13:00 487P - First-line (1-L) bevacizumab plus chemotherapy (Bev/CT) in colorectal cancer (CRC) patients with potentially resectable liver only (LM) or liver and lung metastases (LLM): KRAS mutation analysis of the non-interventional PICASSO study

D. Malka¹, J.-P. Metges², D. Elias¹, J. Bennouna³, F. Bonnetain⁴, L.-M. Dourthe⁵, M. Ben Abdelghani⁵, A. Radji⁶, P. Laplaige⁷, F. Petit Laurent⁸, J. Telliez⁹, S. Bakiri⁹, M. Rivoire¹⁰; ¹Villejuif, FR, ²Brest, FR, ³Nantes, FR, ⁴Besançon, FR, ⁵Strasbourg, FR, ⁶Rouen, FR, ⁷La Chaussee St. Victor, FR, ⁸Gleizé, FR, ⁹Boulogne-Billancourt, FR, ¹⁰Lyon, FR

13:00 - 13:00 488P - Survival after resection of colorectal cancer with synchronous metastases – a Danish population based historical cohort study

A. Boysen¹, A. Ording², H. Sørensen², D. Farkas², K.-L. Spindler¹; ¹Aarhus, DK, ²Aarhus C, DK

13:00 - 13:00 489P - Perioperative triplet chemotherapy plus bevacizumab (bev) in patients with borderline resectable colorectal cancer liver metastases (CLM): Preliminary safety and activity

A. Mennitto, C. Cotsoglou, M. Caporale, M. Scotti, R. Berenato, J. Coppa, M. Di Bartolomeo, M. Milione, I. Bossi, F. de Braud, V. Mazzaferro, P. Filippo; Milano, IT

13:00 - 13:00 490P - Phase 2 of intra-arterial hepatic (IAH) bevacizumab with systemic chemotherapy (CT) in second line treatment of liver metastases of colorectal cancer (LMCRC)

M. Ducreux¹, O. Glehen², G. Tergemina-Clain¹, D. Smith³, B. Lacas¹, V. Boige¹, D. Malka¹, J.-P. Pignon¹, E. Dupont-Bierre⁴, R. Guimbaud⁵; ¹Villejuif, FR, ²Lyon, FR, ³Bordeaux, FR, ⁴St. Grégoire, FR, ⁵Toulouse, FR



- 13:00 - 13:00 491P - Impact of surgical resection of liver metastases on outcome of patients with KRAS-wildtype exon 2 (KRAS-wt) metastatic colorectal carcinoma (mCRC) treated with a cetuximab-based first-line therapy - Interim analysis of the German non-interventional study ERBITAG
U. Neumann¹, T. Goehler², C. Hering-Schubert³, J. Janssen⁴, S. Sahn⁵, M. Schwittay⁶, M. Zahn⁷, K. Stenzel⁸, F. Overkamp⁹; ¹Aachen, DE, ²Dresden, DE, ³Eisenach, DE, ⁴Westerstede, DE, ⁵Offenbach, DE, ⁶Groitzsch, DE, ⁷Goslar, DE, ⁸Darmstadt, DE, ⁹Recklinghausen, DE
- 13:00 - 13:00 492P - Selective internal radiation therapy (SIRT) in metastatic colorectal cancer (mCRC): Safety, efficacy and survival outcomes from the South Australian registry
A. Ayoola¹, S. Vantandoust², A. Roy³, T. Price⁴, M. Kitchener³, D. Roder³, S. Quinn⁴, G. Kichenadasse⁴, C. Piantadosi⁴, R. Padbury³, C. Karapetis²; ¹Newcastle, AU, ²Bedford Park, AU, ³Adelaide, SA/AU, ⁴Adelaide, AU
- 13:00 - 13:00 493P - Secondary resectability rates observed in a multicenter randomized phase II study of modified capecitabine/irinotecan (mXELIRI) plus bevacizumab (bev) followed by capecitabine/oxaliplatin (XELOX) plus bev or the reverse sequence in patients with metastatic colorectal cancer (mCRC)
W. Scheithauer¹, G. Prager¹, R. Greil², B. Mlineritsch², R. Schaberl-Moser³, A. Gerger³, F. Längle⁴, I. Viragos-Toth⁴, J. Andel⁵, A. Pichler⁶, M. Pecherstorfer⁷, A. Kretschmer⁸, A. Seebacher¹, B. Jagdt⁹, W. Eisterer¹⁰, P. Krippel¹¹; ¹Vienna, AT, ²Salzburg, AT, ³Graz, AT, ⁴Wiener Neustadt, AT, ⁵Steyr, AT, ⁶Leoben, AT, ⁷Krems, AT, ⁸Waidhofen A.d.thaya, AT, ⁹Ried Im Innkreis, AT, ¹⁰Innsbruck, AT, ¹¹Fuerstenfeld, AT
- 13:00 - 13:00 494P - DC-beads loaded with irinotecan combined with systemic chemotherapy for pretreated liver dominant metastatic colorectal cancer: Procedure and outcomes of 49 patients
A.-L. Pointet, S. Pernot, O. Pellerin, G. Amouyal, A. Berger, P. Rougier, M. Sapoval, J. Taieb; Paris, FR
- 13:00 - 13:00 495P - Cetuximab (Cmab) plus irinotecan (I) versus panitumumab (Pmab) in patients with refractory metastatic colorectal cancer (mCRC) in Ontario
K. Jerzak¹, C. Earle¹, Y.-J. Ko², S. Berry², K. Chan¹; ¹Toronto, ON/CA, ²Toronto, CA
- 13:00 - 13:00 496P - A triplet combination with oxaliplatin/capecitabine/irinotecan (XELOXIRI) plus cetuximab (Cmab) as a first-line therapy in wild-type KRAS, metastatic colorectal cancer: A dose escalating study
Y. Sato, H. Ohnuma, M. Hirakawa, S. Kikuch, M. Takahashi, T. Okamoto, Y. Tsuji, K. Okita, T. Furuhashi, I. Takemasa, J. Kato; Sapporo, JP
- 13:00 - 13:00 497P - Phase II trial of panitumumab monotherapy for patients with KRAS exon2 wild type colorectal cancer after progression on cetuximab. HGCSG1101
S. Yuki¹, Y. Komatsu², T. Muranaka², K. Harada², J. Sugiyama², Y. Tsuji², T. Ando³, A. Hosokawa³, K. Hatanaka⁴, H. Naruse⁴, T. Takahata⁵, A. Sato⁵, Y. Kobayashi⁶, T. Miyagishima⁶, H. Okuda², M. Kudo², M. Nakamura², H. Hisai⁷, N. Sakamoto², Y. Sakata⁸; ¹Sapporo, Hokkaido/JP, ²Sapporo, JP, ³Toyama, JP, ⁴Hakodate, JP, ⁵Hirosaki, JP, ⁶Kushiro, JP, ⁷Date, JP, ⁸Misawa, JP
- 13:00 - 13:00 498P - The colorectal carcinoma – treatment research and treatment reality in oncology practices (Anti-VEGF or Anti-EGFR therapies)
H. Tessen¹, O. Rubanov², A. Schlichting³, A. Valdivia⁴; ¹Goslar, DE, ²Hameln, DE, ³Berlin, DE, ⁴Schwerin, DE



- 13:00 - 13:00 499P - PULSE, a phase 2 study of mFOLFOX6-panitumumab (P) with biomarker stratification as first-line chemotherapy (CT), in patients (pts) with KRAS (exon 2) metastatic colorectal cancer (mCRC). A GEMCAD 09-03 study
J. Maurel¹, C. Fernández Martos², M. Martín Richard¹, V. Alonso³, C. Méndez Méndez⁴, A. Salud⁵, C. Pericay⁶, J. Aparicio², J. Gallego⁷, A. Carmona⁸, E. Casado⁹, H. Manzano¹⁰, C. Horndler³, M. Rubini¹¹, M. Cuatrecasas¹, X. García-Albéniz¹², J. Feliu⁹; ¹Barcelona, ES, ²Valencia, ES, ³Zaragoza, ES, ⁴A Coruna, ES, ⁵Lerida, ES, ⁶Sabadell, ES, ⁷Elche, ES, ⁸Murcia, ES, ⁹Madrid, ES, ¹⁰Palma De Mallorca, ES, ¹¹Ferrara, IT, ¹²Boston, US
- 13:00 - 13:00 500P - S-1 plus oxaliplatin combined with radiation (SOX/RT) for preoperative locally advanced rectal carcinoma: Final results of a phase II study (JACCRO CC-04: SHOGUN trial)
H. Horie¹, S. Matsusaka², S. Ishihara², K. Kondo³, K. Uehara⁴, M. Oguchi², K. Murofushi², M. Ueno², N. Mizunuma², T. Shimbo³, D. Kato², J. Okuda³, Y. Hashiguchi², M. Nakazawa⁵, E. Sunami², K. Kawai², H. Yamashita², T. Okada⁴, T. Nakajima², T. Watanabe²; ¹Shimotsuke, JP, ²Tokyo, JP, ³Osaka, JP, ⁴Nagoya, JP, ⁵Tochigi, JP
- 13:00 - 13:00 501P - Efficacy of first-line modified FOLFOX6 with panitumumab or bevacizumab in RAS wild-type/BRAF wild-type metastatic colorectal cancer: Impact of tumour symptoms and extent of disease
F. Rivera¹, M. Peeters², J.-Y. Douillard³, J. Taieb⁴, R. Koukakis⁵, G. Demonty⁶, S. Siena⁷; ¹Santander, ES, ²Edegem, BE, ³St. Herblain, FR, ⁴Paris, FR, ⁵Uxbridge, GB, ⁶Zug, CH, ⁷Milano, IT
- 13:00 - 13:00 502P - Pharmacological bioequivalence of branded and generic oxaliplatin: From preclinical assessment to clinical incidence of hypersensitivity reactions in patients with colorectal cancer
C. Sonetto, C. Baratelli, M.P. Brizzi, M. Di Maio, G. Scagliotti, M. Tampellini; Orbassano, IT
- 13:00 - 13:00 503P - A 12-week regimen with interdigitating FOLFOX/bevacizumab and pelvic chemoradiation for synchronous primary and metastatic rectal cancer. The CHROME B trial
S. Ngan¹, M. Bressel¹, J. Chu¹, J. McKendrick², S. Chander¹, P. Cooray³, M. Jefford⁴, R. Wong³, M. Steel², T. Leong¹, A. Heriot¹, M. Michael¹; ¹Melbourne, VIC/AU, ²Box Hill, VIC/AU, ³Box Hill, AU, ⁴Melbourne, AU
- 13:00 - 13:00 504P - Calcium gluconate and magnesium sulfate in preventing neurotoxicity in patients receiving oxaliplatin-based combination chemotherapy-capeOX
I. Kiladze, N. Sharikadze, T. Esakia; Tbilisi, GE
- 13:00 - 13:00 505P - Platinum-fluoropyrimidine (PF) and paclitaxel (PTX)-based chemotherapy (CT) in advanced anal cancer (AC)
F. Sclafani¹, F. Morano², C. Baratelli³, E. Kalaitzaki², D. Watkins², N. Starling², I. Chau⁴, D. Cunningham², S. Rao²; ¹London, GB, ²Sutton, GB, ³Orbassano, IT, ⁴London And Surrey, GB
- 13:00 - 13:00 506P - Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) >4 months (m)



R. Garcia-Carbonero¹, E. van Cutsem², F. Ciardiello³, M. Ychou⁴, J.-F. Seitz⁴, R. Hofheinz⁵, Y. Arriaga⁶, U. Verma⁶, A. Grothey⁷, A. Miriyala⁸, J. Kalmus⁸, A. Falcone⁹, C. Kappeler⁸, A. Zaniboni¹⁰; ¹Madrid, ES, ²Leuven, BE, ³Napoli, IT, ⁴Marseille, FR, ⁵Mannheim, DE, ⁶Dallas, TX/US, ⁷Rochester, US, ⁸Berlin, DE, ⁹Pisa, IT, ¹⁰Brescia, IT

13:00 - 13:00 507P - A phase 1 study evaluating the pharmacokinetics (PK) and safety of regorafenib (REG) in patients with advanced solid tumors with severe renal impairment (SRI)

D. Renouf¹, H. Hirte², C. O'Bryant³, Z. Trnkova⁴, A. Cleton⁴, F. Huang⁵, U. Mueller⁶, J.-P. Ayoub⁷, A. Lockhart⁸, D. Quinn⁸, G. Dy⁹, M. Sawyer¹⁰; ¹Vancouver, CA, ²Hamilton, ON/CA, ³Aurora, CO/US, ⁴Berlin, DE, ⁵Whippany, NJ/US, ⁶Wuppertal, DE, ⁷Montreal, QC/CA, ⁸Los Angeles, CA/US, ⁹Buffalo, NY/US, ¹⁰Edmonton, AB/CA

13:00 - 13:00 508P - Cetuximab biweekly (q2w) plus mFOLFOX6 as 1st line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) – Primary endpoint and subgroup analysis of the CEBIFOX trial

S. Kasper¹, J. Meiler¹, H. Knipp¹, T. Höhler², P. Reimer¹, H.T. Steinmetz³, W. Berger¹, G. Linden¹, S. Ting¹, P. Markus¹, A. Paul¹, A. Dechêne¹, B. Schumacher¹, K. Kostbade¹, K. Worm¹, K. Schmid¹, T. Herold¹, M. Schuler¹, T. Trarbach⁴; ¹Essen, DE, ²Recklinghausen, DE, ³Köln, DE, ⁴Wilhelmshaven, DE

13:00 - 13:00 509P - FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS & NRAS

R. Adams¹, E. Brown², L. Brown³, R. Butler¹, S. Falk⁴, D. Fisher³, R. Kaplan³, P. Quirke⁵, S. Richman⁵, L. Samuel⁶, J. Seligmann⁵, M. Seymour⁵, K.K. Shiu³, H. Wasan³, R. Wilson⁷, T. Maughan⁸; ¹Cardiff, GB, ²Edinburgh, GB, ³London, GB, ⁴Bristol, GB, ⁵Leeds, GB, ⁶Aberdeen, GB, ⁷Belfast, GB, ⁸Oxford, GB

13:00 - 13:00 510P - Phase II study of third-line cetuximab rechallenge in patients with metastatic wild-type K-RAS colorectal cancer who achieved a clinical benefit in response to first-line cetuximab plus chemotherapy (JACCRO CC-08)

A. Tsuji¹, T. Eto², T. Masuishi³, H. Satake⁴, Y. Segawa⁵, H. Tanioka⁶, H. Hara⁵, M. Kotaka⁴, T. Sagawa⁷, T. Watanabe⁸, M. Nakamura⁹, T. Takahashi¹⁰, Y. Negoro¹¹, D. Manaka¹², H. Fujita¹³, T. Suto¹⁴, W. Ichikawa¹⁵, M. Fujii¹⁶, M. Takeuchi¹⁶, T. Nakajima¹⁶; ¹Kagawa, JP, ²Ibaraki, JP, ³Aichi, JP, ⁴Kobe, JP, ⁵Saitama, JP, ⁶Okayama, JP, ⁷Sapporo, JP, ⁸Himeji, JP, ⁹Matsumoto, JP, ¹⁰Gifu, JP, ¹¹Kochi, JP, ¹²Kyoto, JP, ¹³Kanazawa, JP, ¹⁴Yamagata, JP, ¹⁵Yokohama, JP, ¹⁶Tokyo, JP

13:00 - 13:00 511P - Adherence to guidelines for colorectal cancer prevention and its relationship to this cancer in the Basque country: A case-control study

B. Chao-Seijo¹, V. Ovejas-Arza¹, I. Alegria-Lertxundi¹, C. Aguirre², L. Bujanda³, F. Fernandez², F. Polo⁴, I. Portillo⁴, M.C. Etxezarraga⁴, I. Zabalza², M. Larzabal³, M. M. de Pancorbo¹, A. Rocandio¹, M. Arroyo-Izaga¹; ¹Vitoria, ES, ²Galdakao, ES, ³San Sebastian, ES, ⁴Bilbao, ES

13:00 - 13:00 512P - Compassionate use program for trifluridine/tipiracil (TAS-102) in metastatic colorectal cancer: A real-life overview



L. Salvatore¹, M. Niger², L. Bellu³, E. Tamburini⁴, P. Garcia-Alfonso⁵, N. Amellal⁶, A.-S. Delmas⁷, M. Wahba⁸, G. Prager⁹; ¹Pisa, IT, ²Milano, IT, ³Padova, IT, ⁴Rimini, IT, ⁵Madrid, ES, ⁶Suresnes, CEDEX/FR, ⁷Suresnes, FR, ⁸Flemington, US, ⁹Vienna, AT

- 13:00 - 13:00 513P - Pharmacokinetic and pharmacodynamic (PK/PD) analysis results from the phase 3 RECURSE trial of trifluridine and tipiracil (TAS-102) versus placebo (pbo) in patients (pts) with refractory metastatic colorectal cancer (mCRC)
T. Yoshino¹, J. Cleary², R. Mayer², K. Yoshida³, L. Makris⁴, F. Yamashita³, A. Ohtsu¹, H.-J. Lenz⁵, E. Van Cutsem⁶; ¹Kashiwa, JP, ²Boston, US, ³Princeton, US, ⁴New Hope, US, ⁵Los Angeles, US, ⁶Leuven, BE
- 13:00 - 13:00 514P - Role of glutamine for preventing oxaliplatin induced peripheral neuropathy (GELUPO): Results of randomized open-label phase II trial
O. Yazici, A.P. Titiz, N. Ozdemir, S. Aksoy, M. Sendur, B. Arli, N. Zengin; Ankara, TR
- 13:00 - 13:00 515P - RECURSE trial: Performance status at discontinuation in patients receiving trifluridine/tipiracil (TAS-102)
E. Van Cutsem¹, R. Garcia-Carbonero², A. Pastorino³, A. Zaniboni⁴, A. Falcone⁵, N. Amellal⁶, F. Benedetti⁷, R. Mayer⁸, A. Ohtsu⁹, J. Tabernero¹⁰; ¹Leuven, BE, ²Madrid, ES, ³Genova, IT, ⁴Brescia, IT, ⁵Pisa, IT, ⁶Suresnes, CEDEX/FR, ⁷Princeton, US, ⁸Boston, US, ⁹Kashiwa, JP, ¹⁰Barcelona, ES
- 13:00 - 13:00 516P - Characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) who had progression-free survival (PFS) >4 months (m): Subgroup analysis of the phase 3 CORRECT trial
A. Grothey¹, A. Falcone², Y. Humblet³, O. Bouche⁴, L. Mineur⁵, A. Adenis⁶, J. Tabernero⁷, T. Yoshino⁸, H.-J. Lenz⁹, R. Goldberg¹⁰, L. Huang¹¹, A. Wagner¹², E. Van Cutsem¹³; ¹Rochester, US, ²Pisa, IT, ³Brussels, BE, ⁴Reims, FR, ⁵Avignon, FR, ⁶Lille, FR, ⁷Barcelona, ES, ⁸Kashiwa, JP, ⁹Los Angeles, CA/US, ¹⁰Columbus, OH/US, ¹¹Whippany, NJ/US, ¹²Berlin, DE, ¹³Leuven, BE
- 13:00 - 13:00 517P - TRUST: Phase II trial of induction chemotherapy (CT) with FOLFOXIRI + bevacizumab (BV) followed by chemo-radiotherapy (CRT) + BV and surgery in locally advanced rectal carcinoma (LARC)
C. Vivaldi¹, P. Bucciatti¹, G. Musettini¹, F. Bergamo², M.D. Rizzato², A. Sainato¹, A. Martignetti³, S. Lucchesi⁴, M. Franceschi¹, C. Boso², F. Pasqualetti¹, L. Ginocchi⁴, F. Di Clemente³, A. Gonnelli¹, L. Urbani¹, S. Montrone¹, I. Maretto², F. Sidoti¹, A. Falcone¹, G. Masi¹; ¹Pisa, IT, ²Padova, IT, ³Siena, IT, ⁴Pontedera, IT
- 13:00 - 13:00 518P - Circulating tumor cells: A promising marker in predicting tumor response after preoperative chemo-radiation therapy for rectal cancer
W. Sun, Z. Zhang; Shanghai, CN
- 13:00 - 13:00 519P - The gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for proper use of S-1 and tegafur-uracil /leucovorin in preoperative chemoradiotherapy in patients with rectal cancer
S. Sadahiro¹, T. Suzuki¹, A. Tanaka¹, K. Okada¹, G. Saito¹, A. Kamijo¹, H. Nagase²; ¹Isehara, JP, ²Tokushima, JP



- 13:00 - 13:00 520P - B cells and natural killer cells in lymph node (LN) are independent predictors of LN size, the number of retrieved LNs and survival in stage II colon cancer
K. Okada, S. Sadahiro, H. Miyakita, G. Saito, A. Tanaka, T. Suzuki, A. Kamijo; Isehara, JP
- 13:00 - 13:00 521P - Association between HER2 amplification and cetuximab efficacy in patients with RAS wild-type metastatic colorectal cancer
J. Jeong¹, J. Kim², Y.S. Hong², D. Kim², J.E. Kim², S.Y. Kim², K.-P. Kim², T.W. Kim²; ¹Goyang, KR, ²Seoul, KR
- 13:00 - 13:00 522P - Broad detection of alterations predicted to confer lack of benefit from EGFR antibodies or sensitivity to targeted therapy in advanced colorectal cancer
S. Klempner¹, A. Rankin², R. Erlich², J. Sun², A. Grothey³, M. Fakih⁴, T. George, Jr.⁵, J. Lee⁶, J. Ross⁷, P. Stephens², V. Miller², S. Ali⁸, A. Schrock²; ¹Los Angeles, CA/US, ²Cambridge, US, ³Rochester, US, ⁴Duarte, US, ⁵Gainesville, US, ⁶Seoul, KR, ⁷Albany, NY/US, ⁸Cambridge, MA/US
- 13:00 - 13:00 523P - Mutational profiles in paired primary tumours and metastases in colorectal cancer patients: An NGS study of the Hellenic Cooperative Oncology Group
G. Pentheroudakis¹, V. Kotoula², V. Kourvelos³, E. Charalambous³, V. Karavasilis³, E. Giannoulatou⁴, G. Tsoulfas³, E. Pazarli³, G. Glantzounis³, P. Papakostas³, E. Samantas³, D. Pectasides³, G. Fountzilias²; ¹Ioannina, GR, ²Thessaloniki, GR, ³Athens, GR, ⁴Darlinghurst, AU
- 13:00 - 13:00 524P - Phase II study to evaluate the efficacy of regorafenib in metastatic colorectal cancer patients by the assessment using FDG-PET/CT (JACCRO CC-12) metastatic colorectal cancer (JACCRO CC-12)
H. Satake¹, M. Nakamura², A. Tsuji³, T. Sagawa⁴, F. Tamura⁴, Y. Hatachi¹, K. Oguchi², A. Takagane⁵, T. Kaji⁵, T. Sekikawa⁶, M. Furukawa², M. Kochi⁷, W. Ichikawa⁶, M. Takeuchi⁷, M. Fujii⁷, T. Nakajima⁷; ¹Kobe, JP, ²Matsumoto, JP, ³Kagawa, JP, ⁴Sapporo, JP, ⁵Hakodate, JP, ⁶Yokohama, JP, ⁷Tokyo, JP
- 13:00 - 13:00 525P - KRAS mutations in circulating tumour DNA (ctDNA) in MRI-defined, high-risk, locally-advanced rectal cancer (LARC) patients (pts) from the EXPERT-C trial
F. Scalfani¹, I. Chau², D. Cunningham³, G. Vlachogiannis³, Z. Eltahir³, A. Lampis³, C. Braconi³, E. Kalaitzaki³, D. Gonzalez De Castro³, A. Wotherspoon³, J. Capdevila⁴, B. Glimelius⁵, A. Cervantes⁶, R. Begum³, H. Lote³, G. Mentrasti³, J. Hahne³, D. Tait³, G. Brown³, N. Valeri³; ¹London, GB, ²London And Surrey, GB, ³Sutton, GB, ⁴Barcelona, ES, ⁵Uppsala, SE, ⁶Valencia, ES
- 13:00 - 13:00 526P - Performance assessment of blood based RAS mutation testing: Concordance of results obtained from prospectively collected samples
M. Saunders¹, C. Cooney¹, D. Edelstein², S. Mullamitha¹, M. Braun¹, S. Moghadam¹, P. Ronga³, F. Jones⁴, A. Telaranta-Keerie², R. Adams⁵; ¹Manchester, GB, ²Baltimore, MD/US, ³Darmstadt, DE, ⁴Mundelein, IL/US, ⁵Cardiff, GB
- 13:00 - 13:00 527P - Impact of tumor epidermal growth factor receptor (EGFR) status on the outcomes of first-line FOLFOX-4 ± cetuximab in patients (pts) with RAS-wild-type (wt) metastatic colorectal cancer (mCRC) in the randomized phase 3 TAILOR trial
S. Qin¹, J. Xu², L. Wang², Y. Cheng³, T. Liu², J. Chen⁴, S.P. Eggleton⁵, J. Liu⁴, J. Li²; ¹Nanjing, CN, ²Shanghai, CN, ³Changchun, CN, ⁴Beijing, CN, ⁵Darmstadt, DE



- 13:00 - 13:00 528P - Tracking emerging KRAS and BRAF mutations through ccfDNA in colorectal cancers treated with EGFR blockade
T. Yamada, G. Takahashi, T. Iwai, K. Takeda, M. Koizumi, S. Shinji, Y. Yokoyama, K. Hara, M. Hotta, A. Matsuda, S. Matsumoto, K. Ohta, E. Uchida; Tokyo, JP
- 13:00 - 13:00 529P - Factors associated with discordance of KRAS, NRAS, BRAF, PIK3CA mutation status in the primary tumor and metastases in patients (pts) with colorectal cancer (CRC)
M. Fedyanin, A. Stroganova, A. Senderovich, S. Dranko, A. Tryakin, E. Polyanskaya, A. Popova, O. Sekhina, A. Rasulov, S. Gordeev, I. Sagaydak, S. Tjulandin; Moscow, RU
- 13:00 - 13:00 530P - Prognostic value of circulating tumor DNA in advanced colorectal cancer patients: Quantification of hypermethylated or mutant sequences using picoliter droplet digital PC
A. Zaanan, F. Garlan, A. Didelot, G. Perkins, N. Siauve, H. Blons, J. Taieb, V. Taly, P. Laurent-Puig; Paris, FR
- 13:00 - 13:00 531P - Associations between dermatologic toxicity severity, patient characteristics, and efficacy among patients treated with panitumumab (Pmab) and chemotherapy
T. Price¹, J.-Y. Douillard², X. Guan³, C. Bohac³, M. Peeters⁴; ¹Adelaide, AU, ²Nantes, FR, ³Thousand Oaks, CA/US, ⁴Edegem, BE
- 13:00 - 13:00 532P - MicroRNA as predictive biomarker of survival for stage IIIB colon cancer patients
P. Li¹, Q. Ou², G. Chen², F. Oduncu¹; ¹München, DE, ²Guangzhou, CN
- 13:00 - 13:00 533P - Accuracy of plasma RAS mutation testing for therapy selection and monitoring of colorectal cancer patients
J. Vidal Barrull¹, L. Muínelo Romay², A. Dalmases¹, A. Abalo², M.C. Vela¹, M. Abreu Rodríguez², M. Muset¹, J. Ruiz², M. Iglesias¹, C. Blanco², E. López¹, C. Rodríguez², F. Jones³, D. Edelstein⁴, A. Lukas⁵, J. Albanell¹, B. Bellosillo¹, C. Montagut¹, S. Candamio², R. López²; ¹Barcelona, ES, ²Santiago De Compostela, ES, ³Mundelein, IL/US, ⁴Baltimore, MD/US, ⁵Hamburg, DE
- 13:00 - 13:00 534P - Efficacy of obesity in metastatic colorectal cancer patients treated with bevacizumab-based chemotherapy combinations: A Turkish Oncology Group Study
M. Artac¹, L. Korkmaz¹, H. Coskun², F. Dane³, B. Karabulut⁴, M. Karaağaç¹, D. Çabuk⁵, S. Karabulut³, F. Aykan³, H. Doruk⁶, N. Avci⁶, S. Turhal³; ¹Konya, TR, ²Antalya, TR, ³Istanbul, TR, ⁴Izmir, TR, ⁵Kocaeli, TR, ⁶Bursa, TR
- 13:00 - 13:00 535P - Concordance of KRAS, NRAS and BRAF status between primary colorectal tumors and paired metastasis (mts)
J. Alcaide-Garcia¹, T. Pereda¹, E. Perez-Ruiz¹, F. Rivas¹, I. Zarcos Pedrinaci², R. Villatoro¹, D. Perez¹, A. Rueda²; ¹Marbella, ES, ²Malaga, ES
- 13:00 - 13:00 536P - Predictive factors of lymph node metastasis in patients with non-metastatic colorectal adenocarcinoma
E. Karci, E.B. Köksoy, A. Alkan, İ. Dede, G. Tuncay, G. Utkan, Y. Ürün, H. Akbulut; Ankara, TR
- 13:00 - 13:00 537P - Circulating microRNA-126 and epidermal growth factor-like domain 7 protein predict recurrence of colon cancer in patients treated with neoadjuvant chemotherapy



T. Hansen¹, A. Carlsen², J. Tanassi², N. Hegaard², F.O. Larsen³, F. Soerensen¹, L.H. Jensen¹, A. Jakobsen¹; ¹Vejle, DK, ²Copenhagen, DK, ³Herlev, DK

13:00 - 13:00 538P - The genomic complexity of metastatic colorectal tumors by age, gender, race, and location of primary tumor using next-generation sequencing

J. Gong¹, M. Sy², M. Fakih²; ¹Duarte, CA/US, ²Duarte, US

13:00 - 13:00 539P - Circulating pro-angiogenic markers in patients receiving first-line FOLFIRI+bevacizumab. The SENTRAL (Serum angiogenesis-cENTRAL) pre-planned analysis of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL trial (ColorEctalvastiNTRIAlLdh).

M. Scartozzi¹, R. Giampieri², B. Daniele³, D. Ferrari⁴, S. Lonardi⁵, A. Zaniboni⁶, L. Cavanna⁷, G. Rosati⁸, N. Pella⁹, M.G. Zampino⁴, P. Sozzi¹⁰, L. Casula¹, S. Rota⁴, D. Germano³, M. Puzzone¹¹, C. Loretelli², V. Zagonel⁵, R. Labianca¹², L. Frontini⁴, S. Cascinu²; ¹Cagliari, IT, ²Ancona, IT, ³Benevento, IT, ⁴Milano, IT, ⁵Padova, IT, ⁶Brescia, IT, ⁷Piacenza, IT, ⁸Potenza, IT, ⁹Udine, IT, ¹⁰Biella, IT, ¹¹Monserrato, IT, ¹²Bergamo, IT

13:00 - 13:00 540P - Prospective evaluation of BRAF, PI3K and PTEN as predictive and prognostic biomarkers in first-line advanced KRAS wild-type colorectal cancer treated with FOLFOX or FOLFIRI plus bi-weekly cetuximab. GEMCAD 10-02

V. Alonso¹, P. Escudero Emperador¹, M. Mendez Urena², J. Gallego³, J.R. Rodriguez⁴, J. Fernández⁵, A. Salud⁶, E. Falcó⁷, H. Manzano⁷, M. Zanui⁸, M. Gil⁹, U. Bohn Sarmiento¹⁰, C. Fernández Martos⁹, V. Calderero¹¹, A. Ferrer¹², M. Cuatrecasas¹³, F. Rojo¹⁴, J. Feliu¹⁴, J. Maurel¹³, X. García-Albéniz¹⁵; ¹Zaragoza, ES, ²Mostoles, ES, ³Elche, ES, ⁴Badajoz, ES, ⁵Terrassa, ES, ⁶Lerida, ES, ⁷Palma De Mallorca, ES, ⁸Mataro, ES, ⁹Valencia, ES, ¹⁰Las Palmas, ES, ¹¹Barbastro, ES, ¹²Albacete, ES, ¹³Barcelona, ES, ¹⁴Madrid, ES, ¹⁵Boston, US

13:00 - 13:00 541P - Effects of beyond KRAS mutations on the efficacy of cetuximab plus chemotherapy for patients with unresectable colorectal liver-limited metastases (BELIEF): A retrospective biomarker analysis from a Chinese trial

J. Xu¹, L. Ren¹, Y. Wei¹, P. Zheng¹, L. Ye², Q. Feng¹, Q. Lin¹, D. Zhu¹, W. Chang¹, M. Ji¹; ¹Shanghai, CN, ²Wenzhou, CN

13:00 - 13:00 542P - MicroRNA-31 overexpression is able to predict pathological response and outcome in locally advanced rectal cancer

C. Carames, I. Cristobal, P. Minguez, V. Moreno, A. Leon, H. Callata-Carhuapoma, J.I. Martin, M. Domine, R. Hernandez, M. Pedregal, I. Martinez, I. Moreno, A. Correa, F. Rojo, J.M. García-Foncillas López; Madrid, ES

13:00 - 13:00 543P - Organ preservation using contact radiotherapy for early rectal cancer: Outcomes of patients treated at a single centre in the United Kingdom

A. Dhadda, A. Martin, G. Solon, I. Hunter; Kingston Upon Hull, GB

13:00 - 13:00 544P - Capecitabine (cape) dosing using skeletal muscle index (SMI) compared to body surface area (BSA)

J. Sun¹, A. Ilich¹, C. Kim², G. Wong¹, S. Ghosh¹, J. Spratlin¹, K. Mulder¹, M. Danilak¹, C. Chambers¹, M. Sawyer³; ¹Edmonton, AB/CA, ²Winnipeg, CA, ³Edmonton, CA



- 13:00 - 13:00 545P - Geriatric assessment predicts survival and competing mortality in colorectal cancer elderly patients. Can it help in adjuvant therapy decision?
M. Antonio¹, J. Saldaña¹, A. Carmona-Bayonas², V. Navarro¹, C. Tebe³, F. Formiga³, R. Salazar¹, J. Borras¹; ¹Barcelona, ES, ²Murcia, ES, ³L'hospitalet De Llobregat, Barcelona, ES
- 13:00 - 13:00 546P - AVAPLUS: Impact of geriatric assessment on first-line treatment duration (TD) and progression free survival (PFS) in mCRC patients ≥ 70 years
L. Decoster¹, C. Kenis², B. Naessens³, G. Houbiers⁴, M. De Man⁵, G. Lambrecht⁶, E. Monsaert⁵, V. Moons⁷, P. Vergauwe⁸, H. Prenen², E. van Cutsem², E. Beutels¹, D. Frijns¹, H. Wildiers²; ¹Brussels, BE, ²Leuven, BE, ³St Niklaas, BE, ⁴Liège, BE, ⁵Gent, BE, ⁶Oostende, BE, ⁷Bonheiden, BE, ⁸Kortrijk, BE
- 13:00 - 13:00 547P - Updated report: A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402/HGCSG1402)
S. Yuki¹, Y. Komatsu², H. Satake³, Y. Miyamoto⁴, H. Tanioka⁵, A. Tsuji⁶, M. Asayama⁷, T. Shiraishi⁸, M. Kotaka³, A. Makiyama⁹, T. Kashiwada¹⁰, N. Takeuchi¹¹, M. Shimokawa¹², H. Saeki¹², E. Oki¹², Y. Emi¹², H. Baba⁴, Y. Maehara¹²; ¹Sapporo, Hokkaido/Jp, ²Sapporo, JP, ³Kobe, JP, ⁴Kumamoto, JP, ⁵Okayama, JP, ⁶Kagawa, JP, ⁷Saitama, JP, ⁸Matsuyama, JP, ⁹Kitakyushu, JP, ¹⁰Saga, JP, ¹¹Ina, JP, ¹²Fukuoka, JP
- 13:00 - 13:00 548P - Clinical activity of FOLFIRI plus cetuximab in elderly patients (pts) according to extended gene mutation status by next generation sequencing (NGS) in the CAPRI- GOIM trial
E. Martinelli¹, C. Cardone¹, T. Troiani¹, N. Normanno¹, S. Piscanti², R. Bordonaro³, G. Francesco⁴, M. Biglietto¹, C. Barone⁵, A.M. Rachiglio⁶, V. Montesarchio¹, G. Tonini⁵, S. Cinieri⁷, D. Rizzi⁴, A. Febraro⁸, T.P. Latiano⁹, G. Modoni², C. Giuseppe⁴, E. Maiello⁹, F. Ciardiello¹; ¹Napoli, IT, ²Taranto, IT, ³Catania, IT, ⁴Bari, IT, ⁵Roma, IT, ⁶Mercogliano (av), IT, ⁷Brindisi, IT, ⁸Benevento, IT, ⁹San Giovanni Rotondo, IT
- 13:00 - 13:00 549P - Gender and chemotherapy-related toxicity in colon cancer: An analysis of the PETACC-3 trial conducted by the EORTC GI-group
V. Cristina¹, J. Mahachie², M. Mauer², C. Csajka¹, D. Cunningham³, E. van Cutsem⁴, A. Roth⁵, A. Wagner¹; ¹Lausanne, CH, ²Brussels, BE, ³Sutton, GB, ⁴Leuven, BE, ⁵Geneva, CH
- 13:00 - 13:00 550P - A prospective observational study of the impact on bone metabolism of short-term periodic steroid premedication of chemotherapy for gastrointestinal cancer. (ESPRESSO-01 study): Pre-planned subgroup analysis
M. Nakamura¹, A. Ishiguro¹, T. Muranaka¹, S. Yuki², K. Ohno¹, T. Murai¹, C. Matsuda¹, A. Oba¹, K. Itaya¹, M. Yagisawa¹, Y. Koike¹, A. Endo¹, Y. Tsukuda¹, Y. Ono¹, T. Kudo¹, A. Nagasaka¹, S. Nishikawa¹, Y. Komatsu¹; ¹Sapporo, JP, ²Sapporo, Hokkaido/Jp
- 13:00 - 13:00 551P - Bevacizumab combined with 1st line chemotherapy in elderly patients (≥75 years-old) with metastatic colorectal cancer - Interim results according to the chemotherapy regimen (CASSIOPEE)
L. Mineur¹, E. Francois², S. Kim³, F. Burki⁴, P. Laplaige⁵, S. Gourgou⁶, F. Rollot-Trad⁷, J. Telliez⁸, S. Gandon⁸, D. Smith⁹; ¹Avignon, FR, ²Nice, FR, ³Besançon, FR, ⁴Saint Jean, FR, ⁵La Chaussee St. Victor, FR, ⁶Montpellier, FR, ⁷Paris, FR, ⁸Boulogne-Billancourt, FR, ⁹Bordeaux, FR



- 13:00 - 13:00 552P - Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP)
R. Riechelmann¹, V. Srimuninnimit², P. Kavan³, M. Di Bartolomeo⁴, E. Maiello⁵, I. Cicin⁶, H. Kröning⁷, P. Garcia-Alfonso⁸, I. Chau⁹, C. Fernández-Martos¹⁰, M. Ter-Ovanesov¹¹, M. Peeters¹², P. Picard¹³, R. Bordonaro¹⁴; ¹Sao Paulo, BR, ²Bangkok, TH, ³Montreal, CA, ⁴Milano, IT, ⁵San Giovanni Rotondo, IT, ⁶Edirne, TR, ⁷Magdeburg, DE, ⁸Madrid, ES, ⁹London And Surrey, GB, ¹⁰Valencia, ES, ¹¹Moscow, RU, ¹²Antwerp, BE, ¹³Chilly-Mazarin, FR, ¹⁴Catania, IT
- 13:00 - 13:00 553P - Adjuvant chemotherapy for stage III colorectal cancer in the elderly
D. Brungs¹, E. Healey¹, J. Rose¹, T. Tubaro¹, W. Ng², W. Chua², M. Carolan¹, P. de Souza³, M. Aghmesheh¹, M. Ranson¹; ¹Wollongong, AU, ²Sydney, NSW/AU, ³Sydney, AU
- 13:00 - 13:00 554P - Final analysis of patient-reported-outcomes (PRO) and early intervention to toxicities as tools for improving compliance of patients with metastatic colorectal cancer (mCRC) treated with aflibercept+FOLFIRI (A-FOLFIRI) under real-world-conditions in Germany
R. Lipp, M. Feuerbach, F. Freigang, P. Brecht; Hamburg, DE
- 13:00 - 13:00 555P - Integrated safety summary (ISS) for trifluridine/tipiracil (TAS-102)
A. Falcone¹, A. Ohtsu², E. Van Cutsem³, R. Mayer⁴, M. Buscaglia⁵, J. Bendell⁶, S. Kopetz⁷, M. Wahba⁸, P. Bebeau⁸, T. Yoshino²; ¹Pisa, IT, ²Kashiwa, JP, ³Leuven, BE, ⁴Boston, MA/US, ⁵Genova, IT, ⁶Nashville, TN/US, ⁷Houston, TX/US, ⁸Princeton, NJ/US
- 13:00 - 13:00 556P - Evaluation of Charlson comorbidity index as predictor of survival in stage II-III colorectal cancer patients treated with surgery and neoadjuvant/adjuvant chemotherapy: A single Institution observational study
M. Baretta¹, N. Personeni², L. Giordano², M.C. Tronconi², T. Pressiani², S. Bozzarelli², L. Rimassa², A. Santoro²; ¹Rozzano, (MI)/IT, ²Rozzano, IT
- 13:00 - 13:00 557P - Quality of life in patients with metastatic colorectal cancer receiving maintenance therapy after first-line inductive treatment: A quality of life sub-analysis of the AIO KRK 0207 phase III trial
J. Quiddle¹, S. Hegewisch Becker¹, U. Graeven², C. Lerchenmueller³, B. Killing⁴, R. Depenbusch⁵, C.-C. Steffens⁶, T. Lange⁷, G. Dietrich⁸, J. Stoehlmacher⁹, A. Reinacher¹⁰, A. Tannapfel¹⁰, T. Trarbach¹¹, N. Marschner¹¹, H.J. Schmoll¹², A. Hinke¹³, S.-E. Al-Batran¹⁴, D. Arnold¹¹; ¹Hamburg, DE, ²Mönchengladbach, DE, ³Münster, DE, ⁴Wetzlar, DE, ⁵Gütersloh, DE, ⁶Stade, DE, ⁷Weißenfels, DE, ⁸Bietigheim, DE, ⁹Bonn, DE, ¹⁰Bochum, DE, ¹¹Freiburg, DE, ¹²Halle, DE, ¹³Langenfeld, DE, ¹⁴Frankfurt Am Main, DE
- 13:00 - 13:00 558P - Oxaliplatin and erectile dysfunction
P. Dal, M. Dincer, B. Yildiz, O. Kahraman, M. Canhoroz, D. Arik, B. Başeskioglu, H. Yilmaz; Eskisehir, TR
- 13:00 - 13:00 559P - Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance
J. Riedl¹, F. Posch¹, M. Stotz¹, A. Bezan¹, T. Winder², R. Schaberl-Moser¹, M. Pichler¹, H. Stoeger¹, A. Gerger¹; ¹Graz, AT, ²Zürich, CH



- 13:00 - 13:00 560P - Molecular, clinical and prognostic characterization of double KRAS/PIK3CA (dKP) mutated metastatic colorectal cancer (mCRC)
J. Grasselli, E. Elez, G. Argiles Martinez, E. Sanz-Garcia, T. Macarulla, J. Capdevila, M. Alsina, T. Sauri, C. Hierro, H. Verdaguer, I. Matos, A. Garcia, P. Nuciforo, S. Landolfi, H. Garcia Palmer, R. Dienstmann, A. Vivancos, J. Tabernero; Barcelona, ES
- 13:00 - 13:00 561P - CDX2 loss as a prognostic and predictive biomarker in metastatic colorectal cancer
B. Zhang¹, J. Jones², A. Briggler², J. Hubbard², B. Kipp², D. Sargent², J. Dixon², A. Grothey²; ¹Rochester, MN/US, ²Rochester, US
- 13:00 - 13:00 562P - Genomic instability and early-onset colorectal cancer: A new form of classifying the disease?
M. Arriba¹, J. Garcia², J. Cano³, D. Rueda¹, J. Pérez², L. Brandariz¹, T. Fernández¹, O. Nutu¹, L. Alonso¹, M. Urioste¹, R. González-Sarmiento², J. Perea¹; ¹Madrid, ES, ²Salamanca, ES, ³Ciudad Real, ES
- 13:00 - 13:00 563P - Cascade testing following universal immunohistochemistry for mismatch repair proteins
N. Karadawi¹, G. O'Kane², D. Gallagher¹, S. Finn¹, C. Muldoon¹, N. Mulligan¹; ¹Dublin, IE, ²Toronto, CA
- 13:00 - 13:00 564P - Clinical significance of thymidine kinase 1 expression on TAS-102 treatment in RECURSE phase III trial of TAS-102 versus placebo for metastatic colorectal cancer
K. Yamazaki¹, T. Yoshino², E. Shinozaki³, Y. Komatsu⁴, Y. Tsuji⁴, T. Nishina⁵, H. Baba⁶, T. Denda⁷, N. Sugimoto⁸, A. Tsuji⁹, K. Yamaguchi³, T. Takayama¹⁰, Y. Shimada³, Y. Hamamoto³, K. Muro¹¹, M. Gotoh¹², T. Tanase³, A. Ohtsu²; ¹Shizuoka, JP, ²Kashiwa, JP, ³Tokyo, JP, ⁴Sapporo, JP, ⁵Matsuyama, JP, ⁶Kumamoto, JP, ⁷Chiba, JP, ⁸Osaka, JP, ⁹Kagawa, JP, ¹⁰Tokushima, JP, ¹¹Nagoya, JP, ¹²Takatsuki, JP
- 13:00 - 13:00 565P - The impact of mass spectrometry multigenic platform on the management of metastatic colorectal patients
A. Destro, C. Lo Russo, P. Spaggiari, S. Armenia, E. Bellofiore, M. Lorini, T. Brambilla, M.M. Cimino, A. Spinelli, N. Personeni, L. Rimassa, L. Di Tommaso, M. Roncalli; Rozzano, IT
- 13:00 - 13:00 566P - A systematic review and meta-analysis of the prognostic value of total cell-free DNA quantification in metastatic colorectal cancer
K.-L. Spindler¹, A. Boysen², N. Palisgaard³, J. Johansen⁴, J. Tabernero⁵, P.M. Mau-Soerensen⁶, T. Hansen⁷, D. Sefrioui⁸, B. Jensen⁴, B. Soerensen¹, R. Andersen⁷, C. Demuth¹, I. Brandslund⁷, A. Jakobsen⁷; ¹Aarhus C, DK, ²Aarhus, DK, ³Roskilde, DK, ⁴Herlev, DK, ⁵Barcelona, ES, ⁶Copenhagen, DK, ⁷Vejle, DK, ⁸Rouen, FR
- 13:00 - 13:00 567P - The differences between suspicious Lynch and sporadic dMMR colorectal cancers
G. Liu¹, W. Huang², R. Liu², Z. Pan², P. Ding²; ¹Guangzhou, Guangdong/CN, ²Guangzhou, CN
- 13:00 - 13:00 568P - BRAF mutated metastatic colorectal cancers do not always possess poor clinical outcome
J.E. Kim, Y.S. Hong, K.-P. Kim, S.Y. Kim, T.W. Kim, J. Cheon; Seoul, KR



- 13:00 - 13:00 569P - The location of colorectal cancer (right- vs. left-sided colon and rectum) affects the prevalence of BRAF V600E, non-V600E and PIK3CA mutations: A prospective registration study in the Aichi Cancer Network
H. Taniguchi¹, K. Uehara¹, H. Nakayama¹, G. Nakayama¹, T. Takahashi², Y. Nakano¹, H. Matsuoka³, S. Utsunomiya⁴, E. Sakamoto¹, Y. Mori¹, K. Komori¹, M. Tajika¹, K. Muro¹, Y. Yatabe¹; ¹Nagoya, JP, ²Seto, JP, ³Toyoake, JP, ⁴Yatomi-Shi, JP
- 13:00 - 13:00 570P - Diagnostic value of methylation status of T-UCRs for colorectal cancer
A. Kottorou, A. Antonacopoulou, F.-I. Dimitrakopoulos, G. Diamantopoulou, T. Theodorakopoulos, C. Oikonomou, I. Koukourikou, D. Dalla, P. Karatasou, E. Katsakoulis, A. Koutras, T. Makatsoris, M. Stavropoulos, K. Thomopoulos, H. Kalofonos; Patras, GR
- 13:00 - 13:00 571P - Clinical characteristics and outcomes of patients with metastatic colorectal cancer (CRC) harboring NRAS mutations
M.I. Braghiroli¹, J. Chou¹, J. Hechtman¹, M. Capanu¹, A. Cercek², R. Yaeger¹; ¹New York, NY/US, ²New York, US
- 13:00 - 13:00 572P - Tumor-infiltrating lymphocytes (TILs) density as prognostic determinant in stage II colorectal cancer
C. Lo Nigro, A. Comino, D. Vivenza, C. Granetto, M. Ferrero, L. Lattanzio, C. Varamo, V. Ricci, M. Merlano; Cuneo, IT
- 13:00 - 13:00 573P - Characterization of the immunoscore of synchronous resected primary tumor and liver colorectal cancer metastases
M. van den Eynde¹, B. Mlecnik², G. Bindea², J.-P. Machiels¹, A. Jouret-Mourin¹, P. Baldin¹, A. Kartheuser¹, D. Leonard¹, C. Remue¹, J.-F. Gigot¹, C. Hubert¹, Y. Humblet¹, N. Haicheur², F. Marliot², F. Pagès², J. Galon²; ¹Brussels, BE, ²Paris, FR
- 13:00 - 13:00 574P - Prognostic mRNA expression signatures in whole blood in patients with metastatic colorectal cancer treated with 3rd line cetuximab and irinotecan
J. Schou¹, B. Jensen², D.L. Nielsen², J. Palshof², E. Høgdall², M. Yilmaz³, P. Pfeiffer⁴, J. Johansen², S. Rossi⁵; ¹Copenhagen, DK, ²Herlev, DK, ³Aalborg, DK, ⁴Odense C, DK, ⁵Bellinzona, CH
- 13:00 - 13:00 575P - A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy
E. Mini¹, R. D'Aurizio², G. Perrone³, A. Magi³, A. Lapucci³, R. Tassi³, C. Napoli³, L. Picariello³, I. Landini³, M. Brugia³, T. Mazzei³, F. Tonelli³, S. Nobili³; ¹Florence, IT, ²Pisa, IT, ³Firenze, IT
- 13:00 - 13:00 576P - Gene expression profile reveals a nodal status signature in rectal carcinomas
L. Matos Do Canto¹, M. Begnami¹, F. Marchi¹, B. Catin¹, C. Scapulatempo-Neto², S. Aguiar Jr.¹, S. Rogatto³; ¹Sao Paulo, BR, ²Barretos, BR, ³Vejle, DK
- 13:00 - 13:00 577P - Perineural invasion as a prognostic factor in rectal cancer treated with preoperative chemoradiotherapy: A multicenter retrospective study
J.W. Park¹, S.-B. Ryoo¹, B.K. Park², S.-B. Kang³, J.H. Oh², D.-W. Kim³, S.-Y. Jeong¹, K.J. Park¹; ¹Seoul, KR, ²Goyang, KR, ³Seongnam-Si, KR



- 13:00 - 13:00 578P - Family history of colorectal cancer (CRC) in first degree relatives and survival in patients with newly diagnosed synchronous metastatic CRC
S. Ahmed¹, S. Kazmi², M. Emara¹, T. Asif¹, R. Alvi¹, D. Le¹, N. Iqbal¹, A. Zaidi³, T. Abbas³, K. Haider³; ¹Saskatoon, CA, ²Karachi, PK, ³Saskatoon, SK/CA
- 13:00 - 13:00 579P - A nomogram for predicting overall survival (OS) in Japanese patients (pts) with advanced colorectal cancer (aCRC) treated with irinotecan (IRI)-based regimens
W. Ichikawa¹, K. Uehara², K. Minamimura¹, C. Tanaka³, Y. Takii⁴, H. Miyauchi⁵, S. Sadahiro⁶, K. Shinozaki⁷, K. Fukumoto⁸, T. Otsuji⁹, T. Kambara¹⁰, S. Morita⁸, Y. Ando², M. Arai¹, M. Sugihara¹, T. Sugiyama¹¹, Y. Ohashi¹, Y. Sakata¹²; ¹Tokyo, JP, ²Nagoya, JP, ³Gifu, JP, ⁴Niigata, JP, ⁵Chiba, JP, ⁶Isehara, JP, ⁷Hiroshima, JP, ⁸Kyoto, JP, ⁹Yamatotakada, JP, ¹⁰Fukuyama, JP, ¹¹Morioka, JP, ¹²Misawa, JP
- 13:00 - 13:00 580P - Risk factors for brain metastases in patients with metastatic colorectal cancer
T. Christensen¹, J. Palshof¹, F.O. Larsen¹, E. Høgdall¹, T. Poulsen¹, B. Jensen¹, P. Pfeiffer², M. Yilmaz³, I. Christensen¹, D.L. Nielsen¹; ¹Herlev, DK, ²Odense C, DK, ³Aalborg, DK
- 13:00 - 13:00 581P - Prognostic factors in patients with locally advanced rectal cancer who underwent preoperative chemoradiotherapy: Subclassification of patients with ypstage II cancer according to tumor regression grade
T. Suzuki, S. Sadahiro, G. Saito, K. Okada, A. Tanaka; Isehara, JP
- 13:00 - 13:00 582P - Colorectal cancer in octogenarian patients: A single institution experience
E. Inga, G. Padilla, E. Casaut, M. Gonzalez, A. Gonzalez-Haba, J.R. Rodriguez, J. Gomez-Ulla; Badajoz, ES
- 13:00 - 13:00 583P - Prognostic factor analysis for elderly patients treated for metastatic colorectal cancer in the randomized phase II trial PRODIGE 20
T. Aparicio¹, O. Bouché², E. Francois³, E. Maillard⁴, S. Kirscher⁵, J. Taieb⁶, P.-L. Etienne⁷, R. Faroux⁸, F. Khemissa Akouz⁹, F. El Hajbi¹⁰, C. Locher¹¹, Y. Rinaldi¹², T. Lecomte¹³, S. Lavau-Denes¹⁴, M. Baconnier¹⁵, A. Oden-Gangloff¹⁶, D. Genet¹⁴, E. Paillaud¹⁷, F. Retornaz¹², L. Bedenne⁴; ¹Bobigny, FR, ²Reims, FR, ³Nice, FR, ⁴Dijon, FR, ⁵Avignon, FR, ⁶Paris, FR, ⁷Plerin Sur Mer, FR, ⁸La Roche Sur Yon, FR, ⁹Perpignan, FR, ¹⁰Lille, FR, ¹¹Meaux, FR, ¹²Marseille, FR, ¹³Tours, FR, ¹⁴Limoges, FR, ¹⁵Pringy, FR, ¹⁶Rouen, FR, ¹⁷Créteil, FR
- 13:00 - 13:00 584P - Stratification of patients with locally advanced rectal cancer (LARC) treated with preoperative chemoradiation (ChR), according to Valentini's nomograms (VN) and the Neoadjuvant Rectal Score (NAR). External validation in a single Institution.
S. Roselló Keränen, M. Frasson, E. García-Granero, S. Navarro, S. Campos, E. Jordá, P. Esclapez, S. García-Botello, B. Flor, A. Espí, A. Cervantes; Valencia, ES
- 13:00 - 13:00 585P - Brain metastases (BM) in colorectal cancer (CRC): Prognostic factors and survival analysis
L. Del Carpio Huerta, M. Tobeña, A.C. Virgili Manrique, J. Szafranska, M. Martín-Richard, D. Paez, I. Espinoza, A. Sebío Garcia, P. Gomila Pons, M. Andrés Granyo, A. Barba Joaquín, N. Dueñas Cid, A. Vethencourt Casado, M.S. García-Cuerva; Barcelona, ES
- 13:00 - 13:00 586P - 5-fluorouracil degradation rate (5-FU-DR) as a new toxicity predictive biomarker for adjuvant FOLFOX in colorectal cancer (CRC) patients



C.E. Onesti, A. Botticelli, F. Mazzuca, A. Milano, A. Romiti, M. Roberto, R. Falcone, M. Occhipinti, F.R. Di Pietro, L. Lionetto, M. Simmaco, P. Marchetti; Roma, IT

- 13:00 - 13:00 587P - Clinical characteristics of colorectal cancer patients with brain metastases: An "Association des Gastro-Étérologues Oncologues" (AGEO) multicenter study
P. Roussille¹, M. Dior², C. Locher³, M. Mabro², P. Artru⁴, G. Tachon¹, É. Frouin¹, A. Berger¹, M. Wager¹, J.-M. Goujon¹, L. Karayan-Tapon¹, D. Tougeron¹; ¹Poitiers, FR, ²Paris, FR, ³Meaux, FR, ⁴Lyon, FR
- 13:00 - 13:00 588P - Is the derived neutrophil to lymphocyte ratio (dNLR) an independent prognostic marker in patients with metastatic colorectal cancer (mCRC)? Analysis of the CO.17 and CO.20 studies
C. Diakos¹, D. Tu², V. GebSKI³, S. Yip³, K. Wilson³, C. Karapetis⁴, C. O'Callaghan², J. Shapiro⁵, N. Tebbutt⁶, D. Jonker⁷, L. Siu⁸, R. Wong⁹, C. Doyle¹⁰, A. Strickland¹¹, T. Price¹², J. Simes³, S. Clarke¹; ¹St Leonards, AU, ²Kingston, ON/CA, ³Camperdown, NSW/AU, ⁴Bedford Park, SA/AU, ⁵Melbourne, AU, ⁶Heidelberg, AU, ⁷Ottawa, ON/CA, ⁸Toronto, CA, ⁹Winnipeg, CA, ¹⁰Quebec City, QC/CA, ¹¹Melbourne, VIC/AU, ¹²Adelaide, AU
- 13:00 - 13:00 589P - Is baseline neutrophil to lymphocyte ratio (NLR) an independent prognostic biomarker for progression free survival (PFS) and overall survival (OS) in metastatic colorectal cancer (mCRC)? Analysis of the AGITG MAX study
C. Diakos¹, K. Wilson², R. Asher², V. GebSKI², S. Yip², G. van Hazel³, B. Robinson⁴, A. Broad⁵, T. Price⁶, J. Simes⁷, N. Tebbutt⁸, S. Clarke¹; ¹St Leonards, AU, ²Camperdown, NSW/AU, ³Perth, AU, ⁴Christchurch, NZ, ⁵Geelong, VIC/AU, ⁶Adelaide, AU, ⁷Sydney, NSW/AU, ⁸Heidelberg, AU
- 13:00 - 13:00 590P - Prognostic value of neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and mean platelet volume (MPV) in patients with colorectal carcinoma [Izmir Oncology Group (IZOG) study]
U. Oflazoglu, A. Alacacioglu, I. Kundak Somali, M. Yuce, M. Buyruk, U. Varol, T. Salman, H. Taskaynatan, Y. Yildiz, Y. Kucukzeybek, I. Oztop, M. Tarhan; Izmir, TR
- 13:00 - 13:00 591P - Reduction of blood total lymphocyte count after neoadjuvant treatment is correlated with good tumor regression—results from a prospective randomized control trial
Z. Wu, Y. Deng, J. Zhang, Y. Cai, H. Hu, L. Yang; Guangzhou, CN
- 13:00 - 13:00 592P - Is neutropenia a prognostic or a predictive factor for second line metastatic colorectal cancer (mCRC) patients (Pts)? Exploratory analysis from RAISE, a randomized, double-blind, phase III study of ramucirumab (RAM) + FOLFIRI vs placebo (PBO) + FOLFIRI
T.-E. Ciuleanu¹, G. Bodoky², R. Garcia-Carbonero³, P. García Alfonso³, E. Van Cutsem⁴, K. Muro⁵, D. Mytelka⁶, O. Lipkovich⁶, D. Ferry⁷, A. Sashegyi⁶, F. Nasroulah⁶, J. Taberero⁸; ¹Cluj Napoca, RO, ²Budapest, HU, ³Madrid, ES, ⁴Leuven, BE, ⁵Nagoya, JP, ⁶Indianapolis, US, ⁷Bridgewater, NJ/US, ⁸Barcelona, ES
- 13:00 - 13:00 593P - Prognostic value of signet ring cell histology for survival in stage I and II colon cancer patients: A population-based, propensity score matched analysis
U. Gueller, T. Cerny, B. Schmied, R. Warschkow; St. Gallen, CH
- 13:00 - 13:00 594P - Evolution of skeletal muscle mass (SMM) during palliative systemic treatment in metastatic colorectal cancer (mCRC) patients participating in the randomized phase 3 CAIRO3 study



S. Kurk¹, P. Peeters², B. Dorresteijn¹, M. Jourdan¹, H. Kuijff¹, C. Punt³, M. Koopman¹, A. May¹; ¹Utrecht, NL, ²London, GB, ³Amsterdam, NL

- 13:00 - 13:00 595P - Correlation between alternative endpoints and overall survival in metastatic colorectal cancer patients eligible to a maintenance strategy
A. Turpin¹, S. Paget-Bailly², A. Ploquin³, A. Hollebecque⁴, S. Dominguez³, F. Bonnetain², F. El Hajbi³, M. Hebbar³; ¹Lille, CEDEX/FR, ²Besançon, FR, ³Lille, FR, ⁴Villejuif, FR
- 13:00 - 13:00 596P - Prognostic role of tumor location in stage 3 colorectal cancer patients received adjuvant chemotherapy
N. Ozdemir, S. Aslan, K. Erdogan, O. Yazici, M. Sendur, Y. Bozkaya, N. Zengin; Ankara, TR
- 13:00 - 13:00 597P - Neutrophil-to-lymphocyte ratio as a biomarker for prognosis in localized colorectal carcinoma
N. Chic¹, G. Bruixola², O. Reig¹, R. Diaz- Beveridge², E. Buxo¹, E. Pineda¹, A. Prat¹, J. Aparicio², J. Maurel¹; ¹Barcelona, ES, ²Valencia, ES
- 13:00 - 13:00 598TiP - APOLLON study: A phase I/II study for the safety and efficacy of panitumumab in combination with TAS-102 for patients with RAS wild-type metastatic colorectal cancer refractory to standard chemotherapy
K. Yamaguchi¹, Y. Komatsu², E. Oki³, T. Yoshino⁴, K. Yamazaki⁵, K. Shibuya¹, K. Oba¹, T. Kato⁶; ¹Tokyo, JP, ²Sapporo, JP, ³Fukuoka, JP, ⁴Kashiwa, JP, ⁵Shizuoka, JP, ⁶Amagasaki, JP
- 13:00 - 13:00 599TiP - A randomized phase III trial of capecitabine with or without irinotecan driven by UGT1A1 in neoadjuvant chemoradiation of locally advanced rectal cancer (CinClare)
J. Zhu¹, J. Chen², Y. Zhu³, J. Zhou³, Y. Zhu⁴, T. Zhang⁵, J. Jia⁶, C. Zhang⁷, X. Wang⁸, Y. Gao⁹, G. Cai¹, B. Luo¹⁰, J. Wu¹¹, A. Liu¹², B. Xu¹¹, Z. Zhang¹; ¹Shanghai, CN, ²Nanjing, CN, ³Suzhou, CN, ⁴Hangzhou, CN, ⁵Chongqing, CN, ⁶Shenyang, CN, ⁷Ningbo, CN, ⁸Chengdu, CN, ⁹Guangzhou, CN, ¹⁰Wuhan, CN, ¹¹Fuzhou, CN, ¹²Nanchang, CN
- 13:00 - 13:00 600TiP - A phase 1B study of pegylated liposomal mitomycin-C prodrug with or without capecitabine and bevacizumab in third line chemotherapy of colorectal cancer
A. Gabizon¹, T. Grenader¹, E. Tahover¹, H. Shmeeda¹, T. Golan², R. Berger², R. Geva³, I. Wolf³, R. Perets⁴, Y. Amitay¹, P. Ohana¹; ¹Jerusalem, IL, ²Ramat Gan, IL, ³Tel Aviv, IL, ⁴Haifa, IL
- 13:00 - 13:00 601TiP - NORDIC9: A randomized phase II trial exploring treatment of older patients with metastatic colorectal cancer (mCRC) by comparing full dose monotherapy (S-1 followed by irinotecan) with reduced combination regimen (S-1/oxaliplatin followed by S-1/irinotecan)
S. Winther¹, P. Østerlund², Å. Berglund³, B. Glimelius³, C. Qvortrup¹, H. Sorbye⁴, P. Pfeiffer¹; ¹Odense C, DK, ²Helsinki, FI, ³Uppsala, SE, ⁴Bergen, NO
- 13:00 - 13:00 602TiP - Re-RAD-I external beam radiotherapy for pelvic recurrences in rectal cancer patients previously treated with radiotherapy
M. Guren¹, H. Christensen², S. Larsen¹, A. Appelt³, J. Lindegaard², K.-L. Spindler²; ¹Oslo, NO, ²Aarhus C, DK, ³Vejle, DK
- 13:00 - 13:00 603TiP - REINVENT (REgorafenib traNslational eValuation angiogENesis proTocol)



L. Demurtas¹, E. Lai¹, A. Cubeddu¹, M. Puzzone², G. Pusole¹, S. Tolu¹, A. Dessi¹, R. Mascia¹, V. Pusceddu¹, G. Astaro¹, C. Madeddu¹, E. Massa¹, P. Ziranu¹, L. Orgiano¹, L. Casula¹, M. Scartozzi¹; ¹Cagliari, IT, ²Monserrato, IT

- 13:00 - 13:00 604TiP - PRODIGE 25 (FFCD 11-01) - Phase II randomized trial evaluating aflibercept associated with LV5FU2 regimen as first line treatment of non-resectable metastatic colorectal cancers (FOLFA)
- J.L. Legoux¹, K. Le Malicot², R. Faroux³, V. Boige⁴, N. Barriere⁵, J. Egretteau⁶, Y. Rinaldi⁵, E. Maillard⁷, M. Baconnier⁸, C. Lecaille⁹, S. Herrmann-Gandara¹, A. Vimal¹⁰, Y. Touchefeu¹¹, J. Raimbourg¹¹, T. Aparicio¹²; ¹Orleans, FR, ²Dijon, FR, ³La Roche Sur Yon, FR, ⁴Villejuif, FR, ⁵Marseille, FR, ⁶Lorient, FR, ⁷Annecy, FR, ⁸Pringy, FR, ⁹Bordeaux, FR, ¹⁰Clermont-Ferrand, FR, ¹¹Nantes, FR, ¹²Bobigny, FR
- 13:00 - 13:00 605TiP - Randomized phase II study of maintenance treatment with 5-FU/FA plus panitumumab vs 5-FU/FA alone after induction (mFOLFOX6 plus panitumumab) in patients with RAS WT metastatic colorectal cancer
- D.P. Modest¹, S. Kasper², S. Stintzing³, N. Prasnikar⁴, L. Müller⁵, K. Caca⁶, E. Gökkurt⁷, L. Fischer von Weikersthal⁸, H.-G. Kopp⁹, T. Trarbach¹⁰; ¹DE, ²Essen, DE, ³München, DE, ⁴Hamburg, DE, ⁵Leer, DE, ⁶Ludwigsburg, DE, ⁷Eppendorf, DE, ⁸Amberg, DE, ⁹Tübingen, DE, ¹⁰Wilhelmshaven, DE
- 13:00 - 13:00 606TiP - Selection with a molecUlar PanEl foR Panitumumab EfficAcy in K-ras and n-ras wild type metastatic colorectal cancer (SUPER- PEAK)
- M. Puzzone¹, G. Pusole², R. Mascia², L. Demurtas², A. Dessi², A. Cubeddu², E. Lai², S. Tolu², P. Ziranu², L. Orgiano¹, V. Pusceddu², G. Astaro², C. Madeddu², E. Massa², L. Casula², G. Palmieri³, M. Scartozzi²; ¹Monserrato, IT, ²Cagliari, IT, ³Sassari, IT
- 13:00 - 13:00 607TiP - TransSCOT – translational research based on the Short Course Oncology Therapy (SCOT) cohort
- B.E. Engelmann¹, T. Iveson², E. Høgdall¹, N.H. Holländer³; ¹Herlev, DK, ²Southampton, GB, ³Naestved, DK
- 13:00 - 13:00 608TiP - CanStem303C trial: A phase III study of BBI-608 (napabucasin) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC)
- A. Grothey¹, N. Tebbutt², E. Van Cutsem³, J. Taieb⁴, A. Falcone⁵, T. Yoshino⁶, A. Cervantes⁷, L. Borodyansky⁸, C. Li⁹; ¹Rochester, US, ²Heidelberg, AU, ³Leuven, BE, ⁴Paris, FR, ⁵Pisa, IT, ⁶Kashiwa, JP, ⁷Valencia, ES, ⁸Cambridge, MA/US, ⁹Cambridge, US
- 13:00 - 13:00 Gastrointestinal tumours, non-colorectal
- 13:00 - 13:00 623P - Multimodality treatment (MMT) and outcomes of gastric adenocarcinoma (GC) in National Cancer DataBase(NCDB)
- A. Barzi¹, D. Yang², H.-J. Lenz², S. Sadeghi²; ¹Los Angeles, CA/US, ²Los Angeles, US
- 13:00 - 13:00 624P - Programmed death-ligand 1 (PD-L1) and immune infiltrates are prognostic for better outcome and enriched in the ATM (ataxia telangiectasia mutated)-low segment of gastric cancer (GC)



E. Kilgour¹, H. Angell², K.-M. Kim³, S. Ahn³, S.T. Kim³, A. Sharpe², J. Ogden², A. Davenport⁴, J. Barrett⁵, D. Hodgson¹, J. Lee³; ¹Macclesfield, GB, ²Cambridge, GB, ³Seoul, KR, ⁴Manchester, GB, ⁵Boston, MA/US

13:00 - 13:00 625P - Surgically treated esophageal cancer developed in a radiated field: Impact on peri-operative and long-term outcomes

S. Markar¹, C. Gronnier², A. Pasquer², A. Duhamel², H. Behal², J. Thereaux², J. Gagniere², G. Lebreton², C. Brigand², B. Meunier³, D. Collet⁴, C. Mariette²; ¹London, GB, ²Lille, FR, ³Rennes, FR, ⁴Bordeaux, FR

13:00 - 13:00 626P - First-line triplet or doublet chemotherapy for advanced gastric cancer: Analysis of 970 patients from a community practice registry

I. Echavarria Diaz-Guardamino¹, A. Carmona-Bayonas², P. Jimenez Fonseca³, A.J. Muñoz Martin¹, M.L. Sanchez Lorenzo³, A. Custodio¹, M. Garrido⁴, J. Cano⁵, J.E. Lorenzo Barreto⁶, A. Lacalle⁷, M. Ferrer Cardona⁸, M. Manga⁹, L. Visa¹⁰, E. Buxo¹⁰, A. Azkarate¹¹, A. Diaz¹, A. Ramchandani¹², M. Mugica¹³, P. Sala⁷, P. García Alfonso¹; ¹Madrid, ES, ²Murcia, ES, ³Oviedo, ES, ⁴Santiago, CL, ⁵Ciudad Real, ES, ⁶Santa Cruz, ES, ⁷Pamplona, ES, ⁸Sabadell, ES, ⁹Galdakao, ES, ¹⁰Barcelona, ES, ¹¹Palma De Mallorca, ES, ¹²Las Palmas, ES, ¹³Santander, ES

13:00 - 13:00 627P - Histopathological response to neoadjuvant chemotherapy is predictive for prognosis in locally advanced gastroesophageal cancer

S. Spoerl¹, S.-E. Al-Batran², M. Feith³, F. Lordick⁴, P. Thuss-Patience⁵, C. Pauligk², B. Haller³, A. Novotny³, S. Lorenzen³; ¹Munich, DE, ²Frankfurt Am Main, DE, ³München, DE, ⁴Leipzig, DE, ⁵Berlin, DE

13:00 - 13:00 628P - The role of antiangiogenic therapy in advanced gastro-esophageal cancer: A systematic review and meta-analysis

M.C. Riesco-Martinez¹, A. Díaz-Serrano², C. Gomez-Martin², J. Adeva Alfonso², E. Sabater Cabrera², R. Garcia-Carbonero²; ¹Toronto, Ontario/CA, ²Madrid, ES

13:00 - 13:00 629P - Molecular characterization of HER2-positive (HER2+) metastatic gastric and gastro-esophageal junction cancer patients (mGC): Identification of resistance mechanisms to trastuzumab-based therapy (TTZ)

M. Alsina¹, C. Hierro¹, J. Sastre², R. Guardado³, C. Lopez⁴, E. Pineda¹, E. Aranda⁵, J.L. Manzano⁶, M. Galán¹, F. Longo², L. Visa¹, S. Landolfi¹, J. Jimenez¹, J. Sperinde⁷, A. Pandiella⁸, J. Tabernero¹, J. Hernandez-Losa¹, J. Arribas¹, M. Scaltriti⁹, P. Nuciforo¹; ¹Barcelona, ES, ²Madrid, ES, ³Girona, ES, ⁴Santander, ES, ⁵Cordoba, ES, ⁶Badalona, ES, ⁷San Francisco, US, ⁸Salamanca, ES, ⁹New York, US

13:00 - 13:00 630P - Clinical significance of serum factors relating to ERBB signal pathways in a phase II trial of S-1 plus cisplatin combined with trastuzumab for HER2-positive advanced gastric or esophagogastric junction cancer: WJOG7212G (T-SPACE) TR study

Y. Sukawa¹, K. Noshō², Y. Miura¹, T. Takano¹, M. Ito², K. Yonesaka³, M. Mori⁴, S. Tokunaga³, J. Kawada³, H. Okuda², T. Sakamoto⁵, Y. Hirashima⁶, K. Uchino⁷, Y. Miyata⁸, K. Yoshimura⁹, K. Yamazaki¹⁰, S. Hironaka¹¹, N. Boku¹, I. Hyodo¹², K. Muro¹³; ¹Tokyo, JP, ²Sapporo, JP, ³Osaka, JP, ⁴Tochigi, JP, ⁵Kobe, JP, ⁶Oita, JP, ⁷Fukuoka, JP, ⁸Nagano, JP, ⁹Kanazawa, JP, ¹⁰Shizuoka, JP, ¹¹Chiba, JP, ¹²Tsukuba, JP, ¹³Nagoya, JP



- 13:00 - 13:00 631P - The role of cardiovascular risk factors on postoperative course after esophageal cancer surgery
D. Collet¹, C. Gronnier², G. Luc¹, R. Chevalier¹, E. Guinard³, K. Dantrem¹, B. Meunier³; ¹Bordeaux, FR, ²Lille, FR, ³Rennes, FR
- 13:00 - 13:00 632P - KRAS mutation and protein levels in gastric cancer patients and response to MEK inhibitors
J. Wei, Y. Huang, N. Wu, L. Yu, B. Liu; Nanjing, CN
- 13:00 - 13:00 633P - Efficacy and safety of dose-dense taxotere cisplatin fluorouracil regimen (mTCF-dd) in a large cohort of patients (pts) with metastatic or locally advanced non-squamous gastroesophageal cancer (GEC)
L. Toppo¹, G. Tomasello¹, M. Ghidini², C. Caminiti³, G. Maglietta³, S. Lazzarelli¹, W. Liguigli¹, M. Rovatti¹, V. Ranieri¹, G. Tanzi¹, F. Buffoli¹, M. Martinotti¹, R. Passalacqua¹; ¹Cremona, IT, ²Rozzano, IT, ³Parma, IT
- 13:00 - 13:00 634P - Association of disease measurability, quality of life (QoL) and tumor status in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) cancer
I. Chau¹, S.-E. Al-Batran², A. Barzi³, A.M. Liepa⁴, Z. Cui⁴, Y. Hsu⁵, S. Chin⁴; ¹London & Surrey, GB, ²Frankfurt, DE, ³Los Angeles, CA/US, ⁴Indianapolis, IN/US, ⁵Bridgewater, NJ/US
- 13:00 - 13:00 635P - Genetic analysis of gastric cancer with distinctive family history
M. Terashima, K. Hatakeyama, M. Kusuhara, R. Makuuchi, M. Tokunaga, Y. Tanizawa, E. Bando, T. Kawamura, M. Hikage, S. Kaji, K. Ohshima, S. Ohnami, K. Urakami, K. Yamaguchi; Shizuoka, JP
- 13:00 - 13:00 636P - Safety and efficacy profile of ramucirumab alone or combined with paclitaxel in metastatic gastric cancer (MGC): A real-life overview of compassionate-use named patients (pts) (RAMoss study)
M. Di Bartolomeo¹, M. Niger¹, M.M. Laterza², C. Vivaldi³, E. Giommoni⁴, A. Zaniboni⁵, S. Bozzarelli⁶, G. Tomasello⁷, T. Sava⁸, M. Spada⁹, A. Bittoni¹⁰, S. Galdy¹, A. Spallanzani¹¹, F. Bassan¹², S. Scagnoli¹³, F. Morano¹³, R. Berenato¹, M. Caporale¹, P. Filippo¹, F. De Vita²; ¹Milano, IT, ²Napoli, IT, ³Pisa, IT, ⁴Firenze, IT, ⁵Brescia, IT, ⁶Rozzano, IT, ⁷Cremona, IT, ⁸Camposampiero, IT, ⁹Cefalù, IT, ¹⁰Ancona, IT, ¹¹Modena, IT, ¹²Santorso, IT, ¹³Roma, IT
- 13:00 - 13:00 637P - Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer
Y. Choi¹, J.W. Kim¹, K.H. Nam², J.-W. Kim¹, S.-H. Ahn¹, D.J. Park¹, K.-W. Lee¹, H.S. Lee¹, H.-H. Kim¹; ¹Seongnam-Si, KR, ²Busan, KR
- 13:00 - 13:00 638P - Investigating the feasibility of precision medicine in gastrointestinal cancers
S.Y. Moorcraft¹, D. Gonzalez De Castro¹, D. Cunningham², B. Walker¹, T. Jones¹, C. Peckitt¹, S. Hulkki Wilson¹, A. Wotherspoon¹, L. Teixeira Mendes¹, R. Begum¹, Z. Eltahir¹, L. Yuan¹, A. Gillbanks¹, C. Baratelli³, N. Valeri¹, M. Gerlinger², C. Braconi¹, I. Chau², D. Watkins¹, N. Starling¹; ¹Sutton, GB, ²London, GB, ³Orbassano, IT
- 13:00 - 13:00 639P - The final results of a multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201)



H. Bando¹, T. Doi¹, K. Muro², H. Yasui³, T. Nishina⁴, K. Yamaguchi⁵, S. Takahashi⁵, H. Hasegawa¹, S. Nomura¹, H. Kuno¹, K. Shitara¹, A. Sato¹, A. Ohtsu¹; ¹Kashiwa, JP, ²Nagoya, JP, ³Shizuoka, JP, ⁴Matsuyama, JP, ⁵Tokyo, JP

- 13:00 - 13:00 640P - Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with 2 and 4 courses of cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) as neoadjuvant chemotherapy for locally advanced gastric cancer
K. Nishikawa¹, T. Yoshikawa², K. Fujitani¹, K. Tanabe³, S. Ito⁴, T. Matsui⁵, A. Miki⁶, H. Nemoto², K. Sakamaki², H. Cho², T. Fukunaga⁷, Y. Kimura⁸, N. Hirabayashi³; ¹Osaka, JP, ²Yokohama, JP, ³Hiroshima, JP, ⁴Nagoya, JP, ⁵Okazaki, JP, ⁶Kobe, JP, ⁷Kawasaki, JP, ⁸Sakai, JP
- 13:00 - 13:00 641P - FcγR IIA and IIIA polymorphisms predict clinical outcome of trastuzumab treated metastatic gastric cancer
R. Xu, D. Wang; Guangzhou, CN
- 13:00 - 13:00 642P - Plasma mRNA as liquid biopsy in individualized chemotherapy of gastric cancer
J. Shen¹, J. Wei¹, X. Qian², B. Liu¹; ¹Nanjing, CN, ²Nanjing, Jiangsu Province/CN
- 13:00 - 13:00 643P - A randomized phase II study of leucovorin, 5-fluorouracil with or without oxaliplatin (LV5FU2 vs. FOLFOX) for curatively-resected, node-positive esophageal squamous cell carcinoma
S.H. Lim¹, Y.-L. Choi², S.-H. Jung³, M.-J.A. Ahn⁴, K. Park⁴, J.I. Zo², Y.M. Shim², J.-M. Sun²; ¹Hwaseong-Si, KR, ²Seoul, KR, ³Durham, US, ⁴Seoul
- 13:00 - 13:00 644P - Associations between deepness of response and clinical outcomes with advanced HER2-positive gastric cancer with 1st-line chemotherapy and trastuzumab
H. Osumi, E. Shinozaki, K. Chin, M. Ogura, T. Matsushima, T. Wakatsuki, I. Nakayama, T. Ichimura, D. Takahari, K. Yamaguchi; Tokyo, JP
- 13:00 - 13:00 645P - Capecitabine/cisplatin versus 5-fluorouracil/cisplatin in Chinese patients with advanced and metastatic gastric cancer: Re-analysis of efficacy and safety data from the ML17032 study
J. Chen¹, J. Xiong², J. Wang³, L. Zheng³, Y. Gao³, Z. Guan⁴; ¹Nanjing, CN, ²Nanchang, CN, ³Shanghai, CN, ⁴Guangzhou, CN
- 13:00 - 13:00 646P - Clinical significance of microRNA expression in patients with Epstein-Barr virus associated gastric cancer
J.G. Kim¹, B.W. Kang¹, Y.S. Chae¹, S.J. Lee¹, J.H. Baek²; ¹Daegu, KR, ²Ulsan, KR
- 13:00 - 13:00 647P - New approach to gastric cancer classification based on TP53 mutation
R. Makuuchi, K. Hatakeyama, M. Terashima, M. Kusuhara, M. Tokunaga, Y. Tanizawa, E. Bando, T. Kawamura, M. Hikage, S. Kaji, K. Ohshima, K. Urakami, K. Yamaguchi; Shizuoka, JP
- 13:00 - 13:00 648P - Prognostic significance of neutrophil to lymphocyte ratio (NLR) in patients (pts) with resectable gastric/gastroesophageal junction (GOJ) adenocarcinoma undergoing perioperative chemotherapy
Z. Salih, A. Conway, G. Papaxoinis, A. Patrao, K. Fletcher, R. Noble, V. Owen-Holt, W. Mansoor; Manchester, GB



- 13:00 - 13:00 649P - Genomic loss of heterozygosity (LOH) and survival in patients (pts) treated with epirubicin, oxaliplatin, capecitabine (EOC) ± panitumumab (P) in the REAL3 trial
C. Cafferkey¹, E. Smyth¹, A. Loehr², T. Harding², M. Raponi², A. Okines¹, T. Waddell¹, I. Chau¹, D. Cunningham¹; ¹London, GB, ²San Francisco, US
- 13:00 - 13:00 650P - Efficacy and tolerability of first-line chemotherapy in elderly patients (age ≥70 years) with metastatic gastric cancer: A multicenter study of the Anatolian Society of Medical Oncology (ASMO)
M. Aldemir¹, M. Turkeli¹, B. Hacıoglu², A. Sakin³, E. Yaman⁴, E. Coban³, D. Koca⁵, M. Karaca⁶, M. Simsek¹, A. Bahceci⁷, E. Sen⁸, T. Eren⁶, B. Aliustaoglu³, T. Sakalar⁹, N. Kalkan¹⁰, G. Aktas¹¹, M. Bilici¹, S. Turhal⁵, M. Benekli⁶, S. Tekin¹; ¹Erzurum, TR, ²Edirne, TR, ³Istanbul, TR, ⁴Mersin, TR, ⁵Kocaeli, TR, ⁶Ankara, TR, ⁷Sivas, TR, ⁸Konya, TR, ⁹Kayseri, TR, ¹⁰Van, TR, ¹¹Gaziantep, TR
- 13:00 - 13:00 651P - Nab-paclitaxel as second line treatment in advanced gastric cancer: A HORG multicenter phase II study
P. Katsaounis¹, N. Kentepozidis², A. Kotsakis², A. Polyzos², L. Vamvakas², M. Bakogiorgos², I. Boukovinas³, E. Hartabilas², E. Prinarakis², T. Skaltsi², V. Georgoulas⁴, J. Souglakos²; ¹Cholargos, GR, ²Athens, GR, ³Thessaloniki, GR, ⁴Heraklion, GR
- 13:00 - 13:00 652P - Prognostic implications of baseline neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in metastatic gastric cancer (GC) patients
A. Petrillo, M.M. Laterza, J. Ventriglia, B. Savastano, G. Tirino, L. Pompella, E. Martinelli, F. Morgillo, M. Orditura, F. Ciardiello, F. De Vita; Napoli, IT
- 13:00 - 13:00 653P - Differences in gastric adenocarcinoma patients at extremes of the age spectrum
R. Rhome¹, U. Ozbek¹, R. Holcombe¹, M. Buckstein¹, C. Ang²; ¹New York, US, ²New York, NY/US
- 13:00 - 13:00 654P - A randomized phase II study of pancrelipase in patients with gastrectomy to assess the prevention of weight loss
S. Tamara¹, H. Taniguchi², A. Takeno¹, K. Murakami¹, Y. Katsura¹, Y. Ohmura¹, A. Naito¹, Y. Kagawa¹, Y. Takeda¹, T. Kato¹; ¹Amagasaki, JP, ²Minoh, JP
- 13:00 - 13:00 655P - Conditional survival probability in patients with resected oesophageal adenocarcinoma receiving neoadjuvant chemotherapy
D. Graham¹, F. Bannon¹, F. Noble², R. O'Neill³, J. Blayney¹, T. Underwood², R. Kennedy¹, R. Fitzgerald⁴, R. Turkington¹; ¹Belfast, GB, ²Southampton, GB, ³Edinburgh, GB, ⁴Cambridge, GB
- 13:00 - 13:00 656P - Results of a prospective, multicenter, non-interventional trial to analyze disease- and treatment-related effects on the functionality of patients with gastrointestinal tumors ≥ 75 years
J. Hofmann¹, N. Härtel¹, J. Hofmann¹, M. Neugebauer¹, A. Berger², S. Zschäbitz², H. Schulze-Bergkamen³, J. Betge¹, S. Belle¹, R. Jesenofsky¹, N. Schulte¹, U. Wedding⁴, M. Ebert¹, J. Chi-Kern¹; ¹Mannheim, DE, ²Heidelberg, DE, ³Wesel, DE, ⁴Jena, DE
- 13:00 - 13:00 657P - Esophageal adenocarcinoma: Impact of a large hiatal hernia on outcomes after surgery
C. Gronnier, A. Gandon, F. Renaud, P. Borde, M. Vanderbeken, F. Hec, G. Piessen, A. Adenis, X. Mirabel, C. Mariette; Lille, FR



- 13:00 - 13:00 658P - "Many ways to skin gastric cancer" - Robotic versus laparoscopic versus open gastrectomy
E. Kakiashvili, O. Ben Yshai, R. Almog, A. Beny, Y. Kluger; Haifa, IL
- 13:00 - 13:00 659P - PIK3CA mutations up-regulate Akt expression and confer aggressive tumor biology in gastric cancer
K.-W. Lee¹, J.-W. Kim¹, J.W. Kim², H.S. Lee¹; ¹Seongnam, KR, ²Seongnam-Si, KR
- 13:00 - 13:00 660P - A retrospective study of chemoradiotherapy (CRT) versus chemotherapy (CT) as adjuvant treatment for localized gastric cancer (LGC)
D. Girardi¹, G. Pereira², M. Negrão¹, M. Lima², M. Felizola², R. Fogace², F. Caparelli², J. Sabbaga¹, P. Hoff¹; ¹Sao Paulo, BR, ²São Paulo, BR
- 13:00 - 13:00 661P - A phase II study for triplet combination of oxaliplatin, irinotecan, and S-1 in patients with metastatic or recurrent gastric cancer
B. Han¹, S.R. Park², H.S. Kim¹, M.-H. Ryu², J.-S. Kim², S.-Y. Rho², B.W. Kang³, K.H. Lee³, S.Y. Rha², W.K. Kang², Y.-K. Kang², D.Y. Zang¹; ¹Anyang, KR, ²Seoul, KR, ³Daegu, KR
- 13:00 - 13:00 662P - Efficacy of staging laparoscopy for type 4 and large type 3 gastric cancer
M. Tokunaga, R. Makuuchi, Y. Tanizawa, E. Bando, T. Kawamura, M. Terashima; Shizuoka, JP
- 13:00 - 13:00 663P - Predictive biomarkers to ramucirumab in Asian metastatic gastric cancer patients: Circulating angiogenic factors of VEGFR2 and neuropilin are predictive to ramucirumab efficacy in Asian recurrent/metastatic gastric cancer patients
S. Lim, S.J. Heo, T.S. Kim, H.J. Kwon, J.H. Kim, M.K. Jeong, H.S. Kim, S.H. Beom, H.C. Chung, S.Y. Rha; Seoul, KR
- 13:00 - 13:00 664P - Adjuvant concurrent chemoradiotherapy(CRT) plus docetaxel- cisplatin- fluorouracil (DCF) versus CRT plus fluorouracil folinic acid (FUFA) in gastric cancer
A. Alkan, D. Mızrak, E. Karçı, A. Yaşar, E.B. Köksoy, M. Ürün, T. Kütük, Y. Ürün, F. Çay Şenler, S. Akyürek, G. Utkan, A. Demirkazık, Ş.Ç. Gökçe, H. Akbulut; Ankara, TR
- 13:00 - 13:00 665P - Personalized medicine for advanced pancreas cancer: Access to treatment according to molecular profile
C. Romeo, P. Cassier, A. De la Fouchardière, D. Pissaloux, V. Attignon, Q. Wang, M. Sarabi, F. Desseigne, P. Guibert, D. Perol, O. Tredan, J.-Y. Blay, C. de la Fouchardiere; Lyon, FR
- 13:00 - 13:00 666P - A modified regimen of nab-paclitaxel and gemcitabine in advanced pancreatic cancer
M. Osman¹, R. McDermott², D. Fennelly²; ¹Cairo, EG, ²Dublin, IE
- 13:00 - 13:00 667P - Definitive concurrent chemoradiotherapy using S-1 in the treatment of elderly patients with esophageal cancer
Y. Jia, Hangzhou, CN
- 13:00 - 13:00 668P - Risk factors for esophageal fistula in esophageal squamous cell carcinoma invading adjacent organs (T4b) treated with definitive chemoradiotherapy
T. Kawakami, T. Tsushima, K. Hayashi, H. Shirasu, M. Kawahira, S. Kawai, Y. Kito, Y. Yoshida, S. Hamauchi, A. Todaka, N. Machida, K. Yamazaki, T. Yokota, A. Fukutomi, Y. Onozawa, H. Yasui; Shizuoka, JP



- 13:00 - 13:00 669P - Metastasis in the lymph node station 8 in patients with Siewert's type II EGJ adenocarcinoma and its effect on prognosis following radical surgery
R. Bayramov, R. Abdullayeva, S. Huseynova; Baku, AZ
- 13:00 - 13:00 670P - Impact of primary tumour resection on survival and chemotherapy tolerance in patients with metastatic oesophagogastric cancer undergoing palliative chemotherapy
S. Ochendusko, M. Puskulluoglu, K. Konopka, A. Michalowska-Kaczmarczyk, K. Fijorek, M. Pedziwiatr, A. Budzynski; Krakow, PL
- 13:00 - 13:00 671P - Chemoradiotherapy versus surgery for clinical stage I esophageal squamous cell carcinoma: A long-term comparison
S. Mitani¹, S. Kadowaki², I. Oze², T. Masuishi², Y. Narita², H. Taniguchi², T. Ura², M. Ando², M. Tajika², C. Makita², T. Kodaira², N. Uemura², T. Abe², K. Muro²; ¹Nagoya, Aichi/JP, ²Nagoya, JP
- 13:00 - 13:00 672P - Cardiotoxicity of trastuzumab in the patients with HER2 positive advanced gastric cancer
M. Jung, J.S. Park, C.-K. Lee, J.H. Kim, H.S. Park, S.J. Heo, S.H. Beom, H.S. Kim, S.Y. Rha, H.C. Chung, J.-C. Youn; Seoul, KR
- 13:00 - 13:00 673P - The prognostic role and association of 18F-FDG PET CT and HER2 expression in gastric cancer
J.S. Park, N. Lee, J.H. Kim, H.S. Park, S.J. Heo, S.H. Beom, H.S. Kim, S.Y. Rha, H.C. Chung, M. Yun, A. Cho, M. Jung; Seoul, KR
- 13:00 - 13:00 674P - Dynamics of the HER2 receptor in esophageal adenocarcinoma: New opportunities for targeted therapy
A. Creemers, E. Ebbing, G. Hooijer, A. Jibodh-Mulder, S. Gisbertz, M. van Oijen, M. van Berge Henegouwen, M. Bijlsma, S. Meijer, H. van Laarhoven; Amsterdam, NL
- 13:00 - 13:00 675P - CPI-613 enhances FOLFIRINOX response rate in stage IV pancreatic cancer
A. Alistar¹, R. Desnoyers², R. D'Agostino¹, B. Pasche¹; ¹Winston Salem, NC/US, ²Winston Salem, US
- 13:00 - 13:00 676P - Intensified chemotherapy for metastatic pancreatic cancer: Interim analysis of a large retrospective pan-European database and real life evaluation
S. Krug¹, G. Beyer², M.A. Javed³, N. Le⁴, A. Vinci⁵, R.D. Morgan⁶, R. Hubner⁶, J. Valle⁶, H. Wong⁷, S. Chowdhury⁸, Y. Ting Ma⁸, D. Palmer³, P. Maisonneuve⁹, A. Neesse¹⁰, M. Sund¹¹, M. Schober¹; ¹Halle, DE, ²Greifswald, DE, ³Liverpool, GB, ⁴Budapest, HU, ⁵Pavia, IT, ⁶Manchester, GB, ⁷Wirral, GB, ⁸Birmingham, GB, ⁹Milano, IT, ¹⁰Göttingen, DE, ¹¹Umea, SE
- 13:00 - 13:00 677P - Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)
W. Messersmith¹, S. Cohen², S. Shahda³, H.-J. Lenz⁴, C. Weekes¹, E. Dotan², C. Denlinger², B. O'Neil³, A. Kapoun⁵, C. Zhang⁵, R. Henner⁵, F. Cattaruzza⁵, L. Xu⁵, J. Dupont⁵, R. Brachmann⁵, S. Uttamsingh⁵, A. Farooki⁶, J. Berlin⁷; ¹Aurora, CO/US, ²Philadelphia, PA/US, ³Indianapolis, IN/US, ⁴Los Angeles, US, ⁵Redwood, CA/US, ⁶New York, NY/US, ⁷Nashville, US
- 13:00 - 13:00 678P - Observational study of FOLFIRINOX (FFX) for unresectable/recurrent pancreatic cancer (PC) in Japanese patients (pts)(JASPAC 06): Final results



N. Mizuno¹, A. Todaka², K. Mori², N. Boku³, M. Ozaka³, H. Ueno³, S. Kobayashi⁴, K. Uesugi⁵, N. Kobayashi⁴, H. Hayashi⁶, K. Sudo⁷, N. Okano⁸, Y. Horita⁹, K. Kamei¹⁰, S. Yukisawa¹¹, S. Nakamori¹², Y. Yachi³, T. Henmi³, M. Kobayashi², A. Fukutomi²; ¹Nagoya, JP, ²Shizuoka, JP, ³Tokyo, JP, ⁴Yokohama, JP, ⁵Matsuyama, JP, ⁶Sapporo, JP, ⁷Chiba, JP, ⁸Mitaka, JP, ⁹Toyama, JP, ¹⁰Osaka-Sayama, JP, ¹¹Utsunomiya, JP, ¹²Osaka, JP

- 13:00 - 13:00 679P - Gabrinox: A phase I-II of nab-paclitaxel plus gemcitabine followed by folfirinix in metastatic pancreatic adenocarcinoma
E. Assenat¹, C. de la Fouchardiere², C. Mollevi¹, E. Samalin¹, F. Portales¹, F. Desseigne², C. Carencio¹, M. Dupuy¹, E. Lopez-Martinez¹, C. Fiess¹, T. Mazard¹, M. Ychou¹; ¹Montpellier, FR, ²Lyon, FR
- 13:00 - 13:00 680P - Chemotherapy for patients with non-resectable pancreatic cancer with additional chemo-radiotherapy for patients with potentially resectable tumours: Final results
P. Pfeiffer¹, M. Ladekar², M. Mortensen¹, A.-L. Fromm³, J. Bjerregaard¹; ¹Odense C, DK, ²Aarhus C, DK, ³Herlev, DK
- 13:00 - 13:00 681P - Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in unresectable or borderline resectable pancreatic adenocarcinoma
M. Reni, S. Zanon, G. Balzano, P. Passoni, A. Costantino, C. Pircher, M. Chiaravalli, R. Nicoletti, P.G. Arcidiacono, G. Pepe, S. Crippa, C. Doglioni, C. Fugazza, D. Ceraulo, M. Falconi, L. Gianni; Milano, IT
- 13:00 - 13:00 682P - Nab-paclitaxel in substitution of oxaliplatin and irinotecan in folfirinix schedule as first-line therapy in patients with metastatic pancreatic cancer: Results of phase I dose finding of NabucCO study by GOIRC
E. Giommoni¹, E. Maiello², G. Tortora³, V. Vaccaro⁴, E. Rondini⁵, L. Toppo⁶, G. Giordano⁷, T.P. Latiano², L. Calvetti³, L. Antonuzzo¹, C. Lamperini¹, L. Boni¹, F. Di Costanzo¹; ¹Firenze, IT, ²San Giovanni Rotondo, IT, ³Verona, IT, ⁴Roma, IT, ⁵Reggio Emilia, IT, ⁶Cremona, IT, ⁷Benevento, IT
- 13:00 - 13:00 683P - Impact of age, bilirubin, and disease burden in unresectable pancreatic cancer patients receiving first-line chemotherapy: A population-based analysis
Y. Wang, P. Camateros, W. Cheung; Vancouver, CA
- 13:00 - 13:00 684P - Nab-paclitaxel/gemcitabine first line therapy in patients with metastatic pancreatic carcinoma and high-bilirubin values - Data from the German QoIXane pancreatic cancer registry
G. zur Hausen¹, O. Waidmann¹, M. Woerns², H. Hoeffkes³, S. Doerfel⁴, M. Zahn⁵, A. Aldaoud⁶, M. Stauch⁷, C. Springfield⁸, N. Haertel⁹, A. Reichart¹, T. Goetze¹, S. Schwarz¹, C. Pauligk¹, J. Roemmler-Zehrer¹⁰, R.D. Hofheinz⁹, S.-E. Al-Batran¹; ¹Frankfurt Am Main, DE, ²Mainz, DE, ³Fulda, DE, ⁴Dresden, DE, ⁵Goslar, DE, ⁶Leipzig, DE, ⁷Kronach, DE, ⁸Heidelberg, DE, ⁹Mannheim, DE, ¹⁰München, DE
- 13:00 - 13:00 685P - An elevated fibrinogen/CRP ratio predicts a remarkable survival advantage in patients with metastatic pancreatic cancer
T. Winder¹, F. Posch², E. Asamer², M. Stotz², A. Siebenhüner¹, K. Schlick³, T. Magnes³, P. Samaras¹, J. Szkandera², P.-A. Clavien¹, D. Neureiter³, R. Greil³, B. Pestalozzi¹, H. Stoeger², A. Gerger², A. Egle³, M. Pichler²; ¹Zürich, CH, ²Graz, AT, ³Salzburg, AT



- 13:00 - 13:00 686P - Advanced pancreatic adenocarcinoma outcomes with transition from devolved to centralised care in a UK regional cancer centre
O. Faluy, J. Connor, B. Chatterjee, C. Ikin, H. Wong, D. Palmer; Liverpool, GB
- 13:00 - 13:00 687P - Clinical utility of circulating tumor DNA (ctDNA) in resectable pancreatic ductal adenocarcinoma (PDAC)
H.-L. Wong¹, K. Bushell², J. Karasinska², S. Arthur², P. Pararajalingam², R. Morin², D. Schaeffer², D. Renouf³; ¹Parkville, AU, ²Vancouver, CA, ³Vancouver, BC/CA
- 13:00 - 13:00 688P - Prognostic impact of KRAS mutation in metastatic (met) pancreatic cancer patients (pts)
H. Verdaguer, T. Sauri, F. Ruiz, A. Vivancos, P. Nuciforo, J. Capdevila, E. Elez, M. Alsina, G. Argiles Martinez, C. Hierro, J. Grasselli, I. Matos, J. Tabernerero, R. Dienstmann, T. Macarulla; Barcelona, ES
- 13:00 - 13:00 689P - The role of risk factors on survival for patients with pancreatic cancer
K. Bagni¹, C. Dehlendorff¹, B. Jensen², P. Pfeiffer³, A. Johansen², C. Hansen¹, S. Nielsen⁴, M. Yilmaz⁵, N. Holländer⁶, J. Johansen²; ¹Copenhagen, DK, ²Herlev, DK, ³Odense C, DK, ⁴Hillerod, DK, ⁵Aalborg, DK, ⁶Naestved, DK
- 13:00 - 13:00 690P - Efficacy of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma
J. Kang, K.-P. Kim, C. Yoo, J.-L. Lee, B.-Y. Ryoo, H.-M. Chang, S.S. Lee, D.H. Park, T.J. Song, D.W. Seo, S.K. Lee, M.-H. Kim, D.W. Hwang, K.B. Song, J.H. Lee, S.C. Kim; Seoul, KR
- 13:00 - 13:00 691P - Neutrophil to lymphocyte ratio is a predictor of outcome in metastatic pancreatic cancer patients (MPC) treated with nab-paclitaxel and gemcitabine
G. Tirino¹, A. Petrillo¹, M. Huerta², M.M. Laterza¹, B. Savastano¹, V. Gambardella², G. Tirino¹, L. Pompella¹, A. Diana¹, A. Febbraro³, T. Troiani¹, M. Orditura¹, A. Cervantes², F. Ciardiello¹, F. De Vita¹; ¹Napoli, IT, ²Valencia, ES, ³Benevento, IT
- 13:00 - 13:00 692P - Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND)
S. Bozzarelli¹, L. Rimassa¹, L. Giordano¹, S. Sala¹, M.C. Tronconi¹, M. Baretta², N. Personeni¹, T. Pressiani¹, A. Santoro¹; ¹Rozzano, IT, ²Rozzano, (MI)/IT
- 13:00 - 13:00 693P - Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
R. Hubner¹, L.-T. Chen², J. Siveke³, C.-P. Li⁴, G. Bodoky⁵, A. Dean⁶, Y.-S. Shan², G. Jameson⁷, T. Macarulla⁸, K.-H. Lee⁹, D. Cunningham¹⁰, J.-F. Blanc¹¹, C.-F. Chiu¹², G. Schwartzmann¹³, F. Braiteh¹⁴, K. Mamlouk¹⁵, B. Belanger¹⁵, F. de Jong¹⁶, D. von Hoff⁷, A. Wang-Gillam¹⁷; ¹Manchester, GB, ²Tainan, TW, ³Essen, DE, ⁴Taipei, TW, ⁵Budapest, HU, ⁶Subiaco, AU, ⁷Phoenix, US, ⁸Barcelona, ES, ⁹Seoul, KR, ¹⁰London, GB, ¹¹Bordeaux, FR, ¹²Taichung, TW, ¹³Porto Alegre, BR, ¹⁴Las Vegas, NV/US, ¹⁵Cambridge, US, ¹⁶Zürich, CH, ¹⁷St. Louis, US
- 13:00 - 13:00 694P - Prognostic value of the immune-related transcriptome in biliary tract cancers



M. Ghidini¹, L. Cascione², A. Lampis³, R. Pandolfo⁴, P. Carotenuto⁴, F. Trevisani³, J. Hahne³, D. Zito³, V. Guzzardo⁵, A. Zerbi¹, G. Torzilli¹, M. Roncalli¹, L. Rimassa¹, A. Santoro¹, M. Fassan⁵, N. Valeri³, C. Braconi³; ¹Rozzano, IT, ²Bellinzona, CH, ³Sutton, GB, ⁴London, GB, ⁵Padova, IT

- 13:00 - 13:00 695P - Oral rivaroxaban versus subcutaneous low molecular weight heparin treatment for venous thromboembolism in patients with upper gastrointestinal, hepatobiliary and pancreatic cancer
S. Seo, M.-H. Ryu, Y.-K. Kang, K.-P. Kim, H.-M. Chang, B.-Y. Ryoo, S. Kim, J.-L. Lee, S.R. Park; Seoul, KR
- 13:00 - 13:00 696P - Extended RAS and BRAF mutation analysis of circulating tumor DNA in patients with biliary tract cancer
L.H. Jensen, R. Andersen, A. Jakobsen; Vejle, DK
- 13:00 - 13:00 697P - Updated, expanded analysis with next generation sequencing (NGS) of biliary tract cancer confirms association between tumor somatic variants and chemotherapy resistance
D. Ahn¹, D. Catenacci², C. Ahn³, A. Jain⁴, R. Kelley⁵, A. Bocobo⁵, R. Rendak², S. Mikhail¹, C. Wu¹, R. Shroff⁴, M. Borad⁶, J. Chen¹, M. Javle⁴, T. Bekaii-Saab⁶; ¹Columbus, OH/US, ²Chicago, IL/US, ³Dallas, TX/US, ⁴Houston, TX/US, ⁵San Francisco, CA/US, ⁶Phoenix, AZ/US
- 13:00 - 13:00 698P - Phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer (ABC)
J. Eads¹, S. Stein², A. El-Khoueiry³, G. Manji⁴, T. Abrams⁵, A. Khorana¹, R. Miksad⁵, D. Mahalingam⁶, C. Sirard⁷, A. Zhu⁷, L. Goyal⁵; ¹Cleveland, US, ²New Haven, US, ³Los Angeles, US, ⁴New York, US, ⁵Boston, US, ⁶San Antonio, TX/US, ⁷Boston, MA/US
- 13:00 - 13:00 699P - High incidence of metastases detected on 18F-FDG PET-CT in patients with gall bladder cancer incidentally discovered after laparoscopic cholecystectomy
A. Bhattacharya, R. Kumar, S. Vadi, A. Gorla, A. Sood, B. Mittal; Chandigarh, IN
- 13:00 - 13:00 700P - NAB-PACLITAXEL as third-line therapy after failure of gemcitabine and 5-FU based combinations in advanced gall bladder cancer patients
S. Singh Manana, V. Goel, V. Talwar, S. Raina; New Delhi, IN
- 13:00 - 13:00 701P - TrkB/BDNF signaling promotes EMT mediated invasiveness and is a potential therapeutic target for gallbladder cancer
M. Kawamoto, H. Onishi, K. Ozono, A. Yamasaki, A. Imaizumi, M. Nakamura; Fukuoka, JP
- 13:00 - 13:00 702P - Analysis of efficacy and prognostic factors for second-line chemotherapy in gemcitabine-refractory advanced biliary tract cancer
N. Okano, K. Kawai, T. Kobayashi, D. Naruge, F. Nagashima, J. Furuse; Mitaka, JP
- 13:00 - 13:00 703P - HER2/HER3 pathway in biliary tract cancers: A systematic review and meta-analysis. A novel therapeutic druggable target?
S. Galdy¹, A. Lamarca², M. McNamara², R. Hubner², C.A. Cella¹, N. Fazio¹, J. Valle²; ¹Milano, IT, ²Manchester, GB
- 13:00 - 13:00 704P - Analysis of tumor growth rate for advanced hepatocellular cancer patients receiving placebo or sorafenib in the phase 3 SHARP and Asia Pacific trials



G. Meinhardt¹, J. Bruix², J. Llovet³, A.-L. Cheng⁴, C. Kappeler⁵; ¹Whippany, NJ/US, ²Barcelona, ES, ³New York, NY/US, ⁴Taipei, TW, ⁵Berlin, DE

- 13:00 - 13:00 705P - Utility of multidisciplinary tumor board (MTB) in the management of hepatocellular cancer (HCC)
A. Alahmadi, R. Lee, C. Siegel, P. Gholam; Cleveland, OH/US
- 13:00 - 13:00 706P - Prognostic value of the neutrophil-to-lymphocyte ratio in advanced hepatocellular carcinoma: An exploratory analysis from the ARQ197-215 study
N. Personeni¹, L. Giordano¹, G. Abbadessa², C. Porta³, I. Borbath⁴, B. Daniele⁵, S. Salvagni⁶, J.-L. van Laethem⁴, H. Van Vlierberghe⁷, J. Trojan⁸, A. Weiss⁹, A. Gasbarrini¹⁰, D. Shuster¹¹, E.N. De Toni¹², M. Lencioni¹³, S. Miles¹⁴, M.E. Lamar², B. Schwartz², A. Santoro¹, L. Rimassa¹; ¹Rozzano, IT, ²Burlington, US, ³Pavia, IT, ⁴Brussels, BE, ⁵Benevento, IT, ⁶Bologna, IT, ⁷Gent, BE, ⁸Frankfurt Am Main, DE, ⁹Vancouver, CA, ¹⁰Roma, IT, ¹¹Edison, US, ¹²München, DE, ¹³Pisa, IT, ¹⁴Los Angeles, US
- 13:00 - 13:00 707P - Lenalidomide as second-line therapy for advanced hepatocellular carcinoma (HCC): biomarker exploration
Y.-Y. Shao, B.-B. Chen, Z.-Z. Lin, C.-H. Hsu, M.-J. Wang, A.-L. Cheng, C. Hsu; Taipei, TW
- 13:00 - 13:00 708TiP - Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study
A. Casadei Gardini¹, L. Faloppi², B. Daniele³, S. Cascinu², S. Lonardi⁴, G. Masi⁵, F. Negri⁶, D. Santini⁷, N. Silvestris⁸, V. Zagonel⁴, M. Scartozzi⁹; ¹Meldola, IT, ²Ancona, IT, ³Benevento, IT, ⁴Padova, IT, ⁵Pisa, IT, ⁶Parma, IT, ⁷Roma, IT, ⁸Bari, IT, ⁹Cagliari, IT
- 13:00 - 13:00 709TiP - Randomized controlled phase II trial of S-1 maintenance therapy in Caucasian population with metastatic esophagogastric cancer– the multinational MATEO study
G.M. Haag¹, G. Stocker², J. Quidde³, D. Jaeger¹, F. Lordick²; ¹Heidelberg, DE, ²Leipzig, DE, ³Hamburg, DE
- 13:00 - 13:00 710TiP - A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)
A. Zhu¹, P. Galle², M. Kudo³, R. Finn⁴, L. Yang⁵, P. Abada⁶, J. Llovet⁷; ¹Boston, MA/US, ²Mainz, DE, ³Osaka, JP, ⁴Los Angeles, CA/US, ⁵Bridgewater, NJ/US, ⁶Indianapolis, IN/US, ⁷New York, NY/US
- 13:00 - 13:00 711TiP - A phase II study of S-1 with concurrent radiotherapy for elderly esophageal cancer patients
T. Song, S. Lv; Hangzhou, CN
- 13:00 - 13:00 712TiP - Cisplatin and gemcitabine plus ramucirumab or merestininib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase 2 trial
J. Valle¹, N. Bousmans², W. Zhang³, R. Walgren³, A. Vogel⁴; ¹Manchester, GB, ²Belgium, GB, ³Indianapolis, US, ⁴Hannover, DE
- 13:00 - 13:00 713TiP - Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study



R. Finn¹, S. Chan², A. Zhu³, J. Knox⁴, A.-L. Cheng⁵, A. Siegel⁶, O. Bautista⁶, P. Watson⁶, M. Kudo⁷; ¹ Los Angeles, CA/US, ²Hong Kong, HK, ³Boston, MA/US, ⁴Toronto, ON/CA, ⁵Taipei, TW, ⁶Kenilworth, US, ⁷Osaka, JP

- 13:00 - 13:00 714TiP - A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/- nab-paclitaxel in elderly pancreatic cancer patients (GrantPax)
N. Härtel¹, J. Chi-Kern¹, J. Betge¹, S. Belle¹, N. Schulte¹, M. Maenz², U. Wedding³, M. Ebert¹; ¹ Mannheim, DE, ²Berlin, DE, ³Jena, DE
- 13:00 - 13:00 715TiP - Global phase 3, randomized, double-blind, placebo-controlled study evaluating PEGylated recombinant human hyaluronidase PH20 (PEGPH20) plus nab-paclitaxel and gemcitabine in patients with previously untreated, hyaluronan (HA)-high, stage IV pancreatic ductal adenocarcinoma
E. Van Cutsem¹, A. Hendifar², M. Reni³, W. Harris⁴, M. Ducreux⁵, A. Bullock⁶, P. Corrie⁷, V. Heinemann⁸, T. Seery⁹, D. Chondros¹⁰, L. Zheng¹¹; ¹Leuven, BE, ²Los Angeles, US, ³Milano, IT, ⁴Seattle, WA/US, ⁵Paris, FR, ⁶Boston, MA/US, ⁷Cambridge, GB, ⁸Munich, DE, ⁹Irvine, CA/US, ¹⁰San Diego, CA/US, ¹¹Baltimore, MD/US
- 13:00 - 13:00 716TiP - Pembrolizumab in patients with previously treated advanced hepatocellular carcinoma: Phase 2 KEYNOTE-224 study
A. Zhu¹, J. Knox², M. Kudo³, S. Chan⁴, R. Finn⁵, A. Siegel⁶, J. Ma⁶, P. Watson⁶, A.-L. Cheng⁷; ¹ Boston, US, ²Toronto, CA, ³Osaka, JP, ⁴Shatin, HK, ⁵Los Angeles, CA/US, ⁶Kenilworth, US, ⁷Taipei, TW
- 13:00 - 13:00 Gynaecological cancers
- 13:00 - 13:00 861P - ICON8 Stage 1A and 1B analysis: Safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer
E. James¹, J. Hook¹, S. Stenning¹, A. Cook¹, C. Coyle¹, J. Petrie¹, R. Kaplan¹, I. McNeish², T. Perren³, R. Naik⁴, S. Banerjee¹, J. Ledermann¹, A. Clamp⁵; ¹London, GB, ²Glasgow, GB, ³Leeds, GB, ⁴Gateshead, GB, ⁵Manchester, GB
- 13:00 - 13:00 862P - Hormonal therapy for epithelial ovarian cancer: a systematic review and meta-analysis of phase II studies
L. Paleari, N. Provinciali, M. Puntoni, C. Defferrari, M. Di Luca, F. Gorlero, A. Decensi; Genova, IT
- 13:00 - 13:00 863P - Non pegylated liposomal doxorubicin (npld, myocettm) + carboplatin (cb) in patients (pts) with ovarian cancer in late relapse (oclr): A phase 2 gineco study
B. You¹, F. Joly², I. Ray-Coquard³, C. El Kouri⁴, A. Mercier-Blas⁵, D. Berton-Rigaud⁶, E. Kalbacher⁷, O. Cojocarasu⁸, M. Fabbro⁹, J. Cretin¹⁰, A. Zannetti¹¹, S. Abadie-Lacourtoisie¹², D. Mollon¹³, A.-C. Hardy-Bessard¹⁴, M. Provansal¹⁵, G. Freyer¹; ¹Pierre Bénite, FR, ²Caen, FR, ³Lyon, FR, ⁴Nantes, FR, ⁵Saint-Grégoire, FR, ⁶St. Herblain, FR, ⁷Besançon, FR, ⁸Le Mans, FR, ⁹Montpellier, FR, ¹⁰Nimes, FR, ¹¹Cholet, FR, ¹²Angers, FR, ¹³Quimper, FR, ¹⁴Plerin-Sur-mer, FR, ¹⁵Marseille, FR
- 13:00 - 13:00 864P - A phase 1b study of the nanoparticle-drug conjugate (NDC) CRLX101 in combination with weekly paclitaxel in patients (pts) with platinum-resistant ovarian cancer (OC)



C. Krasner¹, R. Schilder², W. Brady³, L. Duska⁴, D. O'Malley⁵, P. Disilvestro⁶, J. Li⁷, W. Downing⁷, A. Senderowicz⁷; ¹Boston, MA/US, ²Philadelphia, PA/US, ³Buffalo, NY/US, ⁴Charlottesville, VA/US, ⁵Columbus, OH/US, ⁶Providence, RI/US, ⁷Waltham, MA/US

- 13:00 - 13:00 865P - Hypersensitivity reactions to antineoplastic agents in BRCA-mutated ovarian cancer (OC) patients: A single centre experience
E. Maccaroni, R. Bracci, R. Giampieri, F. Bianchi, L. Belvederesi, C. Brugiati, S. Pagliaretta, A. Della Mora, F. Tronconi, M. Pistelli, A. Pagliacci, N. Battelli, Z. Ballatore, M. De Lisa, R. Berardi; Ancona, IT
- 13:00 - 13:00 866P - The socioeconomic burden of ovarian cancer in Spain
L. Delgado-Ortega¹, A. Domínguez¹, C. Moya-Alarcón¹, Á. Hidalgo², L. Cordero¹, M. Jiménez¹, A. Gascó¹, R. Villoro¹, J. Borrás³, E. González-Haba¹, S. Menjón⁴, J. Oliva², P. Pérez¹, D. Vicente⁵; ¹Madrid, ES, ²Toledo, ES, ³Barcelona, ES, ⁴Granada, ES, ⁵Sevilla, ES
- 13:00 - 13:00 867P - Impact of age on the safety and efficacy of bevacizumab (BEV)-containing therapy in patients (pts) with primary ovarian cancer (OC): Analyses of the OTILIA German non-interventional study on behalf of the North-Eastern German Society of Gynaecological Oncology Ovarian Cancer Working Group
A. Mustea¹, P. Wimberger², G. Oskay-Oezcelik³, P. Jungberg⁴, W. Meinerz⁴, D. Reichert⁵, J. Janssen⁵, M. Keller³, R. Richter³, J. Harde⁶, S. Klawitter⁷, A. Wegenaer⁷, M. Mueller⁸, J. Sehouli³; ¹Greifswald, DE, ²Dresden, DE, ³Berlin, DE, ⁴Chemnitz, DE, ⁵Westerstede, DE, ⁶Freiburg, DE, ⁷Grenzach-Wyhlen, DE, ⁸Offenburg, DE
- 13:00 - 13:00 868P - Direct effects of platinum-based chemotherapy ± bevacizumab on the bone metabolism of patients with primary and platinum-sensitive recurrent tuboovarian carcinoma
C. Kurbacher, A. Huhmann, S. Herz, K. Monreal, J. Kurbacher; Bonn, DE
- 13:00 - 13:00 869P - Prognostic and predictive significance of VEGF and TNFα levels in ascites of patients with epithelial ovarian cancer. Correlation with lymphocytes subpopulations
M. Liontos, N. Gavalas, K. Tzanis, S.-P. Trachana, E. Kostouros, F. Zagouri, K. Koutsoukos, M. Lykka, G. Tsironis, I. Dimitriadis, E. Terpos, M. Dimopoulos, A. Bamias; Athens, GR
- 13:00 - 13:00 870P - Vascular endothelial growth factor (VEGF) polymorphisms and outcome of epithelial ovarian cancer patients
A. Brito, G. Camerin, S. Derchain, C. Lima; Campinas, BR
- 13:00 - 13:00 871P - Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC)
J. Infante¹, F. Braitheh², L. Emens³, A. Balmanoukian⁴, A. Oaknin⁵, Y. Wang⁶, B. Liu⁶, L. Molinero⁶, M. Fasso⁷, C. O'Hear⁷, M. Gordon⁸; ¹Nashville, TN/US, ²Las Vegas, NV/US, ³Baltimore, MD/US, ⁴Los Angeles, CA/US, ⁵Barcelona, ES, ⁶South San Francisco, CA/US, ⁷South San Francisco, US, ⁸Scottsdale, AZ/US
- 13:00 - 13:00 872P - Lymph node dissection in early epithelial ovarian cancer (EOC) – Results from a population based study
J. Man¹, C. Khoo¹, B. Gao¹, S. Fereday², J. Hung¹, A.O.C.S. Group², P. Harnett³, D. Bowtell², A. Brand¹, A. Defazio¹; ¹Sydney, AU, ²Melbourne, AU, ³Westmead, AU
- 13:00 - 13:00 873P - Effect of age on completion of intraperitoneal chemotherapy in ovarian cancer



M. Tamburelli¹, M. Bluthgen², C. Lindsay², F. Bianchi¹, J. Castillo¹, R. Castaño¹, C. Bas¹, G. Gomez-Abuin¹; ¹Buenos Aires, AR, ²Villejuif, FR

- 13:00 - 13:00 874P - Outcomes of clinical testing for tumor BRAC1 and BRCA2 gene analysis for 354 patients: First experience with tumor companion diagnostic for PARP inhibitors
K. Copeland¹, S. Wehnelt², L. Wange², B. Anwald², A. Weicht², A. Pfeufer²; ¹Zurich, CH, ²München, DE
- 13:00 - 13:00 875P - Impact of genomic heterogeneity and mutation patterns on the outcome of patients with epithelial ovarian cancer (EOC)
V. Kotoula¹, S. Lakis², E. Giannoulatou³, G. Kouvatseas², G. Lazaridis¹, I. Tikas², I. Efstratiou², S. Chrisafi², E. Charalambous², A. Papanikolaou², F. Fostira², B. Tarlatzis², G. Fountzilias¹; ¹Thessaloniki, GR, ²Athens, GR, ³Darlinghurst, AU
- 13:00 - 13:00 876P - A phase 1 study of single agent veliparib in Japanese subjects with advanced solid tumors
 K. Tamura¹, K. Matsumoto², H. Yoshida³, T. Nishikawa¹, Y. Imai³, A.M. Miyasaka³, T. Onoe⁴, S. Yamaguchi⁴, C. Shimizu¹, K. Yonemori¹, T. Shimoi¹, M. Yunokawa¹, H. Xiong⁵, H. Hashiba¹, T. Kiriya¹, T. Leahy⁵, S. Shepherd⁶, K. Fujiwara³; ¹Tokyo, JP, ²Atlanta, US, ³Saitama, JP, ⁴Hyogo, JP, ⁵North Chicago, IL/US, ⁶North Chicago, US
- 13:00 - 13:00 877P - Treatment patterns and BRCA testing practices in platinum-sensitive recurrent serous ovarian cancer: A Spanish medical record review
I. Bover¹, N. Colombo², J. Korach³, K. Davis⁴, J. Kaye⁴, J. Robert Lewis⁵, A. Callejo⁶, A. Gascó⁷; ¹Palma De Mallorca, ES, ²Milano, IT, ³Tel Hashomer, IL, ⁴Waltham, MA/US, ⁵Cambridge, GB, ⁶Pinto, ES, ⁷Madrid, ES
- 13:00 - 13:00 878P - Quantification of genetic variants as marker of Brca-like phenotype in ovarian cancer
J. Garcia-Donas¹, N. Lainez Milagro², E.M. Guerra Alia¹, M. Garrido¹, R. Guarch², A. Acosta¹, A. Herrador¹, M. Prieto Pozuelo¹, J.F. Rodriguez-Moreno¹; ¹Madrid, ES, ²Pamplona, ES
- 13:00 - 13:00 879P - Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary
S. Sato¹, H. Itamochi², N. Oumi¹, T. Oishi¹, T. Shoji², H. Fujiwara³, M. Suzuki⁴, J. Kigawa⁵, T. Harada¹, T. Sugiyama²; ¹Yonago, JP, ²Morioka, JP, ³Shimotsuke, JP, ⁴Utsunomiya, JP, ⁵Matsue, JP
- 13:00 - 13:00 880P - Molecular characterization and comparison of epithelial ovarian carcinoma (EOC) and primary peritoneal carcinoma (PCC)
A. Knipprath¹, D. Arguello², K. Russell², A. Voss¹, V. Heinzelmann-Schwarz¹; ¹Basel, CH, ²Phoenix, US
- 13:00 - 13:00 881P - Response to chemotherapy in relapsed low-grade serous ovarian carcinoma: Royal Marsden series of 46 patients
J. McLachlan¹, N. Tunariu¹, J.P. Lima², A. George², M. Gore¹, S. Kaye¹, S. Banerjee¹; ¹London, GB, ²Sutton, GB



- 13:00 - 13:00 882P - Treatment efficacy and prognostic factors in patients (pts) with malignant ovarian germ cell tumors (MOGCT): Single-center experience
D. Chekini, A. Tryakin, M. Fedyanin, A. Bulanov, M. Ahmedova, I. Pokataev, T. Zakharova, S. Tjulandin; Moscow, RU
- 13:00 - 13:00 883P - Phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha (PI3KCA) and microsatellite instability in ovarian clear cell carcinoma, clinical correlation
M. Batista¹, I. Romero¹, J.P. Molina², L. Brot³, A. Costa³, R. López¹, P. Mallol¹, J. Palacios⁴, C. Illueca¹, C. Mendes⁵, G. Machado⁵, A. Santiago⁵, E. Rego⁵, J.A. López¹, A. Poveda¹; ¹Valencia, ES, ²San Jose, CR, ³São Paulo, BR, ⁴Madrid, ES, ⁵Ribeirao Preto, BR
- 13:00 - 13:00 884P - Ovarian granulosa cell tumours: hormone receptor positivity and response to aromatase inhibitors
K. Herring, R. Ganesan, A. Rao, L. Edwards, J. Pascoe, S. Williams; Birmingham, GB
- 13:00 - 13:00 885P - Fibroblast growth factor receptor 2 (FGFR2) amplification and polysomy in serous ovarian cancer
A. Tyulyandina, I. Demidova, M. Gikalo, I. Tsimafeyu, S. Tjulandin; Moscow, RU
- 13:00 - 13:00 886P - Circulating tumor cell number predicts time to progression (TTP) in patients with heavily pretreated gynecological cancers treated with selinexor (SEL)
M. Crochiere¹, I. Vergote², B. Lund³, H. Havsteen⁴, Z. Ujmajuridze⁵, E. Van Nieuwenhuysen², C. Haslund³, T. Juhler-Nøttrup⁵, M. Mau-Sørensen⁵, P. Berteloot², A. Kranich⁶, J. Meade¹, G. Wright¹, E. Shacham¹, T. Rashal¹, J.-R. Saint-Martin⁷, S. Shacham¹, M. Kauffman¹, M. Raza Mirza¹, Y. Landesman¹; ¹Newton, MA/US, ²Leuven, BE, ³Aalborg, DK, ⁴Herlev, DK, ⁵Copenhagen, DK, ⁶Hamburg, DE, ⁷Natick, US
- 13:00 - 13:00 887P - Screening for Lynch syndrome among endometrial cancer patients less than 60 years
E. Aguirre¹, M. Mele², N. Tuset³, A. Velasco³, J. Tarragona³, M. Sampayo⁴, S. Serrano², F. Riu², M. Rodriguez-Balada², X. Matias-Guiu³, E. Garcia³, E. Ortega³, J. Balmaña⁴; ¹Zaragoza, ES, ²Reus, ES, ³Lerida, ES, ⁴Barcelona, ES
- 13:00 - 13:00 888P - Sequenced aromatase inhibitor use associated with lower risk of endometrial cancer in tamoxifen-treated breast cancer patients: A population-based study
S.-C. Chu, C.-J. Hsieh, T.-F. Wang, M.-K. Hong, T.-Y. Chu; Hualian, TW
- 13:00 - 13:00 889P - Immunohistochemistry (IHC) evaluation of a novel 4-protein prognostic and predictive biomarker panel in endometrial cancer (EC)
B. Kularatne, R. Arora, G. Elshstein, N. Guppy, A. Kirkwood, T. Meyer, R. Kristeleit; London, GB
- 13:00 - 13:00 890P - Cervical cancer: Awareness and misconceptions of risk factors among lay persons and physicians
X. Pivot¹, J.-F. Morère², S. Couraud³, C. Touboul⁴, J.-Y. Blay⁵, A. Cortot⁶, C. Lhomel⁷, F. Eisinger⁸, L. Greillier⁸, J. Viguier⁹; ¹Besançon, CEDEX/FR, ²Villejuif, FR, ³Pierre Bénite, FR, ⁴Paris, FR, ⁵Lyon, FR, ⁶Lille, FR, ⁷Boulogne-Billancourt, FR, ⁸Marseille, FR, ⁹Tours, FR
- 13:00 - 13:00 891P - Sexual satisfaction, anxiety, depression and quality of life among Turkish gynecological cancer patients



Y. Yildiz, M. Akyol, A. Alacacioglu, Y. Kucukzeybek, N. Asik, H. Taskaynatan, U. Varol, I. Yildiz, U. Ofiazoglu, T. Salman, S.U. Ozaltas, M. Tarhan; Izmir, TR

- 13:00 - 13:00 892P - Virological studies in the secondary prevention of cervical cancer
E. Bakhidze, O. Lavrynovych, A. Belyaeva, I. Berlev; St. Petersburg, RU
- 13:00 - 13:00 893P - Chemotherapy-related toxicity in patients receiving concurrent chemoradiation for locally advanced cervical cancer
M. Etsebeth, S. Bassa, R. Lakier; Pretoria, ZA
- 13:00 - 13:00 894P - Comprehensive genomic profiling of uterine carcinosarcomas identifies potential targeted therapy opportunities
J. Elvin¹, L. Gay¹, C. Gunderson², M. Greenwade², S. Ramkissoon¹, S. Ali¹, J.-A. Vergilio¹, J. Suh¹, J. Ross³, K. Moore⁴; ¹Cambridge, MA/US, ²Oklahoma City, OK/US, ³Albany, NY/US, ⁴Oklahoma City, Oklahoma/US
- 13:00 - 13:00 895P - Use of bevacizumab (Bev) in real life for first-line (fl) treatment of ovarian cancer (OC). Part1: The ENCOURAGE cohort of 1158 patients (pts) by GINECO
D. Berton-Rigaud¹, F. Selle², A. Floquet³, D. Mollon⁴, W. Lescaut⁵, M.-C. Kaminsky⁶, I. Ray-Coquard⁷, R. Largillier⁸, A.-M. Savoye⁹, H. Barletta¹⁰, P. Pautier¹¹, H. Orfeuvre¹², M. Baron¹³, A. Marti¹⁴, J.-L. Mouysset¹⁵, J.-B. Paoli¹⁶, P.-E. Cailleux¹⁷, C. Cornea¹⁸, E. Pujade-Lauraine²; ¹St. Herblain, FR, ²Paris, FR, ³Bordeaux, FR, ⁴Quimper, FR, ⁵Monaco, MC, ⁶Vandoeuvre Les Nancy, FR, ⁷Lyon, FR, ⁸Mougins, FR, ⁹Reims, FR, ¹⁰Guilherand-Granges, FR, ¹¹Dechy, FR, ¹²Bourg En Bresse, FR, ¹³Rouen, FR, ¹⁴Auxerre, FR, ¹⁵Aix-En-provence, FR, ¹⁶Marseille, FR, ¹⁷Chambray-Lès-tours, FR, ¹⁸Valenciennes, FR
- 13:00 - 13:00 896P - Overexpression of HER2/neu in uterine carcinosarcoma
T. Nishikawa, K. Yonemori, H. Okuma, A. Kawachi, A. Kitano, T. Shimoi, A. Shimomura, E. Noguchi, M. Yunokawa, H. Yoshida, Y. Fujiwara, C. Shimizu, K. Tamura; Tokyo, JP
- 13:00 - 13:00 897P - Comprehensive genomic profiling of uterine leiomyosarcomas identifies opportunities for personalized therapies
K. Moore¹, C. Gunderson², S. Ramkissoon³, S. Ali³, C. McMahon³, L. Gay³, J. Ross⁴, J. Elvin³; ¹Oklahoma City, Oklahoma/US, ²Oklahoma City, OK/US, ³Cambridge, MA/US, ⁴Albany, NY/US
- 13:00 - 13:00 898P - Uterine carcinosarcoma: A retrospective clinical cohort analysis
C. Perna¹, G. Eminowicz², U. Asghar², G. Imseeh², A. Kirkwood², A. Mitra², R. Arora², R. Kristeleit², M. McCormack²; ¹Guildford, GB, ²London, GB
- 13:00 - 13:00 899P - Defining the genomic landscape of vulvar squamous cell carcinoma (VSCC) using next generation sequencing: The role of HPV infection
J. Weberpals¹, A. Clancy², B. Lo², H. Sekhon², J. Dimitroulakos², G. Goss², J. Spaans², M. Duciaume²; ¹Ottawa, CA, ²Ottawa, ON/CA
- 13:00 - 13:00 900TiP - KEYNOTE-100: Phase 2 trial of pembrolizumab in patients with advanced recurrent ovarian cancer



U. Matulonis¹, M. Chen², M. Puhmann², Y. Shentu², J. Ledermann³; ¹Boston, MA/US, ²Kenilworth, PA/US, ³London, GB

- 13:00 - 13:00 901TiP - Phase Ib/II study to evaluate the efficacy and tolerability of PM01183 (lurbinectedin) in combination with olaparib in patients with advanced solid tumors
A. Poveda¹, A. Oaknin², I. Romero¹, A. Guerrero¹, L. Fariñas Madrid², A. Soto³, C. Peris¹, J.A. Lopez Guerrero¹; ¹Valencia, ES, ²Barcelona, ES, ³Madrid, ES
- 13:00 - 13:00 902TiP - ENDOLA : A GINECO-GINEGEPS French NCI sponsored phase I/II trial to assess the safety and efficacy of metronomic cyclophosphamide, metformin and OLaparib in recurrent advanced/metastatic ENDometrial cancer patients
B. You¹, A. Dugue², A. Leary³, M. Rodrigues⁴, P. Follana⁵, D. Maucort-Boulch¹, S. Verane¹, M. Tod¹, G. Freyer¹; ¹Lyon, FR, ²Caen, FR, ³Villejuif, FR, ⁴Paris, FR, ⁵Nice, FR
- 13:00 - 13:00 903TiP - Preoperative olaparib in early-stage endometrial cancer (EC): A phase 0, window of opportunity trial to evaluate the PARP inhibition effect, targeting cell cycle-related proteins (POLEN study)
I. Romero¹, M.J. Rubio², R. Serrano², M. Medina², L. Minig¹, A. Casado³, P. Coronado³, S. Martínez⁴, C. Orbegoso⁴, P. Fusté⁴, E. Guerra Alia³, M. Sánchez-Martínez³, D. Rubio³, M. Santacana⁵, M. Ruiz⁵, A. Llombart-Cussac⁴, X. Matias-Guiu⁵, A. Poveda¹; ¹Valencia, ES, ²Cordoba, ES, ³Madrid, ES, ⁴Barcelona, ES, ⁵Lerida, ES
- 13:00 - 13:00 904TiP - METRO-BIBF Phase II, randomised, placebo controlled, multicentre, feasibility study of low dose (metronomic) cyclophosphamide (MCy) with and without nintedanib in advanced ovarian cancer (AOC)
M. Hall¹, R. Lillywhite², S. Nicum³, R. Lord⁴, R. Glasspool⁵, M. Feeney², A. Hackshaw²; ¹Northwood, GB, ²London, GB, ³Oxford, GB, ⁴Liverpool, GB, ⁵Glasgow, GB
- 13:00 - 13:00 905TiP - Interim statistical analysis on a phase III randomised trial investigating the addition of modulated electro-hyperthermia to chemoradiation for cervical cancer in HIV positive and negative women in South Africa
C. Minnaar¹, J. Kotzen¹, A. Baeyens²; ¹Johannesburg, ZA, ²Cape Town, ZA
- 13:00 - 13:00 Haematological Malignancies
- 13:00 - 13:00 910P - Outcome of primary gastrointestinal compared to nodal diffuse large B cell lymphoma in a series of consecutive patients treated at a single institution
J. Romejko-Jarosinska, M. Osowiecki, E. Paszkiewicz-Kozik, A. Druzdz-Sitek, K. Martyna, M. Szymański, L. Targonski, J. Walewski; Warsaw, PL
- 13:00 - 13:00 911P - Outcome of primary bone lymphoma: Single center experience
M. Rauf, S. Akhtar, A. Badran, M. Ilyas, Q. Shaikh, M. Zahir, Y. Khafaga, I. Maghfoor; Riyadh, SA
- 13:00 - 13:00 912P - Prognosis of diffuse large B-cell lymphoma: 16 years of experience
E. Esin, A. Saglam, M. Hayran, A. Uner; Ankara, TR



- 13:00 - 13:00 913P - Prevalence, clinico-pathological features and outcomes of 'double-hit' high-grade B-cell non-Hodgkins lymphoma (NHL): A single institution experience
D. McHugh¹, P. Gou², J. Quinn², P. Thornton², B. Bird³, S. Sukor², A. Fortune², K. Perera⁴, L. Bacon², E. Vandenberghe², R. Flavin², C. Grant²; ¹Limerick, IE, ²Dublin, IE, ³Cork, IE, ⁴Tullamore, IE
- 13:00 - 13:00 914P - Impact of the addition of rituximab in overall survival in first line chemotherapy in follicular lymphoma: A population-based study from the Spanish Lymphoma Oncology Group (GOTEL)
M. Torrente¹, P. Sabin¹, J. Gomez Codina², L. de la Cruz Merino³, M. Llanos⁴, J. Guma I Padro⁵, C. Quero⁶, A. Blasco², F.R. Garcia Arroyo⁷, A. Rueda⁶; ¹Madrid, ES, ²Valencia, ES, ³Sevilla, ES, ⁴Santa Cruz De Tenerife, ES, ⁵Reus, ES, ⁶Malaga, ES, ⁷Pontevedra, ES
- 13:00 - 13:00 915P - Cause-specific mortality after follicular non-Hodgkin lymphoma: A report from the Spanish Lymphoma Study Group (GOTEL)
M. Provencio¹, A. Royuela¹, J. Gomez Codina², M. Torrente¹, P. Sabin³, M. Llanos⁴, J. Guma I Padro⁵, C. Quero⁶, A. Blasco², M.A. Cruz⁷; ¹Majadahonda, ES, ²Valencia, ES, ³Madrid, ES, ⁴Santa Cruz De Tenerife, ES, ⁵Reus, ES, ⁶Malaga, ES, ⁷Toledo, ES
- 13:00 - 13:00 916P - Survival in young adults diagnosed with follicular lymphoma in a national registry from the Spanish Lymphoma Oncology Group
V. Calvo de Juan¹, M. Provencio¹, J. Gomez Codina², D. Rodriguez Abreu³, A. Rueda⁴, R. Garcia Arroyo⁵, L. de la Cruz Merino⁶, M. Llanos⁷, J. Guma I Padro⁸, J.J. Sánchez Hernández⁹; ¹Majadahonda, ES, ²Valencia, ES, ³Las Palmas, ES, ⁴Malaga, ES, ⁵Pontevedra, ES, ⁶Sevilla, ES, ⁷Santa Cruz De Tenerife, ES, ⁸Reus, ES, ⁹Monterrey, MX
- 13:00 - 13:00 917P - The role of radiation therapy in DLBCL treatment in a single institution study
I. Kryachok¹, O. Aleksyk¹, K. Filonenko¹, Z. Fedorenko¹, I. Tytorenko¹, A. Martynchyk¹, I. Stepanishyna², L. Koutsenko¹; ¹Kiev, UA, ²Kyiv, UA
- 13:00 - 13:00 918P - A pooled data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL): Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in non-Hodgkin lymphoma (NHL)
R.M. Santi¹, M. Ceccarelli², C. Monagheddu², A. Evangelista², E. Bernocco¹, F. Monaco¹, M. Federico³, U. Vitolo², S. Cortellazzo⁴, M.G. Cabras⁵, M. Spina⁶, L. Baldini⁷, C. Boccomini², A. Chiappella², A. Bari³, S. Luminari³, C. Visco⁸, L. Contino¹, G. Ciccone², M. Ladetto¹; ¹Alessandria, IT, ²Torino, IT, ³Modena, IT, ⁴Bolzano, IT, ⁵Cagliari, IT, ⁶Aviano, IT, ⁷Milano, IT, ⁸Vicenza, IT
- 13:00 - 13:00 919P - 17P deletion and TP53 gene mutation (17P/TP53) testing behaviour and treatment patterns for chronic lymphocytic leukemia (CLL) patients in France, Germany, Italy, Spain and UK (EU5)
 L. Mitrofan, F. Bermudez Canta, Y. Karanis, H. Mistry, C. Anger; London, GB
- 13:00 - 13:00 920P - VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients in the thalidomide era
L. Lopes-Aguiar, M. Delamain, A. Brito, G. Lourenço, E. Costa, G. Oliveira, J. Vassallo, C. De Souza, C. Lima; Campinas, BR
- 13:00 - 13:00 921P - PD-L1 status in refractory lymphomas



S. Vranic¹, J. Jin², J. Kimbrough³, N. Ghosh⁴, N. Bilalovic¹, D. Arguello³, Y. Veloso³, T. Hendershot², A. Dizdarevic¹, S. Reddy³, Z. Gatalica³; ¹Sarajevo, BA, ²Santa Clara, US, ³Phoenix, US, ⁴Charlotte, NC/US

- 13:00 - 13:00 922P - The role of indoleamine 2,3-dioxygenase expression in diffuse large B-cell lymphoma prognosis
I. Kryachok¹, T. Skrypets¹, O. Novosad¹, N. Khranovska¹, O. Skachkova¹, K. Ulianchenko¹, A. Martynchyk¹, I. Tytorenko¹, K. Filonenko¹, I. Stepanishyna², N. Svergun¹, O. Gorbach¹, O. Nevdakh¹; ¹Kiev, UA, ²Kyiv, UA
- 13:00 - 13:00 923P - The predictive value of immunohistochemical expression of Bcl-2, Bcl-6, MUM1, CD10 and CD30 in patients with diffuse large cell lymphoma
I. Kryachok¹, A. Martynchyk¹, K. Filonenko¹, A. Grabovoy¹, S. Antoniuk¹, I. Tytorenko¹, O. Novosad¹, T. Kadnikova¹, O. Aleksik¹, I. Stepanishyna²; ¹Kiev, UA, ²Kyiv, UA
- 13:00 - 13:00 924P - Identification of exosomes in non-Hodgkin B-cell lymphomas. Prognostic usefulness in patients treated with rituximab-chemotherapy: A prospective, multicenter correlation study by the Spanish Lymphoma Oncology Group (GOTEL)
M. Provencio¹, M. Rodriguez-Balada², B. Cantos³, C. Quero⁴, R. Garcia Arroyo⁵, A. Rueda⁴, C. Maximiano³, D. Rodriguez Abreu⁶, A. Sanchez³, V. Garcia³; ¹Majadahonda, ES, ²Reus, ES, ³Madrid, ES, ⁴Malaga, ES, ⁵Pontevedra, ES, ⁶Las Palmas, ES
- 13:00 - 13:00 925P - Role of FDG-PET in detecting bone marrow involvement in mature T-/NK-cell neoplasms
Y.S. Choi, K. Kim, I.-C. Song, Y.J. Yang, H.J. Lee, D.-Y. Jo, S.Y. Park, S. Kim, H.-J. Yun; Daejeon, KR
- 13:00 - 13:00 926P - Reader variability of PET/CT-based response criteria in DLBCL and association to outcome
E.J. Han¹, W.H. Choi², J.H. O²; ¹Daejeon, KR, ²Seoul, KR
- 13:00 - 13:00 927P - Proposal of improved prognostic index for patients with extranodal natural killer/T cell lymphoma treated with non-anthracycline based treatment
Y. Kang, S. Seo, J.Y. Hong, D.H. Yoon, S. Kim, J.S. Park, J. Huh, S.-W. Lee, J.-S. Ryu, C. Suh; Seoul, KR
- 13:00 - 13:00 928P - Chemotherapy-induced interstitial pneumonia in patients with lymphoma
W.P. Liu, X.P. Wang, W. Zheng, M.F. Tu, Y. Xie, N.J. Lin, L. Ping, Z.T. Ying, C. Zhang, L.J. Deng, Y.Q. Song, J. Zhu; Beijing, CN
- 13:00 - 13:00 929P - Pharmacokinetics (PK) and safety of carfilzomib (CFZ) in patients (Pts) with advanced malignancies and varying degrees of hepatic impairment (HI): An open-label, single-arm, phase 1 study
J. Brown¹, R. Plummer², T. Bauer³, S. Anthony⁴, J. Sarantopoulos⁵, F. De Vos⁶, M. White⁷, M. Schupp⁸, Y. Ou⁹, U. Vaishampayan¹⁰; ¹Glasgow, GB, ²Newcastle Upon Tyne, GB, ³Nashville, TN/US, ⁴Spokane, WA/US, ⁵San Antonio, TX/US, ⁶Roermond, NL, ⁷Thousand Oaks, US, ⁸Zug, CH, ⁹South San Francisco, US, ¹⁰Detroit, US
- 13:00 - 13:00 930P - Evaluation of safety, tolerability and efficacy of temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice



M. Dreyling¹, G. Krekeler², A. Neuhof², M. Woike², G. Hess³, D. Kalanovic²; ¹München, DE, ²Berlin, DE, ³Mainz, DE

- 13:00 - 13:00 931P - Final results of a phase II trial of R-IDEA as salvage therapy in patients with relapsed/refractory diffuse large B-cell lymphoma
E. Kondo¹, K. Yamamoto¹, T. Masunari², J. Takizawa³, K. Miura⁴, Y. Masaki⁵, T. Matsumura⁶, Y. Hiramatsu⁶, J. Murakami⁷, H. Tsujimura⁸, N. Tomita⁹, Y. Maeda¹, M. Kanno¹⁰; ¹Okayama, JP, ²Fukuyama, JP, ³Niigata, JP, ⁴Itabashi, JP, ⁵Uchinada, Kahoku, JP, ⁶Himeji, JP, ⁷Toyama, JP, ⁸Chiba, JP, ⁹Kawasaki, JP, ¹⁰Kashihara, JP
- 13:00 - 13:00 932P - Chemotherapy alone or combined chemotherapy and involved field radiotherapy in favorable risk early-stage classical Hodgkin lymphoma-a 10 years experience
S. Ali, A. Basit, A.S. Kazmi, F. Badar, A. Sidhu, A. Hameed; Lahore, PK
- 13:00 - 13:00 933P - CagA and NFAT co-operatively participate in the lymphomagenesis of gastric MALT lymphoma
S.-H. Kuo¹, H.-J. Tsai², K.-H. Yeh¹, C.-W. Lin¹, Y.-S. Zeng¹, M.-S. Wu¹, P.-N. Hsu¹, L.-T. Chen², A.-L. Cheng¹; ¹Taipei, TW, ²Tainan, TW
- 13:00 - 13:00 934P - Dynamics of changes in endocrine status in adolescents with lymphoma
E. Pak¹, O. Kit¹, E. Frantsiyants¹, V. Dmitrieva¹, O. Kozyuk¹, I. Lysenko¹, L. Vladimirova²; ¹Rostov On Don, RU, ²Rostov-On-don, RU
- 13:00 - 13:00 935P - Development of PF-05280586, a potential biosimilar to rituximab
I. Jacobs¹, L. Melia², C. Kirchhoff³, C. Kobryn⁴, P. Nava-Parada¹, J. Rosenberg⁴, A. Ryan⁴, D. Yin²; ¹New York, NY/US, ²San Diego, CA/US, ³Chesterfield, MO/US, ⁴Groton, CT/US
- 13:00 - 13:00 936P - Do MDR1 & CYP3A5 genetic polymorphisms influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
H. Natarajan¹, L. Kumar², S. Bakhshi², A. Sharma², M. Kabra², T. Velpandian², A. Gogia², S. Shastri², Y.K. Gupta²; ¹New Delhi, Delhi/IN, ²New Delhi, IN
- 13:00 - 13:00 937P - Relationship between adherence, drug level and clinical response achieved in patients with chronic myeloid leukemia on imatinib
M. Omeran, R. Abdelfatah, H. Mousa, N. Alieldin, S. Shouman; Cairo, EG
- 13:00 - 13:00 938P - Is there any association between vitamin D receptor polymorphisms and acute myeloid leukemia?
A. Esfahani, Z. Ghoreishi; Tabriz, IR
- 13:00 - 13:00 939P - Identification of aberrant DNA methylation in pediatric acute myeloid leukaemia by multiplex methylation sensitive PCR
V. Rudenko, S. Kazakova, A. Tanas, A. Popa, V. Nemirovchenko, E. Kuznetsova, D. Zaletaev, V. Strelnikov; Moscow, RU
- 13:00 - 13:00 940TiP - Pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM): Randomized, phase 3 KEYNOTE-185 study



A. Palumbo¹, M.-V. Mateos², J. San Miguel³, J. Shah⁴, S. Thompson⁵, P. Marinello⁵, S. Jagannath⁶; ¹Torino, IT, ²Salamanca, ES, ³Pamplona, ES, ⁴Houston, TX/US, ⁵Kenilworth, NJ/US, ⁶New York, NY/US

13:00 - 13:00 941TiP - Pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM): Randomized, phase 3 KEYNOTE-183 study

E. Ocio¹, J. Shah², S. Jagannath³, M.-V. Mateos¹, A. Palumbo⁴, U. Kher⁵, P. Marinello⁵, J. San Miguel⁶; ¹Salamanca, ES, ²Houston, TX/US, ³New York, NY/US, ⁴Torino, IT, ⁵Kenilworth, NJ/US, ⁶Pamplona, ES

13:00 - 13:00 942TiP - Phase 3 trial of pixantrone plus rituximab versus gemcitabine plus rituximab in treating relapsed/refractory transplant-ineligible aggressive non-Hodgkin's lymphoma

P. Georgiev¹, D. Belada², S. Dakhil³, L. Inhorn⁴, D. Andorsky⁵, A.M. Liberati⁶, J.T. Beck⁷, D. Quick⁸, C. Patti⁹, L. Sivcheva¹⁰, J.M. Zaucha¹¹, R. Pettengell¹², T. Devries¹³, J.P. Dean¹³, M. Pavlyuk¹⁴, N. Failloux¹⁴, K. Hübel¹⁵; ¹Plovdiv, BG, ²Hradec Kralove, CZ, ³Wichita, KS/US, ⁴Roanoke, VA/US, ⁵Boulder, CO/US, ⁶Terni, IT, ⁷Lafayetteville, AZ/US, ⁸Lubbock, TX/US, ⁹Palermo, IT, ¹⁰Vratsa, BG, ¹¹Gdansk, PL, ¹²London, GB, ¹³Seattle, WA/US, ¹⁴Suresnes, FR, ¹⁵Koln, DE

13:00 - 13:00 943TiP - ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)

S. Neelapu¹, F. Locke², N. Bartlett³, T. Siddiqi⁴, I. Braunschweig⁵, L. Lekakis⁶, A. Goy⁷, J. Castro⁸, O. Oluwole⁹, D. Miklos¹⁰, J. Timmerman¹¹, C. Jacobson¹², P. Reagan¹³, I. Flinn⁹, U. Farooq¹⁴, P. Stiff¹⁵, L. Navale¹⁶, M. Elias¹⁶, J. Wiezorek¹⁶, W. Go¹⁶; ¹Houston, TX/US, ²Tampa, FL/US, ³St. Louis, MO/US, ⁴Duarte, CA/US, ⁵Bronx, US, ⁶Miami, US, ⁷Hackensack, US, ⁸La Jolla, US, ⁹Nashville, US, ¹⁰Stanford, US, ¹¹Los Angeles, US, ¹²Boston, US, ¹³Rochester, US, ¹⁴Iowa City, US, ¹⁵Maywood, US, ¹⁶Santa Monica, CA/US

13:00 - 13:00 944TiP - Pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) or relapsed or refractory Richter syndrome (rrRS): Phase 2 KEYNOTE-170 study

J.-M. Michot¹, P. Armand², W. Ding³, V. Ribrag¹, B. Christian⁴, A. Balakumaran⁵, P. Marinello⁵, S. Chlosta⁵, Y. Zhang⁵, M. Shipp², P.L. Zinzani⁶; ¹Villejuif, FR, ²Boston, MA/US, ³Rochester, MN/US, ⁴Columbus, OH/US, ⁵Kenilworth, NJ/US, ⁶Bologna, IT

13:00 - 13:00 945TiP - ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)

M. Wang¹, F. Locke², T. Siddiqi³, J. Castro⁴, B. Shah², H. Lee⁵, L. Budde³, M. Choi⁶, C. Anasetti², R. Champlin⁵, S. Forman³, T. Kipps⁶, A. Bot⁷, J. Rossi⁷, L. Navale⁷, Y. Jiang⁷, J. Aycock⁷, M. Elias⁷, J. Wiezorek⁷, W. Go⁷; ¹Houston, US, ²Tampa, FL/US, ³Duarte, CA/US, ⁴La Jolla, US, ⁵Houston, TX/US, ⁶La Jolla, CA/US, ⁷Santa Monica, CA/US

13:00 - 13:00 946TiP - A randomized comparative study of PF-05280586 (a potential biosimilar) vs rituximab for patients with CD20+, low tumor burden, follicular lymphoma

I. Jacobs¹, M. Suster², B. Jin³, D. Yin², L. Melia²; ¹New York, NY/US, ²San Diego, CA/US, ³Cambridge, MA/US



- 13:00 - 13:00 947TiP - Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (cHL): Randomized phase 3 KEYNOTE-204 study
M. Fanale¹, J. Kline², R. Chen³, V. Ribrag⁴, G. Salles⁵, I. Matsumura⁶, Y. Zhu⁷, A. Ricart⁷, A. Balakumaran⁷, P.L. Zinzani⁸; ¹Houston, US, ²Chicago, IL/US, ³Duarte, CA/US, ⁴Villejuif, FR, ⁵Pierre Bénite, FR, ⁶Osaka, JP, ⁷Kenilworth, NJ/US, ⁸Bologna, IT
- 13:00 - 13:00 948TiP - Phase 3 study of quizartinib (AC220) monotherapy vs salvage chemotherapy (SC) in patients (pts) with FLT3-ITD+ acute myeloid leukemia (AML) refractory to or relapsed (R/R) after 1st-line treatment with or without hematopoietic stem cell transplant (HSCT) consolidation: The QuANTUM-R study
J. Cortes¹, G. Gammon², S. Khaled³, G. Martinelli⁴, A. Kramer⁵, B. Steffen⁶, D. Hogge⁷, B. Jonas⁸, H. Dombret⁹, A. Perl¹⁰; ¹Houston, US, ²San Diego, US, ³Duarte, US, ⁴Bologna, IT, ⁵Heidelberg, DE, ⁶Frankfurt Am Main, DE, ⁷Vancouver, CA, ⁸Sacramento, US, ⁹Paris, FR, ¹⁰Philadelphia, US
- 13:00 - 13:00 NSCLC, early stage
- 13:00 - 13:00 1180P - Elevated fraction of CTLA-4(+) and PD-1(+) T cells in peripheral blood with stimulation of Th1, Th2 and Th17 type immune response after stereotactic radiotherapy for early lung cancer – a prospective study
J. Rutkowski, T. Ślebioda, R. Zaucha; Gdansk, PL
- 13:00 - 13:00 1181P - Clinicopathological analysis of programmed death-ligand 1 (PD-L1) expression on tumor cells (TC) and tumor-infiltrating immune cells (IC) in surgically resected non-small cell lung cancer (NSCLC) patients (pts)
K. Saruwatari¹, G. Ishii², S. Nomura², K. Kiritani², S. Umemura², S. Matsumoto³, K. Yoh², S. Niho², H. Ohmatsu², M. Tsuboi², M. Kowanetz⁴, M. Sakai⁵, J. Itabashi⁵, Y. Kamihara⁵, R. Shiokawa⁵, A. Morioka⁵, M. Ueda⁵, K. Goto²; ¹Kumamoto, JP, ²Kashiwa, JP, ³Kashiwa, Chiba/JP, ⁴South San Francisco, AM, ⁵Tokyo, JP
- 13:00 - 13:00 1182P - RICTOR/PI3K/mTOR as a clinically relevant driver of poor prognosis in squamous cell lung carcinoma (SqCLC): Preliminary results of prognostic outliers according to a validated clinicopathological model
S. Pilotto¹, M. Simbolo¹, I. Sperduti², S. Novello³, C. Vicentini¹, U. Peretti¹, S. Pedron¹, M. Milella², A. Mafficini¹, P. Visca², M. Volante³, F. Facciolo², A. Santo¹, M. Infante¹, L. Carbognin¹, M. Brunelli¹, M. Chilosi¹, A. Scarpa¹, G. Tortora¹, E. Bria¹; ¹Verona, IT, ²Roma, IT, ³Orbassano, IT
- 13:00 - 13:00 1183P - Assessment of efficacy of adjuvant chemotherapy for non-small cell lung cancer with metastatic ability involving ACTN4
K. Honda, N. Miura, H. Shiraishi, K. Onidani, H. Shoji, T. Yamada, Y. Fujiwara, Y. Ohe; Tokyo, JP
- 13:00 - 13:00 1184P - Are the criteria indicating patients to be “medically inoperable” that are used in clinical trials on stereotactic body radiotherapy appropriate for patients with early stage non-small cell lung cancer?
K. Takamochi, A. Hattori, T. Maeyashiki, T. Matsunaga, T. Banno, S. Oh, K. Suzuki; Tokyo, JP
- 13:00 - 13:00 1185P - Prognostic role of texture analysis in lung cancer treated with stereotactic ablative radiotherapy (SABR)



V. Nardone, P. Tini, L.N. Mazzone, A. La Penna, M. Biondi, L. Sebaste, T. Carfagno, E. Vanzi, G. De Otto, G. Battaglia, P. Pastina, S.F. Carbone, F. Banci Buonamici, L. Pirtoli; Siena, IT

- 13:00 - 13:00 1186P - Good news for French NSCLC patients: Distance between chest and surgical departments did not impair outcome
D. Debievre¹, B. Asselain², M.L. Braud³, C. Fouret³, S. Larive⁴, L. Falchero⁵, Y. Duval⁶, B. Lemaire⁷, M. Farny⁸, P. Brun⁹, C. Dujon¹⁰, C. Nocent¹¹, P. Dumont¹², P. Le Lann¹³, G.-J. Kassem¹⁴, M. Grivaux¹⁵; ¹Mulhouse, FR, ²Paris, FR, ³Villeneuve Saint-Georges, FR, ⁴Macon, FR, ⁵Villefranche Sur Saone, FR, ⁶Cannes, FR, ⁷Orleans, FR, ⁸Cahors, FR, ⁹Valence, FR, ¹⁰Le Chesnay, FR, ¹¹Bayonne, FR, ¹²Chauny, FR, ¹³Creil, FR, ¹⁴Sedan, FR, ¹⁵Meaux, FR
- 13:00 - 13:00 1187P - Multigene expression profile for predicting efficacy of cisplatin and vinorelbine in non-small cell lung cancer
I. Buhl¹, I. Christensen², E. Santoni-Rugiu¹, J. Ravn¹, A. Hansen³, T. Jensen³, J. Askaa³, P. Jensen⁴, S. Knudsen⁵, J. Soerensen¹; ¹Copenhagen, DK, ²Hvidovre, DK, ³Hoersholm, DK, ⁴Hørsholm, DK, ⁵Scottsdale, AZ/US
- 13:00 - 13:00 1188P - Poly-therapy with EGFR, STAT3 and Src-YAP1 signaling pathway inhibition; A breakthrough for EGFR mutant NSCLC
N. Karachaliou¹, I. Chaib², X. Cai³, X. Li⁴, A.F. Cardona⁵, G. López-Vivanco⁶, A. Vergnenegre⁷, J.M. Sanchez Torres⁸, M. Provencio⁹, F. de Marinis¹⁰, E. Carecereny², N. Reguart¹, R. Garcia Campelo¹¹, S. Viteri¹, M.A. Molina Vila¹, C. Zhou⁴, P. Cao³, P. Ma¹², T. Bivona¹³, R. Rosell²; ¹Barcelona, ES, ²Badalona, ES, ³Nanjing, CN, ⁴Shanghai, CN, ⁵Bogota, CO, ⁶Barakaldo, ES, ⁷Limoges, FR, ⁸Madrid, ES, ⁹Majadahonda, ES, ¹⁰Milano, IT, ¹¹A Coruna, ES, ¹²Morgantown, WV/US, ¹³San Francisco, CA/US
- 13:00 - 13:00 1189P - Functional profiling of oncogenic mutations in lung cancer patients (NCT02274025) - interim results
B. Miron¹, N. Peled², G. Tarcic¹, Z. Barbash¹, O. Edelheit¹, M. Vidne¹, M. Kramer³; ¹Jerusalem, IL, ²Petach Tikva, IL, ³Petach Tikva, IL
- 13:00 - 13:00 1190P - Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer (TORG1018): An interim report
K. Yamada¹, T. Shimokawa², H. Okamoto², H. Tanaka², K. Kubota², K. Kishi³, H. Saiho², Y. Takiguchi⁴, Y. Hosomi², T. Kato², D. Harada⁵, N. Masuda², T. Kasai⁶, Y. Nakamura², K. Minato², T. Kaburagi², K. Naoki², K. Hikino², T. Yamanaka², K. Watanabe²; ¹Kurume, JP, ²Yokohama, JP, ³Tokyo, JP, ⁴Chiba, JP, ⁵Matsuyama, JP, ⁶Utsunomiya, JP
- 13:00 - 13:00 1191P - A phase I / II trial of pemetrexed plus radiation therapy in elderly patients with locally advanced NSCLC
S. Atagi¹, A. Tamiya¹, S. Fukuda¹, Y. Naoki¹, M. Morimoto², T. Ibe³, K. Okishio¹, H. Goto⁴, A. Yoshii⁵, T. Kita⁶, Y. Tomizawa⁵, N. Nogami⁷, Y. Fujita⁸; ¹Sakai, JP, ²Kashihara, JP, ³Tatekawa, JP, ⁴Yokohama, JP, ⁵Shibukawa, JP, ⁶Kanazawa, JP, ⁷Matsuyama, JP, ⁸Asahikawa, JP
- 13:00 - 13:00 1192P - Recurrence pattern and its prognostic impact following definitive chemo-radiotherapy in stage III non-small cell lung cancer



M. Saigi Morgui¹, A. Rullan Iriarte¹, M. Bergamino¹, A. Navarro¹, M.M. Arnaiz¹, R. Palmero¹, M. Plana Serrahima², C. Mesía², S. Padrones¹, S. Aso¹, J. Ruffinelli Rodriguez¹, V. Navarro¹, I. Brao¹, E. Nadal¹, F. Cardenal Alemany¹; ¹Barcelona, ES, ²L'hospitalet De Llobregat, Barcelona, ES

13:00 - 13:00 1193P - Comparison of combined chemoradiotherapy regimens; Paclitaxel plus carboplatin and cisplatin plus etoposide for locally advanced non-small-cell lung cancer: A randomized phase III trial

A. Ata¹, A. Küçük¹, E. Nayir², Ş. Eskici¹; ¹Mersin, TR, ²Kahramanmaras, TR

13:00 - 13:00 1194P - Reaching the pinnacle of stage III NSCLC treatment

A. D'Silva¹, H. Lau², S. Otsuka², R. Tudor², D.G. Bebb²; ¹Calgary, AB/CA, ²Calgary, CA

13:00 - 13:00 1195P - Final overall survival (OS) results of the feasibility study of adjuvant chemotherapy with docetaxel (DOC) plus cisplatin (CDDP) followed by maintenance chemotherapy of S-1 in completely resected non-small cell lung cancer (NSCLC): Thoracic Oncology Research Group (TORG) 0809

S. Niho¹, N. Ikeda², H. Michimae², K. Suzuki², H. Sakai³, T. Kaburagi⁴, K. Yoshiya⁵, K. Minato⁴, T. Kato⁴, H. Okamoto⁴, T. Seto⁶, Y. Hosomi⁴, K. Shimizu⁷, H. Saito⁴, M. Tsuchida⁵, H. Kunitoh², M. Tsuboi¹, M. Takeuchi², K. Watanabe⁴; ¹Kashiwa, JP, ²Tokyo, JP, ³Saitama, JP, ⁴Yokohama, JP, ⁵Niigata, JP, ⁶Fukuoka, JP, ⁷Maebashi, JP

13:00 - 13:00 1196P - Secondary efficacy results from a phase 3 study comparing efficacy and safety of biosimilar candidate ABP 215 with bevacizumab in patients with non-squamous non-small cell lung cancer (NSCLC)

N. Thatcher¹, M. Thomas², G. Ostoros³, J. Pan⁴, J. Goldschmidt⁵, V. Hanes⁴; ¹Manchester, GB, ²Heidelberg, DE, ³Budapest, HU, ⁴Thousand Oaks, CA/US, ⁵Christianburg, VA/US

13:00 - 13:00 1197P - Pathologic response and survival after cisplatin, pemetrexed, and bevacizumab followed by surgery for clinical stage II/IIIA non-squamous non-small cell lung cancer

Y. Tsutani¹, Y. Miyata¹, K. Suzuki², K. Takamochi², F. Tanaka³, H. Nakayama⁴, Y. Yamashita⁵, M. Oda⁶, M. Tsuboi⁷, M. Okada¹; ¹Hiroshima, JP, ²Tokyo, JP, ³Kitakyushu, JP, ⁴Yokohama, JP, ⁵Kure, JP, ⁶Kanazawa, JP, ⁷Kashiwa, JP

13:00 - 13:00 1198P - First site of relapse can predict different clinical courses in recurrent stage IIIA non-small cell lung cancer after definitive chemoradiotherapy

K. Goto, H. Horinouchi, Y. Goto, S. Kanda, Y. Fujiwara, H. Nokihara, N. Yamamoto, Y. Ohe; Tokyo, JP

13:00 - 13:00 1199P - Cardiotoxic effects of gemcitabin/cisplatin vs paclitaxel/carboplatin first-line chemotherapy in patients with advanced non-small cell lung cancer

D. Bursac, T. Sarcev, D. Sazdanic Velikic, A. Tepavac; Novi Sad, RS

13:00 - 13:00 1200P - The impact of staging by positron emission tomography (PET) on overall survival (OS) and progression-free survival (PFS) in the phase III PROCLAIM study

N. Iscoe¹, R. Govindan², A. Hossain³, B. San Antonio⁴, N. Chouaki³, M. Koczywas⁵, E. Vokes⁶, S. Senan⁷; ¹Toronto, CA, ²St. Louis, US, ³Indianapolis, US, ⁴Madrid, ES, ⁵Duarte, US, ⁶Chicago, US, ⁷Amsterdam, NL

13:00 - 13:00 NSCLC, metastatic



- 13:00 - 13:00 1219P - Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC
F. Barlesi¹, E. Garon², D.-W. Kim³, E. Felip⁴, J.-Y. Han⁵, J.-H. Kim⁶, M.-J.A. Ahn⁶, M.J. Fidler⁷, M.A. Gubens⁸, G. Castro, Jr.⁹, V. Surmont¹⁰, Q. Li¹¹, A.C. Deitz¹¹, G. Lubiniecki¹², R.S. Herbst¹³,¹ Marseille, FR, ²Los Angeles, US, ³Seoul, KR, ⁴Barcelona, ES, ⁵Goyang, KR, ⁶Seoul, ⁷Chicago, IL/US, ⁸San Francisco, CA/US, ⁹São Paulo, BR, ¹⁰Gent, BE, ¹¹Kenilworth, NJ/US, ¹²North Wales, US, ¹³New Haven, US
- 13:00 - 13:00 1220P - Healthcare resource utilization (HCRU) in patients with advanced NSCLC in CheckMate 017 and 057 based on treatment-related (TR) adverse events (AEs)
M. Venkatachalam¹, D. Stenehjem², G. Pietri¹, J. Penrod³, B. Korytowsky³,¹Waltham, US, ²Salt Lake City, UT/US, ³Princeton, US
- 13:00 - 13:00 1221P - KEYNOTE-025: Phase 1b study of pembrolizumab (pembro) in Japanese patients (pts) with previously treated PD-L1+ non-small cell lung cancer (NSCLC)
T. Kato¹, T. Takahashi², H. Yoshioka³, K. Nakagawa⁴, M. Maemondo⁵, K. Yamada⁶, M. Ichiki⁷, H. Tanaka⁸, T. Seto⁷, H. Sakai⁹, K. Kasahara¹⁰, M. Satouchi¹¹, K. Noguchi¹², T. Shimamoto¹², M. Nishio¹²,¹Yokohama, JP, ²Suntogun, JP, ³Kurashiki, JP, ⁴Osaka-Sayama, JP, ⁵Natori, JP, ⁶Kurume, JP, ⁷Fukuoka, JP, ⁸Niigata, JP, ⁹Saitama, JP, ¹⁰Kanazawa, JP, ¹¹Akashi, JP, ¹²Tokyo, JP
- 13:00 - 13:00 1222P - Immune checkpoint inhibitors (IC) induce paradoxical progression in a subset of non-small cell lung cancer (NSCLC)
J. Lahmar, L. Mezquita, S. Koscielny, F. Facchinetti, M. Bluthgen, J. Adam, A. Gazzah, J. Remon, D. Planchard, J.-C. Soria, C. Caramella, B. Besse; Villejuif, FR
- 13:00 - 13:00 1223P - HLA-A2 and immune checkpoints inhibitors in advanced non-small cell lung cancer (NSCLC) patients
L. Mezquita, M. Charrier, J. Lahmar, J. Remon, M. Bluthgen, F. Facchinetti, D. Planchard, A. Gazzah, L. Dupraz, J. Adam, N. Chaput, B. Besse; Villejuif, FR
- 13:00 - 13:00 1224P - Cost effectiveness and estimate of economical impact of immune checkpoint inhibitors for NSCLC relative to PD-L1 expression
P. Aguiar Junior¹, R. De Mello², H. Tadokoro¹, H. Babiker³, G. Lopes Jr¹;¹Sao Paulo, BR, ²Porto, PT, ³Scottsdale, AZ/US
- 13:00 - 13:00 1225P - Preliminary efficacy and safety data of nivolumab in never smoker patients with advanced squamous NSCLC: Experience from Italian sites participating in the Expanded Access Programme (EAP)
M. Vitali¹, L. Crinò², A.F. Logroscino³, A. Ardizzoni⁴, S. Caponnetto⁵, L. Landi⁶, P. Bordi⁷, C. Luana⁸, F. Barbieri⁹, A. Santo¹⁰, M. Santarpia¹¹, G. Carteni¹², E. Mini¹³, E. Vasile¹⁴, F. Morgillo¹⁵, F. De Galitiis⁵, R. Conca¹⁶, M. Macerelli¹⁷, N. Tedde¹⁸, F. Vitiello¹⁵;¹Milano, IT, ²Perugia, IT, ³Bari, IT, ⁴Bologna, IT, ⁵Roma, IT, ⁶Livorno, IT, ⁷Parma, IT, ⁸Siena, IT, ⁹Modena, IT, ¹⁰Verona, IT, ¹¹Messina, IT, ¹²Naples, IT, ¹³Florence, IT, ¹⁴Pisa, IT, ¹⁵Napoli, IT, ¹⁶Grosseto, IT, ¹⁷Udine, IT, ¹⁸Olbia, IT



- 13:00 - 13:00 1226P - An interim assessment of key biomarkers (programmed cell death receptor ligand 1 (PD-L1) expression and epidermal growth factor receptor (EGFR) in third-line therapy non-small cell lung cancer (NSCLC) patients: A Danish cohort study
D. Cronin-Fenton¹, T. Dalvi², E. Hedgeman³, M. Norgaard¹, L. Pedersen¹, K. Mortensen¹, A. Midta⁴, N. Shire², R. Brody², J. Fryzek⁵, D. Lawrence⁶, J. Rigas⁷, D. Potter², J. Walker⁶, A. Mellempgaard⁸, T. Rasmussen¹, S. Hamilton-Dutoit¹, H. Sørensen¹; ¹Aarhus C, DK, ²Gaithersburg, US, ³Ann Arbor, US, ⁴Macclesfield, GB, ⁵Rockville, US, ⁶Cambridge, GB, ⁷Hanover, US, ⁸Herlev, DK
- 13:00 - 13:00 1227P - Impact of severe adverse events during second-line therapy on healthcare costs in patients with advanced non-small cell lung cancer (aNSCLC)
Y.M. Yim¹, M. Gandhi¹, A. Guerin², R. Ionescu-Iltu², I. Pivneva², S. Shi², E. Wu³; ¹San Francisco, CA/US, ²Montreal, QC/CA, ³Boston, MA/US
- 13:00 - 13:00 1228P - Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Access Programme (EAP) in Italy
P. Bidoli¹, R. Chiari², A. Catino³, F. Grossi⁴, C. Noberasco⁵, F. Gelsomino⁶, M. Gilli⁷, C. Proto⁵, H.J. Soto Parra⁸, M.R. Migliorino⁹, L. Bonomi¹⁰, D. Tassinari¹¹, A. Frassoldati¹², V. Albanese¹³, G. Fadda¹⁴, F. Cognetti⁹, F. de galitiis⁹, G. Finocchiaro⁵, A. Delmonte¹⁵; ¹Monza, IT, ²Perugia, IT, ³Bari, IT, ⁴Genova, IT, ⁵Milano, IT, ⁶Bologna, IT, ⁷Napoli, IT, ⁸Catania, IT, ⁹Roma, IT, ¹⁰Bergamo, IT, ¹¹Rimini, IT, ¹²Ferrara, IT, ¹³Palermo, IT, ¹⁴Sassari, IT, ¹⁵Meldola, IT
- 13:00 - 13:00 1229P - First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with EGFR mutation (CONVINCE)
Y.-K. Shi¹, L. Wang¹, B. Han², W. Li³, P. Yu⁴, Y. Liu⁵, C. Ding⁶, X. Song⁷, Z. Ma⁸, X. Ren⁹, J. Feng¹⁰, H. Zhang⁹, G. Chen¹¹, N. Wu¹, X. Han¹, C. Yao¹, Y. Song¹⁰, S. Zhang¹, L. Ding¹², F. Tan¹²; ¹Beijing, CN, ²Shanghai, CN, ³Changchun, CN, ⁴Chengdu, CN, ⁵Shenyang, CN, ⁶Shijiazhuang, CN, ⁷Taiyuan, CN, ⁸Zhengzhou, CN, ⁹Xi'an, CN, ¹⁰Nanjing, CN, ¹¹Harbin, CN, ¹²Hangzhou, CN
- 13:00 - 13:00 1230P - Time-to-treatment failure (TTF) with first-line afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) advanced non-small-cell lung cancer (NSCLC): Randomized phase IIb LUX-lung 7 (LL7) trial
M. Schuler¹, E.-H. Tan², K. O'Byrne³, L. Zhang⁴, M. Boyer⁵, T.S.K. Mok⁶, V. Hirsh⁷, J.C.-H. Yang⁸, K.H. Lee⁹, S. Lu¹⁰, Y. Shi¹¹, S.-W. Kim¹², J. Laskin¹³, D.-W. Kim¹⁴, C. Dubos Arvis¹⁵, K. Köllbeck¹⁶, D. Massey¹⁷, J. Fan¹⁸, L. Paz-Ares¹⁹, K. Park¹⁴; ¹Essen, DE, ²Singapore, SG, ³Brisbane, AU, ⁴Guangzhou, CN, ⁵Sydney, AU, ⁶Hong Kong, CN, ⁷Montreal, CA, ⁸Taipei, TW, ⁹Cheong-Ju, KR, ¹⁰Shanghai, CN, ¹¹Beijing, CN, ¹²Seoul, KR, ¹³Vancouver, CA, ¹⁴Seoul, ¹⁵Caen, FR, ¹⁶Stockholm, SE, ¹⁷Bracknell, GB, ¹⁸Ridgefield, US, ¹⁹Madrid, ES
- 13:00 - 13:00 1231P - Efficacy of first-generation EGFR-TKIs on patients with NSCLC harboring EGFR uncommon mutations: A pooled analysis
Y. Zhang, S. Tang, J. Zhang, Q. He, J. He, W. Liang; Guangzhou, CN
- 13:00 - 13:00 1232P - P53 non-disruptive mutation is a negative predictive factor in EGFR M+ NSCLC treated with TKI



F. Griesinger¹, M. Netchaeva², A. Lüers¹, R. Prenzel¹, D. Scriba¹, K. Willborn¹, U. Stropiey¹, C. Hallas³, M. Falk³, M. Tiemann³, N. Neemann⁴, L. Heukamp⁴, J. Roeper¹; ¹Oldenburg, DE, ²Rheine, DE, ³Hamburg, DE, ⁴Köln, DE

- 13:00 - 13:00 1233P - Re-biopsy confers survival benefit through directing salvage treatment for patients failing prior EGFR-TKIs
L. Zhang, J. Sheng, Y. Huang, Y. Yang, H. Zhao, W. Fang, Y. Zhao, Y. Zhang; Guangzhou, CN
- 13:00 - 13:00 1234P - Osimertinib in EGFR T790M positive advanced NSCLC (aNSCLC) – reallife data from the French temporary authorization for use (ATU) program
D. Planchard¹, M. Pérol², X. Quantin³, A. Cortot⁴, J. Cadranel⁵, R. Schott⁶, E. Dansin⁴, G. Fraboulet⁷, D. Moro-Sibilot⁸, J.-C. Soria¹, J. Mazieres⁹, S. Le Moulec¹⁰, M. Coudurier¹¹, E. Pichon¹², M. Licour¹³, D. Maribas¹⁴, A. Gourion⁵, N. Radu¹³, N. Varoquaux¹⁵, C. Chouaid¹⁶; ¹Villejuif, FR, ²Lyon, FR, ³Montpellier, FR, ⁴Lille, FR, ⁵Paris, FR, ⁶Strasbourg, FR, ⁷Pontoise, FR, ⁸La Tronche, FR, ⁹Toulouse, FR, ¹⁰Bordeaux, FR, ¹¹Chambéry, FR, ¹²Chambray-Lès-tours, FR, ¹³Courbevoie, FR, ¹⁴Corolles, FR, ¹⁵Rueil Malmaison, FR, ¹⁶Créteil, FR
- 13:00 - 13:00 1235P - Tumor heterogeneity affects the activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant non-small cell lung cancer (NSCLC) patients (pts)
N. Normanno¹, A.M. Rachiglio², M. Lambiase², F. Fenizia², A. Iannaccone², N. Chicchinelli¹, A. Morabito¹, A. Montanino¹, G. Rocco¹, D. Galetta³, E.S. Montagna³, L. Crino⁴, V. Ludovini⁴, B. Vincenzi⁵, E. Barletta⁶, C. Pinto⁷, F. Ferrau⁸, G. Botti¹, M.C. Piccirillo¹, F. Perrone¹; ¹Napoli, IT, ²Mercogliano (av), IT, ³Bari, IT, ⁴Perugia, IT, ⁵Roma, IT, ⁶Benevento, IT, ⁷Reggio Emilia, IT, ⁸Taormina, IT
- 13:00 - 13:00 1236P - Global named patient use (NPU) program of afatinib, an oral ErbB family blocker, in heavily pretreated advanced non-small cell lung carcinoma (NSCLC) patients who progressed following prior therapies, including erlotinib or gefitinib (E/G)
F. Cappuzzo¹, R. Soo², M. Hochmair³, M. Schuler⁴, T.S.K. Mok⁵, G. Stehle⁶, A. Cseh³, R. Lorence⁷, S. Linden⁸, N. Forman⁷, C.-M. Tsai⁹; ¹Livorno, IT, ²Singapore, SG, ³Vienna, AT, ⁴Heidelberg, DE, ⁵Hong Kong, CN, ⁶Biberach, DE, ⁷Ridgefield, CT/US, ⁸Ingelheim, DE, ⁹Taipei, TW
- 13:00 - 13:00 1237P - Correlation between programmed death-ligand 1 (PD-L1) expression and T790M status in EGFR-mutant non-small cell lung cancer (NSCLC)
A. Hata, N. Katakami, S. Nanjo, C. Okuda, R. Kaji, K. Masago, S. Fujita, Y. Imai; Kobe, JP
- 13:00 - 13:00 1238P - Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, Phase 3 LUX-Lung 8 trial of afatinib versus erlotinib for the second-line treatment of advanced squamous cell carcinoma of the lung
G. Goss¹, K.H. Lee², E. Felip³, M. Cobo⁴, K. Syrigos⁵, E. Goker⁶, V. Georgioulis⁷, S. Guclu⁶, D. Isla⁸, Y.J. Min⁹, A. Morabito¹⁰, N. Dupuis¹¹, V. Chand¹², F. Solca¹³, N. Krämer¹⁴, N. Gibson¹⁵, E. Ehrnrooth¹⁶, J.C. Soria¹⁷; ¹Ottawa, CA, ²Cheong-Ju, KR, ³Barcelona, ES, ⁴Málaga, ES, ⁵Athens, GR, ⁶Izmir, TR, ⁷Heraklion, GR, ⁸Zaragoza, ES, ⁹Ulsan, KR, ¹⁰Napoli, IT, ¹¹Boulder, CO/US, ¹²Ridgefield, CT/US, ¹³Vienna, AT, ¹⁴München, DE, ¹⁵Biberach An Der Riss, DE, ¹⁶Copenhagen, DK, ¹⁷Paris, FR
- 13:00 - 13:00 1239P - Rociletinib-associated cataracts in EGFR-mutant NSCLC



Z. Piotrowska¹, E. Liu¹, A. Varga², M. Thakur³, V. Narayanan⁴, S. Liu⁵, J. Neal⁶, M. Spiegel⁷, B. Solomon⁸, H. Yu⁹, S.-H. Ou¹⁰, V. Papadimitrakopoulou¹¹, S. Gadgeel³, D. Camidge¹², J.-C. Soria², H. Wakelee⁶, J. Goldman¹³, K. Kopani¹, L. Rolfe¹⁴, L. Sequist¹⁵; ¹Boston, US, ²Villejuif, FR, ³Detroit, US, ⁴Denver, US, ⁵Washington, DC/US, ⁶Stanford, US, ⁷Los Angeles, US, ⁸Melbourne, AU, ⁹New York, US, ¹⁰Irvine, CA/US, ¹¹Houston, US, ¹²Aurora, US, ¹³Los Angeles, CA/US, ¹⁴Cambridge, GB, ¹⁵Boston, MA/US

- 13:00 - 13:00 1240P - Randomized phase 2 trial of gefitinib with and without pemetrexed as first-line therapy in East Asian patients with advanced, epidermal growth factor receptor (EGFR) mutation-positive (mt+), nonsquamous (NS) non-small cell lung cancer (NSCLC): Translational research and interim overall survival (OS)
- J. Yang¹, Y. Cheng², H. Murakami³, P.-C. Yang¹, J. He⁴, K. Nakagawa⁵, J.H. Kang⁶, J.-H. Kim⁷, R. Hozak⁸, T. Nguyen⁹, X. Wang¹⁰, S. Enatsu¹¹, T. Puri¹², M. Orlando¹³; ¹Taipei, TW, ²Changchun, CN, ³Shizuoka, JP, ⁴Guangzhou, CN, ⁵Osaka-Sayama, JP, ⁶Seoul, KR, ⁷Seoul, ⁸Indianapolis, US, ⁹Indianapolis, IN/US, ¹⁰Shanghai, CN, ¹¹Kobe, JP, ¹²Gurgaon, IS, ¹³Buenos Aires, AR
- 13:00 - 13:00 1241P - Afatinib efficacy and cerebrospinal fluid concentration in NSCLC patients with EGFR mutation developing leptomeningeal carcinomatosis
- A. Tamiya¹, M. Tamiya², T. Nishihara², T. Shiroyama², K. Nakao³, T. Tsuji³, N. Takeuchi³, S.-I. Isa³, N. Omachi³, N. Okamoto², H. Suzuki², K. Okishio³, A. Iwazaki⁴, K. Imai⁴, T. Hirashima², S. Atagi³; ¹Sakai, Osaka/JP, ²Habikino, JP, ³Sakai, JP, ⁴Hirakata, JP
- 13:00 - 13:00 1242P - Progression of leptomeningeal metastases in advanced EGFR-mutated non-small cell lung cancer
- Q. Zhao¹, L. Deng¹, Y. Zhang¹, X. Zhou¹, Y. Li¹, M. Yu¹, L. Zhou¹, B. Zou¹, Y. Liu², Y. Lu¹; ¹Chengdu, CN, ²Chengdu, Sichuan/CN
- 13:00 - 13:00 1243P - Predictive factors for T790M mutation in plasma in patients after progression to 1st line tyrosine-kinase inhibitor (TKI) with or without subsequent lines of TKI or chemotherapy for metastatic epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC)
- K.-S. Lau, T.-H. So, T.-S. Choy, D. Leung, K.-O. Lam, P.Y.P. Ho, W.-L. Chan, L.-S. Wong, S.-Y. Chan, F.-T. Chan, R. Tse, C.-W. Choi, T.-C. Lam, D. Kwong, A. Lee, T.-W. Leung, V. Lee; Hong Kong, HK
- 13:00 - 13:00 1244P - French real-life efficacy of 1st line gefitinib in EGFR mutation-positive NSCLC in the prospective EPIDAURE study: Results by EGFR exon 19 Del and L858R mutation subtypes
- M. Perol¹, J.-F. Morère², E. Fabre³, B. Lemaire⁴, I. Monnet⁵, E. Brambilla⁶, V. Rondeau⁷, M. Licour⁸, J. Cadranel³; ¹Lyon, FR, ²Villejuif, FR, ³Paris, FR, ⁴Orleans, FR, ⁵Créteil, FR, ⁶Tronch, FR, ⁷Bordeaux, FR, ⁸Courbevoie, FR
- 13:00 - 13:00 1245P - Phase I, safety, tolerability and preliminary efficacy study of tremelimumab (Trem) in combination with gefitinib (Gef) in EGFR-mutant (EGFR-mut) NSCLC (GEFTREM)
- D. Planchard¹, F. Barlesi², C. Gomez-Roca³, J. Mazieres³, A. Varga¹, L. Greillier², N. Chaput¹, C. Parlavacchio¹, K. Malekzadeh¹, M. Ngocamus¹, S. Zahi³, B. Besse¹, E. Lanoy¹, J.-C. Soria¹; ¹Villejuif, FR, ²Marseille, FR, ³Toulouse, FR
- 13:00 - 13:00 1246P - Adjusted indirect comparison using propensity score matching of osimertinib to doublet chemotherapy in patients with EGFRm T790M NSCLC who have progressed after EGFR-TKI



F. Andersohn¹, H. Mann², T. Mitsudomi³, T.S.K. Mok⁴, J. Chih-Hsin Yang⁵, K. Papadakis², C. Hoyle²; ¹Berlin, DE, ²Cambridge, GB, ³Osaka-Sayama, JP, ⁴Hong Kong, CN, ⁵Taipei City, TW

- 13:00 - 13:00 1247P - Monitoring of EGFRm level in cfDNA in patients with advanced NSCLC on the gefitinib therapy
D. Sakaeva¹, M. Gordiev², M. Blokhina¹; ¹Ufa, RU, ²Kazan, RU
- 13:00 - 13:00 1248P - Discordance of EGFR mutation status between primary lung adenocarcinomas and corresponding metastatic tumors and the sensitivity to EGFR tyrosine kinase inhibitors
H.S. Han¹, J. Yang², M.K. Choi², J. Kwon², K.H. Lee², O.-J. Lee²; ¹Cheongju, KR, ²Cheong-Ju, KR
- 13:00 - 13:00 1249P - Detection of EGFR T790M resistance mutation: Real-time allele-specific PCR versus Sanger sequencing
S. Hor, K.S. Chan, E. Chen, M. Goh, L. Oon; Singapore, SG
- 13:00 - 13:00 1250P - Frequency of driver mutations in EGFR wt NSCLC using mass spectrometry: Experience of Area Vasta Romagna
E. Chiadini¹, L. Capelli¹, A. Delmonte¹, N. De Luigi¹, C. Dazzi², C. Casanova², A. Gamboni³, M. Papi⁴, M.M. Tumedei¹, S. Bravaccini¹, A. Dubini⁵, M. Puccetti², L. Crinò⁶, P. Ulivi¹; ¹Meldola, IT, ²Ravenna, IT, ³Faenza, IT, ⁴Rimini, IT, ⁵Forlì, IT, ⁶Perugia, IT
- 13:00 - 13:00 1251P - EGFR mutation in squamous cell carcinoma of lung - Does it carry the same connotation as in adenocarcinomas?
S. Zanwar, A. Joshi, V. Noronha, V. Patil, A. Chougule, S. Kane, R. Kumar, K. Prabhash; Mumbai, IN
- 13:00 - 13:00 1252P - Addressing disease progression in EGFRmut+ NSCLC patients
R. Tudor¹, K. Kopciuk¹, A. D'Silva², D. Brenner¹, D. Morris¹, D.G. Bebb¹; ¹Calgary, CA, ²Calgary, AB/CA
- 13:00 - 13:00 1253P - A prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with radiotherapy for non-small-cell lung cancer patients with bone metastasis
L. Guo, G.F. Ding; Zhengzhou, CN
- 13:00 - 13:00 1254P - Tyrosine kinase inhibitors alone as a first-line treatment for patients with non-small-cell lung cancer harboring mutant epidermal growth factor receptor
T. Iuchi, M. Shingyoji, M. Itakura, Y. Hasegawa, Y. Yoshida, S. Ikegami, T. Setoguchi, H. Ashinuma; Chiba, JP
- 13:00 - 13:00 1255P - Next generation sequencing identifies actionable mutations in EGFR-wild type and KRAS mutant non-small cell lung cancer patients
A. Voutsina, A. Kalikaki, A. Koutsopoulos, M. Sfakianaki, M. Trypaki, E. Tsakalaki, S. Agelaki, V. Georgoulas, D. Mavroudis; Heraklion, GR
- 13:00 - 13:00 1256P - Hypomagnesaemia and its management following treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs): Results from 3 randomized studies of necitumumab (NECI) plus chemotherapy in first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC)



E. Vokes¹, M. Socinski², D. Spigel³, L. Paz-Ares⁴, R. Kurek⁵, S. Nanda⁶, G. Grau⁵, J. Shahidi⁶, N. Thatcher⁷, D. Gandara⁸; ¹Chicago, US, ²Pittsburgh, US, ³Nashville, US, ⁴Madrid, ES, ⁵Bad Homburg, DE, ⁶Indianapolis, IN/US, ⁷Manchester, GB, ⁸Sacramento, US

- 13:00 - 13:00 1257P - Tepotinib plus gefitinib in patients with c-Met-positive/EGFR-mutant NSCLC: Recommended phase II dose (RP2D), tolerability, and efficacy
Y.-L. Wu¹, R. Soo², D.-W. Kim³, J. Yang⁴, U. Stammberger⁵, W. Chen⁶, G. Locatelli⁵, K. Park³; ¹Guangzhou, CN, ²Singapore, SG, ³Seoul, ⁴Taipei, TW, ⁵Darmstadt, DE, ⁶Beijing, CN
- 13:00 - 13:00 1258P - Intercalated combination of chemotherapy and epidermal growth factor receptor inhibitors for patients with advanced non-small-cell lung cancer: A systematic review and meta-analysis
A. Rossi¹, A. La Salvia², D. Galetta³, E. Gobbin², E. De Luca², S. Novello², M. Di Maio²; ¹Avellino, IT, ²Orbassano, IT, ³Bari, IT
- 13:00 - 13:00 1259P - Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer
T. Kaneda¹, H. Yoshioka¹, M. Tamiya², A. Tamiya³, A. Hata⁴, A. Okada⁵, T. Niwa¹, T. Shiroyama², M. Kanazu³, T. Ishida¹, N. Katakami⁴; ¹Kurashiki, JP, ²Habikino, JP, ³Sakai, JP, ⁴Kobe, JP, ⁵Suita, JP
- 13:00 - 13:00 1260P - Safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer (NSCLC): A phase 1b expansion cohort study
B. Besse¹, P. Garrido², J. Bennouna³, L. Mezquita¹, A. Gazzah¹, J. Remon¹, D. Planchard¹, M.E. Olmedo Garcia², J. Raimbourg³, G. Chao⁴, M. Gil⁵; ¹Villejuif, FR, ²Madrid, ES, ³Nantes, FR, ⁴Bridgewater, NJ/US, ⁵Warsaw, PL
- 13:00 - 13:00 1261P - A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
S. Pacey¹, F. Blackhall², J. Garcia-Corbacho¹, A. Lipplaa³, A. Fusi², S. Kumar¹, M. Hategan¹, J. Derham³, G. Laviste², S. Halford⁴, C. Foxton⁴, R. McLeod⁴, S. Wan⁴, D. Talbot³; ¹Cambridge, GB, ²Manchester, GB, ³Oxford, GB, ⁴London, GB
- 13:00 - 13:00 1262P - Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)
M. Faehling¹, J. Achenbach², P. Staib³, U. Steffen⁴, H. Tessen⁵, W. Brugger⁶; ¹Esslingen, DE, ²Lostau, DE, ³Eschweiler, DE, ⁴Wolfsburg, DE, ⁵Goslar, DE, ⁶Villingen-Schwenningen, DE
- 13:00 - 13:00 1263P - Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC)
F. Barlesi¹, A.-M. Dingemans², J.C.-H. Yang³, S.-H.I. Ou⁴, J.S. Ahn⁵, L. De Petris⁶, B. Hughes⁷, H. Lena⁸, W. Bordogna⁹, S. Golding⁹, P.N. Morcos¹⁰, B. Balas⁹, A. Zeaiter⁹, D.-W. Kim⁵; ¹Marseille, FR, ²Maastricht, NL, ³Taipei, TW, ⁴Orange, US, ⁵Seoul, KR, ⁶Stockholm, SE, ⁷Brisbane, AU, ⁸Rennes, FR, ⁹Basel, CH, ¹⁰New York, US
- 13:00 - 13:00 1264P - Automated nCounter-based assay for identifying clinically relevant ALK, ROS1 and RET rearrangements in advanced non-small cell lung cancer (NSCLC)



N. Reguart¹, L. Paré¹, A. Giménez-Capitán¹, C. Teixidó¹, P. Galván¹, S. Viteri¹, S. Rodríguez¹, V. Peg¹, E. Aldeguer¹, E. Ovalle¹, N. Viñolas¹, S. Merkelbach-Bruse², F. Lopez-Rios³, R. Rosell⁴, M.Á. Molina-Vila¹, A. Prat¹; ¹Barcelona, ES, ²Köln, DE, ³Madrid, ES, ⁴Badalona, ES

13:00 - 13:00 1265P - Non-invasive detection of response and crizotinib induced resistance in ROS1 fusion advanced stage Chinese lung adenocarcinoma patients using next-generation genotyping from cfDNA
X. Niu, S. Chuai, S. Lu; Shanghai, CN

13:00 - 13:00 1266P - Clinical analysis of continuing crizotinib treatment beyond disease progression in ALK-positive non-small-cell lung cancer patients
L. Hongmei, M. Huang, Y. Xu, X. Zhou, J. Li, J. Wang, F. Peng, Y. Gong, Z. Ding, J. Zhu, P. Yu, L. Li, M. Hou, L. Ren, Y. Wang, Y. Lu; Chengdu, CN

13:00 - 13:00 1267P - HER2 V659 and G660 transmembrane mutations that stabilize homo- and hetero-dimerization are rare oncogenic drivers in lung adenocarcinoma that are clinically responsive to afatinib
S.-H.I. Ou¹, A. Schrock², E. Bocharov³, S. Klempner⁴, C. Haddad⁵, G. Steinecker⁶, M. Johnson⁷, B. Gitlitz⁴, J. Chung², P. Campregher⁵, J. Ross⁸, P. Stephens², V. Miller², J. Suh⁹, S. Ali², V. Velcheti¹⁰; ¹Orange, CA/US, ²Cambridge, US, ³Moscow, RU, ⁴Los Angeles, CA/US, ⁵Sao Paulo, BR, ⁶Oak Lawn, IL/US, ⁷Nashville, TN/US, ⁸Albany, NY/US, ⁹Cambridge, MA/US, ¹⁰Cleveland, US

13:00 - 13:00 1268P - Non small cell lung cancer (NSCLC) patients harboring BRAF mutation: Clinical characteristics and management in real world setting. Cohort BRAF EXPLORE GFPC 02-14
J.B. Auliac¹, S. Bayle², A. Vergnenegre³, G. Fraboulet⁴, H. Lecaer⁵, L. Falchero⁶, P. Dô⁷, H. Doubre⁸, P.A. Hauss⁹, A. Vinas¹⁰, S. Larive¹¹, A.M. Chiappa¹², B. Marin³, C. Chouaid¹⁰; ¹Mantes La Jolie, FR, ²St. Etienne, FR, ³Limoges, FR, ⁴Pontoise, FR, ⁵Draguignan, FR, ⁶Villefranche Sur Saone, FR, ⁷Caen, FR, ⁸Suresnes, FR, ⁹Elbeuf, FR, ¹⁰Créteil, FR, ¹¹Macon, FR, ¹²Quimper, FR

13:00 - 13:00 1269P - SELECT-3: A phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting
E. Dean¹, N. Steele², H.-T. Arkenau³, F. Blackhall¹, N. Haris⁴, C. Lindsay², S. Rafii¹, R. Califano¹, R. Plummer⁴, M. Voskoboynik³, Y. Summers¹, D. Ghiorghiu⁵, A. Dymond⁶, K. So⁷, A. Greystoke⁴; ¹Manchester, GB, ²Glasgow, GB, ³London, GB, ⁴Newcastle Upon Tyne, GB, ⁵Melbourne, VIC/AU, ⁶Macclesfield, GB, ⁷Royston, GB

13:00 - 13:00 1270P - Id1 and Id3 genes confer poor prognosis in KRAS-mutant (KM) lung adenocarcinoma (LA) patients. Gene silencing reduces metastatic rate to the liver and increases survival
M. Román, I. Lopez, L. Zubiri, R. Sanchez, D. Salas, I. Gardeazabal, I. Baraibar, M. Santisteban, S. Vicent, I. Gil-Aldea, M. Martinez Aguillo, B. Hernandez, J.M. Lopez-Picazo, A. Gurrpide, E. Guruceaga, J.L. Perez-Gracia, M. Collantes, M. Ecaj, I. Gil-Bazo; Pamplona, ES

13:00 - 13:00 1271P - KRAS mutations(m) in lung adenocarcinoma (AC) patients(p) receiving standard chemotherapy (ch) and immune checkpoint inhibitors (i-CI): Impact of KRAS clonality and coexisting TP53m
N. Pardo Aranda, F. Ruiz, A. Martinez Marti, S. Cedres, A. Navarro Mendivil, I. de la fuente, A. Martinez de Castro, A. Vivancos, R. Dienstmann, E. Felipe; Barcelona, ES

13:00 - 13:00 1272P - Analysis of outcomes and brain metastases (BM) of molecular selected non-small cell lung cancer (NSCLC) patients included in clinical trials



S. Cedres, N. Pardo Aranda, A. Martinez de Castro, A. Navarro Mendivil, A. Martinez Marti, C. Ortiz, F. Racca, M. Vilario, L. Carbonell, A. Piera, I. de la fuente, E. Felip; Barcelona, ES

- 13:00 - 13:00 1273P - Cost of care in first line advanced NSCLC patients: Chemotherapy vs targeted therapy
J. Radtchenko¹, B. Korytowsky², K. Tuell³, M. Bhor¹, B. Feinberg¹; ¹Dublin, OH/US, ²Princeton, US, ³Charlotte, US
- 13:00 - 13:00 1274P - A phase 2 study of LY3023414 and necitumumab after first-line chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC)
M. Johnson¹, V. Wacheck², M. Hussein³, M. McCleod⁴, D. Daniel⁵, D. Waterhouse⁶, M. Gil⁷, D. Strickland⁸, J. Bendell⁸; ¹Nashville, US, ²Indianapolis, IN/US, ³St Petersburg, FL/US, ⁴Ft. Myers, FL/US, ⁵Chattanooga, TN/US, ⁶Cincinnati, OH/US, ⁷Warsaw, PL, ⁸Nashville, TN/US
- 13:00 - 13:00 1275P - ANSELMA: ANtiangiogenic SEcond line Lung cancer Meta-Analysis in non-small cell lung cancer (NSCLC)
J. Remon Masip, C.-T. Thuong, J.-P. Pignon, B. Lacas, J.-C. Soria, B. Besse; Villejuif, FR
- 13:00 - 13:00 1276P - Efficacy and safety of nintedanib (NIN)/docetaxel (DOC) in patients with lung adenocarcinoma: Further analyses from the LUME-Lung 1 study
D. Heigener¹, M. Gottfried², J. Bennouna³, I. Bondarenko⁴, J.-Y. Douillard³, M. Krzakowski⁵, A. Mellemegaard⁶, S. Novello⁷, S. Orlov⁸, Y. Summers⁹, J. von Pawel¹⁰, J. Hocke¹¹, R. Kaiser¹², M. Reck¹; ¹Grosshansdorf, DE, ²Kfar Saba, IL, ³St. Herblain, FR, ⁴Dnepropetrovsk, UA, ⁵Warsaw, PL, ⁶Herlev, DK, ⁷Orbassano, IT, ⁸Saint Petersburg, RU, ⁹Manchester, GB, ¹⁰Gauting, DE, ¹¹Biberach, DE, ¹²Ingelheim, DE
- 13:00 - 13:00 1277P - Bevacizumab in routine clinical practice for first-line therapy with platinum-based chemotherapy of patients with advanced adenocarcinoma of the lung in Germany
H.R. Wirtz¹, S. Lang², J. Mezger³, S. Hammerschmidt⁴, T. Gaska⁵, C. Lerchenmueller⁶, M. Reck⁷, S. Haas⁸, D. Reichert⁹, G. Hoeffken¹⁰; ¹Leipzig, DE, ²Gera, DE, ³Karlsruhe, DE, ⁴Chemnitz, DE, ⁵Paderborn, DE, ⁶Münster, DE, ⁷Grosshansdorf, DE, ⁸Neumünster, DE, ⁹Westerstede, DE, ¹⁰Dresden, DE
- 13:00 - 13:00 1278P - Interim safety results from the phase 2 ABOUND.PS2 study evaluating nab-paclitaxel (nab-P) + carboplatin (C) followed by nab-P monotherapy in patients (pts) with NSCLC and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2
A. Gajra¹, H. Ali², K. Amiri³, N. Abdel Karim⁴, M. Matrana⁵, D. Mulford⁶, T.J. Ong⁷, A. Sanford⁸, E. Santos⁹, M. Socinski¹⁰, D. Spigel¹¹, R. Lilenbaum¹²; ¹Syracuse, US, ²Detroit, US, ³Summit, SC/US, ⁴Cincinnati, US, ⁵New Orleans, US, ⁶Rochester, US, ⁷Summit, US, ⁸Summit, NJ/US, ⁹Boca Raton, US, ¹⁰Pittsburgh, US, ¹¹Nashville, US, ¹²New Haven, CT/US
- 13:00 - 13:00 1279P - nab-paclitaxel (nab-P) + carboplatin (C) induction therapy in patients (Pts) with squamous (SCC) NSCLC: Interim quality of life (QoL) outcomes from the phase 3 ABOUND.sqm study
M. Thomas¹, S. Ponce Aix², A. Ko³, R. Jotte⁴, T.J. Ong³, R. Page⁵, M. Socinski⁶, N. Trunova³, V. Villalflor⁷, D. Spigel⁸; ¹Heidelberg, DE, ²Madrid, ES, ³Summit, US, ⁴Denver, CO/US, ⁵Fort Worth, TX/US, ⁶Pittsburgh, US, ⁷Chicago, IL/US, ⁸Nashville, US



- 13:00 - 13:00 1280P - nab-paclitaxel (nab-P) + carboplatin (C) induction therapy in patients (Pts) with squamous (SCC) NSCLC: Interim safety results from the phase 3 ABOUND.sqm study
O.J. Vidal¹, D. Daniel², M. Johnson³, J. Knoble⁴, T. Chen⁵, M. McCleod⁶, T.J. Ong⁷, N. Trunova⁷, E. Kim⁸; ¹Valencia, ES, ²Chattanooga, TN/US, ³Nashville, TN/US, ⁴Columbus, OH/US, ⁵Summit, NJ/US, ⁶Ft. Myers, FL/US, ⁷Summit, US, ⁸Sacramento, CA/US
- 13:00 - 13:00 1281P - Quality of life (QoL) in elderly patients (pts) with advanced NSCLC treated with nab-paclitaxel (nab-P) + carboplatin (C): Interim results from the ABOUND.70+ study
J. Weiss¹, E. Kim², K. Amiri³, E. Anderson⁴, S. Dakhil⁵, D. Haggstrom², R. Jotte⁶, K. Konduri⁷, M. Modiano⁸, T.J. Ong⁹, A. Sanford¹⁰, D. Smith¹¹, M. Socoteanu¹², J. Goldman¹³, C. Langer¹⁴; ¹North Carolina, US, ²Charlotte, NC/US, ³Summit, SC/US, ⁴Portland, OR/US, ⁵Wichita, KS/US, ⁶Denver, CO/US, ⁷Dallas, TX/US, ⁸Tucson, AZ/US, ⁹Summit, US, ¹⁰Summit, NJ/US, ¹¹Ann Arbor, MI/US, ¹²Longview, TX/US, ¹³Los Angeles, CA/US, ¹⁴Philadelphia, PA/US
- 13:00 - 13:00 1282P - A cross-trial comparison of pemetrexed-platinum followed by pemetrexed continuation maintenance versus gemcitabine-cisplatin without maintenance in chemotherapy-naive patients with advanced nonsquamous non-small-cell lung cancer
Y.-L. Wu¹, B. Zhang², X. Wang², M. Orlando³, H. Chi²; ¹Guangzhou, CN, ²Shanghai, CN, ³Buenos Aires, AR
- 13:00 - 13:00 1283P - The role of thymidylate synthase in non-small-cell lung cancer treated with pemetrexed continuation maintenance therapy
M. Yang, W.-F. Fan, X.-L. Pu, L.-J. Meng, J. Wang; Nanjing, CN
- 13:00 - 13:00 1284P - Final results of a phase II study of oral vinorelbine (NVBo) monotherapy in patients (pts) with advanced EGFR-positive non-small-cell lung cancer (NSCLC) after failure of EGFR-TKI in first line (NAVOTRIAL 2)
E.-H. Tan¹, G. Banna², R. Ramlau³, G. Ceresoli⁴, A. Camerini⁵, J. Milanowski⁶, M. Caruso², P. Landreau⁷, J.-C. Vedovato⁷, D. Kowalski⁸; ¹Singapore, SG, ²Catania, IT, ³Poznan, PL, ⁴Bergamo, IT, ⁵Lido Di Camaiore, IT, ⁶Lublin, PL, ⁷Boulogne, FR, ⁸Warsaw, PL
- 13:00 - 13:00 1285TiP - IFCT-1003 LADIE trial: Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC
J. Mazieres¹, F. Barlesi², O. Molinier³, I. Monnet⁴, C. Audigier-Valette⁵, B. Besse⁶, A.-C. Toffart⁷, P.A. Renault⁸, S. Hiret⁹, S. Fraboulet-Moreau¹⁰, B. Mennezier¹¹, P. Masson¹², V. Westeel¹³, P.-J. Souquet¹⁴, E. Pichon¹⁵, E. Amour¹⁶, F. Morin¹⁶, D. Moro-Sibilot¹⁷; ¹Toulouse, FR, ²Marseille, FR, ³Le Mans, FR, ⁴Créteil, FR, ⁵Toulon, FR, ⁶Villejuif, FR, ⁷Grenoble, FR, ⁸Pau, FR, ⁹St. Herblain, FR, ¹⁰Suresnes, FR, ¹¹Strasbourg, FR, ¹²Cholet, FR, ¹³Besançon, FR, ¹⁴Pierre Bénite, FR, ¹⁵Tours, FR, ¹⁶Paris, FR, ¹⁷La Tronche, FR
- 13:00 - 13:00 1286TiP - NEJ026 Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations
M. Maemondo¹, T. Fukuhara¹, S. Sugawara², Y. Takiguchi³, A. Inoue², S. Oizumi⁴, Y. Ishii⁵, H. Yoshizawa⁶, T. Isobe⁷, A. Gemma⁸, S. Morita⁹, K. Hagiwara⁵, K. Kobayashi¹⁰, T. Nukiwa⁸; ¹Natori, JP, ²Sendai, JP, ³Chiba, JP, ⁴Sapporo, JP, ⁵Tochigi, JP, ⁶Niigata, JP, ⁷Shimane, JP, ⁸Tokyo, JP, ⁹Kyoto, JP, ¹⁰Hidaka, JP



- 13:00 - 13:00 1287TiP - Design of a phase II trial comparing tepotinib + gefitinib with cisplatin + pemetrexed in EGFR inhibitor-resistant, c-Met+ NSCLC
Y.-L. Wu¹, K. Park², D.-W. Kim², R. Soo³, U. Stammberger⁴, W. Chen⁵, G. Locatelli⁴, J. Yang⁶; ¹Guangzhou, CN, ²Seoul, ³Singapore, SG, ⁴Darmstadt, DE, ⁵Beijing, CN, ⁶Taipei, TW
- 13:00 - 13:00 1288TiP - Efficacy and safety of first-line gefitinib treatment in metastatic lung adenocarcinoma patients with sensitizing EGFR mutation determined by ddPCR in plasma cell-free DNA (BENEFIT trial)
J. Wang¹, Y. Cheng², Y.-L. Wu³, T. An¹, H. Gao¹, K. Wang⁴, Q. Zhou³, Y. Hu⁵, Y. Song⁶, C. Ding⁷, X. Ye⁸, F. Peng⁹, L. Liang¹, Y. Hu¹, C. Huang¹⁰, C. Zhou⁸, Y.-K. Shi¹, L. Zhang³, Y. Gu⁸; ¹Beijing, CN, ²Changchun, CN, ³Guangzhou, CN, ⁴Hangzhou, CN, ⁵Wuhan, CN, ⁶Nanjing, CN, ⁷Shijiazhuang, CN, ⁸Shanghai, CN, ⁹Chengdu, CN, ¹⁰Fuzhou, CN
- 13:00 - 13:00 1289TiP - ALTA-1L (ALK in lung cancer trial of Brigatinib in 1st Line): A randomized, phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naïve, advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
S. Popat¹, M. Tiseo², S. Gettinger³, S. Peters⁴, J. Haney⁵, D. Kerstein⁵, D. Camidge⁶; ¹London, GB, ²Parma, IT, ³New Haven, US, ⁴Lausanne, CH, ⁵Cambridge, US, ⁶Aurora, US
- 13:00 - 13:00 1290TiP - ALUR: A phase 3 study of alectinib versus chemotherapy in previously treated ALK+ non-small cell lung cancer (NSCLC)
J. Wolf¹, I.-J. Oh², J. Mazieres³, J. de Castro⁴, C. Revil⁵, A. Kotb⁵, H. Johansdottir⁵, A. Zeaiter⁵, S. Novello⁶; ¹Cologne, DE, ²Jeonnam, KR, ³Toulouse, FR, ⁴Madrid, ES, ⁵Basel, CH, ⁶Orbassano, IT
- 13:00 - 13:00 1291TiP - Phase 1b study of crizotinib in combination with pembrolizumab in patients (pts) with untreated ALK-positive (+) advanced non-small cell lung cancer (NSCLC)
F. Vizcarrondo¹, S. Patel², N. Pennell³, S. Pakkala⁴, H. West⁵, R. Kratzke⁶, J. Tarazi⁷, K. Wilner⁸, A. Polli⁹, W. Tan², Y. Liu², O. Valota¹⁰, B. Piperdi¹¹, K. Reckamp¹²; ¹Birmingham, US, ²La Jolla, CA/US, ³Cleveland, US, ⁴Atlanta, US, ⁵Seattle, US, ⁶Minneapolis, US, ⁷San Diego, CA/US, ⁸San Diego, US, ⁹Milano, IT, ¹⁰Milan, IT, ¹¹Kenilworth, NJ/US, ¹²Durate, CA/US
- 13:00 - 13:00 1292TiP - A phase II trial investigating the highly selective c-Met inhibitor tepotinib in stage IIIB/IV lung adenocarcinoma with MET exon 14 alterations after failure of at least one prior therapy
P. Paik¹, U. Stammberger², R. Bruns²; ¹New York, NY/US, ²Darmstadt, DE
- 13:00 - 13:00 1293TiP - Amethyst NSCLC trial: Phase 2, parallel-arm study of receptor tyrosine kinase (RTK) inhibitor, MGCD265 in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating genetic alterations in mesenchymal-epithelial transition factor (MET)
L. Bazhenova¹, R. Mehra², T. Nagy³, L. Cavanna⁴, J.-S. Lee⁵, J.-Y. Han⁶, H.K. Kim⁷, B. Halmos⁸, M. Shum⁹, M. Schreeder¹⁰, I. Rybkin¹¹, F. Badin¹², R. Mena¹³, P. Jänne¹⁴, J. Christensen¹⁵, V. Tassell¹⁵, R. Chao¹⁵, D. Faltaos¹⁵, D.-W. Kim¹⁶; ¹La Jolla, US, ²Philadelphia, PA/US, ³Budapest, HU, ⁴Piacenza, IT, ⁵Seongnam-Si, KR, ⁶Goyang, KR, ⁷Suwon, KR, ⁸New York, US, ⁹Whittier, CA/US, ¹⁰Huntsville, AL/US, ¹¹Detroit, MI/US, ¹²Lexington, KY/US, ¹³Burbank, CA/US, ¹⁴Boston, US, ¹⁵San Diego, CA/US, ¹⁶Seoul



- 13:00 - 13:00 1294TiP - Phase III clinical trials in chemotherapy-naive patients with advanced NSCLC assessing the combination of atezolizumab and chemotherapy
M. Reck¹, V. Papadimitrakopoulou², F. Cappuzzo³, R. Jotte⁴, T.S.K. Mok⁵, A. Sandler⁶, D. Waterkamp⁶, S. Coleman⁶, T. Asakawa⁶, M. Socinski⁷; ¹Grosshansdorf, DE, ²Houston, US, ³Livorno, IT, ⁴Denver, CO/US, ⁵Hong Kong, CN, ⁶South San Francisco, US, ⁷Pittsburgh, US
- 13:00 - 13:00 1295TiP - A phase 2, fast real-time assessment of combination therapies in immuno-oncology trial in patients with advanced non-small cell lung cancer (FRACTION-lung)
P. Fracasso¹, D. Freeman¹, K. Simonsen¹, Y. Shen¹, M. Gupta¹, A. Comprelli¹, J. Gainor², M. Hellmann³, L. Chow⁴, P. Forde⁵, R. Govindan⁶, T. Reilly¹, J. Cassidy¹; ¹Princeton, NJ/US, ²Boston, US, ³New York, US, ⁴Seattle, WA/US, ⁵Baltimore, MD/US, ⁶St. Louis, US
- 13:00 - 13:00 1296TiP - A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC)
L. Sequist¹, I. Anderson², T. Bauer³, N. Demars⁴, E. Felip⁵, N. Frost⁶, W. Harb⁷, L. Horn³, R. Huber⁸, A. Kudla⁴, J. Lee⁹, S. Mathews¹⁰, R. Mehra¹¹, J. Nieva¹², M. Perol¹³, F. Shepherd¹⁴, A. Spira¹⁵, A. Czibere¹⁰; ¹Boston, MA/US, ²Santa Rosa, CA/US, ³Nashville, TN/US, ⁴Cambridge, US, ⁵Barcelona, ES, ⁶Berlin, DE, ⁷Lafayette, IN/US, ⁸München, DE, ⁹New York, NY/US, ¹⁰Cambridge, MA/US, ¹¹Philadelphia, PA/US, ¹²Los Angeles, CA/US, ¹³Lyon, FR, ¹⁴Toronto, ON/CA, ¹⁵Arlington, VA/US
- 13:00 - 13:00 1297TiP - Phase 1b expansion cohort study to evaluate the safety and efficacy of necitumumab and abemaciclib combination therapy in patients with stage IV non-small cell lung cancer (NSCLC)
B. Besse¹, F. Barlesi², M. Ceccarelli³, G. Chao⁴, B. Fridmott-Moller⁵, M. Gil⁶, J. Vansteenkiste⁷; ¹Villejuif, FR, ²Marseille, FR, ³Sesto Fiorentino, IT, ⁴Bridgewater, NJ/US, ⁵Copenhagen, DK, ⁶Warsaw, PL, ⁷Leuven, BE
- 13:00 - 13:00 1298TiP - A single-arm, open-label, phase 2 study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer (NSCLC)
M. Socinski¹, M. Gil², J. Shahidi³, G. Chao³, L. Villaruz⁴; ¹Pittsburgh, US, ²Warsaw, PL, ³Indianapolis, IN/US, ⁴Pittsburgh, PA/US
- 13:00 - 13:00 1299TiP - Carboplatin (Cb) plus nab-paclitaxel (PTX) versus docetaxel (D) for elderly squamous (Sq) non-small cell lung cancer (NSCLC) (CAPITAL study)
Y. Kogure¹, H. Saka¹, Y. Takiguchi², S. Atagi³, T. Kurata⁴, N. Ebi⁵, A. Inoue⁶, K. Kubota⁷, M. Takenoyama⁸, T. Seto⁸, A. Kada¹, T. Yamanaka⁷, M. Ando¹, N. Yamamoto⁹, A. Gemma¹⁰, Y. Ichinose⁸; ¹Nagoya, JP, ²Chiba, JP, ³Sakai, JP, ⁴Hirakata, JP, ⁵Izuka, JP, ⁶Sendai, JP, ⁷Yokohama, JP, ⁸Fukuoka, JP, ⁹Wakayama, JP, ¹⁰Tokyo, JP
- 13:00 - 13:00 SCLC
- 13:00 - 13:00 1428P - Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-stage small-cell lung cancer (LD-SCLC): The final results of TORG 0604



Y. Misumi¹, H. Okamoto¹, K. Naoki¹, Y. Hosomi¹, T. Ogura¹, N. Masuda¹, K. Minato¹, T. Yokoyama², K. Kishi³, M. Nishikawa⁴, T. Kato¹, N. Seki³, I. Goto⁵, K. Watanabe¹; ¹Yokohama, JP, ²Mitaka, JP, ³Tokyo, JP, ⁴Fujisawa, JP, ⁵Takatsuki, JP

- 13:00 - 13:00 1429P - The humanistic burden of small cell lung cancer (SCLC): A systematic review of health-related quality of life (HRQoL) literature
C. Panter¹, B. Bennett¹, Y. Yuan², J. Penrod²; ¹Bollington, GB, ²Princeton, NJ/US
- 13:00 - 13:00 1430TiP - STIMULI: A randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after standard of care chemo-radiotherapy conducted by ETOP and IFCT
D. De Ruyscher¹, J.-L. Pujol², S. Popat³, M. Reck⁴, C. Le Pechoux⁵, A. Liston⁶, D. Speiser⁷, G. Coukos⁷, R. Kammler⁸, O. Dafni⁹, Z. Tsourti⁹, H. Roschitzki⁸, M. Finlayson⁸, A.-C. Piguet⁸, B. Ruepp⁸, R. Maibach⁸, R.A. Stahel¹⁰, S. Peters⁷; ¹Maastricht, NL, ²Montpellier, FR, ³London, GB, ⁴Grosshansdorf, DE, ⁵Villejuif, FR, ⁶Leuven, BE, ⁷Lausanne, CH, ⁸Bern, CH, ⁹Athens, GR, ¹⁰Zürich, CH
- 13:00 - 13:00 1431TiP - A Phase III study of atezolizumab with carboplatin plus etoposide in patients with extensive-stage small cell lung cancer (IMpower133)
L. Horn¹, M. Reck², T.S.K. Mok³, M. Johnson¹, D. Waterkamp⁴, S. Lam⁴, X. Tang⁵, A. Sandler⁴, A. Lopez-Chavez⁴, G. Giaccone⁶, S. Liu⁶; ¹Nashville, TN/US, ²Grosshansdorf, DE, ³Hong Kong, CN, ⁴South San Francisco, US, ⁵Shanghai, CN, ⁶Washington, DC/US
- 13:00 - 13:00 1432TiP - Immune surveillance reactivation to improve overall survival in small cell lung cancer (SCLC): The randomized IMPULSE study
M. Thomas¹, R. Carter², S. Ponce Aix³, J. Riera-Knorrenschild⁴, A. Navarro Mendivil⁵, M. Domine³, J. Kollmeier², P. Sadjadian⁶, R. Huber⁷, M. Wolf⁸; ¹Heidelberg, DE, ²Berlin, DE, ³Madrid, ES, ⁴Marburg, DE, ⁵Barcelona, ES, ⁶Minden, DE, ⁷München, DE, ⁸Kassel, DE
- 13:00 - 13:00 Thoracic malignancies, other
- 13:00 - 13:00 1511P - TKIs in first-line for advanced NSCLC with activating EGFR-mutations: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized controlled trials
J. Giuliani, A. Bonetti; Legnago, IT
- 13:00 - 13:00 1512P - Prognostic value of FGFR1 overexpression and amplification in esophageal squamous cell carcinoma patients: A combined analysis from TCGA database
B. Chen, S. Liu, J. Wang, B. Hu, H. Xu, R. Tong, X. Hu, J. Xue, Y. Lu; Chengdu, CN
- 13:00 - 13:00 1513P - Wait times for diagnosis and treatment of lung cancer: A single centre experience
C. Labbe, M. Anderson, S. Simard, L. Tremblay, F. Laberge, R. Vaillancourt; Quebec City, QC/CA
- 13:00 - 13:00 1514P - Preoperative diffusing capacity correlates with tumor malignant grade and surgical outcome in clinical stage I lung cancer
Y. Miyata, T. Mimura, Y. Tsutani, H. Hanaki, K. Misumi, M. Okada; Hiroshima, JP



- 13:00 - 13:00 1515P - Frequency, patterns and prognostic impact of distant metastases in a large mono-institutional series of malignant pleural mesothelioma (MPM): Not necessarily bad news
F. Grosso¹, A. Roveta¹, G. Gallizzi¹, A. Muzio², S. Zai¹, F. Ugo¹, A. Aurelio¹, R. Libener¹, M. Mancuso¹, G. Ferretti¹, P. Franzone¹, M. Pastormerlo², E. Piccolini², D. Degiovanni², G. Numico¹; ¹Alessandria, IT, ²Casale Monferrato, IT
- 13:00 - 13:00 1516P - Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer TCOG LC-1202
K. Kubota¹, A. Miyanaga², Y. Hosomi¹, Y. Okuma², K. Minato¹, S. Fujimoto³, Y. Takiguchi⁴, H. Okamoto¹, Y. Hattori⁵, H. Isobe⁶, H. Aono²; ¹Yokohama, JP, ²Tokyo, JP, ³Ota, JP, ⁴Chiba, JP, ⁵Akashi, JP, ⁶Sapporo, JP
- 13:00 - 13:00 1517P - Cisplatin-raltitrexed vs cisplatin-pemetrexed in the treatment of advanced pleural mesothelioma. Final results of a network meta-analysis
L.A. Lazzari Agli, C. Cherubini, M. Papi, C. Santelmo, S.V.L. Nicoletti, E. Bianchi, M. Fantini, C. Ridolfi, L. Stocchi, E. Tamburini, D. Tassinari; Rimini, IT
- 13:00 - 13:00 1518P - Malignant pleural effusion (MPE) characterized with 11C-Methionine PET/CT before and after talc pleurodesis: interim evaluation of a prospective clinical trial
E. Lopci¹, P. Zucali¹, G. Ceresoli², A. Testori¹, E. Voulaz¹, K. Marzo¹, L. Leonardi¹, M. Rodari¹, L. Olivari¹, G. Ferraroli¹, E. Bottoni¹, M. Perrino¹, A. Crepaldi¹, A. Galeassi³, L. Gurrieri⁴, G. Veronesi¹, M. Alloisio¹, A. Santoro⁵, A. Chiti¹; ¹Milano, IT, ²Bergamo, IT, ³Castellanza, IT, ⁴Udine, IT, ⁵Rozzano, IT



| 14:45 - 16:30 | Type: Proffered Paper session Title: Melanoma and other skin tumours | Copenhagen |
|---------------|---|------------|
| 14:45 - 15:00 | <p>LBA39 - (Neo-)adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma – initial data from the OpACIN trial</p> <p><u>C. Blank</u>¹, A. van Akkooi¹, E.A. Rozeman¹, P. Kvistborg¹, H. van Thienen¹, B. Stegenga², B. Lamon³, J. Haanen¹, T. Schumacher¹; ¹Amsterdam, NL, ²Utrecht, NL, ³Princeton, US</p> | |
| 15:00 - 15:15 | (Withdrawn) | |
| 15:15 - 15:30 | <p>1111O - Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone</p> <p><u>Y. Yan</u>¹, C. Robert², J. Larkin³, P. Ascierto⁴, B. Dreno⁵, M. Maio⁶, C. Garbe⁷, P. Chapman⁸, J. Sosman⁹, M. Wongchenko¹, J. Hsu¹, I. Chang¹⁰, I. Caro¹, I. Rooney¹⁰, G. McArthur¹¹, A. Ribas¹²; ¹South San Francisco, CA/US, ²Villejuif, FR, ³London, GB, ⁴Napoli, IT, ⁵Nantes, FR, ⁶Siena, IT, ⁷Tübingen, DE, ⁸New York, NY/US, ⁹Nashville, TN/US, ¹⁰South San Francisco, US, ¹¹Melbourne, AU, ¹²Los Angeles, CA/US</p> | |
| 15:30 - 15:45 | <p>Invited discussant abstracts 1111O, LBA39 and one additional LBA</p> <p><u>C. Lebbé</u>, Paris, FR</p> | |
| 15:45 - 16:00 | <p>1106O - Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL)</p> <p><u>P. Ascierto</u>¹, M. Del Vecchio², C. Robert³, A. Mackiewicz⁴, V. Chiarion-Sileni⁵, A.M. Arance Fernandez⁶, H. Schmidt⁷, C. Lebbe⁸, L. Bastholt⁹, O. Hamid¹⁰, P. Rutkowski¹¹, C. McNeil¹², C. Garbe¹³, C. Loquai¹⁴, B. Dreno¹⁵, L. Thomas¹⁶, J.J. Grob¹⁷, D. Hennicken¹⁸, A. Qureshi¹⁹, M. Maio²⁰; ¹Napoli, IT, ²Milano, IT, ³Villejuif, FR, ⁴Poznan, PL, ⁵Padova, IT, ⁶Barcelona, ES, ⁷Aarhus C, DK, ⁸Paris, FR, ⁹Odense C, DK, ¹⁰Los Angeles, CA/US, ¹¹Warsaw, PL, ¹²Camperdown, NSW/AU, ¹³Tübingen, DE, ¹⁴Mainz, DE, ¹⁵Nantes, FR, ¹⁶Pierre Bénite, FR, ¹⁷Marseille, FR, ¹⁸Braine-L'alleud, BE, ¹⁹Princeton, NJ/US, ²⁰Siena, IT</p> | |
| 16:00 - 16:15 | <p>1107O - Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma</p> <p><u>O. Hamid</u>¹, I. Puzanov², R. Dummer³, J. Schachter⁴, A. Daud⁵, D. Schadendorf⁶, C. Blank⁷, L. Cranmer⁸, C. Robert⁹, A. Pavlick¹⁰, R. Gonzalez¹¹, F.S. Hodi¹², P. Ascierto¹³, A. Salama¹⁴, K. Margolin¹⁵, T. Gangadhar¹⁶, Z. Wei¹⁷, S. Ebbinghaus¹⁷, N. Ibrahim¹⁷, A. Ribas¹⁸; ¹Los Angeles, CA/US, ²Nashville, TN/US, ³Zürich, CH, ⁴TeI Hashomer, IL, ⁵San Francisco, CA/US, ⁶Essen, DE, ⁷Amsterdam, NL, ⁸Tucson, AZ/US, ⁹Villejuif, FR, ¹⁰New York, NY/US, ¹¹Aurora, US, ¹²Boston, US, ¹³Napoli, IT, ¹⁴Durham, NC/US, ¹⁵Duarte, CA/US, ¹⁶Philadelphia, US, ¹⁷Kenilworth, NJ/US, ¹⁸Los Angeles, US</p> | |
| 16:15 - 16:30 | <p>Invited discussant abstracts 1106O and 1107O</p> <p><u>O. Michielin</u>, Lausanne, CH</p> | |



| | | |
|---------------|---|-----------|
| 14:45 - 16:15 | Type: Educational session Title: Hot topics in the adjuvant treatment of colorectal cancer Chair(s): R. Adams, GB; J. Taieb, FR | Vienna |
| 14:45 - 15:15 | BRAF, KRAS, MSI and gene signatures: Where are we now? <u>R. Salazar</u> , Barcelona, ES | |
| 15:15 - 15:45 | How best to treat adjuvant rectal cancer <u>R. Adams</u> , Cardiff, GB | |
| 15:45 - 16:15 | Complex colon cancer patients in the adjuvant setting <u>T. André</u> , Paris, FR | |
| 14:45 - 16:15 | Type: Educational session Title: Brain metastases: Are we ready for a paradigm shift? Chair(s): R. Stupp, CH; E. Franceschi, IT | Stockholm |
| 14:45 - 15:15 | The biology of brain metastases: What should we know? <u>M. Valiente</u> , Madrid, ES | |
| 15:15 - 15:45 | Is the blood brain barrier still a limit for targeted therapies in brain metastases? <u>M. Preusser</u> , Vienna, AT | |
| 15:45 - 16:15 | The treatment of brain metastases in the era of immuno-oncology <u>R. Stupp</u> , Zürich, CH | |
| 14:45 - 16:15 | Type: Educational session Title: Difficult decisions in gynaecological oncology Chair(s): I. Ray-Coquard, FR; A. Poveda, ES | Madrid |
| 14:45 - 15:15 | Adjuvant therapy of endometrial cancer <u>C. Creutzberg</u> , Leiden, NL | |
| 15:15 - 15:45 | Management of vulnerable patients with gynaecological cancers <u>G. Freyer</u> , Lyon, FR | |
| 15:45 - 16:15 | Rare ovarian tumours: A special focus on sex cord and germ cell tumours <u>I. Ray-Coquard</u> , Lyon, FR | |



| | | |
|---------------|--|--------|
| 14:45 - 16:15 | Type: Joint Symposium Title: Joint Symposium ESMO-JSMO: How to overcome resistance of target therapy for lung cancer Chair(s): Y. Ohe, JP; S. Peters, CH | Oslo |
| 14:45 - 14:50 | Introduction <u>Y. Ohe</u> , Tokyo, JP | |
| 14:50 - 15:10 | Circumvention of EGFR-TKI resistance in EGFR mutant lung cancer <u>S. Yano</u> , Kanazawa, JP | |
| 15:10 - 15:30 | Treatment decisions at ALK TKI resistance <u>M. Perol</u> , Lyon, FR | |
| 15:30 - 15:50 | Targeting MAPK pathway: Challenges and inherent resistance <u>A. Adjei</u> , Buffalo, US | |
| 15:50 - 16:10 | Development of a nationwide genomic screening network for lung cancer with rare driver oncogenes and investigation of the mechanism of drug resistance <u>K. Goto</u> , Kashiwa, JP | |
| 16:10 - 16:15 | Conclusions and clinical perspectives <u>S. Peters</u> , Lausanne, CH | |
| 14:45 - 16:15 | Type: Joint Symposium Title: Joint Symposium ESMO-ESTRO: Immunotherapy as an interdisciplinary challenge: Focus on medical oncology and radiotherapy Chair(s): C. Zielinski, AT; D. Zips, DE | Athens |
| 14:45 - 14:50 | Introduction <u>C. Zielinski</u> , Vienna, AT | |
| 14:50 - 15:10 | Basic considerations on the interaction of immunotherapy and radiotherapy <u>D. Zips</u> , Tübingen, DE | |
| 15:10 - 15:30 | Combination partners for immunotherapy <u>C. Zielinski</u> , Vienna, AT | |
| 15:30 - 15:50 | The Abscopal Effect in the context of clinical trials <u>E. Deutsch</u> , Villejuif, FR | |
| 15:50 - 16:10 | How to use radiotherapy during targeted therapy <u>B. Escudier</u> , Villejuif, FR | |
| 16:10 - 16:15 | Conclusions and clinical perspectives <u>D. Zips</u> , Tübingen, DE | |



| | | |
|---------------|--|----------|
| 14:45 - 16:15 | Type: Joint Symposium Title: Joint Symposium ESMO-SIOPE: From childhood to adulthood: Cancer in adolescents and young adults Chair(s): J.-Y. Douillard, FR; S. Bielack, DE | Brussels |
| 14:45 - 14:50 | Introduction <u>J.-Y. Douillard</u> , St. Herblain, FR | |
| 14:50 - 15:10 | Adolescents and young adults with cancer: A no man's land? <u>G. Mountzios</u> , Athens, GR | |
| 15:10 - 15:30 | Colorectal cancer in young adults: The focus on hereditary cancer syndromes <u>E. Saloustros</u> , Heraklion, GR | |
| 15:30 - 15:50 | GU tumours in adolescent and young adults: Focus on germ-cell tumours <u>G. Calaminus</u> , Bonn , DE | |
| 15:50 - 16:10 | Subsequent malignant neoplasms in survivors from childhood cancers <u>M. Hawkins</u> , Birmingham, GB | |
| 16:10 - 16:15 | Conclusions and clinical perspectives <u>S. Bielack</u> , Stuttgart, DE | |
| 15:00 - 16:00 | Type: Multidisciplinary patient cases Title: Pain from bone metastases Chair(s): D. Santini, IT | Rome |
| 15:00 - 15:10 | The medical treatment of bone metastases <u>D. Santini</u> , Rome, IT | |
| 15:10 - 15:20 | The role of radiotherapy in the control of bone pain <u>P. Feyer</u> , Berlin, DE | |
| 15:20 - 15:30 | Analgesic multimodal management according to risk factors of cancer pain | |
| 15:30 - 16:00 | Discussion | |



| | | |
|---------------|--|----------|
| 15:00 - 16:00 | Type: Multidisciplinary patient cases Title: Precision medicine in the clinic: How do I provide it? Chair(s): C. Ferte, FR | Helsinki |
| 15:00 - 15:10 | Patient case presentation <u>P. Aftimos</u> , Brussels, BE | |
| 15:10 - 15:20 | From raw data to a comprehensive genetic report <u>A. Vivancos</u> , Barcelona, ES | |
| 15:20 - 15:30 | From a NGS test to a clinical decision <u>C. Ferte</u> , Villejuif, FR | |
| 15:30 - 16:00 | Discussion | |
| 15:00 - 16:00 | Type: Poster Discussion session Title: Breast cancer, early Chair(s): G. Viale, IT; K. Gelmon, CA | Berlin |
| 15:00 - 15:00 | 147PD - First prospectively-designed outcome study in estrogen receptor (ER)+ breast cancer (BC) patients (pts) with N1mi or 1-3 positive nodes in whom treatment decisions in clinical practice incorporated the 21-gene recurrence score (RS) result <u>S. Stemmer</u> ¹ , <u>M. Steiner</u> ² , <u>S. Rizel</u> ¹ , <u>D. Geffen</u> ³ , <u>B. Nisenbaum</u> ⁴ , <u>T. Peretz</u> ⁵ , <u>L. Soussan-Gutman</u> ⁶ , <u>A. Bareket-Samish</u> ⁷ , <u>K. Isaacs</u> ⁸ , <u>O. Rosengarten</u> ⁵ , <u>G. Fried</u> ² , <u>C. Svedman</u> ⁹ , <u>S. Shak</u> ⁹ , <u>N. Liebermann</u> ¹⁰ , <u>N. Ben-Baruch</u> ¹¹ ; ¹ Petach Tikva, IL, ² Haifa, IL, ³ Beer Sheva, IL, ⁴ Kfar Saba, IL, ⁵ Jerusalem, IL, ⁶ Shoham, IL, ⁷ Zichron Yaakov, IL, ⁸ Afula, IL, ⁹ Redwood City, CA/US, ¹⁰ Tel Aviv, IL, ¹¹ Rehovot, IL | |
| 15:00 - 15:00 | 148PD - Analysis of Oncotype DX recurrence score and its clinical implications in invasive lobular carcinomas of the breast <u>C. Truica</u> , J. Felts, B. Han, J. Zhu; Hershey, PA/US | |
| 15:00 - 15:00 | 149PD - Prognostic impact of proliferation for resected early stage breast cancer according to histology: Cut-off analysis of Ki67 in 859 patients with pure invasive lobular and ductal breast carcinoma (ILC/IDC) <u>L. Carbognin</u> ¹ , <u>I. Sperduti</u> ² , <u>M.V. Dieci</u> ³ , <u>I. Zampiva</u> ¹ , <u>G. Griguolo</u> ³ , <u>S. Pilotto</u> ¹ , <u>V. Guarneri</u> ⁴ , <u>M. Brunelli</u> ¹ , <u>R. Nortilli</u> ¹ , <u>E. Manfrin</u> ¹ , <u>E. Fiorio</u> ¹ , <u>V. Parolin</u> ¹ , <u>E. Filippi</u> ¹ , <u>F. Pellini</u> ¹ , <u>F. Bonetti</u> ¹ , <u>G. Pollini</u> ¹ , <u>P.F. Conte</u> ³ , <u>G. Tortora</u> ¹ , <u>E. Bria</u> ¹ ; ¹ Verona, IT, ² Roma, IT, ³ Padova, IT, ⁴ Padua, IT | |
| 15:00 - 15:00 | 150PD - Breast cancer-specific survival in >4,600 patients with lymph node-positive (LN+) hormone receptor-positive (HR+) invasive breast cancer (BC) and 21-gene recurrence score® (RS) results in the SEER registries <u>D. Miller</u> ¹ , <u>M. Roberts</u> ² , <u>V. Petkov</u> ² , <u>S. Shak</u> ¹ , <u>N. Howlander</u> ² , <u>K. Cronin</u> ² , <u>L. Penberthy</u> ² ; ¹ Redwood City, CA/US, ² Rockville, MD/US | |
| 15:00 - 15:20 | Invited discussant abstracts 147PD, 148PD, 149PD and 150PD <u>G. Viale</u> , Milano, IT | |



- 15:20 - 15:30 Questions to discussant
- 15:30 - 15:30 151PD - Prognostic impact of interval breast cancer detection in women with pT1aN0M0 breast cancer with HER2-positive status: Results from a multicenter population-based cancer registry study
A. Musolino¹, A. Sikokis¹, D. Boggiani¹, A. Rimanti¹, B. Pellegrino¹, E. Silini¹, N. Campanini¹, E. Barbieri², L. Cortesi³, M. Panebianco⁴, R. Porzio⁵, A. Frassoldati⁶, P. Sgargi¹, F. Falcini⁷, M. Michiara¹; ¹Parma, IT, ²Bologna, IT, ³Modena, IT, ⁴Reggio Emilia, IT, ⁵Piacenza, IT, ⁶Ferrara, IT, ⁷Meldola, IT
- 15:30 - 15:30 152PD - Serum metabolomic profiles identify ER-positive early breast cancer patients at increased risk of disease recurrence in a multicentre population
C. Hart¹, A. Vignoli², L. Tenori², L. Biganzoli¹, E. Risi³, R. Love⁴, C. Luchinat², A. Di Leo¹; ¹Prato, IT, ²Sesto Fiorentino, IT, ³Roma, IT, ⁴Madison, US
- 15:30 - 15:30 153PD - A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation
J. Litton¹, M. Scoggins¹, D. Ramirez¹, R. Murthy¹, G. Whitman¹, K. Hess¹, B. Adrada¹, S. Moulder¹, C. Barcenas¹, V. Valero¹, D. Booser², J. Schwartz Gomez¹, G. Mills¹, H. Piwnica-Worms¹, B. Arun¹; ¹Houston, TX/US, ²Houston, US
- 15:30 - 15:30 154PD - Gestational breast cancer: Distinctive molecular and clinico-epidemiological features. GEICAM/2012-03 study
J. de la Haba¹, A. Ruiz², M. Pollan³, A. Prat⁴, F. Rojo³, M. Martin³, E. Alba Conejo⁵, J.A. Perez-Fidalgo², J. Gavilá², C. Morales¹, B. Navarro², A. Hernández-Blanquissett², I. Porras¹, A. Rodriguez-Lescure⁶, B. Jiménez-Rodríguez⁵, N. Martín³, L. Pérez-Ramos³, R. Caballero³, E. Carrasco³, A. Lluch-Hernandez²; ¹Cordoba, ES, ²Valencia, ES, ³Madrid, ES, ⁴Barcelona, ES, ⁵Malaga, ES, ⁶Elche, ES
- 15:30 - 15:50 Invited discussant abstracts 151PD, 152PD, 153PD, 154PD
K. Gelmon, Vancouver, CA
- 15:50 - 16:00 Questions to discussant
- 15:00 - 16:00 Type: Poster Discussion session
 Title: Head and neck cancers
 Chair(s): U. Keilholz, DE; R. Mesia Nin, ES
- 15:00 - 15:00 LBA36 - Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC)
J. Bauman¹, R. Ferris², D. Clump³, J. Ohr³, W. Gooding³, S. Kim³, B. Karlovits³, U. Duvvuri³, J. Johnson³, D. Petro³, D. Heron³; ¹Pittsburgh, US, ²Pittsburgh, Pa, US, ³Pittsburgh, PA/US
- 15:00 - 15:00 957PD - Pembrolizumab after progression on platinum and cetuximab in head and neck squamous cell carcinoma (HNSCC): Results from KEYNOTE-055



R. Haddad¹, T. Seiwert², D.G. Pfister³, F. Worden⁴, S.V. Liu⁵, J. Gilbert⁶, N. Saba⁷, J. Weiss⁸, L. Wirth⁹, A. Sukari¹⁰, H. Kang¹¹, M. Gibson¹², E. Massarelli¹³, S. Powell¹⁴, A. Meister¹⁵, X. Shu¹⁵, J. Cheng¹⁵, J. Baum¹⁶; ¹Boston, US, ²Chicago, IL/US, ³New York, NY/US, ⁴Ann Arbor, MI/US, ⁵Washington, DC/US, ⁶Nashville, TN/US, ⁷Atlanta, GA/US, ⁸North Carolina, US, ⁹Boston, MA/US, ¹⁰Detroit, MI/US, ¹¹Baltimore, US, ¹²Cleveland, OH/US, ¹³Houston, TX/US, ¹⁴Sioux Falls, ND/US, ¹⁵Kenilworth, NJ/US, ¹⁶Philadelphia, PA/US

- 15:00 - 15:00 955PD - A comparative study of PD-L1 diagnostic assays in squamous cell carcinoma of the head and neck (SCCHN)
M. Ratcliffe¹, A. Sharpe¹, M. Rebelatto², M. Scott¹, C. Barker¹, P. Scorer¹, J. Walker¹; ¹Cambridge, GB, ²Gaithersburg, MD/US
- 15:00 - 15:15 Invited discussant abstracts LBA36, 957PD and 955PD
U. Keilholz, Berlin, DE
- 15:15 - 15:20 Questions to discussant
- 15:20 - 15:20 952PD - PET-CT surveillance for advanced head and neck cancer: A cost-effective alternative to planned neck dissection?
A. Smith¹, P. Hall², C. Hulme¹, C. McConkey³, J. Dunn³, J. Rahman³, H. Mehanna⁴; ¹Leeds, GB, ²Edinburgh, GB, ³Coventry, GB, ⁴Birmingham, GB
- 15:20 - 15:20 953PD - Final overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib in the phase 3 DECISION trial: An exploratory crossover adjustment analyses
M. Brose¹, B. Jarzab², R. Elisei³, L. Giannetta⁴, L. Bastholt⁵, C. de la Fouchardiere⁶, F. Pacini⁷, R. Paschke⁸, C. Nutting⁹, Y. Shong¹⁰, S. Sherman¹¹, J. Smit¹², J. Chung¹³, G. Meinhardt¹³, M. Schlumberger¹⁴, C. Kappeler¹⁵; ¹Philadelphia, US, ²Gliwice, PL, ³Pisa, IT, ⁴Milano, IT, ⁵Odense C, DK, ⁶Lyon, FR, ⁷Siena, IT, ⁸Leipzig, DE, ⁹London, GB, ¹⁰Seoul, KR, ¹¹Houston, TX/US, ¹²Nijmegen, NL, ¹³Whippany, NJ/US, ¹⁴Villejuif, FR, ¹⁵Berlin, DE
- 15:20 - 15:20 956PD - Development of a predictive radiomics signature for response to immune checkpoint inhibitors (ICIs) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN)
A. Prawira¹, P. Dufort¹, J. Halankar¹, D. Paravasthu¹, A. Hansen¹, A. Spreafico¹, E. Chen², A. Abdul Razak¹, R. Jang¹, U. Metser¹, L. Siu¹; ¹Toronto, CA, ²Toronto, ON/CA
- 15:20 - 15:35 Invited discussant abstracts 952PD, 953PD and 954PD
R. Mesia Nin, Barcelona, ES
- 15:35 - 15:40 Questions to discussant



| | | |
|---------------|--|-----------|
| 15:00 - 16:00 | Type: Special Session Title: Practising Oncologists "How I treat" session: Managing issues in pancreatic cancer Chair(s): G. Lakatos, HU | Amsterdam |
| 15:00 - 15:05 | Pancreatic cancer: FOLFIRINOX in real life <u>G. Lakatos</u> , Budapest, HU | |
| 15:05 - 15:10 | Discussant <u>M. Ducreux</u> , Villejuif, FR | |
| 15:10 - 15:20 | General discussion <u>G. Lakatos</u> ¹ , <u>M. Ducreux</u> ² ; ¹ Budapest, HU, ² Villejuif, FR | |
| 15:20 - 15:25 | Pancreatic cancer: Optimizing neoadjuvant therapy in borderline resectable cases <u>G. Lakatos</u> , Budapest, HU | |
| 15:25 - 15:30 | Discussant <u>M. Ducreux</u> , Villejuif, FR | |
| 15:30 - 15:40 | General discussion <u>G. Lakatos</u> ¹ , <u>M. Ducreux</u> ² ; ¹ Budapest, HU, ² Villejuif, FR | |
| 15:40 - 15:45 | Borderline resectable pancreatic cancer <u>G. Lakatos</u> , Budapest, HU | |
| 15:45 - 15:50 | Discussant <u>M. Ducreux</u> , Villejuif, FR | |
| 15:50 - 16:00 | General discussion <u>G. Lakatos</u> ¹ , <u>M. Ducreux</u> ² ; ¹ Budapest, HU, ² Villejuif, FR | |



| 16:30 - 18:00 | Type: Presidential Symposium Title: Presidential Symposium 1 | Copenhagen |
|---------------|--|------------|
| 16:30 - 16:45 | <p>LBA1_PR - First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC)</p> <p><u>G. Hortobagyi</u>¹, S. Stemmer², H. Burris³, Y.S. Yap⁴, G. Sonke⁵, S. Paluch-Shimon⁶, M. Campone⁷, K. Blackwell⁸, F. André⁹, E. Winer¹⁰, W. Janni¹¹, S. Verma¹², P. Conte¹³, C. Arteaga¹⁴, D. Cameron¹⁵, F. Xuan¹⁶, F. Souami¹⁷, M. Miller¹⁶, C. Germa¹⁶, J. O'Shaughnessy¹⁸; ¹Houston, TX/US, ²Petach Tikva, IL, ³Nashville, US, ⁴Singapore, SG, ⁵Amsterdam, NL, ⁶Tel Aviv, IL, ⁷St. Herblain, FR, ⁸Durham, NC/US, ⁹Villejuif, FR, ¹⁰Boston, MA/US, ¹¹Ulm, DE, ¹²Toronto, CA, ¹³Padova, IT, ¹⁴Nashville, TN/US, ¹⁵Edinburgh, GB, ¹⁶East Hanover, NJ/US, ¹⁷Basel, CH, ¹⁸Dallas, TX/US</p> | |
| 16:45 - 17:00 | <p>Invited discussant LBA1</p> <p><u>S. Johnston</u>, London, GB</p> | |
| 17:00 - 17:15 | <p>LBA2_PR - Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial</p> <p><u>A. Eggermont</u>¹, V. Chiarion-Sileni², J.-J. Grob³, R. Dummer⁴, J.D. Wolchok⁵, H. Schmidt⁶, O. Hamid⁷, C. Robert¹, P. Ascierto⁸, J. Richards⁹, C. Lebbe¹⁰, V. Ferraresi¹¹, M. Smylie¹², J. Weber¹³, C. Taitt¹⁴, V. de Pril¹⁵, G. de Schaezen¹⁶, S. Suci¹⁶, A. Testori¹⁷; ¹Villejuif, FR, ²Padova, IT, ³Marseille, FR, ⁴Zürich, CH, ⁵New York, NY/US, ⁶Aarhus C, DK, ⁷Los Angeles, CA/US, ⁸Naples, IT, ⁹Park Ridge, IL/US, ¹⁰Paris, FR, ¹¹Rome, IT, ¹²Edmonton, AB/CA, ¹³Tampa, FL/US, ¹⁴Princeton, US, ¹⁵Braine-L'alleud, BE, ¹⁶Brussels, BE, ¹⁷Milan, IT</p> | |
| 17:15 - 17:30 | <p>Invited discussant LBA2</p> <p><u>O. Michielin</u>, Lausanne, CH</p> | |
| 17:30 - 17:45 | <p>LBA3_PR - A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial)</p> <p><u>M.R. Mirza</u>¹, B. Monk², A. Oza³, S. Mahner⁴, A. Redondo⁵, M. Fabbro⁶, J. Ledermann⁷, D. Lorusso⁸, I. Vergote⁹, O. Rosengarten¹⁰, J. Berek¹¹, J. Herrstedt¹², A. Tinker¹³, A. Dubois¹⁴, A. Gonzalez Martin⁵, P. Follana¹⁵, B. Benigno¹⁶, B. Rimel¹⁷, S. Agarwal¹⁸, U. Matulonis¹⁹; ¹Copenhagen, DK, ²Phoenix, AZ/US, ³Toronto, CA, ⁴Hamburg, DE, ⁵Madrid, ES, ⁶Montpellier, FR, ⁷London, GB, ⁸Milano, IT, ⁹Leuven, BE, ¹⁰Jerusalem, IL, ¹¹Stanford, US, ¹²Odense, DK, ¹³Vancouver, CA, ¹⁴Essen, DE, ¹⁵Nice, FR, ¹⁶Atlanta, GA/US, ¹⁷West Hollywood, CA/US, ¹⁸Waltham, US, ¹⁹Boston, MA/US</p> | |
| 17:45 - 18:00 | <p>Invited discussant LBA3</p> <p><u>S. Pignata</u>, Napoli, IT</p> | |



| | | |
|---------------|---|-----------|
| 16:30 - 17:30 | Type: Multidisciplinary patient cases Title: Definition and management of oligoprogression during treatment with TKI inhibitors Chair(s): E. Smit, NL | Vienna |
| 16:30 - 16:40 | Practicalities and risks of biopsy <u>J. Barry</u> , Cork, IE | |
| 16:40 - 16:50 | Optimal genome profiling for re-biopsy of TKI resistant tumour <u>K. Kerr</u> , Aberdeen, GB | |
| 16:50 - 17:00 | The perspective of the oncologist <u>E. Smit</u> , Amsterdam, NL | |
| 17:00 - 17:30 | Discussion | |
| 16:30 - 18:00 | Type: Educational session Title: Advances in precision medicine of gastric cancer Chair(s): Y.-K. Kang, KR; Y. Janjigian, US | Stockholm |
| 16:30 - 16:55 | Genetic and immune signatures of gastric cancer to inform prognosis and clinical decision making <u>A. Hillmer</u> , SG | |
| 16:55 - 17:20 | Surgical precision: Novel techniques and perspectives <u>C. Mariette</u> , Lille, FR | |
| 17:20 - 17:45 | Novel drugs: More precise, more efficacious and safer? <u>Y. Janjigian</u> , New York, US | |
| 17:45 - 18:00 | Conclusions and clinical perspectives <u>Y.-K. Kang</u> , Seoul, KR | |



| | | |
|---------------|---|------|
| 16:30 - 18:00 | Type: Proffered Paper session Title: Supportive and palliative care Chair(s): S. Kaasa, NO; F. Scotté, FR | Oslo |
| 16:30 - 16:45 | 1300O - Use of chemotherapy near the end of life for solid cancers: What factors matter? <u>P. Rochigneux</u> ¹ , J.L. Raoul ² , L. Morin ³ ; ¹ Marseille, CEDEX 9/FR, ² Marseille, FR, ³ Stockholm, SE | |
| 16:45 - 17:00 | 1433O - Phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H vs EU-neulasta® in the prophylaxis of chemotherapy-induced neutropenia <u>C. Waller</u> ¹ , C. Blakeley ² , E. Pennella ³ , M. Bronchud ⁴ , O. Berzoy ⁵ , N. Voitko ⁶ , H. Adamchuk ⁷ , Z. Zautashvili ⁸ , Y. Vinnyk ⁹ , G. Nemsadze ⁸ , G. Dzagnidze ⁸ , Y. Shparyk ¹⁰ , I. Lytvyn ¹¹ , A. Rusyn ¹² , V. Popov ¹³ , I. Lang ¹⁴ , R. Sharma ¹⁵ , M. Baczkowski ¹⁶ , M. Kotheke ¹⁷ , A. Barve ³ ; ¹ Freiburg, DE, ² London, GB, ³ Canonsburg, PA/US, ⁴ Barcelona, ES, ⁵ Odessa, UA, ⁶ Kiev, UA, ⁷ Ternopil, UA, ⁸ Tbilisi, GE, ⁹ Kharkiv, UA, ¹⁰ Lviv, UA, ¹¹ Dnepropetrovsk, UA, ¹² Uzhhorod, UA, ¹³ Varna, BG, ¹⁴ Budapest, HU, ¹⁵ Hatfield, GB, ¹⁶ Morgantown, WV/US, ¹⁷ Bangalore, IN | |
| 17:00 - 17:15 | Invitd discussant abstracts 1300O and 1433O <u>S. Kaasa</u> , Oslo, NO | |
| 17:15 - 17:30 | 1434O - ONO-7643/anamorelin for the treatment of patients with non-small cell lung cancer and cachexia: Results from phase 2 study with Japanese patients <u>J. Uchino</u> ¹ , N. Katakami ² , T. Yokoyama ³ , T. Naito ⁴ , M. Kondo ⁵ , K. Yamada ⁶ , H. Kitajima ⁷ , K. Yoshimori ⁸ , K. Sato ⁹ , Y. Takiguchi ¹⁰ , K. Takayama ¹¹ , K. Eguchi ¹² ; ¹ Fukuoka, JP, ² Kobe, JP, ³ Mitaka, JP, ⁴ Shizuoka, JP, ⁵ Nagoya, JP, ⁶ Yokohama, JP, ⁷ Matsuyama, JP, ⁸ Kiyose, JP, ⁹ Nagaoka, JP, ¹⁰ Chiba, JP, ¹¹ Kyoto, JP, ¹² Tokyo, JP | |
| 17:30 - 17:45 | 1435O - Exploration of the heterogeneity of moderately emetogenic chemotherapy on response to fosaprepitant in a randomized phase 3 trial <u>C. Weinstein</u> ¹ , K. Jordan ² , S. Green ¹ , E. Camacho ³ , S. Khanani ⁴ , E. Beckford-Brathwaite ¹ , W. Vallejos ¹ , L. Liang ¹ , S. Noga ⁵ , B. Rapoport ⁶ ; ¹ Kenilworth, NJ/US, ² Halle, DE, ³ Palm Springs, CA/US, ⁴ Worcester, MA/US, ⁵ Baltimore, MD/US, ⁶ Johannesburg, ZA | |
| 17:45 - 18:00 | Invited discussant abstracts 1434O and 1435O <u>F. Roila</u> , Terni, IT | |



16:30 - 17:30 Type: Controversy session Rome
Title: Should every metastatic prostate cancer patient get germline testing?

16:30 - 16:40 Introduction and first vote

16:40 - 17:00 Yes

E. Castro Marcos, Madrid, ES

17:00 - 17:20 No

B. Tombal, Brussels, BE

17:20 - 17:30 Second vote and conclusions

16:30 - 18:00 Type: Special Symposium Athens
Title: Personalising treatment for sarcoma
Chair(s): O. Mir, FR; A. Dei Tos, IT

16:30 - 16:35 Introduction

O. Mir, Villejuif, FR

16:35 - 16:50 Deep sequencing in sarcoma: The pathologist's perspective

A. Dei Tos, Treviso, IT

16:50 - 17:05 Treatment according to histological subtypes

S. Stacchiotti, Milan, IT

17:05 - 17:20 Individualising radiation therapy (use / non-use)

R. Haas, Amsterdam, NL

17:20 - 17:35 Molecular profiling for patients with STS

A. Italiano, Bordeaux, FR

17:35 - 17:50 Personalising treatment of bone sarcoma

E. de Alava, Sevilla, ES

17:50 - 18:00 Conclusions and clinical perspectives

O. Mir, Villejuif, FR

16:30 - 17:30 Type: Poster Discussion session Helsinki
Title: Public health and health economics
Chair(s): J. Cuzick, GB; T. Albrecht, SI



- 16:30 - 16:30 1363PD - EMA support for early access for oncology products
S. Thirstrup, Copenhagen, DK
- 16:30 - 16:30 1021PD - What does society value about oncology drugs? A discrete choice experiment in the Belgian population
K. Pauwels, I. Huys, M. Casteels, M. Vandebroek, S. Simoens; Leuven, BE
- 16:30 - 16:30 1365PD - Do contemporary randomized controlled trials meet ESMO thresholds for clinically meaningful benefit?
J. Del Paggio¹, B. Azariah², R. Sullivan³, W. Hopman¹, F. James², S. Roshni², I. Tannock⁴, C. Booth¹;
¹Kingston, CA, ²Thiruvananthapuram (trivandrum), IN, ³London, GB, ⁴Toronto, CA
- 16:30 - 16:30 1366PD - Factors affecting job retention amongst cancer survivors five years after diagnosis: Evidence from the French VICAN survey
C. Alleaume, A.-D. Bouhnik, M. Bendiane, D. Rey, V. Seror, P. Peretti-Watel; Marseille, FR
- 16:30 - 16:50 Invited discussant abstracts 1363PD_PR, 1021PD, 1365PD and 1366PD
T. Albreht, Ljubljana, SI
- 16:50 - 17:00 Questions to discussant
- 17:00 - 17:00 1367PD - Second cancer screening among 5-years women cancer survivors (French National Survey VICAN5)
M. Bendiane, A.-D. Bouhnik, A. Monet, I. Chatta, D. Rey; Marseille, FR
- 17:00 - 17:00 1324PD - A survey among breast cancer specialists on the low uptake of breast cancer preventive therapy with tamoxifen or raloxifene
A. De Censi¹, S. Noonan², A. Pasa¹, S. Caviglia¹, B. Bonanni², A. Costa²; ¹Genova, IT, ²Milano, IT
- 17:00 - 17:00 1325PD - A 'one stop cancer screening shop', a way of improving screening participation rates?
A. Bobridge, K. Price, A. Taylor; Adelaide, SA/AU
- 17:00 - 17:00 1326PD - HIV1-positive men who have sex with men (HIV1-MSM) knowledge and attitudes towards anal cancer screening: A cross-sectional study
A. Vanhaesebrouck¹, S. Pernot², J. Pavie¹, M.L. Lucas¹, L. Collias¹, H. Péré¹, J. Taieb¹, S. Grabar¹, L. Weiss¹; ¹Paris, FR, ²Boulogne-Billancourt, FR
- 17:00 - 17:20 Invited discussant abstracts 1367PD, 1324PD, 1325PD and 1326PD
J. Cuzick, London, GB
- 17:20 - 17:30 Questions to discussant



| | | |
|---------------|---|----------|
| 16:30 - 17:30 | Type: Poster Discussion session Title: CNS tumours Chair(s): A. Hottinger, CH | Brussels |
| 16:30 - 16:30 | 326PD - Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM) <u>A. Lassman</u> ¹ , M. van den Bent ² , H. Gan ³ , D. Reardon ⁴ , P. Kumthekar ⁵ , N. Butowski ⁶ , Z. Lwin ⁷ , T. Mikkelsen ⁸ , L. Nabors ⁹ , K. Papadopoulos ¹⁰ , M. Penas-Prado ¹¹ , J. Simes ¹² , H. Wheeler ¹² , E. Gomez ¹³ , H.-J. Lee ¹³ , L. Roberts-Rapp ¹³ , H. Xiong ¹³ , E. Bain ¹³ , K. Holen ¹³ , R. Merrell ¹⁴ ; ¹ New York, NY/US, ² Rotterdam, NL, ³ Melbourne, VIC/AU, ⁴ Boston, MA/US, ⁵ Chicago, IL/US, ⁶ San Francisco, CA/US, ⁷ Brisbane, QLD/AU, ⁸ Detroit, MI/US, ⁹ Birmingham, AL/US, ¹⁰ San Antonio, TX/US, ¹¹ Houston, TX/US, ¹² Sydney, NSW/AU, ¹³ North Chicago, IL/US, ¹⁴ Evanston, IL/US | |
| 16:30 - 16:30 | 327PD - PD-L1 and IL17 expression in tumor infiltrating lymphocytes are opposite prognostic factors in glioblastoma <u>E. Bronsart</u> ¹ , V. Derangere ² , M. Boone ¹ , B. Chauffert ¹ , F. Ghiringhelli ² ; ¹ Amiens, FR, ² Dijon, FR | |
| 16:30 - 16:30 | 328PD - Effectiveness of antiangiogenic drugs (ADs) in glioblastoma (GBM) patients (PTS): A metanalysis of randomized clinical trials (RCTs) <u>G. Lombardi</u> , L. Bellu, A. Pambuku, V. Zagonel; Padova, IT | |
| 16:30 - 16:50 | Invited discussant abstracts 326PD, 327PD and 328PD <u>A. Hottinger</u> , Lausanne, CH | |
| 16:50 - 17:00 | Questions to discussant | |
| 17:00 - 17:00 | 329PD - Survival of patients with synchronous and metachronous breast cancer and meningioma <u>C. Ribeiro</u> ¹ , L. Mascarenhas ¹ , J.P. Lavrador ¹ , A. Peralta ¹ , M. Valente ² ; ¹ Lisboa, PT, ² Oxford, GB | |
| 17:00 - 17:00 | 330PD - Temporal muscle thickness (TMT) is an independent prognostic parameter in patients with newly diagnosed brain metastases (BM) of breast cancer (BC) <u>A.S. Berghoff</u> ¹ , J. Furtner ¹ , G. Widhalm ¹ , B. Gatterbauer ¹ , U. Dieckmann ¹ , P. Birner ¹ , R. Bartsch ¹ , C. Zielinski ¹ , V. Schöpf ² , M. Preusser ¹ ; ¹ Vienna, AT, ² Graz, AT | |
| 17:00 - 17:00 | 331PD - Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL) <u>C. Grommes</u> ¹ , I. Gavrilovic ¹ , T. Kaley ¹ , C. Nolan ¹ , A. Omuro ² , J. Wolfe ¹ , E. Pentsova ¹ , V. Hatzoglou ¹ , I. Mellinghoff ¹ , L. Deangelis ¹ ; ¹ New York, NY/US, ² New York, US | |
| 17:00 - 17:20 | Invited discussant abstracts 329PD, 330PD and 331PD | |
| 17:20 - 17:30 | Questions to discussant | |



18:00 - 19:30 Type: Patient Advocacy Track Zagreb
 Title: Adherence to therapy: How hard is it to swallow?
 Chair(s): J. Pelouchova, CZ; A. Aguaron, AF

18:00 - 18:20 Nonadherence: Why it happens and what we should do about it
R. Horne, London, GB

18:20 - 18:40 Why don't cancer patients take their drugs as prescribed? Learnings on the patient perspective from the global CML Adherence Study
G. Sharf, Netanya, IL

18:40 - 19:00 Why does drug packaging influence adherence?
G. Standhard, Gouda, NL

19:00 - 19:30 Discussion

18:30 - 20:00 Type: Industry Satellite Symposium Stockholm
 Title: Industry Satellite Symposium

18:30 - 20:00 Type: Industry Satellite Symposium Madrid
 Title: Industry Satellite Symposium or ESMO Colloquium

18:30 - 20:00 Type: Industry Satellite Symposium Oslo
 Title: Industry Satellite Symposium

18:30 - 20:00 Type: Industry Satellite Symposium Rome
 Title: Industry Satellite Symposium

18:30 - 20:00 Type: Industry Satellite Symposium Athens
 Title: Industry Satellite Symposium or ESMO Colloquium

18:30 - 20:00 Type: Industry Satellite Symposium Helsinki
 Title: Industry Satellite Symposium or ESMO Colloquium

18:30 - 20:00 Type: Industry Satellite Symposium Brussels
 Title: Industry Satellite Symposium or ESMO Colloquium

09-10-2016



08:00 - 09:00 Type: Controversy session Rome
 Title: Rectal cancer: What is the optimal time for surgery?
 Chair(s): K.-L. Spindler, DK

08:00 - 08:10 Introduction and first vote
K.-L. Spindler, Aarhus C, DK

08:10 - 08:30 To wait seems better

08:30 - 08:50 The sooner the better
J. Lefevre, Paris, FR

08:50 - 09:00 Second vote and conclusions
K.-L. Spindler, Aarhus C, DK

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Athens
 Title: Will there be a place for adoptive T-cell therapy in the checkpoint inhibitors?

08:00 - 08:30 Will there be a place for adoptive T-cell therapy in the checkpoint inhibitors?
J. Schachter, Tel Hashomer, IL

08:30 - 09:00 Discussion

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Helsinki
 Title: Management of poor risk germ cell tumours

08:00 - 08:30 Management of poor risk germ cell tumours
C. Kollmannsberger, Vancouver, CA

08:30 - 09:00 Discussion

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Brussels
 Title: Challenges in pancreatic cancer

08:00 - 08:30 Challenges in pancreatic cancer
M. Hidalgo, Madrid, ES

08:30 - 09:00 Discussion



08:00 - 09:00 Type: Challenge Your Expert (CYE) session Berlin
Title: What is the clinical utility of gene expression-based tests in early breast cancer?

08:00 - 08:30 What is the clinical utility of gene expression-based tests in early breast cancer?
A. Prat, Barcelona, ES

08:30 - 09:00 Discussion

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Lisbon
Title: Novel criteria for diagnosing multiple myeloma and their therapeutic implications

08:00 - 08:30 Novel criteria for diagnosing multiple myeloma and their therapeutic implications
J. San Miguel, Salamanca, ES

08:30 - 09:00 Discussion

09:00 - 10:30 Type: Educational session Madrid
Title: Upgrading your knowledge on how drug development works nowadays
Chair(s): U. Banerji, GB

09:00 - 09:30 Defining the right dose: When and how
J. Schellens, Amsterdam, NL

09:30 - 10:00 New side effects of novel drugs that you should be aware of
D. Tan, Singapore, SG

10:00 - 10:30 To test or not to test: The role of biomarkers in assisting drug development
U. Banerji, Sutton, GB



| | | |
|---------------|---|------|
| 09:00 - 10:30 | Type: Special Symposium Title: Translating tumour biology into novel therapeutic approaches in HNSCC Chair(s): A. Chan, HK; R. Ferris, US | Oslo |
| 09:00 - 09:05 | Introduction <u>A. Chan</u> , Hong Kong, HK | |
| 09:05 - 09:25 | Targeting tumour hypoxia <u>V. Grégoire</u> , Brussels, BE | |
| 09:25 - 09:45 | Comparison of the genetic landscape of HPV+ and HPV- head and neck cancers <u>P. Brennan</u> , FR | |
| 09:45 - 10:05 | The role of immunotherapy in HNSCC <u>R. Ferris</u> , Pittsburgh, Pa, US | |
| 10:05 - 10:25 | Novel therapeutic strategies in EBV associated NPC <u>A. Chan</u> , Hong Kong, HK | |
| 10:25 - 10:30 | Conclusions and clinical perspectives <u>R. Ferris</u> , Pittsburgh, Pa, US | |



| | | |
|---------------|--|------|
| 09:00 - 10:30 | Type: Special Session Title: Women 4 Oncology Chair(s): S. Thongprasert, TH; S. Peters, CH | Bern |
| 09:00 - 09:10 | Introduction and results of the 2016 W4O survey <u>S. Peters</u> , Lausanne, CH | |
| 09:10 - 09:25 | The role of mentors and sponsorship in women's careers <u>G. Curigliano</u> , Milan, IT | |
| 09:25 - 09:40 | What are the obstacles for female careers in oncology? Perspectives to help form the politics for political change <u>S. Swain</u> , Washington, US | |
| 09:40 - 09:55 | Imagine you were a woman: How would you plan and proceed with your career? <u>C. Zielinski</u> , Vienna, AT | |
| 09:55 - 10:00 | W4O Award Presentation <u>C. Zielinski</u> , Vienna, AT | |
| 10:00 - 10:15 | W4O Award Recipient lecture <u>S. Thongprasert</u> , Chiang Mai, TH | |
| 10:15 - 10:30 | Q&A and Closing remarks | |



| | | |
|---------------|---|------------|
| 09:15 - 10:45 | Type: Special Symposium Title: New molecular challenges in CRC Chair(s): S. Tejpar, BE; P. Pfeiffer, DK | Copenhagen |
| 09:15 - 09:20 | Introduction <u>P. Pfeiffer</u> , Odense C, DK | |
| 09:20 - 09:35 | New classification of CRC: "Gone molecular"? <u>D. Aust</u> , Dresden, DE | |
| 09:35 - 09:50 | Liquid biopsies: Ever closer to daily practice? <u>P. Laurent-Puig</u> , Paris, FR | |
| 09:50 - 10:05 | BRAF mutations: What are the treatment options? <u>F. Loupakis</u> , Livorno, IT | |
| 10:05 - 10:20 | Patients with rare molecular alterations: Do they need a precision approach? <u>S. Siena</u> , Milan, IT | |
| 10:20 - 10:35 | Immunotherapy in mCRC: MSI and beyond <u>N. Segal</u> , New York, Ny, US | |
| 10:35 - 10:45 | Conclusions and clinical perspectives <u>S. Tejpar</u> , Leuven, BE | |



| | | |
|---------------|--|--------|
| 09:15 - 10:45 | Type: Special Session Title: Adaptive licensing (MAPPs) Chair(s): P. Casali, IT; B. Ryll, SE | Zagreb |
| 09:15 - 09:30 | Regulatory perspectives in MAPPs and the EMA pilot <u>F. Pignatti</u> , London, GB | |
| 09:30 - 09:45 | MAPPs from the HTA perspective <u>S. Garner</u> , London, GB | |
| 09:45 - 10:00 | The industry perspective <u>R. Bergstrom</u> , Brussels, BE | |
| 10:00 - 10:15 | A clinician's perspective: Learning from the rare disease community <u>P. Casali</u> , Milano, IT | |
| 10:15 - 10:30 | The patient perspective: Patientcentric drug development <u>B. Ryll</u> , Uppsala, SE | |
| 10:30 - 10:45 | Discussion: Challenges <u>P. Casali</u> ¹ , <u>B. Ryll</u> ² ; ¹ Milano, IT, ² Uppsala, SE | |
| 09:30 - 10:30 | Type: Multidisciplinary patient cases Title: Can immunotherapy be given safely to special subtypes of cancer patients? Chair(s): P. Nathan, GB | Vienna |
| 09:30 - 09:40 | Auto-immunity and cancer immunotherapy <u>P. Nathan</u> , Northwood, GB | |
| 09:40 - 09:50 | Brain metastases and cancer immunotherapy <u>P. Ascierto</u> , Napoli, IT | |
| 09:50 - 10:00 | Chronic viral infections and cancer immunotherapy <u>E. Romano</u> , Lausanne, CH | |
| 10:00 - 10:30 | Discussion | |



| | | |
|---------------|--|-----------|
| 09:30 - 10:30 | Type: Multidisciplinary patient cases Title: How to approach a patient with oligometastatic NSCLC Chair(s): M. Ahmed, GB | Stockholm |
| 09:30 - 09:40 | A simple case <u>M. Ahmed</u> , London, GB | |
| 09:40 - 09:50 | A difficult case <u>N. Reinmuth</u> , Grosshansdorf, DE | |
| 09:50 - 10:00 | An impossible case <u>J. Soerensen</u> , Copenhagen, DK | |
| 10:00 - 10:30 | Discussion | |
| 09:30 - 10:30 | Type: Controversy session Title: Should combined endocrine therapy with targeted agents now be the standard of care for ER+ metastatic breast cancer? Chair(s): M. Gnant, AT | Rome |
| 09:30 - 09:40 | Introduction and first vote <u>M. Gnant</u> , Vienna, AT | |
| 09:40 - 10:00 | Yes | |
| 10:00 - 10:20 | No <u>J. Bergh</u> , Stockholm, SE | |
| 10:20 - 10:30 | Second vote and conclusions <u>M. Gnant</u> , Vienna, AT | |



| | | |
|---------------|---|----------|
| 09:30 - 10:30 | Type: Multidisciplinary patient cases Title: CNS Lymphoma Chair(s): F. Graus, ES | Athens |
| 09:30 - 09:40 | Primary CNS lymphoma <u>F. Graus</u> , Barcelona, ES | |
| 09:40 - 09:50 | Secondary CNS lymphoma <u>A. Ferreri</u> , Milano, IT | |
| 09:50 - 10:30 | Discussion | |
| 09:30 - 10:30 | Type: Challenge Your Expert (CYE) session Title: BRCA testing in ovarian cancer: Who, why, when and how | Helsinki |
| 09:30 - 09:50 | BRCA testing to drive therapy in ovarian cancer <u>E. Pujade-Lauraine</u> , Paris, FR | |
| 09:50 - 10:10 | BRCA testing and prevention in ovarian cancer <u>J. Balmaña</u> , Barcelona, ES | |
| 10:10 - 10:30 | Discussion | |
| 09:30 - 10:30 | Type: Poster Discussion session Title: Genitourinary tumours, prostate Chair(s): M. Sydes, GB; D. Olmos, ES | Brussels |
| 09:30 - 09:30 | 720PD - Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial <u>C. Sweeney</u> ¹ , Y.-H. Chen ¹ , G. Liu ² , M. Carducci ³ , D. Jarrard ² , M. Eisenberger ³ , Y.-N. Wong ⁴ , L. Patrick-Miller ⁵ , N. Hahn ³ , M. Kohli ⁶ , M. Conney ⁷ , R. Dreicer ⁸ , N. Vogelzang ⁹ , J. Picus ¹⁰ , D. Shevrin ⁵ , M. Hussain ¹¹ , J. Garcia ⁷ , R. Dipaola ¹² ; ¹ Boston, MA/US, ² Madison, US, ³ Baltimore, US, ⁴ Philadelphia, US, ⁵ Chicago, US, ⁶ Rochester, US, ⁷ Cleveland, US, ⁸ Charlottesville, US, ⁹ Las Vegas, NV/US, ¹⁰ St Louis, US, ¹¹ Ann Arbor, US, ¹² Lexington, US | |
| 09:30 - 09:30 | 721PD - FIRSTANA: Health-related quality of life (HRQL) and post-hoc analyses for the phase III study assessing cabazitaxel (C) vs docetaxel (D) in chemotherapy-naïve patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) | |



S. Oudard¹, O. Sartor², L. Sengeløv³, G. Daugaard⁴, F. Saad⁵, S. Hansen⁶, M. Hjelm-Eriksson⁷, J. Jassem⁸, A. Thiery-Vuillemin⁹, O. Caffo¹⁰, D. Castellano¹¹, P.N. Mainwaring¹², J. Bernard¹³, L. Shen¹⁴, M. Chadjaa¹, K. Fizazi¹⁵; ¹Paris, FR, ²New Orleans, US, ³Herlev, DK, ⁴Copenhagen, DK, ⁵Montreal, CA, ⁶Odense C, DK, ⁷Stockholm, SE, ⁸Gdansk, PL, ⁹Besançon, FR, ¹⁰Trento, IT, ¹¹Madrid, ES, ¹²Brisbane, AU, ¹³Bridgewater, US, ¹⁴Bridgewater, NJ/US, ¹⁵Villejuif, FR

09:30 - 09:30 722PD - PROSELICA: Health-related quality of life (HRQL) and post-hoc analyses for the phase 3 study assessing cabazitaxel 20 (C20) vs 25 (C25) mg/m² post-docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

J. de Bono¹, A.-C. Hardy-Bessard², C.S. Kim³, L. Géczi⁴, D. Ford⁵, L. Mourey⁶, J. Carles⁷, P. Parente⁸, A. Font⁹, G. Kacsó¹⁰, M. Chadjaa¹¹, W. Zhang¹², J. Bernard¹², M. Eisenberger¹³; ¹London, GB, ²Plérin, FR, ³Seoul, KR, ⁴Budapest, HU, ⁵Birmingham, GB, ⁶Toulouse, FR, ⁷Barcelona, ES, ⁸Melbourne, AU, ⁹Badalona, ES, ¹⁰Cluj Napoca, RO, ¹¹Paris, FR, ¹²Bridgewater, US, ¹³Baltimore, US

09:30 - 09:30 723PD - Modelling relapse in patients with high-risk localised prostate cancer treated randomly in the GETUG 12 phase III trial reveals two populations of relapsing patients

C. Vicier¹, L. Faivre¹, F. Lesaunier², R. Delva³, G. Gravis⁴, F. Rolland⁵, F. Priou⁶, J.-M. Ferrero⁷, N. Houede⁸, L. Mourey⁹, C. Theodore¹⁰, I. Krakowski¹¹, J.-F. Berdah¹², M. Baciuchka⁴, B. Laguerre¹³, A. Flechon¹⁴, S. Oudard¹⁵, M. Habibian¹⁵, S. Culine¹⁵, K. Fizazi¹; ¹Villejuif, FR, ²Caen, FR, ³Angers, FR, ⁴Marseille, FR, ⁵St. Herblain, FR, ⁶La Roche Sur Yon, FR, ⁷Nice, FR, ⁸Nimes, FR, ⁹Toulouse, FR, ¹⁰Suresnes, FR, ¹¹Vandoeuvre Les Nancy, FR, ¹²Hyerres, FR, ¹³Rennes, FR, ¹⁴Lyon, FR, ¹⁵Paris, FR

09:30 - 09:30 724PD - Risk of prostate cancer mortality in men with an initial benign needle core biopsy set: A population based analysis with up to 20 years of follow-up

N. Klemann, J. Helgstrand, K. Brasso, B. Vainer, B. Toft, M. Røder, P. Iversen; Copenhagen, DK

09:30 - 09:50 Invited discussant abstracts 720PD, 721PD, 722PD, 723PD and 724PD

M. Sydes, London, GB

09:50 - 10:00 Questions to discussant

10:00 - 10:00 725PD - Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study

A. Hansen¹, C. Massard², P. Ott³, N. Haas⁴, J. Lopez⁵, S. Ejadi⁶, J. Wallmark⁷, B. Keam⁸, J.-P. Delord⁹, R. Aggarwal¹⁰, M. Gould¹¹, P. Qiu¹¹, S. Saraf¹², S. Keefe¹², S.A. Piha-Paul¹³; ¹Toronto, CA, ²Villejuif, FR, ³Boston, MA/US, ⁴Philadelphia, US, ⁵London, GB, ⁶Scottsdale, AZ/US, ⁷Rockville, US, ⁸Seoul, ⁹Toulouse, FR, ¹⁰San Francisco, US, ¹¹Kenilworth, US, ¹²Kenilworth, NJ/US, ¹³Houston, TX/US

10:00 - 10:00 726PD - Early responses to enzalutamide in AR-V7 positive first line metastatic castration-resistant prostate cancer (mCRPC). A prospective SOGUG clinical trial: The PREMIERE study



E. Grande¹, M. Fernández Pérez², A. Font³, S. Vazquez⁴, B. Mellado⁵, O. Fernandez Calvo⁶, M.J. Méndez Vidal⁷, M. Climent⁸, A. González del Alba⁹, E. Gallardo¹⁰, A. Rodríguez Sánchez¹¹, C. Santander¹², M. Sáez¹³, I. Duran¹⁴, J. Puente¹, T. Alonso Gordo¹, J. Tudela², A. Martínez², D. Castellano¹, E. González Billalabeitia²; ¹Madrid, ES, ²Murcia, ES, ³Badalona, ES, ⁴Lugo, ES, ⁵Barcelona, ES, ⁶Ourense, ES, ⁷Cordoba, ES, ⁸Valencia, ES, ⁹Palma De Mallorca, ES, ¹⁰Sabadell, ES, ¹¹Leon, ES, ¹²Zaragoza, ES, ¹³Malaga, ES, ¹⁴Sevilla, ES

10:00 - 10:00 727PD - Abiraterone acetate (AA) followed by randomization to dasatinib (D) or sunitinib malate (S) in metastatic castrate resistant prostate cancer (mCRPC)

E. Efstathiou¹, A. Tsikkinis², S. Wen¹, E. Li Ning Tapia¹, A. Hoang¹, A. Aparicio¹, S.-M. Tu¹, G. Rangel¹, P. Troncoso¹, P. Corn¹, J. Araujo¹, C. Logothetis¹; ¹Houston, US, ²Houston, TX/US

10:00 - 10:00 728PD - Impact of AR-V7 protein localization in the prediction of therapeutic benefit of taxanes over androgen receptor signaling inhibitors (ARSi) in metastatic castration resistant prostate cancer (mCRPC)

H. Scher¹, R. Graf², N. Schreiber¹, D. Lu², J. Louw², H. Vargas Alvarez¹, R. Bambury³, D. Danila³, B. McLaughlin¹, G. Heller⁴, M. Fleisher¹, R. Dittamore⁵; ¹New York, Ny, US, ²San Diego, CA/US, ³New York, US, ⁴New York, NY/US, ⁵San Diego, US

10:00 - 10:00 729PD - AR-V7 detection in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer

M. Del Re¹, E. Biasco¹, S. Crucitta¹, L. Derosa², E. Rofi¹, A. Farnesi¹, A. Sbrana¹, G. Restante¹, L. Galli¹, A. Falcone¹, G. Jenster³, R. van Schaik³, R. Danesi¹; ¹Pisa, IT, ²Villejuif, FR, ³Rotterdam, NL

10:00 - 10:00 730PD - Prediction of PARP inhibitor response and resistance utilizing a CTC phenotypic classifier in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from the NCI 9012 trial

F. Feng¹, S. Daignault-Newton², A. Jendrisak³, Y. Wang³, S. Greene³, A. Rodriguez³, J. Lee³, L. Dugan³, J. Siddiqui², J. Louw³, C. Johnson³, P. Twardowski⁴, C. Albany⁵, M. Stein⁶, W. Stadler⁷, L. Kunju², A. Chinnaiyan², M. Landers³, R. Dittamore⁸, M. Hussain²; ¹San Francisco, CA/US, ²Ann Arbor, US, ³San Diego, CA/US, ⁴Duarte, US, ⁵Indianapolis, IN/US, ⁶New Brunswick, US, ⁷Chicago, IL/US, ⁸San Diego, US

10:00 - 10:20 Invited discussant abstracts 725PD, 726PD, 727PD, 728PD, 729PD and 730PD

D. Olmos, Madrid, ES

10:20 - 10:30 Questions to discussant

09:30 - 10:30 Type: Challenge Your Expert (CYE) session
Title: What should not be done when treating patients

Lisbon

09:30 - 09:50 What should not be done when treating patients

L. Ostacoli, Turin, IT



| | | |
|---------------|--|------|
| 10:45 - 12:45 | Type: ESMO Clinical Practice Guidelines session Title: ESMO Clinical Practice Guidelines session 1 | Rome |
| 10:45 - 10:55 | Introduction to the ESMO Clinical Practice Guidelines session <u>G. Pentheroudakis</u> , Ioannina, GR | |
| 10:55 - 11:05 | Questionnaire <u>C. Sessa</u> , Bellinzona, CH | |
| 11:05 - 11:15 | Pancreatic cancer case presentation <u>A. Stein</u> , Hamburg, DE | |
| 11:15 - 11:25 | Discussant: <u>M. Ducreux</u> , Villejuif, FR | |
| 11:25 - 11:30 | Q&A | |
| 11:30 - 11:40 | Secondary Myelodysplastic Syndrome case presentation <u>K. Metzeler</u> , Munich, DE | |
| 11:40 - 11:50 | Discussant: <u>P. Fenaux</u> , Bobigny, FR | |
| 11:50 - 11:55 | Q&A | |
| 11:55 - 12:05 | Chronic lymphocytic leukaemia case presentation | |
| 12:05 - 12:15 | Discussant: <u>B. Eichhorst</u> , Cologne, DE | |
| 12:15 - 12:20 | Q&A | |
| 12:20 - 12:30 | Breast cancer, ER positive case presentation <u>J. Ribeiro</u> , Coimbra, PT | |
| 12:30 - 12:40 | Discussant: <u>E. Senkus-Konefka</u> , Gdansk, PL | |
| 12:40 - 12:45 | Q&A | |



| | | |
|---------------|---|------------|
| 11:00 - 12:30 | Type: Proffered Paper session Title: NSCLC, metastatic 1 Chair(s): E. Smit, NL; S. Peters, CH | Copenhagen |
| 11:00 - 11:15 | LBA42_PR - Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): results from the confirmatory phase 3 ASCEND-5 study <u>G. Scagliotti</u> ¹ , T.M. Kim ² , L. Crinò ³ , G. Liu ⁴ , C. Gridelli ⁵ , S. Novello ⁶ , K. Kiura ⁷ , A. Bearz ⁸ , O. Gautschi ⁹ , E. Felip ¹⁰ , M. Nishio ¹¹ , D. Spigel ¹² , T. Mok ¹³ , P. Urban ¹⁴ , S. Deudon ¹⁴ , C. Zheng ¹⁵ , A. Shaw ¹⁶ ; ¹ Orbassano, IT, ² Seoul, KR, ³ Perugia, IT, ⁴ Toronto, CA, ⁵ Avellino, IT, ⁶ Turin, IT, ⁷ Okayama, JP, ⁸ Aviano, IT, ⁹ Luzern, CH, ¹⁰ Barcelona, ES, ¹¹ Tokyo, JP, ¹² Nashville, US, ¹³ Shatin, CN, ¹⁴ Basel, CH, ¹⁵ East Hanover, US, ¹⁶ Boston, US | |
| 11:15 - 11:30 | 1208O - Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM) <u>E. Felip</u> ¹ , S. Orlov ² , K. Park ³ , C.-J. Yu ⁴ , C.-M. Tsai ⁴ , M. Nishio ⁵ , M. Dols ⁶ , M. McKeage ⁷ , W.-C. Su ⁸ , T.S.K. Mok ⁹ , G. Scagliotti ¹⁰ , D. Spigel ¹¹ , V. Passos ¹² , V. Chen ¹² , F. Munarini ¹³ , A. Shaw ¹⁴ ; ¹ Barcelona, ES, ² St-Petersburg, RU, ³ Seoul, KR, ⁴ Taipei, TW, ⁵ Tokyo, JP, ⁶ Malaga, ES, ⁷ Auckland, NZ, ⁸ Tainan, TW, ⁹ Hong Kong, CN, ¹⁰ Orbassano, IT, ¹¹ Nashville, US, ¹² East Hanover, US, ¹³ Basel, CH, ¹⁴ Boston, US | |
| 11:30 - 11:45 | Invited discussant LBA42 and abstract 1208O <u>E. Smit</u> , Amsterdam, NL | |
| 11:45 - 12:00 | LBA43 - Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7) <u>L. Paz-Ares</u> ¹ , E.H. Tan ² , L. Zhang ³ , V. Hirsh ⁴ , K. O'Byrne ⁵ , M. Boyer ⁶ , J. Yang ⁷ , T.S.K. Mok ⁸ , K.H. Lee ⁹ , S. Lu ¹⁰ , Y. Shi ¹¹ , S.-W. Kim ¹² , J. Laskin ¹³ , D.-W. Kim ¹⁴ , S. Laurie ¹⁵ , K. Kölbeck ¹⁶ , J. Fan ¹⁷ , N. Dodd ¹⁸ , A. Märten ¹⁹ , K. Park ¹² ; ¹ Madrid, ES, ² Singapore, SG, ³ Guangzhou, CN, ⁴ Montreal, CA, ⁵ Brisbane, AU, ⁶ Camperdown, AU, ⁷ Taipei, TW, ⁸ Hong Kong, CN, ⁹ Cheongju, Chungbuk, KR, ¹⁰ Shanghai, CN, ¹¹ Beijing, CN, ¹² Seoul, KR, ¹³ Vancouver, CA, ¹⁴ Seongnam-Si, KR, ¹⁵ Ottawa, CA, ¹⁶ Stockholm, SE, ¹⁷ Ridgefield, CT/US, ¹⁸ Bracknell, GB, ¹⁹ Ingelheim, DE | |
| 12:00 - 12:15 | 1201O - Gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive NSCLC after progression on 1st line gefitinib (IMPRESS study): Final overall survival (OS) analysis <u>J.-C. Soria</u> ¹ , S.-W. Kim ² , Y.-L. Wu ³ , K. Nakagawa ⁴ , J.-J. Yang ³ , M.-J. Ahn ² , J. Wang ⁵ , J.C.-H. Yang ⁶ , Y. Lu ⁷ , S. Atagi ⁸ , S. Ponce Aix ⁹ , Y. Rukazenkov ¹⁰ , R. Taylor ¹⁰ , T.S.K. Mok ¹¹ ; ¹ Villejuif, FR, ² Seoul, KR, ³ Guangzhou, CN, ⁴ Osaka-Sayama, JP, ⁵ Beijing, CN, ⁶ Taipei, TW, ⁷ Sichuan, CN, ⁸ Sakai, JP, ⁹ Madrid, ES, ¹⁰ Macclesfield, GB, ¹¹ Hong Kong, CN | |
| 12:15 - 12:30 | Invited discussant LBA43 and abstract 1201O <u>P. Jänne</u> , Boston, US | |



| | | |
|---------------|---|--------|
| 11:00 - 12:30 | Type: Proffered Paper session Title: Gastrointestinal tumours, non-colorectal 2 Chair(s): I. Chau, GB | Vienna |
| 11:00 - 11:15 | 612O - Clinical next generation sequencing (NGS) of esophagogastric (EG) adenocarcinomas identifies distinct molecular signatures of response to HER2 inhibition, first-line 5FU/platinum and PD1/CTLA4 blockade <u>Y. Janjigian</u> ¹ , F. Sanchez-Vega ² , P. Jonsson ¹ , Y. Tuvy ¹ , N. Bouvier ¹ , J. Riches ¹ , R. Kundra ¹ , G. Ku ² , J. Hechtman ² , D. Kelsen ¹ , L. Tang ² , D. Ilson ¹ , E. Vakiani ² , Z. Stadler ¹ , M. Callahan ¹ , D. Solit ¹ , M. Berger ¹ , B. Taylor ¹ , N. Schultz ¹ ; ¹ New York, US, ² New York, NY/US | |
| 11:15 - 11:30 | 613O - Genomic profiling of small bowel adenocarcinoma: Insights from a comparative analysis with gastric and colorectal cancer and opportunities for targeted therapy <u>A. Schrock</u> ¹ , C. Devoe ² , R. McWilliams ³ , J. Sun ¹ , J. Ruggiero ⁴ , P. Stephens ⁵ , J. Ross ⁶ , R. Wilson ⁷ , V. Miller ¹ , S. Ali ¹ , M. Overman ⁸ ; ¹ Cambridge, US, ² Lake Success, US, ³ Rochester, US, ⁴ New York, US, ⁵ Cambridge, MA/US, ⁶ Albany, NY/US, ⁷ Belfast, GB, ⁸ Houston, TX/US | |
| 11:30 - 11:45 | Invited discussant abstracts 612O and 613O <u>F. Carneiro</u> , Porto, PT | |
| 11:45 - 12:00 | 614O - Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma <u>M. Schuler</u> ¹ , S.-E. Al-Batran ² , Z. Zvirbule ³ , G. Manikhas ⁴ , F. Lordick ⁵ , A. Rusyn ⁶ , Y. Vinnyk ⁷ , I. Vynnychenko ⁸ , N. Fadeeva ⁹ , M. Nechaeva ¹⁰ , A. Dudov ¹¹ , E. Gotovkin ¹² , A. Pechenyi ¹³ , I. Bazin ¹⁴ , I. Bondarenko ¹⁵ , B. Melichar ¹⁶ , C. Huber ¹⁷ , Ö. Türeci ¹⁷ , U. Sahin ¹⁷ ; ¹ Essen, DE, ² Frankfurt, DE, ³ Riga, LV, ⁴ St-Petersburg, RU, ⁵ Leipzig, DE, ⁶ Uzhhorod, UA, ⁷ Kharkiv, UA, ⁸ Sumy, UA, ⁹ Chelyabinsk, RU, ¹⁰ Arkhangelsk, RU, ¹¹ Sofia, BG, ¹² Ivanovo, RU, ¹³ Orel, RU, ¹⁴ Moscow, RU, ¹⁵ Dnepropetrovsk, UA, ¹⁶ Olomouc, CZ, ¹⁷ Mainz, DE | |
| 12:00 - 12:15 | 615O - Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study <u>I. Melero</u> ¹ , B. Sangro ¹ , T. Yau ² , C. Hsu ³ , M. Kudo ⁴ , T. Crocenzi ⁵ , T.-Y. Kim ⁶ , S.-P. Choo ⁷ , J. Trojan ⁸ , T. Meyer ⁹ , T. Welling III ¹⁰ , W. Yeo ² , A. Chopra ⁷ , J. Anderson ¹¹ , C. Dela Cruz ⁷ , L. Lang ¹¹ , J. Neely ¹¹ , A. El-Khoueiry ¹² ; ¹ Pamplona, ES, ² Hong Kong, CN, ³ Taipei, TW, ⁴ Osaka, JP, ⁵ Portland, OR/US, ⁶ Seoul, KP, ⁷ Singapore, SG, ⁸ Frankfurt Am Main, DE, ⁹ London, GB, ¹⁰ Ann Arbor, US, ¹¹ Princeton, NJ/US, ¹² Los Angeles, CA/US | |
| 12:15 - 12:30 | Invited discussant abstracts 614O and 615O <u>I. Chau</u> , Sutton, GB | |



| | | |
|---------------|--|-----------|
| 11:00 - 12:30 | Type: Special Symposium Title: Treatment options in patients with early breast cancer and BRCA mutation or family history of cancer Chair(s): H. Bonnefoi, FR; A. Tutt, GB | Stockholm |
| 11:00 - 11:05 | Introduction <u>H. Bonnefoi</u> , Bordeaux, FR | |
| 11:05 - 11:25 | Surgical options <u>M. Menke-Pluijmers</u> , Dordrecht, NL | |
| 11:25 - 11:45 | Systemic therapy <u>A. Tutt</u> , London, GB | |
| 11:45 - 12:05 | Patient's preference <u>K. Benn</u> , Milan, IT | |
| 12:05 - 12:25 | Fertility issues <u>H.A. Azim Jr.</u> , Brussels, BE | |
| 12:25 - 12:30 | Conclusions and clinical perspectives <u>A. Tutt</u> , London, GB | |
| 11:00 - 12:30 | Type: Educational session Title: Multimodality treatment for hormone-naïve metastatic prostate cancer Chair(s): S. Gillissen, CH; A. Heidenreich, DE | Madrid |
| 11:00 - 11:30 | Docetaxel for prostate cancer: Best timing and right patient <u>N. James</u> , Birmingham, GB | |
| 11:30 - 12:00 | Radiation to the primary tumour in metastatic disease: When and whom <u>A. Bossi</u> , London, GB | |
| 12:00 - 12:30 | Does radical prostatectomy have an impact on long-term outcomes of patients with metastatic prostate cancer? <u>A. Heidenreich</u> , Cologne, DE | |



| | | |
|---------------|--|--------|
| 11:00 - 12:30 | Type: Joint Symposium Title: Joint Symposium ESMO-CSCO: How to translate cancer science to the clinics Chair(s): J. Tabernero, ES; Y.-L. Wu, CN | Oslo |
| 11:00 - 11:05 | Introduction <u>Y.-L. Wu</u> , Guangzhou, CN | |
| 11:05 - 11:25 | Biomarkers for immunotherapy treatment <u>G. Coukos</u> , Epalinges, CH | |
| 11:25 - 11:45 | How to implement limited vs full exome NGS in the clinical practice? <u>X.-C. Zhang</u> , Guangzhou, CN | |
| 11:45 - 12:05 | BRAF mutant population in colorectal cancer: Example of rapid transition from bench to bedside and back <u>J. Tabernero</u> , Barcelona, ES | |
| 12:05 - 12:25 | ALK fusion in cancer <u>Y.-L. Wu</u> , Guangzhou, CN | |
| 12:25 - 12:30 | Conclusions and clinical perspectives <u>J. Tabernero</u> , Barcelona, ES | |
| 11:00 - 12:30 | Type: Joint Symposium Title: Joint Symposium ESMO-EORTC-EACR: What has melanoma taught us about targeted therapies and immunotherapy? Chair(s): R. Marais, GB; R.A. Stahel, CH; R. Stupp, CH | Athens |
| 11:00 - 11:05 | Introduction <u>R.A. Stahel</u> , Zürich, CH | |
| 11:05 - 11:25 | Where next in targeted therapies and melanoma? <u>R. Marais</u> , Manchester, GB | |
| 11:25 - 11:45 | Where next in immunotherapy and melanoma? <u>P. Ascierto</u> , Napoli, IT | |
| 11:45 - 12:05 | How do we combine targeted therapies and immunotherapy? <u>C. Robert</u> , Villejuif, FR | |
| 12:05 - 12:25 | Patient advocacy initiatives <u>B. Ryll</u> , Uppsala, SE | |
| 12:25 - 12:30 | Conclusions and clinical perspectives <u>R. Stupp</u> , Zürich, CH | |



| | | |
|---------------|---|----------|
| 11:00 - 12:00 | Type: Multidisciplinary patient cases Title: Systemic treatment for atypical GIST patients Chair(s): <u>W. van der Graaf</u> , GB | Helsinki |
| 11:00 - 11:10 | Frail elderly <u>R. Jones</u> , London, GB | |
| 11:10 - 11:20 | Drug interactions <u>O. Mir</u> , Villejuif, FR | |
| 11:20 - 11:30 | Local treatments in oligometastatic disease <u>A. Gronchi</u> , Milan, IT | |
| 11:30 - 12:00 | Discussion | |
| 11:00 - 12:30 | Type: Special Session Title: Practising quality oncology across Europe and beyond: How can we get there? Existing projects and future outlooks Chair(s): <u>D. Arnold</u> , DE; <u>S. Rauh</u> , LU | Brussels |
| 11:00 - 11:05 | Introduction <u>D. Arnold</u> , Freiburg, DE | |
| 11:05 - 11:15 | Quality improvement in centre structures. Experience within the German Cancer Society accreditation system <u>J. Bruns</u> , Berlin, DE | |
| 11:15 - 11:25 | What is meant by "quality in oncology care"? <u>P. Castel</u> , Paris, FR | |
| 11:25 - 11:35 | Accreditation and Designation of Comprehensive Cancer Centres in Europe, the OECl's challenge <u>S. Oberst</u> , Cambridge, GB | |
| 11:35 - 12:10 | Round table panel discussion | |
| 12:10 - 12:25 | Q&A | |
| 12:25 - 12:30 | Conclusions <u>S. Rauh</u> , Esch-Sur-alzette, LU | |



| | | |
|---------------|--|--------|
| 11:00 - 12:30 | Type: Special Symposium Title: Moving steps forward: What's new in the treatment of brain tumours Chair(s): P. Wen, US; A. Brandes, IT | Berlin |
| 11:00 - 11:05 | Introduction <u>A. Brandes</u> , Bologna, IT | |
| 11:05 - 11:25 | Immunotherapy for glioblastoma: Quo vadis? <u>M. Weller</u> , Zürich, CH | |
| 11:25 - 11:45 | Identifying and overcoming challenges in immunotherapy for brain tumours: The iRANO approach <u>P. Wen</u> , Boston, Ma, US | |
| 11:45 - 12:05 | Targeting angiogenesis in high-grade gliomas: The long and winding road <u>E. Galanis</u> , Rochester, Mn, US | |
| 12:05 - 12:25 | How can we deal with the toxicity of new agents? <u>D. Blumenthal</u> , IL | |
| 12:25 - 12:30 | Conclusions and clinical perspectives <u>P. Wen</u> , Boston, Ma, US | |



11:00 - 12:30 Type: Proffered Paper session Bern
Title: Haematological malignancies
Chair(s): P. Johnson, GB

11:00 - 11:15 906O - Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR
K. Weisel¹, A. Palumbo², A. Chanan-Khan³, A. Nooka⁴, I. Spicka⁵, T. Masszi⁶, M. Beksac⁷, V. Hungria⁸, M. Munder⁹, M.-V. Mateos¹⁰, T. Mark¹¹, A. Spencer¹², M. Qi¹³, J. Schecter¹⁴, H. Amin¹⁴, X. Qin¹⁵, W. Deraedt¹⁶, T. Ahmadi¹³, P. Sonneveld¹⁷; ¹Tuebingen, DE, ²Torino, IT, ³Jacksonville, FL/US, ⁴Atlanta, GA/US, ⁵Prague, CZ, ⁶Budapest, HU, ⁷Ankara, TR, ⁸São Paulo, BR, ⁹Mainz, DE, ¹⁰Salamanca, ES, ¹¹New York, NY/US, ¹²Melbourne, VIC/AU, ¹³Spring House, PA/US, ¹⁴Raritan, NJ/US, ¹⁵Horsham, PA/US, ¹⁶Beerse, BE, ¹⁷Rotterdam, NL

11:15 - 11:30 907O - Safety and efficacy of clarithromycin monotherapy in patients (pts) with extranodal marginal zone lymphoma (EMZL)
C. Cecchetti¹, B. Kiesewetter², M. Sassone¹, T. Calimeri¹, L. Scarfò¹, M. Raderer², A. Ferreri¹; ¹Milano, IT, ²Vienna, AT

11:30 - 11:45 Invited discussant abstracts 906O and 907O
A. Lopez-Guillermo, Barcelona, ES

11:45 - 12:00 908O - High-dose methotrexate (HD-MTX) as CNS prophylaxis significantly improves outcome in patients with high-risk diffuse large B-cell lymphoma (DLBCL)
T. Calimeri, C. Cecchetti, A. Vignati, M. Sassone, M. Foppoli, L. Scarfò, M. Ponzoni, A. Ferreri; Milano, IT

12:00 - 12:15 909O - R-da-EPOCH vs R-CHOP in patients with primary mediastinal large B-cell lymphoma: Results of randomised (prospective) multicenter study
I. Kryachok¹, I. Stepanishyna², I. Tytorenko¹, A. Martynchyk¹, K. Filonenko¹, O. Novosad¹, T. Kadnikova¹, I. Pastushenko¹, Y. Kushchevyy¹, T. Skrypets¹, O. Aleksyk¹, K. Ulianchenko¹; ¹Kiev, UA, ²Kyiv, UA

12:15 - 12:30 Invited discussant abstracts 908O and 909O
P. Johnson, London, GB

11:00 - 12:00 Type: Young Oncologist Brunch Lisbon
Title: How to find the best literature for your paper: Pubmed and other academic databases
Chair(s): M. Ozturk, TR; J. Corral, ES

11:00 - 11:45 How to find the best literature for your paper: Pubmed and other academic databases
E. Harriss, Oxford, GB

11:45 - 12:00 Interactive discussion with audience



| | | |
|---------------|---|-----------|
| 13:00 - 13:45 | Type: Keynote lecture Title: The art of the possible: Bridging the gap between genomics and patient care? Chair(s): R. Marais, GB | Vienna |
| 13:00 - 13:45 | The art of the possible: Bridging the gap between genomics and patient care? <u>E. Voest</u> , Amsterdam, NL | |
| 13:00 - 14:30 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Stockholm |
| 13:00 - 14:30 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium | Madrid |
| 13:00 - 14:30 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Oslo |
| 13:00 - 14:30 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Athens |
| 13:00 - 14:30 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium | Helsinki |
| 13:00 - 14:30 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium | Brussels |
| 13:00 - 14:30 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium | Berlin |



| | | |
|---------------|---|--------|
| 13:00 - 14:30 | Type: Patient Advocacy Track Title: Immuno-Oncology (I.O.) Chair(s): M. Wartenberg, DE; R. Giles, NL | Zagreb |
| 13:00 - 13:15 | How to use the immune system to fight cancer and how different types of immune therapies work? <u>P. Nathan</u> , Northwood, GB | |
| 13:15 - 13:30 | Practical experiences and challenges of patients and patient groups with Immuno-Oncology: Our experiences in research & clinic using IO in melanoma <u>G. Spurrier-Bernard</u> , Clermont-Ferrand, FR | |
| 13:30 - 13:45 | Practical experiences and challenges of patients and patient groups with Immuno-Oncology: Our experiences in research & clinic using IO in lung cancer <u>S. Vallone</u> , Orbassano, IT | |
| 13:45 - 14:00 | Practical experiences and challenges of patients and patient groups with Immuno-Oncology: Our experiences in research & clinic using IO in kidney cancer <u>R. Giles</u> , Utrecht, NL | |
| 14:00 - 14:30 | Panel Discussion <u>M. Wartenberg</u> ¹ , <u>R. Giles</u> ² ; ¹ Wölfersheim-Berstadt, DE, ² Utrecht, NL | |
| 13:00 - 14:00 | Type: Poster Display Title: Poster display | Hall E |
| 13:00 - 13:00 | CNS tumours | |
| 13:00 - 13:00 | 332P - The pharmacokinetics of methotrexate with and without rituximab in the treatment of primary central nervous system lymphoma (PCNSL) <u>F. Rawat</u> ¹ , A. Nolan ² , S.Y. Teo ² , M. Triggs ² , G. Carroll ² , S. Picardo ² , N. Keegan ² , V. Mallett ² , I. Ismail ² , B. Hennessy ² , W. Grogan ² , O. Breathnach ² , P. Morris ² ; ¹ Dublin, IE/IE, ² Dublin, IE | |
| 13:00 - 13:00 | 333P - IMRT and temozolomide for grade III glioma: Clinical and prognostic factors <u>T. Basu</u> , T. Kataria, S. Goyal, D. Gupta, A. Abhishek, S. Bisht; Gurgaon, IN | |
| 13:00 - 13:00 | 334P - Treatment outcome in medulloblastoma with the POG 9031 protocol : A single institution review <u>A. Philip</u> ¹ , V. Munirathnam ² , K. Pavithran ¹ , J. Wesley M ¹ , D. Poorna ¹ , D. M ¹ , R. Pillai ¹ ; ¹ Cochin, IN, ² Kochi, IN | |
| 13:00 - 13:00 | 335P - Phase II study of single agent buparlisib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL) <u>C. Grommes</u> , E. Pentsova, C. Nolan, J. Wolfe, I. Mellinshoff, L. Deangelis; New York, NY/US | |
| 13:00 - 13:00 | 336P - Case report of the effective use of BRAF inhibitor vemurafenib in a patient with relapse of pleomorphic xanthoastrocytoma | |



D. Naskhletashvili, Moscow, RU

- 13:00 - 13:00 337P - MGMT promoter methylation status in glioblastoma (GBM) patients: A quantitative pyrosequencing approach and its prognostic role
A. Pambuku, G. Lombardi, R. Bertorelle, L. Bellu, P. Fiduccia, M. Gardiman, A. Della Puppa, F. Berti, D. D'Avella, V. Zagonel; Padova, IT
- 13:00 - 13:00 338P - DNA methylated (Met) patients (p) with glioblastoma (GBM) have a better prognosis with an earlier response (ER) than those who have a late response or pseudoprogression (LR/PsP). Results of the Gliocat study
A. Estival¹, E. Pineda², M. Martinez-Garcia², J. Marruecos³, C. Mesía⁴, A. Lucas², M. Macia², M. Gil⁴, O. Gallego², E. Verger², S. Del Barco³, R. Fuentes³, J. Craven², N. García¹, S. Villà¹, J.M. Velarde¹, C. Carrato¹, T. Ribalta², O. Arpi², C. Balana¹; ¹Badalona, ES, ²Barcelona, ES, ³Girona, ES, ⁴L'hospitalet De Llobregat, Barcelona, ES
- 13:00 - 13:00 339P - First steps in the definition of a prognostic score based on MGMT methylation status in patients with glioblastoma
E. De Carlo, L. Gurrieri, G. De Maglio, L. Gerratana, V. Buoro, S. Rizzato, M. Isola, M. Skrap, G. Fasola, F. Puglisi, S. Pizzolitto; Udine, IT
- 13:00 - 13:00 340P - The study of MIB-1 LI and CD-34 as a marker of proliferative activity and angiogenesis in different grades of meningioma
H. Bohra, Jodhpur, IN
- 13:00 - 13:00 341P - Clinical correlation of cancer stem cells in low and high grade glioma of North Indian population
D. Mohania¹, R. Acharya², S. Kalra², K. Jain², D. Tripathi², S. Chandel², S. Mohania², K. Choudhury², S. Jain², S. Bhalla²; ¹New Delhi, IN, ²Delhi, IN
- 13:00 - 13:00 342P - Analysis of EGFRvIII and EGFR overexpression in glioma and its prognostic significance
V. Munirathnam¹, A. Philip², B. R², S. Km², K. Pavithran², J. Wesley M²; ¹Kochi, IN, ²Cochin, IN
- 13:00 - 13:00 343P - The role of ABO blood groups in glial neoplasia
A. Alkan, G. Yazıcı, M. Cengiz, İ. Çelik, A. Kars, F. Zorlu; Ankara, TR
- 13:00 - 13:00 344P - TERT as a prognostic factor for gliomas progression-free survival (PFS)
M.P. Solis Hernandez¹, L. Faez¹, D. Cantero², A. Hernandez Lain², P. Sanchez Gomez², Y. Ruano², M.D.M. Galera², J.M. Sepúlveda Sánchez²; ¹Oviedo, ES, ²Madrid, ES
- 13:00 - 13:00 345P - Concomitant chemoradiation (Ch-RT) in elderly newly diagnosed glioblastoma (GB) patients. Updated clinical outcome and molecular characteristics from the GLIOCAT study
M. Martinez-Garcia¹, E. Pineda¹, S. Del Barco², A. Estival³, E. Verger¹, J. Marruecos², O. Gallego¹, M. Gil⁴, R. Fuentes², J. Craven-Bartle Lamote de Grigno¹, A. Lucas¹, M. Macia¹, C. Mesía⁴, J.M. Velarde³, N. García³, S. Villà³, C. Balana³; ¹Barcelona, ES, ²Girona, ES, ³Badalona, ES, ⁴L'hospitalet De Llobregat, Barcelona, ES
- 13:00 - 13:00 346P - A prospective analysis of quality of life (QoL), cognitive functions (CF) and psychological status (PSY) in glioblastoma (GBM) patients (PTS) treated with RT and temozolomide (TMZ)



E. Bergo, G. Lombardi, P. Del Bianco, F. Berti, L. Bellu, A. Pambuku, V. Zagonel; Padova, IT

- 13:00 - 13:00 347P - Long-term survivors (LTS) in glioblastoma (GBM) patients (pts) homogeneously treated with the Stupp regimen, clinical and molecular characteristics (MGMT and IDH1 status). Initial results from the GLIOCAT study
E. Pineda¹, M. Martinez-Garcia¹, A. Estival², M. Gil-Gil¹, S. Del Barco³, O. Gallego¹, E. Verger¹, J. Marruecos³, R. Fuentes³, J. Craven-Bartle Lamote de Grigno¹, C. Mesía⁴, N. García², F. Alameda¹, J.M. Velarde², T. Pujol¹, L. Oleaga¹, C. Carrato², J. Capellades¹, S. Villà², C. Balana²; ¹Barcelona, ES, ²Badalona, ES, ³Girona, ES, ⁴L'hospitalet De Llobregat, Barcelona, ES
- 13:00 - 13:00 348P - Characteristics of glioblastomas (GBM) not resected (only biopsied) homogeneously treated with Stupp regimen. Results from the GLIOCAT study
O. Gallego¹, A. Estival², M. Martinez-Garcia¹, E. Pineda¹, M. Gil³, S. Del Barco⁴, J. Marruecos⁴, E. Verger¹, R. Fuentes⁴, J.M. Velarde², C. Mesía³, J. Craven¹, S. Bague Rosell¹, C. Quintana¹, L. Del Carpio Huerta¹, E. Granel¹, B. Gómez¹, N. García², S. Villà², C. Balana²; ¹Barcelona, ES, ²Badalona, ES, ³L'hospitalet De Llobregat, Barcelona, ES, ⁴Girona, ES
- 13:00 - 13:00 349P - Anaplastic astrocytoma (AA) and glioblastoma (GBM): A real-life experience in Padua Neuro-Oncology Center
G. Lombardi, A. Pambuku, L. Bellu, P. Fiduccia, A. Della Puppa, M. Gardiman, F. Berti, D. D'Avella, V. Zagonel; Padova, IT
- 13:00 - 13:00 350P - Extended adjuvant temozolamide as prognostic factor of longer overall and progression-free survival in glioblastoma multiforme
S. Póvoa, N. Tavares, M. Ribeiro, D. Azevedo, A. Coelho, A. Fernandes, A. Costa, C. Caeiro, B. Carvalho, P. Linhares, L. Osório, L. Castro, J. Fonseca, M. Damasceno; Porto, PT
- 13:00 - 13:00 351P - Brain metastases in NSCLC patients in the era of precision medicine
S. Mpima, C. Anger, L. Mitrofan; London, GB
- 13:00 - 13:00 352P - Functional status of central nervous system in intensive radiotherapy for brain metastases
M. Zinkovich¹, O. Kit¹, T. Protasova¹, A. Pushkin¹, Y. Arapova¹, E. Korobeynikova¹, A. Shikhlyarova¹, L. Vladimirova²; ¹Rostov On Don, RU, ²Rostov-On-don, RU
- 13:00 - 13:00 353P - Metformin as an adjuvant anticancer therapy in the treatment of high grade glioma
D. Chong, C.K. Tham, W.H. Ng, L.-L. Kwok, E. Aliwarga, Y.L. Kok, P. Lam; Singapore, SG
- 13:00 - 13:00 354P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide In patients with glioblastoma (ART): Interim analysis report
A. Altwairgi, W. Alghareeb, F. Alnajjar, E. Alsaeed, A. Balbaid, H. Alhussain, S. Aldanan, Y. Orz, A. Lari, A. Alsharm; Riyadh, SA
- 13:00 - 13:00 355TiP - METIS: A phase III study of radiosurgery with TTFIELDS for 1-10 brain metastases from NSCLC
M. Mehta¹, V. Gondi², P. Brown³; ¹Baltimore, US, ²Chicago, US, ³Houston, TX/US



- 13:00 - 13:00 356TiP - A randomized phase 2, single-blind study of temozolomide (TMZ) and radiotherapy (RT) combined with nivolumab or placebo (PBO) in newly diagnosed adult patients (pts) with tumor O6-methylguanine DNA methyltransferase (MGMT)-methylated glioblastoma (GBM)—CheckMate-548
M. Weller¹, G. Vlahovic², M. Khasraw³, A. Brandes⁴, R. Zwiertes⁵, K. Tatsuoka⁵, A. Carpentier⁶, D. Reardon⁷, M. van den Bent⁸; ¹Zürich, CH, ²Durham, US, ³Sydney, AU, ⁴Bologna, IT, ⁵Princeton, NJ/US, ⁶Bobigny, FR, ⁷Boston, MA/US, ⁸Rotterdam, NL
- 13:00 - 13:00 Genitourinary tumours, prostate
- 13:00 - 13:00 731P - Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC): Study update
M. Morris¹, N. Vogelzang², O. Sartor³, A. Armour⁴, D. Petrylak⁵, A. Tolcher⁶, S. Ejadi⁷, H. Babiker⁷; ¹New York, US, ²Las Vegas, NV/US, ³New Orleans, US, ⁴Indianapolis, IN/US, ⁵New Haven, US, ⁶San Antonio, US, ⁷Scottsdale, AZ/US
- 13:00 - 13:00 732P - A phase II study of TKI258 in patients with castration-resistant prostate cancer (KCSG-GU11-05)
Y.J. Choi¹, H.S. Kim², S.H. Park¹, B.S. Kim¹, K.H. Kim¹, H.J. Lee³, H.S. Song⁴, D.Y. Shin¹, H.Y. Lee⁵, H.-G. Kim⁶, K.H. Lee⁴, J.-L. Lee¹, K.H. Park¹; ¹Seoul, KR, ²Goyang, KR, ³Daejeon, KR, ⁴Daegu, KR, ⁵Busan, KR, ⁶Jinju, KR
- 13:00 - 13:00 733P - E2809. Androgen receptor (AR) modulation by bicalutamide (Bic) and MK-2206 (MK) in prostate cancer (PC) patients (pts) with rising PSA at high risk of progression after local treatment (tx)
A. Ferrari¹, Y.-H. Chen², G. Hudes³, M. Carducci⁴, E. Antonarakis⁵, N. Hahn⁶, H. Ma⁷, Y.-N. Wong⁸, T. Mayer¹, R. Somer⁹, B. Carthon¹⁰, R. Dipaola¹; ¹New Brunswick, NJ/US, ²Boston, MA/US, ³Philadelphia, PA/US, ⁴Baltimore, US, ⁵Baltimore, MD/US, ⁶Indianapolis, IN/US, ⁷New York, NY/US, ⁸Philadelphia, US, ⁹Camden, NJ/US, ¹⁰Atlanta, GA/US
- 13:00 - 13:00 734P - Neo/adjuvant ADT to EBRT: Randomized phase 2 trial of the oral GnRH antagonist, TAK-385 (relugolix, RGX) and degarelix (DGX) in patients (pts) with prostate cancer (PC)
D. Dearnaley¹, D. Saltzstein², J. Sylvester³, L. Karsh⁴, B. Mehlhaff⁵, C. Pieczonka⁶, J. Bailen⁷, D. Maclean⁸, S. Sankoh⁸, H. Faessel⁸, H.M. Lin⁸, N. Shore⁹; ¹London, GB, ²San Antonio, TX/US, ³Bradenton, FL/US, ⁴Denver, CO/US, ⁵Springfield, OR/US, ⁶Syracuse, NY/US, ⁷Jeffersonville, IN/US, ⁸Cambridge, MA/US, ⁹Myrtle Beach, SC/US
- 13:00 - 13:00 735P - PSA-PFS in metastatic or high risk prostate cancer patients treated with GnRH antagonist (degarelix) versus LHRH agonists – A pooled analysis of data from the Americas, Europe and Asia
N. Shore¹, Z. Bosnyak², M. Gittelman³, A. Malmberg², P.-A. Abrahamsson², L.-P. Xie⁴; ¹Myrtle Beach, SC/US, ²Copenhagen, DK, ³Aventura, FL/US, ⁴Hangzhou, CN
- 13:00 - 13:00 736P - Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): A phase II trial in men with metastatic castrate resistant prostate cancer (mCRPC)
A. Hansen¹, I. Tannock¹, A. Templeton², A. Prawira¹, J. Knox³, F. Vera-Badillo¹, E. Chen³, M.B. Zavitz¹, L. Wang³, A. Evans³, Q. Tan³, B. Wouters³, S. Sridhar³, A. Joshua³; ¹Toronto, CA, ²Basel, CH, ³Toronto, ON/CA



- 13:00 - 13:00 737P - Increased choline uptake in androgen receptor (AR) copy number gain castration-resistant prostate cancers (CRPC)
V. Conteduca¹, V. Casadio¹, P. Caroli¹, E. Scarpi¹, C. Lolli¹, C. Menna¹, E. Bianchi², G. Schepisi¹, S. Testoni¹, G. Gurioli¹, S. Salvi¹, D. Amadori¹, G. Paganelli¹, F. Matteucci¹, G. Attard³, U. De Giorgi¹; ¹Meldola, IT, ²Rimini, IT, ³Sutton, GB
- 13:00 - 13:00 738P - Meta-analysis of randomized clinical trials in metastatic castration resistant prostate cancer: Comparison of hypertension, neurological and psychiatric adverse events on enzalutamide and abiraterone acetate plus prednisone treatment
P. Ruiz Gracia¹, L. Dearden¹, L. Antoni², R. Parra Gabilondo¹, A. Garcia Garcia-Porrero¹, M. Iznaola¹; ¹Madrid, ES, ²Paris, FR
- 13:00 - 13:00 739P - Fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide: data from randomised clinical trials
S. Chowdhury¹, N. Shore², F. Saad³, C. Higano⁴, K. Fizazi⁵, P. Iversen⁶, K. Miller⁷, A. Heidenreich⁸, T. Ueda⁹, C.S. Kim¹⁰, D. Phung¹¹, A. Krivoshik¹², F. Wang¹³, K. Wu¹³, B. Tombal¹⁴; ¹London, GB, ²Myrtle Beach, SC/US, ³Montreal, CA, ⁴Seattle, US, ⁵Paris, FR, ⁶Copenhagen, DK, ⁷Berlin, DE, ⁸Cologne, DE, ⁹Chiba, JP, ¹⁰Seoul, KR, ¹¹Leiden, NL, ¹²Chicago, US, ¹³San Francisco, CA/US, ¹⁴Brussels, BE
- 13:00 - 13:00 740P - Safety of long-term (LT) treatment (tmt) of chemotherapy (chemo)-naïve metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with abiraterone acetate plus prednisone (AA + P) for ≥ 4 years (yrs)
J. Carles¹, I. Davis², J. de Bono³, K. Fizazi⁴, W. Gerritsen⁵, D. Rathkopf⁶, C. Ryan⁷, F. Saad⁸, T. Steuber⁹, G. Wilding¹⁰, Y. Park¹¹, R. Charnas¹², P. De Porre⁴, H. Van Poppel¹³; ¹Barcelona, ES, ²Box Hill, AU, ³London, GB, ⁴Villejuif, FR, ⁵Nijmegen, NL, ⁶New York, NY/US, ⁷San Francisco, CA/US, ⁸Montreal, CA, ⁹Hamburg, DE, ¹⁰Houston, TX/US, ¹¹Raritan, NJ/US, ¹²Los Angeles, CA/US, ¹³Leuven, BE
- 13:00 - 13:00 741P - Prevalence and severity of fatigue in castration-resistant prostate cancer in Spain: VITAL study
L. Martínez-Piñero¹, A. Rodríguez Antolín¹, M.E. Jiménez Romero², J.B. García Ramos³, D. Lopez Bellido⁴, P. Ruiz Gracia¹, A. Garcia Garcia-Porrero¹, F. Gomez Veiga⁵; ¹Madrid, ES, ²Cadiz, ES, ³Huelva, ES, ⁴Ourense, ES, ⁵Salamanca, ES
- 13:00 - 13:00 742P - Clinical outcomes and testosterone levels following continuous androgen deprivation (CAD) in patients with relapsing or locally advanced prostate cancer (PC): A post hoc analysis of the ICELAND study
B. Tombal¹, E. Cornel², V. Matveev³, T. Tammela⁴, J. Schraml⁵, W. Warnack⁶, R. Persad⁷, A. Starl⁸, F.G. Veiga⁹, C. Schulman¹; ¹Brussels, BE, ²Hengelo, NL, ³Moscow, RU, ⁴Tampere, FI, ⁵Usti Nad Labem, CZ, ⁶Hagenow, DE, ⁷Bristol, GB, ⁸London, GB, ⁹Salamanca, ES
- 13:00 - 13:00 743P - Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study



O. Caffo¹, E. Biasco², G. Facchini³, L. Fratino⁴, D. Gasparro⁵, C. Mosillo⁶, U. Basso⁷, D. Santini⁶, M. Tucci⁸, C. Ortega⁹, F. Verderame¹⁰, S. Scagliarini³, G. Lo Re¹¹, G. Procopio¹², G. Fornarini¹³, E. Campadelli¹⁴, R. Sabbatini¹⁵, F. Maines¹, U. De Giorgi¹⁶; ¹Trento, IT, ²Pisa, IT, ³Napoli, IT, ⁴Aviano, IT, ⁵Parma, IT, ⁶Roma, IT, ⁷Padova, IT, ⁸Orbassano, IT, ⁹Candiolo, IT, ¹⁰Palermo, IT, ¹¹Pordenone, IT, ¹²Milano, IT, ¹³Genova, IT, ¹⁴Lugo Di Romagna, IT, ¹⁵Modena, IT, ¹⁶Meldola, IT

13:00 - 13:00 744P - Efficacy of cabazitaxel, abiraterone, enzalutamide and docetaxel sequence in men with metastatic castration-resistant prostate cancer (mCRPC) in real life practice: The multinational, retrospective, observational CATS study

A. Angelergues¹, A. Birtle², A.C. Hardy-Bessard³, O. Caffo⁴, S. Le Moulec¹, M. Krainer⁵, A. Guillot⁶, A. Hasbini⁷, G. Daugaard⁸, S. Chowdhury⁹, D. Spaeth¹⁰, P. Beuzebec¹, J.-C. Eymard¹¹, A. Flechon¹², J. Alexandre¹, F. Priou¹³, N. Delanoy¹, N. El Awadly¹, E. Braychenko¹, S. Oudard¹; ¹Paris, FR, ²Preston, GB, ³PIÉrin, FR, ⁴Trento, IT, ⁵Vienna, AT, ⁶St. Priest En Jarez, FR, ⁷Brest, FR, ⁸Copenhagen, DK, ⁹London, GB, ¹⁰Nancy, FR, ¹¹Reims, FR, ¹²Lyon, FR, ¹³La Roche Sur Yon, FR

13:00 - 13:00 745P - Treatment options in advanced castration-resistant, docetaxel-resistant prostate cancer (ACRDRPC). Final results of a network meta-analysis

C. Cherubini, E. Bianchi, E. Tamburini, F. Drudi, L. Stocchi, S.V.L. Nicoletti, F. Perini, A. Venturi, F. Montanari, D. Tassinari; Rimini, IT

13:00 - 13:00 746P - The prostate cancer registry: Patient characteristics, treatments and preliminary outcomes from a large observational study of metastatic castration-resistant prostate cancer (mCRPC)

S. Chowdhury¹, A. Birtle², A. Bjartell³, L. Costa⁴, S. Feyerabend⁵, L. Galli⁶, E. Kalinka-Warzocha⁷, G. Kramer⁸, J.P. Maroto Rey⁹, N. Lumen¹⁰, V. Matveev¹¹, T. Paiss¹², D. Spaeth¹³, L. Antoni¹⁴, E. Klumper¹⁵, R. Wapenaar¹⁶, E. Lee¹⁴; ¹London, GB, ²Preston, GB, ³Lund, SE, ⁴Lisboa, PT, ⁵Nürtingen, DE, ⁶Pisa, IT, ⁷Lodz, PL, ⁸Vienna, AT, ⁹Barcelona, ES, ¹⁰Gent, BE, ¹¹Moscow, RU, ¹²Ulm, DE, ¹³Nancy, FR, ¹⁴Beerse, BE, ¹⁵Amsterdam, NL, ¹⁶Tilburg, NL

13:00 - 13:00 747P - Global treatment patterns for late-stage prostate cancer: Updated results from ASPIRE-PCA

N. Clarke¹, M. De Santis², A. Costello³, Y.-H. Chang⁴, T. Pickles⁵, A.C. Pompeo⁶, S. Bazarbashi⁷, G. Haas⁸, M. Cooperberg⁹; ¹GB, ²Coventry, GB, ³Melbourne, AU, ⁴Taipei, TW, ⁵Vancouver, CA, ⁶Sao Paulo, BR, ⁷Riyadh, SA, ⁸Northbrook, IL/US, ⁹San Francisco, US

13:00 - 13:00 748P - Switch from abiraterone+prednisone to abiraterone+dexamethasone after PSA progression under abiraterone+prednisone in asymptomatic metastatic castration-resistant prostate cancer (mCRPC) patients

C. Fenioux¹, C. Louvet¹, D. Prapotnich¹, S. Ropert², E. Barret¹, R. Sanchez-Salas¹, A. Mombet¹, N. Cathala¹, B. Poullennec¹, M.-L. Joulia¹, M. Ung¹, X. Cathelineau¹, M. Bennamoun¹; ¹Paris, FR, ²Antony, FR

13:00 - 13:00 749P - Efficacy and safety of enzalutamide (ENZ) vs placebo (PL) in chemotherapy-naïve patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following androgen deprivation therapy (ADT): An Asian multinational study

D. Ye¹, H. Ahn², Y.-S. Pu³, H. Weiqing⁴, L.-P. Xie⁵, S.-P. Huang⁶, H.-C. Wu⁷, L. Ma⁸, S. Yamada⁹, S. Noda⁹, Y. Sun¹⁰; ¹CN, ²Seoul, KR, ³Taipei, TW, ⁴Hunan, CN, ⁵Hangzhou, CN, ⁶Kaohsiung, TW, ⁷Taichung, TW, ⁸Beijing, CN, ⁹Tokyo, JP, ¹⁰Shanghai, CN



- 13:00 - 13:00 750P - Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP)
F. Saad¹, A. Heidenreich², D. Heinrich³, D. Keizman⁴, J. O'Sullivan⁵, J. Carles⁶, M. Wirth⁷, K. Miller⁸, J. Gratt⁹, M. Seger-van Tol¹⁰, S. Nilsson¹¹, S. Gillissen¹²; ¹Montreal, CA, ²Köln, DE, ³Lorenskog, NO, ⁴Kfar Saba, IL, ⁵Belfast, GB, ⁶Barcelona, ES, ⁷Dresden, DE, ⁸Berlin, DE, ⁹New York, US, ¹⁰Whippany, NJ/US, ¹¹Stockholm, SE, ¹²St. Gallen, CH
- 13:00 - 13:00 751P - Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 in an international early access program (EAP)
D. Heinrich¹, S. Gillissen², A. Heidenreich³, D. Keizman⁴, J. O'Sullivan⁵, J. Carles⁶, M. Wirth⁷, K. Miller⁸, G. Procopio⁹, J. Gratt¹⁰, M. Seger-van Tol¹¹, S. Nilsson¹², F. Saad¹³; ¹Lorenskog, NO, ²St. Gallen, CH, ³Köln, DE, ⁴Kfar Saba, IL, ⁵Belfast, GB, ⁶Barcelona, ES, ⁷Dresden, DE, ⁸Berlin, DE, ⁹Milano, IT, ¹⁰New York, US, ¹¹Whippany, NJ/US, ¹²Stockholm, SE, ¹³Montreal, CA
- 13:00 - 13:00 752P - Radium-223 re-treatment from an international, prospective, open-label study in patients with castration-resistant prostate cancer and bone metastases
O. Sartor¹, D. Heinrich², N. Mariados³, M.J. Méndez Vidal⁴, D. Keizman⁵, C. Thellenberg Karlsson⁶, A. Peer⁷, G. Procopio⁸, S. Frank⁹, K.J. Pulkkanen¹⁰, E. Rosenbaum¹¹, S. Severi¹², J.M. Trigo Perez¹³, V. Wagner¹⁴, J. Garcia-Vargas¹⁵, R. Li¹⁶, L. Nordquist¹⁷; ¹New Orleans, US, ²Lorenskog, NO, ³New York, NY/US, ⁴Cordoba, ES, ⁵Kfar Saba, IL, ⁶Umea, SE, ⁷Haifa, IL, ⁸Milano, IT, ⁹Jerusalem, IL, ¹⁰Kuopio, FI, ¹¹Petach Tikva, IL, ¹²Meldola, IT, ¹³Malaga, ES, ¹⁴Aubonne, CH, ¹⁵Montville, US, ¹⁶Whippany, NJ/US, ¹⁷Omaha, NE/US
- 13:00 - 13:00 753P - Phase II study of weekly cabazitaxel for 'unfit' metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. Circulating tumour cell (CTC) analysis (SOGUG-CABASEM Trial)
U. Anido¹, M.J. Juan Fita², L. Munielo-Romay¹, B. Pérez-Valderrama³, B. Mellado⁴, M. Ochoa de Olza⁴, O. Fernandez Calvo⁵, D. Castellano⁶, E. Fernandez Parra³, M. Domenec⁷, S. Hernando⁸, J. Arranz Arijia⁶, C. Caballero², I. Duran³, M. Campayo⁴, M. Climent²; ¹Santiago De Compostela, ES, ²Valencia, ES, ³Sevilla, ES, ⁴Barcelona, ES, ⁵Ourense, ES, ⁶Madrid, ES, ⁷Manresa, ES, ⁸Alcorcon, ES
- 13:00 - 13:00 754P - Bone biomarkers and overall survival (OS) in men with castrate resistant prostate cancer (CRPC) and skeletal metastases: Updated results from SWOG 0421, a phase III trial of docetaxel +/- atrasentan
P. Lara¹, M. Plets², C. Tangen², E. Gertz³, N. Vogelzang⁴, D. Quinn⁵, I. Thompson⁶, M. van Loan³; ¹Sacramento, CA/US, ²Seattle, WA/US, ³Davis, CA/US, ⁴Las Vegas, NV/US, ⁵Los Angeles, CA/US, ⁶San Antonio, TX/US
- 13:00 - 13:00 755P - Neutropenia grade ≥ 3 during treatment with docetaxel (DOC) is associated with an improved overall survival (OS): A retrospective analysis of the TAX327 phase III trial
A. Meisel¹, D. Vogt², R. de Wit³, J. de Bono⁴, O. Sartor⁵, M. Eisenberger⁶, F. Stenner-Liewen²; ¹Zürich, CH, ²Basel, CH, ³Rotterdam, NL, ⁴London, GB, ⁵New Orleans, US, ⁶Baltimore, US
- 13:00 - 13:00 756P - An innate immune response to intrinsic DNA damage predicts resistance to docetaxel in prostate cancer



C. Davidson¹, S. Walker¹, N. McCabe², L. Hill², E. Parkes¹, S. Jain¹, D. O'Rourke¹, R. Kennedy¹; ¹Belfast, GB, ²Craigavon, GB

- 13:00 - 13:00 757P - Myeloid-derived suppressor cells (MDSCs) in metastatic castration-resistant prostate cancer (CRPC) patients (PTS)
N. Mehra¹, G. Seed², M. Lambros², A. Sharp², M. Sousa Fontes², M. Crespo², S. Sumanasuriya², W. Yuan², G. Boysen², R. Riisnaes², A. Calcinotto³, S. Carreira², J. Goodall², Z. Zafeiriou¹, D. Bianchini², A. Morilla¹, R. Morilla², A. Alimonti³, J. de Bono²; ¹Sutton, GB, ²London, GB, ³Bellinzona, CH
- 13:00 - 13:00 758P - Neutrophil to lymphocyte ratio (NLR) impact on the survival and response duration of patients with metastatic castration resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA)
A. Mansinho, D. Macedo, I. Fernandes, A. Quintela, L. Costa; Lisboa, PT
- 13:00 - 13:00 759P - Prognostic factors in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or bicalutamide (BIC) in TERRAIN
A. Heidenreich¹, N. Shore², A. Villers³, L. Klotz⁴, D.R. Siemens⁵, S. van Os⁶, B. Baron⁶, F. Wang⁷, S. Chowdhury⁸; ¹DE, ²Myrtle Beach, SC/US, ³Lille, FR, ⁴Toronto, ON/CA, ⁵Kingston, CA, ⁶Leiden, NL, ⁷San Francisco, CA/US, ⁸London, GB
- 13:00 - 13:00 760P - A post hoc analysis of radiographic progression with nonrising prostate-specific antigen in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PREVAIL study
A. Bryce¹, J. Alumkal², A. Armstrong³, C. Higano⁴, P. Iversen⁵, C. Sternberg⁶, D. Rathkopf⁷, Y. Loriot⁸, J. de Bono⁹, B. Tombal¹⁰, S. Abhyankar¹¹, P. Lin¹², A. Krivoshik¹³, D. Phung¹⁴, T. Beer²; ¹Scottsdale, AZ/US, ²Portland, OR/US, ³Durham, NC/US, ⁴Seattle, US, ⁵Copenhagen, DK, ⁶Roma, IT, ⁷New York, NY/US, ⁸Villejuif, FR, ⁹London, GB, ¹⁰Brussels, BE, ¹¹San Francisco, US, ¹²San Francisco, CA/US, ¹³Chicago, US, ¹⁴Leiden, NL
- 13:00 - 13:00 761P - How should we treat castration-resistant prostate cancer patients who have received androgen deprivation therapy (ADT) plus docetaxel upfront for hormone-sensitive disease? Mature analysis of the GETUG-AFU 15 phase III trial
P. Lavaud¹, G. Gravis², C. Legoupil¹, S. Foulon¹, F. Joly³, S. Oudard⁴, F. Priou⁵, M. Soulié⁶, L. Mourey⁶, I. Latorzeff⁶, R. Delva⁷, I. Krakowski⁸, B. Laguerre⁹, C. Theodore¹⁰, J.-M. Ferrero¹¹, P. Beuzebec⁴, M. Habibian⁴, J.M. Boher², G. Tergemina-Clain¹, K. Fizazi¹; ¹Villejuif, FR, ²Marseille, FR, ³Caen, FR, ⁴Paris, FR, ⁵La Roche Sur Yon, FR, ⁶Toulouse, FR, ⁷Angers, FR, ⁸Vandoeuvre Les Nancy, FR, ⁹Rennes, FR, ¹⁰Suresnes, FR, ¹¹Nice, FR
- 13:00 - 13:00 762P - Effect of baseline metabolic aberrations in men with locally advanced/metastatic prostate cancer treated with ADT on time to disease progression, prostate cancer specific and all cause death
D. Crawley¹, M. van Hemelrijck¹, S. Chowdhury¹, N. James², C. Gilson¹, M. Spears¹, M. Sydes¹, S. Rudman¹; ¹London, GB, ²Coventry, GB
- 13:00 - 13:00 763P - F18 NaF PET/CT and whole body MRI for the detection of metastases in patients with biochemical recurrence of prostate cancer



P. Twardowski¹, S. Pal², C. Stein², P. Frankel², H. Chen², T. Moore², D. Harwood², M. Prajapati², M. Junqueira², S. Chung², S. Rahmanuddin², K. Burns², O. Rodriguez², D. Woo², P. Tryon¹, J. Park²; ¹Duarte, US, ²Duarte, CA/US

- 13:00 - 13:00 764TiP - Cog-Pro: Impact of new generation hormono-therapy on cognitive functions in elderly patients treated for a metastatic prostate cancer
F. Joly¹, M. Lange¹, N. Heutte¹, A. Leconte¹, I. Léger², K. Fizazi², F. Di Fiore³, B. Giffard¹, A. Capel¹, H. Laviec¹, M. Dubois³, B. Clarisse¹, C. Hélène³; ¹Caen, FR, ²Villejuif, FR, ³Rouen, FR
- 13:00 - 13:00 765TiP - Metformin and longevity (METAL): A window of opportunity study investigating the biological effects of metformin in localised prostate cancer
D. Crawley¹, A. Chandra¹, M. Loda², C. Gillett¹, P. Cathcart¹, B. Challacombe¹, G. Cook¹, D. Cahill¹, F. Cahill¹, A. Santa Olalla¹, G. George¹, S. Rudman¹, M. van Hemelrijck¹; ¹London, GB, ²Boston, US
- 13:00 - 13:00 766TiP - CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent
R. de Wit¹, K. Fizazi², E. Efstathiou³, R. Dittamore⁴, S. Hitier⁵, K. Pantel⁶, C. Sternberg⁷, B. Tombal⁸, C. Wülfing⁶, J. de Bono⁹; ¹Rotterdam, NL, ²Villejuif, FR, ³Houston, US, ⁴San Diego, US, ⁵Paris, FR, ⁶Hamburg, DE, ⁷Rome, IT, ⁸Brussels, BE, ⁹London, GB
- 13:00 - 13:00 767TiP - Efficacy and safety of enzalutamide plus androgen deprivation therapy vs placebo plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: the ongoing ARCHES trial
A. Stenzl¹, A. Krivoshik², B. Baron³, M. Hirmand⁴, A. Armstrong⁵; ¹DE, ²Chicago, US, ³Leiden, NL, ⁴San Francisco, CA/US, ⁵Durham, NC/US
- 13:00 - 13:00 769TiP - ATLAS: A phase 3 trial evaluating the efficacy of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy
A. Bossi¹, D. Dearnaley², M. McKenzie³, E. Baskin-Bey⁴, R. Tyler⁴, B. Tombal⁵, S. Freedland⁴, M. Roach III⁶, A. Widmark⁷, A. Dicker⁸, T. Wiegel⁹, N. Shore¹⁰, M. Smith¹¹, M. Yu¹², T. Kheoh¹³, S. Thomas¹⁴, H. Sandler⁴; ¹Villejuif, FR, ²London, GB, ³Vancouver, BC/CA, ⁴Los Angeles, CA/US, ⁵Brussels, BE, ⁶San Francisco, CA/US, ⁷Umea, SE, ⁸Philadelphia, PA/US, ⁹Ulm, DE, ¹⁰Myrtle Beach, SC/US, ¹¹Boston, Ma, US, ¹²Los Angeles, US, ¹³San Diego, CA/US, ¹⁴Spring House, PA/US
- 13:00 - 13:00 770TiP - EMBARK: A phase 3, randomized, efficacy and safety study of enzalutamide plus leuprolide, enzalutamide monotherapy and placebo plus leuprolide in men with high-risk nonmetastatic prostate cancer progressing after definitive therapy
K. Miller¹, P. Mulders², S. Freedland³, H. Scher⁴, N. Shore⁵, E. Park⁶, A. Krivoshik⁷, D. Phung⁸, K. Modelska⁶, P. Scardino⁹; ¹Berlin, DE, ²Nijmegen, NL, ³Los Angeles, CA/US, ⁴New York, Ny, US, ⁵Myrtle Beach, SC/US, ⁶San Francisco, CA/US, ⁷Chicago, US, ⁸Leiden, NL, ⁹New York, NY/US
- 13:00 - 13:00 771TiP - TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)



K. Chi¹, S. Chowdhury², P. Radziszewski³, T. Lebre⁴, M. Ozguroglu⁵, C. Sternberg⁶, R. Sims⁷, M. Yu⁸, V. Naini⁸, M. Darif⁹, A. Merseburger¹⁰; ¹Vancouver, CA, ²London, GB, ³Warsaw, PL, ⁴Suresnes, FR, ⁵Istanbul, TR, ⁶Rome, IT, ⁷Los Angeles, CA/US, ⁸Los Angeles, US, ⁹San Diego, CA/US, ¹⁰Lübeck, DE

13:00 - 13:00 772TiP - Anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 immunotherapy for prostate cancer

S. Tagawa¹, D. Scherr², J. Batra², Y. Jhanwar², B. Robinson², D. Nanus³, H. Beltran³, A. Molina², P. Christos², N. Bander²; ¹New York, US, ²New York, NY/US, ³New York, NY, US

13:00 - 13:00 Genitourinary tumours, non prostate

13:00 - 13:00 783P - Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study

Y. Loriot¹, J. Rosenberg², T. Powles³, A. Necchi⁴, S. Hussain⁵, R. Morales⁶, M. Retz⁷, G. Niegisch⁸, I. Duran⁹, C. Theodore¹⁰, J.L. Perez-Gracia¹¹, E. Grande Pulido¹², A. Thåström¹³, B. Danner¹³, S. Mariathasan¹³, O. Abidoye¹³, M. van der Heijden¹⁴; ¹Villejuif, FR, ²New York, US, ³London, GB, ⁴Milano, IT, ⁵Liverpool, GB, ⁶Barcelona, ES, ⁷München, DE, ⁸Düsseldorf, DE, ⁹Sevilla, ES, ¹⁰Suresnes, FR, ¹¹Pamplona, ES, ¹²Madrid, ES, ¹³South San Francisco, US, ¹⁴Amsterdam, NL

13:00 - 13:00 784P - Nivolumab monotherapy in metastatic urothelial cancer (mUC): Updated efficacy by subgroups and safety results from the CheckMate 032 study

J. Rosenberg¹, P. Bono², J. Kim³, P. Spiliopoulou⁴, E. Calvo⁵, R. Pillai⁶, P. Ott⁷, F. de Braud⁸, M. Morse⁹, D. Le¹⁰, D. Jaeger¹¹, E. Chan¹², C. Harbison¹³, C.S. Lin¹³, M. Tschaika¹³, A. Azrilevich¹³, P. Sharma¹⁴; ¹New York, US, ²Helsinki, FI, ³New Haven, CT/US, ⁴Glasgow, GB, ⁵Madrid, ES, ⁶Atlanta, GA/US, ⁷Boston, MA/US, ⁸Milano, IT, ⁹Durham, NC/US, ¹⁰Baltimore, US, ¹¹Heidelberg, DE, ¹²Nashville, TN/US, ¹³Princeton, NJ/US, ¹⁴Houston, TX/US

13:00 - 13:00 785P - Everolimus / pazopanib (E/P) benefits genomically selected patients (pts) with metastatic urothelial carcinoma (mUC)

J. Bellmunt¹, S. Mullane², S. Jacobus², L. Polacek², D. Takeda², L. Harshman¹, T. Choueiri¹, N. Wagle², E. Van Allen², P. Kantoff³, J. Rosenberg³; ¹Boston, US, ²Boston, MA/US, ³New York, US

13:00 - 13:00 786P - Fibroblast growth factor receptor 3 (FGFR3) mutant muscle invasive bladder cancers (MIBC) are associated with low immune infiltrates

E. Kilgour¹, H. Angell², N. Smith¹, M. Ahdesmaki², J. Barrett³, E. Harrington², C. Hurst⁴, M. Knowles⁴; ¹Macclesfield, GB, ²Cambridge, GB, ³Boston, MA/US, ⁴Leeds, GB

13:00 - 13:00 787P - A phase II study of cabozantinib in patients (pts) with relapsed/refractory metastatic urothelial carcinoma (mUC)

R. Nadal¹, H. Parnes¹, D. Francis¹, L. Cordes¹, M. Berninger¹, R. Costello¹, L. Folio¹, M. Linderberg¹, L. Machado¹, S. Steinberg¹, J. Wright¹, Y. Ning¹, D. Bottaro¹, W. Dahut², A. Apolo²; ¹Bethesda, US, ²Bethesda, MD/US



- 13:00 - 13:00 788P - Interim analysis of a phase I dose escalation trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an antibody drug conjugate (ADC), in patients (Pts) with metastatic urothelial cancer (mUC)
J. Rosenberg¹, E. Heath², R. Perez³, J. Merchan⁴, J. Lang⁵, D. Ruether⁶, D. Petrylak⁷, R. Sangha⁸, D. Smith⁹, S. Sridhar¹⁰, E. Gartner¹¹, M. Vincent¹², R. Chu¹³, B. Anand¹³, F. Donate¹³, A. Melhem-Bertrandt¹⁴, J. Zhang¹⁵; ¹New York, US, ²Detroit, MI/US, ³Fairway, KS/US, ⁴Miami, FL/US, ⁵Madison, WI/US, ⁶Calgary, AB/CA, ⁷New Haven, US, ⁸Edmonton, CA, ⁹Ann Arbor, MI/US, ¹⁰Toronto, ON/CA, ¹¹Seattle, WA/US, ¹²Santa Monica, US, ¹³Santa Monica, CA/US, ¹⁴Northbrook, IL/US, ¹⁵Tampa, FL/US
- 13:00 - 13:00 789P - Pharmacokinetics (PK) of the pan-FGFR inhibitor erdafitinib in urothelial carcinoma
J. Taberero¹, J. Infante², A. Mita³, C. Keung⁴, D. Skee⁴, H. Xie⁵, T. Parekh⁴, P. De Porre⁶, F. Luo⁴, J.-C. Soria⁶; ¹Barcelona, ES, ²Nashville, TN/US, ³Los Angeles, US, ⁴Raritan, NJ/US, ⁵Spring House, PA/US, ⁶Villejuif, FR
- 13:00 - 13:00 790P - Proteomics profiling predicts poor prognosis in patients with muscle invasive urothelial carcinoma
G. De Velasco¹, A. Gámez-Pozo², M. Urbanowicz², G. Ruiz-Ares², J.M. Sepulveda², R. Manneh², B. Homet², L. Trilla-Fuertes², I. Otero², P. Celiz², F. Villacampa², L. Paz-Ares², J. Fresno Vara², D. Castellano²; ¹Boston, US, ²Madrid, ES
- 13:00 - 13:00 791P - Transcriptomic analysis of collecting duct carcinoma of the kidney
A. Tessari¹, I. Testa², E. Verzoni², G. Nigita³, M. Colecchia⁴, D. Palmieri³, P. Grassi², M. Pawlikowski³, C. Maggi², A. Martinetti², F. de Braud², C. Croce¹, G. Procopio²; ¹Columbus, OH/US, ²Milano, IT, ³Columbus, US, ⁴Milan, IT
- 13:00 - 13:00 792P - Clinical significance of early circulating tumor cells (CTC) changes, analyzed by AdnaTest, in patients (pts) receiving first-line methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy (CT) for metastatic urothelial cancer (UC)
E. Fina¹, A. Necchi², P. Giannatempo², M. Colecchia¹, D. Raggi², M.G. Daidone¹, V. Cappelletti¹; ¹Milan, IT, ²Milano, IT
- 13:00 - 13:00 793P - Radio guided sentinel lymph node detection and mapping in invasive urinary bladder cancer - a prospective clinical study
F. Aljabery¹, I. Shabo², H. Olsson¹, O. Gimm¹, S. Jahnson¹; ¹Linköping, SE, ²Stockholm, SE
- 13:00 - 13:00 794P - Impact of race on survival following radical cystectomy for muscle-invasive bladder cancer (MIBC): Analysis of the U.S. National Cancer Database (NCDB)
N. Dizman¹, S. Pal², R. Nelson², J. Hsu², P. Bergerot³, J. Nix⁴, G. Sonpavde⁵; ¹Istanbul, TR, ²Duarte, CA/US, ³São Paulo, BR, ⁴Birmingham, AL/US, ⁵Birmingham, US
- 13:00 - 13:00 795P - Concurrent chemoradiotherapy with paclitaxel and cisplatin in muscle-invasive bladder cancer
R. Abdel Wahab, H. Essa, A. Eltaher, M. Aboziada, S. Shehata; Assiut, EG
- 13:00 - 13:00 796P - Randomized placebo controlled phase II trial (MAJA): Efficacy results of maintenance vinflunine after cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC). SOGUG 2011-02



B. Pérez-Valderrama¹, A. Font², J. Virizuela Echaburu¹, S. Hernando³, M. Climent⁴, J. Arranz Arija⁵, J.C. Villa Guzman⁶, M. Llorente⁷, N. Lainez Milagro⁸, B. Mellado⁹, A. González del Alba¹⁰, E. Gallardo¹¹, D. Castellano⁵, U. Anido¹², M. Domenech¹³, X. Garcia del Muro⁹, J. Puente⁵, R. Morales⁹, J. Bellmunt¹⁴, J. Garcia-Donas⁵; ¹Sevilla, ES, ²Badalona, ES, ³Alcorcon, ES, ⁴Valencia, ES, ⁵Madrid, ES, ⁶Ciudad Real, ES, ⁷Alicante, ES, ⁸Pamplona, ES, ⁹Barcelona, ES, ¹⁰Palma De Mallorca, ES, ¹¹Sabadell, ES, ¹²Santiago De Compostela, ES, ¹³Manresa, ES, ¹⁴Boston, US

13:00 - 13:00 797P - Nomogram-based prediction of overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (UC) receiving first-line platinum-based chemotherapy: Retrospective international study of invasive/advanced cancer of the urothelium (RISC)

A. Necchi¹, G. Sonpavde², S. Lo Vullo³, A. Bamias⁴, S. Crabb⁵, L. Harshman⁶, J. Bellmunt⁶, U. De Giorgi⁷, C. Sternberg⁸, S. Ladoire⁹, Y.-N. Wong¹⁰, E. Yu¹¹, S. Chowdhury¹², G. Niegisch¹³, S. Srinivas¹⁴, U. Vaishampayan¹⁵, S. Pal¹⁶, J. Rosenberg¹⁷, L. Mariani³, M. Galsky¹⁷; ¹Milano, IT, ²Birmingham, US, ³Milan, IT, ⁴Athens, GR, ⁵Boston, Ma, US, ⁶Boston, US, ⁷Meldola, IT, ⁸Rome, IT, ⁹Dijon, FR, ¹⁰Philadelphia, US, ¹¹Seattle, US, ¹²London, GB, ¹³Düsseldorf, DE, ¹⁴Stanford, CA/US, ¹⁵Detroit, US, ¹⁶Duarte, US, ¹⁷New York, US

13:00 - 13:00 798P - Patterns of chemotherapy utilization in metastatic urothelial cancer (mUC): Analysis from the retrospective international study of invasive/advanced cancer of the urothelium (RISC) database

A. Bamias¹, K. Tzannis¹, M. Liontos¹, L. Harshman², S. Crabb³, Y.-N. Wong⁴, S. Pal⁵, T. Powles⁶, J. Bellmunt², U. De Giorgi³, S. Ladoire⁷, N. Agarwal⁸, E. Yu⁹, G. Niegisch¹⁰, C. Sternberg¹¹, A. Alva¹², S. Srinivas¹³, J. Rosenberg¹⁴, R. Investigators¹⁴, M. Galsky¹⁴; ¹Athens, GR, ²Boston, US, ³Boston, Ma, US, ⁴Philadelphia, US, ⁵Duarte, US, ⁶London, GB, ⁷Dijon, FR, ⁸Salt Lake City, UT/US, ⁹Seattle, US, ¹⁰Düsseldorf, DE, ¹¹Roma, IT, ¹²East Lansing, MI/US, ¹³Palo Alto, US, ¹⁴New York, US

13:00 - 13:00 799P - Adherence to cisplatin-based regimens prescription in "fit" patients fulfilling platinum eligibility criteria. Impact on outcomes: A retrospective international study of invasive/advanced cancer of the urothelium (RISC) analysis

A. Bamias¹, K. Tzannis¹, M. Liontos¹, S. Crabb², L. Harshman³, U. De Giorgi⁴, J. Bellmunt³, Y.-N. Wong⁵, S. Pal⁶, S. Ladoire⁷, C. Sternberg⁸, T. Powles⁹, E. Yu¹⁰, G. Niegisch¹¹, A. Necchi¹², U. Vaishampayan¹³, N. Agarwal¹⁴, J. Rosenberg¹⁵, R. Investigators¹⁵, M. Galsky¹⁵; ¹Athens, GR, ²Boston, Ma, US, ³Boston, US, ⁴Meldola, IT, ⁵Philadelphia, US, ⁶Duarte, US, ⁷Dijon, FR, ⁸Roma, IT, ⁹London, GB, ¹⁰Seattle, US, ¹¹Düsseldorf, DE, ¹²Milano, IT, ¹³Detroit, US, ¹⁴Salt Lake City, UT/US, ¹⁵New York, US

13:00 - 13:00 800P - VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium (TCCU): A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through free of charge programme (FOCP) for patients in the UK and Ireland

S. Hussain¹, J. Ansari², R. Huddart³, D. Power⁴, J. Lyons⁵, J. Wylie⁶, M. Vilarino-Varela⁷, N. Elander¹, R. McMenemin⁸, L. Pickering⁷, G. Faust⁹, S. Chauhan¹, R. Jakson¹; ¹Liverpool, GB, ²Glasgow, GB, ³Sutton, GB, ⁴Cork, IE, ⁵Cambridge, GB, ⁶Manchester, GB, ⁷London, GB, ⁸Newcastle Upon Tyne, GB, ⁹Leicester, GB

13:00 - 13:00 801P - Second-line metastatic urothelial carcinoma treatment and survival in real-world patients in the US



S. Pal¹, M. Galsky², S.-W. Lin³, S. Ogale³, M. Zivkovic⁴, J. Simpson³, C. Derleth³, G. Sonpavde⁵; ¹Duarte, US, ²New York, US, ³South San Francisco, CA/US, ⁴Hoboken, US, ⁵Birmingham, US

- 13:00 - 13:00 802P - 281 small cell bladder cancer analysis from spanish institutions
M.J. Juan Fita¹, M. Ramirez-Backhaus¹, X. Bonet Puntí², J. Gomez³, E. Ramos⁴, L. Pesquera⁵, A. Rodriguez-Vida², I. Lacasa Viscasillas⁶, J.C. Villa Guzman⁷, R. Sanchez-Salas⁸, J.L. Sanchez Sanchez⁹, M.J. Miranda¹⁰, S. Valverde¹¹, L. Izquierdo², A. Serrano³, P. Pellejero¹², I. Garcia¹³, I. Ortiz¹⁴, J. Rubio Briones¹, M. Climent¹; ¹Valencia, ES, ²Barcelona, ES, ³Madrid, ES, ⁴Santander, ES, ⁵Valladolid, ES, ⁶Bilbao, ES, ⁷Ciudad Real, ES, ⁸Paris, FR, ⁹Alicante, ES, ¹⁰Reus, ES, ¹¹Ávila, ES, ¹²Oviedo, ES, ¹³Toledo, ES, ¹⁴Almeria, ES
- 13:00 - 13:00 803P - Phase 1 study of selective internal radiation therapy (SIRT) with yttrium-90 (Y-90) resin microspheres in patients (pts) with renal cell carcinoma (RCC): RESIRT
P. de Souza¹, P. Aslan², W. Clark², M. Patel³, J. Vass², D. Cade², S. de Silva²; ¹Sydney, AU, ²Sydney, NSW/AU, ³Westmead, NSW/AU
- 13:00 - 13:00 804P - A phase 1b dose-escalation study of TRC105 (endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC)
T. Choueiri¹, M.D. Michaelson², E. Posadas³, G. Sonpavde⁴, D. McDermott¹, B. Seon⁵, M. Jivani⁶, R. Shazer⁶, B. Adams⁶, C. Theuer⁶; ¹Boston, US, ²Boston, MA/US, ³Los Angeles, US, ⁴Birmingham, US, ⁵Buffalo, NY/US, ⁶San Diego, CA/US
- 13:00 - 13:00 806P - New insights in oncogenic alterations in clear-cell renal cell carcinoma with sarcomatoid dedifferentiation
R. Flippot¹, G. Malouf¹, E. Comperat¹, X. Su², R. Mouawad¹, M. Roupret¹, J.-P. Spano¹, D. Khayat¹; ¹Paris, FR, ²Houston, TX/US
- 13:00 - 13:00 807P - Novel angiogenesis markers as long-term prognostic factors in renal cell cancer
J. Virman¹, A. Lampinen², P. Bono², T. Luukkaala¹, K. Sunela¹, P. Kujala¹, P. Saharinen², P.-L. Kellokumpu-Lehtinen¹; ¹Tampere, FI, ²Helsinki, FI
- 13:00 - 13:00 808P - Prediction of total clearance by UGT1A and ABC genes polymorphisms can predict tumor response and proteinuria in axitinib treatment for advanced renal cell carcinoma
H. Matsuyama¹, Y. Yamamoto¹, Y. Kawai¹, Y. Fujita¹, Y. Hamamoto¹, K. Matsuyama², T. Otori², J. Haginaka³; ¹Ube, JP, ²Higashiosaka, JP, ³Mukogawa, JP
- 13:00 - 13:00 809P - Inverse association between baseline renal function and overall survival in patients with metastatic renal cell carcinoma who were treated with molecular-targeted agents
M. Hiroyuki¹, H. Miyake¹, M. Fujisawa²; ¹Kobe, Hyogo/JP, ²Kobe, JP
- 13:00 - 13:00 810P - Influence of diabetes and congestive heart failure (CHF) on selection of first-line (1L) treatment for metastatic renal cell carcinoma (mRCC)
J. Gong¹, D. George², S. Mhatre³, S.-W. Lin³, A. Surinach⁴, H. Wallen³, R. Vohra³, J. Simpson³, S. Ogale³, S. Pal⁵; ¹Duarte, CA/US, ²Durham, US, ³South San Francisco, CA/US, ⁴Hoboken, CA/US, ⁵Duarte, US



- 13:00 - 13:00 811P - Prognostic ability of early tumor shrinkage on overall survival (OS) in metastatic renal cell carcinoma (mRCC) – a validation study
G.R. Pond¹, M. Dietrich², V. Grünwald²; ¹Hamilton, ON/CA, ²Hannover, DE
- 13:00 - 13:00 812P - Prognostic significance of early tumor shrinkage under second-line targeted therapy for metastatic renal cell carcinoma: A retrospective multiinstitutional study in Japan
H. Miyake¹, S. Ozono², M. Fujisawa³; ¹Kobe, Hyogo/JP, ²Hamamatsu, JP, ³Kobe, JP
- 13:00 - 13:00 813P - Correlation of longitudinal target-lesions size with progression-free (PFS) and overall-survival (OS) in 2nd line metastatic renal cell carcinoma: A retrospective analysis of AXIS trial
C. Luhata Lungayo, L. Fournier, S. Oudard, R. El Aidi; Paris, FR
- 13:00 - 13:00 814P - Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial
T. Powles¹, B. Escudier², P. de Souza³, S. Chowdhury¹, D. Pook⁴, U. Harmenberg⁵, N. Basappa⁶, D. Geynisman⁷, J. Merchan⁸, B. Redman⁹, C. Ryan¹⁰, O. Goodman¹¹, T. Ho¹², P. Singh¹³, J. Loughheed¹⁴, M. Patel¹⁴, J. Knox¹⁵, R. Motzer¹⁶, T. Choueiri¹⁷; ¹London, GB, ²Villejuif, FR, ³Kogarah, AU, ⁴Bentleigh East, AU, ⁵Stockholm, SE, ⁶Edmonton, AB/CA, ⁷Philadelphia, PA/US, ⁸Miami, FL/US, ⁹Ann Arbor, MI/US, ¹⁰Portland, OR/US, ¹¹Las Vegas, US, ¹²Phoenix, US, ¹³Tucson, US, ¹⁴South San Francisco, US, ¹⁵Toronto, CA, ¹⁶New York, NY/US, ¹⁷Boston, MA/US
- 13:00 - 13:00 815P - Evaluation of the novel “trial within a trial” design of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC)
C. Hessel¹, M. Mangeshkar¹, R. Motzer², B. Escudier³, T. Powles⁴, G. Schwab⁵, T. Choueiri⁶; ¹South San Francisco, CA/US, ²New York, NY/US, ³Villejuif, FR, ⁴London, GB, ⁵South San Francisco, US, ⁶Boston, MA/US
- 13:00 - 13:00 816P - Quality of life (QoL) in the phase 3 METEOR trial of cabozantinib vs everolimus for advanced renal cell carcinoma (RCC)
D. Cella¹, B. Escudier², N. Tannir³, T. Powles⁴, F. Donskov⁵, K. Peltola⁶, M. Schmidinger⁷, D. Heng⁸, P. Mainwaring⁹, H. Hammers¹⁰, J.-L. Lee¹¹, B. Rini¹², B. Roth¹³, J. Baer¹⁴, M. Mangeshkar¹⁵, C. Scheffold¹⁴, T. Hutson¹⁶, S. Pal¹⁷, R. Motzer¹⁸, T. Choueiri¹⁹; ¹Chicago, IL/US, ²Villejuif, FR, ³Houston, TX/US, ⁴London, GB, ⁵Aarhus C, DK, ⁶Helsinki, FI, ⁷Vienna, AT, ⁸Calgary, CA, ⁹South Brisbane, AU, ¹⁰Baltimore, US, ¹¹Seoul, KR, ¹²Middlesex, GB, ¹³St Louis, MO/US, ¹⁴South San Francisco, US, ¹⁵South San Francisco, CA/US, ¹⁶Dallas, US, ¹⁷Duarte, CA/US, ¹⁸New York, NY/US, ¹⁹Boston, MA/US
- 13:00 - 13:00 817P - Prognostic ability of HR-QoL parameters in metastatic renal cell carcinoma (mRCC)
V. Grünwald¹, M. Dietrich¹, G.R. Pond²; ¹Hannover, DE, ²Hamilton, ON/CA
- 13:00 - 13:00 818P - Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)



N. Tannir¹, T. Powles², R. Motzer³, F. Rolland⁴, G. Gravis⁵, M. Staehler⁶, M. Rink⁷, M. Retz⁸, T. Csoszi⁹, J. McCaffrey¹⁰, U. De Giorgi¹¹, C. Caserta¹², S. Cheporov¹³, E. Esteban Gonzalez¹⁴, I. Duran¹⁵, J. Larkin², W. Berg¹⁶, D. Clary¹⁶, B. Escudier¹⁷, T. Choueiri¹⁸; ¹Houston, TX/US, ²London, GB, ³New York, NY/US, ⁴St. Herblain, FR, ⁵Marseille, FR, ⁶Munich, DE, ⁷Hamburg, DE, ⁸München, DE, ⁹Szolnok, HU, ¹⁰Cork, IE, ¹¹Meldola, IT, ¹²Terni, IT, ¹³Yaroslavl, RU, ¹⁴Oviedo, ES, ¹⁵Sevilla, ES, ¹⁶South San Francisco, CA/US, ¹⁷Villejuif, FR, ¹⁸Boston, MA/US

- 13:00 - 13:00 819P - Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: The Canadian experience
- A.-K. Lalani¹, H. Li², D. Heng², L. Wood³, A. Kalirai⁴, G. Bjarnason⁵, H.-W. Sim⁶, C. Kollmannsberger⁷, A. Kapoor⁸, S. Hotte⁸, M. Vanhuysse⁹, P. Czaykowski¹⁰, M.N. Reaume¹¹, D. Soulieres⁹, P. Venner¹, S. North⁴, N. Basappa¹; ¹Edmonton, AB/CA, ²Calgary, CA, ³Halifax, CA, ⁴Edmonton, CA, ⁵Toronto, CA, ⁶Melbourne, AU, ⁷Vancouver, CA, ⁸Hamilton, CA, ⁹Montreal, CA, ¹⁰Winnipeg, CA, ¹¹Ottawa, CA
- 13:00 - 13:00 820P - Sunitinib (2 weeks on/1 week off schedule) in metastatic renal cell cancer patients. Progression-free and overall survival
- F. Gyergyay, B. Budai, K. Nagyivanyi, K. Biro, L. Géczi; Budapest, HU
- 13:00 - 13:00 821P - Tolerability associated with sunitinib (SU) 2-week on and 1-week off schedule (2/1 schedule) compared with its standard schedule in metastatic RCC (mRCC): Meta-analysis
- H.J. Kang, S. Lee; Seoul, KR
- 13:00 - 13:00 822P - Outcome of patients with multiple glandular metastases from renal cell carcinoma treated with targeted agents
- P. Grassi¹, L. Doucet², P. Giglione³, V. Grünwald⁴, B. Melichar⁵, L. Galli⁶, U. De Giorgi⁷, A. Guida⁸, C. Ortega⁹, M. Santoni¹⁰, A. Bamias¹¹, E. Verzoni¹, L. Derosa², H. Studentova⁵, L. Porcu¹, F. de Braud¹, C. Porta³, B. Escudier², G. Procopio¹; ¹Milano, IT, ²Villejuif, FR, ³Pavia, IT, ⁴Hannover, DE, ⁵Olomouc, CZ, ⁶Pisa, IT, ⁷Meldola, IT, ⁸Modena, IT, ⁹Candiolo, IT, ¹⁰Ancona, IT, ¹¹Athens, GR
- 13:00 - 13:00 823P - Brain and pancreatic metastases: A clinico-pathological comparison of various facets of tumor heterogeneity in renal cell carcinoma - The BRAVE project
- L. Derosa¹, G. Le Teuff¹, B. Chanez², A. Guida³, F. Ruatta¹, G. Gravis², L. Albiges¹, B. Escudier¹; ¹Villejuif, FR, ²Marseille, FR, ³Modena, IT
- 13:00 - 13:00 824P - Efficacy and safety of the combination of bevacizumab (BEV) and temsirolimus (TEM) in patients with metastatic renal cancer (mRCC) after first-line anti-VEGF treatment: A Hellenic Cooperative Oncology group (HeCOG) phase II trial
- K. Koutsoukos¹, F. Zagouri¹, K. Tzannis¹, V. Karavasilis¹, E. Samantas¹, G. Aravantinos¹, A. Koutras², I. Gkerzelis¹, E. Chamylos¹, E. Kostouros¹, M. Lykka¹, G. Tsironis¹, I. Dimitriadis¹, M. Lontos¹, G. Fountzilias³, M. Dimopoulos¹, A. Bamias¹; ¹Athens, GR, ²Patras, GR, ³Thessaloniki, GR
- 13:00 - 13:00 825P - Long-term duration of axitinib treatment in advanced renal cell carcinoma
- B. Rini¹, V. Grünwald², E. Jonasch³, M. Fishman⁴, Y. Tomita⁵, M.D. Michaelson⁶, J. Tarazi⁷, L. Cisar⁸, A. Blair⁹, B. Rosbrook⁷, T. Hutson¹⁰; ¹Middlesex, GB, ²Hannover, DE, ³Houston, US, ⁴Tampa, FL/US, ⁵Niigata, JP, ⁶Boston, MA/US, ⁷San Diego, CA/US, ⁸New York, NY/US, ⁹La Jolla, CA/US, ¹⁰Dallas, US



- 13:00 - 13:00 826P - Post-randomization analysis of OS for patients who did not switch to second line targeted therapy in the TIVO-1 study
J. Belsey, E. Kemadjou; Sudbury, GB
- 13:00 - 13:00 827P - Clinical outcomes and dosing patterns of 2nd targeted therapy in metastatic renal carcinoma: A retrospective chart review in the EU
D. Heng¹, J. Park², J. Signorovitch³, H. Yang³, J. Song⁴, J. Weiss⁵, L. Dezzani², T. Powles⁵; ¹Calgary, CA, ²East Hanover, NJ/US, ³Boston, MA/US, ⁴Los Angeles, CA/US, ⁵London, GB
- 13:00 - 13:00 828P - Rechallenge with axitinib in metastatic renal cell carcinoma (mRCC) - Experience from Gustave Roussy
M. Matias¹, A. Guida², L. Albiges³, Y. Loriot³, C. Massard³, K. Fizazi³, B. Escudier³; ¹Villejuif, Casado (a)/FR, ²Modena, IT, ³Villejuif, FR
- 13:00 - 13:00 829P - Denosumab in patients with bone metastases from renal-cell carcinoma treated with anti-angiogenic therapy: A retrospective study from the GETUG (Groupe Etude des Tumeurs Uro Genitales)
A. Guillot¹, C. Joly², P. Barthelemy³, E. Meriaux⁴, S. Negrier⁵, D. Pouessel⁶, C. Chevreau⁷, H. Mahammedi⁸, N. Houede⁹, G. Roubaud¹⁰, G. Gravis¹¹, S. Tartas⁵, L. Albiges¹², C. Vassal¹³, M. Oriol¹³, F. Tinquaut¹³, S. Espenel¹³, S. Culine⁶, K. Fizazi¹²; ¹St. Priest En Jarez, FR, ²Créteil, FR, ³Strasbourg, FR, ⁴Caen, FR, ⁵Lyon, FR, ⁶Paris, FR, ⁷Toulouse, FR, ⁸Clermont-Ferrand, FR, ⁹Nimes, FR, ¹⁰Bordeaux, FR, ¹¹Marseille, FR, ¹²Villejuif, FR, ¹³Saint Priest En Jarez, FR
- 13:00 - 13:00 830P - Everolimus-induced pneumonitis as predictor of outcome in patients with metastatic renal cell carcinoma
P. Penttila, J. Rautiola, K. Peltola, M. Laukka, P. Bono; Helsinki, FI
- 13:00 - 13:00 831P - Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib
V. Neiman¹, D. Keizman², D. Sarid³, J.-L. Lee⁴, A. Sella⁵, M. Gottfried², H. Hammers⁶, M. Eisenberger⁶, M. Carducci⁶, V. Sinibaldi⁶, E. Rosenbaum¹, A. Peer⁷, A. Neumann⁷, W. Mermershtain⁸, K.R. Rouvinov⁸, R. Berger⁹, I. Yildiz¹⁰; ¹Petach Tikva, IL, ²Kfar Saba, IL, ³Tel Aviv, IL, ⁴Seoul, KR, ⁵Zerifin, IL, ⁶Baltimore, US, ⁷Haifa, IL, ⁸Beer Sheva, IL, ⁹Ramat Gan, IL, ¹⁰Izmir, TR
- 13:00 - 13:00 832P - First-line PAzopanib in Non-clear cell Renal cArcinoMA: The Italian retrospective multicenter PANORAMA study
M. Bersanelli¹, F. Maines², G. Facchini³, F. Gelsomino⁴, F. Zustovich⁵, M. Santoni⁶, E. Verri⁷, U. De Giorgi⁸, C. Masini⁹, F. Morelli¹⁰, M.G. Vitale³, T. Sava¹¹, G. Prati¹², C. Librici¹³, A.P. Fraccon¹⁴, G. Fornarini¹⁵, M. Maruzzo¹⁶, F. Leonardi¹⁷, O. Caffo², S. Buti¹⁷; ¹Noceto, PR/IT, ²Trento, IT, ³Napoli, IT, ⁴Bologna, IT, ⁵Belluno, IT, ⁶Ancona, IT, ⁷Milano, IT, ⁸Meldola, IT, ⁹Reggio Emilia, IT, ¹⁰San Giovanni Rotondo, IT, ¹¹Verona, IT, ¹²Guastalla, IT, ¹³Palermo, IT, ¹⁴Peschiera Del Garda, IT, ¹⁵Genova, IT, ¹⁶Padova, IT, ¹⁷Parma, IT
- 13:00 - 13:00 833P - Retrospective analysis of metastatic non-clear cell renal carcinoma (NCCRC): The Spanish Grupo Centro Experience



L. Rodriguez Lajusticia¹, A. Martín¹, A. Pinto Marin¹, C. Aguado¹, T. Alonso Gordo¹, A. Herrero¹, C. Maximiano¹, M. Garrido Arevalo¹, I. Gallegos², L. Villalobos¹, J. Cassinello³, I. Garcia⁴, J. Espinosa Arranz⁵, J. Garcia-Donas¹, J.J. Tafalla¹, G. Torres¹, J. Puente¹, E. Grande Pulido¹; ¹Madrid, ES, ² Segovia, ES, ³Guadalajara, ES, ⁴Toledo, ES, ⁵Ciudad Real, ES

- 13:00 - 13:00 834P - Results from 4 different risk-adapted surveillance strategies in a single Hospital for patients for stage I seminomatous germ cell tumours
P. Maroto, C. Martin, G. Sancho, J. Palou; Barcelona, ES
- 13:00 - 13:00 835P - Carboplatin dose based on actual renal function vs. dose capping: No excess of hematotoxicity in treatment of seminoma stage I
M. Fehr¹, H. Reichegger¹, A. Fischer Maranta², S. Gillissen¹, R. Cathomas²; ¹St. Gallen, CH, ²Chur, CH
- 13:00 - 13:00 836P - Outcome of patients with metastatic germ cell cancer treated between 2000 and 2013 at two centers in Munich
A. Gerl, J. Debole, M. Hentrich; München, DE
- 13:00 - 13:00 837P - Long-term changes in testosterone levels in testicular cancer survivors
M. Bandak, N. Jørgensen, A. Juul, J. Lauritsen, M. Mortensen, M. Kier, G. Daugaard; Copenhagen, DK
- 13:00 - 13:00 838P - Prognostic factors and survival in germ cell cancer (GCC) patients treated with bleomycin, etoposide, and cisplatin (BEP): A population-based study
M. Kier¹, J. Lauritsen¹, M. Mortensen¹, M. Bandak¹, K. Andersen¹, M. Hansen¹, M. Agerbaek², N. Holm³, S. Dalton¹, C. Johansen¹, G. Daugaard¹; ¹Copenhagen, DK, ²Aarhus C, DK, ³Odense C, DK
- 13:00 - 13:00 839P - Outcomes of peri-operative chemotherapy (PO-CT) for locally advanced penile squamous cell carcinoma (LA-PSCC): Results from a multicenter analysis
A. Necchi¹, G. Pond², D. Raggi¹, S. Ottenhof³, S. Horenblas³, V. Khoo⁴, O. Hakenberg⁵, A. Heidenreich⁶, B. Eigl⁷, L. Nappi⁷, K. Matsumoto⁸, U. Vaishampayan⁹, M. Woods¹⁰, P. Giannatempo¹, D. Geynisman¹¹, M. Preto¹², E. Xylinas¹³, M. Milowsky¹⁰, G. Di Lorenzo¹⁴, G. Sonpavde¹⁵; ¹Milano, IT, ²Hamilton, CA, ³Amsterdam, NL, ⁴London, GB, ⁵Rostock, DE, ⁶Köln, DE, ⁷Vancouver, CA, ⁸Sagamihara, JP, ⁹Detroit, US, ¹⁰Chapel Hill, NC/US, ¹¹Philadelphia, PA/US, ¹²Torino, IT, ¹³Paris, FR, ¹⁴Napoli, IT, ¹⁵Birmingham, US
- 13:00 - 13:00 840P - Dacomitinib as first-line treatment of locally-advanced (LA) or metastatic penile squamous cell carcinoma (PSCC): Interim analysis of an open-label, single-group, phase 2 trial
A. Necchi¹, D. Giardiello², D. Raggi¹, P. Giannatempo¹, N. Nicolai², M. Catanzaro², T. Torelli², D. Biasoni², L. Piva², S. Stagni², G. Calareso², E. Togliardi², L. Mariani², R. Salvioni²; ¹Milano, IT, ²Milan, IT
- 13:00 - 13:00 841P - Micro-RNA and mRNA integrative analysis revealed MMP1 as a predictor of lymph node metastasis in penile carcinomas
H. Kuasne¹, M. Barros-Filho², A. Busso-Lopes², F. Marchi¹, M. Pinheiro², C. Scapulatempo-Neto³, J. Muñoz², A. Lopes², G. Guimarães², E. Faria³, J. Trindade-Filho⁴, S. Drigo⁴, S. Rogatto⁵; ¹Sao Paulo, BR, ²São Paulo, BR, ³Barretos, BR, ⁴Botucatu, BR, ⁵Vejle, DK



- 13:00 - 13:00 842TiP - A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100)
T. Powles¹, P. Grivas², J. Aragon-Ching³, Y. Faroun⁴, E. Kessler⁵, Y. Tomita⁶, D. Chakrabarti⁷, R. Laliberte⁸, M. Shnaidman⁸, D. Petrylak⁹; ¹Albany, LA/US, ²Cleveland, OH/US, ³Fairfax, VA/US, ⁴Bethlehem, PA/US, ⁵Aurora, CO/US, ⁶Niigata, JP, ⁷Chester Springs, US, ⁸New York, NY/US, ⁹New Haven, US
- 13:00 - 13:00 843TiP - Surf: Open label, randomized multi-centre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma (mRCC)
G. Mouillet¹, T. Maurina², M.-J. Paillard², P. Montcuquet², T. Nguyen Tan Hon², H. Almotlak², U. Stein², D. Berthod², E. Robert², A. Meurisse², F. Bonnetain², A. Thiery-Vuillemin²; ¹Besançon, CEDEX/FR, ²Besançon, FR
- 13:00 - 13:00 844TiP - Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)
R. Motzer¹, T. Choueiri², J. Larkin³, L. Albiges⁴, J. Haanen⁵, M. Schmidinger⁶, M. Atkins⁷, M. Mariani⁸, M. Shnaidman¹, A. Di Pietro⁸, B. Rini⁹; ¹New York, NY/US, ²Boston, US, ³London, GB, ⁴Villejuif, FR, ⁵Amsterdam, NL, ⁶Vienna, AT, ⁷Washington, DC/US, ⁸Milano, IT, ⁹Middlesex, GB
- 13:00 - 13:00 845TiP - Ongoing phase 2 study of erdafitinib (JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (M/UR UC) and FGFR gene alterations
A. Siefker-Radtke¹, B. Mellado², K. Decaestecker³, J. Burke⁴, A. O'Hagan⁵, A. Avadhani⁵, B. Zhong⁶, A. Santiago-Walker⁷, P. De Porre⁸, S. Brookman-May⁹, J. Garcia-Donas¹⁰; ¹Houston, TX/US, ²Barcelona, ES, ³Gent, BE, ⁴Aurora, CO/US, ⁵Spring House, PA/US, ⁶Raritan, US, ⁷Raritan, PA/US, ⁸Villejuif, FR, ⁹Neuss, DE, ¹⁰Madrid, ES
- 13:00 - 13:00 846TiP - APACHE: An open label, randomized, phase 2 study of the anti-programmed death-ligand 1 (PD-L1) durvalumab (D, MEDI4736), alone or in combination with tremelimumab (T), in patients (pts) with advanced germ cell tumors (GCT)
A. Necchi¹, L. Mariani², A. Anichini², P. Giannatempo¹, D. Raggi¹, E. Togliardi², G. Calareso², N. Di Genova², F. Crippa², R. Salvioni²; ¹Milano, IT, ²Milan, IT
- 13:00 - 13:00 847TiP - PURE01: An open label, single-arm, phase 2 study of the anti-programmed death (PD)-1 monoclonal antibody (moAb) pembrolizumab for neoadjuvant therapy of muscle-invasive urothelial bladder carcinoma (miUBC)
A. Necchi¹, L. Mariani², A. Anichini², P. Giannatempo¹, D. Raggi¹, E. Togliardi², G. Calareso², N. Di Genova², F. Crippa², R. Salvioni²; ¹Milano, IT, ²Milan, IT
- 13:00 - 13:00 848TiP - Pembrolizumab with ChemoRadiotherapy for Muscle Invasive Bladder Cancer: The ANZUP PCR-MIB trial



A. Weickhardt¹, F. Foroudi¹, S. Sengupta¹, P. Grimison², N. Patanjali², S. Leslie², S. Ng³, C. Tang³, R. Goodwin³, E. Hovey², T. Jarvis², C. Chen², A. Herschtal⁴, L. Galletta⁴, S. Sandhu⁴, K.-H. Tai⁴, N. Lawrentschuk⁴, I. Davis⁵; ¹Melbourne, VIC/AU, ²Sydney, NSW/AU, ³Perth, WA/AU, ⁴Melbourne, AU, ⁵Box Hill, AU

- 13:00 - 13:00 849TiP - Pembrolizumab in patients with Bacillus Calmette Guérin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study
- R. de Wit¹, A.M. Kamat², J. Bellmunt³, T. Choueiri⁴, K. Nam⁵, M. De Santis⁶, R. Dreicer⁷, N. Hahn⁸, R. Perini⁵, A. Siefker-Radtke², G. Sonpavde⁹, J.A. Witjes¹⁰, S. Keefe¹¹, D. Bajorin¹²; ¹Rotterdam, NL, ²Houston, TX/US, ³Boston, US, ⁴Boston, MA/US, ⁵North Wales, PA/US, ⁶Coventry, GB, ⁷Charlottesville, US, ⁸Indianapolis, IN/US, ⁹Birmingham, US, ¹⁰Nijmegen, NL, ¹¹Kenilworth, NJ/US, ¹²New York, NY/US
- 13:00 - 13:00 850TiP - JaNEO – A phase Ib/II study assessing the neo-adjuvant combination therapy of vinflunine (VFL) with cisplatin (CDDP) followed by radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC)
- A. Hegele¹, C.-H. Ohlmann², H. Rexer³, G. Gakis⁴; ¹Marburg, DE, ²Homburg, DE, ³Schwarz, DE, ⁴Tübingen, DE
- 13:00 - 13:00 851TiP - TRAXAR study: A randomized phase 2 trial of axitinib and TRC105 versus axitinib alone in patients with advanced or metastatic renal cell carcinoma (mRCC)
- T. Choueiri¹, N. Agarwal², T. Ho³, S. Pal⁴, B. Seon⁵, M. Jivani⁶, B. Adams⁶, R. Shazer⁶, C. Theuer⁶; ¹Boston, US, ²Salt Lake City, UT/US, ³Scottsdale, CA/US, ⁴Duarte, US, ⁵Buffalo, NY/US, ⁶San Diego, CA/US
- 13:00 - 13:00 852TiP - The PAZOREAL non-interventional study to assess efficacy and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma (mRCC) treatment landscape
- P. Goebell¹, C. Doehn², C. Grüllich³, V. Grünwald⁴, T. Steiner⁵, R. Ehness⁶, M. Welslau⁷; ¹Erlangen, DE, ²Lübeck, DE, ³Heidelberg, DE, ⁴Hannover, DE, ⁵Erfurt, DE, ⁶Nuernberg, DE, ⁷Aschaffenburg, DE
- 13:00 - 13:00 853TiP - Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride in renal cell carcinoma patients with bone metastases
- R. El Aidi¹, Y. Vano¹, N. Aide², L. Fournier¹, D. Deandreis³, F. Tenenbaum¹, R. Lebtahi¹, H. De Clermont-Galleran⁴, L. Albiges³, B. Escudier³, F. Joly², J. Alexandre¹, M. Bernardini¹, S. Baron¹, J. Arfi-Rouche³, C. Noel², E. Braychenko¹, J. O'Quigley¹, J. Medioni¹, S. Oudard¹; ¹Paris, FR, ²Caen, FR, ³Villejuif, FR, ⁴Bordeaux, FR
- 13:00 - 13:00 Health economics
- 13:00 - 13:00 1022P - Assessing the impact of clinical trial designs on progress against cancer using the PACE Continuous Innovation Indicators™
- S. Paddock¹, S. Thomas², A. Kanli³, J. Zummo⁴, D. Grainger⁴, R. Li²; ¹Bethesda, US, ²Bethesda, MD/US, ³Brussels, BE, ⁴Indianapolis, IN/US
- 13:00 - 13:00 1023P - Are the newer chemotherapy drugs worth their high cost? - A survey of UK public's perception of reasonable price for chemotherapy drugs according to their health benefit



S. Sundar, H. Johnson, S. Taylor, S. Thomason; Nottingham, GB

- 13:00 - 13:00 1024P - Methodological differences and the appropriate application of oncology value frameworks to assess clinical value
G. Monnickendam¹, K. Mortaki², J. McKendrick¹; ¹Fleet, GB, ²Maroussi, GR
- 13:00 - 13:00 1025P - The cost-effectiveness of combination therapy: Challenges of the present, solutions for the future? A myeloma analysis
J. Harrison¹, N. Rabin¹, H. Pang¹, C. Davis², H. Kim³; ¹London, GB, ²Princeton, US, ³Melbourne, AU
- 13:00 - 13:00 1026P - A shared-risk model linking patient-level clinical outcomes and drug company reimbursement in cancer care
O. Oren, D. Henry; Philadelphia, PA/US
- 13:00 - 13:00 1027P - Novel therapy options for advanced & metastatic melanoma patients in EU5 countries result in a changing treatment pattern especially in BRAF mutant patients
M. Bernhardt¹, N. Schmidt², K. Acker¹; ¹Frankfurt Am Main, DE, ²Frankfurt, DE
- 13:00 - 13:00 1028P - The relative clinical value of immun-oncology treatment, the NNT values of PD1-inhibitor nivolumab and pembrolizumab in metastatic melanoma patients
E. Pornczy¹, I. Boncz²; ¹Budapest, HU, ²Pecs, HU
- 13:00 - 13:00 1029P - Real-world comparative effectiveness analysis of second-line (2L) nab-paclitaxel (nab-P) vs paclitaxel (Pac) in patients (Pts) with metastatic breast cancer (MBC)
C. Pelletier¹, M. Parisi¹, S. Glück¹, Q. Ni¹, F. Braiteh²; ¹Summit, NJ/US, ²Las Vegas, NV/US
- 13:00 - 13:00 1030P - Real-world comparative effectiveness analysis of second-line (2L) nab-paclitaxel (nab-P) vs eribulin (Erib) in patients (Pts) with metastatic breast cancer (MBC)
M. Parisi¹, S. Glück¹, C. Pelletier¹, Q. Ni¹, F. Braiteh²; ¹Summit, NJ/US, ²Las Vegas, NV/US
- 13:00 - 13:00 1031P - Cost-effectiveness analysis (CEA) of adjuvant trastuzumab therapy use in HER2-positive early-stage breast cancer (EBC)
K. Quintyne¹, B. Woulfe², A. Dee², R. Gupta²; ¹Dublin, IE, ²Limerick, IE
- 13:00 - 13:00 1032P - Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma in Sweden
S. Johal¹, K. Johannesen², B. Malcolm³, J. Doan⁴; ¹London, GB, ²Princeton, NJ/US, ³Uxbridge, GB, ⁴Wallingford, CT/US
- 13:00 - 13:00 1033P - A retrospective, real-world study of treatment patterns and outcomes among metastatic urothelial cancer (mUC) patients in the United States
E. Malangone-Monaco¹, S. Satram-Hoang², K. Wilson¹, H. Varker¹, S.-W. Lin³, D. Tayama³, S. Ogale³; ¹Bethesda, MD/US, ²Granite Bay, CA/US, ³San Francisco, CA/US
- 13:00 - 13:00 1034P - Economic evaluation of pazopanib as first-line treatment of metastatic renal cell carcinoma in Greece



A. Solakidi¹, G. Kourlaba¹, L. Kontovinis², E. Bournakis¹, A. Boutis², K. Koutsoukos¹, J. Syrios¹, A. Tzovaras¹, M. Chatzikou¹, C. Michailidi¹, N. Maniadakis¹; ¹Athens, GR, ²Thessaloniki, GR

- 13:00 - 13:00 1035P - Understanding real world treatment patterns, healthcare resource utilization (HRU) and costs among metastatic renal cell carcinoma (mRCC) patients
R. Copher¹, S. Dacosta Byfield², P. Buzinec², S. Korrer², M. Baig³; ¹Woodcliff Lake, US, ²Eden Prairie, MN/US, ³Woodcliff Lake, NJ/US
- 13:00 - 13:00 1036P - A real-world study of patterns of Bacillus Calmette-Guerin (BCG) use and associated adverse events (AEs) in non-muscle invasive bladder cancer (NMIBC) patients in the United States
K. Wilson¹, E. Malangone-Monaco¹, S. Satram-Hoang², D. Diakun¹, S.-W. Lin³, D. Tayama³, S. Ogale³; ¹Bethesda, MD/US, ²Granite Bay, CA/US, ³San Francisco, CA/US
- 13:00 - 13:00 1037P - Economic burden of cancer associated thrombosis in Germany
R. Lipp¹, M. Feuerbach¹, F. Freigang¹, N. Schmidt², E. Reimer³; ¹Hamburg, DE, ²Frankfurt Am Main, DE, ³Copenhagen, DK
- 13:00 - 13:00 1038P - The impact of cancer-associated thrombosis and treatment related bleedings on patients' quality of life
S. Noble¹, A. Lloyd², S. Dewilde³, E. Reimer⁴, A. Lee⁵; ¹Cardiff, GB, ²Oxford, GB, ³Brussels, BE, ⁴Copenhagen, DK, ⁵Vancouver, CA
- 13:00 - 13:00 1039P - Health care resource use and costs of cancer-associated thrombosis in Sweden
H. Norrild¹, M.V. Holm², J. Norlin¹, P. Svensson², G. Ragnarson Tennvall¹; ¹Lund, SE, ²Malmö, SE
- 13:00 - 13:00 1040P - Dalteparin vs. vitamin K antagonist (VKA) for the prevention of recurrent venous thromboembolism (VTE) in cancer patients with renal insufficiency: A patient level pharmacoeconomic analysis in three European countries
L. Shane¹, G. Dranitsaris², S. Woodruff¹, J.-P. Galanaud³, G. Stemer⁴, P. Debourdeau⁵, B. Valtier⁶, L. Burgers⁷; ¹New York, NY/US, ²Toronto, ON/CA, ³Montpellier, FR, ⁴Vienna, AT, ⁵Lyon, FR, ⁶Paris, FR, ⁷Amsterdam, NL
- 13:00 - 13:00 1041P - Health state utility measured by EQ-5D-5L for EGFRm T790M NSCLC patients treated with osimertinib
C. Bodnar, J. Ryan, M. Green; Cambridge, GB
- 13:00 - 13:00 (Withdrawn)
- 13:00 - 13:00 1043P - Modeling maintenance therapy in ovarian cancer
C. Jones¹, B. Harrow², E. Badamgarav³, S. Agarwal⁴, J. Ledermann⁵, C. Quinn¹; ¹Fleet, GB, ²Waltham, MA/US, ³Zug, CH, ⁴Waltham, US, ⁵London, GB
- 13:00 - 13:00 1044P - Incremental cost-effectiveness analysis of hepatic metastasectomy in patients with advanced colon cancer and liver metastasis
S. Chaintikun, Bangkok, TH



- 13:00 - 13:00 1045P - An Italian cost-effectiveness analysis of paclitaxel albumin (nab®-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: The APICE study
C. Lazzaro¹, C. Barone², F. Caprioni³, S. Cascinu⁴, A. Falcone⁵, E. Maiello⁶, M. Milella², C. Pinto⁷, M. Reni¹, G. Tortora⁸; ¹Milano, IT, ²Roma, IT, ³Genova, IT, ⁴Ancona, IT, ⁵Pisa, IT, ⁶San Giovanni Rotondo, IT, ⁷Reggio Emilia, IT, ⁸Verona, IT
- 13:00 - 13:00 1046P - Incidence, epidemiology and outcome in adults and children with ALL: A review of population-based cancer registries (PBCRs), an experience from Eastern India
S. Banerjee, Kolkata, IN
- 13:00 - 13:00 Head and neck cancer
- 13:00 - 13:00 958P - Tumor growth rate analysis of progression-free survival (PFS) and overall survival (OS) for thyroid cancer patients receiving placebo or sorafenib in the phase 3 DECISION trial
C. Kappeler¹, G. Meinhardt², R. Elisei³, M. Brose⁴, M. Schlumberger⁵; ¹Berlin, DE, ²Whippany, NJ/US, ³Pisa, IT, ⁴Philadelphia, US, ⁵Villejuif, FR
- 13:00 - 13:00 959P - PIK-ORL: A phase II, multicenter trial aiming to evaluate BKM120 in monotherapy in patients (pts) with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) after failure of platin and cetuximab or anti-EGFR-based therapy
J. Fayette¹, L. Digue², C. Ferlay¹, I. Treilleux¹, G. Garin¹, Q. Wang¹, C. Hebert³, C. Even⁴, D. Cupissol⁵, S. Couchon-Thaumat¹, L. Jaouen¹, A. Guyennon¹, C. Le Tourneau⁶, G. Lefebvre⁷, A. Mailliez⁷, M. Matias⁴, M. Degardin⁷, S. Tartas¹, G. Clapisson¹, D. Perol¹; ¹Lyon, FR, ²Bordeaux, FR, ³Nice, FR, ⁴Villejuif, FR, ⁵Montpellier, FR, ⁶Paris, FR, ⁷Lille, FR
- 13:00 - 13:00 960P - Causes of death statistics underestimate the burden of head and neck (H&N) cancers: A nationwide study from France in 2008-2012 (EPICORL study)
C. Even¹, Y. Pointreau², L. Geoffrois³, M. Schwarzingler⁴, M. Bec⁵, C. Godard⁵, F. Huguet⁴, S. Téمام¹, S. Thiébaum⁴; ¹Villejuif, FR, ²Le Mans, FR, ³Vandoeuvre Les Nancy, FR, ⁴Paris, FR, ⁵Courbevoie, FR
- 13:00 - 13:00 961P - Axitinib in recurrent or metastatic nasopharyngeal carcinoma (NPC): Final result of a phase 2 clinical trial with pharmacokinetic (PK) correlation
E. Hui¹, B. Ma¹, F. Mo¹, M. Kam¹, S. Chan¹, H. Loong¹, R. Ho¹, S. Leung¹, A. King¹, K. Wang¹, A. Ahuja¹, C. Chan¹, C. Hui¹, C. Wong¹, A. Chan²; ¹Shatin, HK, ²Hong Kong, HK
- 13:00 - 13:00 962P - Responses in specific metastases following treatment with lenvatinib (LN): Results from the phase 3 SELECT trial
B. Robinson¹, M. Schlumberger², L. Wirth³, C. Dutcus⁴, T. Binder⁴, M. Guo⁴, M. Taylor⁵, S. Kim⁶, M. Krzyzanowska⁷, J. Capdevilla⁸, S. Sherman⁹, M. Tahara¹⁰; ¹Sydney, NSW/AU, ²Villejuif, FR, ³Boston, MA/US, ⁴Woodcliff Lake, NJ/US, ⁵Portland, US, ⁶Seoul, KR, ⁷Toronto, ON/CA, ⁸Barcelona, ES, ⁹Houston, TX/US, ¹⁰Kashiwa, JP
- 13:00 - 13:00 963P - Survival of patients with head and neck (H&N) cancers: A nationwide study from France in 2008-2012 (EPICORL study)



F. Huguet¹, S. Téman², Y. Pointreau³, S. Thiébaud¹, M. Bec¹, L. Lévy-Bachelot⁴, C. Even², L. Geoffrois⁵, M. Schwarzingler¹; ¹Paris, FR, ²Villejuif, FR, ³Le Mans, FR, ⁴Courbevoie, FR, ⁵Vandoeuvre Les Nancy, FR

- 13:00 - 13:00 964P - Molecular profiling of locally advanced/metastatic olfactory neuroblastomas
Z. Gatalica¹, A. Ghazalpour², J. Swensen¹, R. Bender², S. Vranic³, R. Feldman², S. Reddy¹; ¹Phoenix, US, ²Phoenix, AZ/US, ³Sarajevo, BA
- 13:00 - 13:00 965P - Prognostic relevance of molecular characterization of circulating tumor cells (CTC) in head and neck squamous cell carcinoma (HNSCC)
G. Koutsodontis¹, A. Strati¹, G. Papaxoinis², N. Charalambakis¹, I. Kotsantis¹, P. Oikonomopoulou¹, L. Hoxhallari¹, E. Lianidou¹, A. Psyrris¹; ¹Athens, GR, ²Manchester, GB
- 13:00 - 13:00 966P - Mutation profiles of nasopharyngeal carcinomas in South-Eastern European patients
G. Fountzilas¹, A. Psyrris², E. Giannoulatou³, G. Kouvatseas², D. Rontogianni², E. Ciuleanu⁴, T.-E. Ciuleanu⁴, L. Resiga⁴, T. Zaramboukas², M. Bobos², S. Chrisafi², E. Tsolaki², K. Papadopoulou², K. Markou², N. Charalambakis², A. Koutras⁵, A. Kalogera-Fountzila², M. Skondra², D. Pectasides², V. Kotoula¹; ¹Thessaloniki, GR, ²Athens, GR, ³Darlinghurst, AU, ⁴Cluj Napoca, RO, ⁵Patras, GR
- 13:00 - 13:00 967P - Observational study of the cetuximab relative dose intensity (RDI) in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Data on the maintenance and every two weeks use (DIRECT study)
J. Guigay¹, E. Chamorey¹, P. Céruse², F. Mornex², M. Degardin³, M. Alfonsi⁴, L. Digue⁵, A. Berrier⁶, X. Artignan⁷, L. Cals⁸, S. Faivre⁹, E. Vuillemin¹⁰, F. Rolland¹¹, A. Timochenko¹², E. Babin¹³, A. Seronde-Delmas², A. Prevost¹⁴, O. Romano³, F. Peyrade¹, C. Le Tourneau¹⁵; ¹Nice, FR, ²Lyon, FR, ³Lille, FR, ⁴Avignon, FR, ⁵Bordeaux, FR, ⁶Lens, FR, ⁷St. Grégoire, FR, ⁸Montbéliard, FR, ⁹Clichy, FR, ¹⁰Vannes, FR, ¹¹St. Herblain, FR, ¹²St. Priest En Jarez, FR, ¹³Caen, FR, ¹⁴Reims, FR, ¹⁵Paris, FR
- 13:00 - 13:00 968P - Cytokeratin 4 is a novel predictive marker in early stage (T1/2) oral tongue squamous cell carcinoma (TSCC)
T. Enokida¹, S. Fujii¹, M. Takahashi¹, T. Wakasugi¹, T. Yamazaki¹, S. Okano², R. Hayashi¹, M. Tahara¹; ¹Kashiwa, JP, ²Tokyo, JP
- 13:00 - 13:00 969P - New concepts of “minimal residual disease” and “biomarker failure” in nasopharyngeal carcinoma
J.-C. Lin¹, W.-Y. Wang¹, S. Leung², H. Chen³, C.-J. Huang², L.-L. Ting⁴; ¹Taichung, TW, ²Kaohsiung, TW, ³Tainan, TW, ⁴Taipei, TW
- 13:00 - 13:00 970P - Triweekly versus weekly cisplatin concurrent with radiotherapy in locally advanced nasopharyngeal carcinoma
M. Lan¹, S. Wu¹, F. Han¹, M. Deng¹, C. Chen¹, Y. Huang¹, Z. Duan², J. Liao¹, L. Tian¹, L. Zheng¹, T. Lu¹; ¹Guangzhou, CN, ²Chengdu, CN
- 13:00 - 13:00 971P - High incidence of cetuximab-related infusion reactions in head and neck cancer pts (real life data)
V. Palomar, M. Annereau, N. Lezghed, C. Even, L. Mayache-Badis, M. Iacob, C. Leib, M. Matias, P. Bravo, C. Ferte; Villejuif, FR



- 13:00 - 13:00 972P - Dovitinib in advanced adenoid cystic carcinoma of the salivary glands: Ontario Clinical Oncology Group DOVE trial
S. Hotte¹, D. Hao², G. Pond¹, S. Laurie³, E. Winquist⁴, M. Fillion¹, M. Levine¹; ¹Hamilton, CA, ²Calgary, CA, ³Ottawa, CA, ⁴London, ON/CA
- 13:00 - 13:00 973P - The role of pre-treatment plasma Epstein-Barr virus (EBV) DNA as a predictive biomarker of induction chemotherapy for stage IVA or IVB nasopharyngeal carcinoma (NPC) patients – A Subgroup Analysis on Taiwan Cooperative Oncology Group (TCOG) 1303 study
H.-F. Kao¹, C.-F. Hsiao², S.-C. Lai², C.-W. Wang¹, J.-Y. Ko¹, P.-J. Lo¹, T.-J. Lee¹, T.-W. Liu¹, R.-L. Hong¹; ¹Taipei, TW, ²Miao-Li, TW
- 13:00 - 13:00 974P - Prospective study of cetuximab with cisplatin plus docetaxel followed by concurrent radiotherapy plus cetuximab and cisplatin in patients with chemotherapy-naive metastatic nasopharyngeal carcinoma
T. Lin, M. Zhang, H. Huang, X. Li, Y. Huang, C. Chen, Z. Wang, X. Fang; Guangzhou, CN
- 13:00 - 13:00 975P - Individual ADCC capability predict treatment outcome under cetuximab-based therapy in head and neck cancer?
L. Lattanzio¹, D. Vivenza¹, F. Tonissi¹, C. Varamo¹, M. Ferrero¹, G. Strola¹, G. Milano², C. Lo Nigro¹, M. Merlano¹; ¹Cuneo, IT, ²Nice, FR
- 13:00 - 13:00 976P - Prognostic value of HPV infection by E1 detection and p16 expression in 78 oropharyngeal squamous cell carcinomas
C. Lo Nigro, D. Vivenza, L. Lattanzio, M. Fortunato, N. Denaro, C. Varamo, M. Ferrero, E. Russi, M. Merlano; Cuneo, IT
- 13:00 - 13:00 977P - Comorbidity and nutritional factors influence on bioradiotherapy (BRT) outcome in head and neck squamous cell carcinoma (HNSCC) patients
M. Oliva, M. Taberna, A. Rullan Iriarte, M. Bergamino, A. Rovira, R. Montal, L. Hurtos, L. Arribas, E. Vilajosana, A. Lozano, V. Navarro, S. Vazquez, M. Maños, R. Mesía; Barcelona, ES
- 13:00 - 13:00 978P - Prevalence, pattern, and impact of PD-L1 expression and HPV-status in head and neck squamous cell carcinoma
T. Chureemas, N. Larbcharoensub, J. Juengsamarn, T. Layangkool, C. Jiarpinitnun, P. Chansriwong, N. Trachu, P. Pattaranutaporn, N. Ngamphaiboon; Bangkok, TH
- 13:00 - 13:00 979P - Does post-induction chemotherapy PET/CT response predict outcome in young adult nasopharyngeal carcinoma? Prospective study from CCHE
S. Ahmed, M. Amr Abdelwahab, E. A.el-Kholy, A. Kamel, S. A.fadel, H. Taha, I. Zaky, A. Elnashar; Cairo, EG
- 13:00 - 13:00 980P - Advanced acinic cell carcinoma harbors kinase rearrangements including BRAF kinase domain duplications
S. Ali¹, K. Fedorchak¹, A. Schrock¹, J. Johnson², K. Gowen¹, J. Elvin³, J.-A. Vergilio³, S. Klempner⁴, R. Mehra², A. Ho⁵, D. Pavlick¹, J. Suh³, R. Bordoni⁶, D. Jung⁷, P. Stephens³, C. Chung⁸, J. Ross⁹, V. Miller³; ¹Cambridge, US, ²Philadelphia, PA/US, ³Cambridge, MA/US, ⁴Los Angeles, CA/US, ⁵New York, US, ⁶Marietta, US, ⁷Boston, US, ⁸Tampa, US, ⁹Albany, NY/US



- 13:00 - 13:00 981P - Pharmacogenomic predictors of cisplatin oto- and nephrotoxicity in head and neck cancer patients treated with chemoradiation
E. Winqvist, W. Teft, A. Nichols, C. Parker, M. Trinnear, P. Francis, N. Bukhari, J. Lukovic, Y.-H. Choi, S. Kuruvilla, S. Richter, A. Hammond, D. Macneil, N. Read, K. Fung, V. Venkatesan, S. Welch, D. Palma, J. Yoo, R. Kim; London, ON/CA
- 13:00 - 13:00 982P - Metronomic oral cyclophosphamide as 3rd line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma
V. Lee, D. Kwong, Y.-C. Lai, Y. Li, K.-O. Lam, P.Y.P. Ho, W.-L. Chan, L.-S. Wong, D. Leung, S.-Y. Chan, F.-T. Chan, K.-S. Lau, R. Tse, T.-W. Leung, A. Lee; Hong Kong, HK
- 13:00 - 13:00 983P - An advanced tumor shape radiomic signature predicts recurrence of locally advanced (LA) HNSCC patients (pts)
E.J. Limkin, A. Schernberg, S. Reuze, L. Behar, D. Ou, Y.G. Tao, E. Deutsch, C. Robert, C. Ferte; Villejuif, FR
- 13:00 - 13:00 984P - Utility of algorithm-based chemoradioselection for advanced laryngeal and hypopharyngeal carcinoma
M. Masuda, T. Wakasaki, S. Toh, N. Kunitake, F. Rikimaru, Y. Higaki; Fukuoka, JP
- 13:00 - 13:00 985P - Prognostic implication of ERCC-1 protein expression in resected head and neck cancer
Y.H. Ko¹, H.J. An², C.K. Jung³, J.H. Kang³, M.S. Kim³, K.J. Cho¹, H.S. Won¹, D.S. Sun¹; ¹Uijeongbu-Si, KR, ²Suwon, KR, ³Seoul, KR
- 13:00 - 13:00 986P - Pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC): Further evaluation of efficacy including tumor growth rates (GR) analysis. H&N Unicancer Group PACSA trial with the REFCOR
J. Guigay¹, F. Bidault², J. Fayette³, C. Even², D. Cupissol⁴, F. Rolland⁵, F. Peyrade¹, B. Laguerre⁶, C. Le Tourneau⁷, S. Zanetta⁸, L. Bozec Le Moal⁷, C. Borel⁹, L. Digue¹⁰, J. Delaye⁷, S. Diffetocq², V. Costes⁴, A. Auperin², L. Faivre²; ¹Nice, FR, ²Villejuif, FR, ³Lyon, FR, ⁴Montpellier, FR, ⁵St. Herblain, FR, ⁶Rennes, FR, ⁷Paris, FR, ⁸Dijon, FR, ⁹Strasbourg, FR, ¹⁰Bordeaux, FR
- 13:00 - 13:00 987P - Relationships between imaging characteristics and hearing levels in patients with vestibular schwannomas treated by stereotactic radiosurgery
T.-C. Wang, Taichung, TW
- 13:00 - 13:00 988P - Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
A. Castro¹, J. Febra¹, A. Coelho², M. Rocha², S. Lopes³, H. Gouveia³, A. Joaquim⁴, F. Monteiro⁴, T. Mota¹, A. Araujo¹; ¹Porto, PT, ²Vila Real, PT, ³Santa Maria Da Feira, PT, ⁴Vila Nova De Gaia, PT
- 13:00 - 13:00 989P - Ototoxicity in locally advanced head and neck cancer (LAHNC) patients (pts) treated with induction chemotherapy (IC) followed by cisplatin-based chemoradiotherapy (CRT)
C. Driessen¹, A. Snik¹, J. Leijendeckers¹, J.P. de Boer², H. Gelderblom³, C. van Opstal¹, W. van der Graaf¹, J. Kaanders¹, C. van Herpen¹; ¹Nijmegen, NL, ²Amsterdam, NL, ³Leiden, NL



- 13:00 - 13:00 990P - Comparison of the toxicity and response of a novel outpatient weekly CDFLEM (cisplatin, docetaxel, fluorouracil, leucovorin, epirubicin, methotrexate) induction chemotherapy versus triweekly TPF or PF in locally advanced SCCHN
J.-C. Lin, Y.-C. Liu, P.-J. Lin; Taichung, TW
- 13:00 - 13:00 991P - Retrospective study of weekly paclitaxel-cetuximab (WPC) in unselected patients (p) with recurrent/metastatic head and neck squamous cell carcinoma (RM-SCCHN)
I. Pajares Bernad¹, J. Martínez Trufero¹, L. Calera Urquizu¹, A. Cebolledo de Miguel¹, R. Pazo Cid¹, M. Lanzuela Valero¹, M. Agustín¹, E. Millastre¹, C. Santander Lobera¹, M. Alvarez Alejandro¹, N. Gimeno¹, M. Malo Yague², Y. Llorente¹, A. Antón Torres¹; ¹Zaragoza, ES, ²Calatayud, ES
- 13:00 - 13:00 992P - Clinical-dosimetric analysis of factors predisposing to chronic dysphagia measured using CTCAE criteria among locally advanced oropharyngeal cancer patients treated definitively by intensity modulated radiotherapy with concurrent chemotherapy
K. Periasamy¹, R. Pasricha², N. Patni², T. Soni²; ¹Gurgaon, Haryana/IN, ²Jaipur, IN
- 13:00 - 13:00 993P - Baseline neutrophil-to-lymphocyte ratio is associated with outcome in recurrent/metastatic head and neck squamous cell cancer patients treated with platinum and cetuximab in first line setting
M. Siano¹, G. Infante², R. Miceli², C. Resteghini², L. Locati², L. Licitra², P. Bossi²; ¹St. Gallen, CH, ²Milano, IT
- 13:00 - 13:00 994P - Cetuximab in combination with platinum-based chemotherapy or radiotherapy in recurrent and/or metastatic SCCHN in a non-selected patient cohort (interim analysis of the phase IV SOCCER trial)
M. Hecht¹, D. Hahn², D. Beutner³, D. Reichert⁴, T. Göhler⁵, R. Wurm⁶, M. Welslau⁷, L. Renziehausen⁸, P. Balerspås⁹, T. Bergmann¹⁰, M. Aßmann¹¹, C. Belka¹², K. Orłowski¹³, M. Finzsch¹³, G. Illerhaus², R. Fietkau¹; ¹Erlangen, DE, ²Stuttgart, DE, ³Köln, DE, ⁴Westerstede, DE, ⁵Dresden, DE, ⁶Frankfurt An Der Oder, DE, ⁷Aschaffenburg, DE, ⁸Chemnitz, DE, ⁹Frankfurt Am Main, DE, ¹⁰Gera, DE, ¹¹Riesa, DE, ¹²München, DE, ¹³Darmstadt, DE
- 13:00 - 13:00 995P - Role of epidermal growth factor and its soluble receptor in realization of anti-EGFR monoclonal antibodies effect in patients with head and neck cancer (HNC)
A. Agieva¹, O. Kit¹, E. Frantsiyants¹, L. Vladimirova², M. Engibaryan¹, I. Pustovaya¹, N. Cheryarina¹, Y. Pogorelova¹; ¹Rostov On Don, RU, ²Rostov-On-don, RU
- 13:00 - 13:00 996P - Genetic polymorphisms in DNA mismatch repair-related genes predict outcome in patients with head and neck squamous cell carcinoma treated with cisplatin and radiotherapy
G. Lourenço¹, G. Nogueira¹, L. Lopes-Aguiar¹, E. Costa¹, T. Lima¹, M. Visacri¹, E. Pincinato¹, L. Calonga¹, F. Mariano¹, A. Altemani¹, J. Altemani¹, C. Coutinho-Camillo², M. Alves¹, P. Moriel¹, C. Chone¹, C. Ramos¹, C. Lima¹; ¹Campinas, BR, ²São Paulo, BR
- 13:00 - 13:00 997P - Influence of FASL and FAS polymorphisms, enrolled in extrinsic apoptosis pathway, in the inherited increased risk of head and neck squamous cell carcinoma
C. Lima, V. Liutti, T. Lima, E. Costa, L. Lopes-Aguiar, G. Nogueira, F. Leal, V. Santos, C. Oliveira, J. Rinck-Junior, G. Lourenço; Campinas, BR
- 13:00 - 13:00 998P - An optimal cumulative dose of cisplatin in chemoradiotherapy as a definitive treatment for non-metastatic nasopharyngeal carcinoma: A retrospective multicenter study



P. Danchaiwijitr, N. Ngamphaiboon, C. Jiarpinitnun, E. Sirachainan, P. Pattaranutaporn, J. Setakornnukul; Bangkok, TH

- 13:00 - 13:00 999P - Presence of percutaneous endoscopic gastrostomy tube (PEG) is an independent negative prognostic factor in recurrent/metastatic head and neck squamous cell cancer (r/mHNSCC) patients
M. Siano, N. Jarisch, M. Jörger; St. Gallen, CH
- 13:00 - 13:00 1000P - Outcomes of critically ill head and neck cancer (HNC) patients (pts) admitted in medical intensive care units (mICU) after oncological treatments
A.C. Freitas, M.T. Alexandre, I. Sargento, M. Ferreira, M. Ramos, A. Marques, A. Moreira; Lisboa, PT
- 13:00 - 13:00 1001P - Expression of calreticulin is a novel independent prognostic factor for oral squamous cell carcinoma
T. Takenawa, K. Harada, T. Ferdous, Y. Ueyama; Ube, JP
- 13:00 - 13:00 1002P - Phase I study of ribociclib plus cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
E. Seront¹, S. Schmitz², S. Rottey³, S. Henry⁴, C. Lonchay⁵, G. van Caloen², A. Gilain², J.-P. Machiels²; ¹Haine Saint Paul, BE, ²Brussels, BE, ³Gent, BE, ⁴Namur, BE, ⁵Charleroi, BE
- 13:00 - 13:00 1003P - A comparison of cetuximab-containing regimens for recurrent/metastatic squamous cell head and neck carcinoma: the clinical significance of weekly paclitaxel and cetuximab
K. Nakano, S. Marshall, S. Taira, Y. Sato, J. Tomomatsu, T. Sasaki, W. Shimbashi, H. Fukushima, H. Yonekawa, H. Mitani, K. Kawabata, S. Takahashi; Tokyo, JP
- 13:00 - 13:00 1004P - Effect of Hedgehog signaling pathway on the proliferation of high-grade gliomas
S. Cherepanov, Moscow, RU
- 13:00 - 13:00 1005P - Molecular analysis in serial biopsies in sinonasal mucosal melanoma
G. Anguera Palacios¹, M.Á. Molina-Vila¹, J.R. Gras-Cabrerizo¹, X. León¹, C. Mayo¹, J. Codony Servat¹, A. Pérez-Rosado¹, S. Rodríguez¹, M. González-Cao¹, N. Karachaliou¹, A. Barnadas¹, R. Rosell², M. Majem¹; ¹Barcelona, ES, ²Badalona, ES
- 13:00 - 13:00 1006P - Expression profile of papillary thyroid carcinomas according to cervical lymph node metastasis status
M. Barros Filho¹, F. Marchi¹, C. Pinto¹, S. Rogatto², L. Kowalski³; ¹Sao Paulo, BR, ²Vejle, DK, ³São Paulo, BR
- 13:00 - 13:00 1007P - Phase II-trial of concomitant hyperfractionated-accelerated radiotherapy (HART) with cisplatin (Cis) plus cetuximab (Cet) for locoregionally advanced inoperable squamous cell head and neck cancer: 5-year end results
T. Kuhnt¹, A. Schreiber², A. Pirnasch³, M. Hautmann⁴, P. Hass⁵, F. Sieker⁶, R. Engenhardt-Cabilic⁷, M. Richter⁶, K. Dellas⁸, J. Dunst⁸; ¹Leipzig, DE, ²Dresden, DE, ³Rostock, DE, ⁴Regensburg, DE, ⁵Magdeburg, DE, ⁶Halle/saale, DE, ⁷Marburg, DE, ⁸Kiel, DE
- 13:00 - 13:00 1008P - Effect of protracted radiotherapy treatment on outcome of head and neck SCC patients (NEMROCK experience)
L. Ahmed, H. Darwish, S. El-Haddad, T. El-Nahas; Cairo, EG



- 13:00 - 13:00 1009P - A novel treatment of radiation induced xerostomia by autologous platelet-rich-plasma and peripheral stem cells
A. Taghizadeh Kermani, P. Izadpanahi, K. Khazaeni, M. Pezeshki Rad M, R. Asadi, M. Asadi, D. Hamidi Alamdari; Mashhad, IR
- 13:00 - 13:00 1010P - The role of interim FDG-PET after induction chemotherapy as a prediction of the efficacy of concurrent chemoradiotherapy in locally advanced squamous carcinoma of the head and neck
K.-R. Kim, H.-J. Shim, J.-E. Hwang, S.-H. Cho, I.-J. Chung, S.Y. Kwon, W.-K. Bae; Hwasun-Gun, KR
- 13:00 - 13:00 1011P - High expression of FOXM1 is a potential prognostic marker for oral squamous cell carcinoma patients treated with docetaxel-containing regimens
T. Ferdous, K. Harada, Y. Ueyama; Ube, JP
- 13:00 - 13:00 1012P - A multi-institutional dose-finding and efficacy confirmation trial of superselective intra-arterial infusion of cisplatin and concomitant radiotherapy for patients with locally advanced maxillary sinus cancer (JCOG1212, RADPLAT-MS): Results of dose-finding phase
T. Sakashita¹, A. Homma¹, R. Onimaru¹, K. Matsuura², H. Shinomiya³, R. Hayashi⁴, K. Shiga⁵, H. Tachibana⁶, K. Nakamura⁷, J. Mizusawa⁷, M. Fujii⁷; ¹Sapporo, JP, ²Natori, JP, ³Kobe, JP, ⁴Kashiwa, JP, ⁵Morioka, JP, ⁶Nagoya, JP, ⁷Tokyo, JP
- 13:00 - 13:00 1013P - Cervical lymph node metastasis of squamous cell carcinoma of an unknown primary (SCCUP): A single institutional review
J. Silva, M.T. Alexandre, D. Ferreira, M. Ramos, P. Pereira, N. Ferreira, I. Sargento, E. Netto, M. Magalhaes, M. Ferreira, A. Moreira; Lisboa, PT
- 13:00 - 13:00 1014P - Impact of second primary tumors of head and neck region after a previous tumor in that area
C. Salvador Coloma, J. Amerigo, Ó. Niño, J. Caballero Daroqui, D. Akhoundova, C. Escoin, M. Melián Sosa, E. Navarro, J. Montalar, M. Pastor; Valencia, ES
- 13:00 - 13:00 1015P - Percutaneous gastrostomy or tracheostomy do not compromise overall survival in patients treated with chemotherapy for relapsed head and neck cancer
K. Geršak, C. Grasic Kuhar, B. Zakotnik; Ljubljana, SI
- 13:00 - 13:00 1016TiP - A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651
A. Argiris¹, M. Gillison², R. Ferris³, K. Harrington⁴, T. Sanchez⁵, C. Baudalet⁵, W. Geese⁶, J. Shaw⁵, R. Haddad⁷; ¹Athens, GR, ²Columbus, US, ³Pittsburgh, Pa, US, ⁴London, GB, ⁵Princeton, NJ/US, ⁶Lawrence Township, NJ/US, ⁷Boston, US
- 13:00 - 13:00 1017TiP - Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714
R. Haddad¹, M. Gillison², R. Ferris³, K. Harrington⁴, M. Monga⁵, C. Baudalet⁵, W. Geese⁶, A. Argiris⁷; ¹Boston, US, ²Columbus, US, ³Pittsburgh, Pa, US, ⁴London, GB, ⁵Princeton, NJ/US, ⁶Lawrence Township, NJ/US, ⁷Athens, GR



- 13:00 - 13:00 1018TiP - A phase I dose escalation trial of stereotactic body radiotherapy and concurrent cisplatin for re-irradiation of unresectable, recurrent carcinomas of the head and neck
J. Caudell¹, A. Trotti², J. Kish², J. Russell²; ¹Tampa, US, ²Tampa, FL/US
- 13:00 - 13:00 1019TiP - Phase 1b trial of LY2606368 in combination with chemoradiation in patients with locally advanced head and neck squamous cell cancer
E. Yang¹, W. William², J. Fayette³, W. Zhang⁴, A. Fink⁴, A. Lin⁴, E. Deutsch⁵; ¹Birmingham, AL/US, ²Houston, TX/US, ³Lyon, FR, ⁴Indianapolis, IN/US, ⁵Villejuif, FR
- 13:00 - 13:00 Immunotherapy of cancer
- 13:00 - 13:00 1057P - Noninvasive PET imaging of the PD-1/PD-L1 checkpoint in naïve and irradiated tumor-bearing mice
G. Niedermann, M. Hettich; Freiburg, DE
- 13:00 - 13:00 1058P - MVX-ONCO-1 phase 1 final results of the first personalized cell-based immunotherapy using cell encapsulation technology
N. Mach, R. Vernet, M.-C. Belkouch, P. Luy, V. Ancrenaz, P. Teta, N. Blazek, N. Grandjean, J. Wasem, J. Grogg, T. Perez, D. Migliorini; Geneva, CH
- 13:00 - 13:00 1059P - Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) in solid tumors: Results from the pancreatic cancer (PC) and non-small cell lung cancer (NSCLC) cohorts
B. George¹, K. Kelly², A. Ko³, H. Soliman⁴, N. Trunova³, Z. Wainberg⁵, D. Waterhouse⁶, P. O'Dwyer⁷, H. Hochster⁸; ¹Milwaukee, WI/US, ²Sacramento, CA/US, ³Summit, US, ⁴Tampa, FL/US, ⁵Los Angeles, CA/US, ⁶Cincinnati, OH/US, ⁷Philadelphia, PA/US, ⁸New Haven, CT/US
- 13:00 - 13:00 1060P - Prevalence of PD-L1 expression in patients with non-small cell lung cancer screened for enrollment in KEYNOTE-001, -010, and -024
C. Aggarwal¹, D. Rodriguez Abreu², E. Felip³, E. Carcereny⁴, M. Gottfried⁵, T. Wehler⁶, M.-J. Ahn⁷, M. Dolled-Filhart⁸, J. Zhang⁸, Y. Shentu⁹, R. Rangwala⁸, B. Piperdi⁸, P. Baas¹⁰; ¹Philadelphia, PA/US, ²Las Palmas, ES, ³Barcelona, ES, ⁴Badalona, ES, ⁵Kfar Saba, IL, ⁶Homburg, DE, ⁷Seoul, KR, ⁸Kenilworth, NJ/US, ⁹Kenilworth, PA/US, ¹⁰Amsterdam, NL
- 13:00 - 13:00 1061P - The effect of short-course neoadjuvant radiotherapy (5Gy ×5 fractions) on rectal tumor immune microenvironment
X. Wang, P. Shu, Y.-S. Wang; Chengdu, CN
- 13:00 - 13:00 1062P - Updated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): The CheckMate 016 study
H. Hammers¹, E. Plimack², J. Infante³, B. Rini⁴, D. McDermott⁵, L. Lewis⁶, M. Voss⁷, P. Sharma⁸, S. Pal⁹, A. Razak¹⁰, C. Kollmannsberger¹¹, D. Heng¹², J. Spratlin¹³, B. McHenry¹⁴, P. Gagnier¹⁴, A. Amin¹⁵; ¹Baltimore, US, ²Philadelphia, US, ³Nashville, TN/US, ⁴Middlesex, GB, ⁵Boston, US, ⁶Lebanon, NH/US, ⁷New York, US, ⁸Houston, TX/US, ⁹Duarte, US, ¹⁰Toronto, ON/CA, ¹¹Vancouver, CA, ¹²Calgary, CA, ¹³Edmonton, AB/CA, ¹⁴Princeton, NJ/US, ¹⁵Charlotte, NC/US



- 13:00 - 13:00 1063P - Anti-PD1 therapy effects on T cell repertoire and functions in patients with NSCLC cancer: A preliminary study to identify biomarkers of efficacy
G. Barra, G. Pasquale, C.M. Della Corte, F. Papaccio, M. Orditura, F. De Vita, F. Ciardiello, R. De Palma, F. Morgillo; Napoli, IT
- 13:00 - 13:00 1064P - Gamma-delta T cell CARs; A combinatorial approach to immunotherapy
M. Leek, A. Patakas, A. Hannigan, D. Paruzina; Edinburgh, GB
- 13:00 - 13:00 1065P - T cell responses in the microenvironment of primary renal cell carcinoma
R. Andersen, M.C. Westergaard, J. Kjeldsen, Ö. Met, B. Kromann-Andersen, T. Hasselager, M. Donia, I. Svane; Herlev, DK
- 13:00 - 13:00 1066P - Rapid and objective CT-scan prognostic scoring identifies patients with long-term clinical benefit on phase I trials
L. Dercle¹, S. Ammari¹, S. Champiat¹, C. Massard¹, C. Ferte¹, M. Texier¹, E. Lanoy¹, L. Taihi¹, R.-D. Seban¹, S. Aspeslagh¹, S. Antoun¹, L. Mahjoubi², N. Kamsu-Kom¹, C. Robert¹, A. Marabelle¹, M. Schlumberger¹, J.-C. Soria¹, S. Postel-Vinay¹; ¹Villejuif, FR, ²Paris, FR
- 13:00 - 13:00 1067P - Phase 1b/2, open-label, multicenter, dose escalation and expansion trial of intratumoral SD 101 in combination with pembrolizumab in patients with metastatic melanoma
A. Ribas¹, R. Gonzalez², J. Drabick³, S. Kummar⁴, S. Agarwala⁵, J. Nemunaitis⁶, R. Coffman⁷, C. Berman⁷, E. Schmidt⁸, E. Chartash⁸, C. Guiducci⁷, A. Candia⁷, R. Janssen⁷; ¹Los Angeles, CA/US, ²Aurora, US, ³Hershey, PA/US, ⁴Palo Alto, CA/US, ⁵Easton, PA/US, ⁶Dallas, TX/US, ⁷Berkeley, CA/US, ⁸Kenilworth, NJ/US
- 13:00 - 13:00 1068P - Adenosine A2A receptor antagonist, CPI-444, blocks adenosine-mediated T cell suppression and exhibits anti-tumor activity alone and in combination with anti-PD-1 and anti-PD-L1
S. Willingham¹, P. Ho¹, R. Leone², C. Choy¹, J. Powell², I. McCaffery³, R. Miller¹; ¹Burlingame, CA/US, ²Baltimore, MD/US, ³San Francisco, US
- 13:00 - 13:00 1069P - Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression
D. Jackson¹, K. Peace¹, D. Hale¹, T. Vreeland², G. Choy³, B. Nejadnik³, J. Greene¹, E. Schneble¹, J. Berry¹, A. Trappey III¹, M. Hardin⁴, G. Clifton¹, G. Herbert¹, E. Mittendorf⁵, J. Holmes⁶, G. Peoples¹; ¹San Antonio, TX/US, ²Fayetteville, NC/US, ³San Francisco, CA/US, ⁴Tacoma, WA/US, ⁵Houston, US, ⁶Santa Rosa, CA/US
- 13:00 - 13:00 1070P - Impact of non-proportionality of hazards on time-to-event endpoints with nivolumab: Re-analysis of melanoma and NSLCC pivotal trials
K. Vásquez Vivas, S. Oudard, J. O'Quigley, R. El Aidi; Paris, FR
- 13:00 - 13:00 1071P - A phase I dose escalation trial to assess the safety and preliminary efficacy of mFOLFOX6 combined with pembrolizumab (MK3475) in advanced gastrointestinal malignancies
D. Stenehjem¹, S. Gupta¹, M. Wade¹, G. Gilcrease², I. Garrido-Laguna², J. Weis¹, J. Whisenant², S. Sharma¹; ¹Salt Lake City, UT/US, ²Salt Lake City, US



- 13:00 - 13:00 1072P - A Phase 1 first-in-human study of MEDI0680, an anti-PD-1 monoclonal antibody (mAb) in adult patients (pts) with advanced tumors
A. Naing¹, S. Goel², B. Curti³, A. Weise⁴, J. Eder⁵, S. Marshall⁶, C. Morehouse⁶, X. Li⁶, J. Karakunnel⁶, J. Infante⁷; ¹Houston, TX/US, ²New York, NY/US, ³Portland, OR/US, ⁴Detroit, MI/US, ⁵New Haven, CT/US, ⁶Gaithersburg, MD/US, ⁷Nashville, TN/US
- 13:00 - 13:00 1073P - Is anti-PD-1/PD-L1 immunotherapy sensitizing for conventional cancer therapies?
M. Matias¹, S. Aspeslagh², V. Palomar², E. Lanoy², L. Dercle², C. Even², C. Ferte², A. Hollebecque², A. Marabelle², C. Massard², J.-C. Soria², S. Postel-Vinay²; ¹Villejuif, Casado (a)/FR, ²Villejuif, FR
- 13:00 - 13:00 1074P - Antibody mediated blockade of phosphatidylserine improves immune checkpoint blockade by repolarizing immune suppressive mechanisms of the tumor microenvironment
J. Hutchins, Tustin, US
- 13:00 - 13:00 1075P - Open label non-randomized multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259 SPEAR T-cellsTM in HLA-A*02+ patients with synovial sarcoma (NCT01343043)
C. Mackall¹, S. D'Angelo², S. Grupp³, J. Glod⁴, M. Druta⁵, W. Chow⁶, K. Chagin³, M. Mehler³, G. Kari³, T. Trivedi³, T. Holdich⁷, L. Pandite⁸, R. Amado⁹; ¹Stanford, US, ²New York, US, ³Philadelphia, US, ⁴Washington, US, ⁵Tampa, US, ⁶Duarte, US, ⁷Oxford, GB, ⁸Philadelphia, PA/US, ⁹Collegeville, US
- 13:00 - 13:00 1076P - Microsatellite instability and PDL1 expression in small bowel adenocarcinoma - potential for immune checkpoint inhibitor therapies
M. Alvi, S. McQuaid, R. Wilson, M. Salto-Tellez; Belfast, GB
- 13:00 - 13:00 1077P - A meta-analysis of immune-related adverse events (irAE) of immune checkpoint inhibitors (ICI) from cancer clinical trials
B. El Osta, F. Hu, R. Sadek, R. Chintalapally, S.-C. Tang; Augusta, GA/US
- 13:00 - 13:00 1078P - Combining complementary mechanisms of immune activation: NKTR-214, a biased IL-2 pathway agonist and immune checkpoint antagonists
D. Charych, P. Kuo, M. Addepalli, V. Dixit, R. Pena, W. Rubas, U. Hoch, J. Langowski, S. Doberstein, J. Zalevsky; San Francisco, CA/US
- 13:00 - 13:00 1079P - Efficacy and safety of nivolumab in elderly patients (pts) with advanced squamous non small cell lung cancer (Sq-NSCLC) participating in the expanded access programme (EAP) in Italy
F. Grossi¹, L. Crinò², A. Misino³, P. Bidoli⁴, A. Delmonte⁵, F. Gelsomino⁶, C. Proto⁷, M. Mancini⁸, L. Landi⁹, D. Turci¹⁰, S. Quadri¹¹, P. Antonelli¹², P. Marchetti¹³, L. Toschi¹⁴, S. Giusti¹⁵, F. Di Costanzo¹⁶, F. Rastelli¹⁷, P. Sandri¹⁸, V. Scotti¹⁶, F. de Marinis⁷; ¹Genova, IT, ²Perugia, IT, ³Bari, IT, ⁴Monza, IT, ⁵Meldola, IT, ⁶Bologna, IT, ⁷Milano, IT, ⁸Roma, IT, ⁹Livorno, IT, ¹⁰Ravenna, IT, ¹¹Sora, IT, ¹²Busto Arsizio, IT, ¹³Rome, IT, ¹⁴Rozzano, IT, ¹⁵Arezzo, IT, ¹⁶Firenze, IT, ¹⁷Fermo, IT, ¹⁸Pordenone, IT
- 13:00 - 13:00 1080P - Enabling successful T-cell therapy of solid tumors with oncolytic adenoviruses armed with TNFα and IL-2
A. Hemminki¹, R. Havunen¹, M. Siurala¹, S. Tähtinen¹, D. Saha¹, M. Vähä-Koskela¹, M. Behr¹, D. Nettelbeck², A. Ehrhardt³, S. Parviainen¹; ¹Helsinki, FI, ²Heidelberg, DE, ³Witten, DE



- 13:00 - 13:00 1081P - The efficacy of everolimus relies on a modulation of adaptive anti tumor T cell immunity
O. Adotévi¹, L. Mansi¹, L. Beziaud¹, P. Ravel², E. Lauret Marie-Joseph¹, C. Laheurte¹, L. Rangan¹, T. Maurina¹, G. Mouillet³, T. Nguyen Tan Hon¹, E. Curtit¹, X. Pivot³, Y. Godet¹, C. Borg¹, A. Thierry-Vuillemin¹; ¹Besançon, FR, ²Montpellier, FR, ³Besançon, CEDEX/FR
- 13:00 - 13:00 1082P - A rational approach to dose optimisation of pembrolizumab and nivolumab using cost analysis and pharmacokinetic modelling and simulation
K. Ogungbenro, A. Patel, R. Duncombe, J. Clark, P. Lorigan; Manchester, GB
- 13:00 - 13:00 1083P - CXCL12 inhibition with NOX-A12 (olaptosed pegol) increases T and NK cell infiltration and synergizes with immune checkpoint blockade in tumour-stroma spheroids
D. Zboralski, A. Kruschinski, D. Eulberg, A. Vater; Berlin, DE
- 13:00 - 13:00 1084P - Safety of immune check-point inhibitors in patients with autoimmune conditions and advanced cancer
G. Gard¹, T. Van Hagen², M. Ariyapperuma¹, K. Feeney¹, R. Roberts-Thomson³, M. Millward¹, M. Khattak¹; ¹Perth, AU, ²Perth, WA/AU, ³Adelaide, AU
- 13:00 - 13:00 1085P - Dendritic cell vaccination in combination with docetaxel for patients with prostate cancer – a randomized phase II study
P. Kongsted, E. Ellebæk, T. Borch, T. Iversen, R. Andersen, Ö. Met, M. Hansen, L. Sengeløv, I. Svane; Herlev, DK
- 13:00 - 13:00 1086P - Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors
N. Segal¹, J. Infante², R. Sanborn³, G. Gibney⁴, D. Lawrence⁵, N. Rizvi¹, R. Leidner³, T. Gajewski⁶, E. Bertino⁷, W. Sharfman⁸, S. Cooley⁹, S. Topalian¹⁰, W. Urba¹¹, J. Wolchok¹, X. Gu¹², C. Passey¹², D. McDonald¹², P. Aanur¹², S. Srivastava¹², F.S. Hodi¹³; ¹New York, NY/US, ²Nashville, TN/US, ³Portland, OR/US, ⁴Washington, DC/US, ⁵Boston, MA/US, ⁶Chicago, IL/US, ⁷Columbus, OH/US, ⁸Baltimore, US, ⁹Minneapolis, US, ¹⁰Baltimore, MD/US, ¹¹Portland, US, ¹²Princeton, NJ/US, ¹³Boston, US
- 13:00 - 13:00 1087P - A mechanism of action study of intra-tumoral or intravenous dosing of enadenotucirev, an oncolytic adenovirus in patients with colon, lung, bladder and renal carcinoma undergoing resection of primary tumor
R. Garcia-Carbonero¹, V. Boni¹, I. Duran², M. Gil³, M. Espinosa², R. Salazar³, A. Cubillo¹, M. Jurado¹, B. Champion⁴, S. Alvis⁴, K. Fisher⁴, J. Beadle⁵, G. Pover⁴, H. McElwaine-John⁴, C. Ellis⁴, C. Blanc⁴, E. Calvo¹; ¹Madrid, ES, ²Sevilla, ES, ³Barcelona, ES, ⁴Abingdon, GB, ⁵Essex, GB
- 13:00 - 13:00 1088P - Comprehensive assessment of the feasibility of adoptive cell therapy in colorectal carcinoma
B. Navarro Rodrigo¹, S. Viganò¹, P. Gannon¹, P. Baumgartner¹, C. Maisonneuve¹, C. Sempoux¹, M.-O. Sauvain¹, D. Hahnloser¹, M. Hubner¹, N. Demartines¹, L. Kandalaf¹, M. Montemurro¹, A. Harari¹, G. Coukos²; ¹Lausanne, CH, ²Epalinges, CH
- 13:00 - 13:00 1089P - Personalized PD-1/PD-L1 inhibitor therapy for advanced non small cell lung cancer beyond first line; A meta-analysis of potential predictive factors
O. Abdel-Rahman, Cairo, EG



- 13:00 - 13:00 1090P - Identification of patients at risk for severe toxicity under PD1 inhibitors: Role of sarcopenic overweight
P. Boudou Rouquette¹, A. Jouinot², O. Huillard², J. Arrondeau², C. Tlemsani², V. Heidelberg², J. Chapron², N. Kramkimel², D. Damotte², F. Batteux², L. Dehghani², B. Terrier², L. Groussin², N. Dupin², B. Blanchet², M. Alifano², K. Leroy², M.-P. Revel², J. Alexandre², F. Goldwasser²; ¹Paris, CEDEX 14/FR, ²Paris, FR
- 13:00 - 13:00 1091P - Prolactin as a potential negative predictive factor in metastatic non-small cell lung cancers (NSCLC) patients in treatment with Nivolumab (NIVO)
S. Caponnetto¹, M. Mancini¹, C. Manai¹, V. Magri¹, G.M. Iannantuono¹, D. Pellegrino¹, C. Mosillo¹, G. Piesco¹, G. Pomati¹, S. Scagnoli¹, F. Urbano¹, S. Verkhovskaya¹, G. Barchiesi¹, S. Zancla¹, E. Cortesi²; ¹Roma, IT, ²Rome, IT
- 13:00 - 13:00 1092P - Patterns of steroid use in diarrhoea and/or colitis (D/C) from immune checkpoint inhibitors (ICPI)
L. Spain¹, S. Diem², K. Khabra¹, S. Turajlic¹, M. Gore¹, N. Yousaf¹, J. Larkin¹; ¹London, GB, ²St. Gallen, CH
- 13:00 - 13:00 1093P - Switch maintenance therapy with racotumomab or nimotuzumab vs docetaxel for NSCLC patients
M. Hernandez¹, E. Neningen¹, R. Ortiz², K. Camacho³, R. Amador⁴, L. Bello⁵, Y. Flores¹, S. Acosta⁶, G. Pichs⁷, M. Cala⁶, M. Corella⁸, Y. Jimenez⁹, Y. Diaz¹⁰, C. Viada¹, M. Robina¹, A. Valdes¹, I. Mendoza¹, P. Guerra¹, A. Macias¹, T. Crombet¹; ¹Havana, CU, ²Santa Clara, CU, ³Matanzas, CU, ⁴Pinar Del Rio, CU, ⁵Ciego De Avila, CU, ⁶Santiago De Cuba, CU, ⁷Manzanillo, CU, ⁸Holguin, CU, ⁹Sancti Spiritus, CU, ¹⁰Artemisa, CU
- 13:00 - 13:00 1094P - Preclinical development of tumor-infiltrating lymphocyte (TIL) based adoptive cell transfer (ACT) immunotherapy for patients with sarcoma
M. Nielsen¹, A. Krarup-Hansen¹, D. Hovgaard¹, M. Petersen¹, A. Loya¹, N. Junker², I. Svane²; ¹Copenhagen, DK, ²Herlev, DK
- 13:00 - 13:00 1095P - T cell therapy for patients with advanced ovarian cancer: A pilot study in progress
M. Pedersen¹, M.C. Westergaard¹, T. Borch¹, M. Nielsen², T. Juhler-Nottrup¹, P. Kongsted¹, M. Donia¹, I.-M. Svane¹; ¹Herlev, DK, ²Copenhagen, DK
- 13:00 - 13:00 1096P - Expression pattern of immune checkpoint-associated molecules in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
T. Hara¹, H. Miyake¹, M. Fujisawa²; ¹Kobe, Hyogo/JP, ²Kobe, JP
- 13:00 - 13:00 1097P - Optimized neoantigen selection based on tumor exome data
C. Kyzirakos, C. Mohr, S. Armeanu-Ebinger, M. Feldhahn, D. Hadaschik, M. Walzer, D. Döcker, M. Menzel, S. Nahnsen, O. Kohlbacher, S. Biskup; Tübingen, DE
- 13:00 - 13:00 1098P - Assessment of nivolumab (Nivo) benefit-risk profile from a 240-mg flat dose versus a 3-mg/kg dosing regimen in patients (Pts) with solid tumors



X. Zhao¹, S. Suryawanshi¹, M. Hruska¹, Y. Feng¹, X. Wang¹, J. Shen¹, B. McHenry², I. Waxman¹, A. Achanta¹, A. Bello¹, A. Roy¹, S. Agrawal¹; ¹Princeton, NJ/US, ²Wallingford, CT/US

13:00 - 13:00 1100TiP - An open-label, multicenter, phase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or hepatocellular carcinoma (HCC)

Y.-J. Bang¹, L.W. Goff², H. Wasserstrom³, J. Yang³, G. Mi³, M. Karasarides⁴, M. Reck⁵; ¹Seoul, KR, ²Nashville, US, ³Bridgewater, NJ/US, ⁴Wilmington, DE/US, ⁵Grosshansdorf, DE

13:00 - 13:00 1101TiP - Phase II multi-centre, non randomized, open label study of nivolumab in combination with ipilimumab as first line in adults patients with metastatic uveal melanoma. GEM 14-02

A. Rullan Iriarte¹, S. Martín-Algarra², L. de la Cruz Merino³, D. Rodríguez Abreu⁴, E. Espinosa⁵, A. Berrocal⁶, R. López Castro⁷, T. Curiel⁸, P. Luna⁹, A. Lorenzo¹⁰, J. Piulats¹¹; ¹Barcelona, ES, ²Pamplona, ES, ³Sevilla, ES, ⁴Las Palmas, ES, ⁵Madrid, ES, ⁶Valencia, ES, ⁷Valladolid, ES, ⁸Santiago De Compostela, ES, ⁹Palma De Mallorca, ES, ¹⁰Malaga, ES, ¹¹L'hospitalet De Llobregat, Barcelona, ES

13:00 - 13:00 1102TiP - A phase 1b/2 dose escalation and cohort expansion study of the safety, tolerability and efficacy of a transforming growth factor-beta (TGF-β) receptor I kinase inhibitor (galunisertib) in combination with anti-PD-1 (nivolumab) in advanced refractory solid tumours

S. Guba¹, S. Mukhopadhyay¹, D. Desai¹, V. Andre²; ¹Indianapolis, US, ²Erlwood, GB

13:00 - 13:00 1103TiP - MEDIOLA: A phase I/II, open-label trial of olaparib in combination with durvalumab (MEDI4736) in patients (pts) with advanced solid tumours

S. Domchek¹, Y.-J. Bang², G. Coukos³, K. Kobayashi⁴, N. Baker⁵, E. McMurtry⁶, W. Song⁴, B. Kaufman⁷; ¹Philadelphia, PA/US, ²Seoul, KR, ³Lausanne, CH, ⁴Gaithersburg, MD/US, ⁵Cambridge, GB, ⁶Macclesfield, GB, ⁷Tel Hashomer, IL

13:00 - 13:00 1104TiP - Intravenous coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients: Phase Ib KEYNOTE 200 study

H. Pandha¹, K. Harrington², C. Ralph³, A. Melcher³, E. Schmidt⁴, D. Kaufman⁴, M. Grose⁵, R. Karpathy⁶, D. Shafren⁷; ¹Guildford, GB, ²London, GB, ³Leeds, GB, ⁴Kenilworth, NJ/US, ⁵Mississauga, ON/CA, ⁶Sydney, AU, ⁷Sydney, NSW/AU

13:00 - 13:00 1105TiP - Phase 1/1b multicenter trial of the adenosine A2a receptor antagonist (A2aR) CPI-444 as single agent and in combination with atezolizumab (ATZ) in patients(Pts) with advanced cancers

A. Patnaik¹, J. Powderly², J. Luke³, R. Miller⁴, G. Laport⁴; ¹San Antonio, TX/US, ²Huntersville, NC/US, ³Chicago, IL/US, ⁴Burlingame, CA/US

13:00 - 13:00 Melanoma and other skin tumours

13:00 - 13:00 1115P - Estimating the percentage of patients with advanced melanoma achieving long-term survival with pembrolizumab (Pembro) treatment in KEYNOTE-006



C. Blank¹, J. Ma², J.J. Grob³, J. Larkin⁴, B. Neyns⁵, C. McNeil⁶, M. Lotem⁷, E. Richtig⁸, G. Masucci⁹, T. Petrella¹⁰, A. Ribas¹¹, J. Wang², N. Ibrahim², K.M. Anderson², A. Arance¹²; ¹Amsterdam, NL, ²Kenilworth, NJ/US, ³Marseille, FR, ⁴London, GB, ⁵Brussels, BE, ⁶Camperdown, NSW/AU, ⁷Jerusalem, IL, ⁸Graz, AT, ⁹Solna, SE, ¹⁰Toronto, ON/CA, ¹¹Los Angeles, US, ¹²Barcelona, ES

- 13:00 - 13:00 1116P - Complete responders to anti-PD1 antibodies. What happens when we stop?
R. Ladwa, V. Atkinson; Brisbane, AU
- 13:00 - 13:00 1117P - A dose escalation phase 1 study of radiotherapy (RT) in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody ipilimumab (Ipi) in patients (pts) with metastatic melanoma
C. Boutros¹, C. Mateus¹, E. Routier², S. Chouaib¹, C. Libenciu¹, M. Reigneau¹, I. Girault¹, C. Caramella¹, S. Hibat¹, S. Vagner², Y.G. Tao¹, N. Chaput¹, J. Adam¹, J.-C. Soria¹, A. Eggermont¹, E. Deutsch¹, C. Robert¹; ¹Villejuif, FR, ²Paris, FR
- 13:00 - 13:00 1118P - GRAY-B: An open label multicenter phase-2 GEM study on ipilimumab and radiation in patients with melanoma and brain metastases
J. Lopez Martin¹, L. de la Cruz Merino², A.M. Arance Fernandez³, A. Illescas², I. Valduvieu Ruiz³, A. Berrocal⁴, J. Lopez-Torrecilla⁴, I. Marquez Rodas¹, M.V. Soriano Teruel⁴, A. Alvarez Gonzalez¹, M.L. Chust Vicente⁴, D. Rodriguez Abreu⁵, R. Cabrera⁵, M.C. Penas Sanchez¹, T. Curiel⁶, E. Munoz Couselo³, J.J. Aristu⁷, A. Gomez-Caamano⁶, J. Medina Martinez⁸, S. Martin-Algarra⁷; ¹Madrid, ES, ²Sevilla, ES, ³Barcelona, ES, ⁴Valencia, ES, ⁵Las Palmas, ES, ⁶Santiago De Compostela, ES, ⁷Pamplona, ES, ⁸Toledo, ES
- 13:00 - 13:00 1119P - The efficacy of nivolumab for unresectable metastatic mucosal melanoma
A. Takahashi, A. Tsutsumida, K. Namikawa, Y. Nakamura, I. Muto, N. Yamazaki; Tokyo, JP
- 13:00 - 13:00 1120P - Single center experience on patients with advanced melanoma treated with short-term anti-CTLA4 directly followed by anti-PD-1
E.A. Rozeman, A. Meerveld-Eggink, F. Lalezari, J. van Thienen, J. Haanen, C. Blank; Amsterdam, NL
- 13:00 - 13:00 1121P - Real-world survival results of metastatic melanoma patients treated with ipilimumab in the Netherlands
A. Jochems¹, M. Schouwenburg¹, M. Aarts², F. van den Berkmoortel³, A. van den Eertwegh⁴, G. Groenewegen⁵, J.-W. de Groot⁶, J. Haanen⁴, G. Hospers⁷, E. Kapiteijn¹, R. Koornstra⁸, W. Kruit⁹, B. Leeneman⁹, M. Louwman⁵, D. Piersma¹⁰, R. van Rijn¹¹, A. Ten Tije¹², G. Vreugdenhil¹³, M. Wouters⁴, J. van der Hoeven¹; ¹Leiden, NL, ²Maastricht, NL, ³Heerlen, NL, ⁴Amsterdam, NL, ⁵Utrecht, NL, ⁶Zwolle, NL, ⁷Groningen, NL, ⁸Nijmegen, NL, ⁹Rotterdam, NL, ¹⁰Enschede, NL, ¹¹Leeuwarden, NL, ¹²Breda, NL, ¹³Eindhoven, NL
- 13:00 - 13:00 1122P - Impact of ipilimumab on metastatic melanoma: Evaluation using patient registry in Canada
D. Ernst¹, T. Petrella², A. Joshua², T. Cheng³, M. Smylie⁴, T. Baetz⁵, A. Hamou¹, F. Gwadry-Sridhar¹; ¹London, ON/CA, ²Toronto, ON/CA, ³Calgary, AB/CA, ⁴Edmonton, AB/CA, ⁵Kingston, ON/CA



- 13:00 - 13:00 1123P - Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)
- M. Sznol¹, P.F. Ferrucci², D. Hogg³, M. Atkins⁴, P. Wolter⁵, M. Guidoboni⁶, C. Lebbe⁷, J. Kirkwood⁸, J. Schachter⁹, G. Daniels¹⁰, J. Hassel¹¹, J. Cebon¹², W. Gerritsen¹³, V. Atkinson¹⁴, L. Thomas¹⁵, J. McCaffrey¹⁶, D. Power¹⁶, J. Jiang¹⁷, F.S. Hodi¹⁸, J. Wolchok¹⁹; ¹New Haven, US, ²Milano, IT, ³Toronto, CA, ⁴Washington, US, ⁵Leuven, BE, ⁶Meldola, IT, ⁷Paris, FR, ⁸Pittsburgh, US, ⁹Ramat Gan, IL, ¹⁰La Jolla, US, ¹¹Heidelberg, DE, ¹²Heidelberg, AU, ¹³Nijmegen, NL, ¹⁴Greenslopes, AU, ¹⁵Pierre Bénite, FR, ¹⁶Cork, IE, ¹⁷Princeton, US, ¹⁸Boston, US, ¹⁹New York, US
- 13:00 - 13:00 1124P - Detailed safety profile of the anti-PD-1 monoclonal antibody pembrolizumab in 78 consecutive patients (pts) with advanced melanoma
- C. Boutros¹, E. Routier², C. Hua¹, M. Texier¹, C. Mateus¹, C. Libenciuc¹, M. Reigneau¹, N. Benannoune¹, S. Roy¹, E. Lanoy¹, J. Le Pavec³, F.L. Ladurie³, F. Carbonnel⁴, O. Lambotte⁴, H. Izzedine², A. Berdelou¹, S. Champiat¹, J.-C. Soria¹, A. Eggermont¹, C. Robert¹; ¹Villejuif, FR, ²Paris, FR, ³Le Plessis-Robinson, FR, ⁴Le Kremlin Bicetre, FR
- 13:00 - 13:00 1125P - Safety of reduced infusion times for nivolumab plus ipilimumab (N+I) and nivolumab alone (N) in advanced melanoma
- S. Martin-Algarra¹, J. Haanen², C. Horak³, S. Bhatia⁴, A. Ribas⁵, W.-J. Hwu⁶, C. Slingluff, Jr⁷, W. Sharfman⁸, M. Callahan⁹, F.S. Hodi¹⁰, J. Wolchok¹¹, J. Luke¹², T. Young³, A. Qureshi³, W. Urba¹³; ¹Pamplona, ES, ²Amsterdam, NL, ³Princeton, NJ/US, ⁴Seattle, US, ⁵Los Angeles, US, ⁶Houston, US, ⁷Charlottesville, US, ⁸Baltimore, US, ⁹New York, US, ¹⁰Boston, US, ¹¹New York, NY/US, ¹²Chicago, IL/US, ¹³Portland, US
- 13:00 - 13:00 1126P - Slow natural history predicts higher response rate to nivolumab and pembrolizumab in advanced melanoma patients
- N. Kramkimel¹, V. Heidelberger¹, O. Huillard¹, P. Boudou Rouquette², J. Chanal¹, N. Franck¹, J. Arrondeau¹, J. Alexandre¹, B. Blanchet¹, J. Mullaert¹, S. Aractingi¹, N. Dupin¹, F. Goldwasser¹; ¹Paris, FR, ²Paris, CEDEX 14/FR
- 13:00 - 13:00 1127P - Correlation between baseline characteristics and clinical outcome of patients with advanced melanoma treated with pembrolizumab (PEMBRO)
- Y. Jansen¹, E.A. Rozeman², L. Højberg³, M. Geukes Foppen², M. Schreuer¹, J. van Thienen², L. Bastholt⁴, H. Schmidt⁵, J. Haanen², I. Svane⁶, A.M. Arance Fernandez⁷, C. Blank², B. Neyns¹; ¹Brussels, BE, ²Amsterdam, NL, ³Copenhagen, DK, ⁴Odense C, DK, ⁵Aarhus C, DK, ⁶Herlev, DK, ⁷Barcelona, ES
- 13:00 - 13:00 1128P - CAMEL study: Clinical prognostic biomarkers for ipilimumab-related outcome in metastatic melanoma patients
- L. Orgiano¹, F. Bruder², C. Madeddu², R. Marconcini³, E. Gambale⁴, E. Galizia⁵, S. Stucci⁶, F. Spagnolo⁷, L. Di Guardo⁸, C. Loi², F. Pani², D. Massa², E. Massa², G. Astarà², M. Del Vecchio⁸, F. Silvestris⁶, M. de tursi⁴, A. Falcone³, P. Queirolo⁷, M. Scartozzi²; ¹Monsestato, IT, ²Cagliari, IT, ³Pisa, IT, ⁴Chieti, IT, ⁵Fabriano, IT, ⁶Bari, IT, ⁷Genova, IT, ⁸Milano, IT



- 13:00 - 13:00 1129P - Pretreatment prognostic factors and early markers for outcome in advanced melanoma treated with nivolumab
Y. Nakamura, S. Kitano, A. Takahashi, A. Tsutsumida, K. Namikawa, I. Muto, M. Ueno, Y. Muto, N. Yamazaki; Tokyo, JP
- 13:00 - 13:00 1130P - Sarcopenia associated with a body mass index (BMI) > 25 kg/m² predicts severe acute toxicity of nivolumab and pembrolizumab in melanoma patients
V. Heidelberger¹, N. Kramkimel¹, O. Huillard¹, P. Boudou Rouquette², J. Chanal¹, J. Arrondeau¹, N. Franck¹, J. Alexandre¹, B. Blanchet¹, N. Dupin¹, F. Goldwasser¹, S. Aractingi¹; ¹Paris, FR, ²Paris, CEDEX 14/FR
- 13:00 - 13:00 1131P - Radiographic myosteosis is prognostic and predictive of ipilimumab outcomes in melanoma
M. Chu¹, Y. Li², S. Ghosh³, J. Walker², M. Smylie³, M. Sawyer²; ¹Edmonton, Alberta/CA, ²Edmonton, CA, ³Edmonton, AB/CA
- 13:00 - 13:00 1132P - More than 50% of patients with metastatic melanoma are not represented in pivotal phase 3 immunotherapy registration trials
M. Donia¹, M. Kimper-Karl², L. Bastholt², I. Svane¹; ¹Herlev, DK, ²Odense C, DK
- 13:00 - 13:00 1133P - Systemic treatment influences on immune accessibility of melanoma: A retrospective histopathological investigation
L. Krähenbühl¹, S. Goldinger², K. Kerl¹, W. Kempf¹, I. Chevolet³, L. Brochez³, P. Cheng¹, J. Mangana², M. Levesque¹, R. Dummer¹; ¹Zürich, CH, ²Zurich, CH, ³Gent, BE
- 13:00 - 13:00 1134P - Pooled analysis of factors to predict durable clinical outcomes with combination dabrafenib (D) and trametinib (T) across registration trials
M. Davies¹, J.J. Grob², G. Long³, K. Flaherty⁴, P. Nathan⁵, A. Ribas⁶, D. Schadendorf⁷, B. Mookerjee⁸, J. Legos⁸, S. Lane⁸, C. Robert⁹; ¹Houston, TX/US, ²Marseille, FR, ³Sydney, AU, ⁴Boston, Ma, US, ⁵Northwood, GB, ⁶Los Angeles, CA/US, ⁷Essen, DE, ⁸East Hanover, NJ/US, ⁹Villejuif, FR
- 13:00 - 13:00 1135P - COMBI-rechallenge: A phase II clinical trial on dabrafenib plus trametinib in BRAFV600-mutant melanoma patients who previously experienced progression on BRAF(+MEK)-inhibition
M. Schreuer¹, V. Kruse², Y. Jansen¹, B. Neyns¹; ¹Brussels, BE, ²Gent, BE
- 13:00 - 13:00 1136P - Pimasertib (PIM) versus dacarbazine (DTIC) in patients (pts) with cutaneous NRAS melanoma: A controlled, open-label phase II trial with crossover
C. Lebbe¹, C. Dutriaux², T. Lesimple³, W. Kruit⁴, J. Kerger⁵, L. Thomas⁶, B. Guillot⁷, F. de Braud⁸, C. Garbe⁹, J.J. Grob¹⁰, C. Loquai¹¹, V. Ferraresi¹², C. Robert¹³, P. Vasey¹⁴, R. Conry¹⁵, R. Isaacs¹⁶, E. Espinosa¹⁷, A. Schueler¹⁸, A. Markivskyy¹⁸, B. Dreno¹⁹; ¹Paris, FR, ²Bordeaux, FR, ³Rennes, FR, ⁴Rotterdam, NL, ⁵Brussels, BE, ⁶Pierre Bénite, FR, ⁷Montpellier, FR, ⁸Milano, IT, ⁹Tübingen, DE, ¹⁰Marseille, FR, ¹¹Mainz, DE, ¹²Roma, IT, ¹³Villejuif, FR, ¹⁴Auchenflower, AU, ¹⁵Birmingham, AL/US, ¹⁶Palmerston North, NZ, ¹⁷Madrid, ES, ¹⁸Darmstadt, DE, ¹⁹Nantes, FR
- 13:00 - 13:00 1137P - Health-related quality-of-life (HRQOL) impact of dabrafenib (D) and trametinib (T) vs BRAF inhibitor (BRAFi) monotherapy by lactate dehydrogenase (LDH) in patients (pts) with BRAF V600-mutant melanoma



J.J. Grob¹, C. Robert², G. Long³, D. Stroyakovskiy⁴, E. Levchenko⁵, V. Chiarion-Sileni⁶, K. Flaherty⁷, P. Nathan⁸, A. Ribas⁹, M. Davies¹⁰, J. Zhang¹¹, L. Chen¹¹, B. Mookerjee¹¹, S. Redhu¹¹, D. Schadendorf¹²; ¹Marseille, FR, ²Villejuif, FR, ³Sydney, NSW/AU, ⁴Moscow, RU, ⁵St-Petersburg, RU, ⁶Padova, IT, ⁷Boston, Ma, US, ⁸Northwood, GB, ⁹Los Angeles, CA/US, ¹⁰Houston, TX/US, ¹¹East Hanover, NJ/US, ¹²Essen, DE

- 13:00 - 13:00 1138P - Cobimetinib plus vemurafenib to treat unresectable or metastatic melanoma: Data from the French temporary authorization for use
N. Meyer¹, D.-M. Anne-Bénédicte², B. Dreno³, C. Lebbe⁴, O. Zehou⁵, A. Gorana⁶, M. Mourl⁶, A. Bardet⁶, M. Moreau⁶, C. Mateus⁷; ¹Toulouse, FR, ²Rouen, FR, ³Nantes, FR, ⁴Paris, FR, ⁵Créteil, FR, ⁶Boulogne-Billancourt, FR, ⁷Villejuif, FR
- 13:00 - 13:00 1139P - Survival in BRAF-mutant metastatic melanoma in the real-world setting: Results from the Dutch Melanoma Treatment Registry
M. Schouwenburg¹, A. Jochems¹, M. Aarts², F. van den Berkmortel³, A. van den Eertwegh⁴, M. Franken⁵, G. Groenewegen⁶, J.-W. de Groot⁷, J. Haanen⁴, G. Hospers⁸, E. Kapiteijn¹, R. Koornstra⁹, W. Kruit⁵, M. Louwman⁶, D. Piersma¹⁰, R. van Rijn¹¹, A. Ten Tije¹², G. Vreugdenhil¹³, M. Wouters⁴, J. van der Hoeven¹; ¹Leiden, NL, ²Maastricht, NL, ³Heerlen, NL, ⁴Amsterdam, NL, ⁵Rotterdam, NL, ⁶Utrecht, NL, ⁷Zwolle, NL, ⁸Groningen, NL, ⁹Nijmegen, NL, ¹⁰Enschede, NL, ¹¹Leeuwarden, NL, ¹²Breda, NL, ¹³Eindhoven, NL
- 13:00 - 13:00 1140P - Analysis of patient-reported outcomes by disease progression status in patients (pts) with BRAF V600-mutant metastatic melanoma in the COMBI-d and COMBI-v trials
C. Robert¹, D. Schadendorf², G. Long³, D. Stroyakovskiy⁴, E. Levchenko⁵, V. Chiarion-Sileni⁶, K. Flaherty⁷, P. Nathan⁸, A. Ribas⁹, M. Davies¹⁰, J. Zhang¹¹, L. Chen¹¹, B. Mookerjee¹¹, S. Redhu¹¹, J.J. Grob¹²; ¹Villejuif, FR, ²Essen, DE, ³Sydney, NSW/AU, ⁴Moscow, RU, ⁵St-Petersburg, RU, ⁶Padova, IT, ⁷Boston, Ma, US, ⁸Northwood, GB, ⁹Los Angeles, CA/US, ¹⁰Houston, TX/US, ¹¹East Hanover, NJ/US, ¹²Marseille, FR
- 13:00 - 13:00 1141P - Neurological benefit of BRAF-inhibition and MEK-inhibition in patients with brain metastases from BRAF-mutated melanoma
M. Geukes Foppen, W. Boogerd, C. Blank, J. Haanen, J. van Thienen, D. Brandsma; Amsterdam, NL
- 13:00 - 13:00 1142P - Prognostic subgroups and impact of treatment for post-progression overall survival (ppOS) in patients (pts) with BRAFV600-mutated metastatic melanoma treated with dacarbazine (DTIC) or vemurafenib (VEM) ± cobimetinib (COBI): A pooled analysis
P. Ascierto¹, A. Ribas², J. Larkin³, G. McArthur⁴, K. Lewis⁵, A. Hauschild⁶, K. Flaherty⁷, E. McKenna⁸, Q. Zhu⁸, Y. Mun⁸, B. Dréno⁹; ¹Napoli, IT, ²Los Angeles, CA/US, ³London, GB, ⁴East Melbourne, VIC/AU, ⁵Aurora, CO/US, ⁶Kiel, DE, ⁷Boston, MA/US, ⁸South San Francisco, CA/US, ⁹Nantes, FR
- 13:00 - 13:00 1143P - Lower risk of cutaneous squamous cell carcinomas induced by vemurafenib in non melanoma patients



E. Maubec¹, A. Levy², C. Cropet³, J. Mazieres⁴, X. Troussard⁵, S. Leboulleux⁶, D. Malka⁶, M. Dinulescu⁷, F. Granel-Brocard⁸, D. Le Goupil⁹, F. Truchetet¹⁰, S. Dalle³, M.T. Leccia¹¹, N. Hoog-Labouret¹², C. Mahier Ait Oukhatar², B. Busser¹¹, J. Charles¹¹, J.-Y. Blay³; ¹Bobigny, FR, ²Paris, FR, ³Lyon, FR, ⁴Toulouse, FR, ⁵Caen, FR, ⁶Villejuif, FR, ⁷Rennes, FR, ⁸Vandoeuvre Les Nancy, FR, ⁹Brest, FR, ¹⁰Metz, FR, ¹¹Grenoble, FR, ¹²Boulogne-Billancourt, FR

- 13:00 - 13:00 1144P - Next generation sequencing for tissue and plasma profiling of melanoma patients and plasma monitoring of treatment outcome: The MOBILY study
H. Linardou, S. Murray, A. Laskarakis, K. Giati, C. Guedard, A. Tarampikou, K. Tsigaridas, D. Bafaloukos; Athens, GR
- 13:00 - 13:00 1145P - Analysis of BRAF V600E mutation status – concordance of results from circulating tumor DNA and tissue-based testing and impact on prediction of the clinical course in patients undergoing BRAFi therapy
V. Haselmann¹, C. Gebhardt¹, I. Brechtel¹, A. Duda¹, A. Sucker², J. Utikal¹, D. Schadendorf², M. Neumaier¹; ¹Mannheim, DE, ²Essen, DE
- 13:00 - 13:00 1146P - Tumor response from phase II study of combination treatment with intratumoral HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIB, IIIC, or IV unresectable or metastatic melanoma
R. Andtbacka¹, M. Ross², S. Agarwala³, M. Taylor⁴, J. Vetto⁴, R. Neves⁵, A. Daud⁶, H. Khong¹, R. Ungerleider⁷, S. Welden⁷, M. Tanaka⁸, K. Grossmann¹; ¹Salt Lake City, US, ²Houston, TX/US, ³Bethlehem, US, ⁴Portland, US, ⁵Hershey, PA/US, ⁶San Francisco, CA/US, ⁷Princeton, NJ/US, ⁸Shiga, JP
- 13:00 - 13:00 1147P - A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma
P. Ott¹, A. Pavlick², D. Johnson³, L. Hart⁴, J. Infante³, J. Luke⁵, J. Lutzky⁶, N. Rothschild⁷, L. Spittler⁸, C. Cowey⁹, A. Alizadeh¹⁰, A. Salama¹¹, Y. He¹², R. Bagley¹³, J. Zhang¹², O. Hamid¹⁴; ¹Boston, MA/US, ²New York, NY/US, ³Nashville, TN/US, ⁴Ft. Myers, FL/US, ⁵Chicago, IL/US, ⁶Miami Beach, US, ⁷West Palm Beach, FL/US, ⁸San Francisco, CA/US, ⁹Dallas, TX/US, ¹⁰Decatur, GA/US, ¹¹Durham, NC/US, ¹²Hampton, NJ/US, ¹³Needham, MA/US, ¹⁴Los Angeles, CA/US
- 13:00 - 13:00 1148P - A phase I, open-label study of pasireotide in patients with BRAF- and NRAS-wild type, unresectable and or metastatic melanoma
R. Dummer¹, O. Michielin², M. Nägeli³, S. Goldinger³, F. Campigotto⁴, U. Kriemler-Krahn⁵, H. Schmid⁵, A. Pedroncelli⁵, S. Micaletto³, D. Schadendorf⁶; ¹Zürich, CH, ²Lausanne, CH, ³Zurich, CH, ⁴East Hannover, NJ/US, ⁵Basel, CH, ⁶Essen, DE
- 13:00 - 13:00 1149P - Chemotherapy in patients with metastatic melanoma after progression on BRAF/MEK inhibitors
I. Samoylenko, G. Kharkevich, L. Demidov; Moscow, RU
- 13:00 - 13:00 1150P - Use and clinical impact of conventional cytotoxic chemotherapy (CTx) subsequent to immunotherapy in metastatic melanoma
E. Malone, M. Maltese, L. Coady, L. Hammond, N. Silva, G. Gullo, J. Crown; Dublin, IE



- 13:00 - 13:00 (Withdrawn)
- 13:00 - 13:00 1152P - Evaluation of the pharmacokinetic (PK) profile of vismodegib (VISMO) in patients (pts) with multiple basal cell carcinomas (BCCs) across two intermittent treatment regimens in the MIKIE study
D. Schadendorf¹, A. Hauschild², I. Maher³, D. Zloty⁴, B. Labeille⁵, J.J. Grob⁶, S. Puig⁷, M. Makrutzki⁸, I. Templeton⁹, G. Rogers¹⁰, B. Dreno¹¹, R. Kunstfeld¹²; ¹Essen, DE, ²Kiel, DE, ³St. Louis, MO/US, ⁴Vancouver, BC/CA, ⁵Saint-Etienne, FR, ⁶Marseille, FR, ⁷Barcelona, ES, ⁸Basel, CH, ⁹South San Francisco, CA/US, ¹⁰Boston, MA/US, ¹¹Nantes, FR, ¹²Vienna, AT
- 13:00 - 13:00 1153P - Subgroup analysis of patients (pts) with Gorlin syndrome treated with vismodegib (VISMO) in the STEVIE study
N. Basset-Seguin¹, J. Hansson², R. Kunstfeld³, J.J. Grob⁴, B. Dreno⁵, L. Mortier⁶, P. Ascierto⁷, N. Dimier⁸, A. Fittipaldo⁸, I. Xynos⁸, A. Hauschild⁹; ¹Paris, FR, ²Stockholm, SE, ³Vienna, AT, ⁴Marseille, FR, ⁵Nantes, FR, ⁶Lille, FR, ⁷Napoli, IT, ⁸Welwyn Garden City, GB, ⁹Kiel, DE
- 13:00 - 13:00 1154P - Evaluation of real world treatment outcomes in patients with metastatic Merkel cell carcinoma (MCC) following second line chemotherapy
J. Becker¹, E. Lorenz², G. Haas³, C. Helwig³, D. Oksen³, L. Mahnke⁴, M. Bharmal³; ¹Essen, DE, ²Frankfurt Am Main, DE, ³Darmstadt, DE, ⁴Rockland, MD/US
- 13:00 - 13:00 1155P - VISMONEO - A phase II study assessing vismodegib in the neoadjuvant treatment of locally advanced basal cell carcinoma - Patients characteristics
N. Basset-Seguin¹, A. Dupuy², P. Saiag³, S. Dalac-Rat⁴, B. Guillot⁵, E. Routier¹, M.T. Leccia⁶, A. Duhamel⁷, X. Mirabel⁷, I. Benbouta⁷, L. Mirakovska⁷, D. Meddour⁷, M. Dib⁷, A. Mahmoudi³, P. Guerreschi⁷, L. Mortier⁷; ¹Paris, FR, ²Rennes, FR, ³Boulogne-Billancourt, FR, ⁴Dijon, FR, ⁵Montpellier, FR, ⁶Grenoble, FR, ⁷Lille, FR
- 13:00 - 13:00 1156TiP - CONVERCE: Evaluation of cobimetinib and vemurafenib combination treatment in patients with brain metastases from BRAFV600 mutated melanoma
T. Lesimple¹, B. Campillo-Gimenez¹, M.T. Leccia², A. Mahmoudi³, C. Lebbe⁴; ¹Rennes, FR, ²Grenoble, FR, ³Boulogne-Billancourt, FR, ⁴Paris, FR
- 13:00 - 13:00 1157TiP - Phase Ib study of intratumoral oncolytic coxsackievirus A21 (CVA21) and pembrolizumab in subjects with advanced melanoma
H. Kaufman¹, K. Spencer¹, J. Mehnert¹, A. Silk¹, J. Wang¹, A. Zloza¹, M. Kane¹, D. Moore¹, M. Grose², D. Shafren²; ¹New Brunswick, NJ/US, ²New Lambton Heights, NSW/AU
- 13:00 - 13:00 1158TiP - Intralesional rose bengal for stage III and IV melanoma
S. Agarwala¹, R. Andtbacka², A. Hauschild³, K.N. Rice⁴, M. Ross⁵, C.R. Scoggins⁶, M. Smithers⁷, E. Whitman⁸, E.A. Wachter⁹; ¹Bethlehem, US, ²Salt Lake City, UT/US, ³Kiel, DE, ⁴San Diego, CA/US, ⁵Houston, TX/US, ⁶Louisville, KY/US, ⁷Brisbane, AU, ⁸Morristown, NJ/US, ⁹Knoxville, TN/US
- 13:00 - 13:00 Palliative care



- 13:00 - 13:00 1302P - Active palliation for massive malignant ascites using KM-CART (Japanese original ascites treatment system)
K. Matsusaki, A. Yoshizawa, M. Yokoi, K. Ohta; Tokyo, JP
- 13:00 - 13:00 1303P - Safety and effectiveness of interventions for malignant ascites with advanced cancer: Systematic review
D. Martins-Branco¹, C. Ribeiro¹, B. Gomes²; ¹Lisboa, PT, ²London, GB
- 13:00 - 13:00 1304P - Intraperitoneal bevacizumab (Bev) for control of refractory malignant ascites. A single centre experience
C. Satheesh, S. Patil, H. Shashidhara; Bangalore, IN
- 13:00 - 13:00 1305P - Knowledge of pain management in patients with painful bone metastases; A multicentre randomized trial on pain education
J. Geerling¹, A. Reyners¹, Y. van der Linden², V. Mul¹, P. Westhoff³, A. de Graeff⁴, C. Rodenhuis⁴, E. de Nijs², T. Muilenburg⁴; ¹Groningen, NL, ²Leiden, NL, ³Nijmegen, NL, ⁴Utrecht, NL
- 13:00 - 13:00 1306P - Efficacy of Quadramet® (QUA) as treatment of painful bone metastasis: A large single-center study
H. Kolesnikov-Gauthier, N. Lemoine, A. Oudoux, A. Olivier, E. Tresch-Bruneel, N. Penel; Lille, FR
- 13:00 - 13:00 1307P - Use of treatments of questionable benefit in hospitalized patients with metastatic gastric or esophageal cancer near the end of life. A country-wide, register-based study
E. Kempf¹, L. Morin²; ¹Créteil, FR, ²Stockholm, SE
- 13:00 - 13:00 1308P - Undertreatment of cancer pain - a retrospective analysis of medical records of advanced cancer patients hospitalized in a palliative care department
N. Yordanov¹, I. Marinova¹, A. Marinova¹, S. Aleksandrova²; ¹Vratsa, BG, ²Pleven, BG
- 13:00 - 13:00 1309P - Analysis of patient-related barriers to management of cancer pain in Shanghai
Y. Zhao, Q. Xu; Shanghai, CN
- 13:00 - 13:00 1310P - Influence of age on opioid prescription of patients with advanced lung cancer
H.-S. Lee¹, C.-P. Lin², H.-M. Chen², Y.-Y. Shao²; ¹Kaohsiung, TW, ²Taipei, TW
- 13:00 - 13:00 1311P - End of life (EOL) chemotherapy (CT) in gastro-intestinal (GI) cancer patients (pts): A retrospective AGEOS study
A. Lapeyre-Prost¹, G. Perkins¹, M. Vallee², A. Pozet³, D. Tougeron², M. Maillet¹, C. Locher⁴, J. Dreanic¹, J.L. Legoux⁵, A. Lievre⁶, C. Lecaille⁷, J.-M. Sabate⁸, F. Mary⁹, F. Bonnetain³, H. Jaulmes-Bouillot¹, B. Landi¹, J. Taieb¹; ¹Paris, FR, ²Poitiers, FR, ³Besançon, FR, ⁴Meaux, FR, ⁵Orleans, FR, ⁶Rennes, FR, ⁷Bordeaux, FR, ⁸Colombes, FR, ⁹Bobigny, FR
- 13:00 - 13:00 1312P - Provision of spiritual care to advanced cancer patients by doctors and nurses in the Middle East



G. Bar-Sela¹, M. Schultz¹, K. Khader², M. Rassouli³, M. Doumit⁴, I. Ghayeb⁵, R. Kebudi⁶, K. Elshamy⁷, M. Faisal Al-Jadiry⁸, R. Fahmi⁹, H. Charalambous¹⁰, S. Razaq⁸, N. Gafer¹¹, G. Can⁶, R. Obeidat¹², R. Punjwani¹³, H. Ayyash¹⁴, M. Khleif¹⁵, M. Najajreh¹⁵, M. Silbermann¹; ¹Haifa, IL, ²Taif, SA, ³Tehran, IR, ⁴Beirut, LB, ⁵East Jerusalem, PS, ⁶Istanbul, TR, ⁷Mansoura, EG, ⁸Baghdad, IQ, ⁹Cairo, EG, ¹⁰Stovros, CY, ¹¹Khartoum, SD, ¹²Zarqa, JO, ¹³Karachi, PK, ¹⁴Khan Yunis, PS, ¹⁵Bethlehem, PS

- 13:00 - 13:00 1313P - Study on Tong-Luo-San in treating hand-foot skin reaction induced by multikinase inhibitors: A randomized, placebo-controlled clinical trial
L. Jia, B. Deng; Beijing, CN
- 13:00 - 13:00 1314P - An end of life prognostic score for patients with metastatic prostate cancer receiving palliative radiotherapy
J. Donaghy, A. Lopes, M. Ali, R. Davda, J. Mascoll, J. Forgenie, S. Howard, U. McGovern, H. Payne, A. Mitra, M. Linch; London, GB
- 13:00 - 13:00 1315P - Antineoplastic therapy near the end of life: A retrospective analysis of the clinical practice in oncological adult patients
E. Llabrés Valentí, J. Brenes, A. Hernández, A. Ramchandani Vaswani, L. Beltrá, E. Vicente, M. Cejuela, D. Rejas; Las Palmas, ES
- 13:00 - 13:00 1316P - The time frame of palliative care referrals
M. Ebert Moltara, Ljubljana, SI
- 13:00 - 13:00 1317P - Supportive home care service: A home-based simultaneous care intervention
M. Pino, L. Brogi, G. Spinelli, L. Fioretto; Firenze, IT
- 13:00 - 13:00 1318P - Percutaneous biliary drainage in malign obstructive jaundice: Is it really necessary for all patients with malign obstructive jaundice?
C. Hoczazade, I. Akmgangit, B. Sever Sayin, M. Doğan, Y. Bozkaya, G. Erdem, N. Zengin; Ankara, TR
- 13:00 - 13:00 1319P - Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small cell lung cancer
H. Ajimizu, H. Ozasa, S. Sato, Y. Sakamori, T. Funazo, Y. Yasuda, T. Nomizo, T. Tsuji, H. Yoshida, Y. Yagi, H. Nagai, A. Sato, M. Tsuchiya, S. Muro, Y. Nagasaka, M. Mishima, Y.H. Kim; Kyoto, JP
- 13:00 - 13:00 1320P - Efficacy and tolerability of transdermal fentanyl versus oral prolonged-release oxycodone/naloxone in patients with moderate to severe cancer pain: A propensity analysis comparison
A. Roberto, M. Greco, L. Legramandi, F. Galli, O. Corli; Milano, IT
- 13:00 - 13:00 1321P - OncoSTRIP for optimizing pharmacotherapy in elderly oncology patients with polypharmacy
T. Oude Munnink, J. de Vries, R. Schaafsma, M. Wymenga, H. Colen; Enschede, NL
- 13:00 - 13:00 1322P - Stereotactic radiosurgery (SRS) for spinal tumors: The Philippine experience
J.R. Baclay, A. Gaerlan, I.M. Sih, K.J. Cortez, J.C. Rojas, M.J. Calaguas, J.M. Magsanoc, R.A.D. Torcuator; Taguig City, PH
- 13:00 - 13:00 1323P - Palliative medicine in Iran
R. Malayeri, A. Hazini, P. Pirjani, M. Sharbafchi, S. Hojjat; Tehran, IR



- 13:00 - 13:00 Prevention and screening
- 13:00 - 13:00 1327P - Opinion on cancer screening: Impact on prescription and participation rates
J.-F. Morère¹, J. Viguier², S. Couraud³, L. Guibaudet⁴, J.-Y. Blay⁵, A. Cortot⁶, C. Lhomel⁷, L. Greillier⁸, X. Pivot⁹, F. Eisinger⁸; ¹Villejuif, FR, ²Tours, FR, ³Pierre Bénite, FR, ⁴Montrouge, FR, ⁵Lyon, FR, ⁶Lille, FR, ⁷Boulogne-Billancourt, FR, ⁸Marseille, FR, ⁹Besançon, CEDEX/FR
- 13:00 - 13:00 1328P - Immunohistochemical biomarkers for risk stratification of neoplastic progression in Barrett esophagus
V. Janmaat, S. van Olphen, K. Biermann, L. Looijenga, M. Bruno, M. Spaander; Rotterdam, NL
- 13:00 - 13:00 1329P - A logistic regression model based on tongue image information for prediction precancerous lesions and early stage esophageal cancer in China
L. Jia¹, J. Duan¹, B. Deng¹, W. Bai², M. Liu¹; ¹Beijing, CN, ²Handan, CN
- 13:00 - 13:00 1330P - Duodenal neoplasm in screening esophagogastroduodenoscopy
T. Nakamura, Y. Kon, S. Shibata, K. Konuma, T. Sanada, H. Gonda, Y. Suto, K. Kobayashi, N. Takita, M. Shimura, H. Yoshida, A. Suzuki, S. Onuki, M. Fukuda, C. Aoyagi, Y. Hasegawa, A. Nishiwaki; Ota, JP
- 13:00 - 13:00 1331P - The prevalence and characteristics of Barrett esophagus of general population in high risk area for esophagus cancer in North China (CiXian County)
L. Jia¹, F. Wu¹, Y. Lou¹, Y. Li¹, J. Da¹, W. Bai², G. Jin²; ¹Beijing, CN, ²Handan, CN
- 13:00 - 13:00 1332P - The hormonal status of girls from Kyiv and evacuees from Pripyat
D. Burlaka, N. Hutnyk; Kyiv, UA
- 13:00 - 13:00 1333P - What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
A. Uluturk¹, L. Pylkkanen², S. Deandrea¹, A. Bramesfeld¹, L. Neamtii¹, Z. Saz Parkinson¹, M. Ambrosio¹, D. Lerda¹; ¹Ispira, IT, ²Helsinki, FI
- 13:00 - 13:00 1334P - A novel way to visualise tumour related angiogenesis and detect breast tumours in women: A combined clinical and optical method for breast cancer screening of well-women in Ghana
F. Ghartey¹, D. Watmough², A. Anyanful¹, S. Debrah¹, M. Morna¹, S. Eliason¹, M. Adamu¹, L. Derkyi-Kwarteng¹; ¹Cape Coast, GH, ²Inverness, GB
- 13:00 - 13:00 1335P - Multigene panel testing for breast cancer patients at high risk for hereditary cancer
H.-C. Shin, T.-K. Yoo, E. Lee, H.-B. Kee, J. Han, Y. Kim, H.-G. Moon, D.-Y. Noh, W. Han; Seoul, KR
- 13:00 - 13:00 1336P - Evaluation of breast cancer patients with genetic risk: Before and after a multidisciplinary hereditary cancer unit implementation
M. Lobo, S. Lopez-Tarruella, S. Luque, S. Lizarraga, P. Rincon, A. Hernandez, E. Mendizabal, O. Bueno, M. Cebollero, S. Perez Ramirez, Y. Jerez, M.I. Palomero Plaza, R. Gonzalez del Val, G. Garcia, I. Echavarría Diaz-Guardamino, A. Calin, J.A. Blanco, C. Flores Sanchez, M. Martin, I. Marquez-Rodas; Madrid, ES



- 13:00 - 13:00 1337P - Frequency and clinical characteristics of breast cancer patients with high-risk features and no BRCA1/2 mutations in a Salentinian cohort
E. De Matteis, M.R. De Giorgio, P. Tarantino, G. Ronzino, M. Ciccarese, L. Palma, G. Surico; Lecce, IT
- 13:00 - 13:00 1338P - Breast cancer in young women survivors of pediatric cancer
C. Salvador Coloma, A. Cañete, J. Balaguer, L. Montero, R. Viquer, A. Santaballa; Valencia, ES
- 13:00 - 13:00 1339P - Leveraging six sigma instruments to optimize cancer screening in an urban community hospital
U. Goldberg, M. Kalavar, V. Patel, R. Mukherji, K. Kodroff, N. Pasco; Brooklyn, NY/US
- 13:00 - 13:00 1340P - Screening colonoscopy in family members of patients with colorectal cancer: A population-based study in Iran
H. Salimzadeh¹, A. Delavari¹, M. Amani¹, F. Bishesari², R. Malekzadeh¹; ¹Tehran, IR, ²Chicago, US
- 13:00 - 13:00 1341P - Proposal of a stage-specific surveillance strategy for colorectal cancer
R. Okamura¹, S. Hasegawa¹, K. Hida¹, R. Takahashi¹, K. Kawada¹, K. Sugihara², Y. Sakai¹; ¹Kyoto, JP, ²Tokyo, JP
- 13:00 - 13:00 1342P - Aspirin utilization, compliance and prevention of colorectal cancer – A single centre perspective
G. Singh Ranger¹, C. McKinley-Brown²; ¹Waterville, CA, ²Waterville, NB/CA
- 13:00 - 13:00 1343P - Knowledge of cervical cancer preventive strategies among market women in Nigeria
Y. Adetule, Ibadan, NG
- 13:00 - 13:00 1344P - Prevalence of cyp1b1 mutations among lung cancer patients
P. Sawrycki, M. Gąsior, K. Domagalski, J. Jarkiewicz-Tretyn, M. Jackowski; Torun, PL
- 13:00 - 13:00 (Withdrawn)
- 13:00 - 13:00 1347P - Naturally occurring immune response against biologically and clinically relevant targets
J. Marquez¹, S. Carrillo², A. Suplee-Rivera², E. Ramos², P. Lucero-Diaz², A. Camacho-Hernandez², J. Matute-Briseno², R. Soto-Soto²; ¹Seattle, US, ²Sonora, MX
- 13:00 - 13:00 1348P - Malignancy registered in Babylon Oncology Center (1990 - 2015)
S. Abood, A. Al-Timimi, H. Al-Dahmishi, R. Alwash, A. Helmi, Y. Alwash, W. Abdul Ameer; Hillah, IQ
- 13:00 - 13:00 Psycho-oncology
- 13:00 - 13:00 1351P - Psychosocial quality of life in 30 survivors of bilateral retinoblastoma
A. Batra, D. Dhawan, S. Bakhshi; New Delhi, IN
- 13:00 - 13:00 1352P - Empowerment in adolescents and young adults (AYA) with cancer and its association with health-related quality of life



S. Kaal¹, O. Husson¹, S. van Duivenboden¹, R. Jansen¹, E. Manten-Horst¹, S. van den Berg¹, J. Prins¹, W. van der Graaf²; ¹Nijmegen, NL, ²London, GB

13:00 - 13:00 1353P - Professional reintegration after cancer treatment: Factors influencing return to work

N. Adam¹, P. van Aalderen¹, L. van Hulle¹, E. Smeyers², T. Van Keymeulen², A. Roelstraete²; ¹Antwerp, BE, ²Aalst, BE

13:00 - 13:00 1354P - Cancer occurrence and cure: the power of the mind

F. Eisinger¹, X. Pivot², L. Greillier¹, C. Touboul³, J.-Y. Blay⁴, S. Couraud⁵, C. Lhomel⁶, A. Cortot⁷, J.-F. Morère⁸, J. Viguier⁹; ¹Marseille, FR, ²Besançon, CEDEX/FR, ³Paris, FR, ⁴Lyon, FR, ⁵Pierre Bénite, FR, ⁶Boulogne-Billancourt, FR, ⁷Lille, FR, ⁸Villejuif, FR, ⁹Tours, FR

13:00 - 13:00 1355P - Stoicism and its relation with clinical-pathological variables in patients with resected cancer undergoing adjuvant chemotherapy treatment

A. Ramchandani Vaswani¹, C. Calderon Garrido², P. Jimenez Fonseca³, A. Carmona-Bayonas⁴, E. Llabrés Valentí¹, C. Beato Zambrano⁵, T. García⁴, M.D.M. Muñoz⁶, B. Castelo⁷, E. Martínez de Castro⁸, J. Rogado Revuelta⁷, M.D. Fenor⁷, M. Mangas Izquierdo⁹, M.Á. Vicente⁴, O. Higuera⁷, P. De La Morena⁴, M.D.L.N. Gomez Camacho¹⁰, S. Fernández Arrojo³, M.D.M. Soriano⁶, C. Jara⁷; ¹Las Palmas, ES, ²Barcelona, ES, ³Oviedo, ES, ⁴Murcia, ES, ⁵Sevilla, ES, ⁶Cuenca, ES, ⁷Madrid, ES, ⁸Santander, ES, ⁹Vizcaya, ES, ¹⁰San Cristobal De La Laguna, ES

13:00 - 13:00 1356P - Short-term quality of life changes after surgery in elderly (>65 years) patients with breast cancer using the medical outcomes study short form (MOS-SF-36) questionnaire

F. Lumachi¹, L. Di Gennaro², P. Ubiali³, S. Basso³; ¹Padova, IT, ²Trieste, IT, ³Pordenone, IT

13:00 - 13:00 1357P - Psychometric properties of the functional assessment for chronic illness therapy-spiritual wellbeing (FACIT-Sp) and its relationship with quality of Life on patients with non-metastatic resected cancer

C. Beato Zambrano¹, C. Calderón², P. Jimenez Fonseca³, A. Carmona-Bayonas⁴, T. García⁴, A. Ramchandani⁵, M.D.M. Muñoz⁶, B. Castelo⁷, E. Martínez de Castro⁸, M.D. Fenor⁷, J. Rogado Revuelta⁷, M. Mangas Izquierdo⁹, M.Á. Vicente⁴, I. Ghanem⁷, A. Fernández⁴, A. Padilla⁵, M.P. Solis Hernandez³, O. Donnay⁷, M.D.M. Soriano⁶, C. Jara⁷; ¹Sevilla, ES, ²Barcelona, ES, ³Oviedo, ES, ⁴Murcia, ES, ⁵Las Palmas, ES, ⁶Cuenca, ES, ⁷Madrid, ES, ⁸Santander, ES, ⁹Vizcaya, ES

13:00 - 13:00 1358P - Evaluation of burnout syndrome and personalized intervention in the medical oncology unit of Second university of Naples (SUN)

F. Fiore, L. Gargiulo, C. Cardone, M.M. Laterza, M. Fasano, F. De Vita, F. Ciardiello; Napoli, IT

13:00 - 13:00 1359P - Evaluation of burnout, anxiety and depression in physicians of an oncology hospital

B. Martins, C.E. Paiva, B. Paiva; Barretos, BR

13:00 - 13:00 1360P - Prevalence of burnout syndrome among Brazilian oncologists, a National survey

L. Dos Santos¹, T. Cordas¹, A. Calabrich², F. Maluf¹; ¹São Paulo, BR, ²Salvador, BR



- 13:00 - 13:00 1361P - Effect of mindfulness training on quality of life and distress in early breast cancer patients treated with endocrine therapy
J. Mebis, S. Censabella, N. Cardinaels, G. Orye, S. Marquette, L. Noe, A. Maes, P. Bulens; Hasselt, BE
- 13:00 - 13:00 Public health
- 13:00 - 13:00 1368P - Access to cancer drugs in Europe years 2005-2014
N. Wilking¹, P. Lindgren¹, U. Wilking², B. Jönsson¹; ¹Stockholm, SE, ²Stockholm, Solna/SE
- 13:00 - 13:00 1369P - Not at all simple: The lay language summary of oncology clinical trials results. Challenges in implementing the new EU regulation (536/2014)
A. Nottbohm, C. Weiss-Haljiti, T. Schindler; Biberach, DE
- 13:00 - 13:00 1370P - An observational study on the chronological efficiency of a short cancer lecture for senior elementary school children
K. Miyazato, K. Kurashita, A. Shinzato; Urasoe, JP
- 13:00 - 13:00 1371P - PREDIT model: PRognostic factor of Early Death In phase II Trials or the end of 'sufficient life expectancy' as an inclusion criterion?
T. Grellety¹, S. Cousin², L. Letinier¹, P. Bosco-Levy¹, S. Hoppe¹, D. Joly¹, N. Penel², S. Mathoulin-Pelissier¹, A. Italiano¹; ¹Bordeaux, FR, ²Lille, FR
- 13:00 - 13:00 1372P - Risks and benefits of phase 1 oncology trials in the era of personalized medicine
C. Chakiba¹, T. Grellety¹, S. Cousin², A. Italiano¹; ¹Bordeaux, FR, ²Lille, FR
- 13:00 - 13:00 1373P - Risk of mortality among cancer patients
N. Zaorsky, T. Churilla, B. Egleston, S. Fisher, J. Ridge, E. Horwitz, J. Meyer; Philadelphia, PA/US
- 13:00 - 13:00 1374P - Socioeconomic position and mortality among patients with prostate cancer: influence of mediating factors
S. Larsen, K. Brasso, J. Christensen, C. Johansen, A. Tjønneland, S. Friis, P. Iversen, S. Dalton; Copenhagen, DK
- 13:00 - 13:00 1375P - Acute diagnostic oncology clinic: Tackling emergency presentations of cancer
T. Newsom-Davis, J. Simmons, M. Bower, S. Cox, A. Gill, L. Henna, A. Robinson, K. Richmond, R. Sharkey; London, GB
- 13:00 - 13:00 1376P - Profile of cancer patients who visit a specialized emergency room in São Paulo, Brazil
M. Rapozo, V. Hatanaka, M. Bernardes, G. Albuquerque, M.D.P. Diz; Sao Paulo, BR
- 13:00 - 13:00 1377P - Highlighting differences in education satisfaction and professional development between medical and clinical oncologists in Europe. A European survey conducted by the Hellenic Group of Young Oncologists (HeGYO)



E. Aravantinou Fatorou¹, G. Papaxoinis¹, K. Kamposioras², A. Korogiannos¹, V. Papadopoulos¹, G. Lazaridis³, M. Nikolaou⁴, E. Voulgaris¹, E. Bournakis¹, K. Tsigaridas¹, M. Lontos¹, E. Pantavou¹, N. Chatzifoti¹, P. Zaxaropoulou¹, I. Varthalitis¹, A. Athanasiadis¹, N. Tsoukalas⁵; ¹Athens, GR, ²Wakefield, GB, ³Thessaloniki, GR, ⁴Larissa, GR, ⁵London, GB

- 13:00 - 13:00 1378P - Education in oncology and career development in the web-era technology: A European survey conducted by the Hellenic Group of Young Oncologists (HeGYO)
N. Tsoukalas¹, K. Kamposioras², G. Papaxoinis², E. Aravantinou-Fatorou², A. Korogiannos², V. Papadopoulos², G. Lazaridis², M. Nikolaou², E. Voulgaris², E. Bournakis², K. Tsigaridas², M. Lontos², E. Papageorgiou², N. Chatzifoti², P. Zaxaropoulou², A. Athanasiadis², I. Varthalitis²; ¹London, GB, ²Athens, GR
- 13:00 - 13:00 1379P - Clinicians identify high need to increase their genomic literacy to applied cancer genomics
J. Laskin¹, D. Ha¹, T. Chan¹, A. Fok², K. Gelmon¹, A. Charters¹, R. Yoshizawa¹, S. Struve¹, C. Ho¹, D. Renouf¹, H. Lim¹, C. Simmons¹, S. Taylor³, A. Tinker¹, J.-P. McGhie⁴, S. Jones², M. Marra², P. Chow-White¹; ¹Vancouver, CA, ²Vancouver, BC/CA, ³Kelowna, CA, ⁴Victoria, CA
- 13:00 - 13:00 1380P - Elicitation of public preferences for lung cancer screening using three screening modalities
M. Ijzerman¹, H. Broekhuizen¹, C. Groothuis-Oudshoorn¹, R. Vliegenthart², H. Groen²; ¹Enschede, NL, ²Groningen, NL
- 13:00 - 13:00 1381P - Current or former smokers: Who wants to be screened?
S. Couraud¹, L. Greillier², X. Pivot³, L. Guibaudet⁴, J.-Y. Blay⁵, C. Lhommel⁶, J. Viguier⁷, J.-F. Morère⁸, F. Eisinger², A. Cortot⁹; ¹Pierre Bénite, FR, ²Marseille, FR, ³Besançon, CEDEX/FR, ⁴Montrouge, FR, ⁵Lyon, FR, ⁶Boulogne-Billancourt, FR, ⁷Tours, FR, ⁸Villejuif, FR, ⁹Lille, FR
- 13:00 - 13:00 1382P - Long-term experience in the management of adolescents and young adults with cancer referred to a regional tertiary center for multidisciplinary care
M. Melián Sosa, R. Díaz, E. Navarro, J.A. Mendez, M.E. Medina, A. Torres, E. García, D. Akhoundova, J. Aparicio; Valencia, ES
- 13:00 - 13:00 1383P - Toxoplasmosis: An overlooked infection in cancer patients
R. Wassef, R. Abdel Malek, E.M. Rizk, A. Boghdady; Cairo, EG
- 13:00 - 13:00 1384P - Evaluation of clinical outcomes of her2/neu positive breast cancer patients treated with adjuvant trastuzumab in two oncology centers from middle income countries
H. Perroud¹, C. Alasino², A. Eniu³, N. Antone⁴; ¹Rosario, Santa Fe/AR, ²Rosario, AR, ³Cluj-Napoca, RO, ⁴Cluj Napoca, RO
- 13:00 - 13:00 1385P - Breast cancer demographics, screening and survival outcome at a regional Australian cancer centre: A retrospective study
H. Mandaliya¹, C. Oldmeadow², T. Evans², P. Troke², M. George³; ¹Newcastle, AU, ²Newcastle, NSW/AU, ³Tamworth, NSW/AU
- 13:00 - 13:00 1386P - Breast cancer fast-track programme - Evolution and guidelines to prioritize patient referral



M.T. Martinez, I. Chirivella Gonzalez, K. Pinilla, A. Fernandez, A. Viala, A. Iranzo, A. Caballero, J. Calvete, A. Sanmartin, J. Navarro, B. Bermejo, A. Lluch-Hernandez; Valencia, ES

- 13:00 - 13:00 1387P - Pain management nursing in oncologic hospital in Albania
S. Enkelejda, S. Diamant, B. Maksim, P. Edmond; Tirana, AL
- 13:00 - 13:00 1388P - Competencies of physicians in management and leadership for a better palliative care treatment
O. Pampuri, H. Zotaj; Tirana, AL
- 13:00 - 13:00 (Withdrawn)
- 13:00 - 13:00 1390P - Changing trends in HIV and cancer
A. Fernández Ruiz, R. Lastra del Prado, P. Iranzo Gomez, A. Rodrigo, A. Callejo Perez, E. Quilez Bielsa, M. Cruellas Lapeña, M.J. Crusells Canales, A. Yubero Esteban, N. Galan Cerrato, J. Lambea Sorrosal, L. Murillo Jaso, R. Andres Conejero, P. Escudero Emperador, E. Pujol Obis, A. Saenz Cusi, D. Isla Casado; Zaragoza, ES
- 13:00 - 13:00 1391P - Oral health disparities among privileged and underprivileged tribes of South India - A study on precancerous oral lesions prevalence
K. Thiyyakandy, Calicut, IN
- 13:00 - 13:00 1392P - Geographical differences in preventable cancers in Turkey
D. Yuce, M. Hayran, S. Eser, S. Uner; Ankara, TR
- 13:00 - 13:00 1393P - Capecitabine/oxaliplatin (XELOX) versus XELOX plus bevacizumab (XELOX+bev) cost-effectiveness for metastatic colorectal cancer (mCRC) in first line treatment: A Brazilian public hospital analysis
F. Peria¹, A. Ungari², F. Dos Santos², T. Lins-Almeida², A. Nunes²; ¹Ribeirao Preto, SP/BR, ²Ribeirao Preto, BR
- 13:00 - 13:00 1394P - Changing treatment patterns in advanced & metastatic melanoma towards targeted therapies in EU5 countries from 2011 to 2015
M. Bernhardt, N. Schmidt, K. Acker; Frankfurt Am Main, DE
- 13:00 - 13:00 Supportive care
- 13:00 - 13:00 1440P - Efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gastrointestinal and colorectal cancers
R. Navari¹, K. Jordan², B. Rapoport³, I. Schnadig⁴, M. Chasen⁵, S. Arora⁶, D. Powers⁶, L. Schwartzberg⁷; ¹South Bend, IN/US, ²Halle, DE, ³Sandton, ZA, ⁴Tualatin, OR/US, ⁵Ottawa, CA, ⁶Waltham, MA/US, ⁷Memphis, TN/US
- 13:00 - 13:00 1441P - Efficacy and safety of rolapitant in the prevention of chemotherapy-induced nausea and vomiting (CINV) in elderly patients
M. Aapro¹, S. Arora², D. Powers²; ¹Genolier, CH, ²Waltham, MA/US



- 13:00 - 13:00 1442P - Safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving breast cancer resistant protein (BCRP) substrate chemotherapy agents
L. Schwartzberg¹, K. Jordan², B. Rapoport³, I. Schnadig⁴, M. Chasen⁵, S. Arora⁶, S. Barbour⁷, D. Powers⁶, R. Navari⁸; ¹Memphis, TN/US, ²Halle, DE, ³Sandton, ZA, ⁴Tualatin, OR/US, ⁵Ottawa, CA, ⁶Waltham, MA/US, ⁷Durham, NC/US, ⁸South Bend, IN/US
- 13:00 - 13:00 1443P - Systematic review of the efficacy and safety of neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: Identification of the relevant clinical trials
G. Lyman¹, D. King², O. Evuarhehe², D. Powers³, B. Harrow³; ¹Seattle, US, ²Oxford, GB, ³Waltham, MA/US
- 13:00 - 13:00 1444P - Impact of chemotherapy-induced nausea and vomiting (CINV) on emergency department (ED) visits and disruption of chemotherapy: Results of a survey of oncology nurses
C. Rittenberg¹, R. Clark-Snow², M.L. Affronti³; ¹Metairie, LA/US, ²Westwood, KS/US, ³Durham, NC/US
- 13:00 - 13:00 1445P - Efficacy of rikkunshito, a Japanese herbal medicine, on nausea, vomiting and anorexia in patients with uterine cervical or corpus cancer treated with cisplatin and paclitaxel –A randomized phase II study
S. Ohnishi¹, H. Watari¹, M. Kanno², Y. Oba¹, S. Takeuchi³, T. Miyaji⁴, S. Oyamada⁴, E. Nomura², H. Kato¹, T. Sugiyama³, M. Asaka¹, N. Sakuragi¹, T. Yamaguchi⁵, Y. Uezono⁴, S. Iwase⁴; ¹Sapporo, JP, ²Tokamkomai, JP, ³Morioka, JP, ⁴Tokyo, JP, ⁵Sendai, JP
- 13:00 - 13:00 1446P - Anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and acute phase protein reaction (APPR): Pooled analysis of two phase 3 trials (ROMANA 1 and ROMANA 2)
D. Currow¹, J. Temel², A. Abernethy³, J. Friend⁴, R. Giordano⁵, K.C. Fearon⁶; ¹Adelaide, AU, ²Boston, MA/US, ³New York, NY/US, ⁴Iselin, NJ/US, ⁵Pambio-Noranco, CH, ⁶Edinburgh, GB
- 13:00 - 13:00 1447P - Malnutrition in 822 Irish cancer patients undergoing chemotherapy: Prevalence and impact on quality of life and survival
L. Daly, É. Ní Bhuachalla, S. Cushen, D. Power, S. O'Reilly, P. McEneaney, D. O'Mahony, R. Bambury, A. Ryan; Cork, IE
- 13:00 - 13:00 1448P - Incidence and clinical outcomes of febrile neutropenia in adult cancer patients with chemotherapy using Korean nationwide health insurance database
S. Hong¹, T. Youk², H.M. You³, S. Lee²; ¹Goyang, Gyeonggi-do/KR, ²Seoul, KR, ³Goyang, KR
- 13:00 - 13:00 1449P - Phase II study of pregabalin for the prevention of chemotherapy induced nausea and vomiting
C. Rossi¹, F. Cruz², A. del Giglio², C. Rodrigues¹, S. Castro¹; ¹Sao Paulo, BR, ²Santo André, BR
- 13:00 - 13:00 1450P - Transdermal granisetron for the prevention of chemotherapy-induced nausea and vomiting in metastatic colorectal cancer patients with high risk of bowel obstruction treated with temozolomide
M.A. Calegari¹, S. Monterisi¹, A. Orlandi¹, A. Inno², R. Barile¹, S. Corallo¹, C. Di Dio¹, V. Zurlo¹, M. Basso¹, A. Cassano¹, C. Barone¹; ¹Roma, IT, ²Negrar, IT
- 13:00 - 13:00 1451P - A pharmacokinetics and pharmacodynamics equivalence trial of proposed pegfilgrastim biosimilar, MYL-1401H vs EU neulasta® and US neulasta®



C. Waller¹, R. Tiessen², T. Lawrence³, A. Shaw³, M. Liu³, R. Sharma⁴, M. Baczkowski³, M. Kothe⁵, R. Dias⁶, A. Barve⁷, E. Pennella⁷; ¹Freiburg, DE, ²Zuidlaren, NL, ³Morgantown, WV/US, ⁴Hatfield, GB, ⁵Bangalore, IN, ⁶Zurich, CH, ⁷Canonsburg, PA/US

- 13:00 - 13:00 1452P - Risk model for clinically relevant neutropenic event among patients with non hematological tumors receiving chemotherapy regimens not classified as high-risk for febrile neutropenia: Results from a multicenter prospective cohort study (NEURISK)
J. Muñoz-Langa¹, P. Borrega², J. García-Bueno³, P. Purificación Martínez del Prado⁴, J. Campos¹, M. Quindos⁵, R. López Castro⁶, V. Valentí Moreno⁷, E. Jiménez Orozco⁸, M. Lazaro⁹; ¹Valencia, ES, ²Alcántara, ES, ³Albacete, ES, ⁴Bilbao, ES, ⁵A Coruna, ES, ⁶Valladolid, ES, ⁷Tarragona, ES, ⁸Jerez De La Frontera, ES, ⁹Vigo, ES
- 13:00 - 13:00 1453P - Antiemetic prophylaxis (AP) in our clinical practice: Are we doing it right?
E. Vasile, G. Musettini, A. Sbrana, A. Farnesi, I. Brunetti, L. Galli, E. Biasco, A. Falcone, S. Ricci, A. Antonuzzo; Pisa, IT
- 13:00 - 13:00 1454P - Impact of sepsis and organ dysfunction on cancer patients' mortality
F. Pereira, S. Alves, J. Dias, I. Guerreiro, M. Silva, A. Afonso, P. Mergulhão, J. Savva-Bordalo, D. Pereira; Porto, PT
- 13:00 - 13:00 1455P - The primary prophylaxis of pneumocystis pneumonia by low-dose trimethoprim-sulfamethoxazole during R-CHOP therapy
A. Sato, H. Tsujimura, K. Ono, X. Wang, T. Sugawara, M. Ise, K. Kumagai; Chiba, JP
- 13:00 - 13:00 1456P - Underutilization of G-CSF in elderly cancer patients – an issue that needs to be urgently addressed
M. Saar, I.-I. Sei, J. Jaal; Tartu, EE
- 13:00 - 13:00 1457P - Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with breast cancer: Results from an interim analysis of the non-interventional study NADIR
C. Kurbacher¹, T. Fietz², T. Trarbach³, C. Salat⁴, M. Rezaei⁵, A. Lorenz⁶, B. Niemeier³; ¹Bonn, DE, ²Singen, DE, ³Freiburg, DE, ⁴München, DE, ⁵Düsseldorf, DE, ⁶Hildburghausen, DE
- 13:00 - 13:00 1458P - Development of a prognostic system to predict the response to treatment of neutropenic fever
H. Zawam, A. Selim, R. Salama, N. Hanna, W. Edesa; Cairo, EG
- 13:00 - 13:00 1459P - Use of lipegfilgrastim in clinical practice for the prophylaxis of chemotherapy-induced neutropenia: Interim results of pan-European non-interventional study
P. Pichler¹, N. Claes², P. Mazza³, B. Zurawski⁴, P. Potocki⁵, E. Petru⁶, M. Šedivá⁷, J. Katolicka⁸, F. Lanza⁹, C. Fontaine¹⁰; ¹St. Poelten, AT, ²Brugge, BE, ³Taranto, IT, ⁴Bydgoszcz, PL, ⁵Krakow, PL, ⁶Graz, AT, ⁷Prague, CZ, ⁸Brno, CZ, ⁹Cremona, IT, ¹⁰Brussels, BE
- 13:00 - 13:00 1460P - A multi-centre study to investigate the natural history of taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast or prostate cancer
R. Fernandes¹, S. Mazzarello², M.F. Ibrahim¹, J. Hilton², A. Joy³, M. Ong², B. Hutton², L. Vandermeer², M. Clemons¹; ¹Ottawa, CA, ²Ottawa, ON/CA, ³Edmonton, AB/CA



- 13:00 - 13:00 1461P - Effect of solution pre-warming, hot compress, plus pH adjustment by combination with dexamethasone on venous pain in cancer patients receiving oxaliplatin via a peripheral vein
S. Sumikawa¹, H. Kawazoe², K. Nakauchi², Y. Yakusijin², A. Tanaka², H. Araki²; ¹Matsuyama, JP, ²Ehime, JP
- 13:00 - 13:00 1462P - Opiophobia – knowledge, attitudes and concerns about opioid medicines among Polish society, cancer patients, families and professionals – the first wave of a survey
A. Kieszkowska-Grudny¹, J. Jarosz², J. Grudny², A. Siwy-Hudowska², D. Jasinska²; ¹Otwock, PL, ²Warsaw, PL
- 13:00 - 13:00 1463P - Denosumab for the prevention of symptomatic skeletal events (SSEs) in patients with bone-metastatic breast cancer: A comparison with skeletal-related events (SREs)
J.-J. Body¹, R. von Moos², A. Lipton³, M. Martin⁴, I. Diel⁵, G. Steger⁶, K. Tonkin⁷, R. de Boer⁸, H.-S. Radcliffe⁹, D. Niepel¹⁰, A. Stopeck¹¹; ¹Brussels, BE, ²Chur, CH, ³Hershey, PA/US, ⁴Madrid, ES, ⁵Mannheim, DE, ⁶Vienna, AT, ⁷Edmonton, CA, ⁸Parkville, VIC/AU, ⁹Uxbridge, GB, ¹⁰Zug, CH, ¹¹Stony Brook, NY/US
- 13:00 - 13:00 1464P - Comparison of the systemic and local pharmacokinetics, safety and tolerability of clonidine mucoadhesive buccal tablets with reference clonidine oral tablets in healthy volunteers
B. Petre-Lazar¹, G. Sharma², S. Hutchings², H. Goodwin², N. Yesiltas Emul¹, G. Dixon¹, B. Vasseur¹; ¹Paris, FR, ²Merthyr Tydfil, GB
- 13:00 - 13:00 1465P - Symptomatic skeletal events (SSEs) versus skeletal-related events (SREs) in patients with advanced cancer and bone metastases treated with denosumab or zoledronic acid
R. von Moos¹, L. Costa², G. Scagliotti³, H. Sleeboom⁴, F. Goldwasser⁵, V. Hirsh⁶, A. Spencer⁷, H.-S. Radcliffe⁸, D. Niepel⁹, D. Henry¹⁰; ¹Chur, CH, ²Lisboa, PT, ³Orbassano, IT, ⁴The Hague, NL, ⁵Paris, FR, ⁶Montreal, CA, ⁷Melbourne, VIC/AU, ⁸Uxbridge, GB, ⁹Zug, CH, ¹⁰Philadelphia, PA/US
- 13:00 - 13:00 1466P - Treatment of opioid-induced constipation with naldemedine in patients with cancer: Onset of action in a randomized phase 3 trial
T. Murata¹, N. Katakami², T. Harada³, K. Shinozaki⁴, M. Tsutsumi⁵, T. Yokota⁶, M. Arai⁷, Y. Suzuki⁷, M. Narabayashi⁸, N. Boku⁸; ¹Okazaki, JP, ²Kobe, JP, ³Sapporo, JP, ⁴Hiroshima, JP, ⁵Hitachi, JP, ⁶London, GB, ⁷Osaka, JP, ⁸Tokyo, JP
- 13:00 - 13:00 1467P - L-carnosine for prevention of oxaliplatin-induced neuropathy in colorectal cancer patients (pts)
A. Saad¹, R. Yehia¹, S. Mostafa², H. Elabhar², M. Schaal¹; ¹Cairo, EG, ²Giza, EG
- 13:00 - 13:00 1468P - An integrated analysis of hyponatremia in cancer patients receiving platinum-based chemotherapy in clinical trials (JCOG1405-A)
Y. Ezo¹, J. Mizusawa², K. Takizawa³, H. Katayama², K. Kataoka², K. Tobinai², M. Muto¹; ¹Kyoto, JP, ²Tokyo, JP, ³Shizuoka, JP
- 13:00 - 13:00 1469P - Impact of hyponatremia in a tertiary cancer center: A one-year-survey at National Cancer Institute of Milan



F. Agustoni¹, G. Fucà¹, G. Corrao¹, C. Vernieri¹, S. Cavalieri¹, A. Raimondi¹, G. Peverelli¹, M. Prisciandaro¹, P. Indelicato¹, K. Dotti¹, F. Morano², G. Lo Russo¹, D. Signorelli¹, C. Proto¹, M. Vitali¹, M. Imbimbo¹, N. Zilembo¹, M. Garassino¹, F. De Braud¹, M. Platania¹; ¹Milano, IT, ²Roma, IT

- 13:00 - 13:00 1470P - Estimation of glomerular filtration rate in patients with abnormal body composition and relation with carboplatin toxicity
M. Bretagne¹, A. Jouinot¹, J.-P. Durand¹, C. Tlemsani¹, J. Arrondeau¹, O. Huillard¹, P. Boudou Rouquette², F. Goldwasser¹, J. Alexandre¹; ¹Paris, FR, ²Paris, CEDEX 14/FR
- 13:00 - 13:00 1471P - Mannitol dosing and cisplatin-induced acute nephrotoxicity
P. Dhillon, E. Amir, M. Lo, A. Kitchlu, C. Chan, P. Yip, S. Cochlin, E. Chen, R. Lee, P. Ng; Toronto, ON/CA
- 13:00 - 13:00 1472P - Chemotherapy in cancer patients undergoing hemodialysis: A multicenter study
T. Funakoshi¹, T. Horimatsu¹, M. Nakamura², K. Suyama³, T. Mizukami⁴, S. Arita⁵, Y. Ozaki⁶, H. Yasui¹, H. Satake⁷, M. Toyoda⁷, S. Yazumi⁸, T. Kirishima¹, A. Nozaki¹, A. Yoshioka¹, T. Matsubara¹, M. Yanagita¹, S. Fukuhara¹, M. Muto¹; ¹Kyoto, JP, ²Sapporo, JP, ³Kumamoto, JP, ⁴Kawasaki, JP, ⁵Fukuoka, JP, ⁶Tokyo, JP, ⁷Kobe, JP, ⁸Osaka, JP
- 13:00 - 13:00 1473P - The effect of rikkunshito, a traditional Japanese herbal medicine, on food intake and plasma acylated ghrelin levels in lung cancer patients treated with platinum-based chemotherapy
T. Yoshiya, M. Ito, K. Misumi, H. Hanaki, Y. Tsutani, K. Satoh, Y. Miyata, M. Okada; Hiroshima, JP
- 13:00 - 13:00 1474P - Hydroactive colloid gel vs historical controls for the prevention of radiotherapy-induced moist desquamation in breast cancer patients: Preliminary results
S. Censabella, S. Claes, M. Orlandini, R. Braekers, P. Bulens; Hasselt, BE
- 13:00 - 13:00 1475P - Photobiomodulation for the prevention of radiodermatitis: Preliminary results of a randomized controlled clinical trial in breast cancer patients
J. Robijns¹, S. Censabella¹, S. Claes¹, L. Bussé², N. Hellings², I. Lambrichts², A. Timmermans¹, A. Maes¹, P. Bulens¹, V. Somers², J. Mebis¹; ¹Hasselt, BE, ²Diepenbeek, BE
- 13:00 - 13:00 1476P - Comparison of the usage of granulocyte colony-stimulating factors (G-CSF) in the Baltic and Nordic countries in 2011-2014
E. Vettus¹, K. Kurvits², K. Oselin²; ¹Tallinn, EE, ²Tartu, EE
- 13:00 - 13:00 1477P - Observational data on the clinical benefit of epoetin beta in cancer patients with anemia
J.-P. Spano¹, F. Barlesi², K. Pestel¹, D. Pau³, C. Dauriac⁴; ¹Paris, FR, ²Marseille, FR, ³Boulogne-Billancourt, FR, ⁴Rennes, FR
- 13:00 - 13:00 1478P - Risk factors for upper limb deep venous thrombosis (DVT) associated with peripherally inserted central catheters (PICCs) in cancer patients
A. Lee, B. Fairfax; Oxford, GB
- 13:00 - 13:00 1479P - Predictive factors for use of parenteral versus oral anticoagulants in the treatment of venous thromboembolism in patients with active cancer



A. Katholing¹, K. Folkerts², M. Bach³, C. Martinez¹; ¹Frankfurt Am Main, DE, ²Wuppertal, DE, ³Berlin, DE

13:00 - 13:00 1480P - A risk assessment model for predicting venous thromboembolic events in chemotherapy-treated germ-cell cancer

M.I. Luengo¹, D. Hervás², N. Sobrevilla³, X. Garcia del Muro⁴, J. Guma I Padro⁵, D. Castellano⁶, J. Aparicio², A. Sánchez Muñoz⁷, E. Buxo⁴, A. Saenz⁸, J.L. Aguilar³, C. Valverde Morales⁴, A. Fernández Aramburu⁹, P. Maroto⁴, M. Espinosa¹⁰, P. Jimenez Fonseca¹¹, S. Ros¹, M. Margeli⁴, J. Sastre⁶, E. Gonzalez-Billalabeitia¹; ¹Murcia, ES, ²Valencia, ES, ³Mexico, MX, ⁴Barcelona, ES, ⁵Reus, ES, ⁶Madrid, ES, ⁷Malaga, ES, ⁸Zaragoza, ES, ⁹Albacete, ES, ¹⁰Sevilla, ES, ¹¹Oviedo, ES

13:00 - 13:00 1481P - Outpatient management of cancer-associated pulmonary embolism (PE): Analysis of lung carcinoma (LC) cohort from the Epiphany study

C. Beato¹, L. Faez², A. Carmona-Bayonas³, M. Mediano¹, C. Font⁴, D. Calvo-Temprano², P. Jimenez Fonseca², A. Dominguez¹, M.P. Solis Hernandez², M. Biosca⁴, I. de la Haba⁴, M. Antonio⁴, O. Madriano⁵, A. Ramchandani⁶, E. Castanon Alvarez⁷, M.J. Martinez⁸, J. Virizuela Echaburu¹, R. Otero¹; ¹Sevilla, ES, ²Oviedo, ES, ³Murcia, ES, ⁴Barcelona, ES, ⁵Madrid, ES, ⁶Las Palmas, ES, ⁷Pamplona, ES, ⁸Cartagena, ES

13:00 - 13:00 1482P - Concerns of young women with breast cancer and their partners from chemotherapy to follow-up: A cross-sectional study

L. Vanlemmens¹, A. Congard², C. Duprez³, A.-S. Baudry³, A. Lesur⁴, C. Loustalot⁵, C. Guillemet⁶, M. Leclercq⁷, C. Levy⁸, D. Carlier⁹, C. Lefeuvre-Plesse¹⁰, H. Simon¹¹, J.-S. Frenel¹², P. Antoine³, V. Christophe³; ¹Lille, CEDEX/FR, ²Aix-En-provence, FR, ³Villeneuve D'ascq, FR, ⁴Nancy, FR, ⁵Dijon, FR, ⁶Rouen, FR, ⁷Marcq En Baroeul, FR, ⁸Caen, FR, ⁹Douai, FR, ¹⁰Rennes, FR, ¹¹Brest, FR, ¹²St. Herblain, FR

13:00 - 13:00 1483P - Supportive and palliative nutritional care for cancer patients (pts) with malnutrition and cachexia – a survey of healthcare providers (HCPs)

F. Strasser¹, R. Audisio², A. Laviano³, N. Georgiou⁴, K.C. Fearon⁵; ¹St. Gallen, CH, ²St Helens, GB, ³Rome, IT, ⁴Amsterdam, NL, ⁵Edinburgh, GB

13:00 - 13:00 1484P - Vaccination perception and attitudes among patients with cancer receiving chemotherapy

S. Akin, O. Dizdar, Y. Karakas, L. Ozisik, M. Durusu Tanriover, S. Kamisli, M. Erman, M. Hayran; Ankara, TR

13:00 - 13:00 1485P - Medical oncologists' attitudes towards vaccination in oncology practice

A. Alkan, E. Karıcı, A. Yaşar, G. Tuncay, M. Ürün, E.B. Köksoy, Y. Ürün, F. Çay Şenler, G. Utkan, A. Demirkazık, H. Akbulut; Ankara, TR

13:00 - 13:00 1486P - Efficacy of influenza vaccine (FluVax) in patients on chemotherapy (POCT): Final data analysis from South Australia

A. Ayoola¹, S. Sukumaran², R. Kumar², D. Gordon², A. Roy³, S. Vantandoust², B. Koczwara², G. Kichenadasse⁴, C. Karapetis²; ¹Newcastle, AU, ²Bedford Park, AU, ³Adelaide, SA/AU, ⁴Adelaide, AU



- 13:00 - 13:00 1487P - Immune-related and adverse events following low versus high initial dose of Viscum album L. in cancer patients
M. Steele, F. Schad; Berlin, DE
- 13:00 - 13:00 1488P - Analysis of cancer outcomes after desensitization protocols in patients with metastatic disease
C. Pulido, J. Caiado, A. Ferreira, I. Vendrell, A.L. Costa, A. Mendes, M.E. Pedro, N. Fernandes, L. Pestana, P. Almeida, C. Pinto, A. Quintela, L. Ribeiro, I. Fernandes, P. Filipe, R. Sousa, C. Abreu, D. Macedo, M. Barbosa, L. Costa; Lisboa, PT
- 13:00 - 13:00 1489P - Compliance with oral cancer medications when dispensed in the oncology clinic vs. when provided directly by healthcare payers: A prospective multicenter study by the Oncoclinicas Group
F. Gomes¹, E. Sobrinho¹, R. Miranda², L. Mercurio³, M. Dias⁴, K. Nascimento¹, A. Alves⁵, E. Tavares⁶, L. Teixeira⁶, O. Silva¹, P. Fernandes³, F. Reis¹, T. Rios¹, C. Silva¹, G. Lopes Jr³; ¹Salvador, BR, ²Sete Lagas, BR, ³Sao Paulo, BR, ⁴Itabira, BR, ⁵Uberlandia, BR, ⁶Rio De Janeiro, BR
- 13:00 - 13:00 1490P - Impact of incoming phone calls on oncology departments in oral therapies era: A large national prospective survey
F. Joly Lobbedez¹, A. Guillot², Y. Vano³, D. Spaeth⁴, D. Topart⁵, P. Roffet³, R. El Amarti⁶, A. Hasbini⁷, A. Flechon⁸; ¹Caen, FR, ²St. Priest En Jarez, FR, ³Paris, FR, ⁴Nancy, FR, ⁵Montpellier, FR, ⁶Le Havre, FR, ⁷Brest, FR, ⁸Lyon, FR
- 13:00 - 13:00 1491P - Decreased body mass index (BMI) associates with impaired survival from diagnosis of brain metastases in lung cancer patients: Analysis of 624 patients
E. Masel, A.S. Berghoff, G. Widhalm, U. Dieckmann, B. Gatterbauer, P. Birner, R. Bartsch, S. Schur, H. Watzke, C. Zielinski, M. Preusser; Vienna, AT
- 13:00 - 13:00 1492P - Prevention of chemotherapy-induced alopecia in patients with breast or female genital tract cancer using sensor-controlled scalp-cooling
C. Kurbacher, S. Herz, G. Kolberg, N. Kettelhoit, A. Kurbacher, C. Schweitzer, K. Monreal, J. Kurbacher; Bonn, DE
- 13:00 - 13:00 1493P - Survival and functional outcomes of patients with metastatic solid organ cancer admitted to the intensive care unit of a general tertiary centre
F. Ha¹, A. Weickhardt², S. Parakh², N. Glassford², S. Warrillow², D. Jones²; ¹Heidelberg, VIC/AU, ²Melbourne, VIC/AU
- 13:00 - 13:00 1494P - A systematic review on the effects of manual lymphatic drainage in operated breast cancer patients with lymphoedema
L. Pylkanen¹, A. Uluturk², Z. Saz Parkinson², S. Deandrea², A. Bramesfeld², L. Neamtiu², M. Ambrosio², D. Lerda²; ¹Helsinki, FI, ²Ispra, IT
- 13:00 - 13:00 1495P - The relation between the severity of breast cancer-related lymphedema and quality-of-life
M. Abou-Elenein, W. Makar, H. Abdel-Azim, S. Alsirafy; Cairo, EG
- 13:00 - 13:00 1496P - Cancer-related fatigue in breast cancer survivors: More evidence for a physiological substrate
J. Ramos, B. Cantos, C. Maximiano, H. Cebolla, C. Fiuza-Luces, L. Gutierrez, P. Osorio, J. Cerrato, J.L. Sanchez, B. Nuñez, A. Garate, I. Pagola, L.B. Alejo, A. Lucia, A. Ruiz-Casado; Madrid, ES



- 13:00 - 13:00 1497P - Impact of cognitive functions on oral anticancer therapies adherence
M. Dos Santos, M. Lange, B. Clarisse, M. Barillet, F. Joly; Caen, FR
- 13:00 - 13:00 1498P - Evaluation of an interactive electronic patient reported outcome (e-PRO) system in outpatient with oral chemotherapy
M. Rasschaert¹, K. Papadimitriou¹, S. Altintas¹, M. Huizing¹, J. Van den Brande¹, T. Van den Mooter¹, P. Specenier², C. Rolfo¹, S. De Keersmaecker¹, I. Van Brussel³, J. Ravelingien³, M. Peeters¹; ¹Edegem, BE, ²Grimbergen, BE, ³Aartselaar, BE
- 13:00 - 13:00 1499P - Evaluation of a clinical decision support system (CDSS) to optimize cytotoxic drug dosing in cancer patients with renal insufficiency
L. Krens, M. Damhof; Hengelo, NL
- 13:00 - 13:00 1500P - Drug-drug interactions in cancer patients: A prospective study of medication surveillance on cytotoxic agents
A. Ramos-Esquivel, A. Viquez-Jaikel, C. Fernandez, Z. Zeledon, F. Jimenez, M. Juarez, L. Corrales, I. Gonzalez-Herrera; San Jose, CR
- 13:00 - 13:00 1501P - Impact of adjuvant anthracycline-based and taxane-based chemotherapy on plasma VEGF levels and cognitive function in early-stage breast cancer patients
R. Ng, X.Y. Phey, T. Ng, H.L. Yeo, M. Shwe, Y.X. Gan, H.K. Ho, A. Chan; Singapore, SG
- 13:00 - 13:00 1502P - Insomnia prevalence in an oncology patient population: An Irish tertiary referral centre experience
E. Harrold¹, A.F. Idris¹, N. Keegan¹, L. Corrigan¹, M.Y. Teo², S.T. Lim¹, E. Duff¹, M. O'Donnell¹, J. Kennedy¹, D. O'Donnell¹, S. Sukor¹, C. Grant¹, D. Gallagher¹, S. Collier¹, T. Kingston¹, A.M. O'Dwyer¹, S. Cuffe¹; ¹Dublin, IE, ²New York, US
- 13:00 - 13:00 1503P - Social supports for patients with cancer in Ireland
Y. Ged¹, I. Ali², O. Ayodele², A. Linkeviciute-Koneko², S. Nwosu², S. Horan³, D. Barry³, C. O'Keefe⁴, P. Calvert², M. O'Connor², A. Horgan²; ¹Dublin, IE, ²Waterford, IE, ³Clonmel, IE, ⁴Kilkenny, IE
- 13:00 - 13:00 1504P - Awareness of cancer diagnosis in Turkish patients can increase anxiety and depression: Is it true?
M. Kalender¹, F. Bulbul¹, G. Aktas¹, T. Kus¹, B. Okyar¹, O. Balakan², C. Camci¹; ¹Gaziantep, TR, ²Kahramanmaraş, TR
- 13:00 - 13:00 1505TiP - The prospective study of relation between 5-HIAA/substance P and nausea/vomiting in patients receiving moderately emetogenic chemotherapy
T. Muranaka¹, Y. Komatsu¹, S. Ohnishi¹, K. Sawada¹, K. Harada¹, Y. Kawamoto¹, H. Nakatsumi¹, S. Yuki², M. Yagisawa¹, M. Nakamura¹, Y. Kobayashi³, S. Sogabe³, T. Miyagishima³, N. Sakamoto¹; ¹Sapporo, JP, ²Sapporo, Hokkaido/JP, ³Kushiro, JP
- 13:00 - 13:00 1506TiP - Quality of life, efficacy, and patient-reported outcome with NEPA as antiemetic prophylaxis in patients receiving highly or moderately emetogenic chemotherapy
M. Karthaus¹, J. Rauh², D. Guth³, V. Heilmann⁴, J. Schilling¹; ¹Berlin, DE, ²Witten, DE, ³Plauen, DE, ⁴Günzburg, DE



13:00 - 13:00 1507TiP - Validation of a risk-assessment score for prediction of venous thromboembolism in cancer outpatients receiving active treatments: ONKOTEV-2 trial

C.A. Cella¹, F. Lordick², N. Fazio¹; ¹Milano, IT, ²Leipzig, DE



| | | |
|---------------|--|------|
| 14:15 - 17:15 | Type: Young Oncologist Masterclass Title: Harnessing the immune system for cancer therapy Chair(s): R. Califano, GB; M. Preusser, AT | Bern |
| 14:15 - 14:40 | Basic immunology for the medical oncologist <u>I. Melero</u> , Pamplona, ES | |
| 14:40 - 14:40 | Session Shooter <u>L. De Mattos-Arruda</u> , Barcelona, ES | |
| 14:40 - 14:55 | Discussion | |
| 14:55 - 15:20 | Immune checkpoint blockade and impact on clinical practice <u>M. Postow</u> , New York, Ny, US | |
| 15:20 - 15:20 | Session Shooter <u>J. Corral</u> , Sevilla, ES | |
| 15:20 - 15:35 | Discussion | |
| 15:35 - 15:55 | Break | |
| 15:55 - 16:20 | Combining immunotherapies with other anti-cancer therapies <u>P. Lorigan</u> , Manchester, GB | |
| 16:20 - 16:20 | Session Shooter <u>M. Petrova</u> , Sofia, BG | |
| 16:20 - 16:35 | Discussion | |
| 16:35 - 17:00 | Managing toxicities: Case based discussions <u>J. Weber</u> , New York, Ny, US | |
| 17:00 - 17:00 | Session Shooter <u>R. De Mello</u> , Porto, PT | |
| 17:00 - 17:15 | Discussion | |



| | | |
|---------------|---|------|
| 14:30 - 16:30 | Type: ESMO Clinical Practice Guidelines session Title: ESMO Clinical Practice Guidelines session 2 | Rome |
| 14:30 - 14:40 | Introduction to the ESMO Clinical Practice Guidelines session <u>G. Pentheroudakis</u> , Ioannina, GR | |
| 14:40 - 14:50 | Questionnaire <u>C. Sessa</u> , Bellinzona, CH | |
| 14:50 - 15:00 | Lung Cancer – an update on systemic treatment for advanced squamous cell carcinoma - case presentation <u>S. Zimmermann</u> , Fribourg, CH | |
| 15:00 - 15:10 | Discussant: <u>A. Adjei</u> , Buffalo, US | |
| 15:10 - 15:15 | Q&A | |
| 15:15 - 15:25 | Thymic epithelial tumours case presentation <u>C. du Vignaux</u> , Lyon, FR | |
| 15:25 - 15:35 | Discussant: <u>N. Girard</u> , Bron, FR | |
| 15:35 - 15:40 | Q&A | |
| 15:40 - 15:50 | Prostate Cancer case presentation <u>M. Strijbos</u> , Brasschaat, BE | |
| 15:50 - 16:00 | Discussant: <u>A. Horwich</u> , Sutton, GB | |
| 16:00 - 16:05 | Q&A | |
| 16:05 - 16:15 | Endometrial Cancer case presentation <u>M.C. Petrella</u> , Florence, IT | |
| 16:15 - 16:25 | Discussant: <u>N. Colombo</u> , Milano, IT | |
| 16:25 - 16:30 | Q&A | |



| | | |
|---------------|--|------------|
| 14:45 - 16:15 | Type: Special Symposium Title: Triple negative breast cancer: Do we now have something to be positive about? Chair(s): A. Tutt, GB; E. Senkus-Konefka, PL | Copenhagen |
| 14:45 - 14:50 | Introduction: The current landscape <u>E. Senkus-Konefka</u> , Gdansk, PL | |
| 14:50 - 15:10 | Molecular "dissection" of TNBC to identify therapeutic targets <u>F. André</u> , Villejuif, FR | |
| 15:10 - 15:30 | Targeting DNA repair mechanisms <u>R. Dent</u> , Singapore, SG | |
| 15:30 - 15:50 | Androgen receptor blockade <u>H. Bonnefoi</u> , Bordeaux, FR | |
| 15:50 - 16:10 | Immunotherapeutic approaches <u>P. Schmid</u> , London, GB | |
| 16:10 - 16:15 | Concluding discussion <u>A. Tutt</u> , London, GB | |
| 14:45 - 16:15 | Type: Proffered Paper session Title: Gastrointestinal tumours, colorectal 1 Chair(s): R. Adams, GB; V. Heinemann, DE | Vienna |
| 14:45 - 14:57 | 452O - Results of a prospective randomised control 6 vs 12 trial: Is greater tumour downstaging observed on post treatment MRI if surgery is delayed to 12-weeks versus 6-weeks after completion of neoadjuvant chemoradiotherapy? <u>J. Evans</u> ¹ , J. Bhoday ¹ , B. Sizer ² , P. Tekkis ¹ , R. Swift ¹ , R. Perez ³ , D. Tait ¹ , G. Brown ¹ ; ¹ London, GB, ² Colchester, GB, ³ São Paulo, BR | |
| 14:57 - 15:09 | 453O - Scheduled use of CEA and CT follow-up to detect recurrence of colorectal cancer: 6-12 year results from the FACS randomised controlled trial <u>S. Pugh</u> ¹ , D. Mant ² , B. Shinkins ³ , J. Mellor ¹ , R. Perera ² , J. Primrose ¹ ; ¹ Southampton, GB, ² Oxford, GB, ³ Leeds, GB | |
| 15:09 - 15:24 | Invited discussant abstracts 452O and 453O <u>F. Huguet</u> , Paris, FR | |
| 15:24 - 15:36 | LBA20_PR - Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study | |



E. Van Cutsem¹, T. Yoshino², H.-J. Lenz³, S. Lonardi⁴, A. Falcone⁵, M.L. Limon⁶, M. Saunders⁷, A. Sobrero⁸, E. Maiello⁹, Y.S. Park¹⁰, R. Ferreiro Monteagudo¹¹, Y.S. Hong¹⁰, J. Tomasek¹², H. Taniguchi¹³, F. Ciardiello¹⁴, J. Hocke¹⁵, Z. Oum'hamed¹⁶, S. Vlassak¹⁷, M. Studeny¹⁸, J. Tabernero¹⁹; ¹Leuven, BE, ²Kashiwa, JP, ³Los Angeles, US, ⁴Padova, IT, ⁵Pisa, IT, ⁶Sevilla, ES, ⁷Manchester, GB, ⁸Genoa, IT, ⁹San Giovanni Rotondo, IT, ¹⁰Seoul, KR, ¹¹Madrid, ES, ¹²Brno, CZ, ¹³Nagoya, JP, ¹⁴Napoli, IT, ¹⁵Tübingen, DE, ¹⁶Reims, FR, ¹⁷Brussels, BE, ¹⁸Vienna, AT, ¹⁹Barcelona, ES

15:36 - 15:48 454O - A randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): The CCTG/AGITG CO.23 trial

D. Jonker¹, L. Nott², T. Yoshino³, S. Gill⁴, J. Shapiro⁵, A. Ohtsu³, J. Zalberg⁵, M. Vickers¹, A. Wei⁶, Y. Gao⁷, N. Tebbutt⁸, B. Markman⁵, T. Esaki⁹, S. Koski¹⁰, M. Hitron⁷, N. Magoski¹¹, J. Simes¹², C. Li⁷, D. Tu¹¹, C. O'Callaghan¹¹; ¹Ottawa, ON/CA, ²Hobart, Tasmania 7008, AU, ³Kashiwa, JP, ⁴Vancouver, BC/CA, ⁵Melbourne, AU, ⁶Toronto, ON/CA, ⁷Boston, MA/US, ⁸Heidelberg, AU, ⁹Fukuoka, JP, ¹⁰Edmonton, AB/CA, ¹¹Kingston, ON/CA, ¹²Sydney, NSW/AU

15:48 - 16:00 455O - Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E-mutated (BRAFM) metastatic colorectal cancer (mCRC)

R. Corcoran¹, T. André², T. Yoshino³, J. Bendell⁴, C. Atreya⁵, J. Schellens⁶, M. Ducreux⁷, A. McRee⁸, S. Siena⁹, G. Middleton¹⁰, M. Gordon¹¹, Y. Humblet¹², K. Muro¹³, E. Elez¹⁴, R. Yaeger¹⁵, R. Sidhu¹⁶, M. Squires¹⁷, S. Jaeger¹⁸, F. Rangwala¹⁹, E. Van Cutsem²⁰; ¹Boston, US, ²Paris, FR, ³Kashiwa, JP, ⁴Nashville, TN/US, ⁵San Francisco, CA/US, ⁶Amsterdam, NL, ⁷Villejuif, FR, ⁸Chapel Hill, NC/US, ⁹Milano, IT, ¹⁰Birmingham, GB, ¹¹Scottsdale, AZ/US, ¹²Brussels, BE, ¹³Nagoya, JP, ¹⁴Barcelona, ES, ¹⁵New York, NY/US, ¹⁶Thousand Oaks, CA/US, ¹⁷Basel, CH, ¹⁸Boston, MA/US, ¹⁹East Rutherford, NJ/US, ²⁰Leuven, BE

16:00 - 16:15 Invited discussant abstracts 454O, 455O and LBA20

V. Heinemann, München, DE

14:45 - 16:15 Type: Educational session Stockholm

Title: Melanoma: Does the run of success continue?

Chair(s): A. Hauschild, DE; D. Schadendorf, DE

14:45 - 15:15 New checkpoints

J. Weber, New York, Ny, US

15:15 - 15:45 Neoantigens

D. Schadendorf, Essen, DE

15:45 - 16:15 Novel immunotherapeutic constructs (MuSK antibodies)

J. Luke, Chicago, IL/US



| | | |
|---------------|---|--------|
| 14:45 - 16:15 | Type: Special Symposium Title: Personalised medicine in gynaecological cancers Chair(s): A. Poveda, ES; C. Gourley, GB | Madrid |
| 14:45 - 14:50 | Introduction <u>A. Poveda</u> , Valencia, ES | |
| 14:50 - 15:10 | Immunotherapy in ovarian cancer <u>L. Kandalaft</u> , Lausanne, CH | |
| 15:10 - 15:30 | Genomic profiling of endometrial cancer <u>X. Matias-Guiu</u> , Lleida, ES | |
| 15:30 - 15:50 | Genomic profiling of ovarian cancer <u>C. Gourley</u> , Edinburgh, GB | |
| 15:50 - 16:10 | How to test and define HRD positive population in ovarian cancer <u>I. McNeish</u> , Glasgow, GB | |
| 16:10 - 16:15 | Conclusions and clinical perspectives <u>C. Gourley</u> , Edinburgh, GB | |
| 14:45 - 16:15 | Type: Poster Discussion session Title: NSCLC, metastatic | Oslo |
| 14:45 - 14:45 | 1203PD - LURET study: Phase 2 study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC) <u>A. Horiike</u> ¹ , K. Yoh ² , T. Seto ³ , M. Satouchi ⁴ , M. Nishio ¹ , N. Yamamoto ¹ , H. Murakami ⁵ , N. Nogami ⁶ , S. Nomura ² , A. Sato ² , A. Ohtsu ² , K. Goto ² ; ¹ Tokyo, JP, ² Kashiwa, JP, ³ Fukuoka, JP, ⁴ Akashi, JP, ⁵ Shizuoka, JP, ⁶ Yokohama, JP | |
| 14:45 - 14:45 | 1204PD - Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung <u>V. Velcheti</u> ¹ , T. Hida ² , K. Reckamp ³ , J. Yang ⁴ , H. Nokihara ⁵ , P. Sachdev ⁶ , K. Feit ⁷ , T. Kubota ⁵ , T. Nakada ⁵ , C. Dutcus ⁷ , M. Ren ⁷ , T. Tamura ⁵ ; ¹ Cleveland, OH/US, ² Nagoya, JP, ³ Durate, CA/US, ⁴ Taipei City, TW, ⁵ Tokyo, JP, ⁶ Woodcliff Lake, US, ⁷ Woodcliff Lake, NJ/US | |
| 14:45 - 14:45 | 1205PD - Ceritinib in ROS1-rearranged non-small-cell lung cancer: A Korean nationwide phase II study <u>S.M. Lim</u> ¹ , B.C. Cho ¹ , H.R. Kim ¹ , J.-S. Lee ² , K.H. Lee ³ , Y.-G. Lee ¹ , Y.J. Min ¹ , E.K. Cho ⁴ , S.-S. Lee ⁵ , B.-S. Kim ¹ , M.Y. Choi ⁵ , H.S. Shim ¹ , J.H. Chung ² , Y.L. Choi ¹ , M.J. Lee ¹ , M.-J. Ahn ¹ ; ¹ Seoul, KR, ² Seongnam-Si, KR, ³ Cheong-Ju, KR, ⁴ Incheon, KR, ⁵ Busan, KR | |
| 14:45 - 14:45 | 1206PD - Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Updated results from PROFILE 1001 | |



A. Shaw¹, G. Riley², Y.-J. Bang³, D.-W. Kim⁴, D. Camidge⁵, M. Varella-Garcia⁵, A. Lafrate¹, G. Shapiro¹, M. Winter¹, T. Usari⁶, S. Wang⁷, K. Wilner⁸, J. Clark¹, S.-H. Ou⁹; ¹Boston, US, ²New York, US, ³Seoul, KR, ⁴Seoul, ⁵Aurora, US, ⁶Milano, IT, ⁷La Jolla, US, ⁸San Diego, US, ⁹Irvine, US

14:45 - 15:00 Invited discussant abstracts 1203PD, 1204PD, 1205PD and 1206PD

E. Felip, Barcelona, ES

15:00 - 15:07 Questions to discussant

15:07 - 15:07 1207PD - Brigatinib (BRG) in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in a phase 1/2 trial

L. Bazhenova¹, S. Gettinger², C. Langer³, R. Salgia⁴, K. Gold⁵, R. Rosell⁶, A. Shaw⁷, G. Weiss⁸, J. Haney⁹, V. Rivera⁹, F. Haluska⁹, D. Kerstein⁹, D. Camidge¹⁰; ¹La Jolla, US, ²New Haven, US, ³Philadelphia, PA/US, ⁴Duarte, US, ⁵La Jolla, CA/US, ⁶Badalona, ES, ⁷Boston, US, ⁸Goodyear, US, ⁹Cambridge, US, ¹⁰Aurora, US

15:07 - 15:07 1209PD - Time to response in patients with ALK+ NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies

L. Gandhi¹, S. Gadgeel², A. Shaw¹, F. Barlesi³, L. Crinò⁴, J.C.-H. Yang⁵, A.-M. Dingemans⁶, D.-W. Kim⁷, F. de Marinis⁸, M. Schulz⁹, S. Liu⁹, S. Fish⁹, A. Kotb¹⁰, S.-H.I. Ou¹¹; ¹Boston, US, ²Detroit, US, ³Marseille, FR, ⁴Perugia, IT, ⁵Taipei, TW, ⁶Maastricht, NL, ⁷Seoul, KR, ⁸Milano, IT, ⁹San Francisco, US, ¹⁰Basel, CH, ¹¹Orange, CA/US

15:07 - 15:07 1210PD - Phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx)

L. Horn¹, H. Wakelee², G. Blumenschein³, K. Reckamp⁴, S. Waqar⁵, C. Carter⁶, B. Gitlitz⁷, J. Infante¹, R. Sanborn⁸, J. Neal², J. Gockerman⁹, G. Dukart¹⁰, K. Harrow¹⁰, C. Liang¹⁰, J. Gibbons¹⁰, J. Hernandez¹¹, T. Newman-Eerkes¹¹, L. Lim¹¹, C. Lovly¹; ¹Nashville, TN/US, ²Stanford, CA/US, ³Houston, TX/US, ⁴Duarte, CA/US, ⁵St Louis, MO/US, ⁶Bethesda, MD/US, ⁷Los Angeles, CA/US, ⁸Portland, OR/US, ⁹Morristown, NC/US, ¹⁰Palm Beach Gardens, FL/US, ¹¹Bellevue, WA/US

15:07 - 15:22 Invited discussant abstracts 1207PD, 1209PD and 1210PD

S. Popat, London, GB

15:22 - 15:29 Questions to discussant

15:29 - 15:29 1211PD - Cost-effectiveness of KRAS, EGFR and ALK testing for therapeutic decision making of advanced stage non-small cell lung cancer (NSCLC): The French IFCT-PREDICT.amm study

A. Drezet¹, S. Loubière¹, M. Wislez², M. Beau-Faller³, I. Nanni-Métellus¹, S. Garcia¹, M.-P. Chenard³, J.-P. Ghnassia³, R. Lacave², M. Antoine², M. Duruisseaux⁴, S. Friard⁵, E. Fabre², C. Daniel², P. Missy², F. Morin², F. Barlesi¹, P. Auquier¹, J. Cadranel²; ¹Marseille, FR, ²Paris, FR, ³Strasbourg, FR, ⁴Grenoble, FR, ⁵Suresnes, FR



- 15:29 - 15:29 1212PD - Lung sarcomatoid carcinoma (LSC) harbors targetable genomic alterations and high mutational burden as observed by comprehensive genomic profiling (CGP)
B. Halmos¹, G. Frampton², J. Suh³, E. Braun⁴, R. Mehra⁵, S. Buck⁶, J. Bufill⁴, N. Peled⁷, N. Karim⁸, P. Fishkin⁹, J. Knost⁹, S.-H. Ou¹⁰, J. Ross¹¹, P. Stephens², V. Miller², S. Ali², A. Schrock²; ¹New York, US, ²Cambridge, US, ³Cambridge, MA/US, ⁴Mishawaka, US, ⁵Philadelphia, PA/US, ⁶Tulsa, US, ⁷Petach Tiqwa, IL, ⁸Cincinnati, US, ⁹Peoria, US, ¹⁰Irvine, CA/US, ¹¹Albany, NY/US
- 15:29 - 15:29 1213PD - A comprehensive analysis of potentially targetable genetic aberrations and clinical findings in 821 patients with squamous-cell NSCLC – a comparison of NGM and TCGA LUSC data
S. Koleczko¹, C. Schäpers¹, M. Scheffler¹, M. Ihle¹, A. Kostenko¹, S. Michels¹, R. Fischer¹, L. Nogova¹, V. Brandes¹, D. Abdulla¹, F. Ueckerth¹, M. Thurat¹, R. Frank¹, A. Eisert¹, E. Bitter¹, C. Wömpner¹, L. Gogl¹, S. Merkelbach-Bruse¹, R. Büttner¹, J. Wolf²; ¹Köln, DE, ²Cologne, DE
- 15:29 - 15:29 1214PD - Detectability of druggable gene fusions by amplicon-based next generation sequencing in nationwide lung cancer genomic screening project (LC-SCRUM-Japan)
S. Matsumoto¹, K. Yoh², M. Kodani³, K. Ohashi⁴, S. Saeki⁵, N. Furuya⁶, Y. Nishioka⁷, Y. Ohe⁸, T. Seto⁹, R. Hayashi¹⁰, Y. Kataoka¹¹, T. Fukui⁸, T. Sakamoto³, S. Ikemura¹², T. Kohno⁸, K. Tsuta¹³, K. Tsuchihara², K. Goto²; ¹Kashiwa, Chiba/J, ²Kashiwa, JP, ³Yonago, JP, ⁴Okayama, JP, ⁵Kumamoto, JP, ⁶Kawasaki, JP, ⁷Tokushima, JP, ⁸Tokyo, JP, ⁹Fukuoka, JP, ¹⁰Toyama, JP, ¹¹Amagasaki, JP, ¹²Ichikawa, JP, ¹³Hirakata, JP
- 15:29 - 15:44 Invited discussant abstracts 1211PD, 1212PD, 1213PD and 1214PD
K. O'Byrne, Brisbane, AU
- 15:44 - 15:51 Questions to discussants
- 15:51 - 15:51 LBA48 - Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: updated outcomes of KEYNOTE-010
R.S. Herbst¹, P. Baas², D.-W. Kim³, E. Felip⁴, J.L. Pérez-Gracia⁵, J.-Y. Han⁶, J. Molina⁷, J.-H. Kim³, C. Dubos Arvis⁸, M.-J.A. Ahn³, M. Majem⁴, M.J. Fidler⁹, G. De Castro Jr.¹⁰, M. Garrido¹¹, Y. Shentu¹², G. Lubiniecki¹³, E. Garon¹⁴; ¹New Haven, US, ²Amsterdam, NL, ³Seoul, ⁴Barcelona, ES, ⁵Pamplona, ES, ⁶Goyang, KR, ⁷Rochester, MN/US, ⁸Caen, FR, ⁹Chicago, IL/US, ¹⁰Sao Paulo, BR, ¹¹Santiago, CL, ¹²Kenilworth, PA/US, ¹³Kenilworth, NJ/US, ¹⁴Los Angeles, CA/US
- 15:51 - 15:51 1215PD - Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update
F. Barlesi¹, M. Steins², L. Horn³, N. Ready⁴, E. Felip⁵, H. Borghaei⁶, D. Spigel⁷, O. Arrieta⁸, S. Antonia⁹, J. Fayette¹⁰, N. Rizvi¹¹, L. Crinò¹², M. Reck¹³, W. Eberhardt¹⁴, M. Hellmann¹⁵, W. Geese¹⁶, A. Li¹⁶, D. Healey¹⁶, J. Brahmer¹⁷, L. Paz-Ares¹⁸; ¹Marseille, FR, ²Heidelberg, DE, ³Nashville, TN/US, ⁴Durham, US, ⁵Barcelona, ES, ⁶Philadelphia, US, ⁷Nashville, US, ⁸Mexico City, MX, ⁹Tampa, FL/US, ¹⁰Lyon, FR, ¹¹New York, NY/US, ¹²Perugia, IT, ¹³Grosshansdorf, DE, ¹⁴Essen, DE, ¹⁵New York, US, ¹⁶Lawrence Township, NJ/US, ¹⁷Baltimore, MD/US, ¹⁸Madrid, ES



- 15:51 - 15:51 1216PD - Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)
S. Antonia¹, J. Brahmer², S. Khleif³, A. Balmanoukian⁴, S.-H. Ou⁵, M. Gutierrez⁶, D.-W. Kim⁷, S.-W. Kim⁷, M.-J. Ahn⁷, J. Leach⁸, R. Jamal⁹, D. Jaeger¹⁰, G. Jerusalem¹¹, X. Jin¹², A. Gupta¹², J. Antal¹², N. Segal¹³; ¹Tampa, FL/US, ²Baltimore, MD/US, ³Augusta, GA/US, ⁴Los Angeles, CA/US, ⁵Irvine, CA/US, ⁶Hackensack, NJ/US, ⁷Seoul, KR, ⁸Minneapolis, MN/US, ⁹Montreal, QC/CA, ¹⁰Heidelberg, DE, ¹¹Liège, BE, ¹²Gaithersburg, MD/US, ¹³New York, NY/US
- 15:51 - 15:51 1217PD - Overall health status (HS) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC treated with nivolumab (nivo) or docetaxel (doc) in CheckMate 057
M. Reck¹, J. Brahmer², B. Bennett³, F. Taylor⁴, J. Penrod⁵, M. Derosa⁴, H. Dastani⁵, R. Gralla⁶; ¹Grosshansdorf, DE, ²Baltimore, MD/US, ³Bollington, GB, ⁴Boston, US, ⁵Princeton, US, ⁶New York, US
- 15:51 - 15:51 1218PD - EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel in patients with non-small-cell lung cancer who had received a platinum-based treatment
M. Nishio¹, T.S.K. Mok², K. Nakagawa³, N. Yamamoto⁴, Y.-K. Shi⁵, L. Zhang⁶, S. Lu⁷, R. Soo⁸, J. Yang⁹, S. Morita¹⁰, S. Sugawara¹¹, H. Nokihara¹, T. Takahashi¹², K. Goto¹³, J. Chang⁷, M. Maemondo¹⁴, Y. Ichinose¹⁵, Y. Cheng¹⁶, W.-T. Lim⁸, T. Tamura¹; ¹Tokyo, JP, ²Hong Kong, CN, ³Osaka-Sayama, JP, ⁴Wakayama, JP, ⁵Beijing, CN, ⁶Guangzhou, CN, ⁷Shanghai, CN, ⁸Singapore, SG, ⁹Taipei, TW, ¹⁰Kyoto, JP, ¹¹Sendai, JP, ¹²Suntogun, JP, ¹³Kashiwa, JP, ¹⁴Natori, JP, ¹⁵Fukuoka, JP, ¹⁶Changchun, CN
- 15:51 - 16:06 Invited discussant abstracts LBA8, LBA48, 1215PD, 1216PD, 1217PD, and 1218PD
F. Blackhall, Manchester, GB
- 16:06 - 16:15 Questions to discussant
- 14:45 - 16:15 Type: Educational session Athens
Title: Induction chemotherapy: Is there any new data to revisit an inconclusive approach?
Chair(s): M. Merlano, IT; J. Bourhis, CH
- 14:45 - 15:15 New data from meta-analysis
W. Budach, Dusseldorf, DE
- 15:15 - 15:45 Emerging clinical trial data
M. Merlano, Cuneo, IT
- 15:45 - 16:15 Induction chemotherapy: Is there any new data from randomised trials to revisit an inconclusive approach?
J. Bourhis, Lausanne, CH



| | | |
|---------------|--|----------|
| 14:45 - 16:15 | Type: Special Session Title: Clinical benefit of cancer drugs Chair(s): E.G.E. de Vries, NL; N. Cherny, IL | Helsinki |
| 14:45 - 14:50 | Introduction <u>E.G.E. de Vries</u> , Groningen, NL | |
| 14:50 - 15:10 | ESMO Magnitude of Clinical Benefit Scale (MCBS): version 1.1 <u>N. Cherny</u> , Jerusalem, IL | |
| 15:10 - 15:30 | The different available approaches to qualify benefit of drugs in oncology <u>E.G.E. de Vries</u> , Groningen, NL | |
| 15:30 - 15:50 | Guidelines including grading of novel drugs with ESMO MCBS <u>A. Cervantes</u> , Valencia, ES | |
| 15:50 - 16:10 | Update from ESMO's Cancer Medicines Working Group <u>J. Taberero</u> , Barcelona, ES | |
| 16:10 - 16:15 | Conclusions <u>E.G.E. de Vries</u> , Groningen, NL | |
| 14:45 - 16:15 | Type: Educational session Title: Desmoid tumours in 2016 Chair(s): D. Strauss, GB; B. Kasper, DE | Brussels |
| 14:45 - 15:15 | Molecular pathology tools <u>F. Chibon</u> , Bordeaux, FR | |
| 15:15 - 15:45 | Local treatments <u>D. Strauss</u> , Surrey, GB | |
| 15:45 - 16:15 | Systemic treatments beyond chemotherapy and TKIs <u>B. Kasper</u> , Mannheim, DE | |
| 15:00 - 16:00 | Type: Poster Discussion session Title: Developmental therapeutics Chair(s): I. Braña, ES; J. Schellens, NL; C. Blank, NL | Berlin |
| 15:00 - 15:00 | 361PD - Interim results from the completed first-in-human phase I dose escalation study evaluating MP0250, a multi-DARPin® blocking HGF and VEGF, in patients with advanced solid tumors | |



M. Middleton¹, A. Azaro², S. Kumar³, P. Niedermann⁴, J. Rodón², K.H. Herbschleb¹, J. Steiner⁵, C. Zitt⁶, D. Feurstein⁶, S. Schreiner⁶, D. Turner⁶, K. Dawson⁶, K. Tadjalli-Mehr⁶, E. vom Baur⁶, M. Stumpp⁶, A. Harstrick⁶, R. Baird³, A. Omlin⁴; ¹Oxford, GB, ²Barcelona, ES, ³Cambridge, GB, ⁴St. Gallen, CH, ⁵Crowthorne, GB, ⁶Schlieren, CH

15:00 - 15:00 362PD - TAX-TORC: An investigator initiated phase I study combining the dual mTORC1/2 inhibitor AZD2014 in combination with weekly paclitaxel in high-grade serous ovarian cancer

U. Banerji¹, B. Basu², J. Spicer³, R. Wilson⁴, E. Hall³, R. Sundar³, S. Kumar², Y. Wu³, V. Coyle⁴, S. Carreira³, M. Parmar³, J. Dawes³, S. Banerjee³, J. de Bono³; ¹Sutton, GB, ²Cambridge, GB, ³London, GB, ⁴Belfast, GB

15:00 - 15:00 363PD - Molecular imaging of PgP/BCRP inhibition at the blood brain barrier using elacridar and [11C]erlotinib PET

R. Verheijen¹, M. Yaqub¹, E. Sawicki¹, O. van Tellingen¹, A. Lammertsma¹, B. Nuijen¹, J. Schellens¹, J. Beijnen², A. Huitema¹, N. Hendrikse¹, N. Steeghs¹; ¹Amsterdam, NL, ²Utrecht, NL

15:00 - 15:10 Invited discussant abstracts 361PD, 362PD and 363PD

I. Braña, Barcelona, ES

15:10 - 15:20 Questions to discussant

15:20 - 15:20 364PD - Anti-tumor activity of PEGylated human IL-10 (AM0010) in renal cancer alone and in combination with anti-PD1

A. Naing¹, K. Papadopoulos², K. Autio³, P. Ott⁴, M. Patel⁵, D. Wong⁶, G. Falchook⁷, S. Pant¹, M. Whiteside⁶, D. Rasco², A. Patnaik², J. Bendell⁸, T. Bauer⁸, R. Colen¹, D. Hong⁹, P. Van Vlasselaer⁶, G. Brown⁶, M. Off⁶, J. Infante⁸, N. Tannir¹; ¹Houston, TX/US, ²San Antonio, TX/US, ³New York, NY/US, ⁴Boston, MA/US, ⁵Sarasota, FL/US, ⁶Redwood City, CA/US, ⁷Denver, US, ⁸Nashville, TN/US, ⁹Houston, US

15:20 - 15:20 365PD - Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study

D. Mahalingam¹, M. Patel², J. Sachdev³, L. Hart⁴, N. Halama⁵, R. Ramanathan³, J. Sarantopoulos¹, X. Liu⁶, S. Yazji⁶, D. Jäger⁵, M. Yoon⁶, G.Ç. Manzur⁶, D. Adib⁶, R. Kerschbaumer⁷, A. Tsimberidou⁸; ¹San Antonio, TX/US, ²Sarasota, FL/US, ³Scottsdale, AZ/US, ⁴Ft. Myers, FL/US, ⁵Heidelberg, DE, ⁶Cambridge, MA/US, ⁷Vienna, AT, ⁸Houston, TX/US

15:20 - 15:30 Invited discussant abstracts 364PD and 365PD

C. Blank, Amsterdam, NL

15:30 - 15:40 Questions to discussant

15:40 - 15:40 366PD - A phase I, open-label, multi-center, dose escalation study of oral NVP-CGM097, a p53/HDM2-protein-protein interaction inhibitor, in adult patients with selected advanced solid tumors



S. Bauer¹, G. Demetri², S. Jeay³, R. Dummer⁴, N. Guerreiro³, D. Tan⁵, A. Kumar⁶, C. Meille³, L. Van Bree³, E. Halilovic⁷, J. Wuerthner³, P. Cassier⁸; ¹Essen, DE, ²Boston, US, ³Basel, CH, ⁴Zürich, CH, ⁵Singapore, SG, ⁶Hyderabad, IN, ⁷Cambridge, MA/US, ⁸Lyon, FR

15:40 - 15:40 367PD - Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)

C. Weekes¹, J. Berlin², H.-J. Lenz³, B. O'Neil⁴, W. Messersmith¹, S. Cohen⁵, C. Dendinger⁵, S. Shahda⁴, A. Kapoun⁶, C. Zhang⁶, R. Jenner⁶, F. Cattaruzza⁶, L. Xu⁶, J. Dupont⁶, R. Brachmann⁶, S. Uttamsingh⁶, A. Farooki⁷, E. Dotan⁵; ¹Aurora, CO/US, ²Nashville, US, ³Los Angeles, US, ⁴Indianapolis, IN/US, ⁵Philadelphia, PA/US, ⁶Redwood, CA/US, ⁷New York, NY/US

15:40 - 15:50 Invited discussant abstracts 366PD and 367PD
J. Schellens, Amsterdam, NL

15:50 - 16:00 Questions to discussant

15:00 - 16:00 Type: Multidisciplinary patient cases Lisbon
Title: Biliary tract cancer: Klatskin tumour
Chair(s): M. Ducreux, FR

15:00 - 15:05 Case presentation
M. Ducreux, Villejuif, FR

15:05 - 15:15 The role of surgery and transplantation
R. Adam, Villejuif, FR

15:15 - 15:25 Medical treatment
M. Ducreux, Villejuif, FR

15:25 - 15:35 Radiation
C. Crane, Houston, Tx, US

15:35 - 16:00 Discussion



| Time | Type: Presidential Symposium Title: Presidential Symposium 2 | Copenhagen |
|---------------|--|------------|
| 16:30 - 16:42 | LBA4 - Patient-Reported Outcomes (PROs) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treated With Nivolumab (Nivo) or Investigator's Choice (IC): CheckMate 141 <u>K. Harrington</u> ¹ , R. Ferris ² , J. Shaw ³ , F. Taylor ⁴ , M. Derosa ⁴ , D. Turner-Bowker ⁴ , L. Morrissey ⁴ , K. Cocks ⁵ , N. Kiyota ⁶ , M. Gillison ⁷ , J. Guigay ⁸ ; ¹ London, GB, ² Pittsburgh, Pa, US, ³ Princeton, NJ/US, ⁴ Boston, US, ⁵ Cheshire, GB, ⁶ Kobe, JP, ⁷ Columbus, US, ⁸ Nice, FR | |
| 16:42 - 16:54 | (Withdrawn) | |
| 16:54 - 17:09 | Invited discussant LBA4 and one LBA TBC <u>A.T.C. Chan</u> , Hong Kong, CN | |
| 17:09 - 17:21 | LBA6_PR - Full-dose neoadjuvant anthracycline+ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial <u>A. Gronchi</u> ¹ , S. Ferrari ² , V. Quagliuolo ³ , J. Martin Broto ⁴ , A. Lopez-Pousa ⁵ , G. Grignani ⁶ , V. Ferraresi ⁷ , J.-Y. Blay ⁸ , P. Rutkowski ⁹ , F. Merlo ¹⁰ , E. Marchesi ² , P. Ledesma ⁴ , A.P. Dei Tos ¹¹ , S. Bague Rosell ⁵ , J.-M. Coindre ¹² , C. Morosi ¹³ , S. Stacchiotti ¹³ , P. Picci ² , P. Bruzzi ¹⁰ , P. Casali ¹³ ; ¹ Milan, IT, ² Bologna, IT, ³ Rozzano, IT, ⁴ Palma De Mallorca, ES, ⁵ Barcelona, ES, ⁶ Candiolo, IT, ⁷ Roma, IT, ⁸ Lyon, FR, ⁹ Warsaw, PL, ¹⁰ Genova, IT, ¹¹ Treviso, IT, ¹² Bordeaux, FR, ¹³ Milano, IT | |
| 17:21 - 17:29 | Invited discussant LBA6_PR <u>A. Le Cesne</u> , Villejuif, FR | |
| 17:29 - 17:41 | LBA8_PR - KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50% <u>M. Reck</u> ¹ , D. Rodríguez-Abreu ² , A. Robinson ³ , R. Hui ⁴ , T. Csoszi ⁵ , A. Fülöp ⁶ , M. Gottfried ⁷ , N. Peled ⁸ , A. Tafreshi ⁹ , S. Cuffe ¹⁰ , M. O'Brien ¹¹ , S. Rao ¹² , K. Hotta ¹³ , M. Leiby ¹⁴ , G. Lubiniecki ¹⁴ , Y. Shentu ¹⁵ , R. Rangwala ¹⁴ , J. Brahmer ¹² ; ¹ Grosshansdorf, DE, ² Las Palmas De Gran Canaria, ES, ³ Kingston, ON/CA, ⁴ Sydney, NSW/AU, ⁵ Szolnok, HU, ⁶ Budapest, HU, ⁷ Kfar Saba, IL, ⁸ Petach Tiqwa, IL, ⁹ Wollongong, NSW/AU, ¹⁰ Dublin, IE, ¹¹ London, GB, ¹² Baltimore, MD/US, ¹³ Okayama, JP, ¹⁴ Kenilworth, NJ/US, ¹⁵ Kenilworth, PA/US | |
| 17:41 - 17:53 | (Withdrawn) | |
| 17:53 - 18:05 | (Withdrawn) | |
| 18:05 - 18:20 | Invited discussant LBA8 and two LBAs TBC <u>N. Rizvi</u> , New York, NY/US | |



16:30 - 17:30 Type: Multidisciplinary patient cases Vienna
 Title: Continuum of management of stage IV in melanoma
 Chair(s): O. Michielin, CH

16:30 - 16:40 First-line
C. Blank, Amsterdam, NL

16:40 - 16:50 Second-line
C. Hoeller, Vienna, AT

16:50 - 17:00 Brain metastasis
L. Bastholt, Odense C, DK

17:00 - 17:30 Discussion

16:30 - 18:00 Type: Educational session Stockholm
 Title: Prophylaxis and treatment of symptoms in oncology
 Chair(s): K. Jordan, DE; F. Roila, IT

16:30 - 17:00 Chemotherapy induced nausea and vomiting focusing on the updated MASCC/ESMO guidelines
K. Jordan, Halle, DE

17:00 - 17:30 Diagnosis and therapy of patients with febrile neutropenia
G. Maschmeyer, Potsdam, DE

17:30 - 18:00 Assessment and therapy of anxiety and depression
J.H. Loge, Oslo, NO



| | | |
|---------------|--|--------|
| 16:30 - 18:00 | Type: Special Symposium Title: Precision medicine in NETs: Myth or reality? Chair(s): K. Oeberg, SE; R. Garcia-Carbonero, ES | Oslo |
| 16:30 - 16:35 | Introduction <u>R. Garcia-Carbonero</u> , Madrid, ES | |
| 16:35 - 16:50 | Molecular tumour profiling and upcoming biomarkers: Will they help to deliver personalised medicine? <u>T. Meyer</u> , London, GB | |
| 16:50 - 17:05 | Minimally invasive surgery: Does it improve precision? <u>M. Falconi</u> , Milano, IT | |
| 17:05 - 17:20 | Nuclear medicine: What do novel isotopes add to the treatment of NETs? | |
| 17:20 - 17:35 | Targeted drugs: Where are we now? <u>M. Pavel</u> , Berlin, DE | |
| 17:35 - 17:50 | Targeted drugs: Where are we heading to? <u>E. Raymond</u> , Lausanne, CH | |
| 17:50 - 18:00 | Conclusions and clinical perspectives <u>K. Oeberg</u> , Uppsala, SE | |
| 16:30 - 17:30 | Type: Poster Discussion session Title: Genitourinary tumours, non-prostate Chair(s): C. Kollmannsberger, CA; M. Schmidinger, AT; A. Bamias, GR | Athens |
| 16:30 - 16:30 | 773PD - Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results <u>M. Atkins</u> ¹ , <u>E. Plimack</u> ² , <u>I. Puzanov</u> ³ , <u>M. Fishman</u> ⁴ , <u>D. McDermott</u> ⁵ , <u>D. Cho</u> ⁶ , <u>U. Vaishampayan</u> ⁷ , <u>S. George</u> ⁸ , <u>T. Olencki</u> ⁹ , <u>J. Tarazi</u> ¹⁰ , <u>B. Rosbrook</u> ¹⁰ , <u>K. Fernandez</u> ¹¹ , <u>S. Keefe</u> ¹² , <u>T. Choueiri</u> ^{5, 1} Washington, DC/US, ² Philadelphia, US, ³ Nashville, TN/US, ⁴ Tampa, FL/US, ⁵ Boston, US, ⁶ New York, NY/US, ⁷ Detroit, US, ⁸ Buffalo, NY/US, ⁹ Columbus, OH/US, ¹⁰ San Diego, CA/US, ¹¹ Cambridge, MA/US, ¹² Kenilworth, NJ/US | |
| 16:30 - 16:30 | 774PD - A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors <u>A. Apolo</u> ¹ , <u>A. Mortazavi</u> ¹ , <u>M. Stein</u> ² , <u>S. Pal</u> ³ , <u>N. Davarpanah</u> ¹ , <u>H. Parnes</u> ⁴ , <u>Y. Ning</u> ⁴ , <u>D. Francis</u> ⁴ , <u>L. Cordes</u> ⁴ , <u>M. Berniger</u> ¹ , <u>S. Steinberg</u> ⁴ , <u>P. Monk</u> ⁵ , <u>T. Lancaster</u> ⁵ , <u>T. Mayer</u> ⁶ , <u>R. Costello</u> ⁴ , <u>D. Bottaro</u> ⁴ , <u>W. Dahut</u> ¹ ; ¹ Bethesda, MD/US, ² New Brunswick, US, ³ Duarte, US, ⁴ Bethesda, US, ⁵ Columbus, OH/US, ⁶ New Brunswick, NJ/US | |



- 16:30 - 16:30 775PD - Phase 1b dose-finding study of avelumab (anti-PD-L1) + axitinib in treatment-naïve patients with advanced renal cell carcinoma
J. Larkin¹, B. Rini², P. Nathan³, F. Thistlethwaite⁴, M. Gordon⁵, M. Martgnoni⁶, D. Magazzu⁶, C. Chiruzzi⁶, A. Di Pietro⁶, T. Choueiri⁷; ¹London, GB, ²Middlesex, GB, ³Northwood, GB, ⁴Manchester, GB, ⁵Scottsdale, AZ/US, ⁶Milano, IT, ⁷Boston, MA/US
- 16:30 - 16:30 776PD - A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients with selected solid tumors
M. Taylor¹, C. Dutcus², E. Schmidt³, T. Bagulho², D. Li², R. Shumaker², D. Rasco⁴; ¹Portland, US, ²Woodcliff Lake, NJ/US, ³Kenilworth, NJ/US, ⁴San Antonio, TX/US
- 16:30 - 16:45 Invited discussant abstracts 773PD, 774PD, 775PD and 776PD
M. Schmidinger, Vienna, AT
- 16:45 - 16:50 Questions to discussant
- 16:50 - 16:50 777PD - Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma progressed after platinum-based therapy or platinum ineligible
M. Patel¹, J. Ellerton², M. Agrawal³, M. Gordon⁴, L. Dirix⁵, K.-W. Lee⁶, J. Infante⁷, M. Schlichting⁸, K. Chin⁹, A. Apolo¹⁰; ¹Sarasota, FL/US, ²Las Vegas, NV/US, ³Rockville, MD/US, ⁴Scottsdale, AZ/US, ⁵Wilrijk, BE, ⁶Seongnam, KR, ⁷Nashville, TN/US, ⁸Darmstadt, DE, ⁹Billerica, MA/US, ¹⁰Bethesda, MD/US
- 16:50 - 16:50 778PD - Quality of life (QoL) and neurotoxicity in germ-cell cancer survivors (GCCS)
J. Lauritsen¹, M. Bandak¹, M. Mortensen¹, M. Kier¹, M. Agerbaek², N. Holm³, R. Gupta⁴, C. Johansen¹, G. Daugaard¹; ¹Copenhagen, DK, ²Aarhus C, DK, ³Odense C, DK, ⁴Lyngby, DK
- 16:50 - 16:50 779PD - Large retroperitoneal lymphadenopathy (RPLN) and increased risk of venous thromboembolism (VTE) in patients (pts) with metastatic germ cell tumours (mGCT): A global germ cell cancer group (G3) study
B. Tran¹, J. Ruiz-Morales², E. González Billalabeitia³, E. Amir⁴, C. Seidel⁵, C. Bokemeyer⁵, C. Fankhauser⁶, T. Hermanns⁶, A. Romyantsev⁷, A. Tryakin⁷, M. Brito⁸, A. Flechon⁹, D. Castellano¹⁰, X. Garcia del Muro¹¹, A. Hamid¹², G. Palmieri¹³, R. Kitson¹⁴, A. Reid¹⁴, D. Heng², P. Bedard¹⁵; ¹Parkville, AU, ²Calgary, CA, ³Murcia, ES, ⁴Toronto, ON/CA, ⁵Hamburg, DE, ⁶Zürich, CH, ⁷Moscow, RU, ⁸Lisboa, PT, ⁹Lyon, FR, ¹⁰Madrid, ES, ¹¹Barcelona, ES, ¹²Heidelberg, AU, ¹³Napoli, IT, ¹⁴London, GB, ¹⁵Toronto, CA
- 16:50 - 16:50 780PD - Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC)
D. Petrylak¹, E. Heath², G. Sonpavde³, S. George⁴, A. Morgans⁵, B. Eigl⁶, J. Picus⁷, S. Cheng⁸, S. Hotte⁹, E. Gartner¹⁰, M. Vincent¹¹, R. Chu¹², B. Anand¹², K. Morrison¹², L. Jackson¹², A. Melhem-Bertrandt¹³, E. Yu¹⁴; ¹New Haven, US, ²Detroit, MI/US, ³Birmingham, US, ⁴Buffalo, NY/US, ⁵Nashville, TN/US, ⁶Vancouver, CA, ⁷St Louis, US, ⁸Toronto, ON/CA, ⁹Hamilton, CA, ¹⁰Seattle, WA/US, ¹¹Santa Monica, US, ¹²Santa Monica, CA/US, ¹³Northbrook, IL/US, ¹⁴Seattle, US



- 16:50 - 17:05 Invited discussant abstracts 777PD, 778PD, 779PD and 780PD
C. Kollmannsberger, Vancouver, CA
- 17:05 - 17:10 Questions to discussant
- 17:10 - 17:10 781PD - Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma
J.-C. Soria¹, A. Italiano², A. Cervantes³, J. Tabernero⁴, J. Infante⁵, P. Lara⁶, A. Spira⁷, E. Calvo⁸, V. Moreno⁸, J.-Y. Blay⁹, R. Lauer¹⁰, N. Chan¹¹, B. Zhong¹², A. Ademi Santiago-Walker¹², J. Bussolari¹², F.R. Luo¹², H. Xie¹², P. Hammerman¹³; ¹Villejuif, FR, ²Bordeaux, FR, ³Valencia, ES, ⁴Barcelona, ES, ⁵Nashville, TN/US, ⁶Sacramento, CA/US, ⁷The Woodlands, TX/US, ⁸Madrid, ES, ⁹Lyon, FR, ¹⁰Albuquerque, US, ¹¹New Brunswick, US, ¹²Raritan, US, ¹³Boston, US
- 17:10 - 17:10 782PD - IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC)
J. Bellmunt¹, A. Balar², M. Galsky³, Y. Loriot⁴, C. Theodore⁵, E. Grande Pulido⁶, D. Castellano⁶, M. Retz⁷, G. Niegisch⁸, S. Bracarda⁹, A. Necchi¹⁰, U. Vaishampayan¹¹, S. Sridhar¹², B. Eigl¹³, S. Hussain¹⁴, M. van der Heijden¹⁵, B. Danner¹⁶, S. Mariathasan¹⁶, F. Legrand¹⁶, J. Rosenberg^{3, 1} Boston, US, ²New York, NY/US, ³New York, US, ⁴Villejuif, FR, ⁵Suresnes, FR, ⁶Madrid, ES, ⁷München, DE, ⁸Düsseldorf, DE, ⁹Arezzo, IT, ¹⁰Milano, IT, ¹¹Detroit, US, ¹²Toronto, ON/CA, ¹³Vancouver, CA, ¹⁴Liverpool, GB, ¹⁵Amsterdam, NL, ¹⁶South San Francisco, US
- 17:10 - 17:25 Invited discussant abstracts 781PD and 782PD
A. Bamias, Athens, GR
- 17:25 - 17:30 Questions to discussant
- 16:30 - 18:00 Type: Educational session Helsinki
 Title: Bad luck or bad knowledge? Evidence-based cancer prevention approaches
 Chair(s): J. Cuzick, GB; S. Franceschi, FR
- 16:30 - 17:00 Where to give prevention advice
H. Grönberg, Stockholm, SE
- 17:00 - 17:30 Proven interventions
S. Franceschi, Lyon, FR
- 17:30 - 18:00 Unproven interventions
G. Evans, London, GB



| | | |
|---------------|---|----------|
| 16:30 - 17:30 | Type: Poster Discussion session Title: Breast cancer, metastatic Chair(s): L. Costa, PT; M. Arnedos, FR; C. Saura, ES | Brussels |
| 16:30 - 16:30 | (Withdrawn) | |
| 16:30 - 16:30 | 224PD - Efficacy and safety of BCD-022, trastuzumab biosimilar candidate, compared to herceptin: Results of international multicenter randomized double blind study in patients with HER2+ mBC <u>M. Shustova</u> ¹ , O. Burdaeva ² , S. Alexeev ¹ , K. Shelepen ³ , A. Khorinko ⁴ , G. Mukhametshina ⁵ , L. Sheveleva ⁶ , R. Ivanov ¹ ; ¹ St. Petersburg, RU, ² Arkhangelsk, RU, ³ Brest, BY, ⁴ Perm, RU, ⁵ Kazan, RU, ⁶ Volgograd, RU | |
| 16:30 - 16:30 | LBA17 - Single Agent Activity of DS-8201a, a HER2-Targeting Antibody-Drug Conjugate, in Breast Cancer Patients Previously Treated with T-DM1: Phase 1 Dose Escalation <u>K. Tamura</u> ¹ , K. Shitara ² , Y. Naito ³ , A. Shimomura ² , Y. Fujiwara ² , K. Yonemori ² , C. Shimizu ² , T. Shimoi ² , Y. Kuboki ³ , N. Matsubara ³ , A. Kitano ² , T. Jikoh ² , Y. Fujisaki ² , A. Yver ⁴ , T. Doi ³ ; ¹ Edison, Nj, US, ² Tokyo, JP, ³ Kashiwa, JP, ⁴ Edison Nj, US | |
| 16:30 - 16:40 | Invited discussant LBA TBC, abstract 224PD and LBA17 <u>C. Saura</u> , Barcelona, ES | |
| 16:40 - 16:46 | Questions to discussant | |
| 16:46 - 16:46 | LBA18 - A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer <u>M. Beeram</u> ¹ , S. Tolaney ² , J.T. Beck ³ , M. Dickler ⁴ , A. Conlin ⁵ , C. Dees ⁶ , T. Helsten ⁷ , P. Conkling ⁸ , W. Edenfield ⁹ , D. Richards ¹⁰ , S.R.P. Kambhampati ¹¹ , T. Costigan ¹¹ , E. Chan ¹² , S. Pant ¹³ , K. Kalinsky ⁴ , H. Burris ¹⁴ , C. Becerra ¹⁵ , B. Rexer ¹⁶ , S. Puhalla ¹⁷ , M. Goetz ¹⁸ ; ¹ San Antonio, TX/US, ² Boston, MA/US, ³ Lafayetteville, AZ/US, ⁴ New York, NY/US, ⁵ Portland, OR/US, ⁶ Chapel Hill, NC/US, ⁷ La Jolla, CA/US, ⁸ Norfolk, VA/US, ⁹ Greenville, SC/US, ¹⁰ Tyler, TX/US, ¹¹ Indianapolis, IN/US, ¹² Indianapolis, US, ¹³ Houston, TX/US, ¹⁴ Nashville, US, ¹⁵ Dallas, TX/US, ¹⁶ Nashville, TN/US, ¹⁷ Pittsburgh, PA/US, ¹⁸ Rochester, MN/US | |
| 16:46 - 16:46 | 225PD - Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naïve postmenopausal patients with ER+ HER2- metastatic breast cancer (MBC): Results from PALOMA-2 <u>H. Rugo</u> ¹ , V. Dieras ² , K. Gelmon ³ , R. Finn ⁴ , D. Slamon ⁵ , M. Miguel ⁶ , P. Neven ⁷ , J. Ettl ⁸ , Y. Shparyk ⁹ , A. Mori ¹⁰ , D.R. Lu ¹¹ , H. Bhattacharyya ¹² , C. Bartlett ¹³ , S. Iyer ¹² , S. Johnston ¹⁴ , N. Harbeck ⁸ ; ¹ San Francisco, CA/US, ² Paris, FR, ³ Vancouver, CA, ⁴ Los Angeles, CA/US, ⁵ Santa Monica, US, ⁶ Madrid, ES, ⁷ Leuven, BE, ⁸ München, DE, ⁹ Lviv, UA, ¹⁰ Milano, IT, ¹¹ La Jolla, CA/US, ¹² New York, US, ¹³ New York, NY/US, ¹⁴ London, GB | |
| 16:46 - 16:46 | 226PD - First line hormone therapy vs chemotherapy for HR+ HER2- metastatic breast cancer in the phase III STIC CTC trial: Clinical choice and validity of CTC count | |



F.-C. Bidard¹, E. Brain², W. Jacot³, T. Bachelot⁴, S. Ladoire⁵, H. Bourgeois⁶, A. Gonçalves⁷, H. Naman⁸, J. Gligorov¹, F. Dalenc⁹, C. Levy¹⁰, M. Espie¹, J.-M. Ferrero¹¹, E. Luporsi¹², M.-P. Sablin¹, C. Dubot¹, M. Chevrier¹, F. Berger¹, C. Alix-Panabieres³, J.-Y. Pierga¹; ¹Paris, FR, ²St. Cloud, FR, ³Montpellier, FR, ⁴Lyon, FR, ⁵Dijon, FR, ⁶Le Mans, FR, ⁷Marseille, FR, ⁸Mougins, FR, ⁹Toulouse, FR, ¹⁰Caen, FR, ¹¹Nice, FR, ¹²Vandoeuvre Les Nancy, FR

- 16:46 - 16:46 227PD - Everolimus use in breast cancer patients: A population-based study
M. Chavez-Macgregor, D. Zhigang, M. Sharma, S. Giordano; Houston, TX/US
- 16:46 - 17:01 Invited discussant LBA18, abstracts 225PD, 226PD and 227PD
M. Arnedos, Villejuif, FR
- 17:01 - 17:08 Questions to discussant
- 17:08 - 17:08 228PD - BRAF genomic alterations in breast cancer
J. Albanell¹, J. Elvin², J. Suh², J.-A. Vergilio², I. Phuong Le³, V. Kaklamani³, S. Ali², V. Miller², P. Stephens², L. Gay², J. Ross⁴; ¹Barcelona, ES, ²Cambridge, MA/US, ³San Antonio, TX/US, ⁴Albany, NY/US
- 17:08 - 17:08 229PD - Comprehensive genomic profiling of 8,654 breast carcinoma reveals therapeutically targetable molecular subtypes beyond those defined by hormone-receptor expression
J. Ross¹, L. Gay², J. Elvin², J. Suh², J.-A. Vergilio², S. Ramkissoon², S. Ali², V. Miller³, P. Stephens³; ¹Albany, NY/US, ²Cambridge, MA/US, ³Cambridge, US
- 17:08 - 17:08 230PD - Phase II randomised clinical study of metformin plus chemotherapy vs chemotherapy alone in HER2 negative metastatic breast cancer: Final results of the MYME trial
A. Gennari¹, O. Nanni², A. Rocca², A. De Censi¹, A. Fieschi³, A. Bologna⁴, L. Gianni⁵, F. Rosetti⁶, L. Amaducci⁷, L. Cavanna⁸, F. Foca², S. Sarti², P. Serra², L. Valmorri², D. Corradengo¹, G. Antonucci¹, P. Bruzzi¹, D. Amadori²; ¹Genova, IT, ²Meldola, IT, ³Aviano, IT, ⁴Reggio Emilia, IT, ⁵Rimini, IT, ⁶Mirano, IT, ⁷Faenza, IT, ⁸Piacenza, IT
- 17:08 - 17:08 231PD - A phase II study of the cell cycle checkpoint kinases 1 and 2 (CHK1/2) inhibitor (LY2606368; prexasertib) in sporadic triple negative breast cancer (TNBC)
F. Karzai¹, A. Zimmer², S. Lipkowitz², C. Annunziata², B. Parker², N. Houston², I. Ekwede², E. Kohn², J.-M. Lee²; ¹Bethesda, MD/US, ²Rockville, US
- 17:08 - 17:23 Invited discussant abstracts 228PD, 229PD, 230PD and 231PD
L. Costa, Lisboa, PT
- 17:23 - 17:30 Questions to discussant



| | | |
|---------------|---|--------|
| 16:30 - 17:30 | Type: Poster Discussion session Title: Basic science and translational research Chair(s): D. Huntsman, CA; C. Dive, GB; D. Schadendorf, DE | Berlin |
| 16:30 - 16:30 | LBA12 - Exploratory biomarkers in MONARCH 1, a phase II study of abemaciclib monotherapy in hormone-receptor positive (HR+) HER2- metastatic breast cancer (MBC) <u>S. Tolaney</u> ¹ , J. Cortes ² , M. Dickler ³ , E. Zamora ⁴ , C. Caldwell ⁵ , T.S. Nguyen ⁶ , S. Nanda ⁶ , A. Koustenis ⁵ , H.S. Rugo ⁷ ; ¹ Boston, MA/US, ² Madrid, ES, ³ New York, NY/US, ⁴ Barcelona, ES, ⁵ Indianapolis, US, ⁶ Indianapolis, IN/US, ⁷ San Francisco, CA/US | |
| 16:30 - 16:30 | 53PD - Copy number alterations as predictive biomarkers for response to bevacizumab in metastatic colorectal cancer <u>N. van Grieken</u> ¹ , M. Cordes ¹ , H. Verheul ¹ , M. Neerincx ¹ , C. Punt ¹ , M. Koopman ² , G. Meijer ¹ , V. Murphy ³ , A. Barat ³ , J. Betge ⁴ , M. Ebert ⁴ , T. Gaiser ⁴ , B. Fender ³ , R. Klinger ³ , S. Das ³ , D. Smeets ⁵ , D. O'Connor ³ , D. Lambrechts ⁵ , A. Byrne ³ , B. Ylstra ¹ ; ¹ Amsterdam, NL, ² Utrecht, NL, ³ Dublin, IE, ⁴ Mannheim, DE, ⁵ Leuven, BE | |
| 16:30 - 16:30 | 54PD - Multidisciplinary molecular tumour board: A tool to improve clinical practice and selection accrual for clinical trials in cancer patients <u>C. Rolfo</u> , A. Machado Coelho, P. Van Dam, A. Dendooven, C. Weyn, M. Rasschaert, L. Van Houten, B. Trinh, J. Van Meerbeeck, P. Pauwels, M. Peeters; Edegem, BE | |
| 16:30 - 16:30 | 55PD - Vemurafenib (VM) in non-melanoma V600 and non-V600 BRAF mutated cancers: First results of the ACSE trial <u>J.-Y. Blay</u> ¹ , J. Mazieres ² , D. Perol ¹ , F. Barlesi ³ , D. Moro-Sibilot ⁴ , G. Quere ⁵ , J. Tredaniel ⁶ , X. Troussard ⁷ , S. Leboulleux ⁸ , D. Malka ⁸ , A. Flechon ¹ , C. Linassier ⁹ , I. Ray-Coquard ¹ , B. Arnulf ⁶ , I. Bieche ⁶ , G. Ferretti ⁴ , F. Nowak ¹⁰ , M. Jimenez ⁶ , N. Hoog-Labouret ¹⁰ , A. Buzyn ¹⁰ ; ¹ Lyon, FR, ² Toulouse, FR, ³ Marseille, FR, ⁴ La Tronche, FR, ⁵ Brest, FR, ⁶ Paris, FR, ⁷ Caen, FR, ⁸ Villejuif, FR, ⁹ Tours, FR, ¹⁰ Boulogne-Billancourt, FR | |
| 16:30 - 16:40 | Invited discussant abstracts 53PD, 54PD, 55PD and LBA12 <u>C. Dive</u> , Manchester, GB | |
| 16:40 - 16:50 | Questions to discussant | |
| 16:50 - 16:50 | 56PD - Extended genotyping of RAS/BRAF for improved selection of metastatic CRC patients to anti-EGFR therapy: Comparison of three platforms <u>D. Azuara</u> ¹ , R. Garcia-Carbonero ² , P. García Alfonso ² , C. Santos-Vivas ¹ , V. Navarro ¹ , M. Varela ³ , A. Carrato ² , E. Elez ¹ , M.T. Cano ⁴ , F. Losa ⁵ , C. Montagut ¹ , B. Massuti Sureda ⁶ , J.L. Manzano ⁷ , J. Vieitez ⁸ , M. Valladares-Ayerbes ⁹ , X. Sanjuan ³ , G. Capellá ¹ , J. Tabernero ¹ , E. Aranda ⁴ , R. Salazar ¹ ; ¹ Barcelona, ES, ² Madrid, ES, ³ Bellvitge, ES, ⁴ Cordoba, ES, ⁵ Hospitalet, ES, ⁶ Alicante, ES, ⁷ Badalona, ES, ⁸ Oviedo, ES, ⁹ A Coruna, ES | |
| 16:50 - 16:50 | 1159PD - Analytic validation of a clinical circulating tumor DNA assay for patients with solid tumors | |



P. Stephens¹, T. Clark², M. Kennedy², J. He², G. Young², M. Zhao², M. Coyne², V. Breese², L. Young², S. Zhong², M. Bailey², B. Fendler², V. Miller¹, E. Schleifman³, E. Peters³, G. Otto², D. Lipson², J. Ross⁴; ¹Cambridge, US, ²Cambridge, MA/US, ³South San Francisco, CA/US, ⁴Albany, NY/US

- 16:50 - 16:50 1521PD - Clinical evaluation of the utility of a liquid biopsy (circulating tumoral cells and ctDNA) to determine the mutational profile (EGFR, KRAS, ALK, ROS1 and BRAF) in advanced NSCLC patients
L. Barrera¹, E. Montes-Servin¹, J. Borbolla², L. Arnold³, J. Poole³, V. Alexiadis³, V. Singh³, B. Gustafson³, O. Arrieta¹; ¹Mexico City, MX, ²Luton, GB, ³San Diego, CA/US
- 16:50 - 16:50 1581PD - Copenhagen prospective personalized oncology (CoPPO): Genomic profiling to select patients for phase 1 trials
I. Tuxen, C. Yde, M. Mau-Sørensen, U. Lassen, E. Santoni-Rugiu, F. Nielsen; Copenhagen, DK
- 16:50 - 17:00 Invited discussant abstracts 56PD, 1159PD, 1521PD and 1581PD
D. Huntsman, Vancouver, CA
- 17:00 - 17:10 Questions to discussant
- 17:10 - 17:10 2PD - Lenvatinib mesilate (LEN) enhanced antitumor activity of a PD-1 blockade agent by potentiating Th1 immune response
Y. Kato¹, X. Bao², S. Macgrath², K. Tabata³, Y. Hori³, S. Tachino³, M. Matijevici², Y. Funahashi⁴, J. Matsui⁴; ¹Tsukuba-Shi, IBARAKI/JP, ²Andover, NJ/US, ³Ibaraki, JP, ⁴Tsukuba, JP
- 17:10 - 17:10 57PD - MHC class II in lung cancer
Y. He¹, L. Rozeboom², R. Dziadziuszko³, C. Rivard⁴, K. Ellison⁴, H. Yu⁴, C. Zhou¹, F. Hirsch⁵; ¹Shanghai, CN, ²Aurora, CO/US, ³Gdansk, PL, ⁴Denver, CO/US, ⁵Denver, US
- 17:10 - 17:10 58PD - Th1 epitopes as potential biomarkers for ipilimumab treatment
J. Marquez¹, E. Ramos², D. Herendeen², K. Quayle², M. Verburg², A. Suplee-Rivera², S. Carrillo², J. Matute-Briseno², R. Soto-Soto², A. Camacho-Hernandez², P. Lucero-Diaz²; ¹Seattle, US, ²Sonora, MX
- 17:10 - 17:20 Invited discussant abstracts 2PD, 57PD and 58PD
D. Schadendorf, Essen, DE
- 17:20 - 17:30 Questions to discussant



| | | |
|---------------|--|--------|
| 16:30 - 18:30 | Type: Special Session Title: ESMO Integrated Oncology & Palliative Care Community Session Chair(s): A.-M. Stevens, GB; F. Strasser, CH | Lisbon |
| 16:30 - 16:35 | Introduction <u>F. Strasser</u> , St. Gallen, CH | |
| 16:35 - 16:55 | The global ESMO Designated Centers of Integrated Oncology and Palliative Care Network: Characteristics, Indicators, Work Force <u>D. Hui</u> , Houston, US | |
| 16:55 - 17:15 | Building the community: Curricula, educational material, and opportunities to become a double-boarded oncologist and palliative care specialist <u>G. Kreye</u> , Krems, AT | |
| 17:15 - 17:35 | Integration of Psychosocial Oncology Care in Routine Oncology <u>L. Travado</u> , Lisbon, PT | |
| 17:35 - 17:55 | Selection of Innovative Practices of Integrated Oncology and Palliative Care performed in designated centers <u>R. Berman</u> , Manchester, GB | |
| 17:55 - 18:00 | Conclusions <u>A.-M. Stevens</u> , London, GB | |
| 18:00 - 18:30 | Designated Centre and Palliative Care Fellowship Awards <u>F. Strasser</u> ¹ , <u>G. Kreye</u> ² , <u>N. Cherny</u> ³ ; ¹ St. Gallen, CH, ² Krems, AT, ³ Jerusalem, IL | |
| 17:30 - 18:00 | Type: Young Oncologist Vesalius Talk Title: Young Oncologists Vesalius Talk Chair(s): F. Ciardiello, IT | Bern |
| 17:30 - 17:35 | Introduction <u>M. Preusser</u> , Vienna, AT | |
| 17:35 - 18:00 | Developing an effective relationship between basic scientists and medical oncologists <u>F. Ciardiello</u> ¹ , <u>R. Marais</u> ² , <u>M. Sibilio</u> ³ , <u>M. Garassino</u> ⁴ ; ¹ Napoli, IT, ² Manchester, GB, ³ Vienna, AT, ⁴ Milan, IT | |



| | | |
|---------------|--|-----------|
| 18:00 - 19:30 | Type: Patient Advocacy Track Title: Learning more about side effects: Why they matter and how to collect them Chair(s): G. Spurrier-Bernard, FR; A. Plate, BE | Zagreb |
| 18:00 - 18:15 | Why the reporting of side-effects is so important <u>D. Athanasiou</u> , Athens, GR | |
| 18:15 - 18:30 | How differently clinicians, patients and carers perceive side effects <u>A. Plate</u> , Brussels, BE | |
| 18:30 - 18:45 | New drugs that are safe - pharmacovigilance in oncology | |
| 18:45 - 19:00 | Innovative ways to record treatment side effects in clinical trials <u>S. O'Brien</u> , Newcastle Upon Tyne, GB | |
| 19:00 - 19:15 | Patient networks driving adverse event reporting: The UMC/ MPNE project <u>R. Chandler</u> , Uppsala, SE | |
| 19:15 - 19:30 | Discussion: what can we as patient advocates do to - increase the safety of our therapies? - ensure that side effects are evaluated according to the true impact for patients? | |
| 18:30 - 20:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium | Stockholm |
| 18:30 - 20:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium | Madrid |
| 18:30 - 20:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Oslo |
| 18:30 - 20:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium | Rome |
| 18:30 - 20:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Athens |
| 18:30 - 20:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium | Helsinki |
| 18:30 - 20:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Brussels |

10-10-2016



08:00 - 09:00 Type: Challenge Your Expert (CYE) session Rome
Title: Synchronous metastatic colorectal cancer: Addressing difficult situations

08:00 - 08:30 Synchronous metastatic colorectal cancer: Addressing difficult situations
G. Folprecht, Dresden, DE

08:30 - 09:00 Discussion

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Athens
Title: Lights and shadows in targeting KRAS driven lung cancer

08:00 - 08:30 Lights and shadows in targeting KRAS driven lung cancer
P. Jänne, Boston, US

08:30 - 09:00 Discussion

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Brussels
Title: Are guidelines necessary for everyday treatment in metastatic breast cancer?

08:00 - 08:30 Are guidelines necessary for everyday treatment in metastatic breast cancer?
F. Cardoso, Lisboa, PT

08:30 - 09:00 Discussion

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Berlin
Title: Management of side effects

08:00 - 08:30 Management of side effects
G. Long, Sydney, AU

08:30 - 09:00 Discussion



08:00 - 09:00 Type: Challenge Your Expert (CYE) session Bern
Title: Management of sinonasal tumours

08:00 - 08:30 Management of sinonasal tumours
P. Bossi, Milano, IT

08:30 - 09:00 Discussion

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Lisbon
Title: The development of novel anticancer drugs: How to raise the bar in oncology

08:00 - 08:30 The development of novel anticancer drugs: How to raise the bar in oncology
A. Sobrero, Genoa, IT

08:30 - 09:00 Discussion



| | | |
|---------------|--|--------|
| 09:00 - 10:45 | Type: Proffered Paper session Title: NSCLC, metastatic 2 Chair(s): F. Blackhall, GB; T.S.K. Mok, HK | Vienna |
| 09:00 - 09:15 | (Withdrawn) | |
| 09:15 - 09:30 | LBA45 - Top-line results from SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel in Patients with Previously Treated Stage IIIb/IV Non-Squamous Non Small Cell Lung Cancer <u>D. Spigel</u> ¹ , I. Bondarenko ² , G. Losonczy ³ , J. Mezger ⁴ , H. Kalofonos ⁵ , M. Reck ⁶ , R. Palmero ⁷ , T. Jang ⁸ , R. Natale ⁹ , R. Sanborn ¹⁰ , J. Lai ¹¹ , N. Kallinteris ¹² , M. Tang ¹¹ , J. Shan ¹³ , D. Gerber ¹⁴ ; ¹ Nashville, US, ² Dnepropetrovsk, UA, ³ Budapest, HU, ⁴ Karlsruhe, DE, ⁵ Patras, GR, ⁶ Grosshansdorf, DE, ⁷ Barcelona, ES, ⁸ Busan, KR, ⁹ Los Angeles, CA/US, ¹⁰ Portland, OR/US, ¹¹ Tustin, CA/US, ¹² Tusitn, US, ¹³ Tustin, US, ¹⁴ Dallas, TX/US | |
| 09:30 - 09:45 | (Withdrawn) | |
| 09:45 - 10:00 | Invited discussant two LBAs and LBA45 <u>S. Peters</u> , Lausanne, CH | |
| 10:00 - 10:15 | LBA47_PR - Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: Results from the phase III SELECT-1 trial <u>P. Jänne</u> ¹ , M. van den Heuvel ² , F. Barlesi ³ , M. Cobo ⁴ , J. Mazieres ⁵ , L. Crinò ⁶ , S. Orlov ⁷ , F. Blackhall ⁸ , J. Wolf ⁹ , P. Garrido ¹⁰ , A. Poltoratskiy ¹¹ , G. Mariani ¹² , D. Ghiorghiu ¹³ , E. Kilgour ¹⁴ , P. Smith ¹⁵ , A. Kohlmann ¹⁵ , D. Carlile ¹⁵ , D. Lawrence ¹⁵ , K. Bowen ¹⁶ , J. Vansteenkiste ¹⁷ ; ¹ Boston, US, ² Amsterdam, NL, ³ Marseille, FR, ⁴ Málaga, ES, ⁵ Toulouse, FR, ⁶ Perugia, IT, ⁷ Saint Petersburg, RU, ⁸ Manchester, GB, ⁹ Köln, DE, ¹⁰ Madrid, ES, ¹¹ St. Petersburg, RU, ¹² Royston, GB, ¹³ Melbourne, VIC/AU, ¹⁴ Macclesfield, GB, ¹⁵ Cambridge, GB, ¹⁶ Gaithersburg, MD/US, ¹⁷ Leuven, BE | |
| 10:15 - 10:30 | 1202O - Clinical and biological characteristics of non-small cell lung cancer (NSCLC) harbouring EGFR mutation: Results of the nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) <u>C. Leduc</u> ¹ , H. Blons ² , B. Besse ³ , J.-P. Merlio ⁴ , D. Debievre ⁵ , A. Lemoine ³ , I. Monnet ⁶ , D. Pouessel ² , P.P. Bringuier ⁷ , M. Poudenx ⁸ , I. Rouquette ⁹ , F. Vaylet ¹⁰ , F. Morin ² , A. Langlais ² , E. Quoix ¹ , G. Zalcman ¹¹ , D. Moro-Sibilot ¹² , J. Cadranet ² , M. Beau-Faller ¹ , F. Barlesi ¹³ ; ¹ Strasbourg, FR, ² Paris, FR, ³ Villejuif, FR, ⁴ Bordeaux, FR, ⁵ Mulhouse, FR, ⁶ Créteil, FR, ⁷ Lyon, FR, ⁸ Nice, FR, ⁹ Toulouse, FR, ¹⁰ Clamart, FR, ¹¹ Caen, FR, ¹² La Tronche, FR, ¹³ Marseille, FR | |
| 10:30 - 10:45 | Invited discussant LBA47 and abstract 1202O <u>T.S.K. Mok</u> , Hong Kong, CN | |



| | | |
|---------------|--|------------|
| 09:00 - 10:30 | Type: Educational session Title: Advances in targeted therapy in gynaecological cancers Chair(s): J. Ledermann, GB; M.R. Mirza, DK | Stockholm |
| 09:00 - 09:30 | Positioning anti-angiogenic therapy in the ovarian cancer treatment pathway <u>P. Harter</u> , Essen, DE | |
| 09:30 - 10:00 | PARP inhibitors in ovarian cancer: What are the next steps? <u>J. Ledermann</u> , London, GB | |
| 10:00 - 10:30 | Cervical cancer therapy in 2016 <u>M.R. Mirza</u> , Copenhagen, DK | |
| 09:00 - 10:30 | Type: Special Symposium Title: Biomarker strategies to improve the treatment of castration-resistant prostate cancer Chair(s): F. Feng, US; D. Olmos Hidalgo, ES | Oslo |
| 09:00 - 09:05 | Introduction <u>D. Olmos</u> , Madrid, ES | |
| 09:05 - 09:25 | Translating the genomics landscape into clinical practice <u>R. Bristow</u> , Toronto, On, CA | |
| 09:25 - 09:45 | What is the role of CTCs? <u>H. Scher</u> , New York, Ny, US | |
| 09:45 - 10:05 | Using circulating tumour DNA studies to improve the management of prostate cancer patients <u>G. Attard</u> , Sutton, GB | |
| 10:05 - 10:25 | Molecularly defining neuroendocrine prostate cancer <u>H. Beltran</u> , New York, Ny, US | |
| 10:25 - 10:30 | Conclusions and clinical perspectives <u>F. Feng</u> , Ann Arbor, US | |
| 09:15 - 11:00 | Type: Proffered Paper session Title: Gastrointestinal tumours, colorectal 2 | Copenhagen |
| 09:15 - 09:27 | 456O - Circulating tumor DNA and circulating tumor cells as predictor of outcome in the PRODIGE14-ACCORD21-METHEP2 phase II trial | |



F.-C. Bidard¹, M. Ychou², J. Madic¹, A. Saliou¹, O. Bouché³, M. Rivoire⁴, F. Ghiringhelli⁵, E. Francois⁶, R. Guimbaud⁷, L. Mineur⁸, F. Khemissa-Akouz⁹, T. Mazard¹⁰, D. Moussata¹¹, W. Cacheux¹, C. Proudhon¹, M.-H. Stern¹, J.-Y. Pierga¹, T. Stanbury¹, S. Thezenas¹⁰, P. Mariani¹; ¹Paris, FR, ²Marseille, FR, ³Reims, FR, ⁴Lyon, FR, ⁵Dijon, FR, ⁶Nice, FR, ⁷Toulouse, FR, ⁸Avignon, FR, ⁹Perpignan, FR, ¹⁰Montpellier, FR, ¹¹Pierre Bénite, FR

- 09:27 - 09:39 457O - MiR-31-3p is a predictive biomarker of cetuximab response in FIRE3 clinical trial
P. Laurent-Puig¹, M.-L. Grisoni², V. Heinemann³, K. Fontaine², C. Vazart², V. Decaulne², F. Rousseau², B. Courtieu², F. Liebert², A. Jung³, D. Neureiter⁴, R. Thiébaud², S. Stintzing³; ¹Paris, FR, ²Evry, FR, ³München, DE, ⁴Salzburg, AT
- 09:39 - 09:51 458O - Frequency of potentially actionable genetic alterations in EORTC SPECTAcOLOR
G. Folprecht¹, P. Beer², R. Salazar³, A. Roth⁴, D. Aust¹, R. Salgado⁵, P. Laurent-Puig⁶, J. Tabernero³, D. Arnold⁷, A. Stein⁸, V. Golfopoulos⁵, A. Atasoy⁵, E. Szepessy⁵, M. Ducreux⁹, T. Gorlia⁵, S. Tejpar¹⁰; ¹Dresden, DE, ²Cambridge, GB, ³Barcelona, ES, ⁴Geneva, CH, ⁵Brussels, BE, ⁶Paris, FR, ⁷Freiburg, DE, ⁸Hamburg, DE, ⁹Villejuif, FR, ¹⁰Leuven, BE
- 09:51 - 10:06 Invited discussant abstracts 456O, 457O and 458O
C. Cremolini, Pisa, IT
- 10:06 - 10:18 459O - ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8)
P. Laurent-Puig¹, R. Balogoun¹, A. Cayre², K. Le Malicot³, J. Tabernero⁴, E. Mini⁵, G. Folprecht⁶, J.-L. van Laethem⁷, J. Thaler⁸, L. Nørgård Petersen⁹, E. Sanchez¹⁰, J. Bridgewater¹¹, S. Ellis¹², C. Locher¹³, C. Lagorce¹, J.-F. Ramé¹⁴, C. Lepage³, F. Penault-Llorca², J. Taieb¹; ¹Paris, FR, ²Clermont-Ferrand, FR, ³Dijon, FR, ⁴Barcelona, ES, ⁵Florence, IT, ⁶Dresden, DE, ⁷Brussels, BE, ⁸Wels, AT, ⁹Roskilde, DK, ¹⁰Porto, PT, ¹¹London, GB, ¹²Perpignan, FR, ¹³Meaux, FR, ¹⁴Nantes, FR
- 10:18 - 10:30 460O - POLE proofreading domain mutation defines a subset of immunogenic colorectal cancers with excellent prognosis
M. Glaire¹, E. Domingo¹, L. Vermeulen², T. van Wezel³, G.-J. Liefers³, R. Lothe⁴, A. Nesbakken⁴, S. Danielsen⁴, I. Zlobec⁵, V. Koelzer¹, M. Berger⁵, S. Castellví-Bel⁶, M. de Bruyn⁷, M. Novelli⁸, S. Tejpar⁹, M. Delorenzi¹⁰, R. Kerr¹, D. Kerr¹, I. Tomlinson¹, D. Church¹; ¹Oxford, GB, ²Amsterdam, NL, ³Leiden, NL, ⁴Oslo, NO, ⁵Bern, CH, ⁶Barcelona, ES, ⁷Groningen, NL, ⁸London, GB, ⁹Leuven, BE, ¹⁰Lausanne, CH
- 10:30 - 10:42 461O - Adjuvant FOLFOX+ cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: Results from the PETACC8 trial
J. Taieb¹, K. Le Malicot², R. Balogoun¹, J. Tabernero³, E. Mini⁴, G. Folprecht⁵, J.-L. van Laethem⁶, J.-F. Emile⁷, C. Mulot¹, S. Fratté⁸, C.-B. Levaché⁹, L. Saban-Roche¹⁰, J. Thaler¹¹, L. Nørgård Petersen¹², E. Sanchez¹³, J. Bridgewater¹⁴, G. Perkins¹, C. Lepage², A. Zaanani¹, P. Laurent-Puig¹; ¹Paris, FR, ²Dijon, FR, ³Barcelona, ES, ⁴Florence, IT, ⁵Dresden, DE, ⁶Brussels, BE, ⁷Boulogne-Billancourt, FR, ⁸Montbéliard, FR, ⁹Périgeux, FR, ¹⁰Saint-Priest-en-jarez, FR, ¹¹Wels, AT, ¹²Roskilde, DK, ¹³Porto, PT, ¹⁴London, GB



10:42 - 10:57 Invited discussant abstracts 459O, 460O and 461O
R. Salazar, Barcelona, ES

09:15 - 10:45 Type: Special Symposium Rome
Title: Clinical challenges and patient needs based on defined supportive and palliative interventions delivered by competent multidisciplinary professionals
Chair(s): F. Scotté, FR

09:15 - 09:20 Introduction
F. Scotté, Paris, FR

09:20 - 09:40 Integrated care pathways
S. Kaasa, Oslo, NO

09:40 - 10:00 Evidence-based supportive care interventions
J. Herrstedt, Odense, DK

10:00 - 10:20 Evidence-based palliative care interventions
F. Strasser, St. Gallen, CH

10:20 - 10:40 Utilising the available multidisciplinary and interprofessional work force for optimal patient care
D. Keefe, Adelaide, AU

10:40 - 10:45 Conclusions and clinical perspectives
F. Scotté, Paris, FR

09:15 - 10:45 Type: Educational session Athens
Title: Rare lymphomas: Recent developments in diagnostic and treatment
Chair(s): C. Thieblemont, FR; A. Lopez-Guillermo, ES

09:15 - 09:45 Enteropathy associated lymphoma
O. Visser, Utrecht, NL

09:45 - 10:15 Marginal zone lymphoma
C. Thieblemont, Paris, FR

10:15 - 10:45 Waldenström's macroglobulinemia
M. Dimopoulos, Athens, GR



| | | |
|---------------|---|----------|
| 09:15 - 10:45 | Type: Joint Symposium Title: Joint Symposium ESMO-DSKO: Perspectives in the registration and use of Big Data and individual molecular profiles Chair(s): F. Ciardiello, IT; U. Lassen, DK | Brussels |
| 09:15 - 09:20 | Introduction | |
| 09:20 - 09:40 | The value of a large clinical database in testicular cancer <u>G. Daugaard</u> , Copenhagen, DK | |
| 09:40 - 10:00 | Big data/cancer epidemiology | |
| 10:00 - 10:20 | International collaboration with molecular profiling (WIN) <u>V. Lazar</u> , Villejuif, FR | |
| 10:20 - 10:40 | Immunoscore and molecular immune profiles | |
| 10:40 - 10:45 | Conclusions and clinical perspectives | |
| 09:30 - 10:30 | Type: Multidisciplinary patient cases Title: Treatment approaches in elderly patients Chair(s): S. Monfardini, IT | Madrid |
| 09:30 - 09:35 | Case presentation <u>S. Monfardini</u> , Milan, IT | |
| 09:35 - 09:45 | Bringing geriatrics into oncology <u>S. Monfardini</u> , Milan, IT | |
| 09:45 - 09:55 | Tailoring local treatment to the elderly <u>I. Kunkler</u> , Edinburgh, GB | |
| 09:55 - 10:05 | Optimising systemic therapy <u>H. Wildiers</u> , Leuven, BE | |
| 10:05 - 10:30 | Discussion | |



09:30 - 10:30 Type: Multidisciplinary patient cases Helsinki
 Title: Targeting the genes is not enough: The patients and tumour behaviour also matter

09:30 - 09:40 One mutation, many cancers
D. Huntsman, Vancouver, CA

09:40 - 09:50 Resistance mutations and cell context specific adaptive responses

09:50 - 10:00 Considering clonal evolution in breast cancer management
C. Caldas, Cambridge, GB

10:00 - 10:30 Discussion

09:30 - 10:30 Type: Poster Discussion session Berlin
 Title: Immunotherapy of cancer
 Chair(s): T. Powles, GB; S. Scholl, FR

09:30 - 09:30 1049PD - A phase 1b study (SCORES) assessing safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of durvalumab combined with AZD9150 or AZD5069 in patients with advanced solid malignancies and SCCHN
D. Hong¹, G. Falchook², C. Cook³, W. Harb⁴, P. Lyne³, P. McCoon³, M. Mehta³, P. Mitchell³, G. Mugundu³, M. Scott³, J. Wang⁵; ¹Houston, US, ²Denver, US, ³Waltham, MA/US, ⁴Lafayette, IN/US, ⁵Sarasota, FL/US

09:30 - 09:30 1050PD - Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: A phase 1, open-label study in advanced malignancies
O. Hamid¹, L. Chow², R. Sanborn³, S. Marshall⁴, C. Black⁴, M. Gribbin⁴, J. McDevitt⁴, J. Karakunnel⁴, J. Gray⁵; ¹Los Angeles, CA/US, ²Seattle, WA/US, ³Portland, OR/US, ⁴Gaithersburg, MD/US, ⁵Tampa, FL/US

09:30 - 09:30 LBA38 - Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P)
R. Herbst¹, J. Martin-Liberal², E. Calvo³, N. Isambert⁴, J. Bendell⁵, P. Cassier⁶, J.L. Perez-Gracia⁷, J. Yang⁸, J. Rege⁸, G. Mi⁹, D. Ferry⁸, L. Paz-Ares¹⁰; ¹New Haven, CT/US, ²Barcelona, ES, ³Madrid, ES, ⁴Dijon, FR, ⁵Nashville, TN/US, ⁶Lyon, FR, ⁷Pamplona, ES, ⁸Bridgewater, NJ/US, ⁹Indianapolis, IN/US, ¹⁰Seville, ES

09:30 - 09:30 1051PD - The MITCI (phase 1b) study: A novel immunotherapy combination of coxsackievirus A21 and ipilimumab in patients with advanced melanoma
B. Curti¹, J. Richards², M. Faries³, R. Andtbacka⁴, M. Grose⁵, R. Karpathy⁶, D. Shafren⁷; ¹Portland, OR/US, ²Chicago, US, ³Los Angeles, US, ⁴Salt Lake City, UT/US, ⁵New Lambton Heights, NSW/AU, ⁶Sydney, AU, ⁷Sydney, NSW/AU

09:30 - 09:50 Invited discussant abstracts 1049PD, 1050PD, 1051PD and LBA38



T. Powles, Albany, LA/US

09:50 - 10:00 Questions to discussant

10:00 - 10:00 1052PD - Phase 1 study of MEDI0562, a humanized OX40 agonist monoclonal antibody (mAb), in adult patients (pts) with advanced solid tumors

B. Glisson¹, R. Leidner², R. Ferris³, J. Powderly⁴, N. Rizvi⁵, J. Norton⁶, J. Burton⁷, M. Lanasa⁶, S. Patel⁸; ¹Houston, TX/US, ²Portland, OR/US, ³Pittsburgh, Pa, US, ⁴Huntersville, NC/US, ⁵New York, NY/US, ⁶Gaithersburg, MD/US, ⁷Cambridge, GB, ⁸La Jolla, CA/US

10:00 - 10:00 1053PD - A first-in-human (FIH) study of PF-04518600 (PF-8600) OX40 agonist in adult patients (pts) with select advanced malignancies

A. Diab¹, A. El-Khoueiry², F. Eskens³, W. Ros⁴, J. Thompson⁵, C. Kontou⁶, C. Bermingham⁶, T. Joh⁷, K. Liao⁸, B. Ganguly⁹, O. Hamid²; ¹Houston, TX/US, ²Los Angeles, CA/US, ³Rotterdam, NL, ⁴Amsterdam, NL, ⁵Seattle, WA/US, ⁶South San Francisco, CA/US, ⁷San Diego, CA/US, ⁸La Jolla, CA/US, ⁹New York, NY/US

10:00 - 10:00 1054PD - Phase I/II CANON study: Oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21

H. Pandha¹, N. Annels¹, M. Arif¹, H. Mostafid², S. Sandhu³, K. Harrington⁴, A. Melcher⁵, D. Mansfield⁴, G. Au⁶, M. Grose⁷, R. Karpathy⁶, D. Shafren⁸; ¹Guildford, GB, ²Surrey, GB, ³Kingston, GB, ⁴London, GB, ⁵Leeds, GB, ⁶Sydney, AU, ⁷New Lambton Heights, NSW/AU, ⁸Sydney, NSW/AU

10:00 - 10:00 1056PD - Preventive dendritic cell vaccination in healthy Lynch syndrome mutation carriers

H. Westdorp, M. Gorris, S. Boudewijns, T. Bisseling, A. de Goede, M. van Rossum, M. Ligtenberg, G. Schreibelt, I. Nagtegaal, C. Figdor, W. Gerritsen, N. Hoogerbrugge, I.J. de Vries; Nijmegen, NL

10:00 - 10:20 Invited discussant abstracts 1052PD, 1053PD, 1054PD and 1056PD

S. Scholl, Paris, FR

10:20 - 10:30 Questions to discussant

09:30 - 10:30 Type: Challenge Your Expert (CYE) session
Title: Genetic essentials for the modern practicing oncologist

Bern

09:30 - 10:00 Genetic essentials for modern practicing oncologist

E. Voest, Amsterdam, NL

10:00 - 10:30 Discussion



09:30 - 10:30 Type: Challenge Your Expert (CYE) session Lisbon
Title: What are genomics adding to patient management?

09:30 - 10:00 What are genomics adding to patient management?
J. Bertherat, Paris, FR

10:00 - 10:30 Discussion

09:30 - 10:30 Type: Young Oncologist Mentorship session Warsaw
Title: ESMO Young Oncologists Mentorship session
Chair(s): M. Strijbos, BE; C. Qvortrup, DK

09:30 - 10:30 Working in academia - Table 1
R. Stupp, Zürich, CH

10:30 - 11:30 Working in academia - Table 2
E. Felip, Barcelona, ES

11:30 - 12:30 Practicing oncologists - Table 1
S. Braga, Lisboa, PT

12:30 - 13:30 Practicing oncologists - Table 2
S. Rauh, Esch-Sur-alzette, LU

13:30 - 14:30 Industry as a career choice - Table 1
T. Lillie, Uxbridge, GB

14:30 - 15:30 Industry as a career choice - Table 2
M. Rashford, Rueil-Malmaison, FR



| | | |
|---------------|---|-----------|
| 11:00 - 12:30 | Type: Special Symposium Title: Immunotherapy in GU malignancies Chair(s): J. Bellmunt, US; M. Schmidinger, AT | Vienna |
| 11:00 - 11:05 | Introduction <u>J. Bellmunt</u> , Boston, US | |
| 11:05 - 11:25 | Biology and new immunological targets in GU malignancies <u>J. Haanen</u> , Amsterdam, NL | |
| 11:25 - 11:45 | Biomarkers of response and progression in (GU) immunotherapy <u>T. Choueiri</u> , Boston, US | |
| 11:45 - 12:05 | Immunotherapy in urothelial cancers <u>J. Bellmunt</u> , Boston, US | |
| 12:05 - 12:25 | Immunotherapy in kidney cancer <u>L. Albiges</u> , Villejuif, FR | |
| 12:25 - 12:30 | Conclusions and clinical perspectives <u>M. Schmidinger</u> , Vienna, AT | |
| 11:00 - 12:30 | Type: Special Session Title: Transforming academia-industry partnerships to expedite clinical development of innovative anti-cancer agents Chair(s): R. Stupp, CH; J. de Bono, GB | Stockholm |
| 11:00 - 11:05 | Introduction <u>R. Stupp</u> , Zürich, CH | |
| 11:05 - 11:25 | Developing drugs targeting the PI3K/AKT signalling <u>L. Yan</u> , Collegeville, US | |
| 11:25 - 11:45 | Pembrolizumab: Rapidly moving the field forward through industry-academic collaborations <u>P. Haluska</u> , Rochester, US | |
| 11:45 - 12:05 | Novel clinical trial designs incorporating genomics for developing anti-cancer drugs: Olaparib in prostate cancer <u>J. de Bono</u> , London, GB | |
| 12:05 - 12:25 | The role of consortia and corporative groups in the modern era of cancer drug development <u>R. Stupp</u> , Zürich, CH | |
| 12:25 - 12:30 | Conclusions <u>J. de Bono</u> , London, GB | |



| | | |
|---------------|---|--------|
| 11:00 - 12:00 | Type: Multidisciplinary patient cases Title: Current options for recurrent platinum sensitive ovarian cancer Chair(s): A. Gonzalez Martin, ES | Madrid |
| 11:00 - 11:05 | Case presentation <u>A. Gonzalez Martin</u> , Madrid, ES | |
| 11:05 - 11:15 | Surgery is an option in platinum sensitive recurrence <u>C. Marth</u> , Innsbruck, AT | |
| 11:15 - 11:25 | How imaging can help select patients for optimal surgery <u>V. Vandecaveye</u> , Leuven, BE | |
| 11:25 - 11:35 | Sensitive pop and systemic treatment: Which option for which patient? <u>A. Gonzalez Martin</u> , Madrid, ES | |
| 11:35 - 12:00 | Discussion | |



| | | |
|---------------|---|------|
| 11:00 - 12:30 | Type: Proffered Paper session Title: Head and neck cancers Chair(s): S. Faivre, FR; J.P. Machiels, BE | Oslo |
| 11:00 - 11:15 | 949O - Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort <u>N. Segal</u> ¹ , S.-H. Ou ² , A. Balmanoukian ³ , E. Massarelli ⁴ , J. Brahmer ⁵ , J. Weiss ⁶ , P. Schoffski ⁷ , S. Antonia ⁸ , C. Massard ⁹ , D. Zandberg ⁵ , C. Maher ¹ , S. Khleif ¹⁰ , X. Jin ¹¹ , M. Rebelatto ¹¹ , K. Steele ¹¹ , J. Antal ¹¹ , A. Gupta ¹¹ , A. Spreafico ¹² ; ¹ New York, NY/US, ² Irvine, CA/US, ³ Los Angeles, CA/US, ⁴ Houston, TX/US, ⁵ Baltimore, MD/US, ⁶ Chapel Hill, NC/US, ⁷ Leuven, BE, ⁸ Tampa, FL/US, ⁹ Villejuif, FR, ¹⁰ Augusta, GA/US, ¹¹ Gaithersburg, MD/US, ¹² Toronto, ON/CA | |
| 11:15 - 11:30 | 954O - Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies <u>L. Gay</u> ¹ , J. Ross ² , K. Wang ³ , J.-A. Vergilio ¹ , J. Suh ¹ , S. Ramkissoon ¹ , D. Bowles ⁴ , H. Serracino ⁴ , J. Russell ⁵ , S. Ali ¹ , V. Miller ¹ , P. Stephens ¹ , J. Elvin ¹ ; ¹ Cambridge, MA/US, ² Albany, NY/US, ³ Hangzhou, CN, ⁴ Denver, CO/US, ⁵ Tampa, FL/US | |
| 11:30 - 11:45 | Invited discussant abstracts 949O and 954O <u>S. Faivre</u> , Clichy, FR | |
| 11:45 - 12:00 | 950O - Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 100 randomized trials and 19,248 patients, on behalf of MACH-NC group <u>P. Blanchard</u> ¹ , C. Landais ¹ , C. Petit ¹ , Q. Zhang ² , V. Grégoire ³ , J. Tobias ⁴ , B. Burtneess ⁵ , M.G. Ghi ⁶ , F. Janot ¹ , J. Overgaard ⁷ , G. Wolf ⁸ , F. Lewin ⁹ , R. Hitt ¹⁰ , R. Corvo ¹¹ , V. Budach ¹² , A. Trotti ¹³ , C. Fortpied ³ , A. Hackshaw ⁴ , J. Bourhis ¹⁴ , J.-P. Pignon ¹ ; ¹ Villejuif, FR, ² Philadelphia, PA/US, ³ Brussels, BE, ⁴ London, GB, ⁵ New Haven, CT/US, ⁶ Venezia, IT, ⁷ Aarhus C, DK, ⁸ Ann Arbor, MI/US, ⁹ Jönköping, SE, ¹⁰ Madrid, ES, ¹¹ Genova, IT, ¹² Berlin, DE, ¹³ Tampa, FL/US, ¹⁴ Lausanne, CH | |
| 12:00 - 12:15 | 951O - Surrogate endpoints for overall survival in loco-regionally advanced nasopharyngeal carcinoma: Results from the individual patient data meta-analysis MAC-NPC2 <u>F. Rotolo</u> ¹ , J.-P. Pignon ¹ , S. Marguet ¹ , J. Ma ² , A. Chan ³ , P.-Y. Huang ² , G. Zhu ⁴ , D. Chua ³ , Y. Chen ² , H.-Q. Mai ² , D. Kwong ³ , Y. Soong ⁵ , J. Moon ⁶ , Y. Tung ³ , K.-H. Chi ⁷ , G. Fountzilas ⁸ , L. Zhang ² , A. Lee ³ , P. Blanchard ¹ , S. Michiels ¹ ; ¹ Villejuif, FR, ² Guangzhou, CN, ³ Hong Kong, HK, ⁴ Shanghai, CN, ⁵ Singapore, SG, ⁶ Seattle, US, ⁷ Taipei, TW, ⁸ Thessaloniki, GR | |
| 12:15 - 12:30 | Invited discussant abstracts 950O and 951O <u>E. Cohen</u> , La Jolla, CA/US | |
| 11:00 - 12:00 | Type: Poster Discussion session Title: Melanoma and other skin tumours Chair(s): A. Hauschild, DE; C. Blank, NL | Rome |
| 11:00 - 11:00 | 1108PD - Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma | |



J. Chesney¹, F. Collichio², R. Andtbacka³, I. Puzanov⁴, J. Glaspy⁵, M. Milhem⁶, O. Hamid⁵, L. Cranmer⁷, Y. Saenger⁸, M. Ross⁹, L. Chen¹⁰, J. Kim¹⁰, H. Kaufman¹¹; ¹Louisville, KY/US, ²Chapel Hill, NC/US, ³Salt Lake City, UT/US, ⁴Nashville, TN/US, ⁵Los Angeles, CA/US, ⁶Iowa City, IA/US, ⁷Tucson, AZ/US, ⁸New York, NY/US, ⁹Houston, TX/US, ¹⁰Thousand Oaks, CA/US, ¹¹New Brunswick, NJ/US

11:00 - 11:00 1109PD - Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma

P. Hwu¹, O. Hamid², R. Gonzalez³, J. Infante⁴, M. Patel⁵, F.S. Hodi⁶, K. Lewis⁷, J. Wallin⁸, G. Mwawasi⁸, E. Cha⁸, N. Richie⁸, M. Ballinger⁹, R. Sullivan⁶; ¹Houston, TX/US, ²Los Angeles, CA/US, ³Aurora, US, ⁴Nashville, TN/US, ⁵Sarasota, FL/US, ⁶Boston, US, ⁷Aurora, CO/US, ⁸South San Francisco, US, ⁹South San Francisco, CA/US

11:00 - 11:00 1110PD - Epcadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037

T. Gangadhar¹, O. Hamid², D. Smith³, T. Bauer⁴, J. Wasser⁵, A. Olszanski⁶, J. Luke⁷, A. Balmanoukian², D. Kaufman⁸, Y. Zhao⁹, J. Maleski⁹, M. Jones⁹, L. Leopold⁹, T. Gajewski⁷; ¹Philadelphia, US, ²Los Angeles, CA/US, ³Ann Arbor, MI/US, ⁴Nashville, TN/US, ⁵Farmington, CT/US, ⁶Philadelphia, PA/US, ⁷Chicago, IL/US, ⁸Kenilworth, NJ/US, ⁹Wilmington, DE/US

11:00 - 11:20 Invited discussant abstracts 1108PD, 1109PD and 1110PD

A. Hauschild, Kiel, DE

11:20 - 11:30 Questions to discussant

11:30 - 11:30 1112PD - PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis

G. Long¹, J. Larkin², P. Ascierto³, F.S. Hodi⁴, P. Rutkowski⁵, V. Sileni⁶, J. Hassel⁷, C. Lebbe⁸, A. Pavlick⁹, J. Wagstaff¹⁰, D. Schadendorf¹¹, R. Dummer¹², D. Hogg¹³, J. Haanen¹⁴, P. Corrie¹⁵, C. Hoeller¹⁶, C. Horak¹⁷, J. Wolchok¹⁸, C. Robert¹⁹; ¹Sydney, AU, ²London, GB, ³Napoli, IT, ⁴Boston, US, ⁵Warsaw, PL, ⁶Padova, IT, ⁷Heidelberg, DE, ⁸Paris, FR, ⁹New York, NY/US, ¹⁰Swansea, GB, ¹¹Essen, DE, ¹²Zürich, CH, ¹³Toronto, CA, ¹⁴Amsterdam, NL, ¹⁵Cambridge, GB, ¹⁶Vienna, AT, ¹⁷Princeton, NJ/US, ¹⁸New York, US, ¹⁹Villejuif, FR

11:30 - 11:30 1113PD - Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma

R. Rai¹, J. McQuade², D. Wang², J. Park³, K. Nahar¹, J. Sosman⁴, K. Beckermann⁴, L. Haydu², S. Lo³, S. Rubinstein⁴, K. Beckermann⁴, M. McKean², S. Matthew⁴, A. Guminski⁵, M. Carlino³, M. Davies², D. Johnson⁴, G. Long³, A. Menzies³; ¹North Sydney, NSW/AU, ²Houston, TX/US, ³Sydney, NSW/AU, ⁴Nashville, TN/US, ⁵St Leonards, AU

11:30 - 11:30 1114PD - Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases

J. Park¹, S. Parakh², S. Mendis², R. Rai¹, S. Lo¹, A. Haydon², M. Andrews², J. Cebon², A. Guminski¹, R. Kefford³, G. Long¹, A. Menzies¹, O. Klein², M. Carlino¹; ¹Sydney, NSW/AU, ²Melbourne, VIC/AU, ³Sydney, AU



11:30 - 11:50 Invited discussant abstracts 1112PD, 1113PD and 1114PD
C. Blank, Amsterdam, NL

11:50 - 12:00 Questions to discussant

11:00 - 12:30 Type: Special Symposium Athens
Title: Using biomarkers to monitor the dynamics of tumour responses to therapy
Chair(s): J. Seoane, ES; A. Sobrero, IT

11:00 - 11:05 Introduction
A. Sobrero, Genoa, IT

11:05 - 11:25 Biomarkers of the host
G. Coukos, Epalinges, CH

11:25 - 11:45 Circulating biomarkers to monitor patient responses
C. Dive, Manchester, GB

11:45 - 12:05 Patient derived models to select treatment
J. Seoane, Barcelona, ES

12:05 - 12:25 Using dynamic changes in inflammation to monitor tumour responses
P. Tume, Los Angeles, Ca, US

12:25 - 12:30 Conclusions and clinical perspectives
J. Seoane, Barcelona, ES



| | | |
|---------------|---|----------|
| 11:00 - 12:30 | Type: Special Symposium Title: Streamlining the equitable delivery of anti-cancer drugs: Sharing common grounds for a pan-European vision of value Chair(s): R. Giuliani, IT; A. Eniu, RO | Helsinki |
| 11:00 - 11:05 | Introduction <u>A. Eniu</u> , Cluj-Napoca, RO | |
| 11:05 - 11:20 | Equitable and affordable cancer care: Is Europe a union for real? <u>R. Sullivan</u> , London, GB | |
| 11:20 - 11:35 | How the European Commission's HTA initiative and the HTA network can promote consistent assessment of cancer care treatments in the EU <u>A. Rys</u> , Brussels, BE | |
| 11:35 - 11:50 | The EMA's initiatives to speed up access to valuable cancer drugs: Adaptive pathways and flexible approaches <u>F. Pignatti</u> , London, GB | |
| 11:50 - 12:05 | Industry's initiatives to reduce inequities and increase access to valuable cancer care: Myth or reality? <u>R. Bergstrom</u> , Brussels, BE | |
| 12:05 - 12:20 | ESMO's initiatives to reduce disparities in cancer care: Promoting access to valuable drugs focusing on the magnitude of benefit <u>E.G.E. de Vries</u> , Groningen, NL | |
| 12:20 - 12:30 | Conclusions and clinical perspectives <u>R. Giuliani</u> , Roma, IT | |
| 11:00 - 12:00 | Type: Poster Discussion session Title: Sarcoma Chair(s): X. Garcia del Muro, ES; M. Toulmonde, FR | Brussels |
| 11:00 - 11:00 | 1398PD - Epigenetic modulation in well differentiated (WD) and dedifferentiated (DD) liposarcoma (LPS): A novel therapeutic approach <u>A. Constantinidou</u> ¹ , J. Selfe ¹ , T. Khin ¹ , S. Popov ¹ , E. Missiaglia ² , E. Aladowicz ¹ , R. Al-Saadi ¹ , D. Olmos ³ , R. Jones ¹ , D. Strauss ¹ , A. Hayes ¹ , W. van der Graaf ¹ , I. Judson ¹ , J. Shipley ¹ ; ¹ London, GB, ² Lausanne, CH, ³ Madrid, ES | |
| 11:00 - 11:00 | 1399PD - PD1 and PDL1 expression, tumoral microenvironment (TME) characterization and clinical implication in localized osteosarcoma <u>E. Palmerini</u> , C. Agostinelli, P. Picci, S. Pileri, P. Lollini, K. Scotlandi, M.S. Benassi, S. Ferrari; Bologna, IT | |
| 11:00 - 11:00 | 1400PD - Anti-PD1 therapy with nivolumab in sarcoma | |



L. Paoluzzi¹, A. Cacavio², M. Ghesani², A. Karambelkar², A. Rapkiewicz², G. Rosen²; ¹New York, NY/US, ²New York, US

11:00 - 11:10 Invited discussant abstracts 1398PD, 1399PD and 1400PD

M. Toulmonde, Bordeaux, FR

11:10 - 11:20 Questions to discussant

11:20 - 11:20 1401PD - Subgroup analysis of leiomyosarcoma (LMS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced liposarcoma (LPS) and LMS

J.-Y. Blay¹, P. Schoffski², S. Bauer³, A. Krarup-Hansen⁴, C. Benson⁵, D. D'Adamo⁶, M. Guo⁶, R. Maki⁷; ¹Lyon, FR, ²Leuven, BE, ³Essen, DE, ⁴Gentofte, DK, ⁵London, GB, ⁶Woodcliff Lake, NJ/US, ⁷New York, NY/US

11:20 - 11:20 1402PD - Exposure-response of olaratumab for survival outcomes and safety when combined with doxorubicin in soft tissue sarcoma (STS) patients

R. Jones¹, G. Mo², J. Baldwin², R. Nichols², R. Ilaria², I. Conti², D. Cronier³, W. Tap⁴; ¹Indianapolis, Indiana/US, ²Indianapolis, US, ³Windlesham, GB, ⁴New York, US

11:20 - 11:30 Invited discussant abstracts 1401PD and 1402PD

X. Garcia del Muro, Barcelona, ES

11:30 - 11:40 Questions to discussant

11:40 - 11:40 1403PD - Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib

N. Lankheet, I. Desar, S. Mulder, D. Burger, C. van Herpen, W. van der Graaf, N. van Erp; Nijmegen, NL

11:40 - 11:40 1404PD - Regorafenib (R) versus placebo (P) in soft tissue sarcomas (STS): Analysis of genetic prognostic and predictive factors

T. Brodowicz¹, B. Liegl-Atzwanger², E. Tresch-Bruneel³, E. Bogart³, O. Mir⁴, J.-Y. Blay⁵, K. Kashofer², A. Le Cesne⁴, R. Hamacher¹, N. Penel³; ¹Vienna, AT, ²Graz, AT, ³Lille, FR, ⁴Villejuif, FR, ⁵Lyon, FR

11:40 - 11:40 1405PD - Circulating vascular endothelial growth factor (VEGF) as prognostic factor of progression-free survival in patients with advanced chordoma receiving sorafenib: An analysis from a phase II trial of the French Sarcoma Group (GSF/GETO)

L. Lebellec¹, F. Bertucci², E. Tresch-Bruneel¹, E. Bompas³, Y. Toiron², L. Camoin², O. Mir⁴, V. Laurence⁵, S. Clisant¹, E. Decoupligny¹, J.-Y. Blay⁶, A. Gonçalves², N. Penel¹; ¹Lille, FR, ²Marseille, FR, ³Saint-Herblain, FR, ⁴Villejuif, FR, ⁵Paris, FR, ⁶Lyon, FR

11:40 - 11:50 Invited discussant abstracts 1403PD, 1404PD and 1405PD

11:50 - 12:00 Questions to discussant



| | | |
|---------------|--|--------|
| 11:00 - 12:00 | Type: Poster Discussion session Title: Endocrine and neuroendocrine tumours | Berlin |
| 11:00 - 11:00 | 420PD - NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate: Efficacy, safety, QoL results and subgroup analysis <u>J. Strosberg</u> ¹ , E. Wolin ² , B. Chasen ³ , M. Kulke ⁴ , D. Bushnell ⁵ , M. Caplin ⁶ , R. Baum ⁷ , P. Kunz ⁸ , T. Hobday ⁹ , A. Hendifar ¹⁰ , K. Oberg ¹¹ , M. Lopera Sierra ¹² , D. Kwekkeboom ¹³ , P. Ruzsiewicz ¹⁴ , E. Krenning ¹³ ; ¹ Geneva, CH, ² Lexington, US, ³ Houston, US, ⁴ Boston, MA/US, ⁵ Indianapolis, IA/US, ⁶ London, GB, ⁷ Bad Berka, DE, ⁸ Palo Alto, CA/US, ⁹ Rochester, US, ¹⁰ Los Angeles, US, ¹¹ Uppsala, SE, ¹² New York, US, ¹³ Rotterdam, NL, ¹⁴ Clichy, FR | |
| 11:00 - 11:00 | 421PD - Impact of prior therapies on everolimus treatment in the subgroup of patients with advanced lung neuroendocrine tumors (NET) in the RADIANT-4 trial <u>R. Buzzoni</u> ¹ , G.D. Fave ² , J. Strosberg ³ , M. Voi ⁴ , A. Ridolfi ⁵ , L. Bubuteishvili-Pacaud ⁶ , F. Herbst ⁶ , E. Wolin ⁷ , N. Fazio ¹ ; ¹ Milano, IT, ² Roma, IT, ³ Tampa, FL/US, ⁴ East Hanover, NJ/US, ⁵ Rueil-Malmaison, FR, ⁶ Basel, CH, ⁷ Bronx, NY/US | |
| 11:00 - 11:00 | 422PD - Integrated placebo-controlled safety analysis from clinical studies of telotristat etiprate for the treatment of carcinoid syndrome <u>M. Kulke</u> ¹ , D. Hörsch ² , M. Caplin ³ , L. Anthony ⁴ , E. Bergsland ⁵ , K. Oberg ⁶ , S. Welin ⁶ , R. Warner ⁷ , C. Lombard Bohas ⁸ , P. Kunz ⁹ , E. Grande ¹⁰ , J. Valle ¹¹ , P. Lapuerta ¹² , P. Banks ¹² , S. Jackson ¹³ , W. Jiang ¹² , T. Biran ¹³ , M. Pavel ¹⁴ ; ¹ Boston, MA/US, ² Bad Berka, DE, ³ London, GB, ⁴ Lexington, KY/US, ⁵ San Francisco, CA/US, ⁶ Uppsala, SE, ⁷ New York, NY/US, ⁸ Lyon, FR, ⁹ Palo Alto, CA/US, ¹⁰ Madrid, ES, ¹¹ Manchester, GB, ¹² The Woodlands, TX/US, ¹³ The Woodlands, US, ¹⁴ Berlin, DE | |
| 11:00 - 11:00 | 423PD - Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs) <u>M. Gutierrez</u> ¹ , G. Giaccone ² , S. Liu ² , A. Rajan ³ , U. Guha ³ , T. Halfdanarson ⁴ , K. Curtis ⁵ , P. Kunz ⁶ , N. Gabrail ⁷ , J. Hinson ⁸ , E. Orlemans ⁹ ; ¹ Hackensack, NJ/US, ² Washington, DC/US, ³ Bethesda, MD/US, ⁴ Rochester, MN/US, ⁵ Scottsdale, AZ/US, ⁶ Palo Alto, CA/US, ⁷ Canton, OH/US, ⁸ Nashville, TN/US, ⁹ Indianapolis, IN/US | |
| 11:00 - 11:10 | Invited discussant abstracts 420PD, 421PD, 422PD and 423PD <u>R. Garcia Carbonero</u> , Madrid, ES | |
| 11:10 - 11:20 | Questions to discussant | |
| 11:20 - 11:20 | 424PD - Prevalence of gastroenteropancreatic and lung neuroendocrine tumours in the European Union <u>A. Bergamasco</u> ¹ , J. Dinet ² , A. Berthon ² , S. Gabriel ² , G. Nayroles ² , Y. Moride ¹ ; ¹ Paris, FR, ² Boulogne-Billancourt, FR | |



- 11:20 - 11:20 425PD - Multicentre evaluation of the role of Gallium DOTA-PET (GaPET) imaging in well differentiated bronchial carcinoids (BC): Impact on patients' (pts) management
A. Lamarca¹, D.M. Pritchard², T. Westwood¹, G. Papaxoinis¹, S. Vinjamuri², J. Valle¹, P. Manoharan¹, W. Mansoor¹; ¹Manchester, GB, ²Liverpool, GB
- 11:20 - 11:20 426PD - A population based analysis of outcome of chemotherapy for metastatic pulmonary large cell neuroendocrine carcinomas: Does the regimen matter?
J. Derks¹, R.J. van Suylen², E. Thunnissen³, M. Den Bakker⁴, H. Groen⁵, E. Smit³, R. Damhuis⁶, E.-J. Speel¹, A.-M. Dingemans¹; ¹Maastricht, NL, ²s-Hertogenbosch, NL, ³Amsterdam, NL, ⁴Rotterdam, NL, ⁵Groningen, NL, ⁶Utrecht, NL
- 11:20 - 11:30 Invited discussant abstracts 424PD, 425PD and 426PD
E. Baudin, Villejuif, FR
- 11:30 - 11:40 Questions to discussant
- 11:40 - 11:40 427PD - Pediatric, adolescent and young adult (PAYA) thyroid carcinoma harbors frequent and diverse targetable genomic alterations including kinase fusions
P. Vanden Borre¹, A. Schrock², P. Anderson³, A. Heilmann¹, O. Holmes², K. Wang¹, S. Khan⁴, J. Morris⁵, S.-H.I. Ou⁶, S. Waguespack⁷, P. Stephens¹, R. Erlich², V. Miller¹, J. Ross⁸, S. Ali¹; ¹Cambridge, MA/US, ²Cambridge, US, ³Cleveland, US, ⁴Dallas, TX/US, ⁵Cincinnati, US, ⁶Orange, CA/US, ⁷Houston, TX/US, ⁸Albany, NY/US
- 11:40 - 11:40 428PD - Damaging germline variants in TSC2 are frequently found among nonsyndromic patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NETs)
R. Linck, P. Asprino, F. Freitas, F. Koyama, P. Galante, R. Riechelmann, L. Reis, F. Costa, P. Hoff, A. Camargo, J. Sabbaga; Sao Paulo, BR
- 11:40 - 11:50 Invited discussant abstracts 427PD and 428PD
- 11:50 - 12:00 Questions to discussant



| | | |
|---------------|---|--------|
| 11:00 - 12:30 | Type: Special Session Title: Reporting clinical trials: Faculty of principles of clinical trials and systemic therapy Chair(s): C. Dittrich, AT; D. Lacombe, BE | Bern |
| 11:00 - 11:05 | Introduction <u>C. Dittrich</u> , Vienna, AT | |
| 11:05 - 11:20 | Improving the reporting of adverse events <u>B. Seruga</u> , Ljubljana, SI | |
| 11:20 - 11:35 | Unplanned versus pre-specified subgroup analysis reporting <u>D. Altman</u> , Oxford, GB | |
| 11:35 - 11:50 | Quality of meta-analyses and why they sometimes lead to different conclusions <u>J.-P. Pignon</u> , Villejuif, FR | |
| 11:50 - 12:05 | Early reporting of efficacy endpoints and its potential impact: Biostatistical part <u>J. Bogaerts</u> , Brussels, BE | |
| 12:05 - 12:20 | Early reporting of efficacy endpoints and its potential impact: Clinical part <u>F. Cardoso</u> , Lisboa, PT | |
| 12:20 - 12:30 | Conclusions <u>D. Lacombe</u> , Brussels, BE | |
| 11:00 - 12:00 | Type: Young Oncologist Brunch Title: What makes a good review article? The Editors perspective Chair(s): N. Volkov, RU; S. Postel-Vinay, FR | Lisbon |
| 11:00 - 11:20 | Original articles <u>O. Mir</u> , Villejuif, FR | |
| 11:20 - 11:40 | Review <u>C. Zielinski</u> , Vienna, AT | |
| 11:40 - 12:00 | Interactive discussion with audience | |



| | | |
|---------------|---|------------|
| 11:15 - 12:50 | Type: Special Session Title: Right or left metastatic colon cancer: Will the side change your treatment? | Copenhagen |
| 11:15 - 11:20 | Introduction <u>F. Ciardiello</u> , Napoli, IT | |
| 11:20 - 11:35 | Sidedness in colon cancer <u>H.-J. Lenz</u> , Los Angeles, US | |
| 11:35 - 11:50 | Outcome according to Left vs. Right side in the Panitumumab studies <u>M. Peeters</u> , Edegem, BE | |
| 11:50 - 12:00 | Outcome according to Left vs. Right side in the FOLFIRI Cetuximab and FIRE 3 study <u>V. Heinemann</u> , München, DE | |
| 12:00 - 12:10 | Outcome according to Left vs. Right side in the FOLFIRI Cetuximab in CRYSTAL study <u>E. Van Cutsem</u> , Leuven, BE | |
| 12:10 - 12:25 | Outcome in the CALGB 80405 <u>A. Venook</u> , San Francisco, US | |
| 12:25 - 12:35 | Pro discussion <u>D. Arnold</u> , Freiburg, DE | |
| 12:35 - 12:45 | Contra discussion <u>A. Cervantes</u> , Valencia, ES | |
| 12:45 - 12:50 | Conclusions <u>J. Tabernero</u> , Barcelona, ES | |
| 13:00 - 13:45 | Type: Keynote lecture Title: The patient journey: Is cancer cure around the corner? Chair(s): <u>F. Ciardiello</u> , IT | Vienna |
| 13:00 - 13:45 | The patient journey: Is cancer cure around the corner? <u>J.-C. Soria</u> , Villejuif, FR | |
| 13:00 - 14:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium | Stockholm |
| 13:00 - 14:30 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Madrid |



| | | |
|---------------|---|----------|
| 13:00 - 14:30 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium | Oslo |
| 13:00 - 14:30 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium | Rome |
| 13:00 - 14:30 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium | Athens |
| 13:00 - 14:30 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Helsinki |
| 13:00 - 14:30 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Brussels |
| 13:00 - 14:30 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Berlin |
| 13:00 - 14:30 | Type: Patient Advocacy Track Title: The Hans Keulen Memorial Debate - Palliative care: Is it suffering from an identity crisis? Chair(s): S. Rauh, LU; K. Oliver, GB | Zagreb |
| 13:00 - 14:00 | Moderated discussion <u>K. Oliver</u> ¹ , <u>S. Rauh</u> ² ; ¹ Surrey, GB, ² Esch-Sur-alzette, LU | |
| 14:00 - 14:30 | Special guests <u>J. Temel</u> ¹ , <u>N. Cherny</u> ² , <u>A.-M. Stevens Macmillan</u> ³ ; ¹ Boston, Ma, US, ² Jerusalem, IL, ³ London, GB | |
| 13:00 - 14:00 | Type: Poster Display Title: Poster display | Hall E |
| 13:00 - 13:00 | Basic Science | |
| 13:00 - 13:00 | 3P - Dissecting the roles of Fra proteins in lung adenocarcinoma <u>A. Alfraidi</u> , L. Bakiri, A. Uceru, M. Musteanu, M. Barbacid, E. Wagner; Madrid, ES | |
| 13:00 - 13:00 | 4P - Metallothionein 1H functions as a tumor suppressor in hepatocellular carcinoma <u>Y. Zheng</u> ¹ , L. Jiang ¹ , N. Xu ¹ , C. Xiao ¹ , Y. Hu ¹ , X. Wang ¹ , L. Chen ² , H. Fang ¹ , J. Zhu ¹ ; ¹ Hangzhou, CN, ² Taizhou, CN | |
| 13:00 - 13:00 | 5P - AMPKalpha1 restrains fibroblasts transformation and tumorigenesis in vivo <u>P. Song</u> , Y. Ding, Q. Lu, M.-H. Zou; Atlanta, GA/US | |



- 13:00 - 13:00 6P - The antitumor activity of lenvatinib (LEN) in combination with everolimus (EVE) in human renal cell carcinoma (RCC) xenograft models is dependent on VEGFR and FGFR signaling
T. Kimura¹, Y. Adachi², M. Matsuki², A. Yamaguchi², Y. Ozawa¹, K. Okamoto¹, K. Mitsunashi¹, T. Hoshi¹, O. Tohyama¹, K. Tai¹, M. Ogo¹, J. Matsui¹, Y. Funahashi¹; ¹Tsukuba, JP, ²Ibaraki, JP
- 13:00 - 13:00 7P - Identification of novel CRC pathway genes in familial CRC
M.S. Lung, A. Trainer, I. Campbell; East Melbourne, VIC/AU
- 13:00 - 13:00 8P - Efficacy of osimertinib in combination with Hedgehog pathway inhibitors in reverting T790M-mediated resistance
G. Esposito, C.M. Della Corte, F. Papaccio, G. Viscardi, M. Fasano, T. Troiani, E. Martinelli, F. Ciardiello, F. Morgillo; Napoli, IT
- 13:00 - 13:00 9P - SYM004, a novel generation anti-EGFR inhibitor, is able to overcome acquired resistance to cetuximab such as MET activation, ERBB2 amplification and EGFR mutations, in colorectal cancer models
S. Napolitano, V. Belli, M.D. Castellone, A. Parascandolo, E. Martinelli, G. Martini, C. Cardone, F. Morgillo, M. Orditura, F. Ciardiello, T. Troiani; Napoli, IT
- 13:00 - 13:00 10P - Efficacy of sequential treatment with first, second and third generation EGFR inhibitors and role of Hedgehog pathway in the acquisition of resistance in in vivo NSCLC models
C.M. Della Corte, F. Papaccio, G. Viscardi, G. Esposito, M. Fasano, M.D. Castellone, A. Parascandolo, F. De Vita, M. Orditura, F. Ciardiello, F. Morgillo; Napoli, IT
- 13:00 - 13:00 11P - Recombinant AAV gene therapy for the treatment of EGFR positive lung cancer
K. Zaki¹, L. Agundez², B. Sanchez³, M. Linden², E. Henckaerts², Y. Takeuchi², M. Collins¹; ¹Potters Bar, GB, ²London, GB, ³Havana, CU
- 13:00 - 13:00 12P - Reversion of mesenchymal behaviour by AZD9291 (osimertinib) in EGFR mutant NSCLC cell lines resistant to first generation EGFR tyrosine kinase inhibitors
B. Savastano, C.M. Della Corte, F. Papaccio, V. Giuseppe, G. Esposito, M. Fasano, M. Orditura, F. De Vita, F. Ciardiello, F. Morgillo; Napoli, IT
- 13:00 - 13:00 13P - Efficacy of second and third generation EGFR tyrosine kinase inhibitors, alone or in combination, in T790M-mediated resistance
F. Papaccio, C.M. Della Corte, G. Viscardi, G. Esposito, M. Fasano, F. De Vita, M. Orditura, F. Ciardiello, F. Morgillo; Napoli, IT
- 13:00 - 13:00 14P - Inhibition of PI3K pathway improves anti HER2 treatment efficacy in a panel of HER2 positive gastric cancer cell lines
V. Gambardella, M. Llorca-Cardeñosa, J. Castillo, N. Tarazona Llaverro, M. Huerta, S. Roselló Keränen, M. Ibarolla-Villava, G. Ribas, A. Gil, A. Cervantes; Valencia, ES
- 13:00 - 13:00 15P - HER2 activation and epithelial-mesenchymal transition (EMT) are involved in the acquired resistance to cetuximab in combination with either regorafenib or refametinib
P.P. Vitiello, G. Martini, V. Belli, C. Cardone, V. Sforza, M. Ferrara, S. Napolitano, C.M. Della Corte, N. Zanaletti, P. Vitale, L. Pompella, F. Morgillo, T. Troiani, F. Ciardiello, E. Martinelli; Napoli, IT
- 13:00 - 13:00 16P - A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediated to cytotoxic T lymphocytes in lung cancer



M. Xie, Y. Gu; Guangzhou, CN

- 13:00 - 13:00 17P - The regulation of PD-L1 in non small cell lung cancer
S. Funaki, Y. Shintani, E. Fukui, T. Kawamura, T. Kimura, R. Kanzaki, M. Minami, M. Okumura; Osaka, JP
- 13:00 - 13:00 18P - PD-L1 pathway activation as an escape mechanism of resistance to MEK inhibitor treatment in a human colorectal cancer model
S. Napolitano, B. Valentina, E. Martinelli, V. Sforza, P.P. Vitiello, F. De Vita, N. Zanaletti, P. Vitale, D. Ciardiello, F. Morgillo, F. Ciardiello, T. Troiani; Napoli, IT
- 13:00 - 13:00 19P - microRNA-145 promotes differentiation in human urothelial carcinoma through down-regulation of syndecan-1
T. Fujii¹, Y. Tatsumi², K. Fujimoto³, N. Konishi²; ¹Nara, 634-8522/JP, ²Nara, JP, ³Kashihara, JP
- 13:00 - 13:00 20P - Analysis of miRNA expression profile induced by zoledronic acid in breast cancer cells
D. Fanale, V. Amodeo, L. Insalaco, L. Incorvaia, A. Listi, V. Calò, V. Bazan, A. Russo; Palermo, IT
- 13:00 - 13:00 21P - MiR-340 inhibits breast cancer cell progression by revering EZH2 mediated miRNAs dysregulated expression
Z. Shi, J. Zhang; Tianjin, CN
- 13:00 - 13:00 22P - microRNA-331-3p inhibits cell proliferation and E7 expression by targeting NRP2 in cervical cancer
T. Fujii¹, Y. Tatsumi², N. Konishi²; ¹Nara, 634-8522/JP, ²Nara, JP
- 13:00 - 13:00 23P - Radioresistance genes in head and neck cancer
A. Naghavi¹, Y. Kim², J. Caudell¹; ¹Tampa, US, ²Tampa, FL/US
- 13:00 - 13:00 24P - Cardiotoxic effects of the novel anti-ErbB2 agent ado trastuzumab emtansine
R. Iaffaioli, C. Coppola, G. Piscopo, G. Riccio, A. Rienzo, C. Maurea, A. Barbieri, C. De Lorenzo, N. Maurea; Napoli, IT
- 13:00 - 13:00 25P - Ranolazine partially blunts ado trastuzumab emtansine related cardiotoxicity
N. Maurea, C. Coppola, G. Piscopo, G. Riccio, A. Rienzo, C. Maurea, A. Barbieri, C. De Lorenzo, R. Iaffaioli; Napoli, IT
- 13:00 - 13:00 26P - Role of the Hedgehog pathway in preventing occurrence of resistance to first, second, third generation EGFR-TKIs in first line therapy of NSCLC models with EGFR activating mutations
G. Viscardi, C.M. Della Corte, F. Papaccio, G. Esposito, M. Fasano, E. Martinelli, T. Troiani, F. Ciardiello, F. Morgillo; Napoli, IT
- 13:00 - 13:00 27P - Hypoxia inducible factor prolyl hydroxylase 2 (PHD2) is a direct regulator of epidermal growth factor receptor (EGFR) signaling in breast cancer
N. Kozlova¹, M. Wottawa², D. Katschinski², G. Kristiansen³, T. Kietzmann¹; ¹Oulu, FI, ²Göttingen, DE, ³Bonn, DE
- 13:00 - 13:00 28P - The resistance mechanism of FGFR2 amplified gastric cancer cells against AZD4547, a fibroblast growth factor receptor inhibitor.



S.Y. Lee, Y. Jeong, Y. Na, J.L. Kim, D.H. Lee, S.C. Oh; Seoul, KR

- 13:00 - 13:00 29P - Anticancer activity of the mTOR inhibitor (everolimus) and dual mTORC1/mTORC2 Inhibitor (AZD2014) on mouse lymphocytic leukemia both in vitro and in vivo.
Y.-C. Su¹, H.-F. Liao², C.-C. Yu², Y.-C. Lin²; ¹Kaohsiung, TW, ²Chiayi, TW
- 13:00 - 13:00 30P - Transforming growth factor beta receptor (TGFβR) pathway is involved in ligand independent transactivation of AXL receptor in colorectal cancer (CRC) cell lines
E. Franzese, G. Martini, C. Cardone, T. Troiani, V. Sforza, M. Ferrara, V. Belli, P.P. Vitiello, S. Napolitano, N. Zanaletti, P. Vitale, F. De Vita, M. Orditura, F. Morgillo, F. Ciardiello, E. Martinelli; Napoli, IT
- 13:00 - 13:00 31P - Taselisib enhances effects of anti-microtubule chemotherapeutic agents in phosphatidylinositol 3-kinase (PI3Kα) mutant breast cancer cell lines
A. Diana, F. Morgillo, C.M. Della Corte, C. Di Mauro, V. Ciaramella, F. De Vita, F. Ciardiello, M. Orditura; Napoli, IT
- 13:00 - 13:00 32P - AXL activation can promote resistance to MEK inhibition in a model of colorectal cancer (CRC)
G. Martini, V. Belli, P.P. Vitiello, T. Troiani, C. Cardone, S. Napolitano, V. Sforza, M. Ferrara, F. Morgillo, D. Ciardiello, E. Giunta, F. Ciardiello, E. Martinelli; Napoli, IT
- 13:00 - 13:00 33P - Ipatasertib (GDC-0068), a novel Akt inhibitor, synergizes with anti-microtubule chemotherapeutic agents in human breast cancer cell lines
C.M. Della Corte, M. Orditura, A. Diana, C. Di Mauro, V. Ciaramella, F. De Vita, F. Ciardiello, F. Morgillo; Napoli, IT
- 13:00 - 13:00 34P - Co-expression of HGFR and CD133 cancer stem cell marker in subepithelial cells of chronically active ulcerative colitis
F. Sipos, Z. Tulassay, G. Múzes; Budapest, HU
- 13:00 - 13:00 35P - Association between polymorphisms in the leptin promoter and leptin receptor genes and cancer in a mediterranean population of the PREDIMED study
J. Ramirez Sabio, J. Sorlí, C. Ortega-Azorín, P. Carrasco, O. Portolés, E. Asensio, D. Corella; Valencia, ES
- 13:00 - 13:00 36P - Radiotherapy-induced apoptotic tumor cells stimulate proliferation of living tumor cells via caspase 3/7–PKCδ–Akt/p38 MAPK pathway
J. Cheng, L. Tian, Q. Huang; Shanghai, CN
- 13:00 - 13:00 37P - Association of IFNγ production and NK cytotoxicity in PBL of breast cancer patients
S. Radenkovic¹, V. Jurisic², R. Dzodic¹, G. Konjevic¹; ¹Belgrade, RS, ²Kragujevac, RS
- 13:00 - 13:00 38P - Antitumor immunity against hCGβ induced by a tumor cell vaccine modified with a fusion gene of hCGβ and polyarginines
Y. Zhang, C. Su, Y.-S. Wang, Y. Lu, Y.-Q. Wei; Chengdu, CN
- 13:00 - 13:00 39P - IL-6 induces and releasing of MMP-9 in murine bone marrow neutrophils by activating STAT3 pathway
X. Wu, B. Yan; Wuhan, CN



- 13:00 - 13:00 40P - Macrophage migration inhibitory factor (MIF) involvement in breast cancer cells metabolism: A 1H-NMR spectroscopy evaluation
V. Richard, R. Conotte, N. Kindt, S. Saussez, J.-M. Colet; Mons, BE
- 13:00 - 13:00 41P - The gelatinases-stimuli nanoparticles reverse docetaxel resistance and epithelial to mesenchymal transition in lung cancer cell line
Q. Liu, R. Li, H. Qian, B. Liu; Nanjing, CN
- 13:00 - 13:00 42P - A novel and unanticipated link between the Werner syndrome protein (WRN) and protein translation
J. Iglesias Pedraz¹, D. Fossati Jara², J. Araujo², J. Pinto², B. Li³, L. Comai³; ¹Lima, Lima/PE, ²Lima, PE, ³Los Angeles, CA/US
- 13:00 - 13:00 43P - Oncoguide system - A computerized self-learning interactive assistance system for the diagnosis and treatment of CML / MPN and MDS
D. Hempel¹, Y. Fischer²; ¹Donauwörth, DE, ²Karlsruhe, DE
- 13:00 - 13:00 44P - Genomic profile of Li-Fraumeni syndrome patients with adrenocortical carcinoma in childhood
F. Fortes¹, L. Canto¹, H. Kwasne¹, F. Marchi¹, P. Miranda¹, K. Andrade¹, K. Santiago¹, S. Rogatto², M.I. Achatz¹; ¹Sao Paulo, BR, ²Vejle, DK
- 13:00 - 13:00 45P - Proteomics-based system biology analyses unravel a functional structure with prognostic value
G. De Velasco¹, L. Trilla-Fuertes², A. Gámez-Pozo², M. Urbanowicz², G. Ruiz-Ares², J.M. Sepulveda², R. Manneh², B. Homet², I. Otero², P. Celiz², F. Villacampa², L. Paz-Ares², J. Fresno Vara², D. Castellano²; ¹Boston, US, ²Madrid, ES
- 13:00 - 13:00 46P - Effect of newly synthesized progesteron derivatives on apoptotic and metastatic pathway in MCF-7 breast cancer cells
S. Yahya, M. Abdelhalim, G. Elsayed, A. Othman; Cairo, EG
- 13:00 - 13:00 47P - A potential natural inhibitor in the autocrine regulation among ovarian stromal cell population & its translational implications
D. Ye¹, E. Smith¹, S. O'Toole², J. O'Leary², B. Hennessy², X.X. Xu¹; ¹Miami, FL/US, ²Dublin, IE
- 13:00 - 13:00 48P - Gender differences in functional activity of the thyroid gland in C57BL/6 mice in dynamics of transplantable B16/F10 melanoma growth
L. Vladimirova¹, V. Bandovkina², E. Franciyans², O. Kit², N. Cheryarina², I. Kaplieva², E. Islamova², A. Salatova², L. Sergostyants², M. Cherkes²; ¹Rostov-On-don, RU, ²Rostov On Don, RU
- 13:00 - 13:00 49P - Fused toes homolog (FTS) can be a target for Notch-mediated cancer stem cell survival in cervical cancer
W.-Y. Park¹, P. Subramaniana¹, J.-R. Yu²; ¹Cheong-Ju, KR, ²Chungju, KR
- 13:00 - 13:00 50P - Functional role of 4F2hc in pancreatic ductal adenocarcinoma



D. Bianconi, M. Herac, A. Gleiss, M. Unseld, R. Weigl, M. Schindl, W. Scheithauer, C. Zielinski, G. Prager; Vienna, AT

- 13:00 - 13:00 51P - Marine-derived bioactive compound MB-E5 as a cytotoxic agent in glioblastoma cell lines
S.Y. Cheng¹, W.-F. Chen¹, P.-J. Sung², Z.-H. Wen¹; ¹Kaohsiung, TW, ²Pingtung, TW
- 13:00 - 13:00 Biomarkers
- 13:00 - 13:00 59P - Genomic alterations in circulating tumor DNA (ctDNA) are associated with clinical outcomes in treatment-naïve metastatic castration-resistant prostate cancer (mCRPC) patients commencing androgen receptor (AR)-targeted therapy
A. Wyatt¹, M. Annala², K. Beja¹, S. Parimi¹, G. Vandekerckhove¹, E. Warner¹, M. Zulficar³, D. Finch⁴, C. Oja³, J. Vergidis⁵, M. Nykter², M. Gleave¹, K. Chi⁶; ¹Vancouver, BC/CA, ²Tampere, FI, ³Abbotsford, BC/CA, ⁴Kelowna, BC/CA, ⁵Victoria, BC/CA, ⁶Vancouver, CA
- 13:00 - 13:00 60P - Circulating free tumour-derived DNA (ctDNA) to detect EGFR mutation in patients (pts) with advanced NSCLC (aNSCLC): French subset analysis of the ASSESS study
M. Denis¹, M.P. Lafourcade², G. Le Garff³, C. Dayen⁴, L. Falchero⁵, P. Thomas⁶, C. Locher⁷, G. Fraboulet⁸, G. Oliviero⁹, M. Licour¹⁰, N. Normanno¹¹, M. Reck¹², O. Molinier¹³; ¹Nantes, FR, ²Angouleme, FR, ³St. Brieuc, FR, ⁴St Quentin, FR, ⁵Villefranche Sur Saone, FR, ⁶Gap, FR, ⁷Meaux, FR, ⁸Pontoise, FR, ⁹Longjumeau, FR, ¹⁰Courbevoie, FR, ¹¹Napoli, IT, ¹²Grosshansdorf, DE, ¹³Le Mans, FR
- 13:00 - 13:00 61P - Frequency and abundance of plasma T790M mutation associated with failure patterns of EGFR-mutant NSCLC treated with tyrosine kinase inhibitors
S. Zhang, L. Zhu, B. Xia, E. Chen, Q. Zhao, X. Chen, L. Wang, H. Jiang, S. Ma; Hangzhou, CN
- 13:00 - 13:00 62P - Ultra-sensitive mass spectrometry allows 33% increased detection of somatic EGFR T790M mutation in plasma cfDNA samples
R. Saffroy, V. Suybeng, N. Bosselut, J. Hamelin, M. Becker, P. Pham, C. Khoja, J.-F. Morère, A. Lemoine; Villejuif, FR
- 13:00 - 13:00 63P - Liquid biopsy testing in routine clinical management of advanced non-small cell lung cancer: Clinical validation in a single biopathology laboratory
A. Falk, M. Ilié, E. Long, V. Tanga, V. Lespinet, O. Bordone, M. Allegra, C. Ribeyre, J. Otto, M. Poudenx, C.-H. Marquette, V. Hofman, P. Hofman; Nice, FR
- 13:00 - 13:00 64P - Circulating cell-free DNA can predict relapse after resection of metastatic liver tumors from colorectal cancer
T. Iwai¹, T. Yamada¹, G. Takahashi¹, S. Matsumoto², M. Koizumi¹, S. Shinji¹, A. Matsuda², Y. Yokoyama¹, K. Hara¹, K. Takeda¹, M. Nakayama³, S. Kitano³, K. Ohta¹, E. Uchida¹; ¹Tokyo, JP, ²Chiba, JP, ³Saitama, JP
- 13:00 - 13:00 65P - Correlation of circulating tumor cells with myeloid-derived suppressive cells in the peripheral blood of patients with advanced small cell lung cancer
I. Messaritakis, A. Koutoulaki, D. Aggouraki, E.K. Vetsika, E. Politaki, S. Apostolaki, V. Georgoulis, A. Kotsakis; Heraklion, GR



- 13:00 - 13:00 66P - The development of a narrow target gene panel makes next generation sequencing effective for circulating free DNA analysis
U. Malapelle¹, C. Mayo², D. Rocco¹, M. Garzon², P. Pisapia¹, R. Sgariglia¹, C. De Luca¹, N. Ariza², F. Pepe¹, D. Espinosa², A. Bueno², M. González-Cao², N. Karachaliou², S. Viteri², M.A. Molina Vila², R. Rosell³, G. Troncone¹; ¹Napoli, IT, ²Barcelona, ES, ³Badalona, ES
- 13:00 - 13:00 (Withdrawn)
- 13:00 - 13:00 68P - Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients. Impact on biomarker testing
A. Romero, I. Nieto-Alcolado, C. Jiménez-Sánchez, V. Calvo de Juan, L. Gutierrez, M. Palka Kotlowska, M. Provencio, M. Torrente; Majadahonda, ES
- 13:00 - 13:00 69P - External quality assessment of EGFR testing in circulating DNA : A french pilot study
M. Denis¹, I. Rouquette², A. Morel³, C. Villalva⁴, A. Lespagnol⁵, C. Caumont⁶, P. Gueguen⁷, K. Durand⁸, C. Collin⁹; ¹Nantes, FR, ²Toulouse, FR, ³Angers, FR, ⁴Poitiers, FR, ⁵Rennes, FR, ⁶Bordeaux, FR, ⁷Brest, FR, ⁸Limoges, FR, ⁹Tours, FR
- 13:00 - 13:00 70P - Diagnostic performance of liquid biopsy for pancreatic solid lesion as alternative to endoscopic ultrasound-guided fine needle aspiration (EUS-FNA)
D. Sefrioui, F. Blanchard, P. Basile, E. Toure, C. Dolfus, L. Beaussire, N. Vasseur, A. Perdrix, A. Gangloff, L. Schwarz, F. Clatot, J.-J. Tuech, J.-C. Sabourin, T. Frebourg, P. Michel, F. Di Fiore; Rouen, FR
- 13:00 - 13:00 71P - Prospective analysis of CEA, CA19.9, circulating DNA (cDNA) and circulating tumor cells (CTC) in patients (pts) treated for a metastatic colorectal cancer (mCRC)_Results of COCA-COLON study
D. Sefrioui¹, N. Vasseur¹, E. Toure¹, F. Blanchard¹, J. Delacour¹, C. Thill¹, L. Beaussire¹, A. Gillibert¹, F. Ziegler¹, A. Gangloff¹, K. Bouhier-Leporrier², A.-C. Lefebvre², A. Parzy², M.-P. Gallais², F. Clatot¹, A. Perdrix¹, J.-C. Sabourin¹, T. Frebourg¹, P. Michel¹, F. Di Fiore¹; ¹Rouen, FR, ²Caen, FR
- 13:00 - 13:00 72P - Survivin gene expression in the primary tumor and circulating tumor cells – a new biomarker of tumor progression of breast cancer
Y. Shliakhtunou, Vitebsk, BY
- 13:00 - 13:00 73P - Evaluation of PD-1 and PD-L1 expression on CTCs isolated from non-small cell lung cancer (NSCLC) tumor patients
G. Kallergi¹, D. Aggouraki¹, P. Katsarlinos¹, E.K. Vetsika¹, E. Lagoudaki¹, F. Koinis¹, A. Koutsopoulos¹, V. Georgoulas¹, A. Kotsakis²; ¹Heraklion, GR, ²Athens, GR
- 13:00 - 13:00 74P - The level of soluble programmed death ligand-1 in lung cancer: An exploratory biomarker study
R. Geng¹, L. Pan², S. Guo², X. Jing², F. Shen², J. Xu², X. Zhang², D. Zhang³, X. Song²; ¹Taiyuan, Shanxi/CN, ²Taiyuan, CN, ³Newcastle, NSW/AU
- 13:00 - 13:00 75P - PD-L1 expression on circulating CD45(-) cells is an independent prognostic factor for overall survival (OS) in patients (Pts) across all stages of treatment-naïve lung cancer in a prospective, multicenter study



R. Graf¹, D. Lu¹, R. Krupa¹, J. Louw¹, L. Dugan¹, A. Jendrisak¹, S. Orr¹, K. Bethel¹, Y. Wang¹, M. Suraneni¹, M. Landers¹, D. Boffa², J. Nieva³, L. Bazhenova¹, M. Salazar², S. Makani¹, M. Magana¹, R. Dittamore⁴; ¹San Diego, CA/US, ²New Haven, CT/US, ³Los Angeles, CA/US, ⁴San Diego, US

- 13:00 - 13:00 76P - Molecular characterization of PDL1 status of circulating tumor cells (CTCs) isolated with a novel label-free inertial microfluidic system from patients (pts) with advanced cancers
J. Fraser-Fish, Z. Ahmad, R. Kumar, B. Ebbs, G. Fowler, P. Flohr, M. Crespo, M. Ahmed, S. Papat, J. Bhosle, U. Banerji, M. O'Brien, J. de Bono, T. Yap; London, GB
- 13:00 - 13:00 77P - Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC
M. Kowanetz¹, W. Zou¹, D. Shames¹, C. Cummings¹, N. Rizvi², A. Spira³, G. Frampton⁴, V. Leveque¹, S. Flynn¹, S. Mocchi¹, G. Shankar¹, R. Funke¹, M. Ballinger¹, D. Waterkamp⁵, A. Sandler⁵, G. Hampton¹, L. Amler¹, P. Hegde¹, M. Hellmann⁶; ¹South San Francisco, CA/US, ²New York, NY/US, ³Fairfax, VA/US, ⁴Cambridge, US, ⁵South San Francisco, US, ⁶New York, US
- 13:00 - 13:00 78P - PD-L1 expression assessment in Non-Small-Cell Lung Cancer shows stability on Ventana's XT Benchmark platform – "Harmonization study".
T. Neuman¹, G. Vainer²; ¹Jerusalem, IL, ²Tel Aviv, IL
- 13:00 - 13:00 79P - CREBBP alterations found in extreme responders to PD-1 inhibition in patients (pts) with refractory solid tumors treated in a phase 1 trials unit
V. Boni, J. Garcia-Donas, E. Garralda, C. Muñoz Sanchez-Miguel, A. Calles, J.F. Rodriguez-Moreno, E. Calvo; Madrid, ES
- 13:00 - 13:00 80P - Dynamics of neutrophil to lymphocyte ratio (NLR) predict effectiveness of PD1/PDL1 inhibition
M. Moschetta¹, B. Kasenda², G. Mak¹, M. Voskoboynik¹, N. Martynyuk¹, S. Rafii³, V. Formica⁴, H.-T. Arkenau¹; ¹London, GB, ²Basel, CH, ³Manchester, GB, ⁴Roma, IT
- 13:00 - 13:00 81P - PD-L1 expression and tumor immune-cell infiltration in non-small cell lung cancer from HIV-infected patients
M. Wislez¹, C. Domblides², M. Antoine¹, C. Hamard¹, N. Rabbe¹, A. Rodenas¹, T. Vieira¹, P. Créquit¹, J. Cadranel¹, A. Lavolé¹; ¹Paris, FR, ²Bordeaux, FR
- 13:00 - 13:00 82P - Biomarkers in cancer immunotherapy: Analysis of clinical, histological and immunohistochemical factors associated with PD-L1 status
A. Bellesoeur¹, C. Massard², J.-C. Soria²; ¹Paris, FR, ²Villejuif, FR
- 13:00 - 13:00 83P - Predictive/prognostic value of circulating regulatory T cell subset in untreated non-small lung cancer patients
E.K. Vetsika¹, F. Koinis¹, A. Katsarou¹, M. Gioulbasani¹, D. Aggouraki¹, N. Kentepozidis², V. Georgoulis¹, A. Kotsakis¹; ¹Heraklion, GR, ²Athens, GR
- 13:00 - 13:00 84P - Prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in triple-negative breast cancers (TNBC) treated with neoadjuvant chemotherapy (NAC)



C. Herrero-Vicent, A. Guerrero, J. Gavilá, F. Gozalbo, S. Blanch, A. Hernández, S. Sandiego, A. Calatrava, V. Guillem, A. Ruiz; Valencia, ES

- 13:00 - 13:00 85P - Correlation of intratumoral CD8(+) T-cells, neutrophils and eosinophils frequency with morphological characteristics and clinical outcome of gastrointestinal adenocarcinomas
N. Beliak, S. Kutukova, G. Manikhas, G. Raskin; Saint Petersburg, RU
- 13:00 - 13:00 86P - Serum interleukin-6 as a prognostic biomarker for survival in patients with unresectable pancreatic cancer
I. Chen¹, C. Dehlendorff², P. Pfeiffer³, B. Jensen¹, S.E. Nielsen⁴, N.H. Holländer⁵, M. Yilmaz⁶, J. Johansen¹; ¹Herlev, DK, ²Copenhagen, DK, ³Odense C, DK, ⁴Hillerod, DK, ⁵Naestved, DK, ⁶Aalborg, DK
- 13:00 - 13:00 87P - Biomarker analysis to predict the pathological response of locally advanced gastric cancer to neoadjuvant chemotherapy: An exploratory study of the randomized phase II COMPASS trial
K. Tanabe¹, T. Yoshikawa², T. Oshima², Y. Miyagi², S. Morita³, K. Nishikawa⁴, Y. Ito⁵, T. Matsui⁶, Y. Kimura⁷, T. Aoyama², T. Hayashi², T. Ogata², H. Cho², A. Tuburaya², J. Sakamoto⁵; ¹Hiroshima, JP, ²Yokohama, JP, ³Kyoto, JP, ⁴Osaka, JP, ⁵Nagoya, JP, ⁶Okazaki, JP, ⁷Sakai, JP
- 13:00 - 13:00 88P - Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients
A. Zick, T. Peretz, M. Lotem, A. Hubert, D. Katz, M. Temper, Y. Rottenberg, B. Uziely, H. Nechushtan, A. Meirovitz, A. Sonnenblick, E. Sapir, D. Edelman, Y. Goldberg, A. Lossos, S. Rosenberg, I. Fried, R. Finkstein, E. Pikarsky, H. Goldshmidt; Jerusalem, IL
- 13:00 - 13:00 89P - A large-scale mCRC study shows that tumor location is associated with RAS/BRAF mutation status and clinical outcome
N. Boeckx¹, A. Toler², K. Op de Beeck¹, G. Kafatos³, V. Deschoolmeester¹, C. Rolfo⁴, K. Lowe⁵, G. Van Camp¹, G. Demonty⁶, M. Peeters⁴; ¹Antwerp, BE, ²Thousand Oaks, CA/US, ³Uxbridge, GB, ⁴Edegem, BE, ⁵Seattle, WA/US, ⁶Zug, CH
- 13:00 - 13:00 90P - The prognostic impact of RAS and RAF serum mutations in localized colon cancer
C. Thomsen, A. Appelt, R. Andersen, J. Lindebjerg, L.H. Jensen, A. Jakobsen; Vejle, DK
- 13:00 - 13:00 91P - Implications of key differences across 12 KRAS mutation detection technologies and their relevance in clinical practice
J. Sherwood¹, A. Rettino², H. Brown¹, A. Schreieck³, B. Claes⁴, G. Clark¹, B. Agrawal⁵, R. Chaston⁶, P. Choppa⁷, A. Nygren⁸, A. Kohlman¹; ¹Cambridge, GB, ²Birmingham, GB, ³Martinsried, DE, ⁴Mechelen, BE, ⁵Singapore, SG, ⁶Newcastle Upon Tyne, GB, ⁷Wset Sacramento, CA/US, ⁸San Diego, CA/US
- 13:00 - 13:00 92P - Impact of Kras mutant subtypes on PD-L1 expression in lung adenocarcinoma
A. Falk¹, N. Yazbeck¹, L. Thon¹, N. Guibert², V. Hofman¹, K. Zahaf¹, V. Lespinet¹, O. Bordone¹, V. Tanga¹, K. Washetine¹, C. Cohen¹, N. Venissac¹, J. Mouroux¹, C.-H. Marquette¹, P. Brest¹, M. Ilié¹, P. Hofman¹; ¹Nice, FR, ²Toulouse, FR
- 13:00 - 13:00 93P - KRAS status and HER2 targeted treatment in advanced gastric cancer



E. Shinozaki, H. Osumi, K. Chin, D. Takahari, M. Ogura, T. Ichimura, T. Matsushima, T. Wakatsuki, I. Nakayama, K. Yamaguchi; Tokyo, JP

- 13:00 - 13:00 94P - An extended KRAS mutation test for the detection of 28 common mutations in FFPE and plasma specimens
J. Li, C. Hoepfner, S. Gan, A. Blair, K. Min, A. Sims, A. Tietz, M. Vinas, T.T. Rehage, K. Malhotra, H. Halait, V. Brophy; Pleasanton, CA/US
- 13:00 - 13:00 95P - Plasma YKL-40 as a biomarker for poor prognosis in patients with metastatic colorectal cancer treated with 3. line cetuximab and irinotecan
B. Jensen¹, K.-L. Spindler², I. Christensen¹, J. Schou³, D.L. Nielsen¹, A. Jakobsen⁴, E. Høgdall¹, P. Pfeiffer⁵, M. Yilmaz⁶, J. Johansen¹; ¹Herlev, DK, ²Aarhus C, DK, ³Copenhagen, DK, ⁴Vejle, DK, ⁵Odense C, DK, ⁶Aalborg, DK
- 13:00 - 13:00 96P - Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
G. Perkins, E. Fabre, V. Fallet, H. Blons, N. Pecuchet, V. Gounant, L. Gibault, E. Michel-Jeljeli, M. Antoine, E. Roux, M. Wislez, D. Le Corre, K. Leroy, R. Lacave, J. Taieb, J. Cadranet, P. Laurent-Puig; Paris, FR
- 13:00 - 13:00 97P - Chitinase activity can predict liver metastases in colorectal cancer in blood
Z. Song, Hangzhou, CN
- 13:00 - 13:00 98P - Genetic variations in the VEGF pathway as prognostic factors in stages II and III colon cancer
A.C. Virgili Manrique, P. Riera Armengol, J. Salazar Blanco, M. Tobeña, A. Sebio Garcia, M. Martín Richard, E. del Río Conde, N. Dueñas Cid, A. Vethencourt Casado, A. Barba Joaquín, M. Andrés Granyo, D. Paez; Barcelona, ES
- 13:00 - 13:00 99P - Clinical characteristics in colorectal cancer harboring BRAF V600E and non-V600E mutations
E. Shinozaki, Y. Miki, M. Ueno, M. Igarashi, K. Chin, D. Takahari, M. Ogura, T. Ichimura, I. Nakayama, H. Osumi, T. Wakatsuki, T. Matsushima, K. Yamaguchi; Tokyo, JP
- 13:00 - 13:00 100P - 5-fluorouracil degradation rate as a predictive toxicity biomarker in early stage gastrointestinal cancer
M. Roberto¹, A. Romiti¹, A. Botticelli¹, F.R. Di Pietro¹, L. Lionetto¹, G. Gentile², F. Mazzuca¹, R. Falcone¹, M. Occhipinti¹, S. Macrini¹, E. Anselmi¹, A. Petremolo¹, C.E. Onesti¹, M. Simmaco², P. Marchetti²; ¹Roma, IT, ²Rome, IT
- 13:00 - 13:00 101P - Predictive value of vascular endothelial growth factor A (VEGF-A) for bevacizumab-based treatments across advanced cancers: A meta-analysis based on eight phase III randomized control trials involving 4,523 patients
S. Tang, Y. Zhang, W. Liang, J. He; Guangzhou, CN
- 13:00 - 13:00 102P - Large scale DFNA5 methylation and expression analysis in primary breast adenocarcinoma using data from The Cancer Genome Atlas
L. Croes¹, M. Beyens², E. Franssen², A. Goepfert², M. Peeters³, P. Pauwels³, G. Van Camp², K. Op De Beeck²; ¹Antwerp, Antwerp/BE, ²Antwerp, BE, ³Edegem, BE



- 13:00 - 13:00 103P - Evaluation of the conversion rate in Ki-67, estrogen receptor (ER), progesterone receptor (PR) and HER2 between primary breast cancer and relapse and their value as a prognostic factor
I. Blancas López-Barajas, A. Muñoz, M. Legerén, F. Galvez, R. González, J.M. Jurado, C.J. Rodriguez, M. Delgado, B. Gonzalez Astorga, M. Yélamos, S. Sequero, V. Chacon; Granada, ES
- 13:00 - 13:00 104P - Evaluation of the association of HER family members with efficacy of trastuzumab therapy in metastatic breast cancer
A. Koutras¹, V. Kotoula², G. Kouvatseas³, C. Christodoulou³, D. Pectasides³, A. Batistatou³, M. Bobos³, E. Tsolaki³, K. Papadopoulou³, G. Pentheroudakis⁴, P. Papakostas³, S. Pervana³, K. Petraki³, S. Chrisafi³, E. Razis³, A. Psyri³, D. Bafaloukos³, K. Kalogeras³, H. Kalofonos³, G. Fountzilas²; ¹Patras, GR, ²Thessaloniki, GR, ³Athens, GR, ⁴Ioannina, GR
- 13:00 - 13:00 105P - Pathology of BRCA1- and BRCA2-associated breast cancers: Known and less known connections
F. Fostira¹, E. Fountzila², A. Vagena¹, P. Apostolou¹, I. Konstanta¹, C. Papadimitriou¹, E. Razis¹, C. Christodoulou¹, E. Timotheadou², V. Mollaki¹, M. Papamentzelopoulou¹, I.S. Vlachos¹, D. Yannoukakos¹, I. Konstantopoulou¹; ¹Athens, GR, ²Thessaloniki, GR
- 13:00 - 13:00 106P - Identification of breast cancer associated altered DNA methylation in peripheral blood using MALDI-TOF mass spectrometry
R. Yang, B. Burwinkel; Heidelberg, DE
- 13:00 - 13:00 107P - Evaluation of RAD50 as a prognostic marker of survival in breast cancer patients
K. Havrysh¹, V. Filonenko², I. Serebriiskii³, R. Kiyamova⁴; ¹Kiev, UA, ²Kyiv, UA, ³Philadelphia, PA/US, ⁴Kazan, RU
- 13:00 - 13:00 108P - HER2 based expression subpopulations in TNBC: Pathological aspects and clinical significance
S.M. Ilie¹, C. Desauw², M. Hebbar²; ¹Bucharest, RO, ²Lille, FR
- 13:00 - 13:00 109P - Genetic influence of EGFR-PI3K-mTOR pathway and other loci in triple-negative breast cancer
C. Cabrera¹, M.J. Arranz², M.L. Surrallés Calnge², A. Salas², X. Tarroch², L. Ibañez², A. Garcia², S. Gonzalez Jimenez², M. Campayo¹, L. Cirera²; ¹Barcelona, ES, ²Terrassa, ES
- 13:00 - 13:00 110P - Biomarkers for afatinib and dasatinib treatment in triple negative breast cancer
A. Canonici¹, M. Ibrahim¹, K. Fanning¹, M. Cremona¹, C. Morgan¹, B. Hennessy¹, F. Solca², J. Crown¹, N. O'Donovan¹; ¹Dublin, IE, ²Vienna, AT
- 13:00 - 13:00 111P - The prognostic impact of PI3K/AKT/mTOR pathway aberrations on luminal breast cancer patients
L. Kassem¹, T. Bachelot², I. Treilleux², C. Zhang², M. Le Romancer²; ¹Giza, EG, ²Lyon, FR
- 13:00 - 13:00 112P - 3-biomarker HRD score versus individual biomarker (LOH, TAI, LST) scores in platinum treated serous ovarian cancer (SOC)
J. Lanchbury¹, K. Timms¹, J. Reid¹, E. Stronach², A. Gutin¹, T. Krivak³, B. Hennessy⁴, J. Paul², R. Brown², R. Nix¹, Z. Sangale¹, E. Hughes¹, V. Abkevich¹, G. Mills⁴; ¹Salt Lake City, UT/US, ²London, GB, ³Pittsburgh, PA/US, ⁴Houston, TX/US



- 13:00 - 13:00 113P - Characteristics of homologous recombination deficiency (HRD) in paired primary and recurrent high-grade serous ovarian cancer (HGSOc)
J. Patel¹, J. Sehouli², K. Timms³, C. Solimeno³, J. Reid³, J. Lanchbury³, I. Braicu², S. Darb-Esfahani², M. Ganapathi¹, R. Ganapathi¹; ¹Charlotte, US, ²Berlin, DE, ³Salt Lake City, UT/US
- 13:00 - 13:00 114P - Prognostic biomarkers in locally advanced cervical cancer (Cx Ca) treated with chemoradiation (CRT)
Y. Kanjanapan¹, S. Deb², R. Young³, M. Bressel², L. Mileskin², D. Rischin³, M. Hofman², K. Narayan², S. Siva²; ¹Toronto, Ontario/CA, ²Melbourne, VIC/AU, ³Melbourne, AU
- 13:00 - 13:00 115P - The molecular landscape of genome instability in prostate cancer (PC)
K. Timms¹, J. Cuzick², C. Neff¹, J. Reid¹, C. Solimeno¹, Z. Sangale¹, D. Pruss¹, A. Gutin¹, J. Lanchbury¹, S. Stone¹; ¹Salt Lake City, UT/US, ²London, GB
- 13:00 - 13:00 116P - Correlation of mutant P53 protein expression and Ki67 index with tumor response to concurrent chemoradiation in locally advanced head and neck cancer
P. Shanmuga, K. Bhowmik, K. Periasamy; New Delhi, IN
- 13:00 - 13:00 117P - Evaluation of tumor- and stromal immune marker heterogeneity in non-small cell lung cancer
D. Casadevall Aguilar, L. Pijuan, S. Clave, A. Taus, A. Hernández, M. Lorenzo, S. Mojal, S. Menéndez, J. Albanell, M. Salido, E. Arriola; Barcelona, ES
- 13:00 - 13:00 118P - Hyponatremia and hypoalbuminemia as predictive factors for response to first line treatment for metastatic non-small cell lung cancer
A. Badawy¹, G. Khedr¹, A. Omar¹, S. Bae², W. Arafat¹, S. Grant³; ¹Alexandria, EG, ²Birmingham, AL/US, ³Winston Salem, NC/US
- 13:00 - 13:00 119P - NGS for precision medicine in non-small cell lung cancer: Challenges and opportunities
V. Mileyko¹, M. Ivanov², E. Novikova², E. Telysheva², P. Chernenko², V. Breder², K. Laktionov², A. Baranova³; ¹Novosibirsk, RU, ²Moscow, RU, ³Washington, US
- 13:00 - 13:00 120P - Detection of early genetic and epigenetic alterations in NSCLC by using mass spectrometry and pyrosequencing analysis
D. Furlan, N. Sahnane, N. Rotolo, F. Franzi, E. Nardecchia, F. Sessa, L. Dominioni, A. Imperatori; Varese, IT
- 13:00 - 13:00 121P - Screening of significant oncogenic changes in air pollution-related lung cancer in a Xuanwei County, China
M. Kanwal, X. Ding, C. Yi, Y. Huang; Kunming, CN
- 13:00 - 13:00 122P - Clinical efficacy of HER3 partners' inhibitors in ERBB3 mutated cancer patients
L. Verlingue¹, C. Massard², A. Hollebecque², E. Castanon Alvarez³, S. Postel-Vinay², E. Angevin², J.-P. Armand², S. Aspeslagh², A. Varga², B. Ratislav², A. Gazzah², J.-M. Michot², L. Lacroix², T. De Baere², A. Marabelle², J.-C. Soria²; ¹Paris, FR, ²Villejuif, FR, ³Pamplona, ES



- 13:00 - 13:00 123P - Signal transducer and activator of transcription-3 (STAT3) expression concordance in paired primary and metastatic colorectal cancers (mCRC)
D. Yokom¹, S. Sud², H. Marginean², T. Asmis², D. Jonker³, G. Martel³, A. Gown⁴, M. Daneshmand³, E.C. Marginean³, R. Goodwin³; ¹Toronto, ON/CA, ²Ottawa, CA, ³Ottawa, ON/CA, ⁴Seattle, WA/US
- 13:00 - 13:00 124P - Tandem repeat variation in HIC1 gene predicts outcome for oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer
S. Okazaki¹, F. Loupakis², M. Schirripa², S. Cao³, W. Zhang³, D. Yang³, Y. Ning³, M. Berger³, Y. Miyamoto³, M. Suenaga³, R. Gopez³, B.B. Borelli⁴, C. Cremolini⁴, A. Falcone⁴, S. Lonardi², L. Salvatore⁴, H. Uetake¹, T. Kawano¹, T. Helentjaris⁵, H.-J. Lenz³; ¹Tokyo, JP, ²Padova, IT, ³Los Angeles, US, ⁴Pisa, IT, ⁵Tucson, AZ/US
- 13:00 - 13:00 125P - Levels of miR-17, miR-21, miR-29a and miR-92 as recurrence markers after adjuvant chemotherapy in Nx lymph node status colon cancer patients
N. Conev¹, A. Konsoulova-Kirova¹, J. Kashlov¹, I. Tonev², I. Donev¹; ¹Varna, BG, ²Plovdiv, BG
- 13:00 - 13:00 126P - Comprehensive analysis of histone related modifications of formaldehyde fixed paraffin embedded and fresh frozen pancreatic tumor xenografts using LC-MS/MS
T. Kristl, M. Bauden, D. Ansari, R. Andersson, G. Marko-Varga; Lund, SE
- 13:00 - 13:00 127P - Immuno-histochemical assessment of hENT1 biomarker as a prognostic biomarker for patients undergoing gemcitabine-based chemotherapy for resected biliary tract cancers: A systematic review and meta-analysis
N. Bird, M. Elmasry, M. Elniel, S. Fenwick, H. Malik; Liverpool, GB
- 13:00 - 13:00 128P - Modulation of specificity protein 1 (SP1) is a novel therapeutic strategy for pancreatic cancer
J.S. Park, Y.S. Lee, D.S. Yoon; Seoul, KR
- 13:00 - 13:00 129P - Early-stage diagnosis of pancreatic cancer offers opportunity to improve overall patient survival
L. Dexlin Mellby¹, A. Holmér¹, C. Wingren¹, J. Johansen², S.E. Bojesen³, B.G. Nordestgaards⁵, C.A. Borrebaeck¹; ¹Lund, SE, ²Herlev, DK, ³Copenhagen, DK
- 13:00 - 13:00 130P - Novel genetic marker of diarrhea in renal cell carcinoma patients treated with sorafenib
F. Innocenti¹, A. Karabinos¹, A. Etheridge¹, C. Pena², D. Crona¹; ¹Chapel Hill, US, ²Whippany, NJ/US
- 13:00 - 13:00 131P - Molecular pathology of the 10q23.3-26.3 chromosome region in glioblastoma
E. Alekseeva, A. Tanas, E. Prozorenko, A. Zaytsev, O. Kirsanova, V. Strelnikov, D. Zaletayev; Moscow, RU
- 13:00 - 13:00 132P - Using diffusion-weighted MRI derived apparent diffusion coefficient as a predictive biomarker of tumor response in non-Hodgkin lymphoma
S. Kharuzhyk, E. Zhavrid, N. Sachivko; Minsk, BY
- 13:00 - 13:00 133P - Identification of an epigenetic biomarker predicting the response to therapy with APG101 in glioblastoma



M. Thiemann¹, C. Gieffers¹, C. Kunz¹, J. Sykora¹, C. Merz¹, H. Fricke¹, B. Wiestler², W. Wick¹; ¹Heidelberg, DE, ²München, DE

- 13:00 - 13:00 134P - APO010 sensitivity in relapsed multiple myeloma patients
A. Vangsted¹, P. Jensen², M. Madsen², P. Gimsing¹, T. Jensen³, A. Hansen³, A. Rasmussen¹, A. Nielsen², U. Buhl², H. Jandu¹, N. Brunner², B. Pratt², U. Frølund⁴, C. Helleberg⁵, N. Abildgaard¹, S. Knudsen³; ¹Copenhagen, DK, ²Hørsholm, DK, ³Scottsdale, AZ/US, ⁴Roskilde, DK, ⁵Herlev, DK
- 13:00 - 13:00 135P - ACE and CXCL10 as predictive biomarkers in the LEA study
J. De la Haba¹, E. Aranda Aguilar¹, S. Morales², J.A. García-Sáenz³, A. Guerrero⁴, N. Martínez³, A. Antón⁵, M. Muñoz⁶, M. Ramos⁷, M. Gil-Gil⁶, M. Margelí⁶, S. Servitja⁶, B. Bermejo⁴, J. Cruz⁸, A. Rodríguez Lescure⁹, M. Casas³, M. Sánchez-Aragó³, R. Caballero³, E. Carrasco³, M. Martín³; ¹Cordoba, ES, ²Lerida, ES, ³Madrid, ES, ⁴Valencia, ES, ⁵Zaragoza, ES, ⁶Barcelona, ES, ⁷A Coruna, ES, ⁸Santa Cruz, ES, ⁹Alicante, ES
- 13:00 - 13:00 136P - Serum phosphorylated neurofilament heavy subunit as a predictive marker of chemotherapy-induced cognitive impairment: A preliminary result
K. Kida¹, M. Sumitani¹, T. Ogata¹, R. Kotake¹, A. Natori², J. Hashimoto¹, H. Yamauchi¹, T. Yamauchi¹; ¹Tokyo, JP, ²Toronto, CA
- 13:00 - 13:00 137P - Paclitaxel-induced sensory peripheral neuropathy is associated with a SCN9A variant
Y. Tanabe, S. Shiraishi, D. Nishizawa, A. Hamada, J. Hasegawa, Y. Ozaki, N. Tamura, A. Shimomura, M. Yunokawa, K. Yonemori, T. Takano, H. Kawabata, K. Ikeda, K. Tamura, Y. Fujiwara, C. Shimizu; Tokyo, JP
- 13:00 - 13:00 138P - Improved efficacy response attributed to diagnostic selection – Interim results of the phase 1 experience from ALKA-372-001
J. Christiansen¹, S. Siena², E. Valtorta³, A. Johnson⁴, D. Murphy⁴, R. Shoemaker⁴, J. Lamoureux⁴, D. Luo⁴, R. Patel⁴, Z. Hornby⁴, P. Multani⁴, E. Chow Maneval⁴, M. Duca², F. Debraud²; ¹San Diego, US, ²Milano, IT, ³Milan, IT, ⁴San Diego, CA/US
- 13:00 - 13:00 139P - Levels of endogenous anti-beta-glucan IgG antibodies (ABA) predict clinical outcomes for imprime PGG: Evidence from phase 3 PRIMUS study in patients (pts) with metastatic colorectal cancer (mCRC)
M. Shum¹, J.T. Beck², J. Meyerhardt³, R. Patel⁴, M. Kochenderfer⁵, T. Crocenzi⁶, M. Patchen⁷, M. Gargano⁷, B. Ma⁷, J. Lowe⁷, J. Iglesias⁸; ¹Whittier, CA/US, ²Lafayetteville, AZ/US, ³Boston, MA/US, ⁴Bakersfield, CA/US, ⁵Roanoke, VA/US, ⁶Portland, OR/US, ⁷Eagan, MN/US, ⁸Oakville, CA
- 13:00 - 13:00 140P - Similarity-based automated evidence ranking for clinical interpretation of multigene diagnostic panels
I. Petak¹, C. Hegedus¹, Z. Binder¹, M. Peeters², C. Rolfo², G. Keri¹, R. Schwab¹, L. Urban³; ¹Budapest, HU, ²Edegem, BE, ³Matrahaza, HU
- 13:00 - 13:00 141P - Identification of baseline parameters associated with the inter-individual variability in cytidine deaminase serum activity, a key enzyme in the metabolism of pyrimidine analogue



R. Cohen¹, L.-H. Preta², A. Bessone², C. Narjoz², I. Nicolis², D. Desaulle², E. Curis², A. Cessot², O. Huillard², A. Thomas-Schoemann², M. Vidal², F. Goldwasser², J. Alexandre², B. Blanchet²; ¹Villejuif, FR, ²Paris, FR

- 13:00 - 13:00 143TiP - A biomarker-guided first-in-human trial of subcutaneous ALM201 in patients with solid tumours
A. El-Helali¹, R. Plummer², G. Jayson³, V. Coyle¹, C. Rogers³, M. D'Arcangelo², D. Graham¹, Y. Drew², A. Clamp³, J. McCann¹, A. McCavigan⁴, L. Knight⁴, N. McCabe⁴, K. Keating⁴, R. Dyer⁴, T. Harrison⁴, P. Harkin⁴, T. Robson¹, R. Kennedy¹, R. Wilson¹; ¹Belfast, GB, ²Newcastle Upon Tyne, GB, ³Manchester, GB, ⁴Craigavon, GB
- 13:00 - 13:00 Breast cancer, early stage
- 13:00 - 13:00 156P - Changes in breast cancer incidence may be attributed to implementation of all-national dispensarization: A population-based study from North-West Russia
L. Bakare, M. Valkov; Arkhangelsk, RU
- 13:00 - 13:00 157P - Accuracy and adequacy of pre-operative bracketing for therapeutic excision of non-palpable malignant breast lesions
S. Zeeshan, S. Khan; Karachi, PK
- 13:00 - 13:00 158P - Ultrasound-guided core needle biopsy could replace sentinel lymph nodes biopsy for patients with suspicious node positive breast cancer
R. Nakamura, N. Yamamoto, K. Fujisaki, R. Teranaka, T. Miyaki, D. Ikebe; Chiba, JP
- 13:00 - 13:00 159P - Endoscopy-assisted breast surgery for breast cancer: Updated results from study conducted by the Taiwan Endoscopic Breast Surgery Cooperative Group
Y.-L. Kuo¹, H.-W. Lai², C.-S. Hung³; ¹Tainan, TW, ²Changhua City, TW, ³Taipei, TW
- 13:00 - 13:00 160P - The role of preoperative breast magnetic resonance (MR) imaging for surgical decision in patients with triple-negative breast cancer
T.J. Kwon, H.Y. Park, J.H. Jung, W.W. Kim, S.O. Hwang, Y.S. Chae, S.J. Lee, J.-Y. Park, J.H. Chung, J. Lee; Daegu, KR
- 13:00 - 13:00 161P - What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
P.P. Bapsy, P. Maurya, S. Dhande, L. K. A. Kamath, C. Mudlapur, S.S. Holla, C. Patil; Bangalore, IN
- 13:00 - 13:00 162P - Menopausal status on tumour biology in early breast cancer
O. Ayodele¹, I. Ali¹, A. Konenko¹, L. Duggan¹, N. O'Mara¹, R. Rahman², Y. Ged², P. Calvert¹, A. Horgan¹, M. O'Connor¹; ¹Waterford, IE, ²Dublin, IE
- 13:00 - 13:00 163P - Breast cancer Ki67, tumor size and axillary nodes relationship: it's complicated
G. Bregni¹, E. Meneghini², G. Galli², S. Cavalieri², F. Di Salvo², H. Amash², B. Paolini², F. De Braud², M.C. De Santis², M. Sant², S. Di Cosimo²; ¹Genova, IT, ²Milano, IT



- 13:00 - 13:00 164P - The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients: An international multicentre hospital-based retrospective cohort study
M. Lambertini¹, A.C. Pinto², L. Ameye², L. Jongen³, L. Del Mastro¹, F. Puglisi⁴, F. Poggio¹, M. Bonotto⁴, G. Floris³, K. van Asten³, H. Wildiers³, P. Neven³, E. de Azambuja², M. Paesmans², H.A. Azim Jr.²; ¹Genova, IT, ²Brussels, BE, ³Leuven, BE, ⁴Udine, IT
- 13:00 - 13:00 165P - Tumor lymphocyte infiltrations decrease the risk of late relapse in breast cancer patients
C. Grasic Kuhar, B. Zakotnik; Ljubljana, SI
- 13:00 - 13:00 166P - The let-7/Lin28 can be an early detection marker of anti-HER2 containing therapy sensitivity in HER2 positive breast cancer
H. Takuwa, F. Sato, J. Itou, M. Toi; Kyoto, JP
- 13:00 - 13:00 167P - Clinicopathological characteristics and BRCA1/2 mutation rate in male breast cancer: A retrospective case series by the Hellenic Society of Medical Oncology
G. Lypas¹, D. Tryfonopoulos¹, E. Saloustros², P. Zacharopoulou¹, L. Florentin¹, A. Apeessos¹, E. Kabletsas¹, E. Prinarakis¹, V. Barbounis¹, G. Fountzilas³, D. Mavroudis², V. Georgoulas²; ¹Athens, GR, ²Heraklion, GR, ³Thessaloniki, GR
- 13:00 - 13:00 168P - Triple-negative breast cancer and BRCA mutation: Looking at the future
Z. Ballatore, M. Pistelli, R. Bracci, F. Bianchi, E. Maccaroni, L. Belvederesi, C. Brugiati, S. Pagliaretta, M. De Lisa, A. Della Mora, L. Cantini, L. Bastianelli, A. Pagliacci, N. Battelli, R. Berardi; Ancona, IT
- 13:00 - 13:00 169P - BRCA mutations and IGF-R1 expression in modulating sensitivity to trastuzumab in HER2-positive breast cancer
M. Pistelli¹, A. Santinelli¹, M. Santoni¹, F. Piva¹, F. Bianchi¹, L. Belvederesi¹, M. De Lisa¹, T. Biscotti¹, Z. Ballatore¹, G. Occhipinti¹, A. Pagliacci¹, E. Maccaroni¹, R. Bracci¹, N. Battelli¹, L. Cantini¹, L. Bastianelli¹, R. Berardi¹, S. Cascinu²; ¹Ancona, IT, ²Modena, IT
- 13:00 - 13:00 170P - Germline BRCA screening in breast cancer patients in Tatar women population
E. Shagimardanova¹, L. Shigapova¹, O. Gusev¹, A. Nikitin², M. Druzhkov¹, R. Enikeev¹, M. Gordiev¹; ¹Kazan, RU, ²Moscow, RU
- 13:00 - 13:00 171P - Transcriptomic stratification of breast carcinomas with double-equivocal HER2 status
C. Marchio¹, P. Dell'Orto², L. Annaratone¹, N. Rangel¹, A. Özgüzer³, L. Verdun Di Cantogno¹, A. Sapino³, G. Viale⁴; ¹Torino, IT, ²Milan, IT, ³Candiolo, IT, ⁴Milano, IT
- 13:00 - 13:00 172P - Screening for caspase activity combined with the ratio of T-cell subsets in the peripheral blood as potential diagnostic tool in breast cancer
U. Bagina¹, L. Shchegoleva², T. Volkova²; ¹Petrozavodsk, Republic of Karelia/RU, ²Petrozavodsk, RU
- 13:00 - 13:00 173P - Expression of androgen receptors in primary breast cancer
A. Ghannam, S. Galal, M. Ellity; Tanta, EG
- 13:00 - 13:00 174P - Immunohistochemical status of p53 as prognostic factor in patients with node negative triple-negative breast cancer



S.Y. Bae, J.E. Lee, S.K. Lee, S.J. Nam; Seoul, KR

- 13:00 - 13:00 175P - First prospective multicenter Italian study on the impact of the 21-gene recurrence score® (RS) in adjuvant clinical decisions for ER+/HER2- early breast cancer patients
M.V. Dieci¹, V. Guarneri², M. Mion³, G. Tortora⁴, P. Morandi⁵, S. Gori⁶, L. Merlini⁷, C. Olini⁸, F. Pasini⁹, G. Bonciarelli³, E. Orvieto¹, P. Del Bianco¹, G.L. De Salvo¹, P.F. Conte¹; ¹Padova, IT, ²Padua, IT, ³Camposampiero, IT, ⁴Verona, IT, ⁵Venezia-Mestre, IT, ⁶Negrar, IT, ⁷Vicenza, IT, ⁸Montecchio Maggiore, IT, ⁹Rovigo, IT
- 13:00 - 13:00 176P - Famosa: Evaluation of a multigene panel in patients with suspected HBOC
E. Adrover¹, I. Esteban², G. Llorca³, S. Servitja², S. Martinez Peralta⁴, I. Garau⁵, J. Cano⁶, R. Serrano⁷, M.J. Juan Fita⁸, A. Casas⁹, B. Graña¹⁰, A. Teulé¹¹, A. Marquez¹², J.E. Ales Martínez¹³, A. Antón¹⁴, J. Brunet¹⁵, F. Balaguer², J. Balmaña², S. Gonzalez¹⁶, C. Alonso¹⁷; ¹Albacete, ES, ²Barcelona, ES, ³Sabadell, ES, ⁴Mataro, ES, ⁵Palma De Mallorca, ES, ⁶Ciudad Real, ES, ⁷Cordoba, ES, ⁸Valencia, ES, ⁹Sevilla, ES, ¹⁰A Coruna, ES, ¹¹L'hospitalet De Llobregat, Barcelona, ES, ¹²Malaga, ES, ¹³Ávila, ES, ¹⁴Zaragoza, ES, ¹⁵Girona, ES, ¹⁶Cáceres, ES, ¹⁷Madrid, ES
- 13:00 - 13:00 177P - The impact of the 21-gene assay in the Czech Republic on adjuvant chemotherapy (CT) recommendations and costs in estrogen receptor positive (ER+) early stage breast cancer (ESBC) patients with grade 2 tumors and risk factors
K. Petrakova¹, L. Petruzelka², M. Holanek¹, T. Svoboda³, M. Palacova¹, Z. Bielcikova², Z. Zbozinkova¹; ¹Brno, CZ, ²Prague, CZ, ³Pizen, CZ
- 13:00 - 13:00 178P - Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: No correlation with clinico-pathological characteristics and outcomes
E. Curtit¹, X. Pivot², J. Henriques¹, S. Paget-Bailly¹, P. Fumoleau³, M. Rios⁴, H. Bonnefoi⁵, P. Soulie⁶, C. Jouannaud⁷, H. Bourgeois⁸, J.-Y. Pierga⁹, I. Tennevet¹⁰, V. Trillet-Lenoir¹¹, P. Kerbrat¹², T. Petit¹³, T. Bachelot¹¹, J.-F. Deleuze⁹, I. Pauporte¹⁴, G. Romieu¹⁵, D. Cox¹¹; ¹Besançon, FR, ²Besançon, CEDEX/FR, ³Dijon, FR, ⁴Vandoeuvre Les Nancy, FR, ⁵Bordeaux, FR, ⁶Angers, FR, ⁷Reims, FR, ⁸Le Mans, FR, ⁹Paris, FR, ¹⁰Rouen, FR, ¹¹Lyon, FR, ¹²Rennes, FR, ¹³Strasbourg, FR, ¹⁴Boulogne-Billancourt, FR, ¹⁵Montpellier, FR
- 13:00 - 13:00 179P - A nomogram for predicting the Oncotype DX recurrence score in women with T1-3N0-1miM0 hormone receptor-positive, human epidermal growth factor-2 (HER2)-negative breast cancer
S. Lee, Seoul, KR
- 13:00 - 13:00 180P - Use of Oncotype DX Recurrence Score® (RS) reduces chemotherapy (CT) beyond treatment decisions using Ki67-based determinations of luminal A and B breast cancer subtypes: A retrospective study in the Spanish population
L. Garcia-Estevez, E. Hernandez, D. Acosta, F. Lopez-Rios, M. Prieto Pozuelo, I. Calvo; Madrid, ES
- 13:00 - 13:00 181P - Budget impact analysis of the 21-gene assay (Oncotype DX® breast cancer) for the breast cancer treatment in the Basque country



M. Toribio¹, J. Mar², E. Galve³, I. Alvarez⁴, A. Lahuerta⁴, G. Unanue¹, O. Ibarondo², P. Novas³, N. Ancizar⁴, L. Larburu⁴, M. Hidalgo¹, J.F. Arango³, C. Churruca⁴, A. Plazaola⁴, I. Perez¹, P. Purificación Martínez del Prado³, S. Dominguez¹, A. Paisan⁴; ¹Vitoria, ES, ²Mondragón, ES, ³Bilbao, ES, ⁴San Sebastian, ES

- 13:00 - 13:00 182P - Patient-private disease evolution and heterogeneity in bilateral breast cancer
E. Fountzila¹, V. Kotoula¹, F. Zagouri², E. Giannoulataou³, G. Kouvatseas², G. Pentheroudakis⁴, T. Koletsa², M. Bobos², K. Papadopoulou², E. Samantas², E. Demiri², S. Miliaras², C. Christodoulou², S. Chrisafi², E. Razis², F. Fostira², D. Pectasides², G. Zografos², G. Fountzilas¹; ¹Thessaloniki, GR, ²Athens, GR, ³Darlinghurst, AU, ⁴Ioannina, GR
- 13:00 - 13:00 183P - Prospective evaluation of the impact of the 21-gene recurrence score® assay on adjuvant treatment decisions for women with node-positive breast cancer in Ontario, Canada
S. Torres¹, M. Trudeau², S. Gandhi², E. Warner², S. Verma¹, K. Pritchard¹, T. Petrella², E. Slodkowska², M. Hew-Shue², C. Chao³, A. Eisen²; ¹Toronto, CA, ²Toronto, ON/CA, ³Redwood City, CA/US
- 13:00 - 13:00 184P - Effects of HER2 immuno-histochemistry expression levels on survival in patients treated by trastuzumab at the adjuvant setting in the SIGNAL/PHARE prospective cohort
E. Curtit¹, A. Vincent-Salomon², S. Paget-Bailly¹, G. Romieu³, P. Fumoleau⁴, H. Bonnefoi⁵, C. Jouannaud⁶, T. Petit⁷, A. Darut-Jouve⁴, V. Trillet-Lenoir⁸, C. Tarpin⁹, J.-Y. Pierga², M. Rios¹⁰, J.P. Jacquin¹¹, T. Bachelot⁸, D. Cox⁸, J.-F. Deleuze², I. Pauporte¹², J. Henriques¹, X. Pivot¹³; ¹Besançon, FR, ²Paris, FR, ³Montpellier, FR, ⁴Dijon, FR, ⁵Bordeaux, FR, ⁶Reims, FR, ⁷Strasbourg, FR, ⁸Lyon, FR, ⁹Marseille, FR, ¹⁰Vandoeuvre Les Nancy, FR, ¹¹Saint Priest En Jarred, FR, ¹²Boulogne-Billancourt, FR, ¹³Besançon, CEDEX/FR
- 13:00 - 13:00 185P - Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
M.T. Martinez, M. Peña-Chilet, S.S. Oltra, J.A. Perez-Fidalgo, E. Alonso, O. Burgues, I. Chirivella Gonzalez, B. Bermejo, A. Lluch-Hernandez, G. Ribas; Valencia, ES
- 13:00 - 13:00 186P - P53 and ERCC1 gene polymorphisms can predict the recurrence risk of breast cancer
T. Kus, G. Aktas, M. Kalender, A. Sevinc, C. Camci; Gaziantep, TR
- 13:00 - 13:00 187P - Luminal androgen receptor role and pathological complete response rate to neoadjuvant chemotherapy in triple negative breast cancer
M. Chica-Parrado¹, A. Santonja¹, A. Lluch-Hernandez², J. Albanell³, A. Sanchez-Muñoz¹, I. Chacón⁴, L. Calvo⁵, P. Sanchez-Rovira⁶, J. De la Haba⁷, L. Vicioso¹, M. Martín⁸, A. Plazaola⁹, A. Prat³, N. Ribelles¹, M. Sánchez-Aragó⁸, J.M. Jerez¹, R. Caballero⁸, M. Escudero⁸, E. Alba Conejo¹, E. Carrasco⁸; ¹Malaga, ES, ²Valencia, ES, ³Barcelona, ES, ⁴Toledo, ES, ⁵A Coruna, ES, ⁶Jaen, ES, ⁷Cordoba, ES, ⁸Madrid, ES, ⁹San Sebastian, ES
- 13:00 - 13:00 188P - Intrinsic subtype and response to neoadjuvant chemotherapy with carboplatin and docetaxel (TCb) in triple-negative breast cancer (TNBC)



I. Echavarria Diaz-Guardamino¹, S. Lopez-Tarruella¹, J.A. Garcia-Sáenz¹, H. Gomez Moreno², F. Moreno¹, Y. Jerez¹, H. Fuentes², I. Marquez-Rodas¹, M. Cebollero¹, M. Del Monte-Millan¹, A. Picornell¹, T. Massarrah¹, A. Barnadas³, A. Prat³, A. Ballesteros Garcia¹, R. Colomer Bosch¹, B. Pelaez⁴, M. González-Rivera¹, C.M. Perou⁵, M. Martin¹; ¹Madrid, ES, ²Lima, PE, ³Barcelona, ES, ⁴Valladolid, ES, ⁵Chapel Hill, NC/US

- 13:00 - 13:00 189P - Breast cancer prognosis after neoadjuvant chemotherapy for breast cancers: Molecular downstaging, proliferation, and endocrine sensitivity importance
M.-A. Benders¹, S. Richard², M. Antoine², D. Buob², S. Zilberman², A. Esteso², J.P. Lotz², K. Kerrou², J. Gligorov²; ¹Villejuif, FR, ²Paris, FR
- 13:00 - 13:00 190P - Measurement of molecular biomarkers to predict tumor response in estrogen receptor positive breast cancer after dose-dense (biweekly) paclitaxel/carboplatin neoadjuvant chemotherapy
K. Wang, T. Zhu, C. Yang, Y. Zhang, L. Zhang; Guangzhou, CN
- 13:00 - 13:00 191P - Effect of body mass index (BMI) on response to neoadjuvant therapy in human epidermal growth factor receptor 2 (HER2) positive breast cancer (BC): Analysis from NeoALLTO trial
G. Galli¹, I. Bradbury², S. Cinieri³, D. Agbor-Tarh², F. De Braud¹, J. Baselga⁴, J. Huober⁵, D. Fumagalli⁶, S. Sarp⁷, M. Piccart⁶, E. de Azambuja⁶, S. Di Cosimo¹; ¹Milano, IT, ²Kincraig, GB, ³Brindisi, IT, ⁴New York, US, ⁵Ulm, DE, ⁶Brussels, BE, ⁷Basel, CH
- 13:00 - 13:00 192P - Effect of body mass index on pharmacokinetics of paclitaxel in women with early breast cancer
V. Gota, A. Bonda, A. Karanam, B. Shriyan, M. Gurjar, A. Patil, A. Singh, M. Nookala, S. Gupta; Mumbai, IN
- 13:00 - 13:00 193P - Effect of body mass index in the outcome of stage I-III triple negative breast cancer
M. Sendur, S. Aksoy, N. Ozdemir, O. Yazici, N. Zengin, K. Altundag; Ankara, TR
- 13:00 - 13:00 194P - Body mass index as a prognostic factor in operable breast cancer patients treated with adjuvant anthracyclines with or without taxanes
W. El-Sadda, M. El-Ibrashi, I. Abdel-Halim; Mansoura, EG
- 13:00 - 13:00 195P - Is there an impact of body mass index on the breast cancer stage at initial diagnosis?
O. Akkar, F. Mamouch, N. Berrada, M. El kabous, H. Errihani; Rabat, MA
- 13:00 - 13:00 196P - Efficacy of statin usage before diagnosis on clinico-pathological characteristics and outcome of invasive breast cancer
M. Sendur, S. Aksoy, N. Ozdemir, O. Yazici, B. Yalçın, N. Zengin, K. Altundag; Ankara, TR
- 13:00 - 13:00 197P - Effect of using different antihypertensive drugs on demographic and clinico-pathological characteristics of breast cancer
M. Sendur, S. Aksoy, N. Ozdemir, O. Yazici, M. Akıncı, D. Dede, B. Yalçın, N. Zengin, K. Altundag; Ankara, TR
- 13:00 - 13:00 198P - Effect of using different antidiabetic drugs on demographic and clinico-pathological characteristics of breast cancer
M. Sendur, S. Aksoy, O. Yazici, N. Ozdemir, D. Dede, M. Akıncı, B. Yalçın, N. Zengin, K. Altundag; Ankara, TR



- 13:00 - 13:00 199P - Impact of vitamin D3 replacement therapy on clinical outcomes and survival rates in patients with early stage breast cancer
O. Yazici, S. Aksoy, M. Sendur, N. Ozdemir, N. Zengin, K. Altundag; Ankara, TR
- 13:00 - 13:00 200P - Metformin anti-proliferative effect on a cohort of non-diabetic breast cancer patients
S. Sadighi¹, M. Saberian¹, M. Nagafi¹, I. Jahanzad¹, R. Omranipoor¹, B. Behrouzi²; ¹Tehran, IR, ²Toronto, ON/CA
- 13:00 - 13:00 201P - Dyslipidaemias after adjuvant chemotherapy in young Chinese breast cancer patients
W. Yeo, F. Mo, J. Suen, H. Loong, E. Pang, C. Yip, G. Liem; Shatin, HK
- 13:00 - 13:00 202P - Influence of adjuvant chemotherapy on anti-müllerian hormone (AMH) level in patients younger than 35 years treated for an early breast cancer (EBC)
M. Saint-Ghislain, F. Clatot, M. Degrémont, M. Leheurteur, M. David, C. Veyret, F. Di Fiore, A. Perdrix; Rouen, FR
- 13:00 - 13:00 203P - Follow-up of chemotherapy induced changes in anti-Mullerian hormone, antral follicle number and ovary volume in premenopausal breast cancer patients
F. Elbuken, C. Ordu, D. Sarsenov, S. Ilgun, K. Pilanci, Z. Erdogan, F. Agacayak, G. Alco, A. Ozturk, Y. Eralp, B. Baysal, V. Ozmen; Istanbul, TR
- 13:00 - 13:00 204P - Dual block versus single agent trastuzumab plus chemotherapy as neoadjuvant treatment of HER2-positive breast cancer: A meta-analysis of randomized trials
M. Clavarezza, M. Puntoni, A. Gennari, L. Paleari, N. Provinciali, M. D'Amico, A. Decensi; Genova, IT
- 13:00 - 13:00 205P - Individual approach to the planning of neoadjuvant chemotherapy (NAC) in patients with luminal B breast cancer
P. Kazantseva, E. Slonimskaya, N. Litviakov, M. Tsyganov; Tomsk, RU
- 13:00 - 13:00 206P - Bevacizumab plus dose-dense neoadjuvant FEC followed by docetaxel chemotherapy in patients with HER2-negative breast cancer: A multicentre, phase 2 study by the Hellenic Oncology Research Group
E. Saloustros¹, I. Boukovinas², K. Kalbakis³, P. Katsaounis⁴, A. Ardavanis³, L. Vamvakas³, K. Papazisis³, E. Prinarakis³, T. Skaltsi³, V. Georgoulis¹, D. Mavroudis¹; ¹Heraklion, GR, ²Thessaloniki, GR, ³Athens, GR, ⁴Cholargos, GR
- 13:00 - 13:00 207P - Survival impact of adjuvant chemotherapy in screening breast cancer
I. Zarcos Pedrinaci¹, A. Romero², J. Louro², M. Banqué², M. Vernet², L. Serrano², R. Funez¹, F. Medina¹, D. Perez¹, A. Rueda¹, M. Sala², M. Redondo¹; ¹Malaga, ES, ²Barcelona, ES
- 13:00 - 13:00 208P - Delayed initiation of HER2-targeted therapy (HER2Tx) is associated with a higher risk of relapse for early stage (ES) HER2-positive (HER2+) breast cancer (BrCa)
G. Gullo, R. Bose, N. Walsh, M. Maltese, D. Fennelly, J. Walshe, J. Ballot, J. Crown; Dublin, IE
- 13:00 - 13:00 209P - Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study



X. Pivot¹, S. Verma², L. Fallowfield³, V. Müller⁴, M. Lichinitser⁵, A. Sánchez Muñoz⁶, Z. Machackova⁷, S. Osborne⁷, J. Gligorov⁸; ¹Besauçon, CEDEX/FR, ²Toronto, CA, ³Falmer, GB, ⁴Hamburg, DE, ⁵Moscow, RU, ⁶Malaga, ES, ⁷Basel, CH, ⁸Paris, FR

13:00 - 13:00 210P - An open-label, multinational, multicentre, phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients with HER2-positive early or metastatic breast cancer (UmbHER1): Interim safety results from early breast cancer studies

X. Pivot¹, C. Poole², M. Martín³, J. Gligorov⁴, C. Barrios⁵, E. Vrdoljak⁶, L. Gianni⁷, A. Ten Tije⁸, Z. Machackova⁹, M. Truman¹⁰, G. Steger¹¹; ¹Besauçon, CEDEX/FR, ²Coventry, GB, ³Madrid, ES, ⁴Paris, FR, ⁵Porto Alegre, BR, ⁶Split, HR, ⁷Milano, IT, ⁸Breda, NL, ⁹Basel, CH, ¹⁰Dee Why, NSW/AU, ¹¹Vienna, AT

13:00 - 13:00 211P - Adjuvant subcutaneous trastuzumab for HER2-positive early breast cancer: Phase III SafeHer study subgroup analyses of body weights, active medical conditions, safety and tolerability

K.H. Jung¹, B. Ataseven², M. Verrill³, X. Pivot⁴, M. De Laurentiis⁵, N. Al-Sakaff⁶, S. Lauer⁶, M. Shing⁷, J. Gligorov⁸, H. Azim⁹; ¹Seoul, KR, ²Essen, DE, ³Newcastle Upon Tyne, GB, ⁴Besauçon, CEDEX/FR, ⁵Napoli, IT, ⁶Basel, CH, ⁷South San Francisco, CA/US, ⁸Paris, FR, ⁹Cairo, EG

13:00 - 13:00 212P - Fatigue and quality of life (QoL) during and after adjuvant treatment by trastuzumab (Herceptin®) among breast cancer patients (BC pts): A case-control study

S. Noal, N. Heutte, D. Allouache, C. Delcambre, A. Faveyrial, C. Levy, C. Segura, J. Geffrelot, C. Rieux, A. Leconte, B. Clarisse; Caen, FR

13:00 - 13:00 213P - Age alone or Charlson comorbidity index – what guides anticancer treatment choice in newly diagnosed, non-metastatic breast cancer in the real life setting?

A. Badora-Rybicka, E. Nowara, D. Starzyczny-Słota; Gliwice, PL

13:00 - 13:00 214P - Effect of polypharmacy on treatment preferences and outcome in older breast cancer patients

M. Sendur, K. Silay, S. Aksoy, S. Özbek, N. Ozdemir, K. Altundag; Ankara, TR

13:00 - 13:00 215P - The prognostic effect of chemotherapy in male breast cancer: An experience of 136 cases from a retrospective study

X.-F. Yu, H.-J. Yang, B. Chen, C. Wang, L.-L. Miao; Hangzhou, CN

13:00 - 13:00 216P - The impact of delay in adjuvant radiotherapy in the combined modality treatment of early stage breast cancer: Single institutional experience

M. Ezz El Din, D. Abd El Ghany; Cairo, EG

13:00 - 13:00 217P - Concurrent paclitaxel and radiotherapy for node positive breast cancer

M. Kassem, A. Hassan, N. Ibrahim, A.A. Toema; Cairo, EG

13:00 - 13:00 218P - Outcomes for radiation associated angiosarcoma of the breast

J. Joseph, E. Thomas, S. Kumar; Leeds, GB

13:00 - 13:00 219TiP - Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)

C. Toms, N. Chopra, L. Houlton, K. Jarman, L. Kilburn, J. Bliss, N. Turner; London, GB



- 13:00 - 13:00 220TiP - Improving outcomes in triple-negative breast cancer (TNBC) using molecular characterization and diagnostic imaging to identify and treat chemo-insensitive disease
S. Moulder¹, J. Litton¹, E. Mittendorf², W. Yang², N. Ueno², K. Hess¹, V. Valero¹, R. Murthy¹, N. Ibrahim², B. Lim¹, B. Arun¹, A. Thompson², H. Piwnica-Worms¹, D. Tripathy², W.F. Symmans²; ¹Houston, TX/US, ²Houston, US
- 13:00 - 13:00 221TiP - A randomized phase II study to investigate the addition of PD-L1 antibody MEDI4673 (durvalumab) to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (GeparNuevo)
S. Loibl¹, A. Schneeweiss², N. Burchardi¹, J.-U. Blohmer³, C. Hanusch⁴, S. Costa⁵, J. Huober⁶, C. Jackisch⁷, G. von Minckwitz¹, S. Kümmel⁸, S. Paepke⁴, C. Denkart³, M. Untch³; ¹Neu-Isenburg, DE, ²Heidelberg, DE, ³Berlin, DE, ⁴München, DE, ⁵Magdeburg, DE, ⁶Ulm, DE, ⁷Offenbach, DE, ⁸Essen, DE
- 13:00 - 13:00 Breast cancer, locally advanced and metastatic
- 13:00 - 13:00 232P - Circulating tumor cells as an early predictive marker of disease progression in metastatic breast cancer patients
S. Algizawy¹, H. Essa², E. El-Gezawy², N. Omar², D. Sayed²; ¹Jazan, Jazan/SA, ²Assiut, EG
- 13:00 - 13:00 233P - Intratumoral heterogeneity of HER2 expression is relevant to breast cancer malignancy
M. Hosonaga, Y. Arima, E. Sato, K. Yamada, H. Kaise, Y. Kawai, S. Teraoka, H. Saya, T. Ishikawa; Tokyo, JP
- 13:00 - 13:00 234P - Faster turnaround time for circulating tumor cell results by CTC rating of hotspots
M. Nielsen¹, H. Stender², T. Glückstadt², J. Kraan³, J. Smith⁴, T. Hillig¹, G. Sölétormos¹; ¹Hillerod, DK, ²Lyngby, DK, ³Rotterdam, NL, ⁴Copenhagen, DK
- 13:00 - 13:00 235P - Phase II trial evaluating the combination of eribulin (E)+ bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): A GINECO group study
A.-C. Hardy-Bessard¹, F. Brocard², M. Leheurteur³, A. Melis⁴, J. Dauba⁵, A. Lortholary⁶, B. You⁷, E. Guardiola⁸, J. Grenier⁹, J. Martin-Babau¹⁰, J. Meunier¹¹, P. Follana¹², A.-M. Savoye¹³, A. Mercier-Blas¹⁴, A. Marti¹⁵, R. Despax¹⁶, N. Barbier¹⁷, N. Gane¹⁸, P. Ardisson¹⁹, C. Segura-Djezzar²⁰; ¹Plerin-Sur-mer, FR, ²Nancy, FR, ³Rouen, FR, ⁴Chalon-Sur-saône, FR, ⁵Mont De Marsan, FR, ⁶Nantes, FR, ⁷Pierre Bénite, FR, ⁸Draguignan, FR, ⁹Avignon, FR, ¹⁰Brest, FR, ¹¹Orleans, FR, ¹²Nice, FR, ¹³Reims, FR, ¹⁴Saint-Grégoire, FR, ¹⁵Auxerre, FR, ¹⁶Toulouse, FR, ¹⁷Perpignan, FR, ¹⁸Paris, FR, ¹⁹Lyon, FR, ²⁰Caen, FR
- 13:00 - 13:00 236P - Efficacy and safety of nab-paclitaxel in patients with metastatic breast cancer: Final results of the non-interventional study NABUCCO
K. Potthoff¹, A. Nusch², U. Söling³, R. Hansen⁴, C. Salat⁵, S. Grebhardt¹, N. Marschner¹; ¹Freiburg, DE, ²Ratingen, DE, ³Kassel, DE, ⁴Kaiserslautern, DE, ⁵München, DE
- 13:00 - 13:00 237P - Real-world effectiveness and safety of first-line bevacizumab (BEV) + paclitaxel (PAC) in >2000 patients (pts) with HER2-negative metastatic breast cancer (mBC)



V. Mueller¹, M. Dank², S. de Ducla³, L. Mitchell³, A. Schneeweiss⁴; ¹Hamburg, DE, ²Budapest, HU, ³Basel, CH, ⁴Heidelberg, DE

13:00 - 13:00 238P - MERIBEL study: Single-agent eribulin as first-line therapy for taxane-resistant HER2[-] metastatic breast cancer (MBC) patients (pts)

V. Ortega¹, J. Lao², I. Garau³, N. Afonso⁴, L. Calvo⁵, Y. Fernández⁶, M. Martinez-Garcia¹, E. Blanco⁷, P. Zamora⁸, M. García⁹, J.J. Illarramendi¹⁰, C. Rodríguez¹¹, E. Aguirre², J. Pérez¹, J. Cortes⁸, A. Llombart-Cussac¹²; ¹Barcelona, ES, ²Zaragoza, ES, ³Palma De Mallorca, ES, ⁴Porto, PT, ⁵A Coruna, ES, ⁶Oviedo, ES, ⁷Badajoz, ES, ⁸Madrid, ES, ⁹Las Palmas, ES, ¹⁰Pamplona, ES, ¹¹Salamanca, ES, ¹²Valencia, ES

13:00 - 13:00 239P - Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Updated safety results of a phase II trial (AGMT MBC-6)

G. Rinnerthaler¹, S.P. Gampenrieder¹, D. Voskova², A. Petzer², M. Hubalek³, E. Petru⁴, B. Hartmann⁵, J. Andel⁶, M. Balic⁴, T. Melchardt¹, B. Mlineritsch¹, R. Greil¹; ¹Salzburg, AT, ²Linz, AT, ³Innsbruck, AT, ⁴Graz, AT, ⁵Feldkirch, AT, ⁶Steyr, AT

13:00 - 13:00 240P - Capecitabine monotherapy in patients aged 70 years and older with metastatic breast cancer (MBC)

D. Okonji¹, S. Redana², K. Mohammed², A. Ring³, S. Johnston²; ¹Auckland, NZ, ²London, GB, ³Sutton, GB

13:00 - 13:00 241P - Safety and effectiveness of nab-paclitaxel in young and elderly patients with metastatic breast cancer: A prospective, multicenter non-interventional study

G. Steger¹, E. Petru², F. Haslbauer³, D. Egle⁴, A. Galid¹, T. Sliwa¹, A. Lang⁵, T. Kühr⁶, A. Petzer⁷, R. Ruckser¹, B. Mlineritsch⁸, R. Greil⁸, M. Seifert¹, C. Singer¹, J. Andel⁹, W. Kwasny¹⁰, C. Marth⁴, P. Pichler¹¹, C. Tinchon¹², R. Bartsch¹; ¹Vienna, AT, ²Graz, AT, ³Voecklabruck, AT, ⁴Innsbruck, AT, ⁵Feldkirch, AT, ⁶Wels, AT, ⁷Linz, AT, ⁸Salzburg, AT, ⁹Steyr, AT, ¹⁰Wiener Neustadt, AT, ¹¹St. Poelten, AT, ¹²Leoben, AT

13:00 - 13:00 242P - Final results of weekly paclitaxel and carboplatin plus bevacizumab as first-line treatment of triple-negative breast cancer. A multicenter phase I-II trial by the Hellenic Oncology Research Group

M. Nikolaou¹, E. Saloustros², A. Polyzos³, C. Christophyllakis³, N. Kentepozidis³, L. Vamvakas³, K. Kalbakis³, S. Agelaki², V. Georgoulis², D. Mavroudis²; ¹Larissa, GR, ²Heraklion, GR, ³Athens, GR

13:00 - 13:00 243P - Feasibility and outcome of chemotherapy in very elderly patients with metastatic breast cancer

A. Overgaauw¹, L. van der Plas¹, M. Hendriks², C. Smorenburg¹; ¹Amsterdam, NL, ²Alkmaar, NL

13:00 - 13:00 244P - Eribulin mesylate may improve the sensitivity of endocrine therapy in metastatic breast cancer

K. Kobayashi, Y. Ito, T. Shibayama, I. Fukada, N. Ishizuka, R. Horii, S. Takahashi, F. Akiyama, T. Iwase, S. Ohno; Tokyo, JP

13:00 - 13:00 245P - Maintenance metronomic chemotherapy combined with conventional treatment for metastatic breast cancer patients

S.F. El Zawawy, G. Khedr, B. Elsabaa; Alexandria, EG



- 13:00 - 13:00 246P - Single arm, multicentre, non-randomized open-label trial to evaluate the safety of eribulin in third line chemotherapy in patients with HER2-negative metastatic or locally advanced breast cancer previously treated with anthracyclines and taxanes: Onsite study (ONCOSUR 2012-02)
L. Manso Sánchez¹, F. Moreno Antón¹, Y. Izarzugaza Perón¹, J.I. Delgado Mingorance², P. Borrega³, M.J. Echarri González⁴, N. Martínez¹, A. López González⁵, C. Olier⁶, A. Ballesteros García¹, I. Chacón⁷, E. Ciruelos¹, J.A. García-Sáenz¹, L. Paz-Ares¹; ¹Madrid, ES, ²Badajoz, ES, ³Cáceres, ES, ⁴Leganes, ES, ⁵Leon, ES, ⁶Alcorcon, ES, ⁷Toledo, ES
- 13:00 - 13:00 247P - Safety and efficacy of eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer (ABC) patients. An Italian multicenter experience
E. Lutrino¹, L. Orlando¹, G. Giordano², C. Zamagni³, C. Calio¹, A. Febbraro², M. Giampaglia⁴, G. Dima⁵, A. Quaranta¹, C. Scavelli⁶, D. Bilancia⁴, G. Filippelli⁵, C. Fontanella⁷, P. Schiavone¹, P. Fedele¹, M. Enrica¹, D. Rubino³, S. Cinieri¹; ¹Brindisi, IT, ²Benevento, IT, ³Bologna, IT, ⁴Potenza, IT, ⁵Paola, IT, ⁶Gallipoli, IT, ⁷Udine, IT
- 13:00 - 13:00 248P - CASCADE study: Pronounced decline in treatment efficacy through the metastatic life of breast cancer patients
L. De Paz Arias¹, P. García Teijido², S. Servitja³, A. Santaballa⁴, J. García⁵, Y. Plata Fernández⁶, I. Garau⁷, J. Florian⁸, I. Chacón⁹, J. de la Haba¹⁰, P. Zamora¹¹, L. Orcajo Rincon¹¹, J. Rodríguez-Villanueva¹¹, M.Á. Seguí¹², E. Martínez¹³; ¹Ferrol, ES, ²Avilés, ES, ³Barcelona, ES, ⁴Valencia, ES, ⁵Ourense (galicia), ES, ⁶Jaen, ES, ⁷Palma De Mallorca, ES, ⁸Barbastro, ES, ⁹Toledo, ES, ¹⁰Cordoba, ES, ¹¹Madrid, ES, ¹²Sabadell, ES, ¹³Castellon, ES
- 13:00 - 13:00 249P - Focalized treatment strategy for patients with 1 to 5 breast cancer brain metastasis: A retrospective study of 70 patients treated with surgery or stereotactic radiosurgery
L. Eberst¹, M. Morelle², M.-P. Sunyach², E. Jouanneau³, P. Heudel², O. Tredan², R. Tanguy², I. Ray-Coquard², T. Bachelot²; ¹Lyon, Cedex 08/FR, ²Lyon, FR, ³Bron, FR
- 13:00 - 13:00 250P - Relationship between progression-free survival and overall survival in advanced breast cancer: A novel approach using first-line treatment data for fulvestrant 500 mg and anastrozole
M. Ouwens¹, L. Grinsted², C. Telford³; ¹Molndal, SE, ²Cambridge, GB, ³Gaithersburg, MD/US
- 13:00 - 13:00 251P - Clinical decision making in patients with metastatic breast cancer in the United Kingdom (UK) and Italy
L. Ferrari¹, L. Gerratana¹, M. Jove², M. Bonotto¹, M. Cinausero¹, C. Twelves², F. Puglisi¹; ¹Udine, IT, ²Leeds, GB
- 13:00 - 13:00 252P - Long lasting survival (LLS) after removal of primary tumor (PT) in metastatic breast cancer (MBC). Impact of age on outcome
J.A. Perez Fidalgo¹, A. Caballero¹, J.M. Cejalvo¹, O. Burgues¹, C. Hernando¹, P. Tolosa¹, A. Iranzo¹, B. Bermejo¹, J. Ramirez Sabio¹, A. Magro², A. Lluch-Hernandez¹; ¹Valencia, ES, ²Gandia, ES
- 13:00 - 13:00 253P - The difference in prognostic outcomes between de novo stage IV and recurrent metastatic patients with hormone receptor-positive, HER2-negative breast cancer: A single-center study
J. Yamamura¹, S. Kamigaki¹, M. Tsujie², J. Fujita², H. Osato²; ¹Sakai, JP, ²Sakai, Osaka, JP



- 13:00 - 13:00 254P - Hemoglobin level trajectories in early treatment period related to survival outcomes in patients of breast cancer
H.-E. Tzeng, C.-L. Lee; Taichung, TW
- 13:00 - 13:00 255P - Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple negative breast cancer
J.-Y. Pierga, F. Riva, A. Houy, A. Saliou, J. Madic, A. Rampanou, C. Hego, M. Milder, P. Cottu, M.-P. Sablin, A. Vincent-Salomon, O. Lantz, M.-H. Stern, C. Proudhon, F.-C. Bidard; Paris, FR
- 13:00 - 13:00 256P - Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumor suppressor in breast cancer
N. Touati¹, K. Tryfonidis¹, F. Caramia², H. Bonnefoi³, D. Cameron⁴, L. Slaets¹, B. Parker⁵, S. Loi⁵; ¹Brussels, BE, ²East Melbourne, AU, ³Bordeaux, FR, ⁴Edinburgh, GB, ⁵Melbourne, AU
- 13:00 - 13:00 257P - Breast-GPA and type of treatment predictors of survival in brain metastasis patients
J. Linares, A. Stradella, S. Pernas, A. Ortega, M. Galdeano, A. Lucas, M. Macia, N. Vidal, I. Morilla, R. Sabela, C. Faló, R. Velasco, M. Gil-Gil; Barcelona, ES
- 13:00 - 13:00 258P - Impact of the biological subtype on the risk of developing brain metastasis in Egyptian breast cancer patients
L. Kassem¹, R. Abdel-Malek², D. Abd El Moneim², M. Ismail², H. Azim²; ¹Giza, EG, ²Cairo, EG
- 13:00 - 13:00 259P - Site of first recurrence of breast cancer after adjuvant therapy: Clinical aspects and outcome analysis
N. Mejri, S. Labidi, M. Afrit, H. El Benna, H. Boussen; Ariana, TN
- 13:00 - 13:00 260P - Impact of palbociclib plus fulvestrant on patient reported general health status compared with fulvestrant alone in HR+, HER2- metastatic breast cancer
S. Loibl¹, A. Demichele², N. Turner³, M. Cristofanilli⁴, S. Loi⁵, S. Verma⁶, H. Bhattacharyya⁷, Z. Ke⁸, C. Giorgetti⁹, C. Bartlett¹⁰, S. Iyer⁷, M. Colleoni⁹, N. Masuda¹¹, S.-A. Im¹², N. Harbeck¹³; ¹Neu-Isenburg, DE, ²Philadelphia, US, ³London, GB, ⁴Chicago, IL/US, ⁵Melbourne, AU, ⁶Toronto, CA, ⁷New York, US, ⁸La Jolla, US, ⁹Milano, IT, ¹⁰New York, NY/US, ¹¹Osaka, JP, ¹²Seoul, KR, ¹³München, DE
- 13:00 - 13:00 261P - Phase I/II trial of palbociclib in combination with bicalutamide for the treatment of androgen receptor (AR)(+) metastatic breast cancer (MBC): Pharmacokinetics (PK)
A. Gucalp, A. Corben, S. Patil, L.A. Boyle, C. Hudis, T. Traina; New York, NY/US
- 13:00 - 13:00 262P - The influence of old age on everolimus exposure in patients with cancer
A. Willemssen¹, C. van Herpen¹, T. Schneider², D. de Wit², E. Kapiteijn², N. van Erp¹; ¹Nijmegen, NL, ²Leiden, NL
- 13:00 - 13:00 263P - Predictors of effectiveness of the use of steroidal aromatase inhibitors after progression on non-steroidal aromatase inhibitors in advanced breast cancer patients
M.M. Ulrich de Menezes Pereira dos Santos, C. Cardoso, M. Sousa, S. Esteves, M. Brito, A. Moreira; Lisboa, PT



- 13:00 - 13:00 264P - Patterns of treatment and outcome of fulvestrant 500mg in postmenopausal women with hormone-positive (HR+)/Her2-negative (HER2-) metastatic breast cancer (MBC): A real life multicenter Italian experience
R. Palumbo¹, A. Ferzi², A. Gambaro³, F. Sottotetti¹, L. Licata¹, C. Teragni¹, B. Tagliaferri¹, E. Pozzi¹, A. Bernardo¹; ¹Pavia, IT, ²Legnano, IT, ³Milano, IT
- 13:00 - 13:00 265P - Fulvestrant (FUL) 500 milligrams as endocrine therapy (ET) for hormone sensitive advanced breast cancer patients. The Ful500 prospective observational trial
L. Moscetti¹, M.A. Fabbri¹, P. Vici², C. Natoli³, T. Gamucci⁴, I. Sperduti², L. Pizzuti², L. Iezzi³, E. Iattoni⁵, C. Roma², A. Vaccaro⁴, G. D'Auria¹, M. Mauri², E. Ruggeri¹; ¹Viterbo, IT, ²Roma, IT, ³Chieti, IT, ⁴Sora, IT, ⁵Modena, IT
- 13:00 - 13:00 266P - Is the overall survival after hormone therapy for hormone-receptor-positive, HER2-negative metastatic breast cancer still better than for triple-negative metastatic breast cancer?
J. Watanabe¹, T. Hayashi², Y. Tadokoro², S. Nishimura², K. Takahashi²; ¹Shizuoka, Shizuoka/JP, ²Shizuoka, JP
- 13:00 - 13:00 267P - Survival pattern of negative lymph node non-metastatic breast cancer females in the United States with radiotherapy treatment according to estrogen and progesterone receptors status
A. Meshref, M. Mousa, M. Ramadan, M. Haggag; Ismailia, EG
- 13:00 - 13:00 268P - Survival patterns of high-grade breast cancer patients in the United States
M. Mousa, A. Meshref, M. Ramadan, M. Haggag; Ismailia, EG
- 13:00 - 13:00 269P - Central nervous system (CNS) disease during trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer (ABC): A single institution experience
T. Irfan¹, N. Turner¹, S. Johnston¹, I. Smith¹, M. O'Brien¹, M. Parton¹, A. Ring², J. Noble², S. Stanway², N. Somaiah², K. Khabra², A. Okines¹; ¹London, GB, ²Sutton, GB
- 13:00 - 13:00 270P - Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
N. Iyengar¹, L. Smyth¹, D. Lake¹, A. Gucalp¹, J. Singh¹, T. Traina¹, P. Defusco¹, M. Dickler¹, M. Fornier¹, S. Goldfarb¹, K. Jhaveri¹, A. Latif¹, S. Modi², T. Troso-Sandoval¹, G. Ulaner¹, M. Jochelson¹, J. Baselga², L. Norton¹, C. Hudis¹, C. Dang¹; ¹New York, NY/US, ²New York, US
- 13:00 - 13:00 271P - HER2 positive breast cancer with central nervous system metastases: Pathological features and clinical outcome
G. Masci, L. Santarpia, G. Bottai, L. Giordano, M. Zuradelli, R. Torrisi, L. Di Tommaso, A. Sagona, V. Errico, W. Gatzemeier, A. Testori, P. Navarra, L. Bello, C. Tinterri, M. Scorsetti, A. Santoro; Rozzano, IT
- 13:00 - 13:00 272P - Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors
C. Omarini¹, C. Caprera¹, S. Manfredini¹, F. Caggia¹, G. Guaitoli¹, M.E. Filieri¹, S.R. Bettelli¹, L. Moscetti¹, S. Kaleci¹, A.V. Tamma¹, S. Cascinu², F. Piacentini¹; ¹Modena, IT, ²Ancona, IT
- 13:00 - 13:00 273P - A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with Her2-positive metastatic breast cancer - E-Vita -



J. Bischoff¹, J. Barinoff², C. Mundhenke³, D. Bauerschlag³, S. Costa⁴, D. Herr⁵, K. Lübe⁶, F. Marmé⁷, N. Maass³, G. von Minckwitz⁸, E.-M. Grischke⁹, V. Müller¹⁰, M. Schmidt¹¹, B. Gerber¹², S. Kümmel¹³, C. Schumacher¹⁴, P. Krabisch¹⁵, M. Thill², V. Nekljudova⁸, S. Loibl⁸; ¹Dessau, DE, ²Frankfurt Am Main, DE, ³Kiel, DE, ⁴Magdeburg, DE, ⁵Würzburg, DE, ⁶Hannover, DE, ⁷Heidelberg, DE, ⁸Neu-Isenburg, DE, ⁹Tübingen, DE, ¹⁰Hamburg, DE, ¹¹Mainz, DE, ¹²Rostock, DE, ¹³Essen, DE, ¹⁴Köln, DE, ¹⁵Chemnitz, DE

- 13:00 - 13:00 274P - Patient preference of trastuzumab administration (SC versus IV) in HER2-positive metastatic breast cancer: Results of the randomised Metaspher study
- X. Pivot¹, J.-P. Spano², E. Marc², P. Cottu², C. Jouannaud³, V. Pottier⁴, L. Moreau⁴, J.-M. Extra⁵, A. Lortholary⁶, P. Rivera⁷, D. Spaeth⁸, H. Attar-Rabia⁹, C. Benkamoun⁹, L. Dima-Martinez⁹, N. Esposito⁹, J. Gligorov²; ¹Besançon, CEDEX/FR, ²Paris, FR, ³Reims, FR, ⁴Clermont-Ferrand, FR, ⁵Marseille, FR, ⁶Nantes, FR, ⁷Toulouse, FR, ⁸Nancy, FR, ⁹Boulogne-Billancourt, FR
- 13:00 - 13:00 275P - Trastuzumab emtansine (T-DM1) in patients (pts) with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC): Results from a multicenter retrospective analysis
- L. Pizzuti¹, I. Sperduti¹, A. Michelotti², C. Omarini³, T. Gamucci⁴, C. Natoli⁵, L. D'Onofrio¹, F. Giotta⁶, C. Ficorella⁷, L. Laudadio⁸, A. Cassano¹, P. Marchetti⁹, V. Adamo¹⁰, M. Mauri¹, A.F. Scinto¹, G. Zampa⁹, A. Fabbri¹¹, L. Mentuccia¹², S. Barni¹³, P. Vici¹; ¹Roma, IT, ²Pisa, IT, ³Modena, IT, ⁴Sora, IT, ⁵Chieti, IT, ⁶Bari, IT, ⁷L'aquila, IT, ⁸Lanciano, IT, ⁹Rome, IT, ¹⁰Messina, IT, ¹¹Viterbo, IT, ¹²Frosinone, IT, ¹³Treviglio, IT
- 13:00 - 13:00 276P - Electrochemotherapy for breast cancer - Results from the INSPECT database
- L. Matthiessen¹, M. Keshtgar², C. Kunte³, E.-M. Grischke⁴, J. Odili², T. Muir⁵, P. Curatolo⁶, D. Mowatt⁷, J. Clover⁸, S. Liew⁹, H. Hansen¹, J. Newby², V. Letulé³, E. Stauss⁴, A. Humphreys⁵, S. Banerjee², A. Klein³, F. de Terlizzi¹⁰, J. Gehl¹; ¹Herlev, DK, ²London, GB, ³München, DE, ⁴Tübingen, DE, ⁵Middlesbrough, GB, ⁶Roma, IT, ⁷Manchester, GB, ⁸Cork, IE, ⁹Liverpool, GB, ¹⁰Carpi, IT
- 13:00 - 13:00 277P - Phase 1b/2 safety and efficacy of TAK-228 (MLN0128), plus exemestane (E) or fulvestrant (F) in postmenopausal women with ER+/HER2- metastatic breast cancer (MBC)
- J. Diamond¹, V. Borges¹, P. Kabos¹, E. Krill-Jackson², R. Graham³, A. Hoffman⁴, B. Lim⁵, D. Richards⁶, M. Salkeni⁷, S. Wilks⁸, C. Patel⁹, R. Neuwirth⁹, M. Kneissl⁹, F. Zohren⁹; ¹Aurora, CO/US, ²Miami Beach, FL/US, ³Chattanooga, TN/US, ⁴Bronx, NY/US, ⁵Houston, TX/US, ⁶Tyler, TX/US, ⁷Morgantown, WV/US, ⁸San Antonio, TX/US, ⁹Cambridge, MA/US
- 13:00 - 13:00 278P - Cutaneous responses in Her-2+ metastatic breast cancer (MBC) on phase 1b study of ONT-380, an oral HER2-specific inhibitor in combination with capecitabine (C) and/or trastuzumab (T) in third line or later treatment
- A. Conlin¹, V. Borges², N. Moxon¹, L. Walker³, S. Moulder⁴; ¹Portland, OR/US, ²Aurora, CO/US, ³Seattle, WA/US, ⁴Houston, TX/US
- 13:00 - 13:00 279P - Phase I/II pharmacokinetics/pharmacodynamics study of irinotecan and S-1 for recurrent/metastatic breast cancer in patients with select UGT1A1 genotypes (the JBCRG-M01 study)



S. Saji¹, H. Ishiguro², S. Nomura³, H. Iwata⁴, S. Tanaka², T. Ueno⁵, M. Onoue⁶, T. Yamanaka⁷, Y. Sasaki⁸, M. Toi²; ¹Fukushima, JP, ²Kyoto, JP, ³Kashiwa, JP, ⁴Nagoya, JP, ⁵Mitaka, JP, ⁶Osaka, JP, ⁷Yokohama, JP, ⁸Tokyo, JP

- 13:00 - 13:00 280P - Phase Ib/II open-label study of Ad-RTS-hIL-12+veledimex gene therapy in chemotherapy-responsive locally advanced or metastatic breast cancer patients
H. McArthur¹, D. Page¹, T. Proverbs-Singh¹, S. Solomon¹, C. Hudis¹, L. Norton¹, S. Patil¹, M. Henrich¹, D. Halpenny¹, J. Erinjeri¹, J. Yuan¹, P. Wong¹, C.A. Jones², M. Escudero², H. Cai², J. Zhou², Y. Yang², J. Barrett², F. Lebel³; ¹New York, NY/US, ²Boston, MA/US, ³Boston, Massachusetts/US
- 13:00 - 13:00 281P - A phase I study of sonidegib (S) in combination with docetaxel (D) in patients (pts) with triple negative (TN) advanced breast cancer (ABC): GEICAM/2012-12 (EDALINE study)
M. Martín¹, M. Ruiz-Borrego², J.M. Trigo Perez³, S. Antolin⁴, J.A. García-Sáenz¹, J. Corral², Y. Jerez¹, A. Urruticoechea⁵, H. Colom⁶, N. Gonzalo⁶, C. Muñoz⁶, J. Cuevas², C. del Monte¹, L. Pérez-Ramos¹, R. Caro¹, A. Blach¹, S. Benito¹, S. Bezares Montes¹, E. Carrasco¹, F. Rojo¹; ¹Madrid, ES, ²Sevilla, ES, ³Malaga, ES, ⁴A Coruna, ES, ⁵San Sebastian, ES, ⁶Barcelona, ES
- 13:00 - 13:00 282P - A new oral dihydroxysterol (24-ethyl-cholestane- 3 β ,5 α ,6 α -triol) showing activity in the treatment of advanced and metastatic breast cancer
N. Habib, H. Daaboul, G. Hage, A. Jabbour, H. Zeitouni, N. Kassem, R. Khalifeh; Beirut, LB
- 13:00 - 13:00 283P - Satisfaction with cancer treatments in HR+/HER2- metastatic breast cancer patients in a real world setting
J. de Courcy¹, R. Wood¹, D. Mitra², S. Iyer³; ¹Bollington, GB, ²New York, NY/US, ³New York, US
- 13:00 - 13:00 284P - Patient reported pain severity and interference in HR+/HER2- advanced/metastatic breast cancer in real world settings
R. Wood¹, J. de Courcy¹, D. Mitra², S. Iyer³; ¹Bollington, GB, ²New York, NY/US, ³New York, US
- 13:00 - 13:00 285P - Association of age and body mass index with paclitaxel-induced peripheral neuropathy in patients with breast cancer
Z. Ghoreishi¹, A. Esfahani¹, S. Keshavarz²; ¹Tabriz, IR, ²Tehran, IR
- 13:00 - 13:00 286P - First-line cobimetinib (C) + paclitaxel (P) in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and tumoral immune cell infiltration data from the phase 2 COLET study
D. Miles¹, S.-B. Kim², T. Velu³, J. García-Saenz⁴, E. Tan-Chiu⁵, J.H. Sohn², L. Dirix⁶, J. Vaňásek⁷, M. Borms⁸, J.I. Delgado Mingorance⁹, M.-C. Liu¹⁰, M. Moezi¹¹, M. Kozloff¹², J. Sparano¹³, N. Xu¹⁴, Y. Yan¹⁴, M. Wongchenko¹⁴, B. Simmons¹⁴, V. McNally¹⁵, A. Brufsky¹⁶; ¹Northwood, GB, ²Seoul, KR, ³Brussels, BE, ⁴Madrid, ES, ⁵Plantation, FL/US, ⁶Wilrijk, BE, ⁷Pardubice, CZ, ⁸Kortrijk, BE, ⁹Badajoz, ES, ¹⁰Taipei, TW, ¹¹Jacksonville, FL/US, ¹²Harvey, IL/US, ¹³Bronx, NY/US, ¹⁴South San Francisco, CA/US, ¹⁵Welwyn Garden City, GB, ¹⁶Pittsburgh, PA/US
- 13:00 - 13:00 287P - Mutation screening and clinical evaluation of multiple-gene sequencing for triple negative breast cancer
J. Zhang, R. Guo, S. Zhang, Y. Hu, J. Liu, J. Bai; Tianjin, CN



- 13:00 - 13:00 288P - Effect of ABCB1 gene polymorphisms C3435T and C1236T on tumour response and plasma levels of docetaxel in locally-advanced breast cancer patients of South India receiving neo-adjuvant chemotherapy
R. Priyadarshini, S. Kayal, R. A. D. Shewade; Puducherry, IN
- 13:00 - 13:00 289P - Prognostic significance of immunohistochemical subtyping and PAM50 intrinsic subtypes in male breast cancer (MaBC)
M. Alvarez¹, A. Sanchez-Muñoz¹, A. Santonja¹, Y. Plata Fernández², J. Miramón³, I. Zarcos Pedrinaci¹, C. Llacer¹, V. de Luque¹, M.J. Lozano León¹, J.M. Jerez¹, L. Pérez Villa¹, R. Lavado¹, C. Ramirez², A. Jiménez¹, I. Rodrigo¹, E. García³, L. Vicioso¹, E. Alba Conejo¹; ¹Malaga, ES, ²Jaen, ES, ³Ronda (málaga), ES
- 13:00 - 13:00 290P - Anthracycline mediated cardiotoxicity: Detection of miRNA based early biomarkers for the prediction of myocardial injury. Hecatos study
C. Salvador Coloma, P. Sepúlveda, A. Hernandez, S. Tejedor, L. Palomar, A. Ruiz, V. Miro, H. De la Cueva, I. Ontoria-Oviedo, A. Salvador, V. Castel, A. Santaballa; Valencia, ES
- 13:00 - 13:00 291P - Prognostic significance of the derived neutrophil-lymphocyte ratio in non-metastatic breast cancer: An institutional analysis from a tertiary care center in India
C. Das, A. Gogia, S. Deo, N. Shukla, S. Mathur, V. Sreenivas, D. Sharma; New Delhi, IN
- 13:00 - 13:00 292P - Clinical implication of PIK3CA activating mutation in ER+HER2+ breast cancer: Based upon explorative mutational analysis of Neo-ALL-IN study
J.H. Park¹, D.-H. Kim², J.-H. Ahn², J.E. Kim², K.H. Jung², G. Gong², S.-H. Ahn², H.J. Lee², B.-H. Son², H.-H. Kim², H.J. Shin², D.-H. Moon², S.-M. Ahn², S.-B. Kim³; ¹Seoul, Songpa-gu/KR, ²Seoul, KR, ³Seoul, ZA
- 13:00 - 13:00 293P - Results of Neoteam: A randomized multicenter phase II study of liposomal doxorubicin hydrochloride + trastuzumab vs conventional doxorubicin both in combination with cyclophosphamide and followed by docetaxel + trastuzumab as neoadjuvant treatment of HER2-positive primary breast cancer
S. Pernas Simon¹, M. Rezaei², M. Hauschild³, J.P. Machiels⁴, S. Paepke⁵, A. Llombart Cussac¹; ¹Barcelona, ES, ²Düsseldorf, DE, ³Rheinfelden, CH, ⁴Brussels, BE, ⁵Berlin, DE
- 13:00 - 13:00 294P - Neoadjuvant chemotherapy carboplatin – taxane response in locally advanced triple negative breast cancer patients in relation to molecular biomarkers
L. Sad¹, S. Younis², M. Abd El Hak²; ¹Tanta, Gharbia/EG, ²Tanta, EG
- 13:00 - 13:00 295P - Neoadjuvant chemotherapy use in breast cancer patients in the Netherlands: An expert opinion on current practice
P. Spronk¹, K. de Ligt², A. van Bommel¹, S. Siesling², M.-J. Vrancken Peeters³, C. Smorenburg³; ¹Leiden, NL, ²Utrecht, NL, ³Amsterdam, NL
- 13:00 - 13:00 296P - Evaluation of neoadjuvant weekly nanoparticle albumin-bound paclitaxel for HER2-negative breast cancer
A. Nagayama¹, A. Matsui², A. Tachibana², N. Suzuki², M. Hirata², Y. Oishi², Y. Hamaguchi², Y. Murata², Y. Okamoto²; ¹Meguro-Ku, JP, ²Tokyo, JP



- 13:00 - 13:00 297P - High-dose chemotherapy for inflammatory breast cancer: Impact of immunohistochemical status on survival outcome
L. Boudin¹, C. Chabannon², R. Sabatier², F. Bertucci², P. Sfumato², C. Tarpin², M. Provansal², G. Houvenaegel², E. Lambaudie², A. Tallet², R. Michel², E. Charafe-Jauffret², B. Calmels², C. Lemarie², B. Jean-Marie², J.-M. Extra², P. Viens², A. Gonçalves²; ¹Toulon, FR, ²Marseille, FR
- 13:00 - 13:00 298P - Survival patterns of T2 & T3 breast cancer according to different modalities of treatment in the United States
M. Ramadan, A. Meshref, M. Mousa; Ismailia, EG
- 13:00 - 13:00 299P - The clonal evolution of a breast tumor during neoadjuvant chemotherapy and metastasis
N. Litviakov¹, N. Cherdyntseva¹, M. Tsyganov¹, M. Ibragimova¹, A. Doroshenko¹, P. Kazantseva¹, J. Kzhyshkowska², E. Slonimskaya¹; ¹Tomsk, RU, ²Heidelberg, DE
- 13:00 - 13:00 300P - Predictive factors for nonsentinel lymph node metastasis in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy
J.M. Ryu, S.J. Nam, J.E. Lee, J. Yu, S.K. Lee, S.Y. Bae, H.-J. Paik, S. Park; Seoul, KR
- 13:00 - 13:00 301P - A multicenter study of the impact of body mass index (BMI) on the incidence of pathologic complete response (pCR) among Saudi patients with locally advanced breast cancer (LABC) post neoadjuvant chemotherapy (NCth)
A. Abdelwarith, K. Alsaleh, N. Abdelaziz, A. Ali, S. Elsamany, A. Rasmy, O. Elfarargy, S. Husain, A. Rikabi; Riyadh, SA
- 13:00 - 13:00 302P - Metformin in neoadjuvant systemic treatment in breast cancer patients with metabolic syndrome
R. Liubota¹, A. Zotov¹, R. Vereshchako¹, V. Cheshuk², N. Anikusko¹, I. Liubota¹; ¹Kiev, UA, ²Kyiv, UA
- 13:00 - 13:00 303P - Metformin and response to neoadjuvant chemotherapy in patients with breast cancer
M. Ghareeb, H. Naser, M. El-Gammal, A. Zeeneldin, A. Bahnacy, H. Khaled; Cairo, EG
- 13:00 - 13:00 304P - Prognostic factors after neoadjuvant chemotherapy in breast cancer: Surgery type as a new prognostic factor
M. Fujihara, T. Kin, Y. Yoshimura, Y. Kajiwara, M. Ito, K. Abe, Y. Sakata, K. Hiraki, S. Ohtani; Hiroshima, JP
- 13:00 - 13:00 305P - Association between physical activity, psychological mood profile and self-esteem among breast cancer survivors
M. Karamouzis¹, E. Patsou², G. Alexias², F. Anagnostopoulos²; ¹Kolonaki, GR, ²Athens, GR
- 13:00 - 13:00 306P - Contrast-enhanced ultrasound features of triple-negative breast cancer
Y. Zhang, M. Chen; Shanghai, CN
- 13:00 - 13:00 307P - Contrast-enhanced ultrasound for evaluating the response of breast cancer to neoadjuvant chemotherapy: Time-intensity curve analysis and texture analysis
C. Yuan, L. Tang, Q. Zhang, W. Jia, M. Chen; Shanghai, CN



- 13:00 - 13:00 308P - The effectiveness of neoadjuvant chemotherapy with recombinant tumor necrosis factor-thymosin- α 1 in locally advanced breast cancer and effect on tumor angiogenesis
L. Vladimirova¹, N. Podzorova¹, E. Nepomnyaschaya¹, I. Novikova², E. Ulyanova², G. Zakora², E. Bondarenko²; ¹Rostov-On-don, RU, ²Rostov On Don, RU
- 13:00 - 13:00 309TiP - METRIC: A randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC)
P. Schmid¹, M. Melisko², D. Yardley³, K. Blackwell⁴, A. Forero⁵, G. Ouellette⁶, Y. He⁶, R. Bagley⁷, J. Zhang⁶, L. Vahdat⁸; ¹London, GB, ²San Francisco, CA/US, ³Nashville, TN/US, ⁴Durham, NC/US, ⁵Birmingham, AL/US, ⁶Hampton, NJ/US, ⁷Needham, MA/US, ⁸New York, NY/US
- 13:00 - 13:00 310TiP - A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative hormone receptor-positive breast cancer and bone metastases
H. Rugo¹, O. Petrenciu², A. Zhang², R. Li², R. Coleman³; ¹San Francisco, CA/US, ²Whippany, NJ/US, ³Sheffield, GB
- 13:00 - 13:00 311TiP - A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)
F. André¹, B. Kaufman², D. Juric³, E. Ciruelos⁴, H. Iwata⁵, I. Mayer⁶, P. Conte⁷, H.S. Rugo⁸, S. Loibl⁹, G. Rubovszky¹⁰, H. Tesch¹¹, K. Inoue¹², Y.-S. Lu¹³, L. Ryvo¹⁴, A.-S. Longin¹⁵, D. Mills¹⁶, C. Wilke¹⁶, C. Germa¹⁷, M. Campone¹⁸; ¹Villejuif, FR, ²Tel Hashomer, IL, ³Boston, MA/US, ⁴Madrid, ES, ⁵Nagoya, JP, ⁶Nashville, TN/US, ⁷Padova, IT, ⁸San Francisco, CA/US, ⁹Neu-Isenburg, DE, ¹⁰Budapest, HU, ¹¹Frankfurt Am Main, DE, ¹²Saitama, JP, ¹³Taipei, TW, ¹⁴Tel Aviv, IL, ¹⁵Paris, FR, ¹⁶Basel, CH, ¹⁷East Hanover, NJ/US, ¹⁸St. Herblain, FR
- 13:00 - 13:00 312TiP - A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC)
G. Curigliano¹, S. Loibl², V. Müller³, X. Pivot⁴, A. Wardley⁵, D. Cameron⁶; ¹Milan, IT, ²Neu-Isenburg, DE, ³Hamburg, DE, ⁴Besançon, CEDEX/FR, ⁵Manchester, GB, ⁶Edinburgh, GB
- 13:00 - 13:00 313TiP - SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours
J. Baselga¹, J. Cortes², M. De Laurentiis³, V. Dieras⁴, N. Harbeck⁵, J. Hsu⁶, H. Jin⁶, F. Schimmoller⁶, T. Wilson⁶, Y.-H. Im⁷, W. Jacot⁸, I. Krop⁹, S. Verma¹⁰; ¹New York, US, ²Madrid, ES, ³Napoli, IT, ⁴Paris, FR, ⁵München, DE, ⁶San Francisco, US, ⁷Seoul, KP, ⁸Montpellier, FR, ⁹Boston, US, ¹⁰Toronto, CA
- 13:00 - 13:00 314TiP - monarchER: A phase 2 randomized open-label study of abemaciclib plus trastuzumab (T) with or without fulvestrant (F) compared to standard-of-care chemotherapy of physician's choice plus T in women with HR+, HER2+ advanced breast cancer
S. Tolaney¹, N. Bourayou², S. Goel¹, T. Forrester³, F. André⁴; ¹Boston, MA/US, ²Paris, FR, ³Indianapolis, US, ⁴Villejuif, FR



- 13:00 - 13:00 315TiP - HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and T-DM1
J. Cortes¹, S. Verma², S. Hurvitz³, I. Krop⁴, D. Tripathy⁵, D. Yardley⁶, M. Dionne⁷, J. Reynolds⁷, T. Wickham⁷, I. Molnar⁸, K. Miller⁹; ¹Madrid, ES, ²Toronto, CA, ³Santa Monica, US, ⁴Boston, US, ⁵Houston, US, ⁶Nashville, TN/US, ⁷Cambridge, MA/US, ⁸Montville, US, ⁹Indianapolis, IN/US
- 13:00 - 13:00 Clinical trials methodology
- 13:00 - 13:00 316P - Comparison of assessments by blinded independent central reviewers and local investigators: An analysis of phase III randomized control trials on solid cancers (2010-2015)
W. Liang, J. Zhang, Q. He, S. Tang, Y. Zhang, J. He; Guangzhou, CN
- 13:00 - 13:00 317P - Valuing the effect sizes hypothesized in phase 3 trials published from 2005 to 2015
N. Lawrence¹, F. Roncolato², M. Stockler²; ¹Camperdown, NSW/AU, ²Camperdown, AU
- 13:00 - 13:00 318P - Comparison of the EORTC criteria and PERCIST in solid tumors
J.H. Kim, S.H. Park, S.N. Yoon; Seoul, KR
- 13:00 - 13:00 319P - Selective registration of non-primary endpoints in randomized clinical trials in oncology: A comparison of endpoint reporting between clinical trial protocols and US national clinical trial registration
V. Serpas, D. Halperin, K. Raghav, M. Overman; Houston, TX/US
- 13:00 - 13:00 320P - Systematic review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy
P. Bossi¹, L. Botta¹, P. Bironzo², C. Sonetto², G. Musettini³, A. Sbrana³, V. Di Giannantonio¹, L. Locati¹, M. Di Maio², A. Antonuzzo³; ¹Milano, IT, ²Orbassano, IT, ³Pisa, IT
- 13:00 - 13:00 321P - The new European Clinical Trial Regulation: Perception and expectations in Italy
C. Cagnazzo¹, S. Campora², F. Arizio³, E. Marchesi⁴; ¹Candiolo, IT, ²Milano, IT, ³Orbassano, IT, ⁴Bologna, IT
- 13:00 - 13:00 322P - Re-treatments after gamma knife radiosurgery for metastatic brain disease
D. Ten Berge, Z. Sadik, G. Beute, S. Leenstra, B. van der Pol, J. Verheul, P. Hanssens; Tilburg, NL
- 13:00 - 13:00 Developmental therapeutics
- 13:00 - 13:00 368P - Suppression of oncogene transcription - PNA as targeted cancer therapy for BRAF-V600E mutant melanoma
J. Rothman, O. Surriga, G. Ambrosini, S. Vasudeva, G. Schwartz; New York, NY/US
- 13:00 - 13:00 369P - Impact of tumor heregulin mRNA expression on outcome of patients with advanced/metastatic squamous NSCLC treated with lumretuzumab, a glycoengineered monoclonal antibody targeting HER3, in combination with erlotinib



D. Meulendijks¹, U. Lassen², A. Cervantes³, J.-Y. Han⁴, A. Calles⁵, E. Felip⁶, S.-W. Kim⁷, J. Schellens¹, A. Taus⁶, M. Sorensen², T. Fleitas³, B. Bossenmaier⁸, F. Michielin⁹, C. Adessi⁹, G. Meneses-Lorente¹⁰, M. Ceppi⁸, I. James¹¹, W. Jacob⁸, M. Weisser⁸, M. Martinez-Garcia⁶; ¹Amsterdam, NL, ²Copenhagen, DK, ³Valencia, ES, ⁴Goyang, KR, ⁵Madrid, ES, ⁶Barcelona, ES, ⁷Seoul, KR, ⁸Penzberg, DE, ⁹Basel, CH, ¹⁰Welwyn, GB, ¹¹Sandwich, GB

13:00 - 13:00 370P - Phase 1 study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours

J. Rodón¹, K. Peltola², A. Azaro¹, E. Castanon Alvarez³, C. Garratt⁴, H. Leskinen², H. Bjorklund², A. Ruck⁴, C. Massard⁵, P. Bono²; ¹Barcelona, ES, ²Helsinki, FI, ³Pamplona, ES, ⁴Nottingham, GB, ⁵Villejuif, FR

13:00 - 13:00 371P - First-in-human phase 1, dose-escalation and -expansion study of ABBV-399, an antibody-drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors

E. Angevin¹, K. Kelly², R. Heist³, D. Morgensztern⁴, C. Weekes⁵, T. Bauer⁶, R. Ramanathan⁷, J. Nemunaitis⁸, X. Fan⁹, O. Olyae⁹, A. Parikh⁹, E. Reilly⁹, D. Afar¹⁰, L. Naumovski¹⁰, J. Strickler¹¹; ¹Villejuif Cedex, FR, ²Sacramento, CA/US, ³Boston, MA/US, ⁴St. Louis, US, ⁵Aurora, CO/US, ⁶Nashville, TN/US, ⁷Scottsdale, AZ/US, ⁸Dallas, TX/US, ⁹North Chicago, IL/US, ¹⁰Redwood City, CA/US, ¹¹Durham, NC/US

13:00 - 13:00 372P - A phase Ib study of lumretuzumab, a glycoengineered monoclonal antibody targeting HER3, in combination with carboplatin and paclitaxel as 1st-line treatment in patients with squamous non-small cell lung cancer

J.M. Cejalvo¹, T. Fleitas¹, E. Felip², A. Navarro Mendivil², M. Martinez-Garcia², A. Taus², N. Leigh³, U. Lassen⁴, M. Mau Soerensen⁴, C. Adessi⁵, F. Michielin⁵, W. Jacob⁶, I. James⁷, M. Ceppi⁶, M. Weisser⁶, A. Cervantes¹; ¹Valencia, ES, ²Barcelona, ES, ³Toronto, CA, ⁴Copenhagen, DK, ⁵Basel, CH, ⁶Penzberg, DE, ⁷Sandwich, GB

13:00 - 13:00 373P - A phase II study of apatinib, a highly selective inhibitor of VEGFR-2, in patients with metastatic solid tumors without standard treatment options

Y.-K. Kang¹, M.-H. Ryu¹, S.R. Park¹, Y.S. Hong¹, C.-M. Choi¹, T.W. Kim¹, B.-Y. Ryoo¹, J.E. Kim¹, S.-W. Kim¹, J. Weis², G. Gilcrease³, C. Davidson², R. Kingsford², J. Collett², N. Orgain², S.R. Kim¹, C.H. Park³, A. McGinn³, S. Sharma²; ¹Seoul, KR, ²Salt Lake City, UT/US, ³Salt Lake City, US

13:00 - 13:00 374P - Phase I dose escalation (esc) trial of weekly intravenous (i.v.) BI 836845 in Japanese patients (pts) with advanced solid tumors

T. Doi¹, K. Shitara¹, Y. Naito¹, Y. Kuboki¹, T. Kojima¹, A. Hosono¹, T. Yoshino¹, H. Kawamoto¹, Y. Tadayasu², H. Ugai³, Y. Takeuchi³, T. Bogenrieder⁴, K. Yoh¹; ¹Kashiwa, JP, ²Kobe, JP, ³Tokyo, JP, ⁴Vienna, AT

13:00 - 13:00 375P - A phase Ib dose-finding study of alpelisib (ALP; BYL719) and paclitaxel (PTX) in advanced solid tumors (aST)

J. Rodón¹, G. Curigliano², J.-P. Delord³, W. Harb⁴, A. Azaro¹, V. Donnet⁵, Y. Han⁶, L. Blumenstein⁷, C. Wilke⁷, J.T. Beck⁸; ¹Barcelona, ES, ²Milan, IT, ³Toulouse, FR, ⁴Lafayette, IN/US, ⁵Paris, FR, ⁶East Hanover, NJ/US, ⁷Basel, CH, ⁸Lafayetteville, AZ/US



- 13:00 - 13:00 376P - Pharmacokinetics (PK) and pharmacogenetics (PG) of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: A pooled analysis
A. Dymond¹, C. Elks², P. Martin³, D. Carlile⁴, G. Mariani⁴, S. Lovick⁵, Y. Huang⁶, U. Lorch⁷, H. Brown², K. So⁴; ¹Manchester, GB, ²Cambridge, GB, ³München, DE, ⁴Royston, GB, ⁵Macclesfield, GB, ⁶Gaithersburg, MD/US, ⁷London, GB
- 13:00 - 13:00 377P - Phase 1 study of investigational oral mTORC1/2 inhibitor TAK-228 (MLN0128): Tolerability and food effects of a milled formulation in patients (pts) with advanced solid tumors
K. Moore¹, T. Bauer², G. Falchook³, C. Patel⁴, R. Neuwirth⁴, A. Enke⁴, F. Zohren⁴, M. Patel⁵; ¹Oklahoma City, Oklahoma/US, ²Nashville, TN/US, ³Denver, US, ⁴Cambridge, MA/US, ⁵Sarasota, FL/US
- 13:00 - 13:00 378P - Determination of recommended phase II dose of ABTL0812, a novel regulator of Akt/mTOR axis, by pharmacokinetic-pharmacodynamic modelling
J. Alfon¹, L. Vidal², L. Gaba², I. Victoria², M. Gil², B. Laquente², M. Brunet², H. Colom², J. Ramis², H. Perez-Montoyo¹, M. Cortal¹, M. Gomez-Ferrera¹, P. Muñoz¹, T. Erazo², J. Lizcano², C. Domenech¹, P. Gascon²; ¹Cerdanyola, ES, ²Barcelona, ES
- 13:00 - 13:00 379P - Phase II studies of AZD1775, a WEE1 kinase inhibitor, and chemotherapy in non-small-cell lung cancer (NSCLC): Lead-in cohort results
D. Spigel¹, S. Dakhil², J.T. Beck³, A. Sadiq⁴, S. Menon⁵, C. Webb⁶, F. Tsai⁷, M. Johnson⁸, S. Jones⁸, C. Greenlees⁹, D. Stults⁸, D. Strickland⁸, C. Cook¹⁰, G. Mugundu¹¹, N. Laing¹⁰, T. French¹², H. Burris¹; ¹Nashville, US, ²Wichita, KS/US, ³Lafayetteville, AZ/US, ⁴Fort Wayne, AR/US, ⁵Fayetteville, TN/US, ⁶Louisville, KY/US, ⁷Scottsdale, AZ/US, ⁸Nashville, TN/US, ⁹London, GB, ¹⁰Boston, MA/US, ¹¹Waltham, MA/US, ¹²Cambridge, GB
- 13:00 - 13:00 380P - Modeling of pharmacokinetics, thrombocytopenia, plasma GDF-15 levels and tumor kinetics in response to treatment with the p53-HDM2 protein-protein interaction inhibitor NVP-CGM097
C. Meille¹, N. Guerreiro¹, S. Bauer², P. Cassier³, G. Demetri⁴, R. Dummer⁵, D. Tan⁶, L. Van Bree¹, T. Ramkumar⁷, E. Halilovic⁷, S. Jeay¹, A. Jullion¹, F. Hourcade-Potelleret¹, J. Wuerthner¹; ¹Basel, CH, ²Essen, DE, ³Lyon, FR, ⁴Boston, US, ⁵Zürich, CH, ⁶Singapore, SG, ⁷Cambridge, MA/US
- 13:00 - 13:00 381P - A phase I, open-label, study of GSK2879552, a lysine-specific demethylase 1 (LSD1) inhibitor, in patients with relapsed/refractory small cell lung carcinoma (SCLC)
V. Moreno¹, T. Bauer², J. Infante², R. Govindan³, B. Besse⁴, E. Bertino⁵, A. Martinez Marti⁶, T. Piontek⁷, A. Dhar⁸; ¹Madrid, ES, ²Nashville, TN/US, ³St Louis, MO/US, ⁴Villejuif, FR, ⁵Columbus, OH/US, ⁶Barcelona, ES, ⁷Collegeville, PA/US, ⁸Collegeville, US
- 13:00 - 13:00 382P - Preclinical characterization of the selective DNA-dependent protein kinase (DNA-PK) inhibitor VX-984 in combination with chemotherapy
D. Boucher, S. Hillier, D. Newsome, Y. Wang, D. Takemoto, Y. Gu, W. Markland, R. Hoover, R. Arimoto, J. Maxwell, S. Fields, P. Charifson, M. Penney, K. Tanner; Boston, MA/US
- 13:00 - 13:00 383P - RAS/AKT pathway mutations as predictive biomarkers in patients with colorectal cancer treated with the exportin 1 (XPO1) inhibitor selinexor (SEL) – inhibition of nuclear-cytoplasmic translocation of p27 as a mechanism of anti-tumour activity



V. Heong, P. Koe, W.P. Yong, R. Soo, C.E. Chee, A. Wong, Y.L. Thian, R. Sundar, J.S. Ho, A. Gopinathan, S.C. Lee, B.C. Goh, D. Tan; Singapore, SG

- 13:00 - 13:00 384P - Initial first-in-human phase 1 results of PTC596, a novel small molecule that targets cancer stem cells (CSCs) by reducing BMI1 protein levels
G. Shapiro¹, J. Infante², T. Bauer², A. Prawira³, P. Bedard³, O. Laskin⁴, M. Weetall⁵, J. Baird⁵, E. O'Mara⁴, R. Spiegel⁴; ¹Boston, US, ²Nashville, TN/US, ³Toronto, CA, ⁴South Plainfield, US, ⁵South Plainfield, NJ/US
- 13:00 - 13:00 385P - Phase 1/2a study of RX-5902 in advanced solid tumors (ST): An orally bioavailable inhibitor of phosphorylated P68 and modulator of β -catenin nuclear translocation
S.G. Eckhardt¹, W. Gluck², M. Gutierrez³, C. Peterson⁴, R. Mazhari⁴, E. Benaim⁴; ¹Denver, US, ²Greenville, SC/US, ³Hackensack, NJ/US, ⁴Rockville, MD/US
- 13:00 - 13:00 386P - PISARRO: A EUTROC phase 1b study of APR-246 with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in relapsed platinum-sensitive high grade serous ovarian cancer (HGSOC)
B. Basu¹, C. Gourley², H. Gabra³, I. Vergote⁴, J. Brenton¹, L. Abrahmsen⁵, A. Smith⁶, M. Von Euler⁵, J. Green⁷; ¹Cambridge, GB, ²Edinburgh, GB, ³London, GB, ⁴Leuven, BE, ⁵Solna, SE, ⁶Crawley, GB, ⁷Liverpool, GB
- 13:00 - 13:00 387P - Phase I dose of oral quisinostat, in combination with gemcitabine (G) and cisplatin (Cis) or paclitaxel (P) and carboplatin (Carbo) in patients (pts) with non-small cell lung cancer or ovarian cancer (OC)
M. Fedyanin¹, S. Tjulandin¹, S. Cheporov², V. Vladimirov³, V. Moiseenko⁴, S. Orlov⁴, G. Manikhas⁵, A. Cakana⁶, V. Azarova¹, O. Karavaeva¹, N. Vostokova¹, S. Baranovskiy⁷; ¹Moscow, RU, ²Yaroslavl, RU, ³Pyatigorsk, RU, ⁴Saint Petersburg, RU, ⁵St-Petersburg, RU, ⁶Beerse, BE, ⁷Himki, RU
- 13:00 - 13:00 388P - A first-in-human (FIH) phase I/II, dose escalation, pharmacokinetic (PK) study to assess the safety and tolerability of VAL-201 in patients with advanced prostate cancer (APC) and other advanced solid tumours
R. Kristeleit, R. Miller, L. Sellers, N. Brown, P. Gougis, A. Boyd, G. Morris, H. Payne, S. Hughes, M. Forster, M. Linch; London, GB
- 13:00 - 13:00 389P - Biomarker and clinical activity of CPI-444, a novel small molecule inhibitor of A2A receptor (A2AR), in a Ph1b study in advanced cancers
I. McCaffery¹, G. Laport², A. Hotson², S. Willingham², A. Patnaik³, M. Beeram³, R. Miller²; ¹San Francisco, US, ²Burlingame, CA/US, ³San Antonio, TX/US
- 13:00 - 13:00 390P - Identification of new prognostic factors in phase I patients treated by immunotherapy
F. Bigot¹, E. Castanon Alvarez², A. Hollebecque¹, A. Carmona³, S. Postel-Vinay¹, E. Angevin¹, J.-P. Armand¹, V. Ribrag¹, S. Aspeslagh¹, A. Varga¹, R. Bahleda¹, A. Gazzah¹, C. Bonnet¹, J.-M. Michot¹, A. Marabelle¹, J.-C. Soria¹, C. Massard¹; ¹Villejuif, FR, ²Pamplona, ES, ³Murcia, ES
- 13:00 - 13:00 391P - Lurbinectedin (PM01183) plus paclitaxel (P), recommended dose (RD) expansion results with or without the addition of bevacizumab (Bev) in patients (pts) with selected solid tumors



A. Drlon¹, E. Garralda², A. Stathis³, S. Szyldergemajn⁴, D. Hyman¹, V. Boni², G. Griguolo⁵, E. Jimenez Martinez⁴, V. Makker¹, L. Canziani³, C. Fernandez Teruel⁴, A. Soto-Matos⁴, C. Sessa³, E. Calvo²; ¹New York, US, ²Madrid, ES, ³Bellinzona, CH, ⁴Colmenar Viejo, ES, ⁵Padova, IT

13:00 - 13:00 392P - Lurbinectedin (PM01183) administered once (D1) every 3 weeks (q3w) in combination with capecitabine (XEL) in patients (pts) with metastatic breast (MBC), colorectal (CRC) or pancreatic (PaC) cancer

T. Sauri¹, A. Awada², E. Calvo³, V. Moreno³, S. Szyldergemajn⁴, E. Elez¹, P. Barthelemy⁵, V. Boni³, B. Doger³, C. Fernandez Teruel⁴, A. Soto-Matos⁴, J. Taberner¹, P. Aftimos²; ¹Barcelona, ES, ²Brussels, BE, ³Madrid, ES, ⁴Colmenar Viejo, ES, ⁵Strasbourg, FR

13:00 - 13:00 393P - Evaluation of weekly dosing of CRLX101 alone and in combination with bevacizumab (bev) in patients (pts) with advanced solid tumors

N. Lakhani¹, S. Piha-Paul², A. Senderowicz³, K. Caliri³, T. Crowell³, H. Wang³, A. Tolcher⁴; ¹Grand Rapids, US, ²Houston, US, ³Waltham, MA/US, ⁴San Antonio, US

13:00 - 13:00 394P - Pharmacokinetics (PK) of CRLX101 administered weekly in patients (pts) with advanced solid tumors

H. Wang¹, W. Zamboni², A. Tolcher³, N. Lakhani⁴, S. Piha-Paul⁵, K. Caliri¹, T. Crowell¹, A. Senderowicz¹; ¹Waltham, MA/US, ²Chapel Hill, US, ³San Antonio, US, ⁴Grand Rapids, US, ⁵Houston, US

13:00 - 13:00 395P - Phase 1 dose-escalation study of the folic acid-tubulysin small-molecule drug conjugate (SMDC) folate-tubulysin EC1456: Study update

J. Sachdev¹, M. Edelman², W. Harb³, A. Armour⁴, D. Wang⁵, A. Starodub⁶; ¹Scottsdale, AZ/US, ²Baltimore, US, ³Lafayette, IN/US, ⁴Indianapolis, IN/US, ⁵Detroit, MI/US, ⁶Goshen, IN/US

13:00 - 13:00 396P - RX-3117, an oral antimetabolite to treat advanced solid tumors (ST): Phase 1 and ongoing phase 2a results

D. Rasco¹, C. Peterson², R. Mazhari², E. Benaim², J. Merchan³; ¹San Antonio, TX/US, ²Rockville, MD/US, ³Miami, FL/US

13:00 - 13:00 397P - Phase 1 study of sorafenib and eribulin in patients with advanced, metastatic or refractory solid tumors

F. Marmé¹, C. Gomez-Roca², K. Graudenz³, F. Huang⁴, J. Lettieri⁴, C. Pena⁴, Z. Trnkova³, J. Eucker³; ¹Heidelberg, DE, ²Toulouse, FR, ³Berlin, DE, ⁴Whippany, NJ/US

13:00 - 13:00 398P - Phase Ib/II trial of NC-6004 (nanoparticle cisplatin) plus gemcitabine (G) in pts with advanced solid tumors

V. Subbiah¹, A. Combest², J. Griley-Olsen³, N. Sharma⁴, E. Andrews⁵, I. Bobe⁶, J. Balkissoon⁷, A. Camp⁸, A. Masada⁹, D. Reitsma¹⁰, L. Bazhenova¹¹; ¹Houston, TX/US, ²Wilmington, NC/US, ³Chapel Hill, NC/US, ⁴Cleveland, OH/US, ⁵Raleigh, NC/US, ⁶Danville, VA/US, ⁷San Francisco, CA/US, ⁸Austin, TX/US, ⁹Tokyo, JP, ¹⁰Rockville, MD/US, ¹¹La Jolla, US

13:00 - 13:00 399P - A phase I dose-escalation trial of bi-daily (BID) weekly oral docetaxel as ModraDoc006 in combination with ritonavir



V. de Weger¹, F. Stuurman¹, M. Mergui-Roelvink¹, B. Nuijen¹, A. Huitema¹, J. Beijnen², J. Schellens¹, S. Marchetti¹; ¹Amsterdam, NL, ²Utrecht, NL

- 13:00 - 13:00 400P - Correlations for tested doses and toxicities between first-in-human trials and registration trials of FDA-approved monoclonal antibodies
M. Viala¹, M. Vinches¹, C. Mollevi¹, L. Gianni², C. Gongora¹, D. Tosi¹; ¹Montpellier, FR, ²Milano, IT
- 13:00 - 13:00 401P - The use of next generation sequencing (NGS) to guide patient selection for phase 1 clinical trials
R. Miller, N. Brown, A. Speirs, H. Shaw, S. Adeleke, P. Gougis, P. Bennett, T. Meyer, C. Swanton, M. Forster, R. Kristeleit; London, GB
- 13:00 - 13:00 402P - Retrospective review of new phase I clinic referrals and enrolment in the molecular screening era
M. Rheaume¹, L. Wang², E. Brookes², H. Chow², A. Spreafico², A. Hansen¹, A. Rasak², L. Siu², P. Bedard²; ¹Toronto, CA, ²Toronto, ON/CA
- 13:00 - 13:00 403P - Clinical outcomes and predicting early death in early phase trials: The NIHR UCLH clinical research facility (CRF) experience
N. Brown, S. Ganguli, A. Kirkwood, G. Imseeh, R. Kristeleit, M. Forster, T. Meyer; London, GB
- 13:00 - 13:00 404P - Clinical outcome of patients with advanced biliary tract cancer in a dedicated phase 1 unit
R. Sundar¹, A. Custodio¹, J. Lim¹, M. Chenard-Poirier¹, D. Collins¹, S. Kaye¹, T. Yap¹, U. Banerji², J. Lopez¹, J. de Bono¹; ¹London, GB, ²Sutton, GB
- 13:00 - 13:00 405P - Patients with metastatic prostate cancer enrolled in phase 1 trials: Outcomes and molecular alterations
C. Bonnet¹, E. Castanon Alvarez², J.-M. Michot³, F. Bigot³, A. Varga³, A. Gazzah³, R. Bahleda³, A. Marabelle³, A. Hollebecque³, S. Aspeslagh³, E. Angevin³, J.-P. Armand³, L. Albiges³, Y. Loriot³, S. Postel-Vinay³, J.-C. Soria³, C. Massard³; ¹Paris, CEDEX 14/FR, ²Pamplona, ES, ³Villejuif, FR
- 13:00 - 13:00 406P - Does dose affect tumour response in phase I oncology trials of non-cytotoxic agents?
J. Ghosh¹, G. Lazaridis², Z. Viney¹, H. Verma¹, I. Sheriff¹, Y. Wang¹, J. Spicer¹, H. Moller¹, D. Sarker¹; ¹London, GB, ²Thessaloniki, GR
- 13:00 - 13:00 407TiP - Phase 1 study of LOXO-101, a selective TRK inhibitor, in pediatric patients with cancer
T. Laetsch¹, R. Nagasubramanian², S. Dubois³, L. Mascarenhas⁴, D. Hawkins⁵, N. Shukla⁶, B. Turpin⁷, S. Smith⁸, M. Reynolds⁸, S. Cruickshank⁸, L. Donahue⁹, M. Cox⁸, A. Pappo¹⁰; ¹Dallas, TX/US, ²Orlando, FL/US, ³Boston, MA/US, ⁴Los Angeles, CA/US, ⁵Seattle, WA/US, ⁶New York, NY/US, ⁷Cincinnati, OH/US, ⁸South San Francisco, CA/US, ⁹Stamford, CT/US, ¹⁰Memphis, TN/US
- 13:00 - 13:00 408TiP - CamBMT1: A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases (mets) for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy



R. Baird¹, J. Garcia-Corbacho¹, N. Ramenatte¹, A. Jonson¹, S. Ahmad¹, D.-M. Smith¹, W. Qian¹, S. Kumar¹, C. Linossi¹, T. Matys¹, M. Graves¹, D. Jodrell¹, C. Caldas¹, S. Pacey¹, G. Whitfield², A. Chalmers³, R. Jena¹, S. Price¹, S. Jefferies¹, C. Watts¹; ¹Cambridge, GB, ²Manchester, GB, ³Glasgow, GB

- 13:00 - 13:00 409TiP - A phase II basket study of the oral TRK inhibitor LOXO101 in adult subjects with NTRK fusion-positive tumors
A. Drlon¹, D. Hong², J. Deeken³, S. Smith⁴, M. Reynolds⁴, S. Cruickshank⁴, M. Deegan⁴, N. Ku⁴, D. Hyman¹; ¹New York, US, ²Houston, US, ³Fairfax, US, ⁴San Francisco, US
- 13:00 - 13:00 410TiP - Phase 2, open-label study of ceritinib in patients (pts) with advanced non-lung solid tumors and hematological malignancies characterized by genetic abnormalities in anaplastic lymphoma kinase (ALK) using a flexible adaptive design: ASCEND-10
I. Kiss¹, J. Rodón², E. Grande Pulido³, S.Y. Rha⁴, S. Sathornsumetee⁵, G. Hess⁶, E. Eigendoff⁷, D. Cestic⁸, S. Sutradhar⁸, B. Pramanik⁸, T.M. Kim⁴; ¹Brno, CZ, ²Barcelona, ES, ³Madrid, ES, ⁴Seoul, KR, ⁵Bangkok, TH, ⁶Mainz, DE, ⁷Jena, DE, ⁸East Hanover, NJ/US
- 13:00 - 13:00 411TiP - First-in-human trial of 4'-thio-2'-deoxycytidine (TdCyd) in patients with advanced solid tumors
G. O'Sullivan Coyne¹, A. Chen², S. Kummar³, J. Collins², R. Meehan², M. Suto⁴, L. Rubinstein¹, R. Kinders⁵, N. Moore¹, R. Parchment⁵, Y. Horneffer², L. Juwara¹, M. Difilippantonio², R. Piekarczyk², J. Doroshov²; ¹Bethesda, US, ²Bethesda, MD/US, ³Palo Alto, CA/US, ⁴Birmingham, US, ⁵Frederick, US
- 13:00 - 13:00 412TiP - The Tailored EDVTM trial: A phase I feasibility study evaluating EGFR-targeted EDVTM nanocells as a therapy platform in patients with refractory advanced solid tumours
S. Clarke¹, S. Sidhu¹, N. Pavlakis¹, H. Brahmabhatt², J. Macdiarmid²; ¹Sydney, AU, ²Sydney, NSW/AU
- 13:00 - 13:00 413TiP - A dose-escalation study of weekly intravenous CRLX301 in patients with advanced solid tumor malignancies
H. Wang¹, B. Markman², P. de Souza³, E. Dees⁴, T. Gangadhar⁵, S. Piha-Paul⁶, W. Zamboni⁴, C. Murphy¹, A. Senderowicz¹; ¹Waltham, MA/US, ²Melbourne, AU, ³Sydney, AU, ⁴Chapel Hill, NC/US, ⁵Philadelphia, US, ⁶Houston, US
- 13:00 - 13:00 414TiP - Agnostos precision medicine project in patients (PTS) with cancer of unknown primary (CUP)
E. Geuna¹, S. Benvenuti¹, F. Verginelli¹, D. Galizia¹, S. Siena², G.M. Stella³, A. Gentile¹, M. Milan¹, A.R. Virzi¹, A. D'ambrosio¹, P. Cassoni⁴, R. Senetta¹, A. Balsamo¹, M. Spione¹, A. Nuzzo¹, A. Sapino¹, S. Marsoni¹, C. Boccaccio¹, P.M. Comoglio¹, F. Montemurro¹; ¹Candiolo, IT, ²Milano, IT, ³Pavia, IT, ⁴Torino, IT
- 13:00 - 13:00 415TiP - ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
B. Shah¹, J. Castro², N. Gökbuget³, M. José Kersten⁴, T. Hagenbeek⁴, W. Wierda⁵, G. Schiller⁶, A. Bot⁷, J. Rossi⁷, Y. Jiang⁷, L. Navale⁷, S. Stout⁷, J. Aycocock⁷, J. Wiezorek⁷, R. Jain⁷; ¹Tampa, FL/US, ²La Jolla, US, ³Frankfurt Am Main, DE, ⁴Amsterdam, NL, ⁵Houston, TX/US, ⁶Los Angeles, CA/US, ⁷Santa Monica, CA/US



- 13:00 - 13:00 New diagnostics
- 13:00 - 13:00 1160P - Genetic testing by a novel high-purity concentration system for circulating tumor cells independent of epithelial markers
H. Ito¹, H. Takagi¹, M. Kozuka¹, S.H. Kim², M. Hirai¹, T. Fujii²; ¹Kyoto, JP, ²Tokyo, JP
- 13:00 - 13:00 1161P - Utility of a targeted NGS oncology assay for circulating tumor DNA in a multi-histology clinical setting
T. Eerkes¹, A. Ademi Santiago-Walker², M. Loreen³, L. Lim¹, J. Hernandez⁴, C. Raymond¹, S. Henderson¹, D. Dipasquo¹, T. Shaffer¹, C. Motely², C. Moy², S. Wallace³, K. Eaton³, J. Karkera², M. Li¹; ¹Bellevue, US, ²Raritan, US, ³Seattle, WA/US, ⁴Bellevue, WA/US
- 13:00 - 13:00 1162P - Analytical performance of a new liquid biopsy mutation panel for detection of clinically actionable variants
C. Svedman, G. Alexander, A. Bergamaschi, J. Han, P. Harrington, C.-J. Ku, Y. Ma, W. Gibb, A. Dei Rossi, L. Shen, A. Goddard, D. Eberhard, K. Clark-Langone; Redwood City, CA/US
- 13:00 - 13:00 1163P - Copy number variant detection by anchored multiplex PCR and next-generation sequencing
J. Haimes, J. Covino, N. Manoj, E. Baravik, L. Johnson, L. Griffin, J. Stahl, J. Myers, B. Culver, B. Kudlow; Boulder, CO/US
- 13:00 - 13:00 1164P - Comprehensive profiling of thyroid and lung cancers by anchored multiplex PCR and next-generation sequencing
J. Stahl, J. Haimes, L. Johnson, J. Covino, N. Manoj, M. Bessette, E. Baravik, A. Licon, R. Walters, L. Griffin, J. Myers, B. Culver, B. Kudlow; Boulder, CO/US
- 13:00 - 13:00 1165P - Genetic aberrations driving MET deregulation detected with anchored multiplex PCR and next-generation sequencing
B. Kudlow¹, J. Haimes¹, M. Bessette¹, N. Manoj¹, L. Griffin¹, D. Murphy², R. Shoemaker², J. Myers¹, J. Stahl¹; ¹Boulder, CO/US, ²San Diego, CA/US
- 13:00 - 13:00 1166P - Internal tandem duplications in FLT3 detected by anchored multiplex PCR and next-generation sequencing
B. van Deusen, M. Bessette, L. Johnson, A. Berlin, M. Banos, L. Griffin, E. Reckase, J. Stahl, A. Licon, J. Myers, B. Kudlow; Boulder, CO/US
- 13:00 - 13:00 1167P - Functional characterization of variants of unknown significance (VUS) in patients and their responsiveness to targeted therapy drugs (TTD)
G. Tarcic¹, C. Walko², H. McLeod², J. Hicks², Z. Barbash¹, O. Edelheit¹, B. Miron¹, M. Vidne¹, E. Padron²; ¹Jerusalem, IL, ²Tampa, FL/US
- 13:00 - 13:00 1168P - Functional characterization of mutations and their interaction using the novel functional annotation for cancer treatment (FACT) platform
B. Miron¹, N. Peled², Z. Barbash¹, O. Edelheit¹, M. Vidne¹, R. Sharivkin¹, G. Tarcic¹; ¹Jerusalem, IL, ²Petach Tiqwa, IL



- 13:00 - 13:00 1169P - Validation of novel diagnostic kits using the semi-dry dot-blot method for detecting metastatic lymph nodes in breast cancer; distinguishing macrometastases and micrometastases
R. Otsubo¹, H. Hirakawa², M. Oikawa³, A. Tanaka¹, M. Matsumoto¹, H. Yano¹, N. Kinoshita¹, K. Abe¹, J. Fukuoka¹, T. Nagayasu¹; ¹Nagasaki, JP, ²Chiba, JP, ³Fukuoka, JP
- 13:00 - 13:00 1170P - A novel Tc-99m and fluorescence labeled peptide: Multimodal imaging agent for targeting angiogenesis in a murine tumor model
D.-W. Kim¹, S.-G. Kim¹, M.H. Kim¹, W.H. Kim², C.G. Kim¹; ¹Iksan, KR, ²Jeon Ju, KR
- 13:00 - 13:00 1171P - The SP142 PD-L1 IHC assay for atezolizumab (atezo) reflects pre-existing immune status in NSCLC and correlates with PD-L1 mRNA
J. Williams¹, M. Kowanetz², H. Koeppen¹, Z. Boyd³, E. Kadel III¹, D. Smith¹, M. McClelland¹, W. Zou¹, P. Hegde¹; ¹South San Francisco, CA/US, ²South San Francisco, AM, ³South San Francisco, US
- 13:00 - 13:00 1172P - NSCLC multiplex IHC diagnosis of small biopsies
K. Holmstrøm¹, T. Møller², H. Stender³, M. Kristensson², B. Nielsen², E. Santoni-Rugiu¹; ¹Copenhagen, DK, ²Hørsholm, DK, ³Gentofte, DK
- 13:00 - 13:00 1173P - Fully automated and sensitive detection of EGFR exon 18, 19, 20 and 21 mutational status in less than 2.5 hours from a single FFPE slice
M. Reijans¹, G. Vandercruyssen¹, I. Keuleers¹, C. Vandesteene¹, I. Vandenbroucke², G. Maertens¹, E. Sablon¹; ¹Mechelen, BE, ²Niel, BE
- 13:00 - 13:00 1174P - Detection of NRAS, KRAS and BRAF mutations in FFPE derived DNA with a novel targeted resequencing-based diagnostics assay
C. Marques, K. Bettens, D. Goossens, L. Heyrman, C. Heusdens, S. Kupers, S. Berwouts, D. Van Barel, A. Rotthier, J. Del-Favero; Antwerp, BE
- 13:00 - 13:00 1175P - Ultra-rapid, sensitive, and fully automated extended RAS testing for metastatic colorectal cancer – evaluation of an NRAS/BRAF/EGFR492 module
E. Vercauteren¹, E. Bellon¹, K. Vermeiren¹, F. De Freitas¹, E. De Haes¹, S. Van Gestel¹, S. Murray², M. Grauslund³, L. Melchior³, N. D'Haene⁴, M. Le Mercier⁴, B. Bellosillo⁵, C. Montagut⁵, M. Van Brussel¹, E. Sablon¹, G. Maertens¹; ¹Mechelen, BE, ²Athens, GR, ³Copenhagen, DK, ⁴Brussels, BE, ⁵Barcelona, ES
- 13:00 - 13:00 1176P - Hybrid-capture based sequencing assays to detect novel alterations in BRAF from tissue and liquid biopsies
J. Müller¹, S. Lakis², E. Mariotti², P. Schneider², C. Glöckner², F. Leenders², A. Hube², G. Gullo³, J. Crown³, F. Griesinger⁴, J. Heuckmann², L. Heukamp², R. Menon²; ¹Cologne, DE, ²Köln, DE, ³Dublin, IE, ⁴Oldenburg, DE
- 13:00 - 13:00 1177TiP - Early non-invasive detection of gastric cancer with plasma pepsinogens in Croatian patients
D. Trivanovic, L. Honovic, J. Vlastic, I. Hrstic; Pula, HR
- 13:00 - 13:00 Sarcoma



- 13:00 - 13:00 1406P - Update of the T-DIS randomized phase II trial: Trabectedin rechallenge versus continuation in patients (pts) with advanced soft tissue sarcoma (ASTS)
N. Kotecki¹, A. Le Cesne², E. Tresch-Bruneel¹, O. Mir², C. Chevreau³, F. Bertucci⁴, C. Delcambre⁵, E. Saada-Bouid⁶, S. Piperno-Neumann⁷, J.-O. Bay⁸, I. Ray-Coquard⁹, T. Ryckewaert¹, N. Isambert¹⁰, A. Italiano¹¹, S. Clisant¹, J.-Y. Blay⁹, N. Penel¹; ¹Lille, FR, ²Villejuif, FR, ³Toulouse, FR, ⁴Marseille, FR, ⁵Caen, FR, ⁶Nice, FR, ⁷Paris, FR, ⁸Clermont-Ferrand, FR, ⁹Lyon, FR, ¹⁰Dijon, FR, ¹¹Bordeaux, FR
- 13:00 - 13:00 1407P - First line therapy with aldoxorubicin and 14 days continuous infusion of ifosfamide/mesna in metastatic or locally advanced sarcomas: A phase I-II study
S. Chawla¹, K. Sankhala¹, S. Chawla², V. Chua¹, E. Gordon¹, N. Chawla¹, K. Sung², D. Quon¹, K. Kim¹, L. Fernandez¹, B. Leong¹, S. Wieland², D. Levitt²; ¹Santa Monica, US, ²Los Angeles, US
- 13:00 - 13:00 1408P - A phase II trial of pazopanib in patients with metastatic alveolar soft part sarcoma
M. Kim, T.M. Kim, B. Keam, D.-W. Kim, D.S. Heo; Seoul, KR
- 13:00 - 13:00 1409P - Tolerability of modified gemcitabine/docetaxel (split-dose) in patients with advanced soft tissue sarcomas
R. Azevedo¹, N. Fraile², E. Saadi Neto³, R.V. Lopez³, D. Tolo², P. Hoff², O. Feher², V. Camargo², R. Munhoz²; ¹São Paulo, SP/BR, ²Sao Paulo, BR, ³São Paulo, BR
- 13:00 - 13:00 1410P - Pazopanib in advanced vascular sarcomas: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis
A. Kollar¹, R. Jones², S. Stacchiotti³, H. Gelderblom⁴, M. Guida⁵, P. Boccone⁶, N. Steeghs⁷, A. Safwat⁸, D. Katz⁹, F. Duffaud¹⁰, S. Sleijfer¹¹, W. van der Graaf², N. Touati¹², S. Litière¹², S. Marreaud¹², A. Gronchi¹³, B. Kasper¹⁴; ¹Bern, CH, ²London, GB, ³Milano, IT, ⁴Leiden, NL, ⁵Bari, IT, ⁶Torino, IT, ⁷Amsterdam, NL, ⁸Aarhus C, DK, ⁹Jerusalem, IL, ¹⁰Marseille, FR, ¹¹Rotterdam, NL, ¹²Brussels, BE, ¹³Milan, IT, ¹⁴Mannheim, DE
- 13:00 - 13:00 1411P - Patient perspective of the diagnostic sarcoma pathway; Results from a national sarcoma patient survey in England
E. Younger, J. Whelan, R. Jones, L. Bennister, W. van der Graaf; London, GB
- 13:00 - 13:00 1412P - Dissecting the role of tumor-infiltrating lymphocytes (TIL) in patients with high-risk soft-tissue sarcoma (STS) receiving neo-adjuvant chemotherapy (NAC) with regional hyperthermia (RHT)
R. Issels, V. Büclein, E. Kampmann, T. Knösel, E. Nössner, M. Subklewe, L. Lindner; München, DE
- 13:00 - 13:00 1413P - ATRX-associated alternative lengthening of telomere (ALT) may be correlated with chemotherapy response in leiomyosarcoma (LMS)
P.-H. Huang, R.-L. Hong, Y.-M. Jeng, J.-Y. Liao, W.-W. Chen; Taipei, TW
- 13:00 - 13:00 1414P - Possible prognostic value of local immunity cellular factors in primary and recurrent soft tissue sarcomas
E. Zlatnik, O. Kit, I. Novikova, T. Aliev, E. Nepomnyashchaya, T. Ausheva, O. Selyutina, I. Dashkova, L. Vashchenko, E. Andreyko, E. Kechedzhieva, I. Sidorenko, E. Velieva; Rostov On Don, RU



- 13:00 - 13:00 1415P - Long-term safety of regorafenib (REG) in advanced gastrointestinal stromal tumors (GIST): Updated safety data of the phase 3 GRID trial
G. Demetri¹, P. Reichardt², Y.-K. Kang³, J.-Y. Blay⁴, H. Joensuu⁵, C. Kappeler², C. Wuchter-Czerwony², J. Chung², A. Wagner², P. Casali⁶; ¹Boston, MA/US, ²Berlin, DE, ³Seoul, KR, ⁴Lyon, FR, ⁵Helsinki, FI, ⁶Milano, IT
- 13:00 - 13:00 1416P - Predictive factors for toxicity and survival of second line sunitinib in advanced gastrointestinal stromal tumours (GIST)
D. Den Hollander¹, W. van der Graaf¹, I. Desar¹, O. Mir², S. Dumont², A. Le Cesne²; ¹Nijmegen, NL, ²Villejuif, FR
- 13:00 - 13:00 1417P - Prediction of long-term survival in metastatic gastrointestinal stromal tumour: Analysis of a large, single-institution patient cohort
I. Hompland, Ø. Bruland, J. Poulsen, S. Stoldt, T. Hølmekjær, K.S. Hall, K. Boye; Oslo, NO
- 13:00 - 13:00 1418P - The role of neoadjuvant imatinib therapy of patients with primary locally advanced GIST
P. Arkhiri, I. Poddubnaya, S. Nered, V. Bokhian, I. Peregorodiev, M. Nikulin, I. Stilidi; Moscow, RU
- 13:00 - 13:00 1419P - Prospective analysis in GIST patients on the role of alpha-1 acid glycoprotein (AGP) in imatinib exposure
S. Bins, K. Eechoute, J. Kloth, F. de Man, A. Oosten, P. de Bruijn, S. Sleijfer, R. Mathijssen; Rotterdam, NL
- 13:00 - 13:00 1420TiP - ANNOUNCE 2: An open-label phase 1b, and a randomized, double-blind phase 2 study of olaratumab with gemcitabine plus docetaxel in the treatment of patients with advanced soft tissue sarcoma (STS)
A. Redondo¹, C. Valverde Morales², N. Hindi³, J. Lopez-Martin¹, G. Honigschmidt⁴, Y. Zeng⁴, J. Chen⁴, D. Tai⁴, G. Mo⁴, R. Ilaria Jr⁴, N. Pillay¹, N. Drove⁴, M. Jamarik⁵; ¹Madrid, ES, ²Barcelona, ES, ³Sevilla, ES, ⁴Indianapolis, US, ⁵Bratislava, SK
- 13:00 - 13:00 1421TiP - A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high grade undifferentiated uterine sarcoma (HGUS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment
I. Ray-Coquard¹, A.P. Dei Tos², C. Coens³, M. Huizing⁴, A. Casado Herraes⁵, A. Westermann⁶, E. Bompas⁷, H. Earl⁸, M.L. Hensley⁹, A. Negrouk³, N. Reed¹⁰; ¹Lyon, FR, ²Treviso, IT, ³Brussels, BE, ⁴Edegem, BE, ⁵Madrid, ES, ⁶Amsterdam, NL, ⁷Saint-Herblain, FR, ⁸Cambridge, GB, ⁹New York, NY/US, ¹⁰Glasgow, GB
- 13:00 - 13:00 1422TiP - Phase II, single-arm, non-randomized, and multicenter clinical trial of regorafenib (REG) as a single agent in the first-line setting for patients with metastatic and/or unresectable KIT/PDGFR wild-type GIST. A GEIS and ISG study
J. Martín Broto¹, E. Fumagalli², V. Martínez³; ¹Sevilla, ES, ²Milano, IT, ³Madrid, ES
- 13:00 - 13:00 Translational research



- 13:00 - 13:00 1522P - Mouse clinical trials of pancreatic cancer: Integration of PDX models with genomics to improve patient outcomes to chemotherapeutics
A. Davies¹, M. Hidalgo², J. Stebbing³, D. Ciznadija¹, A. Katz¹, D. Sidransky⁴; ¹Hackensack, US, ²Madrid, ES, ³London, GB, ⁴Baltimore, MD/US
- 13:00 - 13:00 1523P - Using mouse and human pancreatic organoids to infer resistance to targeted therapy
M. Ponz-Sarvisé¹, V. Corbo², K. Frese³, H. Tiriác², D. Engle², D. Filipini², K. Wright², Y. Park², K. Yu², Ö. Daniel², D. Tuveson²; ¹Pamplona, ES, ²Cold Spring Harbor, NY/US, ³Oxford, GB
- 13:00 - 13:00 1524P - Generation and characterization of a collection of patient-derived xenografts (PDX) models for translational lung cancer research
S. Molina-Pinelo¹, R. Meléndez², R. Suarez¹, L. García¹, L. Ojeda¹, P. Yague¹, L. Paz-Ares¹, I. Ferrer¹; ¹Madrid, ES, ²Sevilla, ES
- 13:00 - 13:00 1525P - Prevalence and clinical associations of PTEN loss in non-small cell lung carcinoma (NSCLC) patients (pts) of the European Thoracic Oncology Platform (ETOP) Lungscape cohort
A. Soltermann¹, U. Rulle¹, O. Dafni², E. Verbeke³, E. Thunnissen⁴, A. Warth⁵, R. Cheney⁶, A. Sejda⁷, E.-J. Speel⁸, L. Bille Madsen⁹, D. Nonaka¹⁰, A. Navarro¹¹, I. Sansano¹², A. Marchetti¹³, S. Finn¹⁴, R. Kammler¹⁵, K. Schulze¹⁶, L. Bubendorf¹⁶, R.A. Stahel¹, O.B.O. Lungscape¹⁵; ¹Zürich, CH, ²Athens, GR, ³Leuven, BE, ⁴Amsterdam, NL, ⁵Heidelberg, DE, ⁶Buffalo, NY/US, ⁷Gdansk, PL, ⁸Maastricht, NL, ⁹Aarhus C, DK, ¹⁰Manchester, GB, ¹¹Valencia, ES, ¹²Barcelona, ES, ¹³Chieti, IT, ¹⁴Dublin, IE, ¹⁵Bern, CH, ¹⁶Basel, CH
- 13:00 - 13:00 1526P - Biomarker driven combinations for synthetic lethal approaches in KRAS mutant (KRASm) lung adenocarcinoma (LAC)
C. Lazzari¹, A. Verlicchi², C. Codony Servat³, J. Codony Servat³, M.A. Molina Vila³, I. Chaib⁴, J.L. Ramírez Serrano⁴, N. Karachaliou³, F. de Marinis¹, R. Rosell⁴; ¹Milano, IT, ²Ravenna, IT, ³Barcelona, ES, ⁴Badalona, ES
- 13:00 - 13:00 1527P - Differential expression profile of lung squamous cell carcinoma (LSCC) and druggable targets to be combined with necitumumab (N)
A. Verlicchi¹, C. Lazzari², C. Codony Servat³, M.A. Molina Vila³, J. Codony Servat³, I. Chaib⁴, J.L. Ramírez Serrano⁴, N. Karachaliou³, C. Dazzi¹, R. Rosell⁴; ¹Ravenna, IT, ²Milano, IT, ³Barcelona, ES, ⁴Badalona, ES
- 13:00 - 13:00 1528P - Repeated exposure to cisplatin enhances NK cell-mediated cytotoxicity via up-regulation of NKG2D ligands in non-small cell lung cancer cells
R. Okita¹, Y. Nojima², A. Maeda², S. Saisho², K. Shimizu², M. Nakata²; ¹Kurashiki, JP, ²Okayama, JP
- 13:00 - 13:00 1529P - DLK1-DIO3 imprinted cluster in lung cancer
A. Quintanal¹, A. Salinas², R. Suarez¹, R. Meléndez², A. Carnero², L. Paz-Ares¹, S. Molina-Pinelo¹; ¹Madrid, ES, ²Sevilla, ES
- 13:00 - 13:00 1530P - Serum microRNAs as potential biomarkers for lung cancer
H.-Y. Lee, S.-S. Han, S.-Y. Song; Chuncheon, KR



- 13:00 - 13:00 1531P - Evaluation of the interindividual variability in plasma nivolumab level in non-small-lung cancer outpatients: Preliminary results
A. Puszkiel, G. Noé, P. Boudou-Rouquette, C. Le Cossec, J. Arrondeau, J.S. Giraud, J. Alexandre, M. Vidal, F. Goldwasser, B. Blanchet; Paris, FR
- 13:00 - 13:00 1532P - New insights from KISS activity: A prognostic biomarker in malignant pleural mesothelioma
V. Ciaramella, C.M. Della Corte, F. Papaccio, V. Giuseppe, G. Esposito, M. Fasano, E. Martinelli, T. Troiani, F. Ciardiello, F. Morgillo; Napoli, IT
- 13:00 - 13:00 1533P - First generation of a small chemical molecule ROR1 RTK tyrosine kinase inhibitor
H. Mellstedt, M. Hojjat-Farsangi, A. Daneshmanesh, A. Moshfegh, S. Byström, M. Norin, T. Olin, J. Schultz, J. Vågberg, A. Österborg; Stockholm, SE
- 13:00 - 13:00 1534P - Effects of MRX34, a liposomal miR--34 mimic, on target gene expression in human white blood cells (hWBCs): qRT--PCR results from a first--in--human trial of microRNA cancer therapy
H. Peltier, K. Kelnar, A. Bader; Austin, TX/US
- 13:00 - 13:00 1535P - circular RNA: A novel regulatory non-coding RNA expressed in prostate cancer
J. Greene, G. Blackshields, O. Casey, L. Brady, A.M. Baird, S. Gray, S. Finn, R. McDermott; Dublin, IE
- 13:00 - 13:00 1536P - Description and prognostic value of the mutational load across various metastatic solid tumors in the prospective MOSCATO-01 and MATCH-R trials
L. Mahjoubi¹, M. Pedredo², C. Massard², E. Castanon Alvarez³, C. Lefebvre², L. Lacroix², Y. Loriot², F. André², J.-C. Soria²; ¹Paris, FR, ²Villejuif, FR, ³Pamplona, ES
- 13:00 - 13:00 1537P - The role of PP2A in innate resistance to HER2-targeted therapy
N. Conlon, M. McDermott, J. Crown, N. O'Donovan; Dublin, IE
- 13:00 - 13:00 1538P - Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as predictive biomarkers of pathologic complete response (pCR) in neoadjuvant breast cancer: An Irish Clinical Oncology Group study (ICORG 16-20)
S. Rafee¹, D. McHugh², M. Grealley³, O. Ayodele⁴, N. Keegan¹, M. Lim¹, A. Hassan⁵, D. O'Mahony⁶, B. Hennessy¹, C. Kelly¹, J. Kennedy¹, J. Walshe¹, M. O'Connor⁴, G. Leonard³, V. Murphy¹, V. Livingstone⁶, M. Corrigan⁶, S. O'Reilly⁶; ¹Dublin, IE, ²Limerick, IE, ³Galway, IE, ⁴Waterford, IE, ⁵Co.dublin, IE, ⁶Cork, IE
- 13:00 - 13:00 1539P - Androgen receptor and estrogen receptor beta interplay in triple negative breast carcinomas
M. Karamouzis¹, A. Anestis², C. Michailidou², A. Papavassiliou²; ¹Kolonaki, GR, ²Athens, GR
- 13:00 - 13:00 1540P - Implementation of an interdisciplinary molecular tumor board in managing of advanced stage breast cancer
S. Armeanu-Ebinger¹, D. Döcker¹, A. Kopic², S. Brucker¹, D. Wallwiener¹, U. Martens³, C. Kyzirakos¹, M. Menzel¹, A. Rinkleb¹, S. Biskup¹; ¹Tübingen, DE, ²Stuttgart, DE, ³Heilbronn, DE
- 13:00 - 13:00 1541P - Presence of tumor-specific cytolytic T cells in human primary breast carcinoma: Consequences for immunotherapy



D. Schröder¹, J. Carrasco², O. Bricard¹, G. Hames¹, N. Remy¹, K. Missault¹, J.-L. Canon², P. Vannuffel³, C. Galant⁴, M. Berlière⁴, P.G. Coulie¹; ¹Bruxelles, BE, ²Charleroi, BE, ³Gosselies, BE, ⁴Brussels, BE

13:00 - 13:00

1542P - Exploratory analyses of candidate predictive and prognostic tissue biomarkers (BMs) in the open-label randomised phase III TANIA trial of bevacizumab (BEV) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

C. Zielinski¹, J. Gligorov², N. Marschner³, F. Puglisi⁴, E. Vrdoljak⁵, J. Cortes⁶, S. de Ducla⁷, R. Deurloo⁷, V. Easton⁷, G. von Minckwitz⁸; ¹Vienna, AT, ²Paris, FR, ³Freiburg, DE, ⁴Udine, IT, ⁵Split, HR, ⁶Madrid, ES, ⁷Basel, CH, ⁸Neu-Isenburg, DE

13:00 - 13:00

1543P - Old friends are better to trust: Repositioning clofazimine and suramin against triple-negative breast cancer

A. Koval, K. Ahmed, V. Katanaev; Lausanne, CH

13:00 - 13:00

(Withdrawn)

13:00 - 13:00

1545P - The number of tumorspheres cultured from CETCs in breast cancer patients is directly related to stage of disease and administration of chemotherapy

M. Pizon, D. Schott, U. Pachmann, K. Pachmann; Bayreuth, DE

13:00 - 13:00

1546P - Preclinical validation of a new tumor imaging agent targeting aVb3 to detect breast tumor using NIR-light imaging

F. Beurrier¹, I. Treilleux¹, Y. Chen¹, E. Froc¹, P. Gayet², S. Guillermet², P. Rizo², N. Chopin¹, C. Faure¹, D. Dammaco¹, S. Klinger¹, D. Ferraioli¹, G. Garin¹, A. Dutour¹; ¹Lyon, FR, ²Grenoble, FR

13:00 - 13:00

1547P - Germline and somatic multi-gene sequencing in patients (pts) with advanced high grade serous ovarian cancer (HGSOC) and triple negative breast cancer (TNBC)

N. Stjepanovic, M. Wilson, V. Mandilaras, B. Clarke, H. Berman, R. Kim, S. Lheureux, S. Randall Armel, J. McCuaig, A. Volenik, R. Demsky, H. Chow, M. Mysura, L. Siu, P. Bedard, S. Kamel-Reid, T. Stockley, A. Oza; Toronto, CA

13:00 - 13:00

1548P - Organotypic slice ovarian cancer model as a platform to test novel therapeutics

A. Michael, G. Falgari, N. Annels, P. Ellis, W. Ashbourne, S. Butler Manuel, H. Pandha; Guildford, GB

13:00 - 13:00

1549P - Response to savolitinib (AZD6094/HMPL-504, a potent and selective MET inhibitor) in a papillary renal cell carcinoma patient harbouring a novel MET activating mutation

M. Frigault¹, D. Stetson¹, E. Maloney¹, J. Kramkowski¹, E. Barry¹, E. Lamberth², S. Signoretti¹, C. D'Cruz¹, B. Dougherty¹, J. Barrett³, T. Choueiri³; ¹Boston, US, ²Nashville, US, ³Boston, MA/US

13:00 - 13:00

1550P - Investigating the combination of bevacizumab and the EGF receptor inhibitor erlotinib for the treatment of metastatic renal cell carcinoma

R. Grepin¹, M. Guyot², J. Durivault¹, B. Front¹, D. Ambrosetti², G. Pagès²; ¹Monaco, MC, ²Nice, FR

13:00 - 13:00

1551P - Epithelial to mesenchymal transition induces autophagy in renal cell carcinoma: Implications in cancer therapy

S. Bhattacharyya, M. Singla, A. Bal, S. Singh, A. Mandal; Chandigarh, IN



- 13:00 - 13:00 1552P - Toward therapeutic drug monitoring of everolimus? Results of an exploratory study of the dose-exposure relationships
S. Falkowski, M. Deppenweiler, C. Monchaud, F. Saint-Marcoux, M.-L. Laroche, N. Picard, L. Venat-Bouvet, N. Tubiana-Mathieu, P. Marquet, J.-B. Woillard; Limoges, FR
- 13:00 - 13:00 1553P - The role of immune system on the efficacy of bevacizumab in patients with metastatic colorectal cancer (mCRC)
H. Akbulut, M. Ocal, G. Sonugur, B. Akay, C. Babahan, S. Abdi Abgarmi, A. Demirkazik, F. Icli; Ankara, TR
- 13:00 - 13:00 1554P - The role of Krüppel-like factor (KLF5) and its mechanism for treatment resistance in preoperative chemoradiation therapy for rectal cancer
J.Y. Kim¹, S.G. Park², N.K. Kim³; ¹Kyung Go Do Hwasung Si, KR, ²Kungki-Do, KR, ³Seoul, KR
- 13:00 - 13:00 1555P - The role of p21 activated kinase (PAK) in human colorectal cancer cell lines and resistance to cetuximab
A. Servetto, V. D'Amato, R. Rosa, C. Di Mauro, P. Ciciola, R. Orsini, R. Marciano, S. de Placido, R. Bianco; Napoli, IT
- 13:00 - 13:00 1556P - Evaluation of exposure of regorafenib and its metabolites in cancer patients with renal impairment by modelling, simulation, and clinical study
M. Block¹, B. Ploeger², J. Grevel³, K. Schnizler¹, M. Gerisch⁴, F.-T. Hafner⁴, S. Reschke², F. Huang⁵, Z. Trnkova², I. Sturm², A. Cleton²; ¹Leverkusen, DE, ²Berlin, DE, ³Loughborough, GB, ⁴Wuppertal, DE, ⁵Whippany, NJ/US
- 13:00 - 13:00 1557P - Identification of evolutionarily conserved DNA damage response (DDR) genes that alter sensitivity to cisplatin
A. Gaponova¹, I. Serebriiskii², G. Andrianov¹, R. Kiyamova¹, E. Golemis²; ¹Kazan, RU, ²Philadelphia, PA/US
- 13:00 - 13:00 1558P - Next-generation sequencing of circulating tumor cells isolated from peripheral blood of patients with head and neck or gastrointestinal cancer
H. Shoji, K. Kato, S. Yoshimoto, F. Kakizaki, K. Furuta, K. Onidani, N. Miura, K. Honda; Tokyo, JP
- 13:00 - 13:00 1559P - Evaluation of exposure of regorafenib (REG) and its metabolites in pediatric patients by modeling, simulation, and clinical study
B. Ploeger¹, J. Grevel², M. Frede¹, M. Block³, K. Schnizler³, M. Gerisch⁴, F.-T. Hafner⁴, Z. Trnkova¹, A. Agostinho⁵, I. Sturm¹, A. Cleton¹; ¹Berlin, DE, ²Loughborough, GB, ³Leverkusen, DE, ⁴Wuppertal, DE, ⁵Whippany, NJ/US
- 13:00 - 13:00 1560P - Quantitative evaluation of HER2-mediated cellular uptake of the HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 suggests potential for treating HER2-intermediate tumors
E. Geretti¹, C. Espelin¹, B. Adiwijaya¹, N. Dumont¹, S. Coma¹, Z. Koncki¹, G. Garcia¹, T. Bloom¹, V. Rimkunas¹, J. Reynolds¹, K. Campbell¹, V. Moyo², I. Molnar³, P. Lorusso⁴, K. Miller⁵, C. Ma⁶, I. Krop⁷, P. Munster⁸, T. Wickham¹; ¹Cambridge, MA/US, ²Cambridge, US, ³Montville, US, ⁴New Haven, CT/US, ⁵Indianapolis, IN/US, ⁶St. Louis, MO/US, ⁷Boston, US, ⁸San Francisco, CA/US



- 13:00 - 13:00 1561P - Survival is associated with circulating cytokine levels in metastatic testicular germ cell tumors
D. Svetlovska, V. Miskovska, D. Cholujoiva, P. Gronosova, S. Cingelova, M. Chovanec, Z. Sycova-Mila, J. Obertova, P. Palacka, J. Rajec, K. Kalavska, V. Usakova, J. Luha, D. Ondrus, S. Spanik, J. Mardiak, M. Mego; Bratislava, SK
- 13:00 - 13:00 1562P - Mechanisms of acquired resistance to the fibroblast growth factor receptor (FGFR) inhibitor BGJ398 in FGFR driven bladder cancer
M. Hodgson-Garms, J. Mariadason, A. Weickhardt; Melbourne, AU
- 13:00 - 13:00 1563P - The oncogenic role of FGFR1 depends on the molecular context
A. Quintanal¹, I. Ferrer¹, L. Ojeda-Márquez¹, Á. Marrugal¹, R. Suarez¹, L. García-Redondo¹, A. Carnero², L. Paz-Ares¹, S. Molina-Pinelo¹; ¹Madrid, ES, ²Sevilla, ES
- 13:00 - 13:00 1564P - FGFR4 exerts differential roles in tumorigenesis through a mechanism of cooperation
A. Quintanal-Villalonga¹, I. Ferrer¹, Á. Marrugal¹, L. Ojeda-Márquez¹, L. García-Redondo¹, R. Suarez¹, J. Zugazagoitia¹, A. Carnero², L. Paz-Ares¹, S. Molina-Pinelo¹; ¹Madrid, ES, ²Sevilla, ES
- 13:00 - 13:00 1565P - Impact of a salvage chemotherapy with carboplatin plus docetaxel on testosterone levels in metastatic castration - and docetaxel-resistant prostate cancer (mDRPC)
C. Reuter, V. Grünwald, P. Ivanyi, A. Ganser; Hannover, DE
- 13:00 - 13:00 1566P - Down--regulation of target gene expression in human white blood cells (hWBCs) by MRX34, a liposomal miR--34 mimic: Next generation sequencing (NGS) results from a first--in-human trial of microRNA cancer therapy
K. Kelnar, H. Peltier, A. Bader; Austin, TX/US
- 13:00 - 13:00 1567P - Adenovirus-based antibody screening method and EphA2-targeted therapy
T. Tanaka, H. Yamada, R. Nogami, S. Kodama, K. Tamura, Y. Takamatsu; Fukuoka, JP
- 13:00 - 13:00 1568P - Development of laser-driven proton beam therapy
L. Karsch, E. Beyreuther, W. Enghardt, M. Gotz, T. Hermannsdörfer, M. Krause, U. Masood, J. Pawelke, R. Sauerbrey, U. Schramm, M. Schürer, M. Baumann; Dresden, DE
- 13:00 - 13:00 1569P - Time structure influence on the radiobiological response to MeV electron beams
E. Beyreuther, M. Gotz, L. Karsch, E. Lessmann, M. Schürer, J. Pawelke; Dresden, DE
- 13:00 - 13:00 1570P - 'Research' vs 'real world' patients: The representativeness of clinical trial participants
Y. Karanis, F. Bermudez Canta, L. Mitrofan, H. Mistry, C. Anger; London, GB
- 13:00 - 13:00 1571P - Reliability of apparent diffusion coefficient assessments according to the QIBA guideline
H. Beaumont¹, B. Moreau², C. Hoog², E. Oubel¹, A. Iannesi²; ¹Valbonne, FR, ²Nice, FR
- 13:00 - 13:00 1572P - Current and future next generation sequencing usage in European molecular oncology diagnostics
C. Whitten, A. Thum, T. Blass; Leipzig, DE



- 13:00 - 13:00 1573P - A candidate gene study for oxaliplatin induced chronic peripheral neuropathy (OICPN) based on a prior genome wide association study (GWAS)
J. Cliff¹, D. Carr², R. Lord¹, A. Jorgensen², M. Pirmohamed²; ¹Wirral, GB, ²Liverpool, GB
- 13:00 - 13:00 1574P - Differential regulation of profibrotic genes responsible for cardiotoxicity after experimental anticancer treatments
M. Gyongyosi, K. Zlabinger, D. Lukovic, A. Spannbauer, G. Maurer, J. Bergler-Klein; Vienna, AT
- 13:00 - 13:00 1575P - 5-Fluorouracil (5FU) intratumoural pharmacokinetics: Rapid uptake in cells and in spheroids (SPH)
M. Jove¹, P. Loadman², J. Wicks², J. Spencer², A. Race², R. Salazar¹, C. Twelves³; ¹Barcelona, ES, ²Bradford, GB, ³Leeds, GB
- 13:00 - 13:00 1576P - Enzymatic action of NQO1 attenuates adriamycin-induced cardiotoxicity in mice
S.-H. Yang¹, D. Khadka², G.-S. Oh², H.-J. Kim², S.-B. Lee², A. Pandit², S. Lee², H.-S. So²; ¹Iksan, Jeonbuk/KR, ²Iksan, KR
- 13:00 - 13:00 (Withdrawn)
- 13:00 - 13:00 1578P - A phase I trial to assess the safety, PK and PD of CXD101 in advanced cancer expressing the biomarker HR23B
T. Eyre, G. Collins, A. Gupta, S. Sheikh, V. Woodcock, J. Whittaker, L.M. Wang, E. Soilleux, F. Tysoe, R. Cousins, N. La Thangue, D. Kerr, M. Middleton; Oxford, GB
- 13:00 - 13:00 1579P - TRAIL-engineered umbilical cord mesenchymal stem cells (UC-MSC) as anti-multiple myeloma (MM) cytotherapy approach
P. Cafforio, F. Mannavola, C. Felici, E. Pellè, F. Silvestris; Bari, IT
- 13:00 - 13:00 1580P - A multicellular 3D cell culture model for investigation of endothelial cell migration
A. Amann, M. Zwierzina, G. Gamerith, S. Koeck, E. Lorenz, H. Zwierzina, J. Kern; Innsbruck, AT
- 13:00 - 13:00 Tumour biology and pathology
- 13:00 - 13:00 1582P - Analysis of circulating cell-free DNA in plasma shows a higher detection rate of EGFR mutations in patients with extrathoracic disease progression
Y. Seki, Y. Fujiwara, T. Kohno, Y. Goto, H. Horinouchi, S. Kanda, H. Nokihara, N. Yamamoto, K. Kuwano, Y. Ohe; Tokyo, JP
- 13:00 - 13:00 1583P - Unsupervised latent class analysis of adult glioma variant profiles reveals biologically and clinically relevant subclasses
M. Chang¹, S. Ramkissoon¹, H. Bokhari², A. Fichtenholtz¹, S. Ali¹, J. Ross³, E. Neumann¹; ¹Cambridge, MA/US, ²Ithaca, NY/US, ³Albany, NY/US
- 13:00 - 13:00 1584P - Germline genetic background contribution to metastatic dissemination in breast cancer extreme phenotype patients



A. Santonja¹, B. Pajares¹, B. Jiménez-Rodríguez¹, C. Fernández-De Sousa¹, N. Ribelles¹, A. Lluch-Hernandez², I. Catoira², E. Perez-Ruiz³, M. Martin⁴, M. Del Monte-Millan⁴, A. Gonzalez-Neira⁴, G. Pita⁴, M.A. Pujana⁵, M. Ruiz⁶, N. Bonifaci⁵, J. De la Haba⁷, P. Sanchez-Rovira⁸, E. Alba¹, A. Romero⁴; ¹Malaga, ES, ²Valencia, ES, ³Marbella, ES, ⁴Madrid, ES, ⁵Barcelona, ES, ⁶Sevilla, ES, ⁷Cordoba, ES, ⁸Jaen, ES

- 13:00 - 13:00 1585P - Differences in incidence and biological characteristics between Roma and non-Roma women with breast cancer in Slovakia
M. Reckova¹, J. Mardiak², L. Plank³, M. Vulevova², S. Cingelova², M. Mego²; ¹SK, ²Bratislava, SK, ³Martin, SK
- 13:00 - 13:00 1586P - Different breast tumor morphological structures reflect specific EMT states and contribute to cancer metastasis
T. Gerashchenko, E. Denisov, D. Pautova, M. Zavyalova, N. Cherdyntseva, V. Perelmuter; Tomsk, RU
- 13:00 - 13:00 1587P - Tumor infiltrating lymphocytes and tertiary lymphoid structures in paired primary tumors and metastases from breast cancer patients
C. Solinas, A. Boisson, D. Brown, R. de Wind, G. van den Eynden, S. Garaud, L. Buisseret, C. Naveaux, C. Sotiriou, D. Larsimont, M. Piccart, K. Willard-Gallo; Brussels, BE
- 13:00 - 13:00 1588P - The comparison between TP53 gene polymorphisms (c.[215G>C]) homozygotes and heterozygotes in breast cancer patients: A clinicopathological analysis
J. Huszno, E. Grzybowska, Z. Kolosza, M. Nycz Bochenek, J. Pamula Pilat, K. Tecza, E. Nowara; Gliwice, PL
- 13:00 - 13:00 1589P - Prognostic impact of tumor-infiltrating lymphocytes (TILs) in male breast cancer
S. Abdeljaoued¹, I. Bettaieb¹, O. Adouni¹, A. Goucha¹, O. El Amine¹, A. Chabchoub¹, H. Bouzaiene¹, J. Ben Hassouna¹, R. Makhoulf¹, T. Ben Dhiab¹, H. Boussen², K. Rahal¹, A. Gamoudi¹; ¹Tunis, TN, ²Ariana, TN
- 13:00 - 13:00 1590P - The prognostic impact of the putative primary site of breast and ovarian cancers in an unfavorable subset of cancer of unknown primary site
M. Kodaira, K. Yonemori, T. Shimoi, A. Shimomura, M. Yunokawa, C. Shimizu, Y. Fujiwara, K. Tamura; Tokyo, JP
- 13:00 - 13:00 1591P - Primordial germ cell as potent cell of origin of mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors
I. Labidi-Galy¹, K. Elias², P. Tsantoulis¹, A. Vitonis², L. Doyle², J. Hornick², D. Cramer², M. Goggins³, C. Kerr³, M. Birrer⁴, M. Hirsch², R. Drapkin⁵; ¹Geneva, CH, ²Boston, MA/US, ³Baltimore, MD/US, ⁴Boston, US, ⁵Philadelphia, PA/US
- 13:00 - 13:00 1592P - Comprehensive molecular and immunological analysis to assess the tumor immune contexture in stage II and III colorectal cancer
K. Silina¹, U. Petrusch¹, F. Posch², S. Leibl¹, A. Mündlein³, H. Moch¹, A. Siebenhüner¹, R. Stupp¹, J. Riedl², B. Pestalozzi¹, P. Schraml¹, A. Gerger², T. Winder¹; ¹Zürich, CH, ²Graz, AT, ³Feldkirch, AT



- 13:00 - 13:00 1593P - The colorectal cancer (CRC) tumour microenvironment recruits and polarises two distinct populations of myeloid cells with unique regulatory profiles
L. Elliott, K. Sheahan, G. Doherty, D. Fennelly, E. Ryan; Dublin, IE
- 13:00 - 13:00 1594P - Qualitative and quantitative differences in a set of criteria for histological grading of colorectal cancer
T. Savchyn¹, S. Antoniuk², A. Grabovoy²; ¹Kyiv, UA, ²Kiev, UA
- 13:00 - 13:00 1595P - MicroRNAs as biomarkers of resistance to HER2 inhibitors in combination with chemotherapy in gastro-oesophageal cancer cell lines
H. Lote¹, D. Zito¹, R. Burke², E. Smyth¹, C. Braconi¹, D. Cunningham¹, N. Valeri¹; ¹Sutton, GB, ²London, GB
- 13:00 - 13:00 1596P - miR-7 modulates pancreatic cancer progression by interfering with aerobic glycolysis via inhibition of autophagy
D.-N. Gu, L. Tian, Q. Huang; Shanghai, CN
- 13:00 - 13:00 1597P - Hepatoma cell functions modulated by NEK2 are associated with liver cancer progression
K.-H. Lin, S.-M. Wu; Taoyuan, TW
- 13:00 - 13:00 1598P - Characteristics and prognostic potential of tertiary lymphoid structures in oral tongue squamous cell carcinoma
X. Liu, Y. Wang, J. Fang, J. Song, Y. Chen, T. Wu, J. Wang, B. Cheng, Z. Wang; Guangzhou, CN
- 13:00 - 13:00 1599P - Management optimization of non small cell lung cancer (NSCLC) specimens. A single institution experience with a multiplexed mass spectrometry approach
G. De Maglio, A. De Pellegrin, A. Follador, S. Distefano, G. Morana, P. Vailati, N. Bergamin, S. Ciani, E. Poletto, E. De Carlo, G. Pelizzari, M. Cattaneo, E. Lugatti, G. Fasola, S. Pizzolitto; Udine, IT
- 13:00 - 13:00 1600P - Typing of non-small cell lung carcinoma and investigation of enteric differentiation in small biopsy specimens
A. Erol, S. Perçinel, A. Demirkazik; Ankara, TR
- 13:00 - 13:00 1601P - Genomic DNA from HT29 cells and its modified forms influence in vitro survival of the same tumor cells via TLR9- and autophagy signaling
G. Múzes, Z. Tulassay, A. L. Kiss, F. Sipos; Budapest, HU
- 13:00 - 13:00 1602P - Syndecan-1 up-regulates microRNA-331-3p and mediates epithelial-to-mesenchymal transition in prostate cancer
T. Fujii¹, K. Shimada², Y. Tatsumi², N. Tanaka³, K. Fujimoto³, N. Konishi²; ¹Nara, 634-8522/JP, ²Nara, JP, ³Kashihara, JP
- 13:00 - 13:00 1604P - Tyrosine kinase inhibitors targeted therapy and the AKT-m-TOR pathway in kidney cancer tissues
L. Spirina, E. Usynin, I. Kondakova, Z. Yurmazov, E. Slonimskaya, E. Kolegova; Tomsk, RU
- 13:00 - 13:00 1605P - Preclinical animal data of the SM88 tyrosine isomer



G. Sokol¹, R. Dickey Iv², G. Del Priore², D. Garzon³, S. Hoffman²; ¹Bethesda, US, ²New York, NY/US, ³Montreal, CA

13:00 - 13:00

142P - Development of an ELISA to detect tumor-associated antigen tNASP in urine

O. Alekseev¹, J. Vaughn², B. Taylor², L. Barba², J. Greiner², C. Dickson², C. Anderson², J. Fullmer², Z. Vaskalis²; ¹Buies Creek, US, ²Buies Creek, NC/US

14:15 - 15:45

Type: Young Oncologist Special session
Title: ESMO Fellowships and Awards

Lisbon

Chair(s): C. Zielinski, AT; M. Preusser, AT

14:15 - 14:20

Introduction

C. Zielinski, Vienna, AT

14:20 - 14:35

The ESMO Fellowship Programme

V. Guarneri, Padua, IT

14:35 - 14:50

Practical tips from a former fellow

D. Kolarevic, Belgrade, RS

14:50 - 15:05

Best fellowship project 1

E. Castro Marcos, Madrid, ES

15:05 - 15:20

Best fellowship project 2

A. Lamarca, Manchester, GB

15:20 - 15:25

Conclusions

M. Preusser, Vienna, AT

15:25 - 15:45

Awards: Presentation of the ESMO 2016 Fellows and 2015 Best Exam Award 2015



| | | |
|---------------|---|------------|
| 14:45 - 16:15 | Type: Educational session Title: The earthquake of immunotherapy in lung cancer Chair(s): L. Paz-Ares, ES; S. Peters, CH | Copenhagen |
| 14:45 - 15:10 | Current results of immunotherapy in thoracic oncology <u>L. Paz-Ares</u> , Madrid, ES | |
| 15:10 - 15:30 | Can we select the right patient for immunotherapy in NSCLC? The clinician's point of view <u>S. Novello</u> , Orbassano, IT | |
| 15:30 - 15:50 | Can we select the right patient for immunotherapy in NSCLC? The pathologist's point of view <u>M. Tsao</u> , Toronto, On, CA | |
| 15:50 - 16:15 | Management of side effects of immunotherapy <u>M. Reck</u> , Grosshansdorf, DE | |
| 14:45 - 16:15 | Type: Special Session Title: Liquid biopsies Chair(s): P. Meldgaard, DK; R. Dziadziuszko, PL | Stockholm |
| 14:45 - 14:50 | Introduction | |
| 14:50 - 15:15 | Solid tumour, liquid biopsy: Can blood samples give us the answers? <u>D.(-M. Lo</u> , Hong Kong, CN | |
| 15:15 - 15:40 | Tracking changes: Monitoring evolution of disease through circulating free DNA <u>P. Meldgaard</u> , Aarhus C, DK | |
| 15:40 - 16:05 | Blood-based tumour genomics: Technological advances <u>T. Würdinger</u> , Amsterdam, NL | |
| 16:05 - 16:15 | Conclusions and clinical perspectives | |



| | | |
|---------------|---|--------|
| 14:45 - 16:15 | Type: Educational session Title: Management of advanced radioactive-iodine (RAI) refractory differentiated thyroid cancer (DTC) Chair(s): M. Schlumberger, FR; J. Capdevila, ES | Oslo |
| 14:45 - 15:15 | New insights in molecular biology of thyroid cancer <u>X. Matias-Guiu</u> , Lleida, ES | |
| 15:15 - 15:45 | Enhancing iodine uptake in DTC <u>J. Capdevila</u> , Barcelona, ES | |
| 15:45 - 16:15 | Treatment options in advanced RAI-refractory DTC <u>M. Schlumberger</u> , Villejuif, FR | |
| 14:45 - 16:15 | Type: Special Symposium Title: Drugs you will be using in 2020 Chair(s): J. Rodón, ES; P. Aftimos, BE | Athens |
| 14:45 - 14:50 | Introduction <u>P. Aftimos</u> , Brussels, BE | |
| 14:50 - 15:05 | Antibody-drug conjugates: Drones targeting tumours? <u>B. Fine</u> , San Francisco, Ca, US | |
| 15:05 - 15:20 | Engineered peptide therapeutics and other protein therapies <u>M. Stumpp</u> , Zurich, CH | |
| 15:20 - 15:35 | Crafting selective and artisan kinase inhibitors <u>B. Hodous</u> , Cambridge, Ma, US | |
| 15:35 - 15:50 | Using viruses and bacteria to treat cancer <u>R. Alemany</u> , L'hospitalet De Llobregat, ES | |
| 15:50 - 16:05 | Genes to treat a genetic disease such as cancer: RNA therapeutics <u>P. Tassone</u> , Catanzaro, IT | |
| 16:05 - 16:15 | Conclusions and clinical perspectives <u>J. Rodón</u> , Barcelona, ES | |



| | | |
|---------------|---|----------|
| 14:45 - 16:15 | Type: Joint Symposium Title: Joint Symposium ESMO-MASCC: Controversies in supportive care Chair(s): I. Olver, AU; N. Cherny, IL | Helsinki |
| 14:45 - 14:50 | Introduction <u>I. Olver</u> , Adelaide, AU | |
| 14:50 - 15:10 | Controversies in treatment-induced emesis <u>D. Warr</u> , Toronto, CA | |
| 15:10 - 15:30 | Controversies in the treatment of brain metastases <u>R. Stupp</u> , Zürich, CH | |
| 15:30 - 15:50 | Controversies in the use of parenteral nutrition in advanced cancer <u>F. Bozzetti</u> , Milan, IT | |
| 15:50 - 16:10 | The controversy of managing spiritual wellbeing <u>I. Olver</u> , Adelaide, AU | |
| 16:10 - 16:15 | Conclusions and clinical perspectives <u>N. Cherny</u> , Jerusalem, IL | |
| 14:45 - 16:15 | Type: Educational session Title: Straightforward options for earlier detection and treatment of challenging cancer types Chair(s): H. De Koning, NL | Brussels |
| 14:45 - 15:05 | Introduction and review of prostate cancer <u>H. De Koning</u> , Rotterdam, NL | |
| 15:05 - 15:35 | Ovarian cancer prevention: Are we finally there? <u>R. Manchanda</u> , London, GB | |
| 15:35 - 16:05 | Novel insights into Barrett's oesophagus <u>M. Di Pietro</u> , Cambridge, GB | |
| 16:05 - 16:15 | Q&A | |



| | | |
|---------------|--|--------|
| 14:45 - 16:15 | Type: Joint Symposium Title: Joint Symposium ESMO-ESOI: Oncologic imaging: A new beginning has just begun Chair(s): E. Voest, NL; R. Beets-Tan, NL | Bern |
| 14:45 - 14:50 | Introduction <u>R. Beets-Tan</u> , Maastricht, NL | |
| 14:50 - 15:10 | The future of oncologic imaging in the era of precision medicine <u>D. Regge</u> , Candiolo, IT | |
| 15:10 - 15:30 | Radiomics: There is more than meets the eye in medical imaging <u>H.J. Aerts</u> , Breda, NL | |
| 15:30 - 15:50 | Immuno-positron emission tomography: Shedding light on immunotherapy <u>G.A. van Dongen</u> , Amsterdam, NL | |
| 15:50 - 16:10 | Oncologic PET/MR: Bringing the best of both modalities together <u>V. Goh</u> , London, GB | |
| 16:10 - 16:15 | Conclusions and clinical perspectives <u>E. Voest</u> , Amsterdam, NL | |
| 15:00 - 16:00 | Type: Multidisciplinary patient cases Title: Special situations in advanced breast cancer: De novo and limited metastatic disease Chair(s): P.F. Conte, IT | Vienna |
| 15:00 - 15:10 | Management of brain metastases in breast cancer <u>N. Lin</u> , Boston, Ma, US | |
| 15:10 - 15:15 | Case presentation <u>P.F. Conte</u> , Padova, IT | |
| 15:15 - 15:25 | Local therapy approaches <u>I. Kunkler</u> , Edinburgh, GB | |
| 15:25 - 15:35 | Systemic therapy approaches <u>P.F. Conte</u> , Padova, IT | |
| 15:35 - 16:00 | Discussion | |



15:00 - 16:00 Type: Multidisciplinary patient cases Madrid
Title: Liver dominant disease
Chair(s): T. Gruenberger, AT

15:00 - 15:10 Is the potential of cure adequately depicted within tumour boards?
T. Gruenberger, Vienna, AT

15:10 - 15:20 What is the best induction, and which post-op therapies should be used?
C.-H. Koehne, Oldenburg, DE

15:20 - 15:30 Radiofrequency and intra-arterial treatments: How to place them
T. de Baere, Villejuif, FR

15:30 - 16:00 Discussion

15:00 - 16:00 Type: Multidisciplinary patient cases Rome
Title: Oligometastatic disease in prostate cancer patients
Chair(s): R. de Wit, NL

15:00 - 15:10 Radiation with curative intent
P. Ost, Ghent, BE

15:10 - 15:20 Radical surgical intervention
S. Joniau, Leuven, BE

15:20 - 15:30 Systemic treatments
R. de Wit, Rotterdam, NL

15:30 - 16:00 Discussion

15:00 - 16:00 Type: Poster Discussion session Berlin
Title: Non-metastatic NSCLC and other thoracic malignancies
Chair(s): A.-M. Dingemans, NL; J. Soerensen, DK; E. Ruffini, IT

15:00 - 15:00 1179PD - Low dose CT scan screening versus empiric surveillance in asbestos exposed subjects: Update of ATOM 002 study
G. Fasola¹, A. Follador¹, F. Barbiero¹, V. Rosolen¹, O. Belvedere², F. Grossi³, C. Rossetto¹, S. Rizzato¹, M. Giavarra¹, L. Gerratana¹, F. Barbone¹; ¹Udine, IT, ²York, GB, ³Genova, IT

15:00 - 15:00 1508PD - Patient-reported outcomes (PROs) and impact of lactate dehydrogenase (LDH) levels on outcomes in a phase 3 trial (NGR015) with best investigator choice (BIC) plus or minus NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM)



V. Gregorc¹, A. Bulotta¹, M.G. Viganò¹, G. Citterio¹, G. Petrella¹, E. Brioschi¹, M. Ducceschi¹, L. Gianni¹, S. Colombi², G. Rossoni², G. Salini², V. Savia², A. Lambiase², C. Bordignon²; ¹Milano, IT, ²Milan, IT

15:00 - 15:10 Invited discussant abstracts 1179PD and 1508PD

J. Soerensen, Copenhagen, DK

15:10 - 15:20 Questions to discussant

15:20 - 15:20 1425PD - Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)

L. Sequist¹, A. Chiang², J. Gilbert³, M. Gordon⁴, P. Conkling⁵, D. Thompson³, J.P. Marcoux¹, S. Antonia⁶, B. Liu⁷, D. Shames⁸, A. Lopez-Chavez⁷, C. O'Hear⁷, M. Fasso⁷, S. Gettinger²; ¹Boston, MA/US, ²New Haven, US, ³Nashville, TN/US, ⁴Scottsdale, AZ/US, ⁵Norfolk, VA/US, ⁶Tampa, FL/US, ⁷South San Francisco, US, ⁸South San Francisco, CA/US

15:20 - 15:20 1426PD - Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in subjects with extensive-disease small cell lung cancer (ED-SCLC)

M. Reck¹, L. Horn², S. Novello³, F. Barlesi⁴, I. Albert⁵, E. Juhasz⁶, J. Chung⁷, A. Fritsch⁷, U. Drews⁷, M. Rutstein⁸, A. Wagner⁷, R. Govindan⁹; ¹Grosshansdorf, DE, ²Nashville, TN/US, ³Orbassano, IT, ⁴Marseille, FR, ⁵Matrahaza, HU, ⁶Budapest, HU, ⁷Berlin, DE, ⁸Whippany, US, ⁹St Louis, MO/US

15:20 - 15:20 1427PD - A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy

Q.S.-C. Chu¹, B. Markman², N. Leigh³, L. Krug⁴, C. Rudin⁵, D. Lathers⁴, P. Basciano⁴, P. Fracasso⁴, G. Kollia⁴, P. Phillips⁴, G. Kolaitis⁴, D. Williams⁴, J. Jackson⁴, N. Ready⁶; ¹Edmonton, CA, ²Melbourne, AU, ³Toronto, CA, ⁴Princeton, NJ/US, ⁵New York, US, ⁶Durham, US

15:20 - 15:30 Invited discussant abstracts 1425PD, 1426PD and 1427PD

A.-M. Dingemans, Maastricht, NL

15:30 - 15:40 Questions to discussant

15:40 - 15:40 1509PD - Quality of resection and outcome in stage III thymic epithelial tumors (TET): A retrospective analysis of 150 cases from the national network RYTHMIC experience

M. Bluthgen¹, E. Dansin², D. Ou¹, H. Lena³, J. Mazieres⁴, E. Pichon⁵, F. Thillays⁶, G. Massard⁷, X. Quantin⁸, Y. Oulkhair⁹, T. Nguyen Tan Hon¹⁰, L. Thiberville¹¹, C. Clement-Duchene¹², C. Lindsay¹, P. Missy¹³, T. Molina¹³, N. Girard¹⁴, B. Besse¹, P. Thomas¹⁵; ¹Villejuif, FR, ²Lille, FR, ³Rennes, FR, ⁴Toulouse, FR, ⁵Tours, FR, ⁶St. Herblain, FR, ⁷Strasbourg, FR, ⁸Montpellier, FR, ⁹Caen, FR, ¹⁰Besançon, FR, ¹¹Rouen, FR, ¹²Nancy, FR, ¹³Paris, FR, ¹⁴Bron, FR, ¹⁵Marseille, FR

15:40 - 15:40 1510PD - Pathological central review of 400 thymic epithelial tumors (TET): The national network RYTHMIC experience



T. Molina¹, M. Bluthgen², L. Chalabreysse³, V. De Montpréville⁴, A. De Muret⁵, V. Hofman⁶, S. Lantuejoul⁷, M. Parrens⁸, I. Rouquette⁹, V. Secq¹⁰, N. Girard¹¹, A. Marx¹², B. Besse²; ¹Paris, FR, ²Villejuif, FR, ³Lyon, FR, ⁴Le Plessis-Robinson, FR, ⁵Tours, FR, ⁶Nice, FR, ⁷Grenoble, FR, ⁸Bordeaux, FR, ⁹Toulouse, FR, ¹⁰Marseille, FR, ¹¹Bron, FR, ¹²Mannheim, DE

15:40 - 15:50 Invited discussant abstracts 1509PD and 1510PD

E. Ruffini, Turin, IT

15:50 - 16:00 Questions to discussant

| | | |
|---------------|--|--------|
| 16:00 - 17:30 | Type: Young Oncologist Forum Title: Professional development and communication skills Chair(s): L. De Mattos-Arruda, ES; S. Banerjee, GB | Lisbon |
|---------------|--|--------|

16:00 - 16:25 Presentation skills and dealing with media

D. Hart, Bishops Stortford, GB

16:25 - 16:45 Interactive discussion with audience

M. Petrova, Sofia, BG

16:45 - 17:10 How to become an effective leader and create a strong team

E. Martinelli¹, E. de Azambuja²; ¹Napoli, IT, ²Brussels, BE

17:10 - 17:30 Interactive discussion with audience

C. Qvortrup, Odense C, DK



16:30 - 18:00 Type: Presidential Symposium
Title: Presidential Symposium 3 Copenhagen

16:30 - 16:45 LBA9_PR - Final overall survival (OS) from the AFFINITY phase 3 trial of custirsen and cabazitaxel/prednisone in men with previously treated metastatic castration-resistant prostate cancer (mCRPC)

K. Fizazi¹, S. Hotte², F. Saad³, B. Alekseev⁴, V. Matveev⁴, A. Flechon⁵, G. Gravis⁶, F. Joly⁷, K. Chi⁸, Z. Malik⁹, P. Stewart¹⁰, C. Jacobs¹⁰, T. Beer¹¹; ¹Villejuif, FR, ²Hamilton, CA, ³Montreal, CA, ⁴Moscow, RU, ⁵Lyon, FR, ⁶Marseille, FR, ⁷Caen, FR, ⁸Vancouver, BC/CA, ⁹Wirral, GB, ¹⁰Bothell, US, ¹¹Portland, OR/US

16:45 - 17:00 Invited discussant LBA9

17:00 - 17:15 (Withdrawn)

17:15 - 17:30 Invited discussant one LBA

17:30 - 17:45 LBA11_PR - Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC)

A. Ravaud¹, R. Motzer², H. Pandha³, M. Staehler⁴, D. George⁵, A. Pantuck⁶, A. Patel⁷, Y.-H. Chang⁸, B. Escudier⁹, F. Donskov¹⁰, A. Magheli¹¹, G. Carteni¹², B. Laguerre¹³, P. Tomczak¹⁴, J. Breza¹⁵, P. Gerletti¹⁶, X. Lin¹⁷, M. Lechuga¹⁶, J.-F. Martini¹⁷, J.-J. Patarid¹³; ¹Bordeaux, FR, ²New York, NY/US, ³Guildford, GB, ⁴Munich, DE, ⁵Durham, US, ⁶Los Angeles, CA/US, ⁷London, GB, ⁸Taipei, TW, ⁹Villejuif, FR, ¹⁰Aarhus C, DK, ¹¹Berlin, DE, ¹²Naples, IT, ¹³Rennes, FR, ¹⁴Poznań, PL, ¹⁵Bratislava, SK, ¹⁶Milan, IT, ¹⁷San Diego, US

17:45 - 18:00 Invited discussant LBA11

16:30 - 18:00 Type: Educational session
Title: Next generation small molecule inhibitors Vienna
Chair(s): T.S.K. Mok, HK

16:30 - 17:00 Third generation EGFR TKI's
T.S.K. Mok, Hong Kong, CN

17:00 - 17:30 Novel ALK inhibitors
S. Peters, Lausanne, CH

17:30 - 18:00 Novel targets in NSCLC and the compounds to combat them
G. Riely, New York, US



| | | |
|---------------|--|-----------|
| 16:30 - 18:00 | Type: Educational session Title: HER2+ advanced breast cancer: A few more questions and many more answers Chair(s): J. Cortes, ES; F. Cardoso, PT | Stockholm |
| 16:30 - 17:00 | Individualising first line treatment options for HER2+ metastatic breast cancer <u>H. Joensuu</u> , Helsinki, FI | |
| 17:00 - 17:30 | Second line, salvage and emerging treatments for HER2+ disease <u>J. Cortes</u> , Madrid, ES | |
| 17:30 - 18:00 | The role of the immune response in HER2+ disease: Is it relevant for patient care? <u>S. Loi</u> , Melbourne, AU | |
| 16:30 - 17:30 | Type: Poster Discussion session Title: Gastrointestinal tumours, colorectal Chair(s): R. Adams, GB; C.-H. Koehne, DE; P. Pfeiffer, DK | Madrid |
| 16:30 - 16:30 | LBA21 - FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial <u>A. Falcone</u> ¹ , C. Cremolini ¹ , F. Loupakis ² , S. Lonardi ³ , M.E. Casagrande ⁴ , S. Murgioni ⁵ , L. Salvatore ¹ , G. Masi ¹ , V. Fanotto ⁴ , C. Granetto ⁶ , F. Marmorino ¹ , L. Ginocchi ⁷ , S. Ziampiri ³ , R. Grande ⁸ , G. Tonini ⁹ , S. Delfanti ¹⁰ , S. Di Donato ¹¹ , G. Fontanini ¹ , L. Boni ¹² , V. Zagonel ³ ; ¹ Pisa, IT, ² Livorno, IT, ³ Padova, IT, ⁴ Udine, IT, ⁵ Ilbono, IT, ⁶ Cuneo, IT, ⁷ Pontedera, IT, ⁸ Frosinone, IT, ⁹ Roma, IT, ¹⁰ Pavia, IT, ¹¹ Prato, IT, ¹² Firenze, IT | |
| 16:30 - 16:30 | LBA22 - FOLFOX / Bevacizumab (Beva) +/- Irinotecan in advanced Colorectal Cancer (CRC): A randomized Phase II trial (AIO KRK 0209, CHARTA) <u>H.J. Schmoll</u> ¹ , B. Garlipp ² , C. Junghanß ³ , M. Leithauser ³ , A. Vogel ⁴ , M. Schaefers ⁵ , U. Kaiser ⁶ , H. Hoeffkes ⁷ , A. Florschütz ⁸ , J. Ruessel ⁹ , S. Kanzler ¹⁰ , T. Edelmann ¹¹ , H. Forstbauer ¹² , T. Göhler ¹³ , C. Hannig ¹⁴ , B. Hildebrandt ¹⁵ , J. Steighardt ¹ , F. Meinert ¹ , F. Cygon ¹ , A. Stein ¹⁶ ; ¹ Halle, DE, ² Magdeburg, DE, ³ Rostock, DE, ⁴ Hannover, DE, ⁵ Düsseldorf, DE, ⁶ Hildesheim, DE, ⁷ Fulda, DE, ⁸ Dessau, DE, ⁹ Halle/saale, DE, ¹⁰ Schweinfurt, DE, ¹¹ Schkeuditz, DE, ¹² Troisdorf, DE, ¹³ Dresden, DE, ¹⁴ Bototrop, DE, ¹⁵ Berlin, DE, ¹⁶ Hamburg, DE | |
| 16:30 - 16:30 | 462PD - Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): The phase II randomized MACBETH trial by GONO <u>C. Cremolini</u> ¹ , C. Antoniotti ¹ , F. Loupakis ² , F. Bergamo ² , L. Ferrari ³ , R. Grande ⁴ , G. Tonini ⁵ , G. Masi ¹ , M. Schirripa ¹ , M. Bonotto ³ , C. Soldà ² , S. Lucchesi ⁶ , D. rossini ⁷ , D. Corsi ⁵ , M. Ronzoni ⁸ , F.L. Rojas Llimpe ⁹ , G. Fontanini ¹ , L. Boni ¹⁰ , V. Zagonel ² , A. Falcone ¹ ; ¹ Pisa, IT, ² Padova, IT, ³ Udine, IT, ⁴ Frosinone, IT, ⁵ Roma, IT, ⁶ Pontedera, IT, ⁷ Rome, IT, ⁸ Milano, IT, ⁹ Bologna, IT, ¹⁰ Firenze, IT | |
| 16:30 - 16:30 | 463PD - Clinical factors influencing outcome in metastatic colorectal cancer (mCRC) patients treated with fluoropyrimidine and bevacizumab (FP+Bev) maintenance treatment (Tx) vs observation: A pooled analysis of the phase 3 CAIRO3 and AIO 0207 trials | |



K. Goey¹, S. Elias¹, A. Hinke², M. van Oijen³, C. Punt³, D. Arnold⁴, S. Hegewisch Becker⁵, M. Koopman¹; ¹Utrecht, NL, ²Langenfeld, DE, ³Amsterdam, NL, ⁴Freiburg, DE, ⁵Hamburg, DE

16:30 - 16:40 Invited discussant abstracts 462PD, 463PD, LBA21 and LBA22

C.-H. Koehne, Oldenburg, DE

16:40 - 16:50 Questions to discussant

16:50 - 16:50 464PD - A multi-center, randomized, double-blind phase II trial of FOLFIRI + regorafenib or placebo for patients with metastatic colorectal cancer who failed one prior line of oxaliplatin-containing therapy

B. O'Neil¹, S. O'Reilly², S. Kasbari³, R. Kim⁴, R. McDermott⁵, D. Moore⁶, W. Grogan⁵, A. Cohn⁷, T. Bekaii-Saab⁸, A. Ivanova⁶, O. Olowokure⁹, N. Fernando¹⁰, J. McCaffrey², B. El-Rayes¹⁰, A. Horgan¹¹, T. Ryan¹², G. Sherrill¹³, G. Yacoub¹⁴, R. Goldberg¹⁵, H. Sanoff⁶; ¹Indianapolis, IN/US, ²Cork, IE, ³Wilson, NC/US, ⁴Tampa, US, ⁵Dublin, IE, ⁶Chapel Hill, NC/US, ⁷Denver, CO/US, ⁸Phoenix, AZ/US, ⁹Cincinnati, OH/US, ¹⁰Atlanta, GA/US, ¹¹Waterford, IE, ¹²New York, NY/US, ¹³Greensboro, NC/US, ¹⁴Winston Salem, NC/US, ¹⁵Columbus, OH/US

16:50 - 16:50 465PD - TERRA: A randomized, double-blind, placebo-controlled phase 3 study of TAS-102 in Asian patients with metastatic colorectal cancer

T.W. Kim¹, L. Shen², J.M. Xu², V. Sriuranpong³, H. Pan⁴, R. Xu⁵, S.-W. Han¹, T. Liu⁶, Y.S. Park¹, C. Shir⁷, Y. Bai⁸, F. Bi⁹, J.B. Ahn¹, S. Qin¹⁰, Q. Li⁶, C. Wu¹¹, F. Zhou¹², D. Ma⁵, V. Srimuninnimit³, J. Li⁶; ¹Seoul, KR, ²Beijing, CN, ³Bangkok, TH, ⁴Hangzhou, CN, ⁵Guangzhou, CN, ⁶Shanghai, CN, ⁷Fuzhou, CN, ⁸Harbin, CN, ⁹Chengdu, CN, ¹⁰Nanjing, CN, ¹¹Changzhou, CN, ¹²Wuhan, CN

16:50 - 16:50 466PD - Sorafenib (Soraf) and irinotecan (Iri) combination for pretreated RAS-mutated metastatic colorectal cancer (mCRC) patients: A multicentre randomized phase II trial (NEXIRI 2-PRODIGE 27)

E. Samalin¹, C. de la Fouchardiere², S. Thezenas¹, V. Boige³, H. Senellart⁴, R. Guimbaud⁵, J. Taieb⁶, E. Francois⁷, M.-P. Galais⁸, A. Adenis⁹, A. Lievre¹⁰, L. Dahan¹¹, F. Di Fiore¹², F. Boissiere¹, E. Crapez¹, F. Bibeau¹, A. Ho-Pun-Cheung¹, S. Pujol¹, T. Mazard¹, M. Ychou¹; ¹Montpellier, FR, ²Lyon, FR, ³Villejuif, FR, ⁴Nantes, FR, ⁵Toulouse, FR, ⁶Paris, FR, ⁷Nice, FR, ⁸Caen, FR, ⁹Lille, FR, ¹⁰Rennes, FR, ¹¹Marseille, FR, ¹²Rouen, FR

16:50 - 17:00 Invited discussant abstracts 464PD, 465PD and 466PD

P. Pfeiffer, Odense C, DK

17:00 - 17:10 Questions to discussant

17:10 - 17:10 467PD - Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: Final analyses



H.J. Schmoll¹, A. Stein², R. Hofheinz³, T. Price⁴, B. Nordlinger⁵, J.-F. Daisne⁶, J.-F. Daisne⁶, J. Janssens⁷, B. Brenner⁸, P. Schmidt⁹, H. Reinel¹⁰, S. Hollerbach¹¹, K. Caca¹², F. Fauth¹³, J. Zalcberg¹⁴, S. Marreaud¹⁵, M. Mauer¹⁵, E. Van Cutsem¹⁶, M. Lutz¹⁷, K. Haustermans¹⁶; ¹Halle, DE, ²Hamburg, DE, ³Mannheim, DE, ⁴Adelaide, AU, ⁵Boulogne-Billancourt, FR, ⁶Namur, BE, ⁷Turnhout, BE, ⁸Haifa, IL, ⁹Neunkirchen, DE, ¹⁰Schweinfurt, DE, ¹¹Celle, DE, ¹²Ludwigsburg, DE, ¹³Hanau, DE, ¹⁴Melbourne, AU, ¹⁵Brussels, BE, ¹⁶Leuven, BE, ¹⁷Saarbruecken, DE

17:10 - 17:10 468PD - Evaluation for surgical treatment options in metastatic colorectal cancer (mCRC) – A retrospective, central evaluation of FIRE-3

U. Neumann¹, T. Denecke², J. Pratschke², H. Lang³, M. Bemelmans⁴, T. Becker⁵, M. Rentsch⁶, D. Seehofer⁷, C.J. Bruns⁸, B. Gebauer², G. Folprecht⁹, S. Stintzing⁶, S. Held¹⁰, V. Heinemann⁶, D.P. Modest¹¹; ¹Aachen, DE, ²Berlin, DE, ³Mainz, DE, ⁴Maastricht, NL, ⁵Kiel, DE, ⁶München, DE, ⁷Leipzig, DE, ⁸Magdeburg, DE, ⁹Dresden, DE, ¹⁰Leverkusen, DE, ¹¹DE

17:10 - 17:10 469PD - Phase III trial of 24 weeks vs. 48 weeks capecitabine adjuvant chemotherapy for patients with stage III colon cancer: Final results of JFMC37-0801

S. Yamaguchi¹, K. Kunieda², T. Sato³, Y. Naramoto⁴, M. Kobayashi⁵, Y. Ogata⁶, T. Furuhashi⁷, Y. Takii⁸, M. Kusunoki⁹, Y. Maehara¹⁰, K. Koda¹¹, K. Okuno¹², M. Ohno¹³, H. Mishima¹⁴, S. Sadahiro¹⁵, C. Hamada¹⁶, J. Sakamoto¹⁶, S. Saji¹⁷, N. Tomita¹⁸; ¹Hidaka, JP, ²Gifu, JP, ³Yamagata, JP, ⁴Okayama, JP, ⁵Kochi, JP, ⁶Kurume, JP, ⁷Sapporo, JP, ⁸Niigata, JP, ⁹Tsu, JP, ¹⁰Fukuoka, JP, ¹¹Ichihara, JP, ¹²Osaka, JP, ¹³Kaibara, JP, ¹⁴Nagakute, JP, ¹⁵Isehara, JP, ¹⁶Tokyo, JP, ¹⁷Fukushima, JP, ¹⁸Nishinomiya, JP

17:10 - 17:10 LBA23_PR - A novel epigenetic immunoassay approach to profiling circulating nucleosomes for CRC detection.

M. Herzog¹, M. Eccleston², D. Pamart¹, B. Cuvelier¹, E. Josseaux¹, J. Micallef¹; ¹Namur, BE, ²-, GB

17:10 - 17:20 Invited discussant abstracts 467PD, 468PD, 469PD and LBA23

R. Adams, Cardiff, GB

17:20 - 17:30 Questions to discussant



| | | |
|---------------|---|------|
| 16:30 - 18:00 | Type: Proffered Paper session Title: Public health and health economics Chair(s): R. Giuliani, IT | Oslo |
| 16:30 - 16:45 | 1362O_PR - Single-arm trials for cancer drug approval and patient access <u>J. Martinalbo</u> ¹ , J. Camarero ² , B. Delgado-Charro ¹ , P. Démolis ³ , J. Ersbøll ⁴ , P. Foggi ⁵ , B. Jonsson ⁶ , D. O'Connor ¹ , F. Pignatti ¹ ; ¹ London, GB, ² Madrid, ES, ³ Paris, FR, ⁴ Copenhagen, DK, ⁵ Roma, IT, ⁶ Uppsala, SE | |
| 16:45 - 17:00 | 1364O_PR - The ESMO-Magnitude of Clinical Benefit Scale (MCBS) in rare tumor entities: A real life experience at the Medical University Vienna <u>B. Kieseewetter</u> , M. Raderer, C. Marosi, T. Brodowicz, G. Prager, M. Krainer, T. Fuereder, G. Locker, C. Zielinski; Vienna, AT | |
| 17:00 - 17:15 | Invited discussant abstracts 1362O_PR and 1364O_PR <u>A. Ocana Fernandez</u> , Albacete, ES | |
| 17:15 - 17:30 | 1020O_PR - The effect of financial difficulties on clinical outcomes in Italian cancer patients: A pooled analysis of 16 academic prospective clinical trials <u>F. Perrone</u> ¹ , C. Jommi ² , M. Di Maio ¹ , A. Gimigliano ¹ , C. Gridelli ³ , S. Pignata ¹ , F. Ciardiello ¹ , F. Nuzzo ¹ , A. de Matteis ¹ , L. Del Mastro ⁴ , J. Bryce ¹ , G. Daniele ¹ , A. Morabito ¹ , M.C. Piccirillo ¹ , G. Rocco ¹ , L. Guizzaro ¹ , C. Gallo ¹ ; ¹ Napoli, IT, ² Novara, IT, ³ Avellino, IT, ⁴ Genova, IT | |
| 17:30 - 17:45 | 1389O_PR - More than 5000 patients with metastatic melanoma in Europe per year do not have access to the new life-saving drugs* <u>L. Kandolf Sekulovic</u> ¹ , K. Peris ² , A. Hauschild ³ , L. Demidov ⁴ , P. Nathan ⁵ , C. Lebbe ⁶ , C. Hoeller ⁷ , C. Blank ⁸ , J. Olah ⁹ , H. Gogas ¹⁰ , R. Dummer ¹¹ , L. Bastholt ¹² , D. Herceg ¹³ , A. Stratigos ¹⁰ , B. Neyns ¹⁴ , J. Hansson ¹⁵ , P. Rutkowski ¹⁶ , C. Garbe ¹⁷ , I. Krajsova ¹⁸ , A.-M. Forsea ¹⁹ ; ¹ Belgrade, RS, ² Rome, IT, ³ Kiel, DE, ⁴ Moscow, RU, ⁵ Northwood, GB, ⁶ Paris, FR, ⁷ Vienna, AT, ⁸ Amsterdam, NL, ⁹ Szeged, HU, ¹⁰ Athens, GR, ¹¹ Zürich, CH, ¹² Odense C, DK, ¹³ Zagreb, HR, ¹⁴ Brussels, BE, ¹⁵ Stockholm, SE, ¹⁶ Warsaw, PL, ¹⁷ Tübingen, DE, ¹⁸ Prague, CZ, ¹⁹ Bucharest, RO | |
| 17:45 - 18:00 | Invited discussant abstracts 1020O_PR and 1389O_PR | |



| | | |
|---------------|---|------|
| 16:30 - 18:00 | Type: Proffered Paper session Title: Endocrine and neuroendocrine tumours | Rome |
| 16:30 - 16:45 | 416O - Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: Results from the randomized, phase 2 LUNA study <u>P. Ferolla</u> ¹ , M. Brizzi ² , T. Meyer ³ , W. Mansoor ⁴ , J. Mazieres ⁵ , C. Cao ⁶ , H. Lena ⁷ , A. Berruti ⁸ , V. Damiano ⁹ , W. Buikhuizen ¹⁰ , M. Stankovic ¹¹ , N. Singh ¹² , E. Chiodini ¹³ , G. Gislumberti ¹³ , K. Oberg ¹⁴ , E. Baudin ¹⁵ ; ¹ Perugia, IT, ² Torino, IT, ³ London, GB, ⁴ Manchester, GB, ⁵ Toulouse, FR, ⁶ Lille, FR, ⁷ Rennes, FR, ⁸ Brescia, IT, ⁹ Napoli, IT, ¹⁰ Amsterdam, NL, ¹¹ Novi Beograd, RS, ¹² Mumbai, IN, ¹³ Origgio, IT, ¹⁴ Uppsala, SE, ¹⁵ Villejuif, FR | |
| 16:45 - 17:00 | 417O - Metformin impact on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNET) receiving everolimus and/or somatostatin analogues. The PRIME-NET (Pancreatic multicentric, Retrospective, Italian METformin) study <u>S. Pusceddu</u> ¹ , R. Marconcini ² , F. Spada ¹ , S. Massironi ¹ , A. Bongiovanni ³ , M.P. Brizzi ⁴ , N. Brighi ⁵ , A. Colao ⁶ , D. Giuffrida ⁷ , G. Delle Fave ⁸ , S. Cingarlini ⁹ , F. Aroldi ¹⁰ , L. Antonuzzo ¹¹ , R. Berardi ¹² , L. Catena ¹³ , C. de divitis ⁶ , P. Ermacora ¹⁴ , M. Di Maio ⁴ , R. Buzzoni ¹ , F. de Braud ¹ ; ¹ Milano, IT, ² Pisa, IT, ³ Meldola, IT, ⁴ Orbassano, IT, ⁵ Bologna, IT, ⁶ Napoli, IT, ⁷ Viagrande, IT, ⁸ Roma, IT, ⁹ Verona, IT, ¹⁰ Brescia, IT, ¹¹ Firenze, IT, ¹² Ancona, IT, ¹³ Monza, IT, ¹⁴ Udine, IT | |
| 17:00 - 17:15 | Invited discussant abstracts 416O and 417O <u>J. Yao</u> , Houston, US | |
| 17:15 - 17:30 | 418O - Pancreatic neuroendocrine tumour (pNET) profiles in the NETwork! programme: Clinic-enabled genomics for genomic-enabled clinical decisions <u>B. Lawrence</u> ¹ , C. Blenkiron ¹ , K. Parker ¹ , S. Fitzgerald ¹ , P. Shields ¹ , P. Tsai ¹ , S. James ¹ , N. Poonawala ¹ , M.L. Yeong ¹ , N. Kramer ¹ , B. Robinson ² , S. Connor ² , R. Ramsaroop ¹ , M. Yozu ¹ , M. Elston ¹ , C. Jackson ³ , R. Carroll ⁴ , D. Harris ² , M. Findlay ¹ , C. Print ¹ ; ¹ Auckland, NZ, ² Christchurch, NZ, ³ Dunedin, NZ, ⁴ Wellington, NZ | |
| 17:30 - 17:45 | 419O - Genomic profile in pulmonary neuroendocrine tumors (puNETs): The whole-exome sequencing (WES) as a strategic tool <u>I. Sullivan</u> ¹ , M. Deloger ² , L. Lacroix ² , B. Job ² , N. Dorvault ² , J. Adam ² , A. Honore ² , L. Gianoncelli ³ , G. Le Teuff ² , V. de Montpreville ⁴ , B. Besse ² , J.-C. Soria ² , J.-Y. Scoazec ² , E. Baudin ² , D. Planchard ² ; ¹ Barcelona, ES, ² Villejuif, FR, ³ Rozzano, IT, ⁴ Le Plessis-Robinson, FR | |
| 17:45 - 18:00 | Invited discussant abstracts 418O and 419O <u>K. Oberg</u> , Uppsala, SE | |



| | | |
|---------------|--|----------|
| 16:30 - 17:30 | Type: Multidisciplinary patient cases Title: Challenges in the management of HPV - associated OPC Chair(s): D. Rischin, AU | Athens |
| 16:30 - 16:40 | Early stage HPV positive OPC patient <u>C. Simon</u> , Lausanne, CH | |
| 16:40 - 16:50 | Locally advanced HPV positive OPC: Selection of deintensification candidates and deintensification strategies <u>D. Rischin</u> , Melbourne, AU | |
| 16:50 - 17:30 | Discussion | |
| 18:30 - 20:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium | Madrid |
| 18:30 - 20:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Oslo |
| 18:30 - 20:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Rome |
| 18:30 - 20:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Athens |
| 18:30 - 20:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Helsinki |
| 18:30 - 20:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium | Brussels |
| 18:30 - 20:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium | Berlin |
| 11-10-2016 | | |



| | | |
|---------------|---|------------|
| 09:00 - 12:40 | Type: Congress highlights Title: Congress Highlights Session 1 – The best of the ESMO 2016 Congress Chair(s): F. Ciardiello, IT; A. Cervantes, ES | Copenhagen |
| 09:00 - 09:20 | Breast cancer, early <u>M. Colleoni</u> , Milano, IT | |
| 09:20 - 09:40 | Breast cancer, metastatic <u>R. Coleman</u> , Sheffield, GB | |
| 09:40 - 10:00 | Basic science and translational research <u>G. Ramaswamy</u> , St. Louis, Mi, US | |
| 10:00 - 10:20 | CNS tumours <u>E. Franceschi</u> , Bologna, IT | |
| 10:20 - 10:40 | NETs and endocrine tumours <u>J. Valle</u> , Manchester, GB | |
| 10:40 - 11:00 | Break | |
| 11:00 - 11:20 | GU prostate <u>E. Efstathiou</u> , Houston, US | |
| 11:20 - 11:40 | GU non-prostate <u>A. Necchi</u> , Milano, IT | |
| 11:40 - 12:00 | Non-metastatic NSCLC and other thoracic malignancies <u>D. De Ruyscher</u> , Maastricht, NL | |
| 12:00 - 12:20 | NSCLC, metastatic | |
| 12:20 - 12:40 | Developmental therapeutics <u>C. Twelves</u> , Leeds, GB | |



| | | |
|---------------|--|------|
| 09:00 - 12:40 | Type: Congress highlights Title: Congress Highlights Session 2 – The best of the ESMO 2016 Congress Chair(s): J. Tabernero, ES; A. Sobrero, IT | Oslo |
| 09:00 - 09:20 | GI, colorectal <u>J. Taieb</u> , Paris, FR | |
| 09:20 - 09:40 | GI, non-colorectal <u>A. Roth</u> , Geneva, CH | |
| 09:40 - 10:00 | Sarcoma <u>S. Bauer</u> , Essen, DE | |
| 10:00 - 10:20 | Gynaecological cancers <u>C. Sessa</u> , Bellinzona, CH | |
| 10:20 - 10:40 | Supportive and palliative care <u>F. Scotté</u> , Paris, FR | |
| 10:40 - 11:00 | Break | |
| 11:00 - 11:20 | Immunotherapy of cancer <u>J. Haanen</u> , Amsterdam, NL | |
| 11:20 - 11:40 | Melanoma and other skin tumours <u>R. Dummer</u> , Zürich, CH | |
| 11:40 - 12:00 | Head and neck cancer <u>J.-P. Machiels</u> , Brussels, BE | |
| 12:00 - 12:20 | Public health and health economics <u>R. Giuliani</u> , Roma, IT | |
| 12:20 - 12:40 | Haematological malignancies <u>S. Le Gouill</u> , Nantes, FR | |